<SEC-DOCUMENT>0001404644-25-000041.txt : 20250509
<SEC-HEADER>0001404644-25-000041.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509071922
ACCESSION NUMBER:		0001404644-25-000041
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neurogene Inc.
		CENTRAL INDEX KEY:			0001404644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				980542593
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36327
		FILM NUMBER:		25928376

	BUSINESS ADDRESS:	
		STREET 1:		535 W 24TH STREET
		STREET 2:		5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10011
		BUSINESS PHONE:		(877) 237-5020

	MAIL ADDRESS:	
		STREET 1:		535 W 24TH STREET
		STREET 2:		5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neoleukin Therapeutics, Inc.
		DATE OF NAME CHANGE:	20190812

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINOX PHARMACEUTICALS, INC
		DATE OF NAME CHANGE:	20140128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINOX PHARMACEUTICALS (USA) INC
		DATE OF NAME CHANGE:	20070626
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ngne-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:455e46d4-7342-4901-9012-cb7d8f12b78e,g:0c981b7d-7032-4dc2-af2a-101f291ef69a,d:2c10432fd4514957b2f0bdfad1948d4e-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ngne="http://www.neurogene.com/20250331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ngne-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001404644</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-29">False</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-30">12/31</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-266">one</ix:nonFraction><ix:nonNumeric contextRef="c-167" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-620">404</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ngne-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ngne:segment</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="term"><xbrli:measure>ngne:Term</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>ngne:tranche</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ngne:Phase1NL201TrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ngne:Phase1NL201TrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ngne:Phase1NL201TrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:BlaineLeaseInSeattleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:EastlakeLeaseInSeattleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:EastlakeLeaseInSeattleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:EastlakeLeaseInSeattleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:April2024CVRLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:December2023CVRLicensingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:December2023CVRLicensingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:April2024CVRLicensingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:April2024CVRLicensingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:IntellectualPropertyCVRNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:IntellectualPropertyCVRNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:SalesTaxCVRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:LeaseCVRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:LeaseCVRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:LeaseCVRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:IntellectualPropertyCVRNettingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:SalesTaxCVRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:RegulatoryRelatedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:SalesRelatedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:SalesRelatedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:VirovekIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:VirovekIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:VirovekIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:SigmaAldrichCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:SigmaAldrichCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:SigmaAldrichCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:StanfordLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2025InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ngne:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ngne:December2023PreferredStockConversionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ngne:December2023PreClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2025InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:RettSyndromeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:RettSyndromeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:BattenDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:BattenDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:EarlyDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:EarlyDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:PersonnelRelatedExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:PersonnelRelatedExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ShareBasedCompensationExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ShareBasedCompensationExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ManufacturingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ManufacturingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:OfficeRelatedExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:OfficeRelatedExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-14</xbrli:startDate><xbrli:endDate>2025-04-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ngne:StuartCobbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ngne:StuartCobbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_1"></div><div style="min-height:72pt;width:100%"><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-top:10pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:139%">UNITED STATES</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">__________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:139%">FORM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">__________________________________________________</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">(Mark One)</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&#160;OF&#160;1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2025</ix:nonNumeric></span></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OR</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT&#160;OF&#160;1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">For the transition period from ________ to ________</span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Commission file number:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36327</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">__________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Neurogene Inc.</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">__________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">98-0542593</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">535 W 24th St.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">5th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NY</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">10011</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">855</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">508-3568</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#181717;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common stock, par value $0.000001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">NGNE</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:360pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:360pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#181717;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As of May&#160;5, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">14,262,066</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-right:-22.5pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:7.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.825%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_10">Part I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_10">Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_76">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_76">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_106">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_109">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_112">Part II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_112">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_112">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_115">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_115">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_118">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_118">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_118">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_121">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_121">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_124">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_124">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_124">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_127">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_127">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_127">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_130">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_130">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_130">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_133">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_133">86</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_136">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2c10432fd4514957b2f0bdfad1948d4e_136">87</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;padding-right:-22.5pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I - Financial Information</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_13"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Consolidated Financial Statements</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_16"></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurogene Inc.</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands, Except Share Information)</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:70.283%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.896%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">70,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">136,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-33">221,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-34">175,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">3,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">3,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">296,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">315,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-39">14,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">15,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-41">2,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-43">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-44">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-45">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="f-46">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-47">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-48">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-49">315,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">335,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">3,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">6,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">9,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">3,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-57">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-58">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent value rights liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">14,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">15,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">8,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">9,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-65">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-66">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent value rights liability, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" id="f-67">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" id="f-68">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-69">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-70">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-71">23,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">25,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-73"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-74">0.000001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-80">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-84">0.000001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-86">450,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-88">14,929,566</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-90">14,854,725</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-93">576,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-94">572,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-95">284,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-96">262,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">291,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">310,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">315,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">335,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-1-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurogene Inc.</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands, Except Share Information)</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.076%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-101">17,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">13,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">8,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-105">25,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-106">18,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">25,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">18,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-109">3,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-110">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-111">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-112">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="f-113">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="f-114">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingExpense" scale="3" id="f-115">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingExpense" scale="3" id="f-116">602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">22,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">16,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-119"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-120">1.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-121"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-122">1.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-124">20,996,287</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126">16,903,735</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurogene Inc.</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Stockholders&#8217; Equity </span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands, Except Share Information)</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.666%"><tr><td style="width:1.0%"/><td style="width:42.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional<br/>Paid- In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance- December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-127">14,854,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">572,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-130">262,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">310,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-132">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-133">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-134">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-135">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-136">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-137">73,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">22,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">22,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance- March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-141">14,929,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-143">576,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-144">284,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">291,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.666%"><tr><td style="width:1.0%"/><td style="width:42.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional<br/>Paid- In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance- December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-146">12,823,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">373,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">187,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-150">186,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-151">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-152">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-153">37,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-154">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-155">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">16,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">16,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance- March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-158">12,860,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">374,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">204,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-162">170,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Neurogene Inc.</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"/><td style="width:69.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">22,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">16,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-165">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-166">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-167">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-168">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-170">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-171">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-172">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-173">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-174">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization and accretion of premiums/discounts on held-to-maturity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-175">1,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-176">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in contingent value rights liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ngne:IncreaseDecreaseInContingentValueRightsLiability" scale="3" id="f-177">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ngne:IncreaseDecreaseInContingentValueRightsLiability" scale="3" id="f-178">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-179">278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-180">1,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-181">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-182">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-183">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-184">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-185">2,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-186">4,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-187">706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-188">609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-189">20,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-190">21,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-191">780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-192">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of held-to-maturity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-193">88,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of held-to-maturity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-195">44,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-196">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-197">45,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-198">29,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Offering costs in connection with pre-closing financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-200">4,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs related to reverse merger </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-202">2,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-203">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-204">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-205">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-206">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-207">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-208">6,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-209">65,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-210">1,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-211">136,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-212">148,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-213">71,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-214">150,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions to operating lease right of use assets from new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-216">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-217">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-218">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-219">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-220">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROGENE INC.</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_31"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-221" continuedAt="f-221-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Organization and Description of Business</span></ix:nonNumeric></div><ix:continuation id="f-221-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurogene&#160;Inc. (formerly known as Neoleukin Therapeutics, Inc.) (the &#8220;Company&#8221; or &#8220;Neurogene&#8221;) is a clinical-stage biotechnology company that is a result of the reverse merger discussed below. The operating entity of Neurogene Inc. is the wholly owned subsidiary incorporated in the state of Nevada and also named Neurogene Inc. (&#8220;Neurogene OpCo&#8221;). Neurogene OpCo was incorporated as a limited liability company in Delaware on January 26, 2018 and converted into a Delaware corporation on July 3, 2018, and then merged with a wholly owned subsidiary of the parent company and re-domiciled to Nevada on December 18, 2023 after completing a reverse merger with Neoleukin Therapeutics, Inc (the &#8220;Closing&#8221;), in accordance with the terms of the Agreement and Plan of Merger, dated as of July 17, 2023 (the &#8220;Merger Agreement&#8221;). Both Neurogene and Neurogene OpCo have a principal place of business in New York, NY. Neurogene was formed to harness the power of gene therapy, combined with its EXACT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene regulation technology, to turn today&#8217;s complex devastating neurological diseases into treatable conditions. The Company&#8217;s first clinical-stage program to utilize the EXACT technology is NGN-401, which is in an ongoing Phase 1/2 clinical trial for the treatment of Rett syndrome. Since beginning operations, the Company has devoted substantially all its efforts to research and development, recruiting management and technical staff, administration, and raising capital.</span></div></ix:continuation><div id="i2c10432fd4514957b2f0bdfad1948d4e_37"></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-222" continuedAt="f-222-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Risks and Uncertainties</span></ix:nonNumeric></div><ix:continuation id="f-222-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of pre-clinical studies, clinical studies and clinical trials, the need to obtain marketing approval for its drug candidates and its consumer products, fluctuations in operating results, economic pressure impacting therapeutic pricing and reimbursement, dependence on key personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to transition from pilot scale manufacturing to large scale production.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-223">22.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-224">16.9</ix:nonFraction> million for the three months ended March 31, 2025 and 2024, respectively. In addition, the Company used cash in operations of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-225">20.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-226">21.7</ix:nonFraction> million for the three months ended March 31, 2025 and 2024, respectively, and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-227">284.9</ix:nonFraction> million as of March&#160;31, 2025. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="f-228">292.6</ix:nonFraction> million. The Company expects its available cash and cash equivalents on hand as of the issuance date </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these financial statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be sufficient to fund its obligations as they become due for at least one year beyond the issuance date of these financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company&#8217;s operations, a sale of assets, or other alternatives with strategic or financial partners. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-229" continuedAt="f-229-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Summary of Significant Accounting Policies </span></ix:nonNumeric></div><ix:continuation id="f-229-1" continuedAt="f-229-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-230" continuedAt="f-230-1" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, these financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March 24, 2025.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-230-1">In management&#8217;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2025, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December&#160;31, 2025.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-231" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining the incremental borrowing rate for calculating lease liabilities and related right-of-use assets and finance lease assets, clinical trial accruals, accrual estimates for all contingent value rights (&#8220;CVRs&#8221;), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the value attributed to employee stock options and other stock-based awards. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-232" continuedAt="f-232-1" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><ix:continuation id="f-232-1" continuedAt="f-232-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines and presents operating segments based on the information internally provided to the Chief Operating Decision Makers (&#8220;CODM&#8221;) in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 280,&#160;Segment Reporting. The Company&#8217;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-233">one</ix:nonFraction> reportable segment. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information, </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-232-2">for further information related to the Company&#8217;s segment.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-234" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with original maturities of 90 days or less at time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and are stated at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-236" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-235" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:59.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-237">70,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-238">136,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-239">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-240">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-241">71,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-242">136,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds in which the carrying value equals the fair value. Restricted cash includes $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="f-243">0.3</ix:nonFraction> million in cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-229-2" continuedAt="f-229-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-244" continuedAt="f-244-1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-244-1">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of March&#160;31, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ngne:CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" scale="6" id="f-245">70.6</ix:nonFraction> million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="ngne:ContingentValueRightsPolicyTextBlock" id="f-246" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the reverse merger, the Company entered into a CVR Agreement on December 18, 2023 with the Rights Agent named therein (the &#8220;CVR Agreement&#8221;) prior to Closing. Included in the CVR Agreement are three different types of CVRs: (i) the Lease CVR, (ii) the Intellectual Property CVR, and (iii) the Sales Tax CVR (each as defined in the CVR Agreement). The Company evaluated each of the CVRs to determine if they qualified as derivatives under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that since certain scope exceptions were met, the CVRs did not qualify as derivatives. Instead, the Company records a contingent consideration liability associated with the CVRs when payments are probable and estimable under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In assessing whether payments are probable and estimable, the Company considers the existence of or ability to enter into agreements with third parties or government agencies and the timing of potential payments. Refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the CVRs.</span></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="f-247" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit and Disposal Costs</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the reverse merger and through early fiscal 2025, the Company has incurred costs to wind-down Neoleukin&#8217;s Phase 1 trial of the NL-201 study. This trial has ceased further development, and the Company has no plans to continue developing Neoleukin&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein technology. As a result, the trial&#8217;s activities do not provide the Company any future economic benefit. In accordance with ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accrued the remaining costs incurred in the trial. The liability was classified as accrued expenses and other current liabilities in the condensed consolidated balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-248" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the accrued liabilities activity recorded in connection with the wind-down of Neoleukin&#8217;s Phase 1 trial of NL-201 for the three months ended March&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:42.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amounts Paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial wind-down costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 NL-201 Trial</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-249">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="3" id="f-250">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="f-251">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-252">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited financial statements filed with the Company&#8217;s Annual Report on Form 10-K for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the date of those financial statements, there have been no changes to the Company&#8217;s significant accounting policies.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-253" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net income attributable to the Company by the weighted-average number of shares of common stock outstanding during the period. In periods of losses, diluted net loss per share is computed on the same basis as basic net loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive. Outstanding pre-funded warrants as of March&#160;31, 2025 and March&#160;31, 2024 are <ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-254">6,124,996</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-255">4,062,361</ix:nonFraction> respectively. Pre-funded warrants are considered outstanding as of their issuance date and are included in basic and diluted net loss per share because they are fully vested and exercisable for nominal cash consideration.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-229-3" continuedAt="f-229-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-256" escape="true"><div style="margin-top:10pt;padding-left:13.5pt;text-indent:37.11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"/><td style="width:66.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-257">2,086,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-258">1,475,458</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-259">279,458</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-260">222,530</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-261">252,124</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-262">252,124</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-263">2,617,916</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-264">1,950,112</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-265" continuedAt="f-265-1" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its condensed financial statements or disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which requires public entities to provide disaggregated disclosure of income statement expenses. Public entities are required to disaggregate, in a tabular presentation, each relevant expense caption on the face of the consolidated statements of operations such as the following expenses: purchases of inventory, employee compensation, intangible asset amortization, and depreciation. In January 2025, the FASB issued ASU 2025-01 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to clarify the effective date. The updated effective date for the Company to adopt ASU 2024-03 is for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2024-03 will have on its financial statement disclosures. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><ix:continuation id="f-265-1" continuedAt="f-265-2"><ix:continuation id="f-229-4" continuedAt="f-229-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-265-2"><ix:continuation id="f-229-5"> to expand the disclosure requirements for income taxes. Upon adoption, the Company will be required to disclose standardized categories in the rate reconciliation in both percentage and dollar amounts. ASU 2023-09 will also require income taxes paid to be disaggregated by jurisdiction, among other disclosure requirements. The Company adopted ASU 2023-09 for annual periods beginning January 1, 2025. The adoption does not have a material impact to the interim financial statements.</ix:continuation></ix:continuation> </span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_46"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-267" continuedAt="f-267-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Investments </span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="f-268" continuedAt="f-268-1" escape="true"><ix:continuation id="f-267-1" continuedAt="f-267-2"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following table summarizes the Company&#8217;s investment securities as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:35.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized cost, as adjusted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-269">66,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="f-271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-272">66,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-273">221,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="f-274">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="f-275">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-276">221,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-277">288,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="f-278">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="f-279">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-280">288,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments mature within the next 12 months.</span></div></ix:continuation></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-268-1"><ix:continuation id="f-267-2"><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:35.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized cost, as adjusted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">131,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="3" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-284">131,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-285">175,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="f-286">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="f-287">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-288">175,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-289">307,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="f-290">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="f-291">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-292">307,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i2c10432fd4514957b2f0bdfad1948d4e_49"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-293" continuedAt="f-293-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair Value of Financial Instruments</span></ix:nonNumeric></div><ix:continuation id="f-293-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-294" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:54.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-295">66,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-298">221,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-301">288,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:54.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-304">131,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-307">175,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-310">307,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are cash equivalents and are included in cash and cash equivalents in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024.</span></div></ix:continuation><div id="i2c10432fd4514957b2f0bdfad1948d4e_52"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherAssetsDisclosureTextBlock" id="f-313" continuedAt="f-313-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Prepaid expenses and other current assets</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-314" escape="true"><ix:continuation id="f-313-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:68.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds and other receivables </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ngne:RefundsAndOtherReceivablesCurrent" scale="3" id="f-315">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ngne:RefundsAndOtherReceivablesCurrent" scale="3" id="f-316">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-317">2,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-318">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-319">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-320">981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-321">3,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-322">3,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-323" continuedAt="f-323-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Property and Equipment, Net</span></ix:nonNumeric></div><ix:continuation id="f-323-1" continuedAt="f-323-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-324" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:67.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.839%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-325">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-326">3,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-327">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-328">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-329">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-330">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-331">15,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-332">15,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-333">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-334">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-335">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-336">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-337">26,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-338">26,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-339">11,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-340">11,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-341">14,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-342">15,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded depreciation and amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-343">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-344">0.8</ix:nonFraction> million for the three months ended March&#160;31, 2025 and 2024, respectively.  </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-323-2">Management has reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. During the three months ended March 31, 2025 there were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-345">no</ix:nonFraction> impairment losses and for the three months ended March 31, 2024, the Company recorded impairment losses on idle equipment of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="f-346">0.1</ix:nonFraction> million. Impairment losses are charged to research and development expenses in the condensed consolidated statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets</ix:continuation>.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_58"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-347" continuedAt="f-347-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Accrued Expenses and Other Current Liabilities</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-348" escape="true"><ix:continuation id="f-347-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:69.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, bonuses and related benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-349">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-350">4,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ngne:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-351">4,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ngne:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-352">5,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ngne:AccruedSeveranceBonusAndRetentionCostsCurrent" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ngne:AccruedSeveranceBonusAndRetentionCostsCurrent" scale="3" id="f-354">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-355">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-356">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-357">6,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-358">9,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-359" continuedAt="f-359-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Commitments and Contingencies</span></ix:nonNumeric></div><ix:continuation id="f-359-1" continuedAt="f-359-2"><div style="margin-top:10pt;padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Headquarters Lease</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company commenced a sub-lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-65" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-360">6,000</ix:nonFraction> square feet of office space for the corporate headquarters in New York, New York with a term expiring in June 2023. In connection with the lease, the Company established an irrevocable letter of credit for approximately $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="f-361">0.4</ix:nonFraction> million. Monthly lease payments were approximately $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-4" name="ngne:OperatingLeaseMonthlyPayments" scale="6" id="f-362">0.04</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the sublessor was released from the original lease by the landlord, and the Company attorned to the landlord the executory terms and provisions of the sub-lease. In February 2022, the Company entered into an extension of the New York office lease (retroactive to December 2021) through June 2026, with new monthly lease payments ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-4" name="ngne:OperatingLeaseMonthlyPayments" scale="6" id="f-363">0.03</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-4" name="ngne:OperatingLeaseMonthlyPayments" scale="6" id="f-364">0.04</ix:nonFraction> million. The Company accounted for the amendment as a contract modification, and accordingly, recorded an additional operating&#160;right-of-use asset of approximately $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-365"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-366">1.0</ix:nonFraction></ix:nonFraction> million and an additional operating lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-367"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-368">1.0</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Houston Lease</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into an agreement to lease approximately <ix:nonFraction unitRef="sqft" contextRef="c-70" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-369">26,905</ix:nonFraction> square feet in Houston, Texas to build a manufacturing facility and office with a term expiring in August 2029. The Company has the option to renew the lease term for <ix:nonFraction unitRef="term" contextRef="c-70" decimals="INF" name="ngne:LesseeOperatingLeaseNumberOfRenewalTerm" format="ixt-sec:numwordsen" scale="0" id="f-370">two</ix:nonFraction> additional <ix:nonNumeric contextRef="c-70" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-371">five-year</ix:nonNumeric> terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset. Monthly rent payments were approximately $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-4" name="ngne:OperatingLeaseMonthlyPayments" scale="6" id="f-372">0.03</ix:nonFraction> million. In connection with the lease, the Company paid a security deposit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-4" name="us-gaap:SecurityDeposit" scale="6" id="f-373">0.04</ix:nonFraction> million and prepaid rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-4" name="us-gaap:PrepaidRent" scale="6" id="f-374">0.04</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company amended the lease agreement to further increase the rentable space to <ix:nonFraction unitRef="sqft" contextRef="c-72" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-375">42,342</ix:nonFraction> square feet. The commencement date of the expansion space lease was January&#160;1, 2021 and the monthly rent payments increased to a range of approximately $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-4" name="ngne:OperatingLeaseMonthlyPayments" scale="6" id="f-376">0.05</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-4" name="ngne:OperatingLeaseMonthlyPayments" scale="6" id="f-377">0.06</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Blaine Lease in Seattle</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the reverse merger, the Company assumed an operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="c-75" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-378">33,300</ix:nonFraction> square feet of office space in Seattle, Washington for offices, a laboratory for research and development, and related uses. The lease expires on February 1, 2029, with the option to extend the lease for <ix:nonFraction unitRef="term" contextRef="c-75" decimals="INF" name="ngne:LesseeOperatingLeaseNumberOfRenewalTerm" format="ixt-sec:numwordsen" scale="0" id="f-379">two</ix:nonFraction> <ix:nonNumeric contextRef="c-75" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-380">five-year</ix:nonNumeric> terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eastlake Lease in Seattle</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the reverse merger, the Company assumed an operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="c-76" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-381">6,272</ix:nonFraction> square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses (the &#8220;Eastlake Lease&#8221;). The lease expires on September 30, 2026. The Company also assumed the existing agreement to sublease the Eastlake Lease to an unrelated third party (&#8220;Eastlake Sublease&#8221;). Pursuant to the terms of the Eastlake Sublease, Neurogene is entitled to receive approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="f-382">1.6</ix:nonFraction> million in lease payments. The Company recorded sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="f-383">0.1</ix:nonFraction> million for the three months ended March 31, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="f-384">0.1</ix:nonFraction> million for the three months ended March 31, 2024. Sublease income is included in other income in the statement of operations. The term of the sublease is through September 30, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-359-2" continuedAt="f-359-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-385" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental lease expense for the three months ended March 31, 2025 and 2024 was as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:69.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-386">484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-387">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-388">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-389">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-390">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-391">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-392">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-393">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-394">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-395">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-396">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-397">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CVR Agreement, each CVR holder is eligible to receive certain net savings, if any, realized by June 30, 2029 in connection with certain legacy lease obligations. As of March&#160;31, 2025, approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-398">1.2</ix:nonFraction>&#160;million was recorded as a component of the contingent value rights liability on the Company&#8217;s condensed consolidated balance sheet consisting of lease commitments that were probable and estimable at the Closing. The commitments relate to Neoleukin&#8217;s sublease agreement, effective October 31, 2023, for one of its properties with an unrelated third party for the remainder of the lease term.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CVR Agreement, each CVR holder is eligible to receive <ix:nonFraction unitRef="number" contextRef="c-79" decimals="INF" name="ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" scale="-2" id="f-399">100</ix:nonFraction>% of the net proceeds, if any, derived from any consideration paid as a result of the disposition of Neoleukin&#8217;s pre-merger legacy assets pursuant any agreements entered into before the Closing, and <ix:nonFraction unitRef="number" contextRef="c-79" decimals="INF" name="ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" scale="-2" id="f-400">80</ix:nonFraction>% of net proceeds, if any, derived from any consideration paid as a result of the disposition of Neoleukin&#8217;s pre-merger legacy assets pursuant any agreements entered into within one year after the Closing (the &#8220;Intellectual Property CVR&#8221;). Contingent consideration liabilities related to the CVR Agreement will only be recorded if the liabilities are probable and estimable as of the balance sheet date. Refer to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2023 CVR Licensing Agreement and April 2024 CVR Licensing Agreement subsections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for further detail on the current agreements related to our Intellectual Property CVR. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2023 CVR Licensing Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Closing, Neoleukin entered into a licensing agreement on December 13, 2023 with an unrelated third party to develop and commercialize certain legacy Neoleukin assets (the &#8220;December 2023 CVR Licensing Agreement&#8221;). In June 2024, an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-401">0.2</ix:nonFraction>&#160;million was received by the Company and $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-402">0.2</ix:nonFraction>&#160;million was recorded as licensing revenue within the consolidated statements of operations. Since the December 2023 CVR Licensing Agreement was entered into before the Closing, the CVR holders are eligible to receive <ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" scale="-2" id="f-403">100</ix:nonFraction>% of the net proceeds derived from the December 2023 CVR Licensing Agreement. The December 2023 CVR Licensing Agreement contains development, regulatory and commercialization milestones totaling up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-404">13.4</ix:nonFraction> million, as well as royalty payments. However, as of March&#160;31, 2025, no other development and sales milestones were achieved nor deemed probable of achievement under the December 2023 CVR Licensing Agreement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">April 2024 CVR Licensing Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a licensing and intellectual property assignment agreement with another unrelated third party to develop and commercialize certain legacy Neoleukin assets (the &#8220;April 2024 CVR Licensing Agreement&#8221;). In April 2024, the Company received a one-time upfront payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-405">0.8</ix:nonFraction> million and reimbursement of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="ngne:CollaborativeArrangementRightsAndObligationsReimbursement" format="ixt:num-dot-decimal" scale="0" id="f-406">10,000</ix:nonFraction> for patent expenses under the April 2024 CVR Licensing Agreement. Accordingly, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-407">0.8</ix:nonFraction> million as licensing revenue within the condensed consolidated statements of operations. Since the April 2024 CVR Licensing Agreement was entered into within one year after the Closing, the CVR holders are eligible to receive <ix:nonFraction unitRef="number" contextRef="c-79" decimals="INF" name="ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" scale="-2" id="f-408">80</ix:nonFraction>% of the net proceeds derived from the April 2024 CVR Licensing Agreement. The April 2024 CVR Licensing Agreement contains development, regulatory and commercialization milestones totaling up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-409">11.0</ix:nonFraction> million, as well as royalty payments. However, as of March&#160;31, 2025, no other development and sales milestones were achieved nor deemed probable of achievement under the April 2024 CVR Licensing Agreement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-359-3" continuedAt="f-359-4"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2023 CVR Licensing Agreement and April 2024 CVR Licensing Agreement collectively account for the total Intellectual Property CVR. The total amount of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ngne:IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" scale="6" id="f-410">0.9</ix:nonFraction> million due under the Intellectual Property CVR was offset by approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ngne:IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" scale="6" id="f-411">0.4</ix:nonFraction> million due to permitted deductions under the Merger Agreement and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="ngne:AssetAcquisitionContingentConsiderationCashPayment" scale="6" id="f-412">0.5</ix:nonFraction> million was paid to the CVR holders as discussed below. As of March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="6" id="f-413">0.3</ix:nonFraction> million is recorded within the contingent value rights liability on the Company&#8217;s condensed consolidated balance sheet arising from offsets to permitted deductions to the Intellectual Property CVR that were incurred subsequent to the CVR payment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Tax CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Closing, Neoleukin entered into an agreement with an unrelated third party for refund analysis services of Washington state sales tax. As discussed and defined within the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Value Right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the terms of the CVR Agreement include that CVR holders are eligible to receive net proceeds derived from an anticipated sales tax refund from Washington state relating to tax returns filed by Neoleukin prior to Closing. As of March&#160;31, 2025, it was deemed probable that the Company will receive proceeds from Washington state for the sales tax refund and will remit the proceeds to the CVR holders. As of March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="6" id="f-414">0.4</ix:nonFraction> million is accrued as a component of the contingent value rights liability arising from the Sales Tax CVR in the condensed consolidated balance sheet.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CVR Payment</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company made the first CVR payment to CVR holders, net of expenses, for $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="ngne:AssetAcquisitionContingentConsiderationCashPayment" scale="6" id="f-415">0.6</ix:nonFraction> million. $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="ngne:AssetAcquisitionContingentConsiderationCashPayment" scale="6" id="f-416">0.5</ix:nonFraction> million was applied to the Intellectual Property CVR and $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="ngne:AssetAcquisitionContingentConsiderationCashPayment" scale="6" id="f-417">0.1</ix:nonFraction> million was applied to the Lease CVR, reducing the respective liabilities. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock" id="f-418" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the contingent value rights liability in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.272%"><tr><td style="width:1.0%"/><td style="width:41.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease CVR</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="f-419">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" id="f-420">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="f-421">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" id="f-422">718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property CVR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="f-423">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="f-425">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Tax CVR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="f-427">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" id="f-429">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CVR liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-431">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" id="f-432">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-433">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" id="f-434">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the CVR Agreement, the total amount owed to CVR holders, after deductions permitted under the Merger Agreement, must be at least $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ngne:AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" scale="6" id="f-435">0.5</ix:nonFraction> million to trigger a CVR payment prior to the end of the CVR term. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other payments under the CVR Agreement were not considered probable and estimable as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and therefore no additional contingent consideration liability has been recorded. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will evaluate the probable and estimable range of outcomes under the CVR Agreement at each reporting period until the end of the CVR term and adjust the amounts accrued for as necessary.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has employment and consulting agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Development Arrangements </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had standing agreements with consultants, contractors or service providers that generally can be terminated by the Company with 30 to 60 days written notice, unless otherwise indicated.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-359-4"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Legal Proceedings</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to litigation and other claims that arise in the ordinary course of business. While the ultimate result of outstanding legal matters cannot presently be determined, the Company does not expect that the ultimate disposition will have a material effect on its results of financial condition, results of operations or cash flows. However, legal matters are inherently unpredictable and subject to significant uncertainties, some of which are beyond the Company&#8217;s control. As such, there can be no assurance that the final outcome of any particular legal matter will not have a material adverse effect on the Company&#8217;s financial condition results of operations or cash flows.</span></div></ix:continuation><div id="i2c10432fd4514957b2f0bdfad1948d4e_64"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-436" continuedAt="f-436-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Licenses</span></ix:nonNumeric></div><ix:continuation id="f-436-1" continuedAt="f-436-2"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with The University of Edinburgh</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the University Court of the University of Edinburgh (the &#8220;University of Edinburgh&#8221;) and Neurogene entered into the Master Collaboration Agreement (&#8220;MCA&#8221;). Under the MCA, Neurogene and the University of Edinburgh agreed to collaborate on certain research and development projects (&#8220;Projects&#8221;) and Neurogene agreed to provide funding for such Projects for a <ix:nonNumeric contextRef="c-93" name="ngne:CollaborativeArrangementRightsAndObligationsTerm" format="ixt-sec:durmonth" id="f-437">40</ix:nonNumeric>-month initial term,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which term was extended in November 2023 for an additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-94" name="ngne:CollaborativeArrangementRightsAndObligationsAdditionalTerm" format="ixt-sec:durmonth" id="f-438">33</ix:nonNumeric></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months and may be further extended by mutual agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In exchange for such funding, the University of Edinburgh granted Neurogene the option to exclusively license any intellectual property arising from such Projects. If Neurogene exercises an exclusive option for a particular Project, Neurogene will enter into a separate exclusive license agreement on its own terms with the University of Edinburgh. Under the MCA, Neurogene is obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the <ix:nonNumeric contextRef="c-93" name="ngne:CollaborativeArrangementRightsAndObligationsTerm" format="ixt-sec:durmonth" id="f-439">40</ix:nonNumeric>-month period. Either party may terminate the MCA for convenience upon <ix:nonNumeric contextRef="c-93" name="ngne:ResearchCollaborationAndLicenseAgreementOptionToTerminate" format="ixt-sec:durday" id="f-440">90</ix:nonNumeric> days&#8217; notice. If Neurogene terminates the MCA, it would be responsible for all non-cancellable costs and commitments related to any particular Project and any and all funding costs for any person working on such Project. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Neurogene exercised its option through the collaboration under the MCA and entered into a License Agreement (the &#8220;March 2022 Edinburgh License Agreement&#8221;) with the University of Edinburgh, pursuant to which Neurogene licensed certain patents and know-how related to the EXACT technology and optimized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MECP2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cassettes on an exclusive basis. Under the March 2022 Edinburgh License Agreement, Neurogene obtained an exclusive, worldwide license to the licensed patents to develop, manufacture, supply, sell, and commercialize any products that utilize the licensed patents (the &#8220;Licensed Products&#8221;) in exchange for low single-digit percentage royalties on future commercial net sales of the Licensed Products. Royalties are payable on a Licensed Product-by-Licensed Product and country-by-country basis until the latest of the expiration of the last licensed patent covering such Licensed Product in the country where the Licensed Product is sold, or, if no licensed patent exists or has expired in such country, then ten years from first commercial sale of such Licensed Product in such country. In connection with the license, Neurogene is also obligated to pay the University of Edinburgh up to $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-441">5.3</ix:nonFraction> million in regulatory-related milestones and up to $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-442">25.0</ix:nonFraction> million in sales-related milestones based on annual net sales of Licensed Products in excess of defined thresholds. During the year ended December 31, 2023, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsExpense" scale="6" id="f-443">0.3</ix:nonFraction> million for a milestone related to the first patient dosing in the Phase 1/2 trial for Rett syndrome.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, Neurogene and University of Edinburgh amended the MCA. Under the amended MCA, Neurogene and University of Edinburgh agreed to continue collaborating on certain Projects and Neurogene agreed to provide funding for such Projects through December 2026, or an additional <ix:nonNumeric contextRef="c-94" name="ngne:CollaborativeArrangementRightsAndObligationsAdditionalTerm" format="ixt-sec:durmonth" id="f-444">33</ix:nonNumeric> months. Neurogene is obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the entire period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2025 and 2024, the expense recorded by the Company related to the MCA was $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" scale="6" id="f-445">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" scale="6" id="f-446">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Virovek</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Neurogene entered into a Non-Exclusive License Agreement with Virovek, Inc., pursuant to which Neurogene has a license to use certain patents and know-how on a non-exclusive basis related to Neurogene&#8217;s baculovirus (&#8220;baculo&#8221;) process in exchange for low single-digit percentage royalties on future commercial net sales of each product using the baculo process, development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-447">0.2</ix:nonFraction> million in the aggregate, and a nonrefundable annual license fee. During the three months ended March 31, 2025, <ix:nonFraction unitRef="usd" contextRef="c-101" decimals="INF" name="ngne:CollaborativeArrangementRightsAndObligationsExpense" format="ixt:fixed-zero" scale="0" id="f-448">no</ix:nonFraction> milestone expense was recorded. During the three months ended March 31, 2024, the Company recorded a milestone expense of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsExpense" scale="6" id="f-449">0.1</ix:nonFraction> million for the Rett Syndrome Investigational New Drug filing. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-436-2"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Sigma-Aldrich Co</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Neurogene entered into a Non-Exclusive License Agreement with Sigma-Aldrich Co. LLC, pursuant to which Neurogene has a license to certain patents and know-how on a non-exclusive basis related to certain cell lines used in Neurogene&#8217;s baculo process in exchange for a small annual fee on a product-by-product basis, payable once the first product candidate enters the clinic. In addition, on a product-by-product basis, Neurogene is obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" scale="6" id="f-450">2.5</ix:nonFraction> million in the aggregate for development-related milestones. The Company recorded a license expense of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-4" name="ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" scale="6" id="f-451">0.06</ix:nonFraction> million for the three months ended March 31, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-4" name="ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" scale="6" id="f-452">0.06</ix:nonFraction> million for the three months ended March 31, 2024.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Stanford</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into a Nonexclusive License Agreement with the Board of Trustees of Leland Stanford Junior University (the &#8220;Stanford License Agreement&#8221;) to license, on a non-exclusive basis, certain biological materials used by the Company in the manufacturing process of Neurogene&#8217;s product candidates, including NGN-401. Over the <ix:nonNumeric contextRef="c-106" name="ngne:CollaborativeArrangementTermOfAgreement" format="ixt-sec:duryear" id="f-453">10</ix:nonNumeric>-year term of the Stanford License Agreement, the Company is obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" scale="6" id="f-454">0.5</ix:nonFraction> million in licensing fees. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expenses were recorded related to other in-process license agreements during the three months ended March 31, 2025 and 2024. None will be due under these agreements unless and until certain development milestones are reached.</span></div></ix:continuation><div id="i2c10432fd4514957b2f0bdfad1948d4e_67"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-455" continuedAt="f-455-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Stockholders&#8217; Equity (Deficit)</span></ix:nonNumeric></div><ix:continuation id="f-455-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock and pre-funded warrants</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company&#8217;s board of directors approved the Neurogene Inc. 2025 Inducement Plan, which reserves for issuance up to <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-456">500,000</ix:nonFraction> shares of common stock underlying inducement awards.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has pre-funded warrants outstanding to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-457">6,124,996</ix:nonFraction> shares of common stock as of March&#160;31, 2025. The pre-funded warrants are exercisable at any time for exercise prices ranging from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-29" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-458">0.000001</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-459">0.001</ix:nonFraction>, except that the pre-funded warrants cannot be exercised by a holder if, after giving effect thereto, such holder would beneficially own more than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ngne:PercentageOfOutstandingStockPerStockholderMaximum" scale="-2" id="f-460">9.99</ix:nonFraction>% of the outstanding common stock, subject to certain exceptions. However, any holder may increase or decrease such percentage to any other percentage (not in excess of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ngne:PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" scale="-2" id="f-461">19.99</ix:nonFraction>%) upon at least <ix:nonNumeric contextRef="c-1" name="ngne:ClassOfWarrantOrRightNoticePeriod" format="ixt-sec:durday" id="f-462">61</ix:nonNumeric> days&#8217; prior notice from the holder to the Company. The holders of the pre-funded warrants will not have the right to vote the shares underlying the pre-funded warrants on any matter except to the extent required by <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-463" continuedAt="f-463-1" escape="true">Delaware law. These warrants were classified as equity. Information on the outstanding warrants is as follows: </ix:nonNumeric></span></div><ix:continuation id="f-463-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:29.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Type of Financing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-464">0.000001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="0" name="ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" format="ixt:num-dot-decimal" scale="0" id="f-465">425,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy pre-funded warrants outstanding</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-466">0.000001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" format="ixt:num-dot-decimal" scale="0" id="f-467">1,708,332</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023 Preferred stock conversion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-468">0.000001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" format="ixt:num-dot-decimal" scale="0" id="f-469">1,825,635</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023 Pre-Closing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-470">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="0" name="ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" format="ixt:num-dot-decimal" scale="0" id="f-471">2,165,042</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2024 private placement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" format="ixt:num-dot-decimal" scale="0" id="f-472">6,124,996</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="ngne:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="f-473" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for future issuance as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:61.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-474">279,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-475">222,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-476">252,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-477">252,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-478">2,086,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-479">1,387,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2023 Equity Incentive Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-480">1,218,072</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-481">1,458,188</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2025 Inducement Plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-482">500,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="f-483">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future issuance under the 2023 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-484">321,770</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-485">173,223</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-funded warrants outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-486">6,124,996</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-487">6,124,996</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total common stock reserved</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-488">10,782,754</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-489">9,618,617</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-490" continuedAt="f-490-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Stock-Based Compensation</span></ix:nonNumeric></div><ix:continuation id="f-490-1" continuedAt="f-490-2"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-491" continuedAt="f-491-1" escape="true">The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-491-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:67.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.468%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-492">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-493">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-494">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-495">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-496">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-497">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-498" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option activity:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:56.604%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-499">1,387,556</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-500">28.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-501">7.80</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-502">725,191</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-503">16.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-504">1,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-505">10.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-506">24,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-507">35.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-508">2,086,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-509">24.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-510">8.36</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-511">655,763</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-512">22.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-513">6.34</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the aggregate intrinsic value of outstanding options and exercisable options was approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-514">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-515">0.7</ix:nonFraction> million, respectively. The aggregate intrinsic value of options exercised was immaterial for the three months ended March 31, 2025.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-516">12.78</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-517">25.97</ix:nonFraction> per share for the three months ended March&#160;31, 2025 and 2024, respectively. The Company recorded stock-based compensation related to stock options of approximately $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-518">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-519">1.0</ix:nonFraction> million for the three months ended March&#160;31, 2025 and 2024. As of March&#160;31, 2025, the total unrecognized compensation expense related to unvested stock option awards was approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-520">25.5</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="c-130" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-521">3.12</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><ix:continuation id="f-490-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-522" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option was estimated on the grant date using the weighted average assumptions in the table below:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:67.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.468%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-523">93.99</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-524">96.49</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-525">86.39</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-526">87.64</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-527">3.97</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-528">4.42</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-529">3.97</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-5" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-530">4.32</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-531">5.60</ix:nonNumeric>-<ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-532">6.96</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-533">5.77</ix:nonNumeric>-<ix:nonNumeric contextRef="c-135" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-534">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-537" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit (&#8220;RSU&#8221;) activity and related information for the three months ended March 31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:67.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.153%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-538">222,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-539">36.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-540">135,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-541">16.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-542">73,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-543">36.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-544">5,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-545">36.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-546">279,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-138" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-547">26.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSUs of approximately $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-548">0.6</ix:nonFraction> million for the three months ended March 31, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-549">0.1</ix:nonFraction> million for the three months ended March 31, 2024. As of March&#160;31, 2025, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-550">7.2</ix:nonFraction> million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately <ix:nonNumeric contextRef="c-137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-551">2.26</ix:nonNumeric> years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-552" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A summary of the Company&#8217;s performance stock unit (&#8220;PSU&#8221;) activity and related information for the three months ended March 31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:63.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-553">252,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-554">36.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-561">252,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-562">36.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSUs were granted with vesting in <ix:nonFraction unitRef="tranche" contextRef="c-114" decimals="INF" name="ngne:ShareBasedPaymentArrangementNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-563">two</ix:nonFraction> equal tranches based on certain performance conditions. Each PSU entitles the holder to receive <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="0" name="ngne:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" format="ixt-sec:numwordsen" scale="0" id="f-564">one</ix:nonFraction> share of the Company's common stock when the PSU vests. Stock-based compensation expense for PSUs will be recognized when it is probable that the performance conditions will be achieved. As of March&#160;31, 2025, the performance conditions underlying the first tranche of <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="ngne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" format="ixt:num-dot-decimal" scale="0" id="f-565">126,062</ix:nonFraction> PSUs were deemed probable of achievement for the first milestone and are currently considered probable to vest. The Company recorded stock-based compensation expense related to PSUs of approximately $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-566">1.6</ix:nonFraction> million for the three months ended March 31, 2025. As of March&#160;31, 2025, the second tranche of <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="ngne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" format="ixt:num-dot-decimal" scale="0" id="f-567">126,062</ix:nonFraction> PSUs were not deemed probable of achievement and are not currently considered probable to vest. As of March&#160;31, 2025, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-568">7.5</ix:nonFraction> million of unrecognized compensation cost related to PSUs.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_626"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-569" continuedAt="f-569-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Segment Information</span></ix:nonNumeric></div><ix:continuation id="f-569-1"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODMs in deciding how to allocate resources and in assessing performance. The Company&#8217;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-570"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-571">one</ix:nonFraction></ix:nonFraction> reportable segment. In addition to reviewing the expenses in the consolidated statement of operations, the CODMs are provided with research and development costs for Rett syndrome, Batten disease, Early Discovery and Discontinued Programs, as well as categorized general and administrative expenses. The research and development programs are considered significant by the Company. The CODM assesses the financial performance of the segment and decides how to allocate resources based on net loss on a consolidated basis. The measure of segment assets is reported on the consolidated balance sheets as total consolidated asset</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODMs also assess performance of the segment according to preclinical and clinical data, the stage of development of the research and development programs, along with program specific expenses and market conditions in the pharmaceutical and biotechnology sectors. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-572" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and 2024, the Company did not have any significant long-lived assets located outside of the United States. Information on the segment and reconciliation to net loss is as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:58.333%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.868%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program specific expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rett syndrome</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-573">4,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-574">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batten disease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-575">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-576">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early Discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-577">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-578">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated internal expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-579">5,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-580">4,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-581">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-582">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-583">3,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-584">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-585">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-586">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-587">17,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-588">13,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative specific expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-589">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-590">2,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-591">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-592">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional and consultant fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-594">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-595">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-596">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-597">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-598">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-599">8,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-600">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-601">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-602">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-603">22,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-604">16,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other expense segment items category within research and development expense is mainly comprised of: Consultant fees for programs not specified above, IT Software and network support and rent expenses. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other expense segment items category within general and administrative expense is mainly comprised of: Insurance, IT software and network support, market research, and tax expenses.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) included in net loss includes interest income, interest expense, other income and other expense.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-605" continuedAt="f-605-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Subsequent Events</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-605-1"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2025, the Company entered into an exchange agreement with existing stockholders to exchange an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-606">667,500</ix:nonFraction> shares of the Company&#8217;s common stock for an aggregate of pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-607">667,563</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-165" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-608">0.001</ix:nonFraction> per share.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From April 1, 2025 until the financial statements were issued, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-609">7,695</ix:nonFraction> options to employees.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt;text-align:center;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROGENE MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited interim condensed consolidated financial </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and notes thereto included elsewhere in this report and our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December&#160;31, 2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, include forward-looking statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results or outcomes, or the timing of our results or outcomes, could differ materially from the results or outcomes described in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of the Annual Report on Form 10-K as well as the risk factors included in Part II, Section 1A of this Quarterly Report on Form 10-Q to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. Except as required by law, we do not undertake any obligation to revise or update publicly any forward-looking statements after completion of the filing of this Quarterly Report on Form 10&#8209;Q to reflect later events or circumstances or to reflect the occurrence of unanticipated events, or otherwise.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this section, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and &#8220;the Company&#8221; refer to post-merger Neurogene Inc. and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">our wholly owned subsidiary incorporated in the state of Nevada, also named Neurogene Inc. (&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurogene OpCo&#8221;), unless otherwise indicated.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_79"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming these limitations and turning today&#8217;s complex devastating neurological diseases into treatable conditions. By harnessing our proprietary transgene regulation technology, EXACT</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Expression Attenuation via Construct Tuning), we are building a robust and differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet need not otherwise addressable by conventional gene therapy. Our EXACT approach leverages key scientific breakthroughs, including gene transfer technology, microRNA-based genetic circuits, and adeno-associated virus (&#8220;AAV&#8221;) delivery, and is designed to deliver therapeutic levels of transgene to key areas of the brain that underlie neurological disease pathology.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first clinical-stage program to utilize the EXACT platform is NGN-401, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. We are conducting a Phase 1/2 open-label, multi-center clinical trial of NGN-401 gene therapy for the treatment of female patients with classic Rett syndrome that is assessing the safety, tolerability, and efficacy of NGN-401 at a dose of 1E15 vg. The trial is evaluating NGN-401 in eight pediatric participants ages 4-10 years old and in a pilot cohort of three participants ages 11 years and older. Clinical grade NGN-401 was manufactured at our manufacturing facility and is being used for dosing in the Phase 1/2 clinical trial. NGN-401 is delivered using a one-time intracerebroventricular (&#8220;ICV&#8221;) procedure, which we believe is the most suitable route of administration to achieve optimal biodistribution in key regions of the brain and other parts of the nervous system that underlie Rett syndrome pathophysiology.   </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received clearance of our Investigational New Drug (&#8220;IND&#8221;) application by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in January 2023, and the clinical trial has since been initiated in the United Kingdom (&#8220;UK&#8221;) and Australia. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants have been dosed in all three regions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we announced positive interim clinical data in participants receiving the 1E15 vg dose (n=4 for efficacy data; n=5 for safety data) in the Phase 1/2 clinical trial with a data cut-off date of October 17, 2024. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The baseline demographics of the first five participants who received the 1E15 vg dose NGN-401 include:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><img src="ngne-20250331_g1.jpg" alt="1E15 vg image.jpg" style="height:285px;margin-bottom:5pt;vertical-align:text-bottom;width:636px" id="i-1"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*CGI-S = Clinician Global Impression-Severity</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent, concordant and durable improvements were observed as measured from baseline across multiple Rett syndrome clinical assessments. Participants also achieved meaningful gains of skills and developmental milestones in hand function, gross motor, and communication, all of which are core clinical domains of Rett syndrome. These gains of skills and developmental milestones are not expected to occur when compared and contextualized against the natural history of Rett syndrome. Additionally, objective improvements in autonomic function were recorded.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent improvements were observed in the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><img src="ngne-20250331_g2.jpg" alt="Heatmap.jpg" style="height:236px;margin-bottom:5pt;vertical-align:text-bottom;width:636px" id="i-2"/></div><div style="margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Each participant achieved a 2-point improvement or &#8220;much improved&#8221; from baseline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also announced safety and tolerability data from the Phase 1/2 clinical trial as of the data cut-off date of October 17, 2024. We believe that NGN-401 has been generally well-tolerated at the 1E15 vg dose. There continue to be no signs or symptoms indicating MeCP2 overexpression toxicity. In November 2024, we also shared that we had gained alignment with the FDA on our potency assay strategy and CMC scale-up planning for the program.We continue to expect to provide an update on safety and efficacy data in the second half of 2025, and therefore we do not plan to share interim data updates from the trial before that time. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to share information about our registrational study in the first half of 2025.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we also announced that post-data cut-off date of October 17, 2024, the third participant receiving a 3E15 vg dose of NGN-401 (high dose) in the trial died following complications from a rare hyperinflammatory syndrome associated with systemic exposure to high doses of AAV, and we discontinued use of that dose level. Hyperinflammatory syndromes can include hemophagocytic lymphohistiocytosis (&#8220;HLH&#8221;) and multisystem inflammatory syndrome. Based on research we conducted related to hyperinflammatory syndromes and AAV gene therapy, HLH has only been reported following doses of AAV that are generally in the 1E14 vg/kg range or higher. The 1E15 vg dose level we are moving forward in the trial translates into the E13 vg/kg range, and we are not aware of any case of HLH ever being reported at this dose level.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, we updated our Phase 1/2 protocol to remove the 3E15 vg dose from the trial, and we are currently enrolling participants. Despite our research related to hyperinflammatory syndromes and AAV gene therapy showing that HLH has only been reported following doses of systemic AAV that are higher than the 1E15 vg dose level, in an abundance of caution, we have incorporated into our protocol additional monitoring for markers using the HLH diagnostic criteria, such as ferritin, and a treatment algorithm. When administered early, this treatment algorithm has been used successfully to treat cases of HLH both in AAV gene therapy and other known causes of HLH.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we announced that NGN-401 was one of four sponsors selected by the Center for Biologics Evaluation and Research at the FDA to participate in the FDA&#8217;s Support for clinical Trials Advancing Rare disease Therapeutics (&#8220;START&#8221;) Pilot Program based on potential for clinical benefits and clinical development program readiness. As part of the START Program, we have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401&#8217;s development. These opportunities are designed to provide frequent advice and regular ad-hoc conversations to address product-specific development issues, including, but not limited to, clinical study design, choice of control group and fine-tuning the choice of patient population. In August 2024, we announced that NGN-401 also received Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation from the FDA. RMAT designation is granted for regenerative medicines intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and with preliminary clinical evidence that indicates that the drug has the potential to address unmet medical needs. Benefits of the RMAT designation program include all the benefits of Fast Track and Breakthrough Therapy designation programs, including early and frequent communications with FDA senior managers, intensive guidance on efficient drug development and eligibility for an Accelerated Approval pathway and Priority Review.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our EXACT platform has broad applicability in complex neurological diseases not otherwise easily addressable by conventional gene therapy. In addition to our Rett syndrome program, we are in the early discovery stage for other potential programs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to NGN-401, we have also been pursuing a conventional gene therapy program in a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n ongoing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 1/2 clinical trial of NGN-101 for the treatment of CLN5 Batten disease. This patient population has a significant unmet need and experiences extensive neurological and physical impairment leading to blindness, loss of motor function and early mortality. Our Phase 1/2 clinical trial of NGN-101 was the first trial to assess the treatment of both neurodegenerative and ocular disease manifestations of Batten disease. In November 2024, we announced that we do not expect to move forward with the NGN-101 CLN5 Batten disease gene therapy program at this time. Given the rarity of the disease, continued investment in the program was predicated on alignment on a streamlined registrational pathway with the FDA. To support a streamlined pathway, we submitted an RMAT application to the FDA. Despite our belief that we met the standard of preliminary clinical evidence required to obtain an RMAT designation, the RMAT application was denied. We are currently evaluating options for the program. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also established a fully operational </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current good manufacturing practices (&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMP&#8221;) facility in Houston, Texas used to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture current and future product for research, toxicology and clinical studies. We believe that our in-house manufacturing capabilities better enable control of product quality and development timelines, strategic pipeline and financial flexibility, and clinical-to-commercial continuity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Background</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in 2018, and have devoted substantially all of our resources to conducting research and development activities (including with respect to the&#160;NGN-401&#160;and&#160;NGN-101&#160;programs) and undertaking preclinical studies, establishing our manufacturing facility, conducting clinical trials and the manufacturing of product used in our clinical trials and preclinical studies, business planning, developing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily with outside capital (e.g., proceeds from the sale of preferred stock and common stock) and have raised aggregate net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$521.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from these private placements. However, we have incurred significant recurring losses, including a net loss of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. In addition, as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had an accumulated deficit of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$284.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and cash, cash equivalents and short-term investments totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$292.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In order to continue our operations, we must achieve profitable operations and/or obtain additional equity or debt financing. Until we achieve profitability, management plans to fund our operations and capital expenditures with cash on hand and the sale and issuance of securities. There can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we may be compelled to consider actions such as reducing the scope of our operations and planned capital expenditures or selling certain assets, including intellectual property assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses may fluctuate significantly from&#160;quarter-to-quarter&#160;and&#160;year-to-year,&#160;depending on a variety of factors, including the timing, scope and results of our research and development activities. Management expects that our expenses and capital requirements will increase substantially in connection with our ongoing activities as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance the NGN-401 program through clinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance discovery programs from preclinical development into and through clinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish sales, marketing and distribution infrastructure to commercialize any approved product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish a commercialization infrastructure and scale up internal and external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expand clinical, scientific, management and administrative teams;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">implement operational, financial and management systems; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">incur additional legal, accounting and other expenses related to operating as a public company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for commercial sale and have not generated any commercial revenue from product sales. Our ability to generate product revenue sufficient to achieve and maintain profitability will depend upon the successful development and eventual commercialization of one or more of our product candidates, which we expect, if it ever occurs, will take many years. We expect to spend a significant amount in development and marketing costs prior to such time. We will therefore require substantial additional capital to develop our product candidates and support our continuing operations. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our preclinical and clinical trials. In November 2024, we announced that the Company does not expect to move forward with the NGN-101 CLN5 Batten disease gene therapy program at this time. Given the rarity of the disease, continued investment in the program was predicated on alignment on a streamlined registrational pathway with the FDA. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support a streamlined pathway, we submitted an RMAT application to the FDA. Despite our belief that the application met the standard of preliminary clinical evidence required to obtain an RMAT designation, the RMAT application was denied. We are currently evaluating options for the program. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future elect to discontinue, delay, or modify additional preclinical and clinical trials of our other product candidates. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time that we can generate a sufficient amount of revenue from product sales or other sources, if ever, management expects to finance our operations through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. However, we may be unable to raise additional capital from these sources on favorable terms, or at all. Our failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to delay, reduce or curtail our research, product development or future commercialization efforts. We may also be required to license rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. Our management cannot provide assurance that we will ever generate positive cash flow from operating activities. See &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into the Master Research Collaboration (&#8220;MCA&#8221;) with the University Court of the University of Edinburgh (the &#8220;University of Edinburgh&#8221;) to support our pipeline development and expansion, and to accelerate scientific innovation to continue to improve upon conventional gene therapy. In November 2023, the collaboration agreement was amended and extended through December 2026. The University of Edinburgh has a vibrant community of over 500 neuroscience researchers and is widely recognized as a preeminent center for neuroscience research, especially in areas of neurodegeneration and in neurodevelopmental disorders, such as Rett syndrome. For example, researchers currently in neuroscience centers at the University of Edinburgh conducted the seminal preclinical work for Rett syndrome, including discovery of the MeCP2 protein, its function as a transcriptional repressor, developing the first and most widely adopted animal model of Rett syndrome, demonstrating for the first time the reversibility of phenotypes in any neurodevelopmental disorder as well as the first ever preclinical gene therapy efforts in Rett syndrome. Under the terms of the agreement, we have the option to&#160;in-license&#160;product candidates from Dr.&#160;Stuart Cobb&#8217;s laboratory. Dr. Cobb is a Professor in Translational Neuroscience at the Patrick Wild Centre and the Centre for Discovery Brain Sciences at the University of Edinburgh and also serves as our Chief Scientific Officer. Due to his position with the University of Edinburgh, he may be entitled to receive in the future a percentage of certain license-related payments from Neurogene to the University of Edinburgh in accordance with the University of Edinburgh&#8217;s standard policies for professor inventors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Global Economic Events</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in the global economy presents significant risks to our business. We are subject to continued risks and uncertainties related to the current macroeconomic </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including high inflation, high interest rates, changes in foreign currency exchange rates, changes in trade policies, including the implementation of tariffs, sanctions, export or import controls and other actions or the threat of such actions that restrict international trade by the United States, China or other countries, changes in domestic and global monetary and fiscal policy, volatility in financial markets, rapid changes in our regulatory landscape in the United States, including significant staffing reductions, unexpected shifts in leadership of certain federal agencies, and an uncertain legislative environment, recent bank failures, proposed or adopted federal U.S. legislation seeking to limit the provision of services in our sector by certain non-U.S. entities, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, the impacts of climate change, and supply chain disruptions. While management is closely monitoring the impact of the current macroeconomic conditions on aspects of our business, including the impacts on our participants in our clinical trials, employees, suppliers, vendors and business partners, the ultimate extent of the direct and indirect impacts on our business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside of our control and could exist for an extended period of time. Management will continue to evaluate the nature and extent of the potential impacts to our business, results of operations, liquidity and capital resources. For additional information, see the section entitled &#8220;Risk Factors.&#8221;</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_88"></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale and have never generated any revenue from product sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated licensing revenue from the recognition of upfront payments received under agreements with third parties for the disposition of legacy Neoleukin assets (the &#8220;December 2023 CVR Licensing Agreement&#8221; and the &#8220;April 2024 CVR Licensing Agreement&#8221;) that are related to the legacy Neoleukin business as part of the reverse merger. See Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details regarding these licensing agreements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred, including:</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct the necessary discovery-stage laboratory work, preclinical studies and clinical trials required to obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquired licenses and intellectual property that are accounted for as asset acquisitions and have no alternative future use;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel expenses, including salaries, benefits and stock-based compensation expense for our employees engaged in research and development functions;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research performed by third parties, including pursuant to agreements with clinical research organizations (&#8220;CROs&#8221;) that conduct our clinical trials, as well as investigative sites, consultants and CROs that conduct our preclinical and nonclinical studies;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with our third-party contract development and manufacturing organizations (&#8220;CDMOs&#8221;), as well as internal manufacturing&#160;scale-up&#160;expenses, including the cost of acquiring and manufacturing preclinical study and clinical trial materials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants who assist with research and development activities;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to regulatory activities, including filing fees paid to regulatory agencies; and</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated expenses for facility costs, including rent, utilities, depreciation and maintenance.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a product receives regulatory approval, we record upfront and milestone payments to third parties under licensing arrangements as expense, provided that there is no alternative future use of the rights in other research and development projects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-refundable&#160;prepayments for research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided. Costs for certain development activities, such as outside research programs funded by us, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense as applicable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track outsourced development costs and other external research and development costs to specific product candidates on a&#160;program-by-program&#160;basis, including fees paid to CROs, CDMOs and research laboratories in connection with our preclinical development, process development, and clinical development activities. We also incur personnel and other operating expenses for research and development programs, which are presented in aggregate.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including stock-based compensation, conduct clinical trials, including later-stage clinical trials for current and future product candidates, and prepare regulatory filings for our product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense, for employees and consultants in executive, finance and accounting, legal, operations support, information technology and human resource functions. General and administrative expenses also include corporate facility costs not otherwise included in research and development expense, including rent, utilities, depreciation and maintenance, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting services.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense will increase in the future to support our continued research and development activities and potential commercialization efforts. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, legal support and accountants, among other expenses. If any of our current or future product candidates obtains U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team, as well as an expanded regulatory and compliance function.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our cash equivalents and short-term investments. We expect our interest income to fluctuate depending on interest rates and the amount of cash that is invested.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our income tax positions and record tax benefits based upon management&#8217;s evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, we record the amount of tax benefit with a greater than 50&#160;percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions for which it is not more likely than not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have not recorded any income tax benefits for net operating losses (&#8220;NOLs&#8221;) or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. Accordingly, we have established a valuation allowance against such deferred tax assets for all periods since inception.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had federal and state NOL carryforwards in the amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$319.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, which may be available to offset future taxable income. The state NOL carryforwards will begin to expire in 2038, unless previously utilized. Most federal NOL carryforwards were generated subsequent to January 1, 2018, and therefore are able to be carried forward indefinitely. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we also had federal research tax credit and federal orphan drug tax credit carryforwards of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, which may be used to offset future tax liabilities. These tax and orphan drug credit carryforwards begin to expire in 2039 and 2043, respectively, unless previously utilized.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_91"></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Months Ended March&#160;31, 2025 and 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated (in thousands):</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.212%"><tr><td style="width:1.0%"/><td style="width:59.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,779)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,921)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,726)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the periods indicated (in thousands):</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:59.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.482%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program specific expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rett syndrome</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batten disease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early Discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated internal expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,541&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $17.8 million&#160;for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to the Rett syndrome program increased primarily due to a $1.2 million increase in preclinical costs, $0.6 million increase in clinical trial costs related to the Phase 1/2 clinical trial of NGN-401 and a $0.5 million increase in chemistry, manufacturing and controls costs. The decrease in expenses related to the Batten disease program was primarily driven by a $0.3&#160;million decrease in clinical trial costs for the Phase 1/2 clinical trial of&#160;NGN-101. The decrease in expenses related to the Early Discovery program was primarily driven by a $0.1&#160;million decrease in preclinical costs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in unallocated internal expenses was driven primarily by higher salaries, benefits, and stock-based compensation costs due to an increase in research and development headcount, as well as an increase in consulting costs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development and, as we continue to develop additional product candidates, build our manufacturing capabilities and develop our EXACT technology. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the periods indicated:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"/><td style="width:56.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative specific expenses: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional and consultant fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $8.2&#160;million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024. The increase was primarily attributable to: (i) an increase of approximately $0.4 million in personnel-related expenses driven by an increase in headcount to support business operations, (ii) an increase of approximately $2.0 million in stock-based compensation expense, driven by an increase in headcount as well as by an increase of approximately $1.3 million related to PSUs as the first underlying performance condition was deemed probable of achievement and currently considered probable to vest, and (iii) an increase in other costs of approximately $0.7 million related to corporate related expenses and market research costs, as well as to the recovery of approximately $0.3 million related to a business email compromise attack by a third party in the prior period. These expenses were partially offset by a decrease of approximately $0.2 million in professional services and consulting fees associated with the transition from a private company to a public company in the prior period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $0.9 million for the three months ended March 31, 2025, as compared to the three months ended March 31, 2024. The increase was primarily due to a significant increase in the amount of our cash, cash equivalents and short-term investments driven by the November 5, 2024 private placement, which was partially offset by a moderate decrease in interest rates.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses decreased by $0.5 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. The decrease was primarily due to approximately $0.6 million of accrual of contingent consideration liabilities related to the Intellectual Property CVR (as defined in Note 9, Commitments and Contingencies </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the notes to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in connection with the December 2023 Licensing Agreement and the April 2024 Licensing Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing for our product candidates to support commercialization and providing general and administrative support for our operations, including the costs associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements or other sources. We believe that our existing capital resources will be sufficient to fund our operations through at least 12 months following the filing date of this Form 10-Q. See the section entitled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had cash, cash equivalents and short-term investments totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$292.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since inception and through the issuance of these financial statements, we have funded our operations primarily through private placements of convertible preferred stock and common stock for net proceeds of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$521.9&#160;million.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that management believes will be necessary to commercialize product candidates, if approved, we will require substantial additional capital. Accordingly, until such time as we can generate a sufficient amount of revenue from product sales or other sources, if ever, management expects to seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. To the extent that we raise additional capital through equity financings or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, including restricting our operations and limiting our ability to incur liens, issue additional debt, pay dividends, repurchase our own common stock, make certain investments or engage in merger, consolidation, licensing, or asset sale transactions. If we raise capital through collaborations, partnerships, and other similar arrangements with third parties, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We may be unable to raise additional capital from these sources on favorable terms, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from macroeconomic conditions, geopolitical instability, government regulation and otherwise. The failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including by requiring us to delay, reduce or curtail our research, product development or future commercialization efforts. We may also be required to license rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. Management cannot provide assurance that we will ever generate positive cash flow from operating activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue our operations, we must achieve profitable operations and/or obtain additional equity or debt financing. Until we achieve profitability, management plans to fund our operations and capital expenditures with cash on hand and the sale and issuance of securities. We may not be successful in raising additional capital and such capital, if available, may not be on terms that are acceptable to us.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred, and expect to continue to incur, additional costs associated with operating as a public company. In addition, we anticipate that we will need substantial additional funding in connection with our continuing operations. Management bases its projections of operating capital requirements on our current operating plan, which includes several assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than management expects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our capital requirements. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, progress, results, and costs of researching and developing genetic medicines, and conducting larger and later-stage clinical trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, timing, progress, results, and costs of researching and developing other product candidates that we may pursue;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of attracting, hiring, and retaining skilled personnel to support our operations and continued growth;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to establish, maintain, and derive value from collaborations, partnerships or other marketing, distribution, licensing, or other strategic arrangements with third parties on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or&#160;in-license&#160;other product candidates and technologies, if any; and</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with operating as a public company.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other factors with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional capital to meet the capital requirements associated with such operating plans.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:70.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,774)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,650)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(45,045)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(65,815)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, we used $20.8 million of cash in operating activities. Cash used in operating activities reflected our net loss of $22.6 million, a $1.4 million net decrease in our operating assets and liabilities and noncash charges of $3.3 million, which consisted primarily of $4.0 million of stock-based compensation, $0.7 million in depreciation, partially offset by $1.7 million in accretion on the held-to-maturity investments. The primary use of cash was to fund our operations related to the development of our product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, we used $21.7&#160;million of cash in operating activities. Cash used in operating activities reflected our net loss of $16.9 million and a $6.7 million net decrease in our operating assets and liabilities, offset by non-cash charges of $2.0 million, which consisted primarily of $0.8 million in depreciation and $1.0 million in stock-based compensation. The primary use of cash was to fund our operations related to the development of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2025, net cash flows used in investing activities consisted of purchases of investments of $89.0 million and purchases of property and equipment of $0.8 million, partially offset by proceeds from maturities of short-term investments of $44.7 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net cash flows provided by investing activities consisted primarily of proceeds from the maturities of investments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, net cash flows provided by financing activities were insignificant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, net cash flows used in financing activities consisted of $4.3 million in offering costs paid in connection with the Pre-Closing Financing and $2.9 million in transaction costs related to the Reverse Merger (defined below), partially offset by proceeds of $0.6 million from the exercise of stock options.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_97"></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Headquarters Lease</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sub-lease approximately 6,000 square feet of office space for our corporate headquarters in New York, New York, with a term expiring in June 2026.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Houston Lease</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease 42,342 square feet for a manufacturing facility in Houston, Texas. The lease expires in August 2029. We have the option to renew the lease term for two additional five-year terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Blaine Lease in Seattle</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease approximately 33,300 square feet of office space in Seattle, Washington that was previously used by Neoleukin for offices, a laboratory for research and development, and related uses (the &#8220;Blaine Lease&#8221;). The lease expires on February 1, 2029, with the option to extend the lease for two five-year terms. The renewal periods were not included in the lease term for purposes of determining the lease liability.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eastlake Lease in Seattle</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease approximately 6,272 square feet of office space in Seattle, Washington, that was previously used by Neoleukin for additional office and laboratory space for research and development and related uses (the &#8220;Eastlake Lease&#8221;). The lease expires on September 30, 2026. We also assumed the existing agreement to sublease the Eastlake Lease to an unrelated third party (&#8220;Eastlake Sublease&#8221;). Pursuant to the terms of the Eastlake Sublease, we are entitled to receive a total of approximately $1.6 million in lease payments. The term of the sublease is through September 30, 2026.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each contingent value right (&#8220;CVR&#8221;) distributed pursuant to the CVR Agreement, dated December 18, 2023, by and between us and the Rights Agent (the &#8220;CVR Agreement&#8221;) contains the contractual right to receive </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain net savings, if any, realized by June 30, 2029 in connection with certain legacy lease obligations related to our business prior to the Reverse Merger (the &#8220;Lease CVR&#8221;).</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million was recorded as a component of the contingent value rights liability arising from the Lease CVR</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated balance sheet. The commitment relates to Neoleukin&#8217;s sublease agreement, effective October 31, 2023, for one of its properties with an unrelated third party for the remainder of the lease term. For more information on the Lease CVR, see Note 9, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Lease CVR</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the notes to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2023 CVR Licensing Agreement and April 2024 CVR Agreement collectively account for the total Intellectual Property CVR. As of March&#160;31, 2025, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.3 million was recorded within the contingent value rights liability as an offset arising from the Intellectual Property CVR on our condensed consolidated balance sheet due to deductions permitted under the Merger Agreement.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For more information on the Intellectual Property CVR, see Note 9, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Intellectual Property CVR</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the notes to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Tax CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of the Sales Tax CVR within the CVR Agreement, we accrued a contingent consideration liability on our condensed consolidated balance sheet. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the CVR Agreement include that CVR holders are eligible to receive certain net proceeds derived from an anticipated sales tax refund from Washington state relating to tax returns filed by Neoleukin prior to Closing. As of March&#160;31, 2025, the liability in the condensed consolidated financial statements arising from the Sales Tax CVR was $0.4 million.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For more information on the Sales Tax CVR, see Note 9, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Sales Tax CVR</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the notes to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the contingent value rights liability as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.000%"><tr><td style="width:1.0%"/><td style="width:40.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease CVR</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property CVR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Tax CVR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CVR liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development and Manufacturing Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with contract development and manufacturing organizations and development and clinical trial services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement. These obligations and commitments are not presented separately.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with The University of Edinburgh</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into the MCA with University of Edinburgh. Under the MCA, we and the University of Edinburgh agreed to collaborate on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain research and development projects (&#8220;Projects&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and we agreed to provide funding for such Projects for a 40-month initial term, which term was extended in November 2023 for an additional 33 months and may be further extended by mutual agreement. In exchange for such funding, the University of Edinburgh granted us the option to exclusively license any intellectual property arising from such Projects. Under the MCA, we are obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the 40-month period. Either party may terminate the MCA for convenience upon 90 days&#8217; notice. If we terminate the MCA, we would be responsible for all non-cancellable costs and commitments related to any particular Project and any and all funding costs for any person working on such Project.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we exercised our option through the collaboration under the MCA, and entered into a License Agreement (the &#8220;March 2022 Edinburgh License Agreement&#8221;) with University of Edinburgh, pursuant to which we licensed certain patents and know-how related to the EXACT technology and optimized </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MECP2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cassettes on an exclusive basis. Under the March 2022 Edinburgh License Agreement, we obtained an exclusive, worldwide license to the licensed patents to develop, manufacture, supply, sell, and commercialize any products that utilize the licensed patents (the &#8220;Licensed Products&#8221;) in exchange for low single-digit percentage royalties on future commercial net sales of the Licensed Products. Royalties are payable on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the expiration of the last licensed patent covering such Licensed Product in the country where the Licensed Product is sold, or, if no licensed patent exists or has expired in such country, then ten years from first commercial sale of such Licensed Product in such country (the &#8220;Royalty Term&#8221;). The term of the March 2022 Edinburgh License Agreement continues until the end of the Royalty Term and the expiration of all of the payment obligation thereunder. We may terminate the March 2022 Edinburgh License Agreement for convenience upon 90 days&#8217; notice. In connection with the license, we are also obligated to pay the University of Edinburgh up to $5.3 million in regulatory-related milestones and up to $25.0 million in sales-related milestones based on annual net sales of Licensed Products in excess of defined thresholds.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Virovek</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a Non-Exclusive License Agreement with Virovek, Inc., pursuant to which we have a license to use certain patents and know-how on a non-exclusive basis related to our baculovirus process in exchange for low single-digit percentage royalties on future commercial net sales of each product using the baculovirus process, development milestone payments of up to $0.2 million in the aggregate, and a nonrefundable annual license fee. This agreement continues until the later of (a) the expiration of the last to expire patent right that covers the manufacture, use, offer for sale, sale, importation, export or supply of any licensed product, (b) ten years after the first commercial sale of any licensed product, or (c) the expiration of all regulatory or market exclusivities. We may terminate this agreement for convenience upon 60 days&#8217; notice.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Sigma-Aldrich Co</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we entered into a Non-Exclusive License Agreement with Sigma-Aldrich Co. LLC, pursuant to which we have a license to certain patents and know-how on a non-exclusive basis related to certain cell lines used in our baculovirus process in exchange for a small annual fee on a product-by-product basis, payable once the first product candidate enters the clinic. In addition, on a product-by-product basis, we are obligated to pay up to $2.5 million in the aggregate for development-related milestones. This agreement remains in force for as long as we continue to possess and use the licensed technology. We may terminate this agreement for convenience upon 60 days&#8217; notice.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Stanford</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, we entered into a Nonexclusive License Agreement with the Board of Trustees of Leland Stanford Junior University (the &#8220;Stanford License Agreement&#8221;) to license, on a non-exclusive basis, certain biological materials used in the manufacturing process of our product candidates, including NGN-401. Over the 10-year term of the Stanford License Agreement, we are obligated to pay up to $0.5 million in licensing fees. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate this agreement for convenience upon 30 days&#8217; notice.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_100"></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance&#160;Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have, and did not have during the periods presented, any&#160;off-balance&#160;sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_103"></div><div style="margin-top:18pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared in accordance with U.S. GAAP. The preparation of the financial statements and related disclosures requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management evaluates estimates and assumptions on a periodic basis. Our actual results may differ from these estimates. A summary of our significant accounting policies is presented in Part II, Item 8 of our Annual Report on Form 10-K for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There have been no material changes to our significant accounting policies during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the notes to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_106"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K, we are not required to provide quantitative and qualitative disclosures about market risk.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_109"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the supervision and with the participation of our principal executive and our principal financial officer, our management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on management&#8217;s evaluation, our principal executive and our principal financial officer concluded that our disclosure controls and procedures are designed to, and are effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There have not been any changes in our internal control over financial reporting during the quarter ended March&#160;31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - Other Information</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_115"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time be named as a party to legal claims, actions and complaints, including matters involving employment, intellectual property or others. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_118"></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K before making an investment decision. The occurrence of any of the following risks could materially and adversely affect our business, financial condition, reputation, or results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment. It is not possible to predict or identify all such risks; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face. Moreover, some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events or contingencies have occurred in the past, and instead reflect our beliefs and opinions as to the factors, events or contingencies that could materially and adversely affect us in the future.</span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, and our results may vary from quarter to quarter.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception, expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products for sale, have not generated any product revenue and may never generate product revenue or become profitable.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NGN-401 and our other programs are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we or our current or future collaborators are unable to complete development of, or commercialize, our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">most advanced product candidate, NGN-401, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our ongoing and anticipated clinical trials of NGN-401 may not be successful.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in developing our manufacturing capabilities or failure to achieve operating efficiencies from such capabilities may require us to devote additional resources and management time to manufacturing operations and may delay our product development timelines.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a number of academic collaborations, and currently rely on our collaboration with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">University Court of the University of Edinburgh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for certain aspects of our preclinical research and development programs, including working in collaboration to discover and preclinically develop potential product candidates for our near-term future pipeline. Failure or delay of the University of Edinburgh or any other collaborator to fulfil all or part of its obligations under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of the relationship would materially harm our business.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval processes of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock may continue to be volatile.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be required to allocate resources to fulfilling the requirements of the Contingent Value Rights Agreement entered into in connection with the Reverse Merger related to certain legacy lease obligations which may take away from our core programs and create a distraction for our management and employees.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future sales of shares by existing stockholders could cause our stock price to decline.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, and our results may vary from quarter to quarter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with limited operating history. Since our inception in 2018, we have incurred significant operating losses and have used substantially all of our resources to conduct research and development activities, preclinical studies and Phase 1/2 clinical trials of our most advanced product candidates, establish&#160;in-house&#160;manufacturing capabilities, including analytical and process development operations to support ongoing manufacturing&#160;operations, manufacture product candidates, conduct business planning, develop and maintain our intellectual property portfolio, hire personnel, raise capital, and provide general and administrative support for these activities. We have limited experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, we cannot be certain that our current and planned clinical trials will begin on time, meet our anticipated timelines for enrollment and data analysis, or be completed on time, if at all. In addition, while we are conducting a Phase 1/2 clinical trial of NGN-401 in patients with Rett syndrome and have completed enrollment in a Phase 1/2 clinical trial of NGN-101 in patients with CLN5 Batten disease, we have not yet demonstrated our ability to successfully complete clinical trials (including Phase 3 or other pivotal clinical trials), obtain regulatory or marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with an early research and development focus to a company capable of supporting larger pivotal clinical trials and eventually commercial activities, including the manufacture of commercial scale product. We may not be successful in such a transition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing biotechnology products is a long, time-consuming, expensive and uncertain process that takes years to complete. Since our inception, we have funded our operations primarily through private financings and have incurred significant recurring losses, including a cumulative net loss from inception through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$284.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to conduct a Phase 1/2 clinical trial of NGN-401 in patients with Rett syndrome, with the expectation that we will also initiate additional clinical trials in the future, and continue to research, develop and conduct preclinical studies of our other potential product candidates. We also anticipate that we may have near term expenses related to NGN-101 as we continue to evaluate options for the program following the denial by the FDA of an RMAT designation, which precludes our ability to use a streamlined registrational pathway necessary for further investment in the program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we obtain regulatory approval for any product candidate for commercial sale,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> including&#160;NGN-401</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;we anticipate incurring significant commercialization expenses related to product manufacturing, marketing, sales and distribution activities to launch any such product. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Because the design and outcome of our current, planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. Our future capital requirements depend on many factors, including factors that are not within our control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to continue to incur additional costs associated with operating as a public company, and we do not anticipate achieving any significant revenue in the near term given the development stage of our product candidates. Accordingly, we will require substantial additional funding to continue our operations. Based on our current operating plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we believe that our existing cash, cash equivalents and short-term investments should be sufficient to fund our operations into the second half of 2027. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This estimate is based on assumptions that may prove to be materially wrong, and we could deplete our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and progress of preclinical and clinical development activities, including any impact to our NGN-401 clinical trial activities relating to our participation in the FDA&#8217;s Support for clinical Trials Advancing Rare disease Therapeutics (&#8220;START&#8221;) program and the Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) program;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and scope of preclinical and clinical programs we pursue to develop our gene therapy candidate pipeline and EXACT </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Expression Attenuation via Construct Timing)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to secure appropriate animal models for the conduct of investigational new drug (&#8220;IND&#8221;)-enabling studies in a timely and financially feasible manner, especially large animal models, such as non-human primates (&#8220;NHPs&#8221;) needed for toxicology studies;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish an acceptable safety profile with IND-enabling toxicology studies to enable clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful patient enrollment in, and the initiation and completion of, larger and later-stage clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of subjects that participate in clinical trials and per subject trial costs;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and extent of trials required for regulatory approval;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the countries in which the trials are conducted;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the length of time required to enroll eligible subjects in clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the drop-out and discontinuation rate of subjects;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the duration of subject participation in the trials and follow-up;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we encounter any serious adverse events in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of receipt of regulatory approvals from applicable regulatory authorities, including those required to initiate clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing, receipt and terms of any marketing approvals and post-marketing approval commitments from applicable regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we establish collaborations, strategic partnerships, or other strategic arrangements with third parties, if any, and the performance of any such third party;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scale up of our clinical and regulatory capabilities, including establishing our current good manufacturing practices (&#8220;cGMP&#8221;) manufacturing capabilities to support expansion of our pipeline and future registration-enabling clinical trials, and obtaining cGMP material for clinical trials or potential commercial sales;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hiring and retaining research, clinical, regulatory, manufacturing (including quality control and quality assurance) and administrative personnel;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our arrangements with third-party contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and contract research organizations (&#8220;CROs&#8221;);</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the outfitting and validation of our cGMP manufacturing facility;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external sources of funds, and adequate additional financing may not be available to us on acceptable terms, or at all. We may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Such financing may dilute our stockholders or the failure to obtain such financing may restrict our operating activities. Any additional fundraising efforts may divert our management from their&#160;day-to-day&#160;activities, which may adversely affect our business. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect your rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to future collaborations with third parties, we may have to relinquish valuable rights to product development programs, or grant licenses on terms that are not favorable to us. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all. Our ability to raise additional capital may be adversely impacted by global macroeconomic conditions, including rising interest rates, escalating trade tensions and restrictions, including tariffs, geopolitical instability, changes in government regulations and significant volatility in the credit and financial markets in the United States and worldwide, particularly in the biotechnology and biopharmaceutical industries, over which we may have no or little control. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate clinical trials, product development programs or future commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products for sale, have not generated any product revenue and may never generate product revenue or become profitable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in biotechnology product development is a highly speculative undertaking and entails substantial upfront expenditures and significant risks that any program will fail to demonstrate adequate efficacy or potency or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale, have not generated any revenue from product sales to date, and continue to incur significant research and development and other expenses related to our ongoing operations. We do not expect to generate product revenue unless or until we successfully complete clinical development and obtain regulatory approval of, and then successfully commercialize, at least one product candidate. We may never succeed in these activities and, even if we do, we may never generate product revenue or revenues that are significant or large enough to achieve profitability. If we are unable to generate sufficient revenue through the sale of any approved products, we may be unable to continue operations without additional funding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in each period since we commenced operations in 2018. Our net loss was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2025 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our cumulative net loss from inception as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$284.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to continue to incur significant losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance our existing and future programs through preclinical and clinical development, including expansion into additional indications;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to identify additional programs and additional product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue to develop our gene therapy product candidate pipeline and our EXACT platform;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain, expand, enforce, defend and protect our intellectual property portfolio;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek regulatory and marketing approvals for product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to identify, establish and maintain additional collaborations and license agreements, including those which may enhance the biodistribution and delivery of our product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ultimately establish a sales, marketing and distribution infrastructure to commercialize any biological products for which we may obtain marketing approval, either by ourselves or in collaboration with others;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">generate revenue from commercial sales of products for which we receive marketing approval;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hire additional personnel, including research and development, clinical and commercial;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">add operational, financial and management information systems and personnel to support further expansion and operation as a public company;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acquire or in-license products, intellectual property and technologies which may enhance our current technology; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish commercial-scale cGMP capabilities through our own or third-party manufacturing facilities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our expenses will increase if, among other things, we are required by the FDA or other regulatory authorities to perform trials or studies in addition to, or different than, those that we currently anticipate, there are any delays in completing our clinical trials or the development of any product candidates, or there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain marketing approval for, and are successful in commercializing, one or more product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional programs and/or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to become profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in our value could also cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop programs for the diseases we plan to address with&#160;NGN-401&#160;and&#160;other product candidates in development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of biological products is highly competitive. If approved, NGN-401&#160;or any other product candidates we may develop will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, NGN-401&#160;and any other product candidates we may develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K, our competitors have developed, are developing or may develop programs or clinical stage products competitive with&#160;NGN-401&#160;or our other earlier stage product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community for Rett syndrome and any new treatments for Rett syndrome. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy or potency, dosing and/or presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective or potent, have a more attractive or less invasive dosing profile or presentation or are less expensive than any products we may develop, or if competitors develop competing products that enter the market more quickly than we are able to, if we are able to at all, and are able to gain market acceptance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NGN-401&#160;and our preclinical programs are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our current or future collaborators are unable to complete development of, or commercialize, our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products on the market and NGN-401&#160;is in the early stages of clinical development. In addition, we announced that unless we are able to find an alternative pathway for advancement, we will need to discontinue our NGN-101 program following the denial of RMAT designation for NGN-101 by the FDA, which would preclude a streamlined path to regulatory approval. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other programs are in early stages of preclinical development. As a result, we expect it will be many years before we commercialize our product candidates and ultimately may not be successful in commercializing any of our product candidates. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, our lead product candidate&#160;NGN-401&#160;or other product candidates, either alone or with third parties, and we cannot guarantee that we will ever obtain regulatory approval for any product candidates we may develop. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience as a company in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA or comparable foreign regulatory authorities. We have not yet demonstrated our ability to obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety, purity and efficacy or potency in humans of such product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we announced that we do not expect to move forward with the NGN-101 gene therapy program for CLN5 Batten disease at this time. Given the rarity of the disease, continued investment in the program was predicated on alignment on a streamlined registrational pathway with the FDA. To support a streamlined pathway, we submitted an RMAT application to the FDA. Despite our belief that we met the standard of preliminary clinical evidence required to obtain an RMAT designation, the RMAT application was denied. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar challenges may prevent our success with or increase the cost of other current, planned or future clinical trials. We or our collaborators may experience delays in initiating or completing clinical trials, and also may experience unforeseen events during, or as a result of, any current or future clinical trials that could delay or prevent our ability to receive marketing approval or commercialize&#160;NGN-401&#160;or any other product candidates, including:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may experience delays in reaching, or may fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the observation of an actual or suspected unexpected serious adverse reaction, serious adverse events, or adverse events of special interest could result in a partial or complete clinical hold for an unpredictable length of time, delay or halt future enrollment, require increased staggering between patient dosing, require dose reductions that could adversely affect the anticipated efficacy or potency product profile, or require a program discontinuation;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trial sites may fail to meet enrollment targets, may deviate from trial protocol, or may experience patients dropping out of a trial;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trials of any product candidates may fail to show safety or efficacy or potency, or produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of subjects required for clinical trials of any of our product candidates may be larger than we anticipate, especially if the effect size observed in future clinical data from a Phase 1/2 clinical trial is small or is difficult to ascertain relative to natural history as a comparator, or if regulatory authorities require completion of a sham-controlled clinical trial;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">enrollment in clinical trials may be slower than we anticipate or subjects may drop out of clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may elect to, or regulators, independent data and safety monitoring boards (&#8220;DSMBs&#8221;), IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research or trials, or delay further recruitment, enrollment or dosing of subjects in clinical trials or specific trial sites, for various reasons, including noncompliance with regulatory requirements, internal processes or protocols of the relevant review body, a finding that the participants in our trials are being exposed to unacceptable health risks, or any other development that may impact the benefit-risk assessment of our product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of clinical trials of any of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to manufacture sufficient quantities at adequate scales of our product candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reports from clinical testing of other therapies may raise safety, efficacy or potency concerns about our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate and data emerging from other therapies in the same class as our product candidates; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safety concerns develop with respect to our product candidates or clinical trial designs, we may be delayed in our development plans as we may need to pause our enrollment in a clinical trial, revise our trial designs, investigate potential safety developments, or take other measures that may increase the amount of time and resources required to bring our product candidates forward. For example, on November 11, 2024, we were advised of a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">severe adverse event (&#8220;SAE&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experienced by a participant in the 3E15 vg dose of our Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome. The participant subsequently died following complications from a rare and life-threatening hyperinflammatory syndrome associated with systemic exposure to high doses of AAV. The FDA completed a review of the safety data for NGN-401 and allowed us to continue with the Phase 1/2 trial using the 1E15 vg dose. We paused further use of the 3E15 vg dose upon initial notification of the SAE and made the determination to remove that dose level from the trial protocol as we do not plan to enroll any further participants at the 3E15 vg dose level.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND or, if commenced in other jurisdictions, acceptance by the comparable foreign regulatory agency of a similar application, as well as finalizing the trial design. In the event that the FDA or applicable foreign regulatory agency requires us to complete additional preclinical studies, or we are required to satisfy other regulatory requests prior to commencing clinical trials, the start of our clinical trials may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other jurisdictions, including the United Kingdom (&#8220;UK&#8221;), Australia and the European Union (&#8220;EU&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to modify existing collaborations or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize,&#160;NGN-401&#160;or any other product candidates we are developing or may develop in the future. We or our current or future collaborators&#8217; inability to complete development of, or commercialize,&#160;NGN-401&#160;or any other product candidates or significant delays in doing so, could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently utilize adeno-associated virus serotype 9 (&#8220;AAV9&#8221;) capsid for delivery of therapeutic transgenes to deliver our product candidates, which may limit the safety, purity, and efficacy or potency of such product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current approach is to identify, develop and commercialize gene therapy product candidates using an AAV9 capsid for delivery of therapeutic transgenes to certain kinds of cells.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although AAV9 has been tested in numerous clinical trials and is an approved serotype for at least one gene therapy product, we cannot be certain that our AAV9 product candidates will successfully advance through preclinical studies and clinical trials, or that they will not cause significant adverse events or toxicities. For more information, please refer to the risk factor below titled &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Participants in our clinical trials may experience undesirable side effects, which could cause delays or prevent regulatory approval of our product candidates, limit the commercial potential or create significant negative consequences to our development plans, even if such side effects are ultimately determined not to be attributable or possibly attributable to our product candidates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, a participant who had been recently dosed at the 3E15 vg dose of NGN-401 in our Phase 1/2 clinical trial for the treatment of Rett syndrome experienced an SAE consistent with known risks of AAV gene therapy and ultimately died from this complication. While this reaction was very rare, we cannot ensure that other SAEs related to the use of AAV9 will not occur, or that we will not experience delays or other negative impacts to our clinical trial related to this or other AAV-related SAEs. We also cannot be certain that we will be able to avoid triggering toxicities in our future preclinical studies or clinical trials or that our chosen routes of administration to deliver such therapies will not cause unforeseen side effects or other challenges. Although AAV9 has been shown to facilitate biodistribution and cell transduction to the central nervous system (&#8220;CNS&#8221;), the potentially limited levels of AAV9 transduction of cells in the CNS may also limit the potential efficacy or potency of any of our product candidates, including&#160;NGN-401. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Participants in our clinical trials may experience undesirable side effects, which could cause delays or prevent regulatory approval of our product candidates, limit the commercial potential or create significant negative consequences to our development plans, even if such side effects are ultimately determined not to be attributable or possibly attributable to our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary product candidates, including NGN-401 for the treatment of Rett syndrome, are AAV-based gene therapies. AAV-based gene therapies in development or approved for use carry a risk of certain adverse side effects, known and unknown, including the potential for inflammatory events such as heightened innate or adaptive immune reactions in response to the presence of the AAV vector, including the development of a T-cell and/or B-cell immune response, complement system activation, thrombotic microangiopathy, thrombocytopenia, toxicity due to damage of the dorsal root ganglia, loss of nerve conductivity with or without the diminishment or loss of reflexes and sensory symptoms, increased liver enzymes and liver toxicity, organ damage to kidneys or the heart, or in rare cases, death. In addition, some participants in our AAV-based gene therapy clinical trials may have pre-existing conditions, such as diminished lean muscle mass, impaired function of biological systems or vital organs, or recent viral infections, or complications relating to their genetic makeup, and, as such, those participants may present a different risk profile and may have an increased potential for serious adverse events such as a heightened immune response, the re-activation of a viral infection due to immunosuppression measures that are taken in conjunction with administration of AAV-based gene therapy, or a diminished capacity to withstand treatment-related side effects that might be mild if they were to present in another participant. Because of the novel nature of gene therapy in general and specifically AAV-based gene therapy, not all side effects may have been discovered, and we may not be able to identify all of the increased risk factors for our participants, and additional unexpected serious adverse events may occur as a result. In addition, due to components of our product candidates used to carry the genetic materials, it is possible that some participants could develop delayed side effects from treatment. There can also be significant variability in how patients respond to gene therapy, especially in a mosaic disease presentation like Rett syndrome in females where some of the cells carry a correct copy of the DNA sequence for the impacted gene while other cells have a mutated variant. As a result, some patients may not respond as well to gene therapy as others.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serious adverse events related to our trial or to other clinical trials using AAV-based gene therapy, even if those other trials are not related to our product candidates or targeted disease states, and even if such adverse events are not ultimately attributable to the relevant product candidates or products, may result in unfavorable public sentiment about our clinical trial and our product candidates, increased government regulation, potential regulatory delays for approval of our product candidates, stricter labeling requirements, the imposition of additional monitoring of our products if they are approved, challenges in enrolling patients in our clinical trials and a decrease in demand for our product candidates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are believed to be or shown to be associated with side effects that significantly alter the benefit-risk determination of any of our product candidates, we may not be able to continue development of that product candidate. Some product candidates that have shown positive safety results in early clinical testing have later been found to cause side effects that required the abandonment of further development of that product candidate. We may also be required to delay or slow the development of a particular product candidate if there are side effects whose cause is unclear or uncertain in order to further understand the nature of such side effects, which could materially impact our plans for development and financial position.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to identify and develop novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested in early-stage research and development with the goal of identifying and developing additional product candidates. Our future success may depend in part on the successful development of novel therapeutic approaches, including new therapies that may be able to use our EXACT technology or other transgene regulation technology. However, while our preclinical research and clinical trials may initially show promise in identifying potential product candidates, they may ultimately fail to yield product candidates for a number of reasons. For example, although EXACT is designed to deliver therapeutic levels of transgene while avoiding overexpression toxicity and&#160;off-target&#160;effects, there can be no assurance that any EXACT transgene regulation will result in product candidates that are shown in clinical trials to be safe, pure, and effective or potent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, very few products that utilize gene transfer have been approved in the United States, Europe or other markets, and no products have been approved using our EXACT technology or technology similar to it. There have been a limited number of clinical trials of gene transfer technologies, with only very few product candidates ever approved by the FDA or comparable foreign regulatory authorities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, it is difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our approach to gene therapy will result in the identification, development, and regulatory approval of any product candidates, or that other gene therapy programs will not be considered better or more attractive. There can be no assurance that any development problems we experience in the future related to our current gene therapy approaches or product candidates or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. Research programs to identify new product candidates require substantial technical, financial, and human resources. If we are unable to identify suitable gene therapy product candidates for preclinical and clinical development in a cost-effective manner, we may not be able to successfully implement this portion of our business strategy, and may have to delay, reduce the scope of, suspend or eliminate one or more of our current or future product candidates, clinical trials or future commercialization efforts, which would negatively impact our financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The disorders we seek to treat have low prevalence and it may be difficult to identify and enroll patients with these disorders. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful and timely completion of clinical trials will require that we enroll and maintain a sufficient number of patients. Patient enrollment is affected by many factors, including the size and nature of the patient population and competition for patients with other trials. Genetic diseases generally, and especially the rare diseases for which some of our current product candidates are targeted, have low incidence and prevalence. For example, we estimate global incidence of Rett syndrome to be approximately one in 10,000 live female births. Accordingly, it may be difficult for us to identify and timely recruit a sufficient number of eligible patients to conduct our clinical trials. Further, any natural history studies that we or our collaborators may conduct may fail to provide us with patients for our clinical trials because patients enrolled in the natural history studies may not be good candidates for our clinical trials, or may choose to not enroll in our clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) in the United Kingdom, the Therapeutic Goods Association (&#8220;TGA&#8221;) in Australia, the European Medicines Agency (&#8220;EMA&#8221;) or other foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the eligibility criteria for the trial in question;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timely diagnosis of disease to meet such eligibility criteria;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the size of the patient population and process for identifying patients;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the perceived risks and benefits of the product candidate in the trial, especially by clinician experts and patient advocacy organizations, including relating to AAV9-based gene therapy, which may evolve over time as more AAV-based gene therapy trials are conducted, and intracerebral spinal fluid delivery system;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the availability of competing commercially available therapies and other competing therapeutic candidates&#8217; clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of caregivers to enroll their children in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential disruptions caused by pandemics or other public health crises, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the patient referral practices of physicians;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to enroll a sufficient number of patients in our clinical trials, we may have difficulty maintaining enrollment of such patients. Our inability to enroll or maintain a sufficient number of patients would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs, or may require us to abandon one or more clinical trials altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of our most advanced product candidate,&#160;NGN-401, and our ongoing and anticipated clinical trials of NGN-401 may not be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, our most advanced product candidate,&#160;NGN-401.&#160;We are investing a majority of our efforts and financial resources into the research and development of this product candidate, as we are currently conducting a Phase 1/2 clinical trial of NGN-401 in patients with Rett syndrome. Based on the initial interim positive clinical trial data from our 1E15 vg dose of NGN-401 in our Phase 1/2 clinical trial for the treatment of Rett syndrome, we expect to advance that product candidate to a registrational clinical trial, pending future regulatory feedback on various aspects of development such as the pivotal trial design. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NGN-401&#160;will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate revenues from product sales, if any. We are not permitted to market or promote this product candidate, or any other product candidates we may develop, before we receive marketing approval from the FDA and/or comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of&#160;NGN-401&#160;will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot guarantee that we will ever be able to generate revenue through the sale of this product candidate, even if approved. If we are not successful in commercializing&#160;NGN-401,&#160;or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in identifying and advancing a strategy to continue the development of NGN-101 for CLN5 Batten disease, and in the meantime, may incur additional costs as we continue the post-dosing phases of our clinical trial for NGN-101.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we announced that we do not expect to move forward with the NGN-101 CLN5 Batten disease gene therapy program at the present time because of an inability to align on a streamlined registrational pathway with the FDA for that product </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but that we would continue to evaluate options for that program. We may consider a range of potential alternatives for the program, which could include continuing to discuss possibilities for a streamlined pathway to registration with the FDA, looking for a partner or out-licensing the product candidate entirely, but there can be no assurance that we will find any alternative to move the program forward.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we have completed dosing in the Phase 1/2 clinical trial of NGN-101 for CLN5 Batten disease, we do intend to continue to follow the patients who received treatment in the clinical trial and therefore may continue to incur certain incremental costs related to the continued observations in that clinical trial, even if we are not able to find a future path to commercialization for this product candidate.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our programs are focused on the development of therapeutics for patients with neurological diseases, which is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates is novel and may never lead to approved or marketable products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discovery and development of therapeutics for patients with neurological diseases is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work, that our programs have the potential to be disease-modifying therapies, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain indications. The patient populations for our product candidates are limited to those with specific neurological diseases. We cannot be certain that the patient populations for each specific disease will be large enough to allow us to successfully obtain approval and commercialize our product candidates and achieve profitability. Further, our Phase&#160;1/2 clinical trial&#160;of&#160;NGN-401&#160;will involve a small patient population. Because of the small sample sizes, the expansion of our clinical trial to an adolescent/adult cohort and the heterogeneity of the disease state, the results of this trial may not be indicative of results of future clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of&#160;NGN-401&#160;or any other product candidates may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of&#160;NGN-401&#160;or any other product candidates may be delayed or never achieved and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies, which are a lengthy, time-consuming and expensive process with a high risk of failure. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several&#160;years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. For example, we depend on the availability of NHPs to conduct certain preclinical studies that we are required to complete prior to submitting an IND and initiating clinical development. A sustained global shortage of NHPs available for biological product development could cause the cost of obtaining NHPs for our future preclinical studies to increase significantly and result in delays to our development timelines. However, after conducting preclinical studies, we must then conduct extensive clinical trials to demonstrate the safety, purity, and efficacy or potency of our product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, failure can occur at any time during the preclinical study or clinical trial process, and the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials, especially as our initial clinical trials do not contain a control arm. In addition, we have designed our initial clinical trials with relatively small cohorts before expanding in size and dosing in subsequent cohorts. If safety issues arise in an early cohort, we may be delayed or prevented from dose escalating or subsequently expanding into larger trial cohorts. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For example, on November 11, 2024, we were advised of an SAE experienced by a recently dosed participant at the 3E15 vg dose in our Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome. The participant subsequently died following complications from a rare and life threatening hyperinflammatory syndrome associated with systemic exposure to high doses of AAV. The FDA completed a review of the safety data for NGN-401 and allowed us to proceed with the Phase 1/2 trial using the 1E15 vg dose, although we decided to revise our trial protocol before resuming dosing, and have removed the 3E15 vg dose level from the trial protocol as we do not plan to enroll any further participants at the that dose level.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Earlier gene therapy clinical trials conducted by others also utilized AAV vectors. However, these studies should not be relied upon as evidence that our planned clinical trials will succeed. In addition, we expect to rely on patients, caregivers and clinicians to provide feedback on measures, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from day to day for a particular patient, and from patient to patient or caregiver to caregiver and from site to site within a clinical trial.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that the FDA or comparable foreign regulatory authorities will agree with our clinical development plan. We are conducting a Phase 1/2 clinical trial of NGN-401 in patients with Rett syndrome. If the FDA or any comparable regulatory authorities require us to conduct additional trials or enroll additional patients, our development timelines may be delayed, or we may not be able to pursue further development due to such delays. For example, i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n November 2024, we announced that the Company does not expect to move forward with the NGN-101 for CLN5 Batten disease gene therapy program at this time. Given the rarity of the disease, continued investment in the program was predicated on alignment on a streamlined registrational pathway with the FDA. To support a streamlined pathway, we submitted an RMAT application to the FDA. Despite our belief that we met the standard of preliminary clinical evidence required to obtain an RMAT designation, the RMAT application was denied. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that submission of an IND application, clinical trial application (&#8220;CTA&#8221;) or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to require us to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; difficulties in patient enrollment in our clinical trials for a variety of reasons; delays related to safety concerns; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practices (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to larger-scale facilities operated by a CDMO and delays or failure by our CDMOs or us to make any necessary changes to such manufacturing process and demonstrate comparability to materials used in earlier clinical phases; and third parties being unwilling or unable to satisfy their contractual obligations to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is placed on clinical hold, suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA, the competent authorities and/or ethics committees of the UK, Australia, EU Member States or other regulatory authorities, if a clinical trial is recommended for suspension or termination by the DSMB or equivalent body for such trial, or on account of changes to federal, state, or local laws. If we are required to conduct additional clinical trials or other testing of&#160;NGN-401&#160;or any other product candidates beyond those that we contemplate, if we are unable to successfully complete clinical trials of&#160;NGN-401&#160;or any other product candidates, if the results of such trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may incur significant additional costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we are able to successfully complete the clinical trial for&#160;NGN-401,&#160;we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. This is particularly true for clinical trials in very rare diseases, such as with our Phase 1/2 clinical trial of&#160;NGN-401&#160;for the treatment of Rett syndrome, where the very small patient population makes it difficult to conduct two traditional, adequate and well-controlled studies. In such cases, the FDA or comparable foreign regulatory authorities are often required or permitted to exercise flexibility in approving therapies for such diseases, but obtaining flexibility is uncertain and may never occur. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in the other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or applicable regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary,&#160;&#8220;topline&#8221;&#160;or interim data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary, interim or&#160;topline&#160;data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. Preliminary, interim or&#160;topline&#160;results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously disclosed. These preliminary, interim or topline data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments. For example, in June 2024, we announced initial safety data related to the dosing of our first four participants at the 1E15 vg dose in our Phase 1/2 clinical trial of NGN-401 for the treatment of Rett syndrome which suggested a favorable safety profile for the 1E15 vg dose. In November 2024, an SAE was reported in a participant who received the 3E15 vg dose, which caused us to revise our assumptions regarding the safety profile of the 3E15 vg dose. Because of this potential for change, preliminary, interim and topline data should be viewed with caution until final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of a particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary,&#160;interim&#160;or topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,&#160;NGN-401&#160;or any other product candidate may be harmed, which could harm our business, operating results, prospects or financial condition. In addition, differences between preliminary, interim or topline data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future clinical trials may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of&#160;NGN-401&#160;or any other product candidates or result in potential product liability claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. We believe NGN-401 has been generally well-tolerated at the 1E15 vg dose; however, we have not yet completed this clinical trial and the benefit-risk assessments of our product candidates remains ongoing. In November 2024, a participant who had recently received the 3E15 vg dose of NGN-401 experienced an SAE consistent with the known risks of AAV gene therapy and subsequently died following complications from a rare and life-threatening hyperinflammatory syndrome associated with systemic exposure to high doses of AAV. Participants at the 1E15 vg dose level have also experienced adverse events, and may experience adverse events in the future. If additional SAEs or other adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to such trials, patients may drop out of our trials, patients may be harmed, or we may be required to delay enrollment or abandon one or more cohorts of a trial or delay or abandon the trials or our development efforts of one or more product candidates altogether, including&#160;NGN-401.&#160;We, the FDA, MHRA, or other applicable regulatory authorities, or an IRB, may require suspension of any clinical trials of&#160;NGN-401&#160;or any other product candidates at any time for various reasons, including a finding that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude a product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of an approved product due to its tolerability versus other therapies. In addition, as gene replacement has a potentially life-long activity, with no ability to withdraw the product as with other treatment modalities, this profile could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment-emergent adverse events could also affect patient recruitment or the ability of enrolled subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with&#160;NGN-401&#160;or any other product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from&#160;NGN-401&#160;or any other product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we successfully advance&#160;NGN-401&#160;or any other product candidates through clinical trials, such trials will only include a limited number of patients and limited duration of follow up to such product candidates. As a result, we cannot be assured that adverse effects of&#160;NGN-401&#160;or any other product candidates will not be uncovered when a significantly larger number of patients are exposed to such product candidate after approval, or a significantly longer follow up post-dosing is obtained as part of regulators&#8217; recommendations for long-term follow up of clinical study subjects treated with gene therapy. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using our product candidates over a multi-year period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expended substantial efforts and costs testing our EXACT technology in preclinical studies of NGN-401, including completing toxicology studies prior to the FDA providing clearance of the IND for NGN-401. However, we cannot guarantee that significant adverse effects will not be seen in clinical trials for NGN-401, which could result in clinical holds, delays, suspension or withdrawal of our IND.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the foregoing events occur or if&#160;NGN-401, NGN-101&#160;or any other product candidates prove to be unsafe, our entire pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate, such as&#160;NGN-401, and fail to capitalize on candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we intend to focus our research and development efforts on certain selected product candidates. For example, to date we have allocated significant resources to our most advanced product candidates,&#160;NGN-401&#160;and&#160;NGN-101.&#160;As a result, we may forgo or delay pursuit of opportunities with other potential candidates that may later prove to have greater commercial potential. For example, i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n November 2024, we announced that the Company does not expect to move forward with the NGN-101 for CLN5 Batten disease gene therapy program at this time. Given the rarity of the disease, continued investment in the program was predicated on a streamlined registrational pathway with the FDA. To support a streamlined pathway, we submitted an RMAT application to the FDA. Despite our belief that we met the standard of preliminary clinical evidence required to obtain an RMAT designation, the RMAT designation was denied. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if regulatory approval is obtained, any approved products resulting from&#160;NGN-401 or any other product candidate may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval is obtained for&#160;NGN-401&#160;or any other product candidates, our product candidates may not gain market acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There is currently one&#160;FDA-approved&#160;product and multiple other product candidates in various stages of development for the treatment of Rett syndrome. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a gene therapy replacement with a target product profile such as that of&#160;NGN-401 or for its targeted indications, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of&#160;NGN-401&#160;or any other product candidates will depend on many factors, including factors that are not within our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of biological products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that any of our approved products are safe, therapeutically effective or potent, cost effective or less burdensome as compared with competing treatments. If&#160;NGN-401 or any other product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product and may not become or remain profitable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate and may lack the necessary expertise, personnel and resources to successfully commercialize a product candidate on our own or together with suitable collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never commercialized a product candidate and currently have no sales force, marketing or distribution capabilities. To achieve commercial success for a product candidate, we may opt to license such product candidate to others, in which case we may rely on the assistance and guidance of our collaborators on that license arrangement. For a product candidate for which we retain commercialization rights and marketing approval, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. Factors that may affect our ability to commercialize a product candidate, if approved, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of our approved product candidate, ensuring regulatory compliance of our company, employees and third parties under applicable healthcare laws and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of a product candidate upon approval. Moreover, we may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of an approved product candidate, we may not generate revenues from them or be able to reach or sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never completed any late-stage clinical trials and may not be able to file an IND application or other applications for regulatory approval to commence additional clinical trials on the timelines we expect. Even if we are able to complete such trials, the FDA or comparable foreign regulatory authorities may not permit us to proceed or could suspend or terminate any such trial after it has been initiated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our development efforts and will need to successfully complete later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market our product candidates. Carrying out clinical trials and the submission of a successful IND or CTA is a complicated process. Even though our product candidate NGN-401 for Rett syndrome has been accepted into the FDA&#8217;s START program and RMAT program, the combination of which is expected to allow access to frequent advice from FDA staff, intensive guidance on efficient drug development and eligibility for an Accelerated Approval pathway and Priority Review, our lack of experience with FDA submissions may still slow our progress towards FDA approval. We have not yet completed a Phase 1/2 clinical trial and have limited experience as a company in preparing, submitting and prosecuting regulatory filings. Based on the initial positive interim data from the 1E15 vg dose of NGN-401 in our Phase 1/2 clinical trial of&#160;NGN-401, we intend to engage with the FDA and other comparable foreign regulators to determine the requirements to support initiation of a pivotal clinical trial. However, regulatory authorities may recommend changes to the study design for&#160;NGN-401,&#160;including the number and size of registrational clinical trials required to be conducted in that program. In addition, regulatory authorities could require manufacturing changes or have us implement additional analytical processes prior to initiation of a future clinical trial. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of our product candidates or we may determine that the regulatory requirements for submission are too burdensome to support continued development of one or more of our product candidates, as we did with our NGN-101 product candidate for CLN5 Batten disease, which we plan to terminate due to a lack of alignment with the FDA on a streamlined pathway to registration. Additionally, even if regulatory authorities agree with the design and implementation of the clinical trials set forth in a regulatory meeting, such regulatory authorities may change their requirements in the future. The FDA or comparable foreign regulatory authorities may require the analysis of data from trials assessing different doses of the product candidate alone or in combination with other therapies to justify the selected dose prior to the initiation of large trials in a specific indication. Any delays or failure to initiate clinical trials or obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. We are subject to similar risks related to the review and authorization of our protocols and amendments by comparable foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our preclinical pipeline, if the&#160;IND-enabling&#160;studies support a decision to advance into clinical development, we would plan to submit an IND or CTA with a foreign regulatory authority. We may not be able to file the IND or CTA in accordance with our desired timelines for future product candidates. For example, we may experience manufacturing delays or other delays with&#160;IND-enabling&#160;studies, including with suppliers, study sites, or third-party contractors and vendors on which we depend. Moreover, we cannot be sure that submission of an IND application will result in the FDA or comparable foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that lead us to suspend or terminate such clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of gene therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical studies. While we have established our own manufacturing facility to provide clinical and commercial supply of our product candidates, we expect to rely on contract manufacturers for certain portions of our manufacturing needs for the foreseeable future, such as those related to research grade material for our early preclinical studies.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturers of biological and pharmaceutical products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure of us or our CDMOs to adhere to or document compliance with such regulatory requirements could lead to a delay or interruption in the availability of our program materials for clinical trials or enforcement action from the FDA, EMA or other foreign regulatory authorities. If we or our manufacturers were to fail to comply with the FDA, EMA or other regulatory authority, it could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates. Our potential future dependence upon others for the manufacture of our product candidates may also adversely affect our future profit margins and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological products are inherently difficult to manufacture. Although we believe that the manufacture of our product candidates may be simplified due to their shared raw materials and other similarities, we cannot be certain that this will be the case and we may be required to develop manufacturing methods that ultimately differ significantly between product candidates, which would require that we invest substantial time and capital to develop suitable manufacturing methods. Our program materials are manufactured using technically complex processes requiring specialized equipment and facilities, highly specific raw materials, cells, and reagents, and other production constraints. Our production process requires a number of highly specific raw materials, cells and reagents with limited suppliers. Even though we aim to have backup supplies of raw materials, cells and reagents whenever possible, we cannot be certain those supplies will be sufficient if our primary sources are unavailable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our suppliers is the sole source of certain materials used by us in our manufacturing process, and a disruption of the supply of those materials could also negatively impact our ability to manufacture clinical supply as we would have to suspend or revise our operations to accommodate for any disruption in the supply of those materials. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shortage of a critical raw material, cell line, or reagent, or a technical issue during manufacturing, may lead to delays in clinical development or commercialization plans. We are particularly susceptible to any shortages, delays or inability to obtain suitable raw materials, given that all of our current and planned product candidates require this starting material. Any changes in the manufacturing of components of the raw materials we use could result in unanticipated or unfavorable effects in our manufacturing processes, resulting in delays.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the biological products are manufactured, the product must be analyzed utilizing assays and meet&#160;pre-determined&#160;specifications in order to be used in certain preclinical studies, in any clinical trial, and, if approval is obtained, for commercial distribution. This testing is performed&#160;in-house&#160;and at third-party contract manufacturers. Delays or other unexpected obstacles in developing analytical methods or in performing the tests and obtaining the results&#160;in-house&#160;or at a third-party contractor could result in unanticipated impact to our ability to supply material as needed for&#160;pre-clinical,&#160;clinical, or commercial needs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contract manufacturers for AAV9 are subject to significant regulation with respect to manufacturing of our products. The third-party manufacturing facilities on which we rely, our&#160;in-house manufacturing facility, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the raw materials, including plasmids and virus banks, required by the manufacturing processes of our product candidates. Virus intended for use in our early preclinical studies has been and can be externally supplied; however, if we experience slowdowns or problems with our&#160;in-house&#160;manufacturing facility and are unable to establish or scale our internal manufacturing capabilities, we will need to continue to contract with manufacturers to produce the preclinical, clinical and commercial supply and such supply will be more uncertain and subject to delays. In addition, each supplier may require licenses to manufacture certain components of the supply if such processes are not owned by the supplier or in the public domain and we may be unable to license such intellectual property rights on reasonable commercial terms or to transfer or sublicense the intellectual property rights we may have with respect to such activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for components of our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including recordkeeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a biologics license application (&#8220;BLA&#8221;) or marketing authorization application (&#8220;MAA&#8221;) on a timely basis. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must&#160;pass&#160;a&#160;pre-approval&#160;inspection&#160;for&#160;compliance with the applicable regulations as a condition of regulatory approval of our current or future product candidates. In addition, regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our current or future product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted, and they could put a hold on one or more of our clinical trials if the facilities of our CDMOs do not pass such audit or inspections. If these facilities do not pass a&#160;pre-approval&#160;plant inspection, the FDA or other foreign regulatory agency approval of the products will not be granted.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities also may, at any time following approval of a product for sale, inspect or audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could harm our business. If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other foreign regulatory agencies can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation&#160;of&#160;a&#160;pre-existing&#160;approval.&#160;As&#160;a result, our business, financial condition and results of operations may be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA and/or MAA supplement, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully, if approved. Further, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose future potential revenue, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability and quality of supplies and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to manufacture gene therapy products. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our larger competitors. We cannot be certain that our suppliers will continue to provide us with the quantities of raw materials that we require or satisfy our anticipated specifications and quality requirements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our suppliers is the sole source of certain materials used by us in our manufacturing process, and a disruption of the supply of those materials could also negatively impact our ability to manufacture clinical supply as we would have to suspend or revise our operations to accommodate for any disruption in the supply of those materials.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in developing our&#160;manufacturing&#160;capabilities or failure to achieve operating efficiencies from such capabilities may require us to devote additional resources and management time to&#160;manufacturing&#160;operations and may delay our product development timelines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a GMP manufacturing facility located in Houston, Texas that includes process, analytical and bioanalytical development labs with experienced teams.&#160;NGN-401&#160;was manufactured at our Houston facility and clinical-grade product is available for dosing in the Phase&#160;1/2 clinical trial of&#160;NGN-401&#160;that is currently enrolling patients. However, we will need to conduct additional&#160;NGN-401&#160;manufacturing campaigns to generate additional clinical supply, as well as supply for our preclinical studies for our discovery programs, and we may not be able to satisfy such supply through production at our own facility and may need to outsource some or all of our production work.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks relating to the manufacture of biologics and drug products include: production interruptions, delays in quality/release testing, equipment malfunctions, facility contamination, labor problems, natural disasters, disruption in utility services, terrorist activities, war, cases of force majeure, weather-related events, acts of god (such as public health crises) or other events beyond our control and, in each case, could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of gene therapy manufacturing, there is a risk of contamination. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully manufacture our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing resulting approved products, if any.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have manufactured&#160;NGN-401&#160;in quantities and quality adequate for preclinical, toxicology and clinical studies. In order to conduct clinical trials for a product candidate and for commercialization of the resulting product if that product candidate is approved for sale, we will need to manufacture product candidates in additional cGMP campaigns or in larger batch sizes. We may not be able to successfully repeat or increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner or at all. Significant changes or&#160;scale-up&#160;of manufacturing may require additional validation studies and/or analytical comparability studies, which are costly and which regulatory authorities must review and approve. In addition, quality issues may arise during those changes or&#160;scale-up&#160;activities. If we are unable to successfully manufacture any of our product candidates in sufficient quality and quantity, the development of that product candidate and regulatory approval or commercial launch for any resulting products may be delayed or there may be a shortage in supply, which could significantly harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics. Such changes carry the risk that they will not achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or approval from the FDA or foreign regulatory agencies. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes to our upstream and downstream processes across our pipeline, which could delay the development of our future product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a number of academic collaborations, and currently rely on our collaboration with the University of Edinburgh for certain aspects of our preclinical research and development programs, including working in collaboration to discover and preclinically develop our potential product candidates for our near-term future pipeline. Failure or delay of the University of Edinburgh or any other collaborator to fulfil all or part of its obligations under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of the relationship would materially harm our business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery engine is supplemented by academic collaborations to expand our platform, which we rely upon to advance discovery and development of product candidates. For example, our collaboration with the University of Edinburgh is critical to our business. In December 2020, we entered into a Master Collaboration Agreement (the &#8220;MCA&#8221;) with the University of Edinburgh, which we rely on to conduct certain aspects of the preclinical development of our pipeline candidates, including&#160;NGN-401&#160;and all of our early-stage pipeline product candidates. Further, in March 2022, we entered into an exclusive license agreement with the University of Edinburgh for, with respect to certain University of Edinburgh-owned technology, a worldwide, exclusive, sublicensable license to develop, have developed, use, manufacture, have manufactured, supply, have supplied, sell, have sold, offer for sale, commercialize, import, export, register, reproduce, dispose of or otherwise exploit any products, processes, components, services and/or technologies incorporating the technology for the prevention or treatment of disease or medical or genetic conditions in humans. We also currently rely on the University of Edinburgh for portions of preclinical research capabilities under the direction of Dr.&#160;Stuart Cobb, Professor in Translational Neuroscience at the University of Edinburgh and our Chief Scientific Officer. Pursuant to the MCA, we and the University of Edinburgh agreed to collaborate on certain research and development projects (the &#8220;Projects&#8221;), and we agreed to provide funding for such Projects. In exchange for such funding, the University of Edinburgh grants us an option to exclusively license any intellectual property arising from such Projects. Either party has the right in certain circumstances to terminate the collaboration pursuant to the terms of the MCA. If the MCA is not renewed or is terminated, our pipeline of product candidates would be significantly adversely affected, and our business would be materially harmed.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an amendment to the MCA in November 2023, the term of the research funding portion of the MCA, under which we have the ability to acquire exclusive rights to additional technology and gene therapy products, now expires in December 2026. If we need to extend the term of this provision beyond that date, we will need to negotiate an additional extension with the University of Edinburgh, and we may not be able to agree on such an extension on terms that are acceptable to us, or at all. We may have disagreements with the University of Edinburgh with respect to the interpretation of the MCA, use of resources or otherwise that could cause our relationship to deteriorate. As a result, the University of Edinburgh may reduce focus on, and resources allocated to, our programs, potentially delaying or terminating our ability to advance product candidates through preclinical studies. Additionally, if Dr.&#160;Cobb were to leave the University of Edinburgh or to otherwise no longer be meaningfully involved with us, our preclinical research and development capabilities may be substantially reduced.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the MCA, the University of Edinburgh is primarily responsible for prosecuting and maintaining our licensed intellectual property, and it may fail to properly prosecute, maintain or defend such intellectual property. In such event, if we are unable to otherwise maintain or defend such intellectual property, we could face the potential invalidation of the intellectual property or be subjected to litigation or arbitration, any of which would be time-consuming and expensive. To enforce the licensed intellectual property rights under the MCA, we will need to coordinate with the University of Edinburgh, which could slow down or hamper our ability to enforce our licensed intellectual property rights. If this happens, we could face increased competition that could materially and adversely affect our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further description of the MCA, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;License and Collaboration Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also currently have or may in the future engage in other academic collaborations to supplement our internal discovery and product development program. While these academic institutions have contractual obligations to us, they are independent entities and are not under our control or the control of our officers or directors. Our research and licensing agreements with academic collaborators generally provide academic collaborators with license maintenance fees, development and regulatory milestone payments, royalties on net sales of products and a portion of sublicense income that we receive. Upon the scheduled expiration of any academic collaboration, we may not be able to renew the related agreement, or any renewal could be on terms less favorable to us than those contained in the existing agreement. Furthermore, either we or the academic institution generally may terminate the sponsored research agreement for convenience following a specified notice period. If any of these academic institutions decides to not renew or to terminate the related agreement or decides to devote fewer resources to such activities, our discovery efforts would be diminished, while our royalty obligations, if any, would continue unmodified.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely, and intend in the future to rely, on third parties to conduct a significant portion of our preclinical studies and existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged CROs or other third parties to conduct preclinical and IND enabling studies and our clinical trials, including our Phase 1/2 clinical trial of&#160;NGN-401.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third parties, including CROs, medical institutions and clinical investigators, to conduct those clinical trials. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative third parties or do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not such third parties devote sufficient time and resources to our clinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, we may incur additional and unexpected costs related to such failures, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, while our reliance on these third parties for research and development activities will reduce our control over these activities, we will not be relieved of our responsibilities for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, MHRA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP conditions. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval&#160;of NGN-401&#160;or any other product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently store drug product for clinical trial sites in the United States, and currently rely on and expect in the future to rely on third parties to distribute product supplies for our clinical trials, as well as to store and distribute supply for clinical trial sites outside of the United States. Any performance failure on the part of us or our distributors could result in an unexpected increase in costs to us, delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial condition also may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions, tariffs or other extraordinary taxes, and other foreign regulatory requirements affecting our collaborators. We currently rely to some degree on foreign </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs in the UK and Australia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and may need to rely on foreign </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMOs in the future. We or the foreign CROs or CDMOs we may work with may be subject to U.S. legislation, including the potential passing of an act similar to the previously proposed BIOSECURE Act, sanctions, trade restrictions, increased taxes or tariffs and other foreign regulatory requirements which could increase the cost or reduce the supply of certain material we use, delay the procurement or supply of such material or disrupt our supply chain for certain raw materials or medical devices necessary for our clinical trial. For example, in April 2025, the United States government imposed significant tariffs on imports from China and other countries and may impose more restrictions on goods, including biologically derived substances, manufactured in or imported from China or impose other restrictions on companies&#8217; ability to work with Chinese biotechnology companies or other foreign counterparties. To the extent these or future tariffs are applicable to the material we may import from China and other countries or if we are not able to secure supply of our product candidates as a result of applicable legislation, our business and financial condition could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over time, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of preclinical and clinical biological product development, technical operations, clinical operations, regulatory affairs, manufacturing and, potentially, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems, expand our facilities and recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our managerial, scientific and medical personnel, including our Founder and Chief Executive Officer, President and Chief Financial Officer, and Chief Scientific Officer, as well as other key members of our leadership team. Our executive officers may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key personnel may be difficult and may take an extended period of time. Failure to attracting and retaining qualified personnel could materially and adversely affect our business, financial condition and results of operations. We could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources on our employee recruitment and retention efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize&#160;NGN-401&#160;or other product candidates in foreign markets for which we may rely on collaborations with third parties. We are not permitted to market or promote any product candidates before we receive regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of&#160;NGN-401&#160;or other product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets or to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of&#160;NGN-401&#160;or other product candidates will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of&#160;NGN-401&#160;or other product candidates and ultimately commercialize such product candidates in foreign markets, we would be subject to the risks and uncertainties of operating in such foreign markets, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CDMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CDMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. It is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our systems, or those of any of our CROs, manufacturers, other contractors, third party service providers or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures in an effort to protect systems that store our information, given the size and complexity of such systems and the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs, other contractors (including sites performing our clinical trials), third-party service providers and supply chain companies, consultants and other partners, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. From time to time, we are subject to business email compromise attack attempts. In August 2023, we discovered a business email compromise attack that resulted in the misappropriation of approximately $0.9 million. While we have implemented remedial measures in response to this incident and recovered $0.8 million of those losses through insurance claims, we cannot guarantee that such measures will prevent additional related, as well as unrelated incidents, or that we will be able to defend against or successfully remediate any such attacks that may occur in the future. If a material system failure, accident or security breach were to occur and cause interruptions in our operations or the operations of third-party collaborators, service providers, contractors and consultants, it could result in a material disruption of our development programs and significant reputational, financial, legal, regulatory, business or operational harm.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, since we sponsor clinical trials, any breach that compromises patient data and identities causing a breach of privacy could have significant adverse consequences on our business. For example, the loss of clinical trial data from completed or future clinical trials could affect trust in us, negatively impacting our ability to recruit for future clinical trials, result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or inappropriate disclosure of confidential proprietary information, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of&#160;NGN-401&#160;or other product candidates could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our employees work remotely and use network connections, computers, and devices outside of our premises or network, including working at home, while in transit and in public locations, there are risks to our information technology systems and data. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders, patients or other individuals, regulators or, in certain circumstances, the media of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences, including damage to our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers and technologies to operate critical business systems, including to process sensitive information in a variety of contexts. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences as a result. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our monetary, reputational and other damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been and will not be compromised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experiences a security incident or is perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing personal information (including sensitive data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); increased investigation and compliance costs; financial loss; and other similar harms. Security incidents and attendant consequences may cause our stakeholders (including investors and potential customers) to stop supporting our business, deter new customers from our products, deter patients from participating in clinical trials and negatively impact our ability to grow and operate our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices or from disruptions in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored, or that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation, injunctive restrictions on data processing and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and third parties with whom we work, are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which are changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. In addition, there is proposed legislation in the U.S. Congress that could restrict working with certain biotech providers who are deemed &#8220;companies of concern&#8221; which may impact the ability of certain third parties with whom we work to meet their performance obligations. We are or may become subject to the terms of contractual obligations related to privacy, data protection, and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject us to injunctive restrictions on data processing, adversely impact our ability to appropriately manage third parties with whom we work and otherwise cause a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Data Privacy and Security&#8221; and &#8220;&#8212;Other Regulatory Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had net operating loss (&#8220;NOL&#8221;) carryforwards for federal and state income tax purposes of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$319.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. The federal NOLs will not be subject to expiration and can be carried forward indefinitely; however, they are limited to a deduction to 80% of annual taxable income. The state NOLs begin to expire in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent that our taxable income exceeds any current year operating losses, we plan to use our carryforwards to offset income that would otherwise be taxable. Also, for state income tax purposes, the extent to which states will conform to the federal laws is uncertain and there may be periods during which the use of NOL carryforwards are suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. In addition, under Section&#160;382 of the Code, changes in our ownership may limit the amount of our NOL carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of more than 50% (as measured by value) among a stockholder or one or more groups of stockholders who own at least 5% of our stock within a three-year period. We have not performed an analysis to determine whether there has been an ownership change pursuant to Section&#160;382. Any such limitation may significantly reduce our ability to utilize our NOL carryforwards and tax credit carryforwards before they expire. Any such limitation, whether as the result of a public offering, private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or our stockholders. We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations and employees to determine the potential effect on our business and any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the United States recently enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years. The U.S. Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision will be repealed or otherwise modified.&#160;Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We maintain our cash at financial institutions, at times in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash held in&#160;non-interest-bearing&#160;and interest-bearing accounts at financial institutions can at times exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the end of August 2023, we identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our share price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal controls related to the cash disbursements process were not adequately designed to identify unauthorized payment requests, resulting in the identification of a material weakness. Specifically, at the end of August 2023, we discovered that we were subject to a business email compromise attack by a third party. This deficiency in our controls resulted in the diversion of payments to fraudulent bank accounts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that certain internal controls required for safeguarding our cash assets were not properly designed due to insufficient specificity regarding our policies and procedures surrounding supplier banking information changes, not identifying segregation of duties, and insufficient training on exercising professional skepticism. We therefore implemented steps to remediate this control deficiency, including increasing communication of and training around our controls relating to changes made to information, emphasizing security awareness and the importance of professional skepticism and designing a process to review supplier information changes prior to release of payments. While our management determined based on the assessment of internal control over financial reporting that as of December 31, 2023, this material weakness had been remediated, there can be no assurance that the remediation plans we implemented relating to this business email compromise attack will be successful in preventing a repeat of that attack or that we will be able to avoid potential future material weaknesses. If we are unable to successfully remediate existing or any future material weakness in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law and applicable stock exchange listing requirements regarding timely filing of periodic reports, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely and expect to continue to rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates and technologies and to prevent third parties from unfairly competing with us. Our success depends in large part on our ability to obtain and maintain patent protection for platform technologies, including our EXACT transgene regulation platform, product candidates and their uses, as well as the ability to operate without infringing on or violating the proprietary rights of others. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we license</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29 patent applications, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncluding U.S. patent applications, international patent applications under the Patent Cooperation Treaty or otherwise, and expect to continue to file patent applications in the United States and abroad related to discoveries and technologies that are important to our business. However, we may not be able to protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on product candidates worldwide would be prohibitively expensive and our intellectual property rights in some foreign jurisdictions may be less extensive than those in the United States. As such, we do not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Competitors may operate in countries where we do not have patent protection and could then freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where patent protection has not been requested. In addition, competitors may be able to design around our patents to create technologies that directly compete with ours without infringing our intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property portfolio is at an early stage. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we do not own or&#160;in-license&#160;any issued patents. Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that may be licensed or owned covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if we encounter delays in any clinical trials or delays in obtaining regulatory approval, the period of time during which we could market product candidates under patent protection would be reduced. Thus, the patents that we may own or license may not afford any meaningful competitive advantage.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented&#160;know-how,&#160;technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share facilities or third-party consultants and vendors that we engage to perform researches, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in the market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in markets of interest and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product candidates through acquisitions and&#160;in-licenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our development programs require and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire,&#160;in-license,&#160;or use these third-party proprietary rights. We may be unable to acquire or&#160;in-license&#160;any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to a product candidate, there may be times when the filing and prosecution activities for patents and patent applications relating to a product candidate are controlled by future licensors or collaboration partners. For example, we currently license several patent families from the University of Edinburgh covering the EXACT transgene regulation platform, as well as the NGN-401 product candidate and its uses. If any of such licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering a product candidate, we could lose rights to the intellectual property or exclusivity with respect to those rights, our ability to develop and commercialize such candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications which may be licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of licensees, future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that future licensors are not the sole and exclusive owners of the patents we&#160;in-license.&#160;If other third parties have ownership rights to future&#160;in-licensed&#160;patents, they may be able to license such patents to our competitors, and the competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be&#160;non-exclusive,&#160;thereby giving competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing the same, or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology or manufacturing methods, our product candidates, or future methods or product candidates, resulting in either an injunction prohibiting manufacture or future sales, or, with respect to future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and to what extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions and&#160;know-how&#160;resulting from the joint creations or use of intellectual property by future licensors and us and/or our partners; and the priority date of an invention of patented technology.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our current product candidates and research programs are licensed from or based upon licenses from a third party and are field limited to certain indications. If these license agreements are terminated or interpreted to narrow our rights, our ability to advance our current product candidates or develop new product candidates based on these technologies will be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on, and will continue to depend on, our current licenses with the University of Edinburgh, Virovek, Inc. (&#8220;Virovek&#8221;), Sigma-Aldrich Co. LLC (&#8220;Sigma&#8221;), and Leland Stanford Junior University (&#8220;Stanford&#8221;), and on licenses and sublicenses from other third parties, as well as potentially on other strategic relationships with third parties, for the research, development, manufacturing and commercialization of our current product candidates. If any of our licenses or relationships or any&#160;in-licenses&#160;on which our licenses are based are terminated or breached, we may:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">lose our rights to develop and market our current product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">lose patent or trade secret protection for our current product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">experience significant delays in the development or commercialization of our current product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">not be able to obtain any other licenses on acceptable terms, if at all; or</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">incur liability for damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even if not terminated or breached, our intellectual property licenses or sublicenses may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience any of the foregoing, it could have a materially adverse effect on our business and could force us to cease operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements with the University of Edinburgh, Virovek, Sigma and Stanford and may from time to time in the future be party to other license and collaboration agreements with third parties to advance our research or allow commercialization of current or future product candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Despite our best efforts, our licensors might conclude that we have materially brea</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ched our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these licenses are terminated for any reason, or if the underlying patents fail to provide the intended exclusivity, we could lose significant rights and our ability to commercialize our current or future product candidates may be harmed, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our diligence obligations with respect to the use of the licensed technology in relation to the development and commercialization of our current or future product candidates, and what activities satisfy those diligence obligations;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the priority of invention of any patented technology; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and by us and our other partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs, liability and diversion of resources, and prevent or delay us from commercializing potential products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third party rights. If certain of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of such product candidates infringing. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that our intellectual property, methods or products infringes their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy received may not be commercially valuable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to defend intellectual property actions brought by third parties, or if we sue to protect our own intellectual property rights or otherwise to protect our proprietary information and to prevent its disclosure, or if we are involved in other litigation, whether as a plaintiff or defendant, and whether or not successful, we may incur substantial legal expenses and the attention of our management and key personnel may be diverted from business operations. Further, some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use, and may not be able to obtain such licenses on terms acceptable to us, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology industry, in addition to employees, we engage consultants to assist in the development of our product candidates. Many of these consultants, and many of our employees, were or may have been previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees or consultants working on our behalf have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information,&#160;know-how&#160;or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her&#160;non-competition&#160;or&#160;non-solicitation&#160;agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may litigate to defend ourselves against these claims, and even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), could increase the uncertainties and costs surrounding the prosecution of our owned and any future&#160;in-licensed&#160;patent applications and the maintenance, enforcement or defense of our owned and any future&#160;in-licensed&#160;issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution along with additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;16, 2013, under the Leahy-Smith Act, the United States transitioned to a&#160;first-to-file&#160;system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, our operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. Accordingly, our competitive position may be impaired, and our business, financial condition, operations and prospects may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) came into force in June 2023. The UPC is a common patent court to hear patent infringement and revocation proceedings effective for member states of the EU. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. We currently have three pending European applications, and if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents obtained. We may decide to opt out from the UPC for any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for&#160;non-compliance&#160;and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non-compliance&#160;events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our pending applications or any future issued patents, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or&#160;co-inventor.&#160;The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding&#160;co-ownership&#160;of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government or academic institutions, such that our licensors are not the sole and exclusive owners of the patents we&#160;in-licensed.&#160;If other third parties have ownership rights or other rights to our&#160;in-licensed&#160;patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.&#160;non-provisional&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and future licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have&#160;in-licensed&#160;may have been discovered through government funded programs and thus may be subject to federal regulations such as&#160;&#8220;march-in&#8221;&#160;rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with&#160;non-U.S.&#160;manufacturers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the intellectual property rights we have licensed are generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980 (the &#8220;Bayh-Dole Act&#8221;) and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a&#160;non-exclusive,&#160;non-transferable,&#160;irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require our or our licensors&#8217; to grant exclusive, partially exclusive, or&#160;non-exclusive&#160;licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as&#160;&#8220;march-in&#160;rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail, or the applicable licensor, fails to disclose the invention to the government and fails to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with&#160;non-U.S.&#160;product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, or if we determine that we are not willing or able to complete the regulatory approval process given the resources required to do so, we will not be able to commercialize, or will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. While our product candidate NGN-401 for Rett syndrome has been accepted into the FDA&#8217;s START program and the RMAT program, which we expect together will allow us to have access to more frequent advice from FDA staff, intensive guidance on efficient drug development and eligibility for an Accelerated Approval pathway and Priority Review, participation in these programs is not a guarantee that our approval process with the FDA will be faster or that we will ultimately achieve approval of a pivotal trial design or approval of NGN-401 as an accepted therapy for Rett syndrome. We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. In addition, we may determine that the resources required to complete the regulatory approval process are in excess of what we are able or willing to expend on a particular program. For example, in November 2024, we announced that we do not expect to move forward with the NGN-101 gene therapy program for CLN5 Batten disease. Given the rarity of the disease, continued investment in the program was predicated on an alignment on a streamlined registrational pathway with the FDA. To support a streamlined pathway, we submitted an RMAT application to the FDA. Despite our belief that we met the standard of preliminary clinical evidence required to obtain an RMAT designation, the RMAT application was denied. We are currently evaluating options for the program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of our product candidates, including our most advanced product candidate, NGN-401, we&#160;must demonstrate through lengthy, complex and expensive preclinical and clinical trials that such product candidates are safe, pure and effective or potent for each targeted indication. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval also requires the submission of information about the biological product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, a product candidate may not be effective or potent, may be only moderately effective or potent or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude its obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. A product candidate could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe, pure, and effective or potent for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected product-related side effects may be experienced by participants in our clinical trials or by individuals using drugs or biological products similar to a product candidate; we may be unable to demonstrate that a candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of a product candidate may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of a product candidate; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in us failing to obtain regulatory approval to market NGN-401 or other product candidates, which would significantly harm our business, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to obtain approval, regulatory authorities may approve any such product candidate for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for a product candidate, we will not be able to commercialize, or will be delayed in commercializing, such product candidate and our ability to generate revenue may be materially impaired. In addition, the FDA and foreign regulatory authorities may undergo leadership changes, change their policies, issue additional regulations or revise existing regulations, or take other actions, such as those implemented by the recently established Department of Government Efficiency (&#8220;DOGE&#8221;), which may impact our clinical development plans or prevent or delay approval of our product candidates under development on a timely basis.  Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals and increase the costs of compliance. Additionally, changes in the leadership of the FDA and other federal agencies under President Trump&#8217;s administration (the &#8220;Trump Administration&#8221;) may also lead to new policies and changes in the regulations and operations of the FDA, which may impact our clinical development plans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict the time and cost of obtaining regulatory approval, if received at all, for any product candidates we may develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory requirements that will govern any novel gene therapy product candidates we develop are not entirely clear and are subject to change. Within the broader genetic medicine field, very few therapeutic products have received marketing authorization from the FDA or the EMA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial overlap in those responsible for review and regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Therapeutic Products within its Center for Biologics Evaluation and Research (&#8220;CBER&#8221;), as part of its reorganization of the Office of Tissues and Advanced Therapies, to consolidate the review of gene therapy and related products. In addition, the Cellular, Tissue and Gene Therapies Advisory Committee advises CBER on its review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates will need to meet safety, purity and efficacy or potency standards applicable to any new biologic under the regulatory framework administered by the FDA. In addition to FDA oversight and oversight by IRBs under guidelines promulgated by the National Institutes of Health (&#8220;NIH&#8221;) gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH guidelines voluntarily follow them. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The same applies in the EU. The EMA&#8217;s Committee for Advanced Therapies (&#8220;CAT&#8221;) is responsible for assessing the quality, safety, and efficacy of advanced-therapy medicinal products. Advanced-therapy medicinal products include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the EU, the development and evaluation of a gene therapy product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any gene therapy product candidate we may develop, but that remains uncertain at this point.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, the EMA, and other regulatory authorities to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety, purity and efficacy or potency of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. Because of this complexity, even though our product candidate NGN-401 for Rett syndrome has been accepted into the FDA&#8217;s START program and the RMAT program, which we expect together will allow us to have access to more frequent advice from FDA staff, intensive guidance on efficient drug development and eligibility for an Accelerated Approval pathway and Priority Review, the regulatory approval process for product candidates such as those being developed by us can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we are developing novel potential treatments for diseases in which, in some cases, there is little clinical experience with potential new endpoints and methodologies, heightened risk that the FDA, the EMA or other regulatory authorities may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. In addition, we may not be able to identify or develop appropriate animal disease models to enable or support planned clinical development. Any natural history studies that we may conduct or rely upon in our clinical development may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies and regulatory authorities could negatively affect the review of our regulatory submissions or impact our ability to access the public markets, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and other regulatory authorities to review and approve regulatory submissions can be affected by a variety of factors, including statutory, regulatory and policy changes, inadequate government budget funding levels or a reduction in the FDA&#8217;s workforce and its ability to hire and retain key personnel, disruptions caused by government shutdowns and public health crises. There have been mass layoffs of federal government employees since the start of the Trump Administration in January 2025, the full impact of which is unclear at this time. Average review times at the agency have fluctuated as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. In addition, the Trump Administration has made and is expected to continue to make changes in the leadership of various U.S. federal regulatory agencies and changes to U.S. federal government policy that have led to, in some cases, legal challenges and uncertainty around the funding, functioning and policy priorities of the U.S. federal regulatory agencies, including the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the extent to which the current U.S. federal administration may impose or seek to impose leadership or policy changes at the U.S. federal regulatory agencies responsible for regulating our business or changes to rules and policies impacting our operations. It is unclear how these executive actions or other potential actions by the Trump Administration or other parts of the federal government will impact the FDA or other regulatory authorities that oversee our business.  Government proposals to reduce or eliminate budgetary deficits or limit federal agency personnel may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may reduce the FDA&#8217;s ability to perform its responsibilities, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates and could result in delays in our clinical trial timelines. Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for the review and approval of CTAs or MAAs, which would adversely affect our business. If a significant reduction in the FDA&#8217;s workforce occurs, the FDA&#8217;s budget is significantly reduced or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions or take other actions critical to the development, manufacturing or marketing of our most advanced product candidate,  NGN-401, or other product candidates, if approved, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our contract manufacturing partners are able to characterize, control and manufacture our biological products safely and in accordance with regulatory requirements. This includes manufacturing the drug substance, developing an acceptable formulation, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biological products meet stability requirements. Meeting these chemistry, manufacturing and control (&#8220;CMC&#8221;) requirements is a complex task that requires specialized expertise. If we are not able to meet the CMC requirements, we may not be successful in getting our products approved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to deliver our product candidates via a drug delivery device that will have its own regulatory, development, supply and other risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to deliver our product candidates via a drug delivery device, such as a catheter or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. We expect to use drug delivery devices authorized for marketing under clearances or approvals held by third parties. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent on those third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently and may in the future conduct clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to conduct clinical trials outside the United States, including in Australia, the UK, Europe or other foreign jurisdictions. For example, we are currently conducting our Phase 1/2 clinical trials for&#160;NGN-401&#160;in the United States, the UK and Australia. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and (iii)&#160;the data may be considered valid without the need for&#160;an&#160;on-site&#160;inspection&#160;by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through&#160;an&#160;on-site&#160;inspection&#160;or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. Even if the FDA accepts such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting international clinical trials include: foreign regulatory requirements, differences in healthcare services, and differences in cultural customs that could restrict or limit our ability to conduct our clinical trials; administrative burdens of conducting clinical trials under multiple sets of foreign regulations; foreign exchange fluctuations; diminished protection of intellectual property in some countries; and political and economic risks relevant to foreign countries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA-licensed&#160;reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this&#160;12-year&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investigational biological products, if approved, could be considered reference products entitled to&#160;12-year&#160;exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider a product candidate to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of&#160;NGN-401&#160;or other product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we may receive for&#160;NGN-401&#160;or other product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety, purity and efficacy or potency of such product candidates, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy in order to approve a product candidate, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve a product candidate, the products and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, purity, efficacy or potency, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well&#160;as&#160;on-going&#160;compliance&#160;with current cGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, requiring creation of a medication guide outlining the risk of such side effects for distribution to patients, withdrawal or suspension of existing approvals or licenses, refusal to approve pending applications or supplements, restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize&#160;NGN-401&#160;or&#160;other product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from healthcare legislative reform measures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of&#160;NGN-401&#160;or other product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for a more detailed description of healthcare reforms measures that may prevent us from being able to generate revenue, attain profitability, or commercialize product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly-applicable fraud and abuse and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Other Healthcare Laws and Compliance Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in our Annual Report on Form 10-K for a more detailed description of the laws that may affect our ability to operate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply wit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations&#160;of&#160;non-compliance,&#160;disgorgement,&#160;individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize&#160;NGN-401&#160;or other product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such products at competitive prices which would seriously harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market&#160;NGN-401&#160;and other product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for such product candidates, we will be subject to rules and regulations in those jurisdictions. Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product candidates are approved and we are found to have improperly promoted&#160;off-label&#160;uses of those programs, we may become subject to significant liability, which would materially adversely affect our business and financial conditi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation&#8212;Coverage and Reimbursement&#8221; and &#8220;&#8212;Regulation in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#160;in our Annual Report on Form 10-K for a more detailed description of the government regulations and third-party payor practices that may affect our ability to commercialize product candid</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. In addition, the U.S. Congress is currently contemplating legislation that could have the impact of limiting the ability of us and certain of our vendors to work with certain designated biotech companies from China and other nations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States may impose strict price controls, which may adversely affect our revenue, if any.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly member states of the EU, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between&#160;low-priced&#160;and high-priced member states, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators of ours may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of a product to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the UK determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">While we have received Fast Track designation for NGN-401 for the treatment of Rett syndrome and NGN-401 has been accepted into the FDA&#8217;s START Pilot Program and RMAT program and has received PRIME designation from the EMA, such designations may not lead to a faster development or regulatory review or approval process. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the FDA began accepting applications from sponsors for the START pilot program with the purpose of further accelerating the pace of development of novel drug and biological products that are intended to address an unmet medical need as a treatment for rare disease. The pilot is designed to be milestone-driven (i.e. to facilitate the progression of a development program to pivotal clinical study stage or the pre-BLA meeting stage) where product development programs selected would benefit from enhanced communication with the FDA. The START pilot program is intended to provide a mechanism for addressing clinical development issues that otherwise would delay or prevent a promising novel drug or biological product from progressing to the pivotal clinical trial stage or pre-BLA meeting stage. Participants in the START Pilot Program will receive enhanced communications with the FDA review staff.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These enhanced communications will include at a minimum an initial meeting to review features of the pilot, discuss a pathway intended to support a marketing application, and to discuss specific issues for which a sponsor requests enhanced communications with the FDA. Additional communications will include ongoing interactions via email or teleconference that take place on a scheduled and/or as needed basis as agreed upon by the sponsor information on how best to facilitate more efficient development of potentially life-saving therapies for rare diseases and help sponsors generate high-quality, actionable data to support future new drug or biologics license applications. In June 2024, we announced that our product candidate NGN-401 had been accepted into the FDA&#8217;s START Pilot Program, which we expect will allow us to have access to more frequent advice from FDA staff to address product-specific development issues, possibly including clinical study design, choice of control group, patient population choices and other early development issues. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s RMAT designation program is intended to fulfill the requirement of the 21st Century Cures Act that the FDA facilitate an efficient development program for, and expedite review of, any product that meets the following criteria: (1) it qualifies as an RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. In 2024, the FDA granted an RMAT designation for NGN-401 for the treatment of Rett syndrome. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or may be able to rely upon data obtained from a meaningful number of sites, including through expansion to additional sites. RMAT designation does not change the standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. We have received Fast Track designation in the United States for NGN-401 for the treatment of Rett syndrome and we may seek additional designations for one or more of our other product candidates that could expedite review and approval by the FDA. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participation in the START Pilot Program, RMAT designation and the designation of a product for Fast Track review are within the discretion of the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the START Pilot Program is in its first year as a pilot program, so there is no historical information on how that program is expected to be administered, and the stated intentions of the program may not be met, or the program may cease to have appropriate funding due to changes in the regulatory landscape.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, neither participation in the START Pilot Program nor the receipt of either Fast Track designation or RMAT designation for a product candidate is any guarantee that there will be faster development or a faster or more streamlined regulatory review or approval process compared to products considered for approval under conventional FDA procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither participation in the START Pilot Program nor either Fast Track designation or RMAT designation will assure ultimate approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet the conditions to qualify for those programs, and we may not receive the benefits of those programs for the relevant product candidate, or decide that the time period for FDA review or approval will not be shortened. Additionally, changes in the leadership of the FDA and other actions taken by the Trump Administration, including mass layoffs within the federal government, may impose constraints on the FDA&#8217;s ability to engage in activities in the normal course and may result in reductions to the FDA&#8217;s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to take advantage of the benefits for the START program and progress development of our product candidates or obtain regulatory approval for our product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have also received PRIME designation from the EMA for NGN-401.  PRIME is intended to enhance support for the development of medicines that target an unmet medical need, and is expected to allow enhanced interaction and early dialogue between us and the EMA on development plans for NGN-401 and to potentially speed up the evaluation process. However, similar to the START Pilot Program and Fast Track designation, we cannot be sure that the PRIME designation will actually result in a faster development time or more streamlined review, or that we will necessarily pursue the benefits of the program with respect to development of our product in the European market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy and Priority Review designations by the FDA, however, even if we receive such designations, there is no guarantee that they would lead to faster development or regulatory review timelines or increase the likelihood of marketing approval for such product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to have one or more of our products designated as a Breakthrough Therapy, which is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life threatening disease or condition where preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek an RMAT designation or a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate qualifies as an RMAT, that is intended to treat, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition, the FDA may grant participation in the RMAT program for that product candidate. If the FDA determines that a product candidate offers a treatment for a serious condition, and if approved, would provide a significant improvement in safety or effectiveness where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with the Fast Track designation and selection for participation in the START Pilot Program, these designations are within the discretion of the FDA. Even if we believe that one or more of our product candidates meets the criteria for these designations, the FDA may not agree and instead determine to not make such a designation. Even if one or more of our product candidates qualifies for either or both of these designations, the FDA may later decide that such product candidate no longer meets the conditions for those designations, and we may not receive the benefits of the designation for that product candidate. If a product candidate is awarded one or both designations by the FDA, it may not result in a faster or more streamlined regulatory review or approval process compared to products considered for approval under conventional FDA procedures, and it does not assure ultimate marketing approval of such product candidate by the FDA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have received orphan drug designation for&#160;NGN-401&#160;for the treatment of Rett syndrome and we may seek orphan drug designation for certain future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received orphan drug designation from the FDA and orphan drug designation and advanced therapy medicinal product designation from the European Medicines Agency (EMA) for&#160;NGN-401&#160;for the treatment of Rett syndrome. Although we may seek orphan product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biological product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan drug designation must be requested before submitting a BLA. In the EU, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with an orphan drug designation for our current and potential future product candidates, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for an existing or future product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties still can be approved for the same condition even with an orphan drug designation. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have received Rare&#160;Pediatric&#160;Disease designation by the FDA for&#160;NGN-401&#160;for the treatment of Rett syndrome. However, Rare Pediatric Disease designation for any of our product candidates does not guarantee that the BLA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying BLA for the treatment of a rare pediatric disease, the sponsor of such an application would be eligible for a rare pediatric disease priority review voucher that can be used to obtain priority review for a subsequent BLA or NDA. If a product candidate is designated before September&#160;30, 2024, it is eligible to receive a voucher if it is approved before September&#160;30, 2026. While we have obtained Rare Pediatric Disease designation for&#160;NGN-401&#160;for the treatment of Rett syndrome, it is unlikely that this product candidate will be approved by September&#160;30, 2026. If approval is not obtained by then, we would not be in a position to obtain a priority review voucher, unless Congress further reauthorizes the program beyond the current sunset dates, which require that a product designated as being for a rare pediatric disease be approved by September 30, 2026. Additionally, designation of a biological product for a rare pediatric disease does not guarantee that a BLA will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Finally, a Rare Pediatric Disease designation does not lead to faster development or regulatory review of the product or increase the likelihood that it will receive marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and even if the markets&#160;in which we compete&#160;achieve&#160;the forecasted&#160;growth, our business&#160;may&#160;not grow at similar&#160;rates, or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the current and future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for our products or any prospects for commercialization of our products. Although we believe we currently maintain adequate product liability insurance for&#160;NGN-401, NGN-101&#160;and other product candidates, it is possible that our liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facility is located in Houston, Texas, making us vulnerable to risks (including weather-related risks) associated with maintaining those operations in a single geographic area.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facility is located in Houston, Texas, which is subject to extreme weather events such as hurricanes and other significant storms, which can cause interruption to our utilities and potentially result in damage to our facility, limit the ability of suppliers to reach us during such disruptions and adversely impact our manufacturing processes. For example, in July 2024, our facility in Houston sustained five days of power loss from the impact of Hurricane Beryl, which was a Category 1 hurricane. While we were able to maintain power to critical systems through the use of our generators, the outage caused a minor delay in our development activities and caused disruptions in our manufacturing processes, including in our clean rooms. The impact of Hurricane Beryl was not material to our operations, however, future weather events could cause more disruption, including the potential for a sustained loss of power that could result in costly delays to our manufacturing process or the loss of certain materials stored in our facility, which could in turn have a material adverse effect on our product development timeline and results of operations. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation costs and the outcome of litigation could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time&#160;we&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of our business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, fluctuating interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced and may experience in the future extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, new or increased tariffs and other barriers to trade, especially in light of recent executive orders made by the Trump Administration, trade and other international disputes, increases in inflation rates, fluctuating interest rates, slower growth or recession, tighter credit, volatility in financial markets, high unemployment, labor availability constraints, public health crises, significant natural disasters, including as a result of climate change, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotechnology areas), political and military conflict, and uncertainty about economic stability. In recent months, the U.S. has announced tariffs on imports from most countries, including significant tariffs on imports from China. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. There is substantial uncertainty about the duration of existing tariffs and whether additional tariffs may be imposed, modified or suspended. Fluctuating interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East, and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of economic or political uncertainty, political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including materials, operational, labor and employee benefit costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical events and global economic conditions may also affect the ability of the FDA and other regulatory authorities to perform routine functions. If such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Owning Our Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may continue to be volatile.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock following the merger has been and may continue to be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">timing and results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future collaborators;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to meet or exceed financial and development projections that we may provide to the public;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additions or departures of key personnel;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales of securities by us or our securityholders in the future;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">if we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">trading volume of our common stock;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the introduction of technological innovations or new therapies that compete with our products; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. For example, escalating trade tensions, elevated interest rates and regulatory uncertainty have caused significant market volatility in recent months, and particularly in the biotechnology and biopharmaceutical industries. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased stockholder activism or securities litigation if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows. Class action securities litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to allocate resources to fulfill the requirements of the CVR Agreement entered into in connection with the Reverse Merger (as defined below) related to certain legacy lease obligations which may take away from our core programs and create a distraction for our management and employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2023, we completed our business combination with our wholly owned subsidiary incorporated in the state of Nevada and also named Neurogene Inc. (&#8220;Neurogene OpCo&#8221;) in accordance with the terms of the Agreement and Plan of Merger, dated as of July 17, 2023 (the &#8220;Merger Agreement&#8221;), by and among the Company, Project North Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and Neurogene OpCo, pursuant to which, among other matters, Merger Sub merged with and into Neurogene OpCo, with Neurogene OpCo surviving as a wholly owned subsidiary of the Company (the &#8220;Reverse Merger&#8221;).  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Reverse Merger, we declared a dividend, to each person who, as of immediately prior to the effective time of the Reverse Merger, was a stockholder of the Company or had the right to receive our common stock pursuant to an existing pre-funded&#160;warrant, of the right to receive one&#160;non-transferable&#160;contingent value right (each, a &#8220;CVR&#8221;) for each then outstanding share of our common stock (before giving effect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a 1-for-4 reverse stock split (the &#8220;Reverse Stock Split&#8221;) that was implemented immediately prior to the effective time</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), each representing the&#160;non-transferable&#160;contractual right to receive certain contingent payments from the Company upon the occurrence of certain events within agreed time periods. Holders of options to purchase our common stock outstanding immediately prior to the effective time of the merger will also receive four CVRs for each share of our common stock that may be issued upon exercise of such option, such that they will receive the same number of CVRs as they would have received if the option had been exercised before the Reverse Stock Split, subject to certain conditions set forth in the CVR Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the CVR Agreement, the holders of our common stock prior to the effective time of the Reverse Merger, including holders of existing pre-funded warrants and holders of options to purchase our common stock outstanding immediately prior to the effective time of the merger and exercised after the effective time of the merger, rather than all of our current holders of our common stock, are the primary recipients of any net proceeds of the disposition of the legacy assets related the business of Neoleukin Therapeutics, Inc. as it existed prior to the effective time of the Reverse Merger, the mitigation of legacy lease obligations related the business of Neoleukin Therapeutics, Inc. as it existed prior to the effective time of the Reverse Merger or receipt of any sales tax refund from the State of Washington based on tax returns filed by the Company prior to the effective time of the Reverse Merger. While we have entered into agreements for the disposition of certain legacy assets of Neoleukin, we are still pursuing a resolution of the legacy lease obligations of Neoleukin and expect that we will need to allocate resources, including payment of certain up-front costs, and time from employees and management to complete the resolution of such obligations and to administer the provisions of the CVR Agreement and distribution of any payments to holders of the CVRs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may be required to allocate a portion of our funds, time and resources to such activities and not our core programs and the foregoing could be a distraction to our management and employees. As a result, our operations and financial condition may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred, and will continue to incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and will continue to incur significant legal, accounting and other expenses as a public company that may not be reflected in our historical financial statements, which reflect our operation as a private company. Some of these additional expenses include costs associated with public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Our management team consists of our executive officers prior to the merger. These executive officers and other personnel will need to devote substantial time to complying with public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these requirements. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. We expect to still qualify as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2&#160;under the Exchange Act, in at least the near term, which allows us to take advantage of many exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Once we are no longer a smaller reporting company or otherwise no longer qualify for this exemption, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant additional legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our independent auditor identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, any of which would require additional financial and management resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in each Annual Report on Form&#160;10-K, as required by Section&#160;404 of the Sarbanes-Oxley Act. Prior to the merger in December 2023, our operating and finance teams were part of a private company, and therefore were not previously required to test internal controls within a specified period. As a result, we have incurred and may continue to incur substantial professional fees and internal costs to expand our accounting and finance functions as well as to expend significant management efforts. We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, our internal controls related to the cash disbursements process were not adequately designed to identify unauthorized payment requests, resulting in the identification of a material weakness. Specifically, at the end of August 2023, we discovered that we were subject to a business email compromise attack by a third party. This deficiency in our controls resulted in the diversion of payments to a fraudulent bank account. While management has determined in its assessment of our internal control over financial reporting as of December 31, 2023, that we have remediated this material weakness, there can be no assurance that the remediation will prevent similar attacks in the future or that we will not identify other material weaknesses in the future. If we are unable to successfully remediate a material weakness in our internal control over financial reporting, or if we identify any other material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult and may prevent attempts by our stockholders to replace or remove management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish a classified board of directors such that all members of the board are not elected at one time;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limit who may call a special meeting of stockholders;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require the approval of the holders of at least 66 2/3% of the votes that all stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i)&#160;any derivative action or proceeding brought on the company&#8217;s behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to the company or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws, (iv)&#160;any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws, or (v)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; Our governing documents further provide that, unless we consent in writing to an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum Provision.&#8221; Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause our stock price to decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. Based on shares outstanding as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there are approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,929,566</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock outstanding or issuable on exercise of pre-funded warrants to purchase common stock. All outstanding shares of common stock and any shares issuable on exercise of pre-funded warrants or vested options to purchase our common stock, other than shares held by our affiliates or otherwise subject to restrictions on vesting and exercise, are freely tradable, without restriction, in the public market. If a significant number of these shares are sold, the trading price of our common stock could decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and principal stockholders beneficially own a significant percentage of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent our acquisition on terms that other stockholders may desire.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be exposed to increased litigation, including stockholder litigation, which could have an adverse effect on our business and operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be exposed to increased litigation from stockholders, suppliers and other third parties, which may have an adverse impact on our business and results of operations or may cause disruptions to our operations. In the past, stockholders have initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock, and we may also be subject to threats of litigation based on our recent merger activity. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_121"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_124"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_127"></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-610"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-611"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-612">Trading Plans</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-613" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2025, no director or officer (as defined in Section 16 of the Exchange Act) adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) as amended (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Rule&#8221;), or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Item 408(a) of Regulation S-K,  except as described below:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name &amp; Title</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date Adopted</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Character of Trading Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Number of Shares of Common Stock to be Purchased or Sold Pursuant to Trading Arrangement</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Material Terms</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date Terminated</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-167" name="ecd:TrdArrIndName" id="f-614">Stuart Cobb</ix:nonNumeric>, <ix:nonNumeric contextRef="c-167" name="ecd:TrdArrIndTitle" id="f-615">Chief Scientific Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-167" name="ecd:TrdArrAdoptionDate" id="f-616">2/6/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-167" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-617">Rule 10b5-1 Trading Arrangement</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="f-618">27107</ix:nonFraction> shares sold</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-167" name="ecd:TrdArrExpirationDate" id="f-619">3/17/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except as indicated by footnote, each trading arrangement marked as a &#8220;Rule 10b5-1 Trading Arrangement&#8221; is intended to satisfy the affirmative defense of the Rule.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table. This trading arrangement only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule. This arrangement also provides for automatic expiration in the event of death, a personal bankruptcy filing, public announcement of a merger, recapitalization, acquisition, tender or exchange offer, or other business combination or reorganization resulting in the exchange or conversion of the common stock of the Company into shares of another company, or the conversion of the Company&#8217;s securities into rights to receive fixed amounts of cash or into debt securities and/or preferred stock (whether in whole or in part).</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"/><td style="width:8.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.007%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">N</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">eurog</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">ene 2025 Inducement Plan (Incorporated by reference to Exhibit 99.3 of the Registrant</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">s </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">Registration Statement on Form S-8 filed with t</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">he Securities and Exch</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">ange Commi</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">ssion on March 24, 2025</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000162828025014508/exhibit993-sx8.htm">.)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025inducementplanformofo.htm">F</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025inducementplanformofo.htm">orm of Option Grant and Option Award Agreement for </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025inducementplanformofo.htm">Registrant</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025inducementplanformofo.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2025inducementplanformofo.htm">s 2025 Inducement Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">A</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">mend</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">ment to Letter Agreement b</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">etween Baker Bros. Advisors LP and </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">Neurog</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">ene Inc. (</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">Incorporated by reference to </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">Exhibit 10.1 o</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">f</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm"> t</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">he Registra</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">nt</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">s Current Report on Form </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">8</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">-K filed with the Securitie</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">s a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">nd Exchange Commission on </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">April 14, 2025</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">.</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001404644/000140464425000029/ngne_amendmenttobbsidelett.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ngne-2025formq110xqxex311p.htm">Certification of the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ngne-2025formq110xqxex312p.htm">Certification of the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ngne-2025formq110xqxex321.htm">Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><div id="i2c10432fd4514957b2f0bdfad1948d4e_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:24pt;padding-right:-22.5pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline" href="#i2c10432fd4514957b2f0bdfad1948d4e_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:18pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:18pt;padding-left:144pt;padding-right:144pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;9, 2025</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurogene Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Rachel McMinn                                       </span></div></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rachel McMinn, Ph.D.                           </span></div></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Chief Executive Officer (Principal Executive Officer)             </span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;9, 2025</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurogene Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Christine Mikail                                        </span></div></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christine Mikail, J.D.                                </span></div></td></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">President and Chief Financial Officer (Principal Financial Officer)        </span></div></td></tr></table></div><div style="margin-top:18pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>a2025inducementplanformofo.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1e326291f3654687ab1f13ade7701746_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Exh</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:101%">NEUROGENE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:101%">2025 INDUCEMENT PLAN<br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NEW HIRE EMPLOYEE GRANT NOTICE FOR<br>NONQUALIFIED STOCK OPTIONS</font></div><div style="margin-bottom:12pt;margin-top:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOR GOOD AND VALUABLE CONSIDERATION, Neurogene Inc. (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), hereby grants to the Participant named below the Nonqualified Stock Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, and upon the terms and subject to the conditions set forth in this Grant Notice, the Neurogene Inc. 2025 Inducement Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Standard Terms and Conditions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Standard Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promulgated under such Plan and attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Option is granted pursuant to the Plan and is subject to and qualified in its entirety by the Standard Terms and Conditions. This Option is not intended to qualify as an incentive stock option under Section 422 of the Code. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Name of Participant&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:0.97pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Grant Date&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:0.97pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Participant&#8217;s Start Date&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:0.97pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Number of Shares of Common Stock covered by Option&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:0.97pt;text-align:justify"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Exercise Price Per Share&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:-2.63pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Expiration Date&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:-2.63pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Vesting Schedule&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.77pt;padding-right:10.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt">Subject to the Plan and the Standard Terms and Conditions, the Option shall vest in accordance with the following schedule, so long as Participant remains continuously employed by the Company or its Subsidiaries from the Grant Date through each such vesting date&#58; &#91;(i) 25% of the Option shall vest on the first anniversary of Participant&#8217;s Start Date and (ii) 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:12.00pt;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.00pt"> of the Option shall vest at the end of each successive one-month period following such first anniversary&#93;.</font></div><div style="padding-left:2.77pt;padding-right:-2.98pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1e326291f3654687ab1f13ade7701746_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By accepting this Grant Notice, Participant acknowledges that he or she has received and read, and agrees that this Option shall be subject to, the terms of this Grant Notice, the Plan, and the Standard Terms and Conditions.</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NEUROGENE INC.</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font><br></font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature Page to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New Hire Employee Grant Notice for</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonqualified Stock Options</font></div></div></div><div id="i1e326291f3654687ab1f13ade7701746_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NEUROGENE INC.<br>2025 INDUCEMENT PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STANDARD TERMS AND CONDITIONS FOR<br>NONQUALIFIED STOCK OPTIONS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These Standard Terms and Conditions apply to the Options granted pursuant to the Neurogene Inc. 2025 Inducement Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which are identified as nonqualified stock options and are evidenced by a Grant Notice or an action of the Committee that specifically refers to these Standard Terms and Conditions. In addition to these Standard Terms and Conditions, the Options shall be subject to the terms of the Plan, which are incorporated into these Standard Terms and Conditions by this reference. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">TERMS OF OPTION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neurogene Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has granted to the Participant named in the Grant Notice provided to said Participant herewith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) a Nonqualified Stock Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to purchase up to the number of shares of Common Stock at an Exercise Price per share, each as set forth in the Grant Notice. The Option is subject to the conditions set forth in the Grant Notice, these Standard Terms and Conditions, and the Plan. For purposes of these Standard Terms and Conditions and the Grant Notice, any reference to the Company shall include a reference to any Subsidiary. The Option is not intended to be an incentive stock option under Section 422 of the Code and will be interpreted accordingly.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">EXERCISE OF OPTION</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Option shall not be exercisable as of the Grant Date set forth in the Grant Notice. After the Grant Date, to the extent not previously exercised, and subject to termination or acceleration as provided in these Standard Terms and Conditions and the Plan, the Option shall be exercisable only to the extent it becomes vested, as described in the Grant Notice or the terms of the Plan, to purchase up to that number of shares of Common Stock as set forth in the Grant Notice&#59; provided, that (except as set forth in Section 3(b) below) the Participant remains employed with the Company and does not experience a Termination of Employment. The vesting period and&#47;or exercisability of an Option may be adjusted by the Committee to reflect the decreased level of employment during any period in which the Participant is on an approved leave of absence or is employed on a less than full time basis.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To exercise the Option (or any part thereof), the Participant shall deliver to the Company a &#8220;Notice of Exercise&#8221; in a form specified by the Committee, specifying the number of whole shares of Common Stock the Participant wishes to purchase and how the Participant&#8217;s shares of Common Stock should be registered (in the Participant&#8217;s name only or in the Participant&#8217;s and the Participant&#8217;s spouse&#8217;s names as community property or as joint tenants with right of survivorship).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The exercise price (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Option is set forth in the Grant Notice. The Company shall not be obligated to issue any shares of Common Stock until the </font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Standard Terms and Conditions for </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nonqualified Stock Options</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Participant has paid the total Exercise Price for that number of shares of Common Stock. The Exercise Price may be paid in cash, including an irrevocable commitment by a broker to pay over such amount from a sale of the Common Stock issuable under the Option, or in such other manners as may be permitted by the Committee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Fractional shares may not be exercised. Shares of Common Stock will be issued as soon as practical after exercise. Notwithstanding the above, the Company shall not be obligated to deliver any shares of Common Stock during any period when the Company determines that the exercisability of the Option or the delivery of shares of Common Stock hereunder would violate Company policy or any federal, state or other applicable laws.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">EXPIRATION OF OPTION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Option shall expire and cease to be exercisable as of the earlier of (a) the Expiration Date set forth in the Grant Notice or (b) the date specified below in connection with the Participant&#8217;s Termination of Employment&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If the Participant&#8217;s Termination of Employment is as a result of the Participant&#8217;s death or Disability, the Participant may exercise any portion of the Option that is vested and exercisable at the time of such Termination of Employment until the first anniversary of the Termination Date (as defined below).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If the Participant&#8217;s Termination of Employment is by the Company for Cause, the entire Option, whether or not then vested and exercisable, shall be immediately forfeited and canceled as of the Termination Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">If the Participant&#8217;s Termination of Employment is for any reason other than as set forth in Section 3(b)(i) or 3(b)(ii), the Participant may exercise any portion of the Option that is vested and exercisable at the time of such Termination of Employment until the date that is three months following the Termination Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Any portion of the Option that is not vested and exercisable at the time of a Termination of Employment (after taking into account any accelerated vesting under Section 15 of the Plan or any other agreement between the Participant and the Company) shall be forfeited and canceled as of the Termination Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">As used in this Section 3, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date of the Participant&#8217;s Termination of Employment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">RESTRICTIONS ON RESALES OF SHARES ACQUIRED PURSUANT TO OPTION EXERCISE</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any shares of Common Stock issued as a result of the exercise of the Option, including (a) restrictions under an insider trading policy, (b) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by the Participant and other option holders and (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">INCOME TAXES</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall not deliver shares of Common Stock in respect of the exercise of any Option unless and until the Participant has made arrangements satisfactory to the Company to satisfy applicable withholding tax obligations. Unless the Participant pays the withholding tax obligations to the Company by cash or check in connection with the exercise of the Option (including an irrevocable commitment by a broker to pay over such amount from a sale of the Common Stock issuable under the Option), withholding shall be effected by withholding Common Stock issuable in connection with the exercise of the Option. The Participant acknowledges that the Company shall have the right to deduct any taxes required to be withheld by law in connection with the exercise of the Option from any amounts payable by it to the Participant (including future cash wages).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">NON&#173;TRANSFERABILITY OF OPTION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as permitted by the Committee or as permitted under the Plan, the Participant may not assign or transfer the Option to anyone other than by will or the laws of descent and distribution and the Option shall be exercisable only by the Participant during his or her lifetime. The Company may cancel the Option if the Participant attempts to assign or transfer it in a manner inconsistent with this Section 6.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">OTHER AGREEMENTS SUPERSEDED</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Grant Notice, these Standard Terms and Conditions and the Plan constitute the entire understanding between the Participant and the Company regarding the Option. Any prior agreements, commitments or negotiations concerning the Option are superseded. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">LIMITATION OF INTEREST IN SHARES SUBJECT TO OPTION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neither the Participant (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Participant shall have any right, title, interest, or privilege in or to any shares of Common Stock allocated or reserved for the purpose of the Plan or subject to the Grant Notice or these Standard Terms and Conditions except as to such shares of Common Stock, if any, as shall have been issued to such person upon exercise of the Option or any part of it. Nothing in the Plan, in the Grant Notice, these Standard Terms and Conditions or any other instrument executed pursuant to the Plan shall confer upon the Participant any right to continue in the Company&#8217;s employ or service nor limit in any way the Company&#8217;s right to terminate the Participant&#8217;s employment at any time for any reason.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">NO LIABILITY OF COMPANY</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company and any Affiliate which is in existence or hereafter comes into existence shall not be liable to the Participant or any other person as to&#58; (a) the non&#173;issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any shares hereunder&#894; and (b) any tax consequence expected, but not </font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">realized, by the Participant or other person due to the receipt, exercise or settlement of any Option granted hereunder.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">GENERAL</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event that any provision of these Standard Terms and Conditions is declared to be illegal, invalid or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid and enforceable, or otherwise deleted, and the remainder of these Standard Terms and Conditions shall not be affected except to the extent necessary to reform or delete such illegal, invalid or unenforceable provision.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The headings preceding the text of the sections hereof are inserted solely for convenience of reference, and shall not constitute a part of these Standard Terms and Conditions, nor shall they affect its meaning, construction or effect. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. References herein to any agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan or these Standard Terms and Conditions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">These Standard Terms and Conditions shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">These Standard Terms and Conditions shall be construed in accordance with and governed by the laws of the State of Delaware, without regard to principles of conflicts of law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event of any conflict between the Grant Notice, these Standard Terms and Conditions and the Plan, the Grant Notice and these Standard Terms and Conditions shall control. In the event of any conflict between the Grant Notice and these Standard Terms and Conditions, the Grant Notice shall control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">All questions arising under the Plan or under these Standard Terms and Conditions shall be decided by the Committee in its total and absolute discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">CLAWBACK</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By accepting the Award, the Participant is agreeing (i) to repay any incentive-based compensation the Participant receives, whether paid pursuant to this Option or any other incentive-based compensation plan or agreement maintained in the past or adopted in the future by the Company, to the extent repayment is required under any clawback policy heretofore or hereafter adopted by the Company in compliance with stock exchange rules and Section 10D of the Act regarding erroneously awarded compensation, (ii) that the repayment of any incentive-based compensation as described in (i) shall not be an event giving rise to a right to resign for &#8220;good reason&#8221; or be deemed a &#8220;constructive termination&#8221; (or any similar term) as such terms are </font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">used in any agreement between the Participant and the Company or benefit plan covering the Participant, and (iii) that the Company shall not indemnify the Participant against any liability or loss (including without limitation the loss of any incentive-based compensation, any payment or reimbursement for the cost of third-party insurance purchased by the Participant to fund potential recovery obligations with respect to any clawback policy maintained by the Company, or any judgments, fines, taxes, penalties or amounts paid in settlement by or on behalf of the Participant) incurred by the Participant in connection with or as a result of any action taken by the Company to enforce the terms of any clawback policy or provision applicable to the Participant (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Clawback Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or provide any indemnification or advancement of expenses (including attorneys&#8217; fees) incurred by the Participant in connection with any such Clawback Proceeding.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">ELECTRONIC DELIVERY</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By executing the Grant Notice, the Participant hereby consents to the delivery of information (including information required to be delivered to the Participant pursuant to applicable securities laws) regarding the Company and the Subsidiaries, the Plan, the Option and the Common Stock via Company web site or other electronic delivery.</font></div><div><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ngne-2025formq110xqxex311p.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia5b55d786d534bc69f15754fe39d7adc_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Rachel McMinn, certify that&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of of Neurogene Inc&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:14pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date&#58; May&#160;9, 2025</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.134%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rachel McMinn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rachel McMinn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ngne-2025formq110xqxex312p.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iefcef874627c42ef97883e20d125dd12_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christine Mikail, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of of Neurogene Inc&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:14pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2025 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.134%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christine Mikail</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Mikail</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer (Principal Financial Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ngne-2025formq110xqxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i89b39e285f174b4fb68197ab8b0ee78f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">NEUROGENE INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Quarterly Report on Form 10-Q of Neurogene Inc. (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Rachel McMinn, Chief Executive Officer of the Company, and Christine Mikail, President and Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:11pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">, the undersigned have set their hands hereto as of May&#160;9, 2025. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.222%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rachel McMinn</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christine Mikail</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rachel McMinn</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Mikail</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neurogene Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Note&#58; A signed original of this written statement required by &#167;906 has been provided to Neurogene Inc. and will be retained by Neurogene Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ngne-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:455e46d4-7342-4901-9012-cb7d8f12b78e,g:0c981b7d-7032-4dc2-af2a-101f291ef69a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ngne="http://www.neurogene.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurogene.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ngne-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ngne-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ngne-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ngne-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurogene.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofStockholdersEquity" roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity">
        <link:definition>9952154 - Statement - Condensed Consolidated Statement of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.neurogene.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>9952156 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandUncertainties" roleURI="http://www.neurogene.com/role/RisksandUncertainties">
        <link:definition>9952157 - Disclosure - Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.neurogene.com/role/Investments">
        <link:definition>9952159 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://www.neurogene.com/role/FairValueofFinancialInstruments">
        <link:definition>9952160 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Prepaidexpensesandothercurrentassets" roleURI="http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets">
        <link:definition>9952161 - Disclosure - Prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.neurogene.com/role/PropertyandEquipmentNet">
        <link:definition>9952162 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952163 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.neurogene.com/role/CommitmentandContingencies">
        <link:definition>9952164 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Licenses" roleURI="http://www.neurogene.com/role/Licenses">
        <link:definition>9952165 - Disclosure - Licenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.neurogene.com/role/StockholdersEquityDeficit">
        <link:definition>9952166 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.neurogene.com/role/StockBasedCompensation">
        <link:definition>9952167 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.neurogene.com/role/SegmentInformation">
        <link:definition>9952168 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.neurogene.com/role/SubsequentEvents">
        <link:definition>9952169 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.neurogene.com/role/InvestmentsTables">
        <link:definition>9955513 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://www.neurogene.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>9955514 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesandothercurrentassetsTables" roleURI="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables">
        <link:definition>9955515 - Disclosure - Prepaid expenses and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetTables">
        <link:definition>9955516 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9955517 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.neurogene.com/role/CommitmentandContingenciesTables">
        <link:definition>9955518 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitTables" roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitTables">
        <link:definition>9955519 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.neurogene.com/role/StockBasedCompensationTables">
        <link:definition>9955520 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.neurogene.com/role/SegmentInformationTables">
        <link:definition>9955521 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RisksandUncertaintiesDetails" roleURI="http://www.neurogene.com/role/RisksandUncertaintiesDetails">
        <link:definition>9955522 - Disclosure - Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Summary of Accrued Liabilities Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails" roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Potentially Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.neurogene.com/role/InvestmentsDetails">
        <link:definition>9955527 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955528 - Disclosure - Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesandothercurrentassetsDetails" roleURI="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails">
        <link:definition>9955529 - Disclosure - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetPropertyandEquipmentDetails" roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails">
        <link:definition>9955530 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetNarrativeDetails" roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails">
        <link:definition>9955531 - Disclosure - Property and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9955532 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLeaseCostsDetails" roleURI="http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails">
        <link:definition>9955533 - Disclosure - Commitment and Contingencies - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>9955534 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesContingentValueRightsLiabilityDetails" roleURI="http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails">
        <link:definition>9955535 - Disclosure - Commitment and Contingencies - Contingent Value Rights Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicensesDetails" roleURI="http://www.neurogene.com/role/LicensesDetails">
        <link:definition>9955536 - Disclosure - Licenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitNarrativeDetails" roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails">
        <link:definition>9955537 - Disclosure - Stockholders&#8217; Equity (Deficit) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails" roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails">
        <link:definition>9955538 - Disclosure - Stockholders&#8217; Equity (Deficit) - Schedule of Exercise Of Pre-Funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails" roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails">
        <link:definition>9955539 - Disclosure - Stockholders&#8217; Equity (Deficit) - Reserved Shares for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOperatingExpensesDetails" roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails">
        <link:definition>9955540 - Disclosure - Stock-Based Compensation - Summary of Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOptionActivityDetails" roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails">
        <link:definition>9955541 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955542 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails" roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails">
        <link:definition>9955543 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOtherAwardsDetails" roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails">
        <link:definition>9955544 - Disclosure - Stock-Based Compensation - Summary of Other Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.neurogene.com/role/SegmentInformationDetails">
        <link:definition>9955545 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.neurogene.com/role/SubsequentEventsDetails">
        <link:definition>9955546 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ngne_IncreaseDecreaseInContingentValueRightsLiability" abstract="false" name="IncreaseDecreaseInContingentValueRightsLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_LicenseAgreementsAbstract" abstract="true" name="LicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ngne_ContingentValueRightsPolicyTextBlock" abstract="false" name="ContingentValueRightsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ngne_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" abstract="false" name="CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_Phase1NL201TrialMember" abstract="true" name="Phase1NL201TrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_RefundsAndOtherReceivablesCurrent" abstract="false" name="RefundsAndOtherReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_AccruedResearchAndDevelopmentCurrent" abstract="false" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" abstract="false" name="AccruedSeveranceBonusAndRetentionCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_NewYorkHeadquartersLeaseMember" abstract="true" name="NewYorkHeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_HoustonLeaseMember" abstract="true" name="HoustonLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_BlaineLeaseInSeattleMember" abstract="true" name="BlaineLeaseInSeattleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_EastlakeLeaseInSeattleMember" abstract="true" name="EastlakeLeaseInSeattleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_April2024CVRLicensingAgreementMember" abstract="true" name="April2024CVRLicensingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_December2023CVRLicensingAgreementMember" abstract="true" name="December2023CVRLicensingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_IntellectualPropertyCVRNettingMember" abstract="true" name="IntellectualPropertyCVRNettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_LeaseCVRMember" abstract="true" name="LeaseCVRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_SalesTaxCVRMember" abstract="true" name="SalesTaxCVRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_OperatingLeaseMonthlyPayments" abstract="false" name="OperatingLeaseMonthlyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_LesseeOperatingLeaseNumberOfRenewalTerm" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" abstract="false" name="CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" abstract="false" name="CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsReimbursement" abstract="false" name="CollaborativeArrangementRightsAndObligationsReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" abstract="false" name="IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" abstract="false" name="IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_AssetAcquisitionContingentConsiderationCashPayment" abstract="false" name="AssetAcquisitionContingentConsiderationCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" abstract="false" name="AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_UniversityOfEdinburghMember" abstract="true" name="UniversityOfEdinburghMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_VirovekIncMember" abstract="true" name="VirovekIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_SigmaAldrichCoMember" abstract="true" name="SigmaAldrichCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_StanfordLicenseAgreementMember" abstract="true" name="StanfordLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_RegulatoryRelatedMilestonesMember" abstract="true" name="RegulatoryRelatedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_SalesRelatedMilestonesMember" abstract="true" name="SalesRelatedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsAdditionalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" abstract="false" name="ResearchCollaborationAndLicenseAgreementOptionToTerminate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsExpense" abstract="false" name="CollaborativeArrangementRightsAndObligationsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ngne_CollaborativeArrangementTermOfAgreement" abstract="false" name="CollaborativeArrangementTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ngne_A2025InducementPlanMember" abstract="true" name="A2025InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_PercentageOfOutstandingStockPerStockholderMaximum" abstract="false" name="PercentageOfOutstandingStockPerStockholderMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" abstract="false" name="PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ngne_ClassOfWarrantOrRightNoticePeriod" abstract="false" name="ClassOfWarrantOrRightNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ngne_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_December2023PreferredStockConversionMember" abstract="true" name="December2023PreferredStockConversionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_December2023PreClosingMember" abstract="true" name="December2023PreClosingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ngne_A2023EquityIncentivePlanMember" abstract="true" name="A2023EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_A2023EmployeeStockPurchasePlanMember" abstract="true" name="A2023EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ShareBasedPaymentArrangementNumberOfTranches" abstract="false" name="ShareBasedPaymentArrangementNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" abstract="false" name="NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ngne_RettSyndromeMember" abstract="true" name="RettSyndromeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_BattenDiseaseMember" abstract="true" name="BattenDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_EarlyDiscoveryMember" abstract="true" name="EarlyDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_PersonnelRelatedExpenseMember" abstract="true" name="PersonnelRelatedExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ShareBasedCompensationExpenseMember" abstract="true" name="ShareBasedCompensationExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ManufacturingExpenseMember" abstract="true" name="ManufacturingExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ProfessionalAndConsultantFeesMember" abstract="true" name="ProfessionalAndConsultantFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_OfficeRelatedExpenseMember" abstract="true" name="OfficeRelatedExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ngne_StuartCobbMember" abstract="true" name="StuartCobbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ngne-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:455e46d4-7342-4901-9012-cb7d8f12b78e,g:0c981b7d-7032-4dc2-af2a-101f291ef69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ceabcdf9-f648-416c-b127-bc7af67b079f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_82a8f509-44da-4d60-9906-ee0a5776243f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ceabcdf9-f648-416c-b127-bc7af67b079f" xlink:to="loc_us-gaap_Liabilities_82a8f509-44da-4d60-9906-ee0a5776243f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd26f870-12f3-4185-8941-f242d227c299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ceabcdf9-f648-416c-b127-bc7af67b079f" xlink:to="loc_us-gaap_StockholdersEquity_dd26f870-12f3-4185-8941-f242d227c299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_59c3b87f-a6d4-427d-b267-de949d509f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e7a94551-9b7e-4941-9eac-b743915070c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_59c3b87f-a6d4-427d-b267-de949d509f86" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e7a94551-9b7e-4941-9eac-b743915070c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ee3a9e89-9a8a-457e-af0a-e53a2de7d985" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_59c3b87f-a6d4-427d-b267-de949d509f86" xlink:to="loc_us-gaap_ShortTermInvestments_ee3a9e89-9a8a-457e-af0a-e53a2de7d985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_79ac0a77-c8b7-476a-a87a-1cd07d94a916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_59c3b87f-a6d4-427d-b267-de949d509f86" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_79ac0a77-c8b7-476a-a87a-1cd07d94a916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_39c5eb46-fe27-4292-bc0d-6b7b81e8c668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_eca6886b-6d23-419a-bd52-ed15f6c8a462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_39c5eb46-fe27-4292-bc0d-6b7b81e8c668" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_eca6886b-6d23-419a-bd52-ed15f6c8a462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_40cffdde-1fed-430a-a103-a8db53168200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_39c5eb46-fe27-4292-bc0d-6b7b81e8c668" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_40cffdde-1fed-430a-a103-a8db53168200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_1ca48cd4-e1e3-41e1-8f80-75abe7b74e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_39c5eb46-fe27-4292-bc0d-6b7b81e8c668" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_1ca48cd4-e1e3-41e1-8f80-75abe7b74e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4695417-2e1c-415c-bd2b-98ce0a687355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_39c5eb46-fe27-4292-bc0d-6b7b81e8c668" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4695417-2e1c-415c-bd2b-98ce0a687355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_93c1823f-8126-419b-9a5d-d4a2531ce9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_39c5eb46-fe27-4292-bc0d-6b7b81e8c668" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_93c1823f-8126-419b-9a5d-d4a2531ce9f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cde442cd-db56-414e-a019-08bbadb64517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ef0c6d33-9843-4a33-af07-dae9b49f414b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde442cd-db56-414e-a019-08bbadb64517" xlink:to="loc_us-gaap_CommonStockValue_ef0c6d33-9843-4a33-af07-dae9b49f414b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_edbbcd25-74d6-4806-a92f-0903bac5c7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde442cd-db56-414e-a019-08bbadb64517" xlink:to="loc_us-gaap_AdditionalPaidInCapital_edbbcd25-74d6-4806-a92f-0903bac5c7f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eecd199c-d5bd-445b-832d-02c9ae37da6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde442cd-db56-414e-a019-08bbadb64517" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eecd199c-d5bd-445b-832d-02c9ae37da6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2fbd17cc-5c11-4409-a3f6-ba0746109ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde442cd-db56-414e-a019-08bbadb64517" xlink:to="loc_us-gaap_PreferredStockValue_2fbd17cc-5c11-4409-a3f6-ba0746109ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4790ce4-4feb-46af-b68a-f7c6a0ca1d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_021f20cd-44d2-4bae-aac7-06889314a51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4790ce4-4feb-46af-b68a-f7c6a0ca1d5f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_021f20cd-44d2-4bae-aac7-06889314a51b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ca0ee318-756a-4e76-9721-6afbc4ebf3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4790ce4-4feb-46af-b68a-f7c6a0ca1d5f" xlink:to="loc_us-gaap_AccountsPayableCurrent_ca0ee318-756a-4e76-9721-6afbc4ebf3cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_35602366-6f9f-448d-be43-692f067043fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4790ce4-4feb-46af-b68a-f7c6a0ca1d5f" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_35602366-6f9f-448d-be43-692f067043fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_164f9179-368d-4b9d-846f-4da191ed1b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4790ce4-4feb-46af-b68a-f7c6a0ca1d5f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_164f9179-368d-4b9d-846f-4da191ed1b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fbe035af-df9d-4a71-b195-f9cdb2db470b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4790ce4-4feb-46af-b68a-f7c6a0ca1d5f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fbe035af-df9d-4a71-b195-f9cdb2db470b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff3bed14-d5c8-4035-9214-cc558e9d99df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff3bed14-d5c8-4035-9214-cc558e9d99df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3f9fbec-2800-4b63-8b10-d7a9f976b6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3f9fbec-2800-4b63-8b10-d7a9f976b6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_9949fbdb-ec1a-400f-8182-010abfe88305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_9949fbdb-ec1a-400f-8182-010abfe88305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_62df6997-f030-47c7-a952-a3ee08020732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_62df6997-f030-47c7-a952-a3ee08020732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ad602d33-7bb6-45a4-b3b6-e67662ff20c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:to="loc_us-gaap_AssetsCurrent_ad602d33-7bb6-45a4-b3b6-e67662ff20c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a65188c6-08ac-4f5c-ac40-051c7d7c1544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76c01abc-5342-4911-8551-1b3215703a9f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a65188c6-08ac-4f5c-ac40-051c7d7c1544" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e49a36fb-6bd0-4765-b292-d6ed94f6b585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_aa0931dc-95a4-4d5e-bab1-7e99323d4746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e49a36fb-6bd0-4765-b292-d6ed94f6b585" xlink:to="loc_us-gaap_OtherNonoperatingIncome_aa0931dc-95a4-4d5e-bab1-7e99323d4746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b0546214-6865-42e2-95ec-4d5314ac3f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e49a36fb-6bd0-4765-b292-d6ed94f6b585" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b0546214-6865-42e2-95ec-4d5314ac3f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_2c29fdec-406e-49ca-8bd9-7cabb96ca664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e49a36fb-6bd0-4765-b292-d6ed94f6b585" xlink:to="loc_us-gaap_OtherNonoperatingExpense_2c29fdec-406e-49ca-8bd9-7cabb96ca664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_55e2c23f-a36c-447e-8316-71c8549e140e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e49a36fb-6bd0-4765-b292-d6ed94f6b585" xlink:to="loc_us-gaap_InvestmentIncomeInterest_55e2c23f-a36c-447e-8316-71c8549e140e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a7bab2cd-7fa1-419c-a6ee-5eb039dd48ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e49a36fb-6bd0-4765-b292-d6ed94f6b585" xlink:to="loc_us-gaap_OperatingIncomeLoss_a7bab2cd-7fa1-419c-a6ee-5eb039dd48ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5a784140-5901-461d-968d-7b2761dcf093" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_587e3471-7293-48d6-a10a-606c5d3ebb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5a784140-5901-461d-968d-7b2761dcf093" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_587e3471-7293-48d6-a10a-606c5d3ebb6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47b8f937-972e-4f8c-87cc-f8c2636eee56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5a784140-5901-461d-968d-7b2761dcf093" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47b8f937-972e-4f8c-87cc-f8c2636eee56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_add02e3f-8bc6-4109-a601-4587b4a6bc08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6df82302-2e4d-41c6-8428-e9e4e3170d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_add02e3f-8bc6-4109-a601-4587b4a6bc08" xlink:to="loc_us-gaap_OperatingExpenses_6df82302-2e4d-41c6-8428-e9e4e3170d14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475368e7-cb27-4d69-938d-9e8b109a62d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_815ebd70-16de-4ac5-b94d-677ebe2b9f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475368e7-cb27-4d69-938d-9e8b109a62d1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_815ebd70-16de-4ac5-b94d-677ebe2b9f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_fd3c2a39-d860-494b-ab95-0f1299ed809a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475368e7-cb27-4d69-938d-9e8b109a62d1" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_fd3c2a39-d860-494b-ab95-0f1299ed809a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_24a4aa30-4df7-47c8-a678-2eee2f357108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475368e7-cb27-4d69-938d-9e8b109a62d1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_24a4aa30-4df7-47c8-a678-2eee2f357108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_fed752c9-5f78-44bd-b636-e28af85777a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_475368e7-cb27-4d69-938d-9e8b109a62d1" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_fed752c9-5f78-44bd-b636-e28af85777a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e4d1ff1-cf2f-4f2b-af70-d67f8d0f99f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_81b5a1ae-a4ea-4182-bab0-264e9aec0185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e4d1ff1-cf2f-4f2b-af70-d67f8d0f99f8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_81b5a1ae-a4ea-4182-bab0-264e9aec0185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69d761c8-25aa-46ae-932c-3c8b0335905d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e4d1ff1-cf2f-4f2b-af70-d67f8d0f99f8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69d761c8-25aa-46ae-932c-3c8b0335905d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_4a389eca-68e6-46ed-9c8d-707ecae49a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e4d1ff1-cf2f-4f2b-af70-d67f8d0f99f8" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_4a389eca-68e6-46ed-9c8d-707ecae49a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4a8517bf-e0ed-4ad7-ae71-8dc5b6711ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a8b19d93-8cff-497b-b0d0-428c8686d58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4a8517bf-e0ed-4ad7-ae71-8dc5b6711ced" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a8b19d93-8cff-497b-b0d0-428c8686d58d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49e55897-f2ad-4cc6-bfa3-5f80f864f83d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4a8517bf-e0ed-4ad7-ae71-8dc5b6711ced" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49e55897-f2ad-4cc6-bfa3-5f80f864f83d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08e48906-9867-49e5-9770-4b9bec1e76bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4a8517bf-e0ed-4ad7-ae71-8dc5b6711ced" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_08e48906-9867-49e5-9770-4b9bec1e76bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2e19f0da-e44e-4211-8f32-9462ddd13a19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_ShareBasedCompensation_2e19f0da-e44e-4211-8f32-9462ddd13a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_add7a690-4196-4257-9d7f-44bf7bbfabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_NetIncomeLoss_add7a690-4196-4257-9d7f-44bf7bbfabe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_89b4d5b1-02b6-4305-91ed-ef49b1995f91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_OperatingLeaseExpense_89b4d5b1-02b6-4305-91ed-ef49b1995f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4f1bd6cc-732b-4c56-8728-8aff0fcf5a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4f1bd6cc-732b-4c56-8728-8aff0fcf5a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dcd0c689-ce78-4b48-b5bb-4640b55cf119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dcd0c689-ce78-4b48-b5bb-4640b55cf119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ffa2c319-02f0-44c0-98b8-08afb82dec0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ffa2c319-02f0-44c0-98b8-08afb82dec0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b9970d2e-2f59-4e00-98fb-513e01bef3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b9970d2e-2f59-4e00-98fb-513e01bef3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_455a2b43-39b9-46d2-904e-25f4bb9a3a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_455a2b43-39b9-46d2-904e-25f4bb9a3a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_65c3ff37-7fa2-4bba-916a-c86cb37719e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_65c3ff37-7fa2-4bba-916a-c86cb37719e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bab5d9c2-7981-40aa-b267-4cdef746435b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bab5d9c2-7981-40aa-b267-4cdef746435b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a981c6d4-3193-4a5f-a5b7-386a7a3a5cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_AssetImpairmentCharges_a981c6d4-3193-4a5f-a5b7-386a7a3a5cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_92de7b88-9311-48a6-87b6-0d3d81c8fc22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_92de7b88-9311-48a6-87b6-0d3d81c8fc22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IncreaseDecreaseInContingentValueRightsLiability_01c3f0ea-9913-4c00-93a6-1aed36234e3e" xlink:href="ngne-20250331.xsd#ngne_IncreaseDecreaseInContingentValueRightsLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_21ebaba9-c9fa-432a-b227-5e594d0fd096" xlink:to="loc_ngne_IncreaseDecreaseInContingentValueRightsLiability_01c3f0ea-9913-4c00-93a6-1aed36234e3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26c39768-cbf8-4cc0-a20d-d0e8acf187a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_37720646-a312-48ed-8980-7be4800dcbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26c39768-cbf8-4cc0-a20d-d0e8acf187a5" xlink:to="loc_us-gaap_RestrictedCash_37720646-a312-48ed-8980-7be4800dcbf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77ab817f-a71e-4738-9aa0-2a2ec0c604c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26c39768-cbf8-4cc0-a20d-d0e8acf187a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77ab817f-a71e-4738-9aa0-2a2ec0c604c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_46766fea-269f-48b0-96bd-8c2aa0f2676b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_67e4c462-864c-4fb1-92de-a2b6d01c51f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_46766fea-269f-48b0-96bd-8c2aa0f2676b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_67e4c462-864c-4fb1-92de-a2b6d01c51f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_617725b2-ec32-4827-9cde-7318a2d03221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_46766fea-269f-48b0-96bd-8c2aa0f2676b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_617725b2-ec32-4827-9cde-7318a2d03221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_a858a78a-6c8b-4222-beb0-a66f98494432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_46766fea-269f-48b0-96bd-8c2aa0f2676b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_a858a78a-6c8b-4222-beb0-a66f98494432" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1d8be44c-ff94-4142-87ec-c6c0d0753236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_72229add-4cbe-4faf-88f7-9e8d8d5ca24e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1d8be44c-ff94-4142-87ec-c6c0d0753236" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_72229add-4cbe-4faf-88f7-9e8d8d5ca24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b0b59700-d973-4382-b740-946c94946ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1d8be44c-ff94-4142-87ec-c6c0d0753236" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b0b59700-d973-4382-b740-946c94946ac0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#PrepaidexpensesandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9fb63f6f-8f62-4697-ae80-455f03e1d36e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2e453dc2-38fb-473f-b14b-052a96e0a362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9fb63f6f-8f62-4697-ae80-455f03e1d36e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2e453dc2-38fb-473f-b14b-052a96e0a362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RefundsAndOtherReceivablesCurrent_e360f81e-087c-4ab5-be31-f897963670ad" xlink:href="ngne-20250331.xsd#ngne_RefundsAndOtherReceivablesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9fb63f6f-8f62-4697-ae80-455f03e1d36e" xlink:to="loc_ngne_RefundsAndOtherReceivablesCurrent_e360f81e-087c-4ab5-be31-f897963670ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_966ab0cf-fd10-4e82-b54f-dfe2a717cd10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9fb63f6f-8f62-4697-ae80-455f03e1d36e" xlink:to="loc_us-gaap_OtherAssetsCurrent_966ab0cf-fd10-4e82-b54f-dfe2a717cd10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#PropertyandEquipmentNetPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44e7be51-2011-4b41-9e02-31b51facd1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ade4fbd1-a21d-453b-b3e1-5fc3850e502f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_44e7be51-2011-4b41-9e02-31b51facd1b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ade4fbd1-a21d-453b-b3e1-5fc3850e502f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dfeff97c-42fe-43d8-94cf-79fef7fe7274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_44e7be51-2011-4b41-9e02-31b51facd1b0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dfeff97c-42fe-43d8-94cf-79fef7fe7274" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7549ba28-6bb4-4c02-8f7b-fecf04a4a513" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_39561079-f6f4-4b96-9198-26b88c5700ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7549ba28-6bb4-4c02-8f7b-fecf04a4a513" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_39561079-f6f4-4b96-9198-26b88c5700ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AccruedResearchAndDevelopmentCurrent_27f696f2-8938-4ce3-bece-512f6cb973c9" xlink:href="ngne-20250331.xsd#ngne_AccruedResearchAndDevelopmentCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7549ba28-6bb4-4c02-8f7b-fecf04a4a513" xlink:to="loc_ngne_AccruedResearchAndDevelopmentCurrent_27f696f2-8938-4ce3-bece-512f6cb973c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6b417664-791a-4f0b-8e7f-c55acbafc26e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7549ba28-6bb4-4c02-8f7b-fecf04a4a513" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6b417664-791a-4f0b-8e7f-c55acbafc26e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_81f31772-310f-446a-80f8-9f6c3987a7fb" xlink:href="ngne-20250331.xsd#ngne_AccruedSeveranceBonusAndRetentionCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7549ba28-6bb4-4c02-8f7b-fecf04a4a513" xlink:to="loc_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_81f31772-310f-446a-80f8-9f6c3987a7fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f6cb32ed-ddf8-415b-81da-de1c986528d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_61679c64-cfe1-4d01-8c04-500dbcfa2f87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f6cb32ed-ddf8-415b-81da-de1c986528d6" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_61679c64-cfe1-4d01-8c04-500dbcfa2f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_efb16e9b-de2b-4c7e-8d87-8ba4affb752f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f6cb32ed-ddf8-415b-81da-de1c986528d6" xlink:to="loc_us-gaap_VariableLeaseCost_efb16e9b-de2b-4c7e-8d87-8ba4affb752f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a5955cd4-57b6-4465-afd5-668203f8029e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f6cb32ed-ddf8-415b-81da-de1c986528d6" xlink:to="loc_us-gaap_ShortTermLeaseCost_a5955cd4-57b6-4465-afd5-668203f8029e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_49e996e7-2162-437f-b0f5-f96c32e6fed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f6cb32ed-ddf8-415b-81da-de1c986528d6" xlink:to="loc_us-gaap_OperatingLeaseCost_49e996e7-2162-437f-b0f5-f96c32e6fed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_23ba605d-9bcb-488e-ac46-7eaf7fa1730f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f6cb32ed-ddf8-415b-81da-de1c986528d6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_23ba605d-9bcb-488e-ac46-7eaf7fa1730f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SegmentInformationDetails"/>
  <link:calculationLink xlink:role="http://www.neurogene.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0286edf-a120-446a-816c-ce91f3cfbc10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_840baa55-0453-42ac-9faf-eb7a63cf2265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e0286edf-a120-446a-816c-ce91f3cfbc10" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_840baa55-0453-42ac-9faf-eb7a63cf2265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_59e07905-66ef-4d3b-a916-48fdabae4b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e0286edf-a120-446a-816c-ce91f3cfbc10" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_59e07905-66ef-4d3b-a916-48fdabae4b38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_130cb4bc-b481-49dd-9b42-fdeb891b046f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e0286edf-a120-446a-816c-ce91f3cfbc10" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_130cb4bc-b481-49dd-9b42-fdeb891b046f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ngne-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:455e46d4-7342-4901-9012-cb7d8f12b78e,g:0c981b7d-7032-4dc2-af2a-101f291ef69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedStatementofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c43a7b3-5cd4-4edc-bbe0-fea6265beb93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3c43a7b3-5cd4-4edc-bbe0-fea6265beb93" xlink:to="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d23c59d9-253a-43e8-8ef7-0e4d900aeacf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:to="loc_us-gaap_EquityComponentDomain_d23c59d9-253a-43e8-8ef7-0e4d900aeacf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:to="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0dc9d119-8033-4039-9c51-23817531fc56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:to="loc_us-gaap_CommonStockMember_0dc9d119-8033-4039-9c51-23817531fc56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_46dcf968-30f4-4646-900e-c122f407e5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_46dcf968-30f4-4646-900e-c122f407e5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3d8695c9-d83c-487c-8533-0dd13c5d2174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:to="loc_us-gaap_RetainedEarningsMember_3d8695c9-d83c-487c-8533-0dd13c5d2174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c43a7b3-5cd4-4edc-bbe0-fea6265beb93" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f76c7d53-fe8c-416e-9ed0-7fa15e50db76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f76c7d53-fe8c-416e-9ed0-7fa15e50db76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94245390-a46c-487a-8044-e4d917d9796e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockholdersEquity_94245390-a46c-487a-8044-e4d917d9796e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fccb737a-e634-4481-b700-278b7fd8adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fccb737a-e634-4481-b700-278b7fd8adbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78c31229-78b3-41af-bb84-6417a4ed304b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78c31229-78b3-41af-bb84-6417a4ed304b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b406d16b-63c4-47d4-8345-97160f1da785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b406d16b-63c4-47d4-8345-97160f1da785" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d8616e7b-84db-4f43-a162-503a7e052577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d8616e7b-84db-4f43-a162-503a7e052577" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed14aaef-4239-4d15-8734-67398e01253f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_NetIncomeLoss_ed14aaef-4239-4d15-8734-67398e01253f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1e5bf3b6-9440-4426-8acc-63e53ae74249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07783a94-5528-48dc-b718-767686ea5a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0b325ad7-499e-4d3b-8f3d-a9fce233ac18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0b325ad7-499e-4d3b-8f3d-a9fce233ac18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_566907b8-3873-4cda-8070-f79b9fc76b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_566907b8-3873-4cda-8070-f79b9fc76b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_b620b366-93a3-49ea-9736-8609dbbf733d" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_566907b8-3873-4cda-8070-f79b9fc76b1f" xlink:to="loc_ngne_PreFundedWarrantsMember_b620b366-93a3-49ea-9736-8609dbbf733d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cecbb1c6-419b-45a4-b7c2-bcceb68f1f95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cecbb1c6-419b-45a4-b7c2-bcceb68f1f95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_83a189b3-8dd9-4f06-a47d-1c38ebe74410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_NumberOfReportableSegments_83a189b3-8dd9-4f06-a47d-1c38ebe74410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_70a6ba8d-6c78-4251-8a4a-4da2a943667b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_RestrictedCash_70a6ba8d-6c78-4251-8a4a-4da2a943667b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_6952de8d-a5d2-43e7-a948-1df248687454" xlink:href="ngne-20250331.xsd#ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_6952de8d-a5d2-43e7-a948-1df248687454" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6a520102-4dbc-488c-bba6-4edd121a49af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6a520102-4dbc-488c-bba6-4edd121a49af" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c92f434f-3cca-4dac-a43a-ec42c7fcd6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92f434f-3cca-4dac-a43a-ec42c7fcd6f2" xlink:to="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:to="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5b5c4c3d-4bd6-403d-83e2-a95999677757_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:to="loc_us-gaap_RestructuringPlanDomain_5b5c4c3d-4bd6-403d-83e2-a95999677757_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3abfd93f-9fcf-47a0-89b1-c4f127d4d4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:to="loc_us-gaap_RestructuringPlanDomain_3abfd93f-9fcf-47a0-89b1-c4f127d4d4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_Phase1NL201TrialMember_a7564739-3e68-43ff-9d5e-432fa42de8b1" xlink:href="ngne-20250331.xsd#ngne_Phase1NL201TrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3abfd93f-9fcf-47a0-89b1-c4f127d4d4db" xlink:to="loc_ngne_Phase1NL201TrialMember_a7564739-3e68-43ff-9d5e-432fa42de8b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92f434f-3cca-4dac-a43a-ec42c7fcd6f2" xlink:to="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e0a65761-7ccf-48a2-8fdb-37f042fbb32d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_RestructuringReserve_e0a65761-7ccf-48a2-8fdb-37f042fbb32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_49429c1e-130c-4d41-956c-cd01d20326bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_49429c1e-130c-4d41-956c-cd01d20326bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_5a853dc5-436a-4aee-81f6-e78642a0c000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_PaymentsForRestructuring_5a853dc5-436a-4aee-81f6-e78642a0c000" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_38df8a51-9338-4bc4-bf3a-d0f492a86c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_177ce0dd-d9a8-4eb4-a22d-173b3df8013e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_177ce0dd-d9a8-4eb4-a22d-173b3df8013e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6e7e320e-e3de-47dd-b5c0-f5684dbb572f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6e7e320e-e3de-47dd-b5c0-f5684dbb572f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_336610df-1fc0-47f5-98a4-6e53d88985e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_336610df-1fc0-47f5-98a4-6e53d88985e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bbfb9cb7-96a2-461c-bd91-e66fb0af0c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bbfb9cb7-96a2-461c-bd91-e66fb0af0c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_08bc4340-55d8-4013-9983-a8ff9e00475c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:to="loc_us-gaap_PerformanceSharesMember_08bc4340-55d8-4013-9983-a8ff9e00475c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50a622ab-b921-48d8-a057-1bcb2683270a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_177ce0dd-d9a8-4eb4-a22d-173b3df8013e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50a622ab-b921-48d8-a057-1bcb2683270a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:to="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_613c9955-0e3b-4cca-8fcd-bc478e3cd40f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_613c9955-0e3b-4cca-8fcd-bc478e3cd40f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d2a6d14c-8909-4969-8205-306fcf152200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d2a6d14c-8909-4969-8205-306fcf152200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_5063d005-1bab-4a90-abc6-f39acd9d04e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_5063d005-1bab-4a90-abc6-f39acd9d04e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e4913eee-c924-470a-b651-105e99db0703_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e4913eee-c924-470a-b651-105e99db0703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_0d78df3d-9f5e-4acc-ad34-c22e35297265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_0d78df3d-9f5e-4acc-ad34-c22e35297265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_601d5863-b43d-4195-a8dd-074e20c2a454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_601d5863-b43d-4195-a8dd-074e20c2a454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_b3e45f9e-75d7-4af9-a4ec-726d030789f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_b3e45f9e-75d7-4af9-a4ec-726d030789f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cefa37b8-b2be-494c-a1b2-9716740e27b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cefa37b8-b2be-494c-a1b2-9716740e27b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_cdff19c5-4937-47f4-a12a-7605a95c68ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_cdff19c5-4937-47f4-a12a-7605a95c68ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c33fc58e-9eeb-4ab9-bfdc-62dc3e1ecd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c33fc58e-9eeb-4ab9-bfdc-62dc3e1ecd6b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_330aea5d-fe00-46e2-ae66-9f86efc691f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_330aea5d-fe00-46e2-ae66-9f86efc691f3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_97342f79-5924-4a96-bdba-53c8e0bba9b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_97342f79-5924-4a96-bdba-53c8e0bba9b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5de95e86-874f-492f-9750-bd39974fb29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5de95e86-874f-492f-9750-bd39974fb29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8aefe557-3fea-49fc-a937-303ef4c393f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5de95e86-874f-492f-9750-bd39974fb29b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8aefe557-3fea-49fc-a937-303ef4c393f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f827ed67-2cac-4d5d-b328-319285bb2d01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f827ed67-2cac-4d5d-b328-319285bb2d01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b7a42a0b-7956-4f96-962a-2b2ea7301732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b7a42a0b-7956-4f96-962a-2b2ea7301732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd888baf-5f6d-4176-8dd1-d874b633e13e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd888baf-5f6d-4176-8dd1-d874b633e13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2e063d4-6259-4434-b7e0-78b6f39c9135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2e063d4-6259-4434-b7e0-78b6f39c9135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_700b1b9e-bc7a-4558-9ae2-c4689bd7830a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_700b1b9e-bc7a-4558-9ae2-c4689bd7830a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9c4c379d-f589-426e-9e25-5f47ff52658b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9c4c379d-f589-426e-9e25-5f47ff52658b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_83eabdf1-7722-4017-b7d3-b9fbba2dee01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9c4c379d-f589-426e-9e25-5f47ff52658b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_83eabdf1-7722-4017-b7d3-b9fbba2dee01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_330aea5d-fe00-46e2-ae66-9f86efc691f3" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_354cfeec-22eb-48f2-a5b1-d3ecc88e492e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_354cfeec-22eb-48f2-a5b1-d3ecc88e492e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ea2110bd-1bb8-4d98-b218-955bb94b8178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ea2110bd-1bb8-4d98-b218-955bb94b8178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_919bd587-c2a7-489c-8af9-027c1c101b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_919bd587-c2a7-489c-8af9-027c1c101b9d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#PropertyandEquipmentNetPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34ec81af-e15d-4982-a585-e32f11c2b378_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34ec81af-e15d-4982-a585-e32f11c2b378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LabEquipmentMember_533d20e6-7cc4-4fca-afa2-e7ddd7d9d072" xlink:href="ngne-20250331.xsd#ngne_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_ngne_LabEquipmentMember_533d20e6-7cc4-4fca-afa2-e7ddd7d9d072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ManufacturingEquipmentMember_6dec9225-7131-4a89-8fe6-21c3bc6e80e9" xlink:href="ngne-20250331.xsd#ngne_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_ngne_ManufacturingEquipmentMember_6dec9225-7131-4a89-8fe6-21c3bc6e80e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a30a485f-80df-4e7a-8588-802d424a0fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_OfficeEquipmentMember_a30a485f-80df-4e7a-8588-802d424a0fe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_55f76d91-0e3b-489a-a5c4-52477856debd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_55f76d91-0e3b-489a-a5c4-52477856debd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9c47bcc5-f5bb-44bc-a7e2-65f1e72bc612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9c47bcc5-f5bb-44bc-a7e2-65f1e72bc612" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2d65dae0-eff7-4381-a953-bb41c865c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_ConstructionInProgressMember_2d65dae0-eff7-4381-a953-bb41c865c95b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7020366-baee-4b7b-a809-e5e483ddba90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7020366-baee-4b7b-a809-e5e483ddba90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d91ab28-77c6-43bc-bd4c-d5292f35ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d91ab28-77c6-43bc-bd4c-d5292f35ae58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b9f8e185-89e1-4ce2-9fdb-96cbf270706a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b9f8e185-89e1-4ce2-9fdb-96cbf270706a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_224a7916-6a94-4d64-ac95-02d889d64cd2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_224a7916-6a94-4d64-ac95-02d889d64cd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_NewYorkHeadquartersLeaseMember_174be79d-557f-4c88-8d3a-f807f81fdfea" xlink:href="ngne-20250331.xsd#ngne_NewYorkHeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_NewYorkHeadquartersLeaseMember_174be79d-557f-4c88-8d3a-f807f81fdfea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_HoustonLeaseMember_8f212006-16b7-4cb3-85fa-94c274a94967" xlink:href="ngne-20250331.xsd#ngne_HoustonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_HoustonLeaseMember_8f212006-16b7-4cb3-85fa-94c274a94967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_BlaineLeaseInSeattleMember_308cbfa8-2e4f-4b37-9309-a6f2cb9fdb90" xlink:href="ngne-20250331.xsd#ngne_BlaineLeaseInSeattleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_BlaineLeaseInSeattleMember_308cbfa8-2e4f-4b37-9309-a6f2cb9fdb90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_EastlakeLeaseInSeattleMember_e916ea74-df66-4a90-a1e4-fac91500d0cf" xlink:href="ngne-20250331.xsd#ngne_EastlakeLeaseInSeattleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_EastlakeLeaseInSeattleMember_e916ea74-df66-4a90-a1e4-fac91500d0cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1f81ad8-062c-4c62-b27d-f96d0749c01b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:to="loc_srt_RangeMember_c1f81ad8-062c-4c62-b27d-f96d0749c01b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:to="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1dab13e4-09f4-437c-be1c-f0dbd393ec1f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:to="loc_srt_MinimumMember_1dab13e4-09f4-437c-be1c-f0dbd393ec1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49855f1d-7f08-4359-9107-ce80aa5de32c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:to="loc_srt_MaximumMember_49855f1d-7f08-4359-9107-ce80aa5de32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34dbddf-8dd4-4982-8b6f-89c65970d279_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c34dbddf-8dd4-4982-8b6f-89c65970d279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_April2024CVRLicensingAgreementMember_4ec41afa-dc56-458d-a326-a18be2fcf4c0" xlink:href="ngne-20250331.xsd#ngne_April2024CVRLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:to="loc_ngne_April2024CVRLicensingAgreementMember_4ec41afa-dc56-458d-a326-a18be2fcf4c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023CVRLicensingAgreementMember_b3d4e600-792b-47a8-b26d-a06fd45d508d" xlink:href="ngne-20250331.xsd#ngne_December2023CVRLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:to="loc_ngne_December2023CVRLicensingAgreementMember_b3d4e600-792b-47a8-b26d-a06fd45d508d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_999e8bfa-b234-4f97-bcf3-dc1175b61c2e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:to="loc_srt_ProductsAndServicesDomain_999e8bfa-b234-4f97-bcf3-dc1175b61c2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:to="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b5fa6f38-49fb-4e78-a079-aa4bd55bd99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:to="loc_us-gaap_LicenseMember_b5fa6f38-49fb-4e78-a079-aa4bd55bd99d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember_960f26ae-5079-4908-b2e1-20c58a3c2a6a" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:to="loc_ngne_IntellectualPropertyCVRNettingMember_960f26ae-5079-4908-b2e1-20c58a3c2a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LeaseCVRMember_1b9bef42-fa6a-4090-b3dd-4ca70c0c86ae" xlink:href="ngne-20250331.xsd#ngne_LeaseCVRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:to="loc_ngne_LeaseCVRMember_1b9bef42-fa6a-4090-b3dd-4ca70c0c86ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87c28035-77d2-4b2f-afa9-8275d185939c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_87c28035-77d2-4b2f-afa9-8275d185939c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ad6255a-1e97-4de7-a72c-3b8ad05f7cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ad6255a-1e97-4de7-a72c-3b8ad05f7cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_13f3bbc6-4026-41a3-9229-4b9f398be38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ad6255a-1e97-4de7-a72c-3b8ad05f7cc7" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_13f3bbc6-4026-41a3-9229-4b9f398be38e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_55fe7904-ff68-447b-8bb3-77ac7b0c0729_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_55fe7904-ff68-447b-8bb3-77ac7b0c0729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember_c0d6292a-5c3f-4f88-8ebe-7efafd5e8f37" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:to="loc_ngne_IntellectualPropertyCVRNettingMember_c0d6292a-5c3f-4f88-8ebe-7efafd5e8f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesTaxCVRMember_6024120a-af0d-41fb-a84e-6fdcfaf9772b" xlink:href="ngne-20250331.xsd#ngne_SalesTaxCVRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:to="loc_ngne_SalesTaxCVRMember_6024120a-af0d-41fb-a84e-6fdcfaf9772b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_227282a8-1fcb-432c-987d-5513ee1a44a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_227282a8-1fcb-432c-987d-5513ee1a44a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8d387272-2dd9-489d-9c7a-98b734bc463d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8d387272-2dd9-489d-9c7a-98b734bc463d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_OperatingLeaseMonthlyPayments_f16547e5-5bc6-4b57-b2dd-e47c749671e3" xlink:href="ngne-20250331.xsd#ngne_OperatingLeaseMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_OperatingLeaseMonthlyPayments_f16547e5-5bc6-4b57-b2dd-e47c749671e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_410e704d-7002-4732-930a-533bb59c6327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_410e704d-7002-4732-930a-533bb59c6327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8ad137e7-fc15-492f-bc96-f09ccceee5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_OperatingLeaseLiability_8ad137e7-fc15-492f-bc96-f09ccceee5f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_e38a61d6-ce51-4542-b9b4-6c12f177d422" xlink:href="ngne-20250331.xsd#ngne_LesseeOperatingLeaseNumberOfRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_e38a61d6-ce51-4542-b9b4-6c12f177d422" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dc650b53-8a60-4bb7-9d47-a8e444900cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dc650b53-8a60-4bb7-9d47-a8e444900cfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_5ebc92dc-b9bc-42e0-8956-f05592ef56a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_SecurityDeposit_5ebc92dc-b9bc-42e0-8956-f05592ef56a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_ff1bfb41-c8a2-4a66-b7d8-ccc1a8a15085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_PrepaidRent_ff1bfb41-c8a2-4a66-b7d8-ccc1a8a15085" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_385f0b23-aeb6-4eac-8ae5-59d0575c44a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_385f0b23-aeb6-4eac-8ae5-59d0575c44a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_64b125a9-1636-42f7-8ac9-63569dcc0011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_64b125a9-1636-42f7-8ac9-63569dcc0011" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_002f59e9-712a-454c-b6b6-67201eef66de" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_002f59e9-712a-454c-b6b6-67201eef66de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_0934de2a-9555-4692-ad62-7357303cb594" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_0934de2a-9555-4692-ad62-7357303cb594" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eda68757-30f8-4dff-82f7-6fe0f3b73635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eda68757-30f8-4dff-82f7-6fe0f3b73635" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_1cec173c-df94-480d-b4ba-497fc9644d54" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_1cec173c-df94-480d-b4ba-497fc9644d54" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_868074ec-55fb-46c1-9b7c-59303a799b7d" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_868074ec-55fb-46c1-9b7c-59303a799b7d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_f610e7c9-96ce-4c74-a723-24c228b4f6a5" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_f610e7c9-96ce-4c74-a723-24c228b4f6a5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_026e0d45-9518-4738-8820-0e9f5a672064" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_026e0d45-9518-4738-8820-0e9f5a672064" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AssetAcquisitionContingentConsiderationCashPayment_6ca71c48-b24d-40ce-ad33-dfed725fcc26" xlink:href="ngne-20250331.xsd#ngne_AssetAcquisitionContingentConsiderationCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_AssetAcquisitionContingentConsiderationCashPayment_6ca71c48-b24d-40ce-ad33-dfed725fcc26" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_43e8abf9-d9db-48fe-9419-3542ce69b49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_43e8abf9-d9db-48fe-9419-3542ce69b49f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_f96e32df-0d66-4df4-b88a-4f3a6650dcd5" xlink:href="ngne-20250331.xsd#ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_f96e32df-0d66-4df4-b88a-4f3a6650dcd5" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesContingentValueRightsLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:to="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_10fa5728-17e4-438a-a627-70c79c8e22f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_10fa5728-17e4-438a-a627-70c79c8e22f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LeaseCVRMember_ac59e363-c8df-41e7-9b19-ad29e4187bb1" xlink:href="ngne-20250331.xsd#ngne_LeaseCVRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:to="loc_ngne_LeaseCVRMember_ac59e363-c8df-41e7-9b19-ad29e4187bb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember_e765f05a-cf8b-4622-b67d-40bb1745487d" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:to="loc_ngne_IntellectualPropertyCVRNettingMember_e765f05a-cf8b-4622-b67d-40bb1745487d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesTaxCVRMember_cab2fb3f-c9b6-442e-94e2-db4a2a6d6cac" xlink:href="ngne-20250331.xsd#ngne_SalesTaxCVRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:to="loc_ngne_SalesTaxCVRMember_cab2fb3f-c9b6-442e-94e2-db4a2a6d6cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_6c66de65-d588-4304-b119-bb2c634be417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_6c66de65-d588-4304-b119-bb2c634be417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_b45bd7af-a97b-4a62-99b7-afbf13055e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_b45bd7af-a97b-4a62-99b7-afbf13055e2f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/LicensesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#LicensesDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/LicensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d704a63-fd95-4e98-a882-794c3f704a94_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d704a63-fd95-4e98-a882-794c3f704a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_UniversityOfEdinburghMember_c25c1c02-6f1e-4c13-aebc-3a975d28d285" xlink:href="ngne-20250331.xsd#ngne_UniversityOfEdinburghMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_UniversityOfEdinburghMember_c25c1c02-6f1e-4c13-aebc-3a975d28d285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_VirovekIncMember_8acaa9c2-91fc-4c75-9e41-82734de2acc4" xlink:href="ngne-20250331.xsd#ngne_VirovekIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_VirovekIncMember_8acaa9c2-91fc-4c75-9e41-82734de2acc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SigmaAldrichCoMember_24a48736-5d43-49d5-8870-0484fe8010c7" xlink:href="ngne-20250331.xsd#ngne_SigmaAldrichCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_SigmaAldrichCoMember_24a48736-5d43-49d5-8870-0484fe8010c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_StanfordLicenseAgreementMember_2f2b51f5-8bb5-4e89-98fe-39181218245d" xlink:href="ngne-20250331.xsd#ngne_StanfordLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_StanfordLicenseAgreementMember_2f2b51f5-8bb5-4e89-98fe-39181218245d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5690096-ae80-4584-9ec9-7fd0086093a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5690096-ae80-4584-9ec9-7fd0086093a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2c5e936-c256-4c2f-bc1a-331ec89195e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2c5e936-c256-4c2f-bc1a-331ec89195e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_820c51e3-a2b5-4f30-b398-47e64c20c385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2c5e936-c256-4c2f-bc1a-331ec89195e3" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_820c51e3-a2b5-4f30-b398-47e64c20c385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fbb1397d-accf-4dd0-86ea-f0aa70e94aba_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:to="loc_srt_ProductsAndServicesDomain_fbb1397d-accf-4dd0-86ea-f0aa70e94aba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:to="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RegulatoryRelatedMilestonesMember_ef4c832c-cf67-4416-87a1-6bff0d3c5f26" xlink:href="ngne-20250331.xsd#ngne_RegulatoryRelatedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:to="loc_ngne_RegulatoryRelatedMilestonesMember_ef4c832c-cf67-4416-87a1-6bff0d3c5f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesRelatedMilestonesMember_c81bc8d5-9f39-4371-990e-6e463bdf3e41" xlink:href="ngne-20250331.xsd#ngne_SalesRelatedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:to="loc_ngne_SalesRelatedMilestonesMember_c81bc8d5-9f39-4371-990e-6e463bdf3e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsTerm_8da7d9bc-7e4d-4e97-a0e7-912773508e71" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsTerm_8da7d9bc-7e4d-4e97-a0e7-912773508e71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_93c18178-ea46-49df-b3c9-492f5ea3065c" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_93c18178-ea46-49df-b3c9-492f5ea3065c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_178a32e2-853f-4f0d-b1b9-5f3998c529da" xlink:href="ngne-20250331.xsd#ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_178a32e2-853f-4f0d-b1b9-5f3998c529da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_7ef6e99c-d24f-487b-be3d-07052762d2cd" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_7ef6e99c-d24f-487b-be3d-07052762d2cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsExpense_fe00aa75-07f3-4c87-a2c2-14072ef90bef" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsExpense_fe00aa75-07f3-4c87-a2c2-14072ef90bef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_7233bdbf-03d4-457d-8d0c-f04e5894b06b" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_7233bdbf-03d4-457d-8d0c-f04e5894b06b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementTermOfAgreement_5b67b6f6-6a4a-4e07-9e79-0996ef099687" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementTermOfAgreement_5b67b6f6-6a4a-4e07-9e79-0996ef099687" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ee20af8-a3a2-4eb2-8e33-95242820085f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:to="loc_us-gaap_PlanNameDomain_3ee20af8-a3a2-4eb2-8e33-95242820085f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_03544c5d-3bb9-4655-9a1b-2cd20693dadf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:to="loc_us-gaap_PlanNameDomain_03544c5d-3bb9-4655-9a1b-2cd20693dadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2025InducementPlanMember_32a65584-50fb-494c-9509-ee9f51ba7891" xlink:href="ngne-20250331.xsd#ngne_A2025InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_03544c5d-3bb9-4655-9a1b-2cd20693dadf" xlink:to="loc_ngne_A2025InducementPlanMember_32a65584-50fb-494c-9509-ee9f51ba7891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aaa3ad01-e152-4d5b-863c-3f7cd478efb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aaa3ad01-e152-4d5b-863c-3f7cd478efb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9ab3acad-f73c-4973-ad6b-13ed42a9bf69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9ab3acad-f73c-4973-ad6b-13ed42a9bf69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_65d80bce-60f2-4661-b8ef-e5bf405bb571" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9ab3acad-f73c-4973-ad6b-13ed42a9bf69" xlink:to="loc_ngne_PreFundedWarrantsMember_65d80bce-60f2-4661-b8ef-e5bf405bb571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_599f38df-789c-42ed-9ddb-474e531dc9af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_599f38df-789c-42ed-9ddb-474e531dc9af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_851558d9-86ed-408e-b341-7da1c08933f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_851558d9-86ed-408e-b341-7da1c08933f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c1030ad-ea52-408d-bf2e-f03d415d881d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c1030ad-ea52-408d-bf2e-f03d415d881d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab3bfdcf-b6e1-4798-95ae-104110ab4e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab3bfdcf-b6e1-4798-95ae-104110ab4e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_060e749c-7903-4d6c-9088-eb7eb4d3d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_060e749c-7903-4d6c-9088-eb7eb4d3d46d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PercentageOfOutstandingStockPerStockholderMaximum_cd3f8728-02ad-43d8-80f7-5a28032b65c0" xlink:href="ngne-20250331.xsd#ngne_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_ngne_PercentageOfOutstandingStockPerStockholderMaximum_cd3f8728-02ad-43d8-80f7-5a28032b65c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_de142f0c-4592-4356-aa3e-d8d89ed650e4" xlink:href="ngne-20250331.xsd#ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_de142f0c-4592-4356-aa3e-d8d89ed650e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ClassOfWarrantOrRightNoticePeriod_4bb53c4b-3293-4477-a2ba-b5e5aade100e" xlink:href="ngne-20250331.xsd#ngne_ClassOfWarrantOrRightNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_ngne_ClassOfWarrantOrRightNoticePeriod_4bb53c4b-3293-4477-a2ba-b5e5aade100e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_594a3c31-cc66-4113-85a6-d3337d1f9b23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_594a3c31-cc66-4113-85a6-d3337d1f9b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_633ef057-17d5-4636-84f7-5bc6a0190742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_633ef057-17d5-4636-84f7-5bc6a0190742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_3ce93ca5-3ba6-4d1f-934e-23750103889b" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_633ef057-17d5-4636-84f7-5bc6a0190742" xlink:to="loc_ngne_PreFundedWarrantsMember_3ce93ca5-3ba6-4d1f-934e-23750103889b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b13e76c-c268-4e59-856a-f0751d2e1367_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b13e76c-c268-4e59-856a-f0751d2e1367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantMember_5906f0b6-b84b-4ad6-bfb3-881b672853ca" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_ngne_PreFundedWarrantMember_5906f0b6-b84b-4ad6-bfb3-881b672853ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023PreferredStockConversionMember_5b22ecf6-92d3-4519-a61a-28183627847b" xlink:href="ngne-20250331.xsd#ngne_December2023PreferredStockConversionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_ngne_December2023PreferredStockConversionMember_5b22ecf6-92d3-4519-a61a-28183627847b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023PreClosingMember_e03ec592-64fe-440c-b0fc-03cd1a91847a" xlink:href="ngne-20250331.xsd#ngne_December2023PreClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_ngne_December2023PreClosingMember_e03ec592-64fe-440c-b0fc-03cd1a91847a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9f0d9e2d-7f89-4772-bf53-68a357d8d976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_us-gaap_PrivatePlacementMember_9f0d9e2d-7f89-4772-bf53-68a357d8d976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7be3329d-8285-4d94-8ea7-f02df1e1aa78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7be3329d-8285-4d94-8ea7-f02df1e1aa78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_6914e79d-9406-4383-8867-db150aa54482" xlink:href="ngne-20250331.xsd#ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:to="loc_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_6914e79d-9406-4383-8867-db150aa54482" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_61cea535-f5ff-4b5c-a73b-5234cb81ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_61cea535-f5ff-4b5c-a73b-5234cb81ef4d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:to="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69dff46c-d09c-4948-8f81-0b85e35b2154_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69dff46c-d09c-4948-8f81-0b85e35b2154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_15fedd71-5fef-4b6d-aba9-8d8e7b73e026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_15fedd71-5fef-4b6d-aba9-8d8e7b73e026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_229aea20-c0c2-45af-83e2-824968ae349e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_us-gaap_PerformanceSharesMember_229aea20-c0c2-45af-83e2-824968ae349e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bcf64fa9-71e6-472e-9521-5a1f37fcc858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bcf64fa9-71e6-472e-9521-5a1f37fcc858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_b5003d60-6589-47bf-b38f-c53790ea9535" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_ngne_PreFundedWarrantsMember_b5003d60-6589-47bf-b38f-c53790ea9535" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:to="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_42cc25e9-e22b-4304-b37d-91eff8dc8423_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:to="loc_us-gaap_PlanNameDomain_42cc25e9-e22b-4304-b37d-91eff8dc8423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:to="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2023EquityIncentivePlanMember_cdcfd55d-440f-43e6-8ea2-8b3e279522d4" xlink:href="ngne-20250331.xsd#ngne_A2023EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:to="loc_ngne_A2023EquityIncentivePlanMember_cdcfd55d-440f-43e6-8ea2-8b3e279522d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2025InducementPlanMember_836931cd-6abe-448d-a8d4-fe56b9a44da9" xlink:href="ngne-20250331.xsd#ngne_A2025InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:to="loc_ngne_A2025InducementPlanMember_836931cd-6abe-448d-a8d4-fe56b9a44da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2023EmployeeStockPurchasePlanMember_6c00b1f9-49ec-4a85-bfd9-9c6ddb542965" xlink:href="ngne-20250331.xsd#ngne_A2023EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:to="loc_ngne_A2023EmployeeStockPurchasePlanMember_6c00b1f9-49ec-4a85-bfd9-9c6ddb542965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e250ffb8-1083-4424-9dc6-1d82e79b3ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_61cea535-f5ff-4b5c-a73b-5234cb81ef4d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e250ffb8-1083-4424-9dc6-1d82e79b3ae2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56f978eb-1a50-4df5-b1ce-b596daf5b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56f978eb-1a50-4df5-b1ce-b596daf5b6c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9db85705-1df6-4bba-b9a7-d15625142380_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9db85705-1df6-4bba-b9a7-d15625142380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1de3b178-1b19-4fcc-834d-d5dfaa95bc76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1de3b178-1b19-4fcc-834d-d5dfaa95bc76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_512b01af-8cd5-4df7-b830-445332874e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_512b01af-8cd5-4df7-b830-445332874e31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3fb4f15-38d7-42fe-a31a-b801a4ef518c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56f978eb-1a50-4df5-b1ce-b596daf5b6c9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3fb4f15-38d7-42fe-a31a-b801a4ef518c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:to="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ddb38ff-e99c-49aa-8e59-51ee41034279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ddb38ff-e99c-49aa-8e59-51ee41034279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df6eb187-0205-439d-81d1-1e69dd717eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df6eb187-0205-439d-81d1-1e69dd717eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2f8b7be8-32b0-4ac5-bc6b-81caa3bf8999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:to="loc_us-gaap_RestrictedStockMember_2f8b7be8-32b0-4ac5-bc6b-81caa3bf8999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad840a45-39c7-4a35-9642-e142e5e21426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:to="loc_us-gaap_PerformanceSharesMember_ad840a45-39c7-4a35-9642-e142e5e21426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:to="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c6403304-9982-47fc-996d-83ea2d8c6013_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:to="loc_us-gaap_VestingDomain_c6403304-9982-47fc-996d-83ea2d8c6013_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:to="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_204aa543-44e8-49e2-83ff-2b2e21deabb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_204aa543-44e8-49e2-83ff-2b2e21deabb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cef8667f-83da-4471-b87a-4a761d3aefc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cef8667f-83da-4471-b87a-4a761d3aefc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c7b65689-a49b-4a82-a407-47f30fecf351" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c7b65689-a49b-4a82-a407-47f30fecf351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ef3aeb42-b258-4f4e-b13b-4b8ec0ebd0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ef3aeb42-b258-4f4e-b13b-4b8ec0ebd0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfc10e79-3fe0-41d5-ac91-a3a1cc7cc4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfc10e79-3fe0-41d5-ac91-a3a1cc7cc4ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_807c9549-c969-4d05-99df-fa4da2520f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_807c9549-c969-4d05-99df-fa4da2520f59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93ca693d-3632-489e-8b4a-6329dfa8f012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93ca693d-3632-489e-8b4a-6329dfa8f012" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66016404-861e-4dd1-b698-3420d52114e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66016404-861e-4dd1-b698-3420d52114e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8d839070-38d6-48d5-b1e7-1ee904086214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8d839070-38d6-48d5-b1e7-1ee904086214" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedPaymentArrangementNumberOfTranches_5e21d3aa-c49f-4290-9fd5-c76a2859b76e" xlink:href="ngne-20250331.xsd#ngne_ShareBasedPaymentArrangementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_ShareBasedPaymentArrangementNumberOfTranches_5e21d3aa-c49f-4290-9fd5-c76a2859b76e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_b8e63b5a-3a94-40d0-a254-c050a18c7d45" xlink:href="ngne-20250331.xsd#ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_b8e63b5a-3a94-40d0-a254-c050a18c7d45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_bce189d5-6970-4c70-8563-127e2c7510dd" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_bce189d5-6970-4c70-8563-127e2c7510dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_b9023afc-0d34-4afe-8656-27eca61f8266" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_b9023afc-0d34-4afe-8656-27eca61f8266" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:to="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b7abdf8-68e4-4df9-ae54-20a24036437c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b7abdf8-68e4-4df9-ae54-20a24036437c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d64abbd-5c7d-41ce-91f2-c28566370186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d64abbd-5c7d-41ce-91f2-c28566370186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_deb9a589-4f63-40f1-98d1-82c423f1a962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d64abbd-5c7d-41ce-91f2-c28566370186" xlink:to="loc_us-gaap_EmployeeStockOptionMember_deb9a589-4f63-40f1-98d1-82c423f1a962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:to="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77582a1a-beca-4e81-bb40-aab358eb32c8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:to="loc_srt_RangeMember_77582a1a-beca-4e81-bb40-aab358eb32c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:to="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b180021d-01c8-4401-800a-bf23a97f65a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:to="loc_srt_MinimumMember_b180021d-01c8-4401-800a-bf23a97f65a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_147c87c6-3dc7-4aed-b871-74095358ed2a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:to="loc_srt_MaximumMember_147c87c6-3dc7-4aed-b871-74095358ed2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5b8c23a2-bbf8-4a52-9e34-82e87bc846fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5b8c23a2-bbf8-4a52-9e34-82e87bc846fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4a3124e1-4544-4606-822e-7af9f98c0752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4a3124e1-4544-4606-822e-7af9f98c0752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0aec3238-5637-467d-82c3-8dc671e44834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0aec3238-5637-467d-82c3-8dc671e44834" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7c9cc761-ca77-4ec7-9d30-bc012941e7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7c9cc761-ca77-4ec7-9d30-bc012941e7a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c13e6dfb-b99f-44e7-ba3a-8adf4fce2b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c13e6dfb-b99f-44e7-ba3a-8adf4fce2b76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1df536e7-0079-4da6-b2e6-d9ef34e00c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1df536e7-0079-4da6-b2e6-d9ef34e00c9e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofOtherAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:to="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c03b1a14-5026-4970-bc99-d1e23d59c205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:to="loc_us-gaap_RestrictedStockMember_c03b1a14-5026-4970-bc99-d1e23d59c205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_aca61584-319d-41a1-af35-3ddcac3782e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:to="loc_us-gaap_PerformanceSharesMember_aca61584-319d-41a1-af35-3ddcac3782e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b298ae25-64af-4869-985e-5dc27d53c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b298ae25-64af-4869-985e-5dc27d53c7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_356db58c-3232-4d34-95b2-66f0d4db1560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_356db58c-3232-4d34-95b2-66f0d4db1560" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b1316059-fc53-477f-b1cc-2efdf2e01ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b1316059-fc53-477f-b1cc-2efdf2e01ff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80535cff-152a-4837-a7e6-366e46234a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80535cff-152a-4837-a7e6-366e46234a0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1644fdbf-aa42-4d99-bb8e-0055450ea151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a08809b5-8c55-4a72-9427-68a2e71dd663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a08809b5-8c55-4a72-9427-68a2e71dd663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c42fa478-f565-4c4f-99a2-7e29a86ec953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c42fa478-f565-4c4f-99a2-7e29a86ec953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7061b749-f890-4b7a-bf69-98c69449fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7061b749-f890-4b7a-bf69-98c69449fed7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_996d8ee4-0a07-4c51-b218-739c903e890a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_996d8ee4-0a07-4c51-b218-739c903e890a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d9638341-ff49-48f6-b56d-015d8558f37b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_049ccfb0-51ed-48b3-aa82-f475adae8625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_049ccfb0-51ed-48b3-aa82-f475adae8625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RettSyndromeMember_7ebc0c8b-5f97-417a-bd9d-0f179230a08b" xlink:href="ngne-20250331.xsd#ngne_RettSyndromeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_RettSyndromeMember_7ebc0c8b-5f97-417a-bd9d-0f179230a08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_BattenDiseaseMember_d504eaab-0664-4cc5-a684-2e7080287e65" xlink:href="ngne-20250331.xsd#ngne_BattenDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_BattenDiseaseMember_d504eaab-0664-4cc5-a684-2e7080287e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_EarlyDiscoveryMember_2980ff87-3f8d-489d-992f-b80d37789442" xlink:href="ngne-20250331.xsd#ngne_EarlyDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_EarlyDiscoveryMember_2980ff87-3f8d-489d-992f-b80d37789442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PersonnelRelatedExpenseMember_983c7f0d-75b5-4b53-932f-127064d4d319" xlink:href="ngne-20250331.xsd#ngne_PersonnelRelatedExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_PersonnelRelatedExpenseMember_983c7f0d-75b5-4b53-932f-127064d4d319" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationExpenseMember_1c1cbc7b-0fcd-4a92-b230-7d537d31a048" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_ShareBasedCompensationExpenseMember_1c1cbc7b-0fcd-4a92-b230-7d537d31a048" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ManufacturingExpenseMember_9e32569a-378a-448d-afed-25aed2d4b945" xlink:href="ngne-20250331.xsd#ngne_ManufacturingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_ManufacturingExpenseMember_9e32569a-378a-448d-afed-25aed2d4b945" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_d9c44c41-7bad-4d83-a17a-30766d033cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_us-gaap_OtherExpenseMember_d9c44c41-7bad-4d83-a17a-30766d033cb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ProfessionalAndConsultantFeesMember_a195cd6c-1a4e-44ec-8065-a1ba60855279" xlink:href="ngne-20250331.xsd#ngne_ProfessionalAndConsultantFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_ProfessionalAndConsultantFeesMember_a195cd6c-1a4e-44ec-8065-a1ba60855279" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_OfficeRelatedExpenseMember_ffbe14b6-5b63-4832-b784-740108f8bec2" xlink:href="ngne-20250331.xsd#ngne_OfficeRelatedExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_OfficeRelatedExpenseMember_ffbe14b6-5b63-4832-b784-740108f8bec2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4aaabbfe-d977-4527-b16b-893748ba8c60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:to="loc_us-gaap_SegmentDomain_4aaabbfe-d977-4527-b16b-893748ba8c60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_edb499f9-484c-480f-9422-afde308034b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:to="loc_us-gaap_SegmentDomain_edb499f9-484c-480f-9422-afde308034b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ReportableSegmentMember_5bd1179c-967f-4e13-ac3e-a116c1b58f96" xlink:href="ngne-20250331.xsd#ngne_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_edb499f9-484c-480f-9422-afde308034b7" xlink:to="loc_ngne_ReportableSegmentMember_5bd1179c-967f-4e13-ac3e-a116c1b58f96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bbdfa788-cde8-4d8b-9e1b-48dcba7a4fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bbdfa788-cde8-4d8b-9e1b-48dcba7a4fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ce0d4f6b-eebd-4e81-8e69-461b4d9f660d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NumberOfReportableSegments_ce0d4f6b-eebd-4e81-8e69-461b4d9f660d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_b1e16403-cb76-41ac-a333-85189390cb68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_b1e16403-cb76-41ac-a333-85189390cb68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fff9b997-e135-461c-9188-b010a76fbe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_b1e16403-cb76-41ac-a333-85189390cb68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fff9b997-e135-461c-9188-b010a76fbe3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02f57eb8-4dc7-49cc-b9ba-e8d0ca3801d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02f57eb8-4dc7-49cc-b9ba-e8d0ca3801d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6ecc9a78-7c0c-45bf-90a9-78050ae71d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02f57eb8-4dc7-49cc-b9ba-e8d0ca3801d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6ecc9a78-7c0c-45bf-90a9-78050ae71d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_81e5ff8d-daf8-48a3-a021-5c93019e0c61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_81e5ff8d-daf8-48a3-a021-5c93019e0c61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e2732b8-aea4-4368-9c7e-e981c3d3fbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NetIncomeLoss_1e2732b8-aea4-4368-9c7e-e981c3d3fbc3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.neurogene.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_26550317-5d99-42c1-ad8b-109af0412dfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_26550317-5d99-42c1-ad8b-109af0412dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08638540-478f-421d-862c-487e28f4f2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_08638540-478f-421d-862c-487e28f4f2fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_988108a6-5cc6-4397-bcc3-d4d69fc33506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_08638540-478f-421d-862c-487e28f4f2fc" xlink:to="loc_us-gaap_SubsequentEventMember_988108a6-5cc6-4397-bcc3-d4d69fc33506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f51f61c3-9643-4e47-89fd-c6d035365f93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f51f61c3-9643-4e47-89fd-c6d035365f93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ee131e25-4406-404f-b589-714d32768d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ee131e25-4406-404f-b589-714d32768d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_88acd5ee-de61-4336-a579-ed98b8110f8d" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ee131e25-4406-404f-b589-714d32768d7e" xlink:to="loc_ngne_PreFundedWarrantsMember_88acd5ee-de61-4336-a579-ed98b8110f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ed508fca-e560-4f51-a7e6-e3fc2cc5a8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ed508fca-e560-4f51-a7e6-e3fc2cc5a8d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_58df43aa-b1dd-4fb4-baed-a91229e555cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_58df43aa-b1dd-4fb4-baed-a91229e555cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7c88247-cfad-4cf3-91ab-8fb3080226a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7c88247-cfad-4cf3-91ab-8fb3080226a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd887f52-360f-4043-a015-52c8463a564d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd887f52-360f-4043-a015-52c8463a564d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3755cc96-2188-4d58-87af-a6b3a73dcc37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3755cc96-2188-4d58-87af-a6b3a73dcc37" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_StuartCobbMember_263f44bd-2419-4431-9796-43a0805d8f30" xlink:href="ngne-20250331.xsd#ngne_StuartCobbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ngne_StuartCobbMember_263f44bd-2419-4431-9796-43a0805d8f30" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ngne-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:455e46d4-7342-4901-9012-cb7d8f12b78e,g:0c981b7d-7032-4dc2-af2a-101f291ef69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33ae52f9-999c-4f64-9716-30f346cbfa68_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_UniversityOfEdinburghMember_f51b74db-39a6-42a4-887f-c3aafaa48aeb_terseLabel_en-US" xlink:label="lab_ngne_UniversityOfEdinburghMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">University of Edinburgh</link:label>
    <link:label id="lab_ngne_UniversityOfEdinburghMember_label_en-US" xlink:label="lab_ngne_UniversityOfEdinburghMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Edinburgh [Member]</link:label>
    <link:label id="lab_ngne_UniversityOfEdinburghMember_documentation_en-US" xlink:label="lab_ngne_UniversityOfEdinburghMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">University of Edinburgh</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_UniversityOfEdinburghMember" xlink:href="ngne-20250331.xsd#ngne_UniversityOfEdinburghMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_UniversityOfEdinburghMember" xlink:to="lab_ngne_UniversityOfEdinburghMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_944c285f-f3c8-42fe-887e-7d2ceb0ede66_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2ab904e6-6023-4401-a605-f76f3eadff0c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f5f8afa9-86ee-4796-b42d-ac377c5712ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid, and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_cf285b09-5eca-4a2b-8abd-8725ab885c25_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_PersonnelRelatedExpenseMember_e3b3b92f-34c7-4dd3-b72b-3c444dd416c9_terseLabel_en-US" xlink:label="lab_ngne_PersonnelRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel-related</link:label>
    <link:label id="lab_ngne_PersonnelRelatedExpenseMember_label_en-US" xlink:label="lab_ngne_PersonnelRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel-Related Expense [Member]</link:label>
    <link:label id="lab_ngne_PersonnelRelatedExpenseMember_documentation_en-US" xlink:label="lab_ngne_PersonnelRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Personnel-Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PersonnelRelatedExpenseMember" xlink:href="ngne-20250331.xsd#ngne_PersonnelRelatedExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_PersonnelRelatedExpenseMember" xlink:to="lab_ngne_PersonnelRelatedExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d8aacda1-218a-4e56-a9c3-1d95a63fc17d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8797badf-c893-4de8-aafd-5c2f449d409b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a06f925d-2a33-4635-8169-0d559003d63b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7e8affb4-3e08-4edf-98d0-33d59f50a0be_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_95104244-9790-4c69-9e8f-5280d201cee9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ClassOfWarrantOrRightNoticePeriod_d73c8fbd-6712-4d12-aaca-b452f1cf8ad6_terseLabel_en-US" xlink:label="lab_ngne_ClassOfWarrantOrRightNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, notice period</link:label>
    <link:label id="lab_ngne_ClassOfWarrantOrRightNoticePeriod_label_en-US" xlink:label="lab_ngne_ClassOfWarrantOrRightNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Notice Period</link:label>
    <link:label id="lab_ngne_ClassOfWarrantOrRightNoticePeriod_documentation_en-US" xlink:label="lab_ngne_ClassOfWarrantOrRightNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ClassOfWarrantOrRightNoticePeriod" xlink:href="ngne-20250331.xsd#ngne_ClassOfWarrantOrRightNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ClassOfWarrantOrRightNoticePeriod" xlink:to="lab_ngne_ClassOfWarrantOrRightNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_1e299211-3a42-4947-8766-02f4ce1d0f54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_81edce55-7a5e-4c09-9695-ea54ef4a3542_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_April2024CVRLicensingAgreementMember_1f4c6dc6-9470-4362-b667-3dbb880469cd_terseLabel_en-US" xlink:label="lab_ngne_April2024CVRLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2024 CVR Licensing Agreement</link:label>
    <link:label id="lab_ngne_April2024CVRLicensingAgreementMember_label_en-US" xlink:label="lab_ngne_April2024CVRLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2024 CVR Licensing Agreement [Member]</link:label>
    <link:label id="lab_ngne_April2024CVRLicensingAgreementMember_documentation_en-US" xlink:label="lab_ngne_April2024CVRLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2024 CVR Licensing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_April2024CVRLicensingAgreementMember" xlink:href="ngne-20250331.xsd#ngne_April2024CVRLicensingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_April2024CVRLicensingAgreementMember" xlink:to="lab_ngne_April2024CVRLicensingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5e480c59-99ad-4c44-8334-32e60807c12e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_abcbeeb8-e948-4776-b7a7-337472e5a949_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_dfb3938a-4e42-49df-a60e-659c2f5f651e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_ceefdb6b-d497-4c0a-a9ab-0c2b3d883c00_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit and Disposals Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e01437c1-5682-4203-845a-31241e5c463d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_62f5c33e-6899-42fe-8e87-96733149d486_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0ce7f14a-b540-40ae-8c55-8fbe7f2b2d00_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_A2025InducementPlanMember_3bdd9fd4-6de4-4b6d-9907-45978d3385e4_terseLabel_en-US" xlink:label="lab_ngne_A2025InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Inducement Plan</link:label>
    <link:label id="lab_ngne_A2025InducementPlanMember_label_en-US" xlink:label="lab_ngne_A2025InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Inducement Plan [Member]</link:label>
    <link:label id="lab_ngne_A2025InducementPlanMember_documentation_en-US" xlink:label="lab_ngne_A2025InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2025InducementPlanMember" xlink:href="ngne-20250331.xsd#ngne_A2025InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_A2025InducementPlanMember" xlink:to="lab_ngne_A2025InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_000d6917-cc83-48fa-8bf1-2810352ace4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_11491790-c702-4f75-aa14-73ba9a724b31_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e225ab54-fe1e-4683-a793-a58a12053c89_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2c954026-bcfc-45eb-8048-6c38fec661e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_0a1efc17-88d1-477e-bd90-3712556af792_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_0dda9eed-6ba7-4a41-b7f2-ee0e346981f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_28554fca-5922-42fd-b17d-a098e4e1e32a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ad5c615c-ab34-4572-b602-d052b344c512_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_StuartCobbMember_label_en-US" xlink:label="lab_ngne_StuartCobbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stuart Cobb [Member]</link:label>
    <link:label id="lab_ngne_StuartCobbMember_documentation_en-US" xlink:label="lab_ngne_StuartCobbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stuart Cobb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_StuartCobbMember" xlink:href="ngne-20250331.xsd#ngne_StuartCobbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_StuartCobbMember" xlink:to="lab_ngne_StuartCobbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e3052403-38b1-411b-9a22-ed9c1997da05_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_deabe9cd-08cc-400b-8ea0-ed1b1355204f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_bfc19cbd-6f69-46fe-852a-9409d13187d2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ca5bafe8-1337-48ee-9a59-66deb00b20dc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d1ebd8f5-42db-43b0-86b9-7b2292f38640_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9eab83a5-3882-4751-b92e-a482de8435a9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0542892d-9622-47f7-bcf0-a7427845926a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_BattenDiseaseMember_115c0379-641d-4e59-b508-6d4c7899ba6f_terseLabel_en-US" xlink:label="lab_ngne_BattenDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Batten disease</link:label>
    <link:label id="lab_ngne_BattenDiseaseMember_label_en-US" xlink:label="lab_ngne_BattenDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Batten disease [Member]</link:label>
    <link:label id="lab_ngne_BattenDiseaseMember_documentation_en-US" xlink:label="lab_ngne_BattenDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Batten disease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_BattenDiseaseMember" xlink:href="ngne-20250331.xsd#ngne_BattenDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_BattenDiseaseMember" xlink:to="lab_ngne_BattenDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_913e623d-b08e-4eed-919f-c8f25c49c412_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5de4bcbc-8299-488c-9c6a-ff6a83b0df40_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4c99527d-c906-480f-a84a-c35a9e26f2ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash used in operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0a9d6627-671e-4bfd-9cfa-7e3aff28814c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8a6194a3-ce42-45af-82f3-16016c79eca5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_536c83e3-e01a-4717-b6aa-a53dde56379f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_582128c8-1960-4e86-a47e-0b91c83a8ac4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d68188ee-c708-42e3-8f4c-e1d7122a2ab8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_4fe5ec9d-e255-462c-990d-5d53debc62d4_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f501aa47-07cd-463a-aafc-6b07c9952de5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5db407da-56cc-435e-83a3-faeac10b847e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches_bf134139-3389-4bb4-9849-464aa7c48c37_terseLabel_en-US" xlink:label="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, number of tranches</link:label>
    <link:label id="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches_label_en-US" xlink:label="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Number Of Tranches</link:label>
    <link:label id="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches_documentation_en-US" xlink:label="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedPaymentArrangementNumberOfTranches" xlink:href="ngne-20250331.xsd#ngne_ShareBasedPaymentArrangementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ShareBasedPaymentArrangementNumberOfTranches" xlink:to="lab_ngne_ShareBasedPaymentArrangementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_89ea40a0-d169-48b0-a76c-99cc65795faf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_99e86312-19cb-4714-bfe2-95d3c545831a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding option intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_LabEquipmentMember_74a55061-21c5-4527-a238-37becc83f3b5_terseLabel_en-US" xlink:label="lab_ngne_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_ngne_LabEquipmentMember_label_en-US" xlink:label="lab_ngne_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_ngne_LabEquipmentMember_documentation_en-US" xlink:label="lab_ngne_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LabEquipmentMember" xlink:href="ngne-20250331.xsd#ngne_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_LabEquipmentMember" xlink:to="lab_ngne_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f70c0a05-897e-4675-be58-d9cc4af28592_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d2030e5d-8dcb-4123-9cc4-22c7053ccfb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs Associated With Exit or Disposal Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9fe27d2f-e659-4ee8-885b-748d4b5a8242_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe92ea3d-47d3-4ed6-b64b-a41bb7896b58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_19c0b01e-d445-43aa-b11c-2ce3cdd7367e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liability Adjustment</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_dbff9044-84d3-4ea6-9dcb-4ffdbb2ffd9b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_19db6861-f134-4d65-a882-8ddcd61a1bb5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f56fefe4-0985-4141-9ed4-0e945b0649af_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d97bea7e-4397-4ffe-b19f-edfc49c00279_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_68f8f02d-30d8-4d7e-bf27-8dbdde72cee1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of held-to-maturity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_22bbc93b-a9dc-42b4-9120-a9549db4d047_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fd2860a5-a164-49f9-938c-9ec90774b217_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_4e74b035-3820-4f46-89dc-93753404a978_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_eb42e436-359d-41b5-83aa-477bb00fe10d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts Paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_80470f4a-9371-4efd-b16a-30577d3cc577_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a706ccc0-c3b3-46cc-a4c1-6be2d34525a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5068ae9-9931-4eb2-b188-aff8a4a2f462_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cec3b7f-63ec-4404-966a-663ced0f4ea6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_63b59c9c-0051-46dd-9747-32dfcf1b0494_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization and accretion of premiums/discounts on held-to-maturity investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9377a670-362c-46d5-9e1a-e0ea206a6eb3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_de6b330a-fa8a-420d-bbb2-898b1145a55f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Held-to-Maturity Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Held-to-Maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_75ad01ff-59c9-48f8-ac39-14ade51b7122_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_e4f4ffe5-08bf-4b71-a57f-787db9cf2054_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cb567ffe-81fc-48f7-ac60-e5198143acee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_557de7ca-0cee-4542-9978-b96e728f3428_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8ced5da5-3bac-40b5-acb3-9bcbec103e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_44e6120c-e432-4580-9ad5-1302970c9829_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, eligibility to received net proceeds, percentage</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Percentage</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_19dbd651-a74d-4102-bdc5-8dc8bc03680a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f21ab9c-2ca8-4d69-9b68-29bc2eebc08e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f2bc4bed-e0ec-43b5-824d-b7da1a22eca3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_54ca954e-e4d7-4e46-85d0-7eb1d9a3a685_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6e910f1b-9f6a-420a-b052-8a47ea67f3b0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_af1d8abd-a552-418e-a67b-3b3efc07bb94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRent_6b337276-e11b-49ff-af83-ff3c910a09bc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_label_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c971f441-c570-4b2e-913a-970552b903b0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash&#160;and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_A2023EquityIncentivePlanMember_2f46a249-50b9-4b13-8cd8-6cb7836c1fb5_terseLabel_en-US" xlink:label="lab_ngne_A2023EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Equity Incentive Plan</link:label>
    <link:label id="lab_ngne_A2023EquityIncentivePlanMember_label_en-US" xlink:label="lab_ngne_A2023EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ngne_A2023EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ngne_A2023EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2023EquityIncentivePlanMember" xlink:href="ngne-20250331.xsd#ngne_A2023EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_A2023EquityIncentivePlanMember" xlink:to="lab_ngne_A2023EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_034e3272-7c7f-4a5c-b437-a3dcc957582b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1c756d81-da9a-4d79-8f31-8a543504f90f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_07da45d0-cb3b-4a86-9822-b1f0c25b3604_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7cfeea86-d9ee-4b94-bbd1-93a57dfc2b14_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5dbd51f9-8531-4ac3-9e73-dcb5f34fe647_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_EarlyDiscoveryMember_a4ab61c0-5f7d-49ea-901c-4382fef22bb6_terseLabel_en-US" xlink:label="lab_ngne_EarlyDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early Discovery</link:label>
    <link:label id="lab_ngne_EarlyDiscoveryMember_label_en-US" xlink:label="lab_ngne_EarlyDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Discovery [Member]</link:label>
    <link:label id="lab_ngne_EarlyDiscoveryMember_documentation_en-US" xlink:label="lab_ngne_EarlyDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Discovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_EarlyDiscoveryMember" xlink:href="ngne-20250331.xsd#ngne_EarlyDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_EarlyDiscoveryMember" xlink:to="lab_ngne_EarlyDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c295abf5-1c6b-4a0f-8061-0f07c796546d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_LeaseCVRMember_0d78de56-0a93-4777-a4cd-af710ad75a05_terseLabel_en-US" xlink:label="lab_ngne_LeaseCVRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease CVR</link:label>
    <link:label id="lab_ngne_LeaseCVRMember_label_en-US" xlink:label="lab_ngne_LeaseCVRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease CVR [Member]</link:label>
    <link:label id="lab_ngne_LeaseCVRMember_documentation_en-US" xlink:label="lab_ngne_LeaseCVRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease CVR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LeaseCVRMember" xlink:href="ngne-20250331.xsd#ngne_LeaseCVRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_LeaseCVRMember" xlink:to="lab_ngne_LeaseCVRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_06214926-df8b-45f3-b637-d22263907159_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par or stated value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_600ebdb8-2979-4e4f-aab8-d45e96cd6618_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7e588939-7171-44de-9eaf-fea017e1b711_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28a23e09-846d-4032-8cde-0df1ff0d8d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_RettSyndromeMember_28463e82-d83d-45d4-b388-40a440966716_terseLabel_en-US" xlink:label="lab_ngne_RettSyndromeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rett syndrome</link:label>
    <link:label id="lab_ngne_RettSyndromeMember_label_en-US" xlink:label="lab_ngne_RettSyndromeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rett syndrome [Member]</link:label>
    <link:label id="lab_ngne_RettSyndromeMember_documentation_en-US" xlink:label="lab_ngne_RettSyndromeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rett syndrome</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RettSyndromeMember" xlink:href="ngne-20250331.xsd#ngne_RettSyndromeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_RettSyndromeMember" xlink:to="lab_ngne_RettSyndromeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_37d1e397-de52-40a2-9510-f2ae614913d4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4b4f3e91-d20e-4c18-82e4-d1a2cf90cd84_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f83de8c2-1d7c-4da3-ad6f-ab0ac61c6f0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_26432602-be8e-410a-8b59-68ecc6f91c27_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, reimbursement</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Reimbursement</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsReimbursement" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsReimbursement" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_a7e459ba-837a-4c9a-b0cd-5b26087e1a3f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value rights liability, non-current</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_28082a18-734a-496f-8221-8038295c7ad1_terseLabel_en-US" xlink:label="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares common stock holder to receive when restricted stock unit vests (in shares)</link:label>
    <link:label id="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_label_en-US" xlink:label="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests</link:label>
    <link:label id="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_documentation_en-US" xlink:label="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:href="ngne-20250331.xsd#ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:to="lab_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_945d906c-272b-40ab-9507-185688bc258a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c9f3d29d-1d95-4fa8-a7ef-6b1bd5031d94_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_VirovekIncMember_0bc17443-4f14-4c54-a475-a9e2ed14b99e_terseLabel_en-US" xlink:label="lab_ngne_VirovekIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Virovek, Inc License Agreement</link:label>
    <link:label id="lab_ngne_VirovekIncMember_label_en-US" xlink:label="lab_ngne_VirovekIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Virovek, Inc [Member]</link:label>
    <link:label id="lab_ngne_VirovekIncMember_documentation_en-US" xlink:label="lab_ngne_VirovekIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Virovek, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_VirovekIncMember" xlink:href="ngne-20250331.xsd#ngne_VirovekIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_VirovekIncMember" xlink:to="lab_ngne_VirovekIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_297f67a3-f285-499d-ae89-d7afd2cdabd9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_484bea08-1b01-444f-8a92-e2429fc2a9a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8bd1fca-1b2d-45ee-9a70-6502e3144622_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_Phase1NL201TrialMember_669b2681-81e3-4c1b-8535-56c509554705_terseLabel_en-US" xlink:label="lab_ngne_Phase1NL201TrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 1 NL-201 Trial</link:label>
    <link:label id="lab_ngne_Phase1NL201TrialMember_label_en-US" xlink:label="lab_ngne_Phase1NL201TrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 1 NL-201 Trial [Member]</link:label>
    <link:label id="lab_ngne_Phase1NL201TrialMember_documentation_en-US" xlink:label="lab_ngne_Phase1NL201TrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 1 NL-201 Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_Phase1NL201TrialMember" xlink:href="ngne-20250331.xsd#ngne_Phase1NL201TrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_Phase1NL201TrialMember" xlink:to="lab_ngne_Phase1NL201TrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_35c55a65-edd4-439d-b1cd-0e68f23a4950_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_74bda276-367c-4556-830a-905dfaede740_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2797a7f3-7e0e-449a-a41c-a953343caf2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_91c438e8-4dbc-492b-917b-708ca6f87ae8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7e582a7d-b438-4a04-b612-07f3f8381e8a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_95ee2996-8d81-4c91-9fc0-ac0f2fd10960_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4ea02950-ec36-4aa6-b8ff-5cf6fcfd47c8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cd378c8d-023d-4e83-b842-cc57e03784b7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a3081574-2ab5-4cbb-a3f6-23315b4bf0a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8667d1ac-c713-42df-a43d-7aff8fe41a35_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_934289ee-66e4-4fd0-a936-657fd50bc029_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a1b06715-51c4-473e-80bc-1901cc20f65c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_e1fe22fd-df07-4165-ba5c-ffaf03f7e45f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c617f835-0e28-4baf-96e0-3b3089250431_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_deeccb75-f0be-4349-8402-17fc70a04947_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_e66c8b19-85f6-4f5d-a129-d93554262189_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a428070d-9025-4b9f-96b2-b95cb4deda5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_772d5ed1-a693-4ecb-a807-9d397743091c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f41d88d4-d0ba-4592-8de1-d4ccdeb65adb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_09a64115-b2f0-483a-b4e6-835ca4a22fc0_terseLabel_en-US" xlink:label="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property contingent value rights liability, current, deductions</link:label>
    <link:label id="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_label_en-US" xlink:label="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Contingent Value Rights Liability, Current, Deductions</link:label>
    <link:label id="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_documentation_en-US" xlink:label="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Contingent Value Rights Liability, Current, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" xlink:to="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11abe0e1-2c5e-4296-9b1b-06dcfee4af14_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_18eee5db-2014-47a2-9297-7ec0b946913a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b6d33ce0-13d4-4819-afa9-9739f6dfe6f7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4f0920f4-7f95-4cc7-9086-95d376f41aab_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c32105af-142e-40dc-b976-452b612fdfdb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_17365e7b-faf7-42c2-bcd2-4ad6268656e1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8dfd36fa-490b-4cbe-acab-2ac16a07f2ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7bf743b0-7b0b-4c82-874b-dd036d32fe13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a0608acd-764a-4be8-b9f7-06243e12cee9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9f0a7306-a323-4593-8d4c-bd4bcd0879a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Results Of Operations by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_14795db9-a935-4750-9faf-6eb4586ce3a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a3f63e45-6bc2-4fa4-bd57-54de9af0ec09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_ee7a1c58-ab2b-49cf-abfd-7252512990db_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_438819fa-bddd-4945-9e87-353087d39d88_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_bbb7d598-84b2-4edd-a8a4-61d60f2ca15f_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, additional term</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Additional Term</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Additional Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e21fd467-e3e3-40be-a496-a5e59c84b292_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_1eb8a99f-9a10-4f54-a90a-2095e0b8d27c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Offering costs in connection with pre-closing financing</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ManufacturingExpenseMember_d7c09149-f8aa-431b-ac7d-38dab6b75e76_terseLabel_en-US" xlink:label="lab_ngne_ManufacturingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing</link:label>
    <link:label id="lab_ngne_ManufacturingExpenseMember_label_en-US" xlink:label="lab_ngne_ManufacturingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Expense [Member]</link:label>
    <link:label id="lab_ngne_ManufacturingExpenseMember_documentation_en-US" xlink:label="lab_ngne_ManufacturingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ManufacturingExpenseMember" xlink:href="ngne-20250331.xsd#ngne_ManufacturingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ManufacturingExpenseMember" xlink:to="lab_ngne_ManufacturingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6d434ce5-b07b-4e2e-be84-f60c3b28b4e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a9b07e72-9f9c-4db4-93e8-9a246cdfb514_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7781e447-49b4-4ca7-be24-8745118678e8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5b184bce-ed12-4046-b634-534020913f54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_833a4b70-26c7-4fb4-88a7-c90655958d18_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost, as adjusted</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d0f678b7-1fbe-4bec-bda5-f23e26553b7f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7e4db02e-1748-49ba-b90e-7e2c75d6b9d0_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_3e6be7bb-bebc-488d-b460-84f896690bfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_87bf2325-fcb8-4fa0-9791-0ffa9abe6261_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a9fbf0ff-3b0b-4c78-98f0-e155a967271a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_04908962-6ebb-453c-a841-18d835b53536_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_867112f8-e4ea-483b-9d4c-7b31bb3f4d7a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_970b0bbe-d669-4cad-b359-a072b3476eeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract_b120966b-b5d4-4bcd-b7a0-a17ee51c6241_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program specific expenses:</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d6f6b052-f3b3-4200-85bf-7ca892443213_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fb49bff7-fe8f-435f-8458-48fb5030ee0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_892cc177-95d1-4729-8f09-3d301d18e4bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid- In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_164c9627-7cdc-4687-98f6-7f8124d70d10_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c0fdd8c4-71eb-41b8-90c3-b60eda58dfe3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1d4aa14a-2978-4f63-978b-ab359845b6bd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_159bda6e-c277-4e43-b49d-020237f5296d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_07a4c62d-9aaf-4a4d-8695-baa02f22166e_terseLabel_en-US" xlink:label="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreement, option to terminate</link:label>
    <link:label id="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_label_en-US" xlink:label="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:label id="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_documentation_en-US" xlink:label="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:href="ngne-20250331.xsd#ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:to="lab_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6592b019-eeed-45f6-b812-2bed97b6f10c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c6de89d7-25f4-476d-bcb3-6a62e5f79a2e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_97950d79-32cf-4bae-a2da-3bd55980c892_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1d22a240-f952-42e6-9cc2-b0382cdebcb2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_a722971a-d133-4dd9-bac5-afe82c7a8b13_terseLabel_en-US" xlink:label="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding stock per stockholder, upon notice, maximum</link:label>
    <link:label id="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_label_en-US" xlink:label="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Outstanding Stock per Stockholder, Upon Notice, Maximum</link:label>
    <link:label id="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_documentation_en-US" xlink:label="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Outstanding Stock per Stockholder, Upon Notice, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" xlink:href="ngne-20250331.xsd#ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" xlink:to="lab_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_OfficeRelatedExpenseMember_35b766eb-57df-41fe-b77b-8e8f300b01d2_terseLabel_en-US" xlink:label="lab_ngne_OfficeRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office-related</link:label>
    <link:label id="lab_ngne_OfficeRelatedExpenseMember_label_en-US" xlink:label="lab_ngne_OfficeRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office-Related Expense [Member]</link:label>
    <link:label id="lab_ngne_OfficeRelatedExpenseMember_documentation_en-US" xlink:label="lab_ngne_OfficeRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office-Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_OfficeRelatedExpenseMember" xlink:href="ngne-20250331.xsd#ngne_OfficeRelatedExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_OfficeRelatedExpenseMember" xlink:to="lab_ngne_OfficeRelatedExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_ed5267f8-ed99-478b-a3c8-fdedce161c10_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses on idle equipment</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bdce6a65-14c6-4179-8dbd-7a113d0c08f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Exercise Of Pre-Funded Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_fb1b3ccc-7702-4f0b-987d-50330c555526_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0614f215-2ebc-4b0b-8dcc-187d7676719d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_99f227f1-51fd-41b5-9210-b5bc16de1466_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to reverse merger</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_96fbe909-ba25-42f0-a1f4-828736513418_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_December2023PreClosingMember_2be4e846-362e-4f3d-a4ca-63d3cd464c2e_terseLabel_en-US" xlink:label="lab_ngne_December2023PreClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2023 Pre-Closing</link:label>
    <link:label id="lab_ngne_December2023PreClosingMember_label_en-US" xlink:label="lab_ngne_December2023PreClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2023 Pre Closing [Member]</link:label>
    <link:label id="lab_ngne_December2023PreClosingMember_documentation_en-US" xlink:label="lab_ngne_December2023PreClosingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2023 Pre Closing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023PreClosingMember" xlink:href="ngne-20250331.xsd#ngne_December2023PreClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_December2023PreClosingMember" xlink:to="lab_ngne_December2023PreClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_917583d9-0ede-4a2a-b128-a3575f0eb27c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_11984174-c104-400f-8527-108f8d586e59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_cd4b9eba-ca90-4ef9-a8db-ba1bff192714_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_021a9a44-ab58-45da-8827-ac300c597e4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired/Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_81f2e842-ae53-4ee5-8afb-7457adda1377_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_db8c479a-be7c-4179-b8d3-dba9c8549859_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_bba6ea71-b194-4c44-b71e-afa09351300f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_7291bb7d-37e0-474d-a6ab-1b2e645ee559_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_SigmaAldrichCoMember_9715b290-18b8-4a7b-bdc0-5c351abde4d6_terseLabel_en-US" xlink:label="lab_ngne_SigmaAldrichCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sigma-Aldrich Co</link:label>
    <link:label id="lab_ngne_SigmaAldrichCoMember_label_en-US" xlink:label="lab_ngne_SigmaAldrichCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sigma-Aldrich Co [Member]</link:label>
    <link:label id="lab_ngne_SigmaAldrichCoMember_documentation_en-US" xlink:label="lab_ngne_SigmaAldrichCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sigma-Aldrich Co</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SigmaAldrichCoMember" xlink:href="ngne-20250331.xsd#ngne_SigmaAldrichCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_SigmaAldrichCoMember" xlink:to="lab_ngne_SigmaAldrichCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_918b11e8-3e8b-45cc-a660-398263f8178f_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt Securities, Held-to-Maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a869512-160b-4075-8585-053e6f775868_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f2a81b9d-576e-4375-99ed-d7031102abae_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_2c11cdde-0fad-4b7d-882c-67e9b0d29bb9_terseLabel_en-US" xlink:label="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="ngne-20250331.xsd#ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_7c028cae-2faf-43c1-b9eb-01b8e3c31cce_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_062aecf5-2c59-4491-9a71-a6966bb6dadb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a8de76a7-86a1-45c5-ab3b-a25f3c5a0588_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_60ca24d3-87de-4a8c-b80e-2223377cc7a9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation, bonuses and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_43f34ff0-e8fb-467f-b751-50bcb35576d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b44d07c8-40d7-42f8-98ab-74378bb98c2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_b21f5577-1607-468d-a9aa-8ffb53c491ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_HoustonLeaseMember_4937751e-e728-4f82-91f6-b14c4dbe0aef_terseLabel_en-US" xlink:label="lab_ngne_HoustonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Houston Lease</link:label>
    <link:label id="lab_ngne_HoustonLeaseMember_label_en-US" xlink:label="lab_ngne_HoustonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Houston Lease [Member]</link:label>
    <link:label id="lab_ngne_HoustonLeaseMember_documentation_en-US" xlink:label="lab_ngne_HoustonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Houston Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_HoustonLeaseMember" xlink:href="ngne-20250331.xsd#ngne_HoustonLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_HoustonLeaseMember" xlink:to="lab_ngne_HoustonLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_155fe63f-e798-4975-b687-4a0109df2968_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_bfe267f7-e1ce-48ff-99e5-2a4f93ec7e8f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_a7cff30f-33ed-474a-90c5-2a1c892a60cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d76acecc-137d-444d-8e0f-287bb113ac8c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to operating lease right of use assets from new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_5200c85a-83cb-4157-b43e-5060a5d17cf3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Asset Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_23f77f25-b46f-42fb-8195-596829eaef65_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c783bb6f-efbd-431b-ba15-f589808badcc_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessor, operating lease, payment to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_5bd8378d-81a0-4058-b3fd-dbd939a2d5f2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc9e8313-fb7f-4194-a7cb-d47e95a96dfa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_921d93df-be98-4f4a-b658-200416fbeb71_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9d108298-f761-4b37-bcb3-5b7cbed1969e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_820668be-fa85-4ea6-b7e9-f533e07c81c2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_383ee837-0cbb-4f2b-8cb5-cd2f4d6a815d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_A2023EmployeeStockPurchasePlanMember_dfafb311-da31-45b2-b78c-84ba7f3f7a68_terseLabel_en-US" xlink:label="lab_ngne_A2023EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_ngne_A2023EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ngne_A2023EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ngne_A2023EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ngne_A2023EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2023EmployeeStockPurchasePlanMember" xlink:href="ngne-20250331.xsd#ngne_A2023EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_A2023EmployeeStockPurchasePlanMember" xlink:to="lab_ngne_A2023EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_480ffbb6-3149-4778-b054-f8d038d96767_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cfaf4cab-900f-4f54-9026-512f081d5816_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08017342-237d-4be2-a908-3757b4f01bd0_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_7793b994-2558-4404-a952-413d16349a1c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ReportableSegmentMember_42e1e84a-977d-4f7c-932f-b200685f8ce8_terseLabel_en-US" xlink:label="lab_ngne_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_ngne_ReportableSegmentMember_label_en-US" xlink:label="lab_ngne_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_ngne_ReportableSegmentMember_documentation_en-US" xlink:label="lab_ngne_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ReportableSegmentMember" xlink:href="ngne-20250331.xsd#ngne_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ReportableSegmentMember" xlink:to="lab_ngne_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e86a1046-f363-4981-a7f4-c9fddeac1894_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46cb53fe-8b70-45b6-b30a-f383e511f38a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2423ac8b-7686-4b52-b5f1-d858028451a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_AccruedResearchAndDevelopmentCurrent_91333467-1708-454d-9cbc-51896067d101_terseLabel_en-US" xlink:label="lab_ngne_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ngne_AccruedResearchAndDevelopmentCurrent_label_en-US" xlink:label="lab_ngne_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:label id="lab_ngne_AccruedResearchAndDevelopmentCurrent_documentation_en-US" xlink:label="lab_ngne_AccruedResearchAndDevelopmentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AccruedResearchAndDevelopmentCurrent" xlink:href="ngne-20250331.xsd#ngne_AccruedResearchAndDevelopmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_ngne_AccruedResearchAndDevelopmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_692e1e81-18bf-40f4-8ff9-84a3b6e72bfb_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1e5bb85-c42e-4114-b371-60d356a820f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b74a4040-bd7a-4694-9475-0dcdc8fb7143_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da926947-863a-4eb5-b671-31185932e691_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0b7e7db8-96ce-4a1f-b502-77b86d212a13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_33b128e5-1a76-4db3-8015-45980ac39ad4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_af93bad8-278e-42c4-8888-7d9ce9ebbeef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d11aeca9-2ee7-41ee-909a-0223e503fd1d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_b90716f4-a89f-4e60-8433-105ddbd5212d_terseLabel_en-US" xlink:label="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, not probable to vest</link:label>
    <link:label id="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_label_en-US" xlink:label="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Not Probable To Vest</link:label>
    <link:label id="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_documentation_en-US" xlink:label="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Not Probable To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" xlink:to="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_21c66808-1467-45ee-a8ea-a1fd41d51604_verboseLabel_en-US" xlink:label="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued severance</link:label>
    <link:label id="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_label_en-US" xlink:label="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Severance, Bonus, And Retention Costs, Current</link:label>
    <link:label id="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_documentation_en-US" xlink:label="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Severance, Bonus, And Retention Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" xlink:href="ngne-20250331.xsd#ngne_AccruedSeveranceBonusAndRetentionCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" xlink:to="lab_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm_d48600b1-49cc-4a0a-ab3f-8f0136b6f903_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, term</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Term</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsTerm" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsTerm" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_a0e76279-7dd3-4c4f-a1fe-a55e44842ea7_terseLabel_en-US" xlink:label="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal terms</link:label>
    <link:label id="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_label_en-US" xlink:label="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Term</link:label>
    <link:label id="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_documentation_en-US" xlink:label="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:href="ngne-20250331.xsd#ngne_LesseeOperatingLeaseNumberOfRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:to="lab_ngne_LesseeOperatingLeaseNumberOfRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ffc30a4a-3c59-49ab-bd54-d6bdad2c0bb1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_28f00323-cd21-4e60-9fad-364cb0e67fbf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8db3110a-86d4-4d3c-80e2-843f095c86a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c7e81114-4994-4130-b7b5-c3bff01614dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_0b28dbd4-d945-48d6-9f81-45579b23adfc_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_9addd330-59dc-4768-9d98-dc0f88d74251_terseLabel_en-US" xlink:label="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, probable to vest</link:label>
    <link:label id="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_label_en-US" xlink:label="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Probable To Vest</link:label>
    <link:label id="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_documentation_en-US" xlink:label="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Probable To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" xlink:to="lab_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_RegulatoryRelatedMilestonesMember_15205502-a8f1-4afe-902e-c5871496ab96_terseLabel_en-US" xlink:label="lab_ngne_RegulatoryRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory-Related Milestones</link:label>
    <link:label id="lab_ngne_RegulatoryRelatedMilestonesMember_label_en-US" xlink:label="lab_ngne_RegulatoryRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory-Related Milestones [Member]</link:label>
    <link:label id="lab_ngne_RegulatoryRelatedMilestonesMember_documentation_en-US" xlink:label="lab_ngne_RegulatoryRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory-Related Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RegulatoryRelatedMilestonesMember" xlink:href="ngne-20250331.xsd#ngne_RegulatoryRelatedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_RegulatoryRelatedMilestonesMember" xlink:to="lab_ngne_RegulatoryRelatedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_507ece33-812d-4a57-93da-0bbcb3d108f9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementTermOfAgreement_4f495db9-2ff7-4b65-91f7-4b70fcf26bfb_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementTermOfAgreement_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Of Agreement</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementTermOfAgreement_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementTermOfAgreement" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementTermOfAgreement" xlink:to="lab_ngne_CollaborativeArrangementTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_d9fbdd22-bdf3-4b8c-be1f-2b0d75fbedb3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_December2023CVRLicensingAgreementMember_6d07cfd8-b92c-478e-856d-ec359358d8c6_terseLabel_en-US" xlink:label="lab_ngne_December2023CVRLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2023 CVR Licensing Agreement</link:label>
    <link:label id="lab_ngne_December2023CVRLicensingAgreementMember_label_en-US" xlink:label="lab_ngne_December2023CVRLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2023 CVR Licensing Agreement [Member]</link:label>
    <link:label id="lab_ngne_December2023CVRLicensingAgreementMember_documentation_en-US" xlink:label="lab_ngne_December2023CVRLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2023 CVR Licensing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023CVRLicensingAgreementMember" xlink:href="ngne-20250331.xsd#ngne_December2023CVRLicensingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_December2023CVRLicensingAgreementMember" xlink:to="lab_ngne_December2023CVRLicensingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_PreFundedWarrantMember_5dfdd154-9d7a-4c2a-9516-2b6c155637e8_terseLabel_en-US" xlink:label="lab_ngne_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy pre-funded warrants outstanding</link:label>
    <link:label id="lab_ngne_PreFundedWarrantMember_label_en-US" xlink:label="lab_ngne_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_ngne_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_ngne_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantMember" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_PreFundedWarrantMember" xlink:to="lab_ngne_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_33337565-d67b-41ae-9d24-e114c93c0592_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9d50b445-3d0b-4c17-8e71-279e5d712d9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_RefundsAndOtherReceivablesCurrent_e7bfdc8c-1b5b-4db4-9479-412dae887391_terseLabel_en-US" xlink:label="lab_ngne_RefundsAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refunds and other receivables</link:label>
    <link:label id="lab_ngne_RefundsAndOtherReceivablesCurrent_label_en-US" xlink:label="lab_ngne_RefundsAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds And Other Receivables, Current</link:label>
    <link:label id="lab_ngne_RefundsAndOtherReceivablesCurrent_documentation_en-US" xlink:label="lab_ngne_RefundsAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refunds And Other Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RefundsAndOtherReceivablesCurrent" xlink:href="ngne-20250331.xsd#ngne_RefundsAndOtherReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_RefundsAndOtherReceivablesCurrent" xlink:to="lab_ngne_RefundsAndOtherReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_185d82b0-2116-4793-ae86-36bba819e16a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10323252-f1ea-4796-8494-00cc017bf4ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total common stock reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4b1b712a-5ea3-48af-9a0a-633f8337f443_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_PreFundedWarrantsMember_66417061-e99b-405b-b343-5dd8ec882d6a_terseLabel_en-US" xlink:label="lab_ngne_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants</link:label>
    <link:label id="lab_ngne_PreFundedWarrantsMember_432ad1c4-a8a9-4c6d-90ef-c4f74bf9a8db_verboseLabel_en-US" xlink:label="lab_ngne_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants outstanding</link:label>
    <link:label id="lab_ngne_PreFundedWarrantsMember_label_en-US" xlink:label="lab_ngne_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:label id="lab_ngne_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_ngne_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_PreFundedWarrantsMember" xlink:to="lab_ngne_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense_783fe27f-4074-4e3a-adae-dfe48cf7580e_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, expense</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Expense</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsExpense" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsExpense" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_d826c4a9-187a-4f52-a0b6-caf79b14c699_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value rights liability, current</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c95cf419-a96c-43c8-ae4d-e148da503f8b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability_b61d47d7-eb61-46b7-891f-de1e8d6cb13f_terseLabel_en-US" xlink:label="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in contingent value rights liability</link:label>
    <link:label id="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability_label_en-US" xlink:label="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Contingent Value Rights Liability</link:label>
    <link:label id="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability_documentation_en-US" xlink:label="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Contingent Value Rights Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IncreaseDecreaseInContingentValueRightsLiability" xlink:href="ngne-20250331.xsd#ngne_IncreaseDecreaseInContingentValueRightsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_IncreaseDecreaseInContingentValueRightsLiability" xlink:to="lab_ngne_IncreaseDecreaseInContingentValueRightsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_cd979ecc-6c88-4939-84f3-018ef35da336_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_99a3eb92-b5b4-41e1-bcc4-dd50ddd0c317_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_bc4f74c0-e2db-46c5-80f7-a412580aa0c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_d7bdc1f9-514b-46cc-87e9-6ba7ba1d3e84_terseLabel_en-US" xlink:label="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right exercise price of warrants or rights amount (in shares)</link:label>
    <link:label id="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_label_en-US" xlink:label="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Shares</link:label>
    <link:label id="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_documentation_en-US" xlink:label="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" xlink:href="ngne-20250331.xsd#ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" xlink:to="lab_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_b9b604d2-c153-4ec9-8ed9-40ecf97199bf_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b2ada937-ac50-46a9-999d-0bbd7245cffb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c5ceaf62-fe3b-4b65-b20c-2c83f37e8228_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a014fd05-2e20-4f65-a76d-048616576a92_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb5e81b2-284d-4c00-9a28-48f99cffdcfe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8cfacca7-6383-43fe-aaa3-df9aea337505_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9bde1a35-1e50-4353-831c-41be1962d6be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c4a5632c-5b07-4fd2-9506-6400ff5a3557_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6851d873-ef6d-4184-baa4-516ac793089c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f0598a42-5dcd-4bd7-b220-32b3e5b9ffb6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9248f9de-42d7-4c29-860a-d5ec0372bfc0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_StanfordLicenseAgreementMember_b5fbfb5d-5ec4-4074-8f67-bda898613181_terseLabel_en-US" xlink:label="lab_ngne_StanfordLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stanford License Agreement</link:label>
    <link:label id="lab_ngne_StanfordLicenseAgreementMember_label_en-US" xlink:label="lab_ngne_StanfordLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stanford License Agreement [Member]</link:label>
    <link:label id="lab_ngne_StanfordLicenseAgreementMember_documentation_en-US" xlink:label="lab_ngne_StanfordLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stanford License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_StanfordLicenseAgreementMember" xlink:href="ngne-20250331.xsd#ngne_StanfordLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_StanfordLicenseAgreementMember" xlink:to="lab_ngne_StanfordLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5d4a4532-a253-4ea9-bab4-d2b5184594ab_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_cc31cabe-6d07-4340-bd3f-c4ef823285bb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_efceecf7-e91f-4e20-a446-eb8a5032283b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ContingentValueRightsPolicyTextBlock_87595d16-8f2c-430c-8631-28616cc6b2dd_terseLabel_en-US" xlink:label="lab_ngne_ContingentValueRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Value Rights</link:label>
    <link:label id="lab_ngne_ContingentValueRightsPolicyTextBlock_label_en-US" xlink:label="lab_ngne_ContingentValueRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Rights [Policy Text Block]</link:label>
    <link:label id="lab_ngne_ContingentValueRightsPolicyTextBlock_documentation_en-US" xlink:label="lab_ngne_ContingentValueRightsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ContingentValueRightsPolicyTextBlock" xlink:href="ngne-20250331.xsd#ngne_ContingentValueRightsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ContingentValueRightsPolicyTextBlock" xlink:to="lab_ngne_ContingentValueRightsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5fc2a381-8b98-46e4-9800-80f80f7a4fda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_7f9acfe8-2c97-4fa3-a2dc-6b32f3f866cb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_65766877-e79a-4590-8742-872e1b732245_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_45020d1d-56fa-487a-8739-f057e5154a83_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4bbcb867-8478-4d9a-befb-9c737fa29660_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par or stated value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f16bb1fc-bf7c-4520-95dc-8de7cf51a984_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_EastlakeLeaseInSeattleMember_61e0a072-ad88-4ae0-a918-77691219ffe0_terseLabel_en-US" xlink:label="lab_ngne_EastlakeLeaseInSeattleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eastlake Lease in Seattle</link:label>
    <link:label id="lab_ngne_EastlakeLeaseInSeattleMember_label_en-US" xlink:label="lab_ngne_EastlakeLeaseInSeattleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eastlake Lease in Seattle [Member]</link:label>
    <link:label id="lab_ngne_EastlakeLeaseInSeattleMember_documentation_en-US" xlink:label="lab_ngne_EastlakeLeaseInSeattleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eastlake Lease in Seattle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_EastlakeLeaseInSeattleMember" xlink:href="ngne-20250331.xsd#ngne_EastlakeLeaseInSeattleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_EastlakeLeaseInSeattleMember" xlink:to="lab_ngne_EastlakeLeaseInSeattleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_98d81e91-6e52-478d-8990-7e6483b9da12_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_236ed221-2158-4ece-97ea-70abebfdd693_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_5821e03e-a168-44f8-b9dc-ba86924fe4bb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8d121c19-c2fd-442c-b2e9-1c350316c402_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_febb2e8b-4460-434b-986f-c6a878c419f6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_OperatingLeaseMonthlyPayments_fa7dd7fb-c7da-487f-b356-d9bfbab0449c_terseLabel_en-US" xlink:label="lab_ngne_OperatingLeaseMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, monthly payments</link:label>
    <link:label id="lab_ngne_OperatingLeaseMonthlyPayments_label_en-US" xlink:label="lab_ngne_OperatingLeaseMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Payments</link:label>
    <link:label id="lab_ngne_OperatingLeaseMonthlyPayments_documentation_en-US" xlink:label="lab_ngne_OperatingLeaseMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_OperatingLeaseMonthlyPayments" xlink:href="ngne-20250331.xsd#ngne_OperatingLeaseMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_OperatingLeaseMonthlyPayments" xlink:to="lab_ngne_OperatingLeaseMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ProfessionalAndConsultantFeesMember_58e0f489-28aa-49af-ac97-1e2a1eb30243_terseLabel_en-US" xlink:label="lab_ngne_ProfessionalAndConsultantFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional and consultant fees</link:label>
    <link:label id="lab_ngne_ProfessionalAndConsultantFeesMember_label_en-US" xlink:label="lab_ngne_ProfessionalAndConsultantFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional And Consultant Fees [Member]</link:label>
    <link:label id="lab_ngne_ProfessionalAndConsultantFeesMember_documentation_en-US" xlink:label="lab_ngne_ProfessionalAndConsultantFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Professional And Consultant Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ProfessionalAndConsultantFeesMember" xlink:href="ngne-20250331.xsd#ngne_ProfessionalAndConsultantFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ProfessionalAndConsultantFeesMember" xlink:to="lab_ngne_ProfessionalAndConsultantFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_32174b8a-df54-4c6d-b5a1-fcc1f83fe900_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5109152c-1ac0-4baa-9db0-d4220d7ca022_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f88d9af0-91b2-4fdf-9d24-ec75c1ff9373_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e7e809a2-f11f-4bb9-96f7-951677b3d0c4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_de3746ae-6b73-473f-9f98-af3a81545c6d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_035b539d-56e2-45d2-91a7-efb484defc97_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_92452718-77f3-44a7-8268-a27f3af05128_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2f8a7c4c-522f-4ce5-8d9d-609bf4429e2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenseMember_60f4ad52-2629-4062-9525-d076802efe44_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseMember" xlink:to="lab_us-gaap_OtherExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_30a1f756-9aad-40f7-a2f0-244ed171fa50_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a212e65f-4e6c-412d-bf2e-f568c65fe107_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4e7e43e4-7092-4ec9-b302-8a2ea68f464c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a20bbf1d-bf7e-49ce-a4ba-2fd2631e19ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_68d318d6-e9a1-4c70-b009-49057408115f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5634ad1d-c58a-4a13-aa9c-8c64694ee265_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_d8803a51-f32e-44a5-99ba-177d865c81b8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_a327f7ae-9d4f-4ee9-aaf2-bc6d2f64c504_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e99e33e2-c645-4b00-b4bf-11dac98fa2cf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5fc36d95-b0fc-4244-9e80-463016a257f1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c4f0b059-d49c-4992-b286-3c1fad931891_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ShareBasedCompensationExpenseMember_80a4ab7d-804a-4f19-aba2-6c0602041b63_terseLabel_en-US" xlink:label="lab_ngne_ShareBasedCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_ngne_ShareBasedCompensationExpenseMember_label_en-US" xlink:label="lab_ngne_ShareBasedCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Expense [Member]</link:label>
    <link:label id="lab_ngne_ShareBasedCompensationExpenseMember_documentation_en-US" xlink:label="lab_ngne_ShareBasedCompensationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationExpenseMember" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ShareBasedCompensationExpenseMember" xlink:to="lab_ngne_ShareBasedCompensationExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_December2023PreferredStockConversionMember_dc27f3b8-8236-4808-9f1a-a8541099c86b_terseLabel_en-US" xlink:label="lab_ngne_December2023PreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2023 Preferred stock conversion</link:label>
    <link:label id="lab_ngne_December2023PreferredStockConversionMember_label_en-US" xlink:label="lab_ngne_December2023PreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2023 Preferred Stock Conversion [Member]</link:label>
    <link:label id="lab_ngne_December2023PreferredStockConversionMember_documentation_en-US" xlink:label="lab_ngne_December2023PreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2023 Preferred Stock Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023PreferredStockConversionMember" xlink:href="ngne-20250331.xsd#ngne_December2023PreferredStockConversionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_December2023PreferredStockConversionMember" xlink:to="lab_ngne_December2023PreferredStockConversionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_b8262aad-93fe-4754-a58a-700002034b62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired/Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_19f05a1b-9fcb-4f13-bfc6-5fc2f2a42763_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fa4584aa-3cc6-4529-9495-4667cfb4ad0b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c9a61a98-1260-4df8-9a42-822c8d43009c_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6ac33cfe-a180-4666-910e-d7479273ded1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fd734e91-5253-4d3a-b143-7a5fafd44e67_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_03256028-eb9a-4f3b-a0a5-c23d25d83317_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_908ec437-ea43-41fc-8317-cb4972567850_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unvested performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0a789321-dcc6-472f-833a-fb2e5b04b1f1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d3cad304-5cde-4d64-9cd1-c5ca8883d1a2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dd34a310-f93f-4d8f-8380-cd6f39da58ef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_b31b0295-4907-4508-a44a-09ad8faae48e_terseLabel_en-US" xlink:label="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property total amount</link:label>
    <link:label id="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_label_en-US" xlink:label="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Contingent Value Rights Liability, Current, Total Amount</link:label>
    <link:label id="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_documentation_en-US" xlink:label="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Contingent Value Rights Liability, Current, Total Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" xlink:to="lab_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_74ab5c7d-4e34-40c3-b6ec-e5fc0933d20f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization of property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f38e1c0e-a1a3-4e6e-a909-56e3ab963360_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9990de03-7a87-4781-b212-ef935d8fd222_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ae4d4839-033b-4cc4-b930-5804f89803c1_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8732f7d4-352d-4b06-96ac-7a4578ccbff8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_77f0f027-1d10-4748-ab51-ad0855059d99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0ac68b4d-2517-4613-bb90-1e76a9514b92_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_bdc42e6b-e151-4495-9d8c-1859e4a4ef76_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a92fc11-c993-4ead-9d01-24aae3a83888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dc2c595-4719-4e73-8edd-4eceb655c72d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c1ac8030-f786-42a2-8ec6-1b1b99cbb301_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d809dd04-6731-42ee-a102-5864fe1a6564_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.000001 par value; $450,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; $14,929,566 and $14,854,725 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_SalesRelatedMilestonesMember_edf801b4-f848-4e1e-b21a-e6c8e3ef73e4_terseLabel_en-US" xlink:label="lab_ngne_SalesRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-Related Milestones</link:label>
    <link:label id="lab_ngne_SalesRelatedMilestonesMember_label_en-US" xlink:label="lab_ngne_SalesRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-Related Milestones [Member]</link:label>
    <link:label id="lab_ngne_SalesRelatedMilestonesMember_documentation_en-US" xlink:label="lab_ngne_SalesRelatedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-Related Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesRelatedMilestonesMember" xlink:href="ngne-20250331.xsd#ngne_SalesRelatedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_SalesRelatedMilestonesMember" xlink:to="lab_ngne_SalesRelatedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e8348b5c-23fb-4d59-89a8-60585c7440cb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd657296-9dcd-42e5-ac10-ba5968718d22_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_bb008e47-12ad-4e2a-b1c0-4b4a2daf4a25_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e7dea2ae-b37e-42d8-874b-808eb6d13fcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb0ef5a-f4f7-453c-a091-f2e7b69b80d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ad83b32d-65ab-43dd-9263-37e9eb7d0ea8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.000001 par value; $50,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 0 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_BlaineLeaseInSeattleMember_0736a4af-de01-45f6-a736-215b10f0b2a3_terseLabel_en-US" xlink:label="lab_ngne_BlaineLeaseInSeattleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blaine Lease in Seattle</link:label>
    <link:label id="lab_ngne_BlaineLeaseInSeattleMember_label_en-US" xlink:label="lab_ngne_BlaineLeaseInSeattleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blaine Lease in Seattle [Member]</link:label>
    <link:label id="lab_ngne_BlaineLeaseInSeattleMember_documentation_en-US" xlink:label="lab_ngne_BlaineLeaseInSeattleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blaine Lease in Seattle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_BlaineLeaseInSeattleMember" xlink:href="ngne-20250331.xsd#ngne_BlaineLeaseInSeattleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_BlaineLeaseInSeattleMember" xlink:to="lab_ngne_BlaineLeaseInSeattleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dc104122-2743-4f07-91c3-17040395f5d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dac0f1b0-2f8d-44c1-9125-5c25ebbd4a3a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d5582ae1-158c-4516-8cbd-a7ec68611024_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_a03f905f-e8c9-458f-be08-79364b30fcad_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_348cf30a-c812-40f6-87fd-10946601de2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_51d68aeb-21d4-4ef9-8449-54deb3ba6a45_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_cab5bf20-0a32-49a4-ae07-c4e9bd5ad3b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8e835cd4-3f85-4caa-bcec-7f4e43044a6c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_ef769663-8abd-4fb3-8fe7-eeb9917d8272_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0a1a1582-a02a-44cb-a542-6722575f51d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_219de8f6-e111-4050-8b9c-402247da5162_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a2b9db71-aff4-47ca-9a9f-e157158d1ca7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c49f13ac-ea2d-4e5b-84a8-d3ad52c0f20c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a554bf56-ef11-424d-a64e-6b79262d6ef2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_43b6def9-d6bf-4600-af6f-7215b247b8ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4c1526bb-7631-400f-a4e5-1a06ceea7ffd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a96f36f0-7f07-484a-a672-6c94dc356fcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f40e860b-85a4-4b04-950c-1c47f8aa13da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_aea47ad3-b178-46a9-bd3f-b46ad9dd9266_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_c2f63dcb-eff3-43c0-95e5-318d24876586_verboseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c57b187e-028c-46ac-8dc0-6133bbe52d36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_660925c4-1a85-4ef8-aa9c-ee17ac01654d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a926eafd-b231-44dd-9e82-214451602c43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_8d73b652-3d3f-46ff-932b-887d0bb49486_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6b3995ce-fe98-4b3c-bdb9-c14258b74cca_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_83c0f493-9fab-4f22-b1fd-ab188912fc36_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_2f4e1a34-2e7e-4a35-86f8-7af6b829f3b7_terseLabel_en-US" xlink:label="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at or above FDIC insurance limits</link:label>
    <link:label id="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_label_en-US" xlink:label="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, At Or Above FDIC Insurance Limits</link:label>
    <link:label id="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_documentation_en-US" xlink:label="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents, At Or Above FDIC Insurance Limits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" xlink:href="ngne-20250331.xsd#ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" xlink:to="lab_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_0901abe7-792c-43ae-aed6-18379ce69c08_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative specific expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_018e0a58-c68f-46c9-b22f-b3cf80e9b780_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_788f80b1-4478-4632-9cc2-b033461568ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a4c3f80e-88bb-4b26-9714-31bf1abb3d88_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7a073cda-993e-4e28-853f-1f5f141e003e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_54359f32-742e-41bb-add6-98553c92ed69_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fdca8641-ebf2-4a2c-849f-289d4de704b2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_593cbcd6-249f-47d6-81fb-90d734f62606_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f5de957c-58d2-41cb-bffd-be1aae527687_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4f85b9bd-cca3-47ba-ac50-59b17893c38c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_c10ab86e-0170-4997-b229-3d6fe42bdef8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b9f7ced7-95ed-4a05-84b7-9069433a6ac7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_SalesTaxCVRMember_9beeca5e-5e57-480a-a53b-e99602d3440f_terseLabel_en-US" xlink:label="lab_ngne_SalesTaxCVRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Tax CVR</link:label>
    <link:label id="lab_ngne_SalesTaxCVRMember_label_en-US" xlink:label="lab_ngne_SalesTaxCVRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Tax CVR [Member]</link:label>
    <link:label id="lab_ngne_SalesTaxCVRMember_documentation_en-US" xlink:label="lab_ngne_SalesTaxCVRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Tax CVR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesTaxCVRMember" xlink:href="ngne-20250331.xsd#ngne_SalesTaxCVRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_SalesTaxCVRMember" xlink:to="lab_ngne_SalesTaxCVRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_66ee4764-92f6-4640-9e06-08d3941a440c_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_cd23f413-2d5a-4abd-9cab-f0634c7bfe8a_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of real estate property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_30d0c80c-005e-495a-b4e8-4b8bc333a6c5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_16cc1ad4-0021-4014-a130-40b89729aa8f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_LicenseAgreementsAbstract_label_en-US" xlink:label="lab_ngne_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:label id="lab_ngne_LicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_ngne_LicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LicenseAgreementsAbstract" xlink:href="ngne-20250331.xsd#ngne_LicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_LicenseAgreementsAbstract" xlink:to="lab_ngne_LicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_60a4c9d3-56bd-460c-a6b6-123a19b80e26_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_75308eca-c9bc-474a-aa4e-1132c192a26f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_20f213b9-3aa0-408f-b186-6ac46456a777_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_NewYorkHeadquartersLeaseMember_bafb9c13-6c63-4fce-832a-b169882e5f02_terseLabel_en-US" xlink:label="lab_ngne_NewYorkHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York Headquarters Lease</link:label>
    <link:label id="lab_ngne_NewYorkHeadquartersLeaseMember_label_en-US" xlink:label="lab_ngne_NewYorkHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York Headquarters Lease [Member]</link:label>
    <link:label id="lab_ngne_NewYorkHeadquartersLeaseMember_documentation_en-US" xlink:label="lab_ngne_NewYorkHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New York Headquarters Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_NewYorkHeadquartersLeaseMember" xlink:href="ngne-20250331.xsd#ngne_NewYorkHeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_NewYorkHeadquartersLeaseMember" xlink:to="lab_ngne_NewYorkHeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e7e1b8de-3f89-441c-ab5a-40b1feed91a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2bf6bd4f-e279-4760-9e50-7f94cd9f8fac_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_a1c36c91-e35c-4cbc-ac5e-af4755b5f13b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_53bea733-7040-4b77-a1c6-0eee243ec912_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_332766c7-4cfa-42dc-badf-b91683d4c771_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0f619188-1232-4115-a3ba-901547731bf3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_39d72c1a-47b2-4699-9cba-73ea6eb8249d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_97468e71-c947-47f3-a151-ef65e32c6af9_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_c2b867bc-1978-43ee-87d1-d305b01ab7a6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b8667dc8-2670-4e2b-a5dc-87a38a3b845d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_05fa9c7e-ee5e-4800-b46c-f65c753ce9c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_ManufacturingEquipmentMember_f8225887-3a2d-41f6-af56-b2c56da33312_terseLabel_en-US" xlink:label="lab_ngne_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_ngne_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_ngne_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_ngne_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_ngne_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ManufacturingEquipmentMember" xlink:href="ngne-20250331.xsd#ngne_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_ManufacturingEquipmentMember" xlink:to="lab_ngne_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_519dac14-4230-4b16-9af7-af472e1400fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Arrangement, Performance Shares, Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6194676b-47b1-49c2-8b3f-1a3ad86ecf2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_fee3102d-2734-42df-acf8-cf0ccfb318a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of held-to-maturity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_47302394-9256-4b23-98b6-1a884760507a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cdc77ff5-be1c-429c-acc7-331916959eab_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_07792235-89c0-4759-9746-0a153df726e1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2f5d4290-073f-43e7-bebf-272f8eaef9f1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment_b7052d4c-71eb-4d2c-99cc-3e1f52437940_terseLabel_en-US" xlink:label="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, contingent consideration, cash payment</link:label>
    <link:label id="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment_label_en-US" xlink:label="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Cash Payment</link:label>
    <link:label id="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment_documentation_en-US" xlink:label="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AssetAcquisitionContingentConsiderationCashPayment" xlink:href="ngne-20250331.xsd#ngne_AssetAcquisitionContingentConsiderationCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_AssetAcquisitionContingentConsiderationCashPayment" xlink:to="lab_ngne_AssetAcquisitionContingentConsiderationCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_46759615-5341-4810-8015-2bb7daab608a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7cb89525-5a71-4413-8e7a-c4a97ed8d789_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4b786a2e-d179-4dba-9150-a2857e5bc310_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_fa472dd8-0b38-479b-a012-ee2a15827d1a_terseLabel_en-US" xlink:label="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, contingent consideration, covenant, minimum amount owed, net of deductions</link:label>
    <link:label id="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_label_en-US" xlink:label="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Covenant, Minimum Amount Owed, Net Of Deductions</link:label>
    <link:label id="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_documentation_en-US" xlink:label="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Covenant, Minimum Amount Owed, Net Of Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" xlink:href="ngne-20250331.xsd#ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" xlink:to="lab_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_IntellectualPropertyCVRNettingMember_ebf675a9-cbc8-4c1e-96e5-b36c935289e2_terseLabel_en-US" xlink:label="lab_ngne_IntellectualPropertyCVRNettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual Property CVR</link:label>
    <link:label id="lab_ngne_IntellectualPropertyCVRNettingMember_label_en-US" xlink:label="lab_ngne_IntellectualPropertyCVRNettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property CVR, Netting [Member]</link:label>
    <link:label id="lab_ngne_IntellectualPropertyCVRNettingMember_documentation_en-US" xlink:label="lab_ngne_IntellectualPropertyCVRNettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property CVR, Netting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_IntellectualPropertyCVRNettingMember" xlink:to="lab_ngne_IntellectualPropertyCVRNettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_97144016-a838-4d5f-9ed3-194f822add78_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2b966134-7c22-4a07-ba7e-d58866bac1d1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ebb423d-7480-411a-85d0-908f0f22ac26_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_d63d492e-452b-408d-9870-5f439028a95d_terseLabel_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and obligations, eligibility to received net proceeds, maximum percentage</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_label_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Maximum Percentage</link:label>
    <link:label id="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_documentation_en-US" xlink:label="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Maximum Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" xlink:to="lab_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_56bae9ca-33de-48e9-864d-6e00c9d9c0da_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum_4d442863-efd5-4325-b2e5-56548df1e0be_terseLabel_en-US" xlink:label="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding stock per stockholder, maximum</link:label>
    <link:label id="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum_label_en-US" xlink:label="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Stock Per Stockholder, Maximum</link:label>
    <link:label id="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum_documentation_en-US" xlink:label="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Stock Per Stockholder, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PercentageOfOutstandingStockPerStockholderMaximum" xlink:href="ngne-20250331.xsd#ngne_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ngne_PercentageOfOutstandingStockPerStockholderMaximum" xlink:to="lab_ngne_PercentageOfOutstandingStockPerStockholderMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_747a4091-6635-4246-bfbc-195727170eb8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_7f9dde23-c6df-4681-bba2-5e95d1479163_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2024</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_f54df032-86ff-4259-b942-077969f03c04_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2025</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_47b13a8f-1c4e-49be-99e2-1e1b532b95c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_fa167905-2911-414c-aa4e-75d6dc6e20c7_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 2024 private placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ngne-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:455e46d4-7342-4901-9012-cb7d8f12b78e,g:0c981b7d-7032-4dc2-af2a-101f291ef69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurogene.com/role/Cover" xlink:type="simple" xlink:href="ngne-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4d11ec7b-24e8-432f-bfc6-c5f8aa88db71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_DocumentType_4d11ec7b-24e8-432f-bfc6-c5f8aa88db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bbe2c460-1f69-4a14-8eba-a1aaaa05f1f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_DocumentQuarterlyReport_bbe2c460-1f69-4a14-8eba-a1aaaa05f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ddee4e14-11d8-4f8b-91e4-c62927940e9a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_DocumentPeriodEndDate_ddee4e14-11d8-4f8b-91e4-c62927940e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2a0f6862-58ad-4085-b728-aa25fc694531" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_DocumentTransitionReport_2a0f6862-58ad-4085-b728-aa25fc694531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_650f9825-06b7-4393-9b1c-be5c27b9d722" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityFileNumber_650f9825-06b7-4393-9b1c-be5c27b9d722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3adce066-4533-44b7-ba96-f74109d237fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityRegistrantName_3adce066-4533-44b7-ba96-f74109d237fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d46e3203-f8ae-44e5-978c-744956196d77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d46e3203-f8ae-44e5-978c-744956196d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_10d070d4-88c2-4d47-bcde-74f280ec71f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityTaxIdentificationNumber_10d070d4-88c2-4d47-bcde-74f280ec71f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1fde3637-605d-4529-8c82-52a6a87ed13b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityAddressAddressLine1_1fde3637-605d-4529-8c82-52a6a87ed13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b315496f-813d-4f5b-8561-4dcd5ce4d4eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityAddressAddressLine2_b315496f-813d-4f5b-8561-4dcd5ce4d4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1d58eced-1e7f-43ae-b727-2e741bf36c51" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityAddressCityOrTown_1d58eced-1e7f-43ae-b727-2e741bf36c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_413af880-d49a-4142-ba3c-8d2a8ac4a996" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityAddressStateOrProvince_413af880-d49a-4142-ba3c-8d2a8ac4a996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bac77b63-b33f-4965-b11a-a1b7e1435ce1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityAddressPostalZipCode_bac77b63-b33f-4965-b11a-a1b7e1435ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0f9876b9-f10f-4b1f-bc25-df6a1280df7b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_CityAreaCode_0f9876b9-f10f-4b1f-bc25-df6a1280df7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3cc08da8-80b7-424d-80c1-34e912a737f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_LocalPhoneNumber_3cc08da8-80b7-424d-80c1-34e912a737f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f1914e10-72ee-4f28-ba81-da3d2fbe9ccb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_Security12bTitle_f1914e10-72ee-4f28-ba81-da3d2fbe9ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a0b55409-8e00-42bd-bad5-2120e037b495" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_TradingSymbol_a0b55409-8e00-42bd-bad5-2120e037b495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ac09a90e-ad00-49be-9160-689874ebf136" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_SecurityExchangeName_ac09a90e-ad00-49be-9160-689874ebf136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_415a31ad-3762-4d2c-8adf-8d139c45fdd0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityCurrentReportingStatus_415a31ad-3762-4d2c-8adf-8d139c45fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_76d24cbe-2577-4286-8ef5-68810dba2a66" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityInteractiveDataCurrent_76d24cbe-2577-4286-8ef5-68810dba2a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6129931e-ee3e-49dc-8045-f459f971b914" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityFilerCategory_6129931e-ee3e-49dc-8045-f459f971b914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ca33aa89-2a3e-4e4d-8363-83b91d571eef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntitySmallBusiness_ca33aa89-2a3e-4e4d-8363-83b91d571eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_35cb0ac6-2369-4603-a856-1ddceecab2e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityEmergingGrowthCompany_35cb0ac6-2369-4603-a856-1ddceecab2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cd284622-06bb-41b8-8ce0-e1fbcd8eafc5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityShellCompany_cd284622-06bb-41b8-8ce0-e1fbcd8eafc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fe344c21-6c57-4350-9431-3f7b649393f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fe344c21-6c57-4350-9431-3f7b649393f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1cff7855-998b-447d-98bb-7447c0c22b72" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_EntityCentralIndexKey_1cff7855-998b-447d-98bb-7447c0c22b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5370fc4c-de73-4d0b-b9dd-318641dee528" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_DocumentFiscalYearFocus_5370fc4c-de73-4d0b-b9dd-318641dee528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_39b37602-1c88-4700-86e0-24e526678a66" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_39b37602-1c88-4700-86e0-24e526678a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_241f7400-8520-440f-84f1-5c8b66395267" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_AmendmentFlag_241f7400-8520-440f-84f1-5c8b66395267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a44cdf7c-bb56-46f2-a937-d4b08a616858" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d6fc7f4d-4296-486c-b113-a0a4e479a25c" xlink:to="loc_dei_CurrentFiscalYearEndDate_a44cdf7c-bb56-46f2-a937-d4b08a616858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0976399d-99db-4b9f-9ebd-9515610664d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0976399d-99db-4b9f-9ebd-9515610664d7" xlink:to="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e05f890b-7311-477d-b654-146603bfdd06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e05f890b-7311-477d-b654-146603bfdd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31ff0a2b-0c6f-463d-a242-28dffbfc1599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e05f890b-7311-477d-b654-146603bfdd06" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31ff0a2b-0c6f-463d-a242-28dffbfc1599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_894b5d02-a28e-440c-be86-24431fb8b1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e05f890b-7311-477d-b654-146603bfdd06" xlink:to="loc_us-gaap_ShortTermInvestments_894b5d02-a28e-440c-be86-24431fb8b1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d4026f8-d9b1-44c3-a919-92fb8ee574e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e05f890b-7311-477d-b654-146603bfdd06" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d4026f8-d9b1-44c3-a919-92fb8ee574e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b04107f1-62f0-49dd-ab50-444f99651825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e05f890b-7311-477d-b654-146603bfdd06" xlink:to="loc_us-gaap_AssetsCurrent_b04107f1-62f0-49dd-ab50-444f99651825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_89e5ad15-4e42-413e-9d9a-7739d596ddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_89e5ad15-4e42-413e-9d9a-7739d596ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9ea9b5c8-bf97-4922-966d-06ae45b9b3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9ea9b5c8-bf97-4922-966d-06ae45b9b3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_328944f4-2ea4-4d6f-a9da-ebad429a4f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_328944f4-2ea4-4d6f-a9da-ebad429a4f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2ae32b34-b250-4325-85a6-60b001a689b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2ae32b34-b250-4325-85a6-60b001a689b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_18095378-9366-45c3-8f5f-b4cde6630aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_18095378-9366-45c3-8f5f-b4cde6630aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ea91ce08-25f0-4e79-a5d3-ee1be591920e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d4a94db-04e3-48f1-899a-dbfdfb006b7f" xlink:to="loc_us-gaap_Assets_ea91ce08-25f0-4e79-a5d3-ee1be591920e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0976399d-99db-4b9f-9ebd-9515610664d7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9a82e7e5-da56-4e39-95f7-9f7753cdffc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:to="loc_us-gaap_AccountsPayableCurrent_9a82e7e5-da56-4e39-95f7-9f7753cdffc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cb0b0327-1d55-4f53-97ff-3f6b79c32826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cb0b0327-1d55-4f53-97ff-3f6b79c32826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cb21c8c7-4b11-460c-bf7e-4adc9e045611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cb21c8c7-4b11-460c-bf7e-4adc9e045611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b87dfdc7-ce63-4616-a515-96a761555cba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b87dfdc7-ce63-4616-a515-96a761555cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_29939fec-94af-4840-b6d5-6806e6a9e9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_29939fec-94af-4840-b6d5-6806e6a9e9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef927f9d-a30e-48ad-94de-4f7160d8cadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e2cb2709-76de-4ba9-93e9-c514fc2a3a8a" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef927f9d-a30e-48ad-94de-4f7160d8cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75ddc49e-30c0-4dd3-82eb-f89dd3a6a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75ddc49e-30c0-4dd3-82eb-f89dd3a6a9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bcd91f41-75db-4300-bf9c-016c8ceab57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bcd91f41-75db-4300-bf9c-016c8ceab57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_48098771-fb79-47b4-b632-2150e5340c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_48098771-fb79-47b4-b632-2150e5340c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_45276d7a-8000-4d1f-b465-d6150c5331af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_45276d7a-8000-4d1f-b465-d6150c5331af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0291dc90-e983-4f44-b503-23d1583493d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_Liabilities_0291dc90-e983-4f44-b503-23d1583493d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_19cdfee3-5b61-481e-8f4f-c31cf91b98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:to="loc_us-gaap_PreferredStockValue_19cdfee3-5b61-481e-8f4f-c31cf91b98b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b530fd49-2c63-4821-a9fd-77ba9b38ccad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:to="loc_us-gaap_CommonStockValue_b530fd49-2c63-4821-a9fd-77ba9b38ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_581c40ce-c9a3-445c-a0ff-93167f92569f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:to="loc_us-gaap_AdditionalPaidInCapital_581c40ce-c9a3-445c-a0ff-93167f92569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0650c1b7-712e-40d9-9834-8376190fe5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0650c1b7-712e-40d9-9834-8376190fe5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_795fc2d4-66bf-45c0-980e-f3ed57f1b91b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1dbc389b-9fef-4192-9fc1-253cf636ff71" xlink:to="loc_us-gaap_StockholdersEquity_795fc2d4-66bf-45c0-980e-f3ed57f1b91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_37c6cf56-ba57-4146-b8ff-fdbd4d827c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b599d27b-c5ea-46c1-929d-a78a7b1cce0e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_37c6cf56-ba57-4146-b8ff-fdbd4d827c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9e72ba73-dcdf-4341-9701-15eec847b486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9e72ba73-dcdf-4341-9701-15eec847b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5bbd27d7-d768-45d1-a0d7-21bd4f94b681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5bbd27d7-d768-45d1-a0d7-21bd4f94b681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4242c3df-dabd-49e6-9fa1-27aa3fcc67f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4242c3df-dabd-49e6-9fa1-27aa3fcc67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c0b42f1d-c530-4ac9-b8b3-a0319f381314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c0b42f1d-c530-4ac9-b8b3-a0319f381314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7ab6099a-a753-40db-8c23-d3aea6d5248c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7ab6099a-a753-40db-8c23-d3aea6d5248c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3730803c-1696-466d-a79f-b277e03aa130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3730803c-1696-466d-a79f-b277e03aa130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_89288a25-c35c-4c63-b340-a8af4bf7b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_CommonStockSharesIssued_89288a25-c35c-4c63-b340-a8af4bf7b4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0692ab59-1ad7-4ab0-bd67-dceb2629697c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_84b167e9-e507-42e7-9e57-dc078bc336b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0692ab59-1ad7-4ab0-bd67-dceb2629697c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_87c197fe-d059-4ed2-9710-1e064ab5909c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e7f11b4f-4b0c-4d38-a5e1-3fac8bbdcb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_87c197fe-d059-4ed2-9710-1e064ab5909c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e7f11b4f-4b0c-4d38-a5e1-3fac8bbdcb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cab11857-8774-4306-9afc-44198e20215f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e7f11b4f-4b0c-4d38-a5e1-3fac8bbdcb4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cab11857-8774-4306-9afc-44198e20215f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fda83fc2-1b95-4b8f-bee0-f2e48e6702c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e7f11b4f-4b0c-4d38-a5e1-3fac8bbdcb4e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fda83fc2-1b95-4b8f-bee0-f2e48e6702c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5fdc9398-6e9e-4a38-96e5-0685dadb42e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e7f11b4f-4b0c-4d38-a5e1-3fac8bbdcb4e" xlink:to="loc_us-gaap_OperatingExpenses_5fdc9398-6e9e-4a38-96e5-0685dadb42e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_275496a7-5e81-46f1-ba2d-d72a717e0f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_87c197fe-d059-4ed2-9710-1e064ab5909c" xlink:to="loc_us-gaap_OperatingIncomeLoss_275496a7-5e81-46f1-ba2d-d72a717e0f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fb48c9d0-48e0-400a-a837-b05265c10d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_87c197fe-d059-4ed2-9710-1e064ab5909c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fb48c9d0-48e0-400a-a837-b05265c10d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_86d53895-3108-4c2b-a1d9-fa7bc25d8c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fb48c9d0-48e0-400a-a837-b05265c10d6d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_86d53895-3108-4c2b-a1d9-fa7bc25d8c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1d344217-7462-4dfe-905d-399ff4ec32e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fb48c9d0-48e0-400a-a837-b05265c10d6d" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1d344217-7462-4dfe-905d-399ff4ec32e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_4c10a53f-20ca-41c9-bddd-99c34cf6f136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fb48c9d0-48e0-400a-a837-b05265c10d6d" xlink:to="loc_us-gaap_OtherNonoperatingIncome_4c10a53f-20ca-41c9-bddd-99c34cf6f136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_6ba1e9f1-1fbd-41a1-ae17-ccf9e7193ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fb48c9d0-48e0-400a-a837-b05265c10d6d" xlink:to="loc_us-gaap_OtherNonoperatingExpense_6ba1e9f1-1fbd-41a1-ae17-ccf9e7193ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77952b3b-2deb-4da3-95fc-f920b5a704fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_87c197fe-d059-4ed2-9710-1e064ab5909c" xlink:to="loc_us-gaap_NetIncomeLoss_77952b3b-2deb-4da3-95fc-f920b5a704fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f3673a25-e42b-49f3-9026-877293e070d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_87c197fe-d059-4ed2-9710-1e064ab5909c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f3673a25-e42b-49f3-9026-877293e070d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_af917bdb-8ece-45e9-9f67-3b83850189d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3673a25-e42b-49f3-9026-877293e070d6" xlink:to="loc_us-gaap_EarningsPerShareBasic_af917bdb-8ece-45e9-9f67-3b83850189d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c9578612-3945-4605-ae65-85677e6c88e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3673a25-e42b-49f3-9026-877293e070d6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c9578612-3945-4605-ae65-85677e6c88e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e3e7ef6c-5e20-45ba-a3af-6e9c185e1af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3673a25-e42b-49f3-9026-877293e070d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e3e7ef6c-5e20-45ba-a3af-6e9c185e1af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a446530-6249-4307-88eb-6c1f7d7ae93b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3673a25-e42b-49f3-9026-877293e070d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7a446530-6249-4307-88eb-6c1f7d7ae93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedStatementofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2a83b8a-6bc5-4c45-bdae-cfd4245a1ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2a83b8a-6bc5-4c45-bdae-cfd4245a1ed1" xlink:to="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d23c59d9-253a-43e8-8ef7-0e4d900aeacf" xlink:to="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0dc9d119-8033-4039-9c51-23817531fc56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:to="loc_us-gaap_CommonStockMember_0dc9d119-8033-4039-9c51-23817531fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_46dcf968-30f4-4646-900e-c122f407e5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_46dcf968-30f4-4646-900e-c122f407e5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3d8695c9-d83c-487c-8533-0dd13c5d2174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28c2308b-aab7-4204-970a-1cfcd66c2a75" xlink:to="loc_us-gaap_RetainedEarningsMember_3d8695c9-d83c-487c-8533-0dd13c5d2174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c43a7b3-5cd4-4edc-bbe0-fea6265beb93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa007ece-ce5d-490d-bac7-a749cf038832" xlink:to="loc_us-gaap_StatementLineItems_3c43a7b3-5cd4-4edc-bbe0-fea6265beb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c43a7b3-5cd4-4edc-bbe0-fea6265beb93" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f76c7d53-fe8c-416e-9ed0-7fa15e50db76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f76c7d53-fe8c-416e-9ed0-7fa15e50db76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94245390-a46c-487a-8044-e4d917d9796e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockholdersEquity_94245390-a46c-487a-8044-e4d917d9796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fccb737a-e634-4481-b700-278b7fd8adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fccb737a-e634-4481-b700-278b7fd8adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78c31229-78b3-41af-bb84-6417a4ed304b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_78c31229-78b3-41af-bb84-6417a4ed304b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b406d16b-63c4-47d4-8345-97160f1da785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b406d16b-63c4-47d4-8345-97160f1da785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d8616e7b-84db-4f43-a162-503a7e052577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d8616e7b-84db-4f43-a162-503a7e052577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed14aaef-4239-4d15-8734-67398e01253f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_NetIncomeLoss_ed14aaef-4239-4d15-8734-67398e01253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1e5bf3b6-9440-4426-8acc-63e53ae74249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1e5bf3b6-9440-4426-8acc-63e53ae74249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07783a94-5528-48dc-b718-767686ea5a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a55052a-5327-48dc-b738-3e99ea833068" xlink:to="loc_us-gaap_StockholdersEquity_07783a94-5528-48dc-b718-767686ea5a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ngne-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e67f29fb-63fd-4098-8095-139aed8b7089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e67f29fb-63fd-4098-8095-139aed8b7089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b2f06b98-9d80-4e64-84cb-c23856776a06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e67f29fb-63fd-4098-8095-139aed8b7089" xlink:to="loc_us-gaap_NetIncomeLoss_b2f06b98-9d80-4e64-84cb-c23856776a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e67f29fb-63fd-4098-8095-139aed8b7089" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7fbf23ed-10f9-49bc-b850-4a9a3f5a9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_ShareBasedCompensation_7fbf23ed-10f9-49bc-b850-4a9a3f5a9ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_72efb137-24a5-462a-8ff9-7a924d089c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_72efb137-24a5-462a-8ff9-7a924d089c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5d6ab901-5b18-4d5a-ba67-f6d2c3df48d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_AssetImpairmentCharges_5d6ab901-5b18-4d5a-ba67-f6d2c3df48d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_2deece79-2d3a-4f3d-805d-cd5a69e04828" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_OperatingLeaseExpense_2deece79-2d3a-4f3d-805d-cd5a69e04828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_235bf808-f3a8-44d6-8b0e-d4846b7eda43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_235bf808-f3a8-44d6-8b0e-d4846b7eda43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c45c4750-4469-4fe4-9f1c-8dd8cb1e3286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c45c4750-4469-4fe4-9f1c-8dd8cb1e3286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IncreaseDecreaseInContingentValueRightsLiability_2483ff68-4a64-4ed3-ba0b-b98fea0e7147" xlink:href="ngne-20250331.xsd#ngne_IncreaseDecreaseInContingentValueRightsLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_ngne_IncreaseDecreaseInContingentValueRightsLiability_2483ff68-4a64-4ed3-ba0b-b98fea0e7147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ceee2c88-a74c-436e-ace7-52183d7f46ce" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7220912c-ce24-4f45-b8de-64460e68f8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7220912c-ce24-4f45-b8de-64460e68f8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_19c171fc-cd12-4891-89a3-c5d8d67a0ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_19c171fc-cd12-4891-89a3-c5d8d67a0ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_44dcac2c-0420-4c44-8f07-6879fe6e0505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_44dcac2c-0420-4c44-8f07-6879fe6e0505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6230b29e-e4ef-4617-a4b4-7f3d0364e8df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6230b29e-e4ef-4617-a4b4-7f3d0364e8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ef310535-ee46-482c-a538-971f55ac54d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a0f2d4f-5231-462a-9de6-30d8fdd1c826" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ef310535-ee46-482c-a538-971f55ac54d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70d688b4-bfbf-4902-9745-0edeaf2668f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e67f29fb-63fd-4098-8095-139aed8b7089" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70d688b4-bfbf-4902-9745-0edeaf2668f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce35bcc2-b69c-44c0-87c5-58cf46cca2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce35bcc2-b69c-44c0-87c5-58cf46cca2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8ee6cd4-0e98-48fb-9bd1-1c19d1eda0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce35bcc2-b69c-44c0-87c5-58cf46cca2fc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8ee6cd4-0e98-48fb-9bd1-1c19d1eda0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_230041d6-ec16-49a8-a95e-710a75d00856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce35bcc2-b69c-44c0-87c5-58cf46cca2fc" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_230041d6-ec16-49a8-a95e-710a75d00856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_cf137700-7d69-4a81-99d4-fad6e72bd9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce35bcc2-b69c-44c0-87c5-58cf46cca2fc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_cf137700-7d69-4a81-99d4-fad6e72bd9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de42e8e3-bce2-4cdc-bda3-992490c3f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ce35bcc2-b69c-44c0-87c5-58cf46cca2fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de42e8e3-bce2-4cdc-bda3-992490c3f5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_945f6a8b-5af1-4707-a739-182f851c198b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_945f6a8b-5af1-4707-a739-182f851c198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_0456f692-9e22-4b3f-aa94-0fd2a2143819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_0456f692-9e22-4b3f-aa94-0fd2a2143819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b61e7033-0955-4a53-8e47-6ac759a7f026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b61e7033-0955-4a53-8e47-6ac759a7f026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ab4df036-229b-414f-bd8d-1bfdad42a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ab4df036-229b-414f-bd8d-1bfdad42a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7efd43a3-9a0b-465e-be62-2d3ad9910001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_04f0ea91-0f1a-4d2a-ac5c-af46f0a6ae48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7efd43a3-9a0b-465e-be62-2d3ad9910001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50cb06e6-a7c2-4cd5-a586-beafc10900cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50cb06e6-a7c2-4cd5-a586-beafc10900cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b0288a0-aea3-414a-a0c5-f61dd5243707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b0288a0-aea3-414a-a0c5-f61dd5243707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e347a2e3-9d5c-4f3b-997e-858ca59b9e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e347a2e3-9d5c-4f3b-997e-858ca59b9e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c312cb2f-85d9-4a10-b212-53d9c6cf8b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c312cb2f-85d9-4a10-b212-53d9c6cf8b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_05b57451-e6f6-44b3-b97c-4882f1c88ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c312cb2f-85d9-4a10-b212-53d9c6cf8b7c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_05b57451-e6f6-44b3-b97c-4882f1c88ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_db11fc81-e0f7-4b6b-9319-54226703eb98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c312cb2f-85d9-4a10-b212-53d9c6cf8b7c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_db11fc81-e0f7-4b6b-9319-54226703eb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_42169528-1efa-432e-928a-c5541ef6b0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d09044d3-5bbe-413f-ba90-c6deb307e71c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_42169528-1efa-432e-928a-c5541ef6b0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0f0868f0-1615-47f1-af85-5e36f6f95e07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_42169528-1efa-432e-928a-c5541ef6b0e2" xlink:to="loc_us-gaap_InterestPaidNet_0f0868f0-1615-47f1-af85-5e36f6f95e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="ngne-20250331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8111c98-a566-4706-a673-37d2725071e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3f05f966-d117-4fc6-8708-52f5b17c6e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d8111c98-a566-4706-a673-37d2725071e1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_3f05f966-d117-4fc6-8708-52f5b17c6e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/RisksandUncertainties" xlink:type="simple" xlink:href="ngne-20250331.xsd#RisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/RisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8fb327ad-4e95-45db-8020-aed9377f6d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_cdb86e59-7ffc-47e8-be7b-62cd53cc3996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8fb327ad-4e95-45db-8020-aed9377f6d12" xlink:to="loc_us-gaap_NatureOfOperations_cdb86e59-7ffc-47e8-be7b-62cd53cc3996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_589675c0-23ef-47e2-91f6-667f6683cab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2d5f4d6f-d1af-4f73-9e03-d4e45931d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_589675c0-23ef-47e2-91f6-667f6683cab4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2d5f4d6f-d1af-4f73-9e03-d4e45931d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/Investments" xlink:type="simple" xlink:href="ngne-20250331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d39abb1-8dda-4cc3-b91b-8f1748e98ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4afa8bb3-1e9f-4202-8e4e-e774cbac1801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d39abb1-8dda-4cc3-b91b-8f1748e98ba7" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4afa8bb3-1e9f-4202-8e4e-e774cbac1801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="ngne-20250331.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5411eb60-7d20-4352-a44e-ee1858a448eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_680c2fba-2646-49cf-b9ae-9dfe94801a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5411eb60-7d20-4352-a44e-ee1858a448eb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_680c2fba-2646-49cf-b9ae-9dfe94801a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets" xlink:type="simple" xlink:href="ngne-20250331.xsd#Prepaidexpensesandothercurrentassets"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_c4b2e965-c68f-4887-8a40-66f11b7789dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_63aaa477-bc41-425d-bc88-b4ca59df8ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_c4b2e965-c68f-4887-8a40-66f11b7789dc" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_63aaa477-bc41-425d-bc88-b4ca59df8ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="ngne-20250331.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0adec47b-18d3-4ef9-a570-3049ad1496d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e8debee0-220a-4b43-96cb-973586981500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0adec47b-18d3-4ef9-a570-3049ad1496d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e8debee0-220a-4b43-96cb-973586981500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="ngne-20250331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e33e86af-847d-46db-bec6-73c23ee0ead3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0d2ad3f1-823c-45fb-ad76-0e81b1a4b72e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e33e86af-847d-46db-bec6-73c23ee0ead3" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0d2ad3f1-823c-45fb-ad76-0e81b1a4b72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00d9fdfb-6fcf-451c-ae5a-d53f3af9b813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f373ad90-da82-4d9b-b8f3-4c40b90e834c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00d9fdfb-6fcf-451c-ae5a-d53f3af9b813" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f373ad90-da82-4d9b-b8f3-4c40b90e834c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/Licenses" xlink:type="simple" xlink:href="ngne-20250331.xsd#Licenses"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/Licenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LicenseAgreementsAbstract_7b05feb0-3fa9-450c-9c39-cd80883a2e95" xlink:href="ngne-20250331.xsd#ngne_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_099249af-4eb9-4a8c-b031-64eab7b0e066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ngne_LicenseAgreementsAbstract_7b05feb0-3fa9-450c-9c39-cd80883a2e95" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_099249af-4eb9-4a8c-b031-64eab7b0e066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_01a94500-9925-4167-b063-b0a541fe7609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d3234ecb-d14d-4a64-bf01-44a734e4ee75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_01a94500-9925-4167-b063-b0a541fe7609" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d3234ecb-d14d-4a64-bf01-44a734e4ee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f0881d-11ea-4c7f-92d5-6b1022f6bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ed750152-ca1e-4cd3-b6b6-acf5cac1df8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f0881d-11ea-4c7f-92d5-6b1022f6bedd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ed750152-ca1e-4cd3-b6b6-acf5cac1df8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SegmentInformation" xlink:type="simple" xlink:href="ngne-20250331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a7dd7fe9-7adf-4564-9839-225514f85957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_24a5d8f7-8c1a-42f1-a256-22afd3a189f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a7dd7fe9-7adf-4564-9839-225514f85957" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_24a5d8f7-8c1a-42f1-a256-22afd3a189f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ngne-20250331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_44d46bc9-0423-4d9c-aa5e-0f6241835593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_01c9712c-96a7-4e77-a3df-ff35920b8b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_44d46bc9-0423-4d9c-aa5e-0f6241835593" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_01c9712c-96a7-4e77-a3df-ff35920b8b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_71e7cc15-aa71-4591-b27b-f019eb160ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_71e7cc15-aa71-4591-b27b-f019eb160ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_99812b13-7398-4977-ba01-984aa1687304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_UseOfEstimates_99812b13-7398-4977-ba01-984aa1687304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_660f261c-a79d-4bfd-8843-988cdf6e2318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_660f261c-a79d-4bfd-8843-988cdf6e2318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_67fc9ca4-0df0-4cc2-b8bd-b3fa56498779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_67fc9ca4-0df0-4cc2-b8bd-b3fa56498779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_71c454f1-923e-4f3d-b13b-9122221e16d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_71c454f1-923e-4f3d-b13b-9122221e16d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ContingentValueRightsPolicyTextBlock_f813c175-c84b-467b-ba04-83da189ab69f" xlink:href="ngne-20250331.xsd#ngne_ContingentValueRightsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_ngne_ContingentValueRightsPolicyTextBlock_f813c175-c84b-467b-ba04-83da189ab69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d1ff0550-51ea-4974-9c9c-e34a56852fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d1ff0550-51ea-4974-9c9c-e34a56852fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2fedf2e0-96c8-4c2c-8599-83017aff2d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2fedf2e0-96c8-4c2c-8599-83017aff2d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd754ca8-a2b9-4b83-aeb6-d9a81ed6df66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b29ebe9c-9bcb-4af1-afe1-b7b1befd4728" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fd754ca8-a2b9-4b83-aeb6-d9a81ed6df66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_81e0a206-2756-4a6a-8639-44cdc83012cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_eca9df81-0920-4847-935a-a80d9e48168f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81e0a206-2756-4a6a-8639-44cdc83012cb" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_eca9df81-0920-4847-935a-a80d9e48168f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_00196d25-0b2c-4865-9fb5-9d96631f0f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81e0a206-2756-4a6a-8639-44cdc83012cb" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_00196d25-0b2c-4865-9fb5-9d96631f0f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_b619346d-e821-4045-a4ec-ef1fbfcd560c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81e0a206-2756-4a6a-8639-44cdc83012cb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_b619346d-e821-4045-a4ec-ef1fbfcd560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d680206d-98d6-4531-bb02-921c8594614f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81e0a206-2756-4a6a-8639-44cdc83012cb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d680206d-98d6-4531-bb02-921c8594614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/InvestmentsTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f9f49346-c706-4974-8738-75faabd16b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_03216966-a0e8-4ccc-9c8e-7688361e81e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f9f49346-c706-4974-8738-75faabd16b80" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_03216966-a0e8-4ccc-9c8e-7688361e81e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b9e64e75-2510-47b0-9b2c-1daef366370d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2e7e0551-a53e-4f5e-84ac-6c3f22d3ee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b9e64e75-2510-47b0-9b2c-1daef366370d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2e7e0551-a53e-4f5e-84ac-6c3f22d3ee4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#PrepaidexpensesandothercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_97bf22f8-7626-4f28-9730-4e04f5e33861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_9c1adac4-b24c-4927-86e8-15cb15f28d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_97bf22f8-7626-4f28-9730-4e04f5e33861" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_9c1adac4-b24c-4927-86e8-15cb15f28d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_14820e16-1a3c-4b21-ba01-c7fb25b8a16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_96436719-677e-42b4-a0d3-652777491358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_14820e16-1a3c-4b21-ba01-c7fb25b8a16c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_96436719-677e-42b4-a0d3-652777491358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_16068650-3e43-4f2c-9c4f-9447b9e84e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c46802d0-f5a9-4a35-a606-399becf7c023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16068650-3e43-4f2c-9c4f-9447b9e84e3c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c46802d0-f5a9-4a35-a606-399becf7c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02683d95-a858-43d8-b28c-5d0e00d99308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_870d994c-89f1-40fd-ab13-b32d44358b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02683d95-a858-43d8-b28c-5d0e00d99308" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_870d994c-89f1-40fd-ab13-b32d44358b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_66243805-b8f6-4d75-a268-b2ff8c88019a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02683d95-a858-43d8-b28c-5d0e00d99308" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_66243805-b8f6-4d75-a268-b2ff8c88019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_61e46a4b-9daa-4cee-a53d-ede61d297cea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_74084f28-232f-43c1-9f95-c27a86cda73f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61e46a4b-9daa-4cee-a53d-ede61d297cea" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_74084f28-232f-43c1-9f95-c27a86cda73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_8f894d83-7d4a-4a20-8f1c-7134d06e82ed" xlink:href="ngne-20250331.xsd#ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61e46a4b-9daa-4cee-a53d-ede61d297cea" xlink:to="loc_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_8f894d83-7d4a-4a20-8f1c-7134d06e82ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b5ddc5-3b54-4e28-aba6-cac49e28dc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_515384d9-fb91-4145-9dc6-d40b4a8ba5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b5ddc5-3b54-4e28-aba6-cac49e28dc3e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_515384d9-fb91-4145-9dc6-d40b4a8ba5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f3522f7b-04aa-4258-895e-2627fc9e7776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b5ddc5-3b54-4e28-aba6-cac49e28dc3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f3522f7b-04aa-4258-895e-2627fc9e7776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40e3a84e-eeb9-4f6c-828a-d5f69f0eddfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b5ddc5-3b54-4e28-aba6-cac49e28dc3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40e3a84e-eeb9-4f6c-828a-d5f69f0eddfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3422848f-6345-41b5-90e2-8bd95d6902ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b5ddc5-3b54-4e28-aba6-cac49e28dc3e" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3422848f-6345-41b5-90e2-8bd95d6902ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_a79704b6-510b-400a-aaac-ce16a3b65b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89b5ddc5-3b54-4e28-aba6-cac49e28dc3e" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_a79704b6-510b-400a-aaac-ce16a3b65b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ngne-20250331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8bf62139-4ecd-43f2-90a4-5bb79ff012e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3fbb09bb-9053-4fc7-816a-fdf24aeb2ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8bf62139-4ecd-43f2-90a4-5bb79ff012e3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3fbb09bb-9053-4fc7-816a-fdf24aeb2ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/RisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#RisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/RisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91a8a791-ad69-41d0-ae3f-7d9bb86d03fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_57a136ff-6d7c-48db-bcdd-7a8ff206b192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91a8a791-ad69-41d0-ae3f-7d9bb86d03fb" xlink:to="loc_us-gaap_NetIncomeLoss_57a136ff-6d7c-48db-bcdd-7a8ff206b192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09961156-88b6-4e99-8034-50a8d12052b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91a8a791-ad69-41d0-ae3f-7d9bb86d03fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09961156-88b6-4e99-8034-50a8d12052b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8391063a-ec3c-4ec3-bf9a-b0ab4ddde819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91a8a791-ad69-41d0-ae3f-7d9bb86d03fb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8391063a-ec3c-4ec3-bf9a-b0ab4ddde819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_e71cc11d-c638-4055-bbb4-c7f486c302d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91a8a791-ad69-41d0-ae3f-7d9bb86d03fb" xlink:to="loc_us-gaap_InvestmentsAndCash_e71cc11d-c638-4055-bbb4-c7f486c302d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82e45931-7075-4c12-a5bc-3c562d39a031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82e45931-7075-4c12-a5bc-3c562d39a031" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_566907b8-3873-4cda-8070-f79b9fc76b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0b325ad7-499e-4d3b-8f3d-a9fce233ac18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_566907b8-3873-4cda-8070-f79b9fc76b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_b620b366-93a3-49ea-9736-8609dbbf733d" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_566907b8-3873-4cda-8070-f79b9fc76b1f" xlink:to="loc_ngne_PreFundedWarrantsMember_b620b366-93a3-49ea-9736-8609dbbf733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_03e2cbde-7c09-4eb6-86f9-1d81da03be52" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cecbb1c6-419b-45a4-b7c2-bcceb68f1f95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cecbb1c6-419b-45a4-b7c2-bcceb68f1f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_83a189b3-8dd9-4f06-a47d-1c38ebe74410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_NumberOfReportableSegments_83a189b3-8dd9-4f06-a47d-1c38ebe74410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_70a6ba8d-6c78-4251-8a4a-4da2a943667b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_RestrictedCash_70a6ba8d-6c78-4251-8a4a-4da2a943667b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_6952de8d-a5d2-43e7-a948-1df248687454" xlink:href="ngne-20250331.xsd#ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits_6952de8d-a5d2-43e7-a948-1df248687454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6a520102-4dbc-488c-bba6-4edd121a49af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f3129864-1212-4869-99ac-819acc60f69f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6a520102-4dbc-488c-bba6-4edd121a49af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e26b2e58-40bb-4440-9ba6-7d467967f857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f018fefb-a4bc-4b76-875b-de433b64ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e26b2e58-40bb-4440-9ba6-7d467967f857" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f018fefb-a4bc-4b76-875b-de433b64ad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_0d5c3d64-2540-4541-8423-55fb3937296d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e26b2e58-40bb-4440-9ba6-7d467967f857" xlink:to="loc_us-gaap_RestrictedCash_0d5c3d64-2540-4541-8423-55fb3937296d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_665df661-a416-41ec-be02-d502142d3ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e26b2e58-40bb-4440-9ba6-7d467967f857" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_665df661-a416-41ec-be02-d502142d3ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_66c8e026-1610-45e3-ad00-d1f0b2aed68a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66c8e026-1610-45e3-ad00-d1f0b2aed68a" xlink:to="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:to="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3abfd93f-9fcf-47a0-89b1-c4f127d4d4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_5b5c4c3d-4bd6-403d-83e2-a95999677757" xlink:to="loc_us-gaap_RestructuringPlanDomain_3abfd93f-9fcf-47a0-89b1-c4f127d4d4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_Phase1NL201TrialMember_a7564739-3e68-43ff-9d5e-432fa42de8b1" xlink:href="ngne-20250331.xsd#ngne_Phase1NL201TrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3abfd93f-9fcf-47a0-89b1-c4f127d4d4db" xlink:to="loc_ngne_Phase1NL201TrialMember_a7564739-3e68-43ff-9d5e-432fa42de8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c92f434f-3cca-4dac-a43a-ec42c7fcd6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_eaffc822-9c2b-4191-a6e3-21588eb23f09" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_c92f434f-3cca-4dac-a43a-ec42c7fcd6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c92f434f-3cca-4dac-a43a-ec42c7fcd6f2" xlink:to="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e0a65761-7ccf-48a2-8fdb-37f042fbb32d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_RestructuringReserve_e0a65761-7ccf-48a2-8fdb-37f042fbb32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_49429c1e-130c-4d41-956c-cd01d20326bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_49429c1e-130c-4d41-956c-cd01d20326bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_5a853dc5-436a-4aee-81f6-e78642a0c000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_PaymentsForRestructuring_5a853dc5-436a-4aee-81f6-e78642a0c000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_38df8a51-9338-4bc4-bf3a-d0f492a86c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3e281303-8927-44fc-97a5-5ac5fed1fc4a" xlink:to="loc_us-gaap_RestructuringReserve_38df8a51-9338-4bc4-bf3a-d0f492a86c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ee2b5a4d-8dcf-47fe-8e3b-ed066f404526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ee2b5a4d-8dcf-47fe-8e3b-ed066f404526" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e7e320e-e3de-47dd-b5c0-f5684dbb572f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_336610df-1fc0-47f5-98a4-6e53d88985e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_336610df-1fc0-47f5-98a4-6e53d88985e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bbfb9cb7-96a2-461c-bd91-e66fb0af0c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bbfb9cb7-96a2-461c-bd91-e66fb0af0c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_08bc4340-55d8-4013-9983-a8ff9e00475c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aeb8cfd6-1792-4bcb-a5ff-d8cc8b922fbb" xlink:to="loc_us-gaap_PerformanceSharesMember_08bc4340-55d8-4013-9983-a8ff9e00475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_177ce0dd-d9a8-4eb4-a22d-173b3df8013e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3633cc1c-b0bc-4c1a-bf81-e1559110f156" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_177ce0dd-d9a8-4eb4-a22d-173b3df8013e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50a622ab-b921-48d8-a057-1bcb2683270a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_177ce0dd-d9a8-4eb4-a22d-173b3df8013e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_50a622ab-b921-48d8-a057-1bcb2683270a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f947f59-8b76-410c-913d-a167aee0a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1f947f59-8b76-410c-913d-a167aee0a84d" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:to="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_613c9955-0e3b-4cca-8fcd-bc478e3cd40f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d2a6d14c-8909-4969-8205-306fcf152200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d2a6d14c-8909-4969-8205-306fcf152200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_5063d005-1bab-4a90-abc6-f39acd9d04e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e8be306-c4aa-4a45-989b-159dab075a5f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_5063d005-1bab-4a90-abc6-f39acd9d04e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4913eee-c924-470a-b651-105e99db0703" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_0d78df3d-9f5e-4acc-ad34-c22e35297265" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_0d78df3d-9f5e-4acc-ad34-c22e35297265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_601d5863-b43d-4195-a8dd-074e20c2a454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_01a207b1-5603-404d-9dd7-ae2207714d20" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_601d5863-b43d-4195-a8dd-074e20c2a454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_ab96705b-830f-4481-a945-1de347d65c22" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_b3e45f9e-75d7-4af9-a4ec-726d030789f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_b3e45f9e-75d7-4af9-a4ec-726d030789f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cefa37b8-b2be-494c-a1b2-9716740e27b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_cefa37b8-b2be-494c-a1b2-9716740e27b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_cdff19c5-4937-47f4-a12a-7605a95c68ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_cdff19c5-4937-47f4-a12a-7605a95c68ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c33fc58e-9eeb-4ab9-bfdc-62dc3e1ecd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_dff19f79-008f-4ed2-bb19-e3ac6c757fd4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_c33fc58e-9eeb-4ab9-bfdc-62dc3e1ecd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33423654-bf06-417a-b14f-9f2424638c37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33423654-bf06-417a-b14f-9f2424638c37" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5de95e86-874f-492f-9750-bd39974fb29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_97342f79-5924-4a96-bdba-53c8e0bba9b8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5de95e86-874f-492f-9750-bd39974fb29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8aefe557-3fea-49fc-a937-303ef4c393f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5de95e86-874f-492f-9750-bd39974fb29b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8aefe557-3fea-49fc-a937-303ef4c393f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f827ed67-2cac-4d5d-b328-319285bb2d01" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b7a42a0b-7956-4f96-962a-2b2ea7301732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b7a42a0b-7956-4f96-962a-2b2ea7301732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd888baf-5f6d-4176-8dd1-d874b633e13e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd888baf-5f6d-4176-8dd1-d874b633e13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2e063d4-6259-4434-b7e0-78b6f39c9135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e31c88e-e484-4dfc-b6a5-5c829415ee5e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2e063d4-6259-4434-b7e0-78b6f39c9135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9c4c379d-f589-426e-9e25-5f47ff52658b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_700b1b9e-bc7a-4558-9ae2-c4689bd7830a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9c4c379d-f589-426e-9e25-5f47ff52658b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_83eabdf1-7722-4017-b7d3-b9fbba2dee01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9c4c379d-f589-426e-9e25-5f47ff52658b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_83eabdf1-7722-4017-b7d3-b9fbba2dee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_330aea5d-fe00-46e2-ae66-9f86efc691f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_f90e78d5-1259-44e1-8849-6883a3920c13" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_330aea5d-fe00-46e2-ae66-9f86efc691f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_330aea5d-fe00-46e2-ae66-9f86efc691f3" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_354cfeec-22eb-48f2-a5b1-d3ecc88e492e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_354cfeec-22eb-48f2-a5b1-d3ecc88e492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ea2110bd-1bb8-4d98-b218-955bb94b8178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_ea2110bd-1bb8-4d98-b218-955bb94b8178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_919bd587-c2a7-489c-8af9-027c1c101b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_187c3b62-0074-4314-836a-3a0a26cd855e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_919bd587-c2a7-489c-8af9-027c1c101b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#PrepaidexpensesandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73c43db8-833a-47b3-91ff-a029a37e2549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RefundsAndOtherReceivablesCurrent_429aa30a-078f-43a6-8458-36c0b2adb2e3" xlink:href="ngne-20250331.xsd#ngne_RefundsAndOtherReceivablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73c43db8-833a-47b3-91ff-a029a37e2549" xlink:to="loc_ngne_RefundsAndOtherReceivablesCurrent_429aa30a-078f-43a6-8458-36c0b2adb2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1dc07883-de33-4de0-9cf3-f55c1d7d6f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73c43db8-833a-47b3-91ff-a029a37e2549" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1dc07883-de33-4de0-9cf3-f55c1d7d6f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3cdb56fc-2da9-4ab3-b83b-9041a06058ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73c43db8-833a-47b3-91ff-a029a37e2549" xlink:to="loc_us-gaap_OtherAssetsCurrent_3cdb56fc-2da9-4ab3-b83b-9041a06058ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55f1a82f-33bc-4e81-92bb-6366aa1b1b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_73c43db8-833a-47b3-91ff-a029a37e2549" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_55f1a82f-33bc-4e81-92bb-6366aa1b1b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#PropertyandEquipmentNetPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6a80e2f4-b2b5-4587-9034-8f87ce55d877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6a80e2f4-b2b5-4587-9034-8f87ce55d877" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_34ec81af-e15d-4982-a585-e32f11c2b378" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LabEquipmentMember_533d20e6-7cc4-4fca-afa2-e7ddd7d9d072" xlink:href="ngne-20250331.xsd#ngne_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_ngne_LabEquipmentMember_533d20e6-7cc4-4fca-afa2-e7ddd7d9d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ManufacturingEquipmentMember_6dec9225-7131-4a89-8fe6-21c3bc6e80e9" xlink:href="ngne-20250331.xsd#ngne_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_ngne_ManufacturingEquipmentMember_6dec9225-7131-4a89-8fe6-21c3bc6e80e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a30a485f-80df-4e7a-8588-802d424a0fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_OfficeEquipmentMember_a30a485f-80df-4e7a-8588-802d424a0fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_55f76d91-0e3b-489a-a5c4-52477856debd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_55f76d91-0e3b-489a-a5c4-52477856debd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9c47bcc5-f5bb-44bc-a7e2-65f1e72bc612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_9c47bcc5-f5bb-44bc-a7e2-65f1e72bc612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2d65dae0-eff7-4381-a953-bb41c865c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2de7a14d-7dbd-4632-9332-11b1d0dc03de" xlink:to="loc_us-gaap_ConstructionInProgressMember_2d65dae0-eff7-4381-a953-bb41c865c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36f7916a-2af4-4282-8413-24755a381556" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7020366-baee-4b7b-a809-e5e483ddba90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7020366-baee-4b7b-a809-e5e483ddba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d91ab28-77c6-43bc-bd4c-d5292f35ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d91ab28-77c6-43bc-bd4c-d5292f35ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b9f8e185-89e1-4ce2-9fdb-96cbf270706a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc05abeb-49e9-47c5-8387-4ba712e41711" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b9f8e185-89e1-4ce2-9fdb-96cbf270706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_35834a48-0014-4e5f-ae98-77aff8820d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5876a008-b43d-40ad-bed5-681397161bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_35834a48-0014-4e5f-ae98-77aff8820d60" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5876a008-b43d-40ad-bed5-681397161bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_dca84ab6-e70a-42d9-8db0-88dc0823b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_35834a48-0014-4e5f-ae98-77aff8820d60" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_dca84ab6-e70a-42d9-8db0-88dc0823b6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d39375ef-8c18-4ebe-814e-c65bdc914096" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9d157e14-1279-493a-bd6b-9663ee207a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d39375ef-8c18-4ebe-814e-c65bdc914096" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9d157e14-1279-493a-bd6b-9663ee207a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AccruedResearchAndDevelopmentCurrent_64f11d15-1477-458a-aca8-ce14cd37c28d" xlink:href="ngne-20250331.xsd#ngne_AccruedResearchAndDevelopmentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d39375ef-8c18-4ebe-814e-c65bdc914096" xlink:to="loc_ngne_AccruedResearchAndDevelopmentCurrent_64f11d15-1477-458a-aca8-ce14cd37c28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_37c9fa64-998e-41c9-a435-4b9737a8d94a" xlink:href="ngne-20250331.xsd#ngne_AccruedSeveranceBonusAndRetentionCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d39375ef-8c18-4ebe-814e-c65bdc914096" xlink:to="loc_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent_37c9fa64-998e-41c9-a435-4b9737a8d94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_449f4214-489a-4758-b488-0f69cbaed6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d39375ef-8c18-4ebe-814e-c65bdc914096" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_449f4214-489a-4758-b488-0f69cbaed6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_834d8bef-1c7f-44af-a2c6-24638017bfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d39375ef-8c18-4ebe-814e-c65bdc914096" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_834d8bef-1c7f-44af-a2c6-24638017bfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_72e21253-3c4c-4a4f-a018-41722b5a2121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:to="loc_us-gaap_OperatingLeaseCost_72e21253-3c4c-4a4f-a018-41722b5a2121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_f86cd3c7-41f2-498a-9d3b-32f5010cc7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:to="loc_us-gaap_LeaseCostAbstract_f86cd3c7-41f2-498a-9d3b-32f5010cc7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8d74a306-398d-40fe-b6c1-2e629a0f5b83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f86cd3c7-41f2-498a-9d3b-32f5010cc7c8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8d74a306-398d-40fe-b6c1-2e629a0f5b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_63176949-148b-49ac-a47c-3ad60df47f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f86cd3c7-41f2-498a-9d3b-32f5010cc7c8" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_63176949-148b-49ac-a47c-3ad60df47f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_03c756e0-8335-4a44-ba5c-98a2c8366d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:to="loc_us-gaap_VariableLeaseCost_03c756e0-8335-4a44-ba5c-98a2c8366d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_e3d39f96-6d8a-4e1d-a73e-de55c46707c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:to="loc_us-gaap_ShortTermLeaseCost_e3d39f96-6d8a-4e1d-a73e-de55c46707c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_543439cc-72ad-4838-8a10-7dc4bdb5ee72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:to="loc_us-gaap_LeaseCost_543439cc-72ad-4838-8a10-7dc4bdb5ee72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2dca6ede-a24d-42ab-ac47-50569155ec1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1099c78e-e8a9-4430-9886-951bdbf32123" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_2dca6ede-a24d-42ab-ac47-50569155ec1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8f074e07-3120-4e23-b026-0777db2574e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8f074e07-3120-4e23-b026-0777db2574e9" xlink:to="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_224a7916-6a94-4d64-ac95-02d889d64cd2" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_NewYorkHeadquartersLeaseMember_174be79d-557f-4c88-8d3a-f807f81fdfea" xlink:href="ngne-20250331.xsd#ngne_NewYorkHeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_NewYorkHeadquartersLeaseMember_174be79d-557f-4c88-8d3a-f807f81fdfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_HoustonLeaseMember_8f212006-16b7-4cb3-85fa-94c274a94967" xlink:href="ngne-20250331.xsd#ngne_HoustonLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_HoustonLeaseMember_8f212006-16b7-4cb3-85fa-94c274a94967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_BlaineLeaseInSeattleMember_308cbfa8-2e4f-4b37-9309-a6f2cb9fdb90" xlink:href="ngne-20250331.xsd#ngne_BlaineLeaseInSeattleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_BlaineLeaseInSeattleMember_308cbfa8-2e4f-4b37-9309-a6f2cb9fdb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_EastlakeLeaseInSeattleMember_e916ea74-df66-4a90-a1e4-fac91500d0cf" xlink:href="ngne-20250331.xsd#ngne_EastlakeLeaseInSeattleMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb7a3a3d-2c39-4362-9d35-c0f8e643f651" xlink:to="loc_ngne_EastlakeLeaseInSeattleMember_e916ea74-df66-4a90-a1e4-fac91500d0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c1f81ad8-062c-4c62-b27d-f96d0749c01b" xlink:to="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1dab13e4-09f4-437c-be1c-f0dbd393ec1f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:to="loc_srt_MinimumMember_1dab13e4-09f4-437c-be1c-f0dbd393ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49855f1d-7f08-4359-9107-ce80aa5de32c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a13c0470-ed0e-4dc7-8cb1-bd94ec5bcaba" xlink:to="loc_srt_MaximumMember_49855f1d-7f08-4359-9107-ce80aa5de32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c34dbddf-8dd4-4982-8b6f-89c65970d279" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_April2024CVRLicensingAgreementMember_4ec41afa-dc56-458d-a326-a18be2fcf4c0" xlink:href="ngne-20250331.xsd#ngne_April2024CVRLicensingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:to="loc_ngne_April2024CVRLicensingAgreementMember_4ec41afa-dc56-458d-a326-a18be2fcf4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023CVRLicensingAgreementMember_b3d4e600-792b-47a8-b26d-a06fd45d508d" xlink:href="ngne-20250331.xsd#ngne_December2023CVRLicensingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5371914a-b4c9-45c5-ba43-1eb376fb878b" xlink:to="loc_ngne_December2023CVRLicensingAgreementMember_b3d4e600-792b-47a8-b26d-a06fd45d508d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_999e8bfa-b234-4f97-bcf3-dc1175b61c2e" xlink:to="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b5fa6f38-49fb-4e78-a079-aa4bd55bd99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:to="loc_us-gaap_LicenseMember_b5fa6f38-49fb-4e78-a079-aa4bd55bd99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember_960f26ae-5079-4908-b2e1-20c58a3c2a6a" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:to="loc_ngne_IntellectualPropertyCVRNettingMember_960f26ae-5079-4908-b2e1-20c58a3c2a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LeaseCVRMember_1b9bef42-fa6a-4090-b3dd-4ca70c0c86ae" xlink:href="ngne-20250331.xsd#ngne_LeaseCVRMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f1fd11ee-eea7-4370-8d49-8ed2bce8b6db" xlink:to="loc_ngne_LeaseCVRMember_1b9bef42-fa6a-4090-b3dd-4ca70c0c86ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ad6255a-1e97-4de7-a72c-3b8ad05f7cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_87c28035-77d2-4b2f-afa9-8275d185939c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ad6255a-1e97-4de7-a72c-3b8ad05f7cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_13f3bbc6-4026-41a3-9229-4b9f398be38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ad6255a-1e97-4de7-a72c-3b8ad05f7cc7" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_13f3bbc6-4026-41a3-9229-4b9f398be38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_55fe7904-ff68-447b-8bb3-77ac7b0c0729" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember_c0d6292a-5c3f-4f88-8ebe-7efafd5e8f37" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:to="loc_ngne_IntellectualPropertyCVRNettingMember_c0d6292a-5c3f-4f88-8ebe-7efafd5e8f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesTaxCVRMember_6024120a-af0d-41fb-a84e-6fdcfaf9772b" xlink:href="ngne-20250331.xsd#ngne_SalesTaxCVRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f953203f-e9d8-49f5-8888-13eae9f4bb7d" xlink:to="loc_ngne_SalesTaxCVRMember_6024120a-af0d-41fb-a84e-6fdcfaf9772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_80107e18-004e-416b-a168-9f62cb87b8ad" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_227282a8-1fcb-432c-987d-5513ee1a44a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_227282a8-1fcb-432c-987d-5513ee1a44a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8d387272-2dd9-489d-9c7a-98b734bc463d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8d387272-2dd9-489d-9c7a-98b734bc463d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_OperatingLeaseMonthlyPayments_f16547e5-5bc6-4b57-b2dd-e47c749671e3" xlink:href="ngne-20250331.xsd#ngne_OperatingLeaseMonthlyPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_OperatingLeaseMonthlyPayments_f16547e5-5bc6-4b57-b2dd-e47c749671e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_410e704d-7002-4732-930a-533bb59c6327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_410e704d-7002-4732-930a-533bb59c6327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8ad137e7-fc15-492f-bc96-f09ccceee5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_OperatingLeaseLiability_8ad137e7-fc15-492f-bc96-f09ccceee5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_e38a61d6-ce51-4542-b9b4-6c12f177d422" xlink:href="ngne-20250331.xsd#ngne_LesseeOperatingLeaseNumberOfRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_LesseeOperatingLeaseNumberOfRenewalTerm_e38a61d6-ce51-4542-b9b4-6c12f177d422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dc650b53-8a60-4bb7-9d47-a8e444900cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dc650b53-8a60-4bb7-9d47-a8e444900cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_5ebc92dc-b9bc-42e0-8956-f05592ef56a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_SecurityDeposit_5ebc92dc-b9bc-42e0-8956-f05592ef56a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_ff1bfb41-c8a2-4a66-b7d8-ccc1a8a15085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_PrepaidRent_ff1bfb41-c8a2-4a66-b7d8-ccc1a8a15085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_385f0b23-aeb6-4eac-8ae5-59d0575c44a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_385f0b23-aeb6-4eac-8ae5-59d0575c44a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_64b125a9-1636-42f7-8ac9-63569dcc0011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_64b125a9-1636-42f7-8ac9-63569dcc0011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_002f59e9-712a-454c-b6b6-67201eef66de" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage_002f59e9-712a-454c-b6b6-67201eef66de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_0934de2a-9555-4692-ad62-7357303cb594" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage_0934de2a-9555-4692-ad62-7357303cb594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eda68757-30f8-4dff-82f7-6fe0f3b73635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eda68757-30f8-4dff-82f7-6fe0f3b73635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_1cec173c-df94-480d-b4ba-497fc9644d54" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_1cec173c-df94-480d-b4ba-497fc9644d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_868074ec-55fb-46c1-9b7c-59303a799b7d" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsReimbursement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsReimbursement_868074ec-55fb-46c1-9b7c-59303a799b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_f610e7c9-96ce-4c74-a723-24c228b4f6a5" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount_f610e7c9-96ce-4c74-a723-24c228b4f6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_026e0d45-9518-4738-8820-0e9f5a672064" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions_026e0d45-9518-4738-8820-0e9f5a672064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AssetAcquisitionContingentConsiderationCashPayment_6ca71c48-b24d-40ce-ad33-dfed725fcc26" xlink:href="ngne-20250331.xsd#ngne_AssetAcquisitionContingentConsiderationCashPayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_AssetAcquisitionContingentConsiderationCashPayment_6ca71c48-b24d-40ce-ad33-dfed725fcc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_43e8abf9-d9db-48fe-9419-3542ce69b49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_43e8abf9-d9db-48fe-9419-3542ce69b49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_f96e32df-0d66-4df4-b88a-4f3a6650dcd5" xlink:href="ngne-20250331.xsd#ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5f45806-c733-47a8-a3b6-50abab101cb6" xlink:to="loc_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions_f96e32df-0d66-4df4-b88a-4f3a6650dcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#CommitmentandContingenciesContingentValueRightsLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f1b829f0-26fe-4a55-98b6-08ec74b152fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f1b829f0-26fe-4a55-98b6-08ec74b152fc" xlink:to="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_10fa5728-17e4-438a-a627-70c79c8e22f9" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LeaseCVRMember_ac59e363-c8df-41e7-9b19-ad29e4187bb1" xlink:href="ngne-20250331.xsd#ngne_LeaseCVRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:to="loc_ngne_LeaseCVRMember_ac59e363-c8df-41e7-9b19-ad29e4187bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_IntellectualPropertyCVRNettingMember_e765f05a-cf8b-4622-b67d-40bb1745487d" xlink:href="ngne-20250331.xsd#ngne_IntellectualPropertyCVRNettingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:to="loc_ngne_IntellectualPropertyCVRNettingMember_e765f05a-cf8b-4622-b67d-40bb1745487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesTaxCVRMember_cab2fb3f-c9b6-442e-94e2-db4a2a6d6cac" xlink:href="ngne-20250331.xsd#ngne_SalesTaxCVRMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_56b2e5f4-56e7-417d-9f77-0e0437971e23" xlink:to="loc_ngne_SalesTaxCVRMember_cab2fb3f-c9b6-442e-94e2-db4a2a6d6cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5cb163a6-1960-4cd0-9d8e-3f9b631511b7" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_6c66de65-d588-4304-b119-bb2c634be417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_6c66de65-d588-4304-b119-bb2c634be417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_b45bd7af-a97b-4a62-99b7-afbf13055e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_af7bc427-398f-4344-88b9-7681c7a093b0" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_b45bd7af-a97b-4a62-99b7-afbf13055e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/LicensesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#LicensesDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/LicensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ngne_LicenseAgreementsAbstract_339c7cb0-ec95-4f0e-bda1-f609a81d59eb" xlink:href="ngne-20250331.xsd#ngne_LicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ngne_LicenseAgreementsAbstract_339c7cb0-ec95-4f0e-bda1-f609a81d59eb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7d704a63-fd95-4e98-a882-794c3f704a94" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_UniversityOfEdinburghMember_c25c1c02-6f1e-4c13-aebc-3a975d28d285" xlink:href="ngne-20250331.xsd#ngne_UniversityOfEdinburghMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_UniversityOfEdinburghMember_c25c1c02-6f1e-4c13-aebc-3a975d28d285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_VirovekIncMember_8acaa9c2-91fc-4c75-9e41-82734de2acc4" xlink:href="ngne-20250331.xsd#ngne_VirovekIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_VirovekIncMember_8acaa9c2-91fc-4c75-9e41-82734de2acc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SigmaAldrichCoMember_24a48736-5d43-49d5-8870-0484fe8010c7" xlink:href="ngne-20250331.xsd#ngne_SigmaAldrichCoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_SigmaAldrichCoMember_24a48736-5d43-49d5-8870-0484fe8010c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_StanfordLicenseAgreementMember_2f2b51f5-8bb5-4e89-98fe-39181218245d" xlink:href="ngne-20250331.xsd#ngne_StanfordLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c030bc8-11fe-4261-a0af-a2e391cad049" xlink:to="loc_ngne_StanfordLicenseAgreementMember_2f2b51f5-8bb5-4e89-98fe-39181218245d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2c5e936-c256-4c2f-bc1a-331ec89195e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b5690096-ae80-4584-9ec9-7fd0086093a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2c5e936-c256-4c2f-bc1a-331ec89195e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_820c51e3-a2b5-4f30-b398-47e64c20c385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2c5e936-c256-4c2f-bc1a-331ec89195e3" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_820c51e3-a2b5-4f30-b398-47e64c20c385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fbb1397d-accf-4dd0-86ea-f0aa70e94aba" xlink:to="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RegulatoryRelatedMilestonesMember_ef4c832c-cf67-4416-87a1-6bff0d3c5f26" xlink:href="ngne-20250331.xsd#ngne_RegulatoryRelatedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:to="loc_ngne_RegulatoryRelatedMilestonesMember_ef4c832c-cf67-4416-87a1-6bff0d3c5f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_SalesRelatedMilestonesMember_c81bc8d5-9f39-4371-990e-6e463bdf3e41" xlink:href="ngne-20250331.xsd#ngne_SalesRelatedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db64cd15-3c17-478e-aa8c-64a380009e60" xlink:to="loc_ngne_SalesRelatedMilestonesMember_c81bc8d5-9f39-4371-990e-6e463bdf3e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e1f85b73-9744-4265-ad92-076fe82b6a0a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsTerm_8da7d9bc-7e4d-4e97-a0e7-912773508e71" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsTerm_8da7d9bc-7e4d-4e97-a0e7-912773508e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_93c18178-ea46-49df-b3c9-492f5ea3065c" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm_93c18178-ea46-49df-b3c9-492f5ea3065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_178a32e2-853f-4f0d-b1b9-5f3998c529da" xlink:href="ngne-20250331.xsd#ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate_178a32e2-853f-4f0d-b1b9-5f3998c529da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_7ef6e99c-d24f-487b-be3d-07052762d2cd" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_7ef6e99c-d24f-487b-be3d-07052762d2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsExpense_fe00aa75-07f3-4c87-a2c2-14072ef90bef" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsExpense_fe00aa75-07f3-4c87-a2c2-14072ef90bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_7233bdbf-03d4-457d-8d0c-f04e5894b06b" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_7233bdbf-03d4-457d-8d0c-f04e5894b06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_CollaborativeArrangementTermOfAgreement_5b67b6f6-6a4a-4e07-9e79-0996ef099687" xlink:href="ngne-20250331.xsd#ngne_CollaborativeArrangementTermOfAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_da586aa1-8ace-43d6-b6a3-bc43fd034a4e" xlink:to="loc_ngne_CollaborativeArrangementTermOfAgreement_5b67b6f6-6a4a-4e07-9e79-0996ef099687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4bf593f0-5a66-49f6-9006-5579592f95d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4bf593f0-5a66-49f6-9006-5579592f95d2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_03544c5d-3bb9-4655-9a1b-2cd20693dadf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3ee20af8-a3a2-4eb2-8e33-95242820085f" xlink:to="loc_us-gaap_PlanNameDomain_03544c5d-3bb9-4655-9a1b-2cd20693dadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2025InducementPlanMember_32a65584-50fb-494c-9509-ee9f51ba7891" xlink:href="ngne-20250331.xsd#ngne_A2025InducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_03544c5d-3bb9-4655-9a1b-2cd20693dadf" xlink:to="loc_ngne_A2025InducementPlanMember_32a65584-50fb-494c-9509-ee9f51ba7891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9ab3acad-f73c-4973-ad6b-13ed42a9bf69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_aaa3ad01-e152-4d5b-863c-3f7cd478efb9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9ab3acad-f73c-4973-ad6b-13ed42a9bf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_65d80bce-60f2-4661-b8ef-e5bf405bb571" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9ab3acad-f73c-4973-ad6b-13ed42a9bf69" xlink:to="loc_ngne_PreFundedWarrantsMember_65d80bce-60f2-4661-b8ef-e5bf405bb571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_851558d9-86ed-408e-b341-7da1c08933f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_599f38df-789c-42ed-9ddb-474e531dc9af" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_851558d9-86ed-408e-b341-7da1c08933f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5885028b-2dc3-4645-bce4-8109d87546f2" xlink:to="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c1030ad-ea52-408d-bf2e-f03d415d881d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c1030ad-ea52-408d-bf2e-f03d415d881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab3bfdcf-b6e1-4798-95ae-104110ab4e64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab3bfdcf-b6e1-4798-95ae-104110ab4e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_060e749c-7903-4d6c-9088-eb7eb4d3d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_060e749c-7903-4d6c-9088-eb7eb4d3d46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PercentageOfOutstandingStockPerStockholderMaximum_cd3f8728-02ad-43d8-80f7-5a28032b65c0" xlink:href="ngne-20250331.xsd#ngne_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_ngne_PercentageOfOutstandingStockPerStockholderMaximum_cd3f8728-02ad-43d8-80f7-5a28032b65c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_de142f0c-4592-4356-aa3e-d8d89ed650e4" xlink:href="ngne-20250331.xsd#ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum_de142f0c-4592-4356-aa3e-d8d89ed650e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ClassOfWarrantOrRightNoticePeriod_4bb53c4b-3293-4477-a2ba-b5e5aade100e" xlink:href="ngne-20250331.xsd#ngne_ClassOfWarrantOrRightNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0e07bed-a637-4fc8-b154-b05656468c60" xlink:to="loc_ngne_ClassOfWarrantOrRightNoticePeriod_4bb53c4b-3293-4477-a2ba-b5e5aade100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a9c37d49-a294-4289-86d9-7efda7ee2f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a9c37d49-a294-4289-86d9-7efda7ee2f72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_633ef057-17d5-4636-84f7-5bc6a0190742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_594a3c31-cc66-4113-85a6-d3337d1f9b23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_633ef057-17d5-4636-84f7-5bc6a0190742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_3ce93ca5-3ba6-4d1f-934e-23750103889b" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_633ef057-17d5-4636-84f7-5bc6a0190742" xlink:to="loc_ngne_PreFundedWarrantsMember_3ce93ca5-3ba6-4d1f-934e-23750103889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8b13e76c-c268-4e59-856a-f0751d2e1367" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantMember_5906f0b6-b84b-4ad6-bfb3-881b672853ca" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_ngne_PreFundedWarrantMember_5906f0b6-b84b-4ad6-bfb3-881b672853ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023PreferredStockConversionMember_5b22ecf6-92d3-4519-a61a-28183627847b" xlink:href="ngne-20250331.xsd#ngne_December2023PreferredStockConversionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_ngne_December2023PreferredStockConversionMember_5b22ecf6-92d3-4519-a61a-28183627847b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_December2023PreClosingMember_e03ec592-64fe-440c-b0fc-03cd1a91847a" xlink:href="ngne-20250331.xsd#ngne_December2023PreClosingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_ngne_December2023PreClosingMember_e03ec592-64fe-440c-b0fc-03cd1a91847a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9f0d9e2d-7f89-4772-bf53-68a357d8d976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6a969720-b8ee-4342-ad25-bc8181f39e00" xlink:to="loc_us-gaap_PrivatePlacementMember_9f0d9e2d-7f89-4772-bf53-68a357d8d976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2b2b6c1a-a6eb-457f-9506-06a5b4f719a8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7be3329d-8285-4d94-8ea7-f02df1e1aa78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7be3329d-8285-4d94-8ea7-f02df1e1aa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_6914e79d-9406-4383-8867-db150aa54482" xlink:href="ngne-20250331.xsd#ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b1c61793-067b-4290-b062-818f841c6f3f" xlink:to="loc_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares_6914e79d-9406-4383-8867-db150aa54482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d594ea08-5783-48c3-b63f-e05bc8204c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d594ea08-5783-48c3-b63f-e05bc8204c2f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:to="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_69dff46c-d09c-4948-8f81-0b85e35b2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_15fedd71-5fef-4b6d-aba9-8d8e7b73e026" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_15fedd71-5fef-4b6d-aba9-8d8e7b73e026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_229aea20-c0c2-45af-83e2-824968ae349e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_us-gaap_PerformanceSharesMember_229aea20-c0c2-45af-83e2-824968ae349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bcf64fa9-71e6-472e-9521-5a1f37fcc858" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bcf64fa9-71e6-472e-9521-5a1f37fcc858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_b5003d60-6589-47bf-b38f-c53790ea9535" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da7bd2d8-879d-4789-be1b-3c1fd24615bc" xlink:to="loc_ngne_PreFundedWarrantsMember_b5003d60-6589-47bf-b38f-c53790ea9535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:to="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_42cc25e9-e22b-4304-b37d-91eff8dc8423" xlink:to="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2023EquityIncentivePlanMember_cdcfd55d-440f-43e6-8ea2-8b3e279522d4" xlink:href="ngne-20250331.xsd#ngne_A2023EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:to="loc_ngne_A2023EquityIncentivePlanMember_cdcfd55d-440f-43e6-8ea2-8b3e279522d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2025InducementPlanMember_836931cd-6abe-448d-a8d4-fe56b9a44da9" xlink:href="ngne-20250331.xsd#ngne_A2025InducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:to="loc_ngne_A2025InducementPlanMember_836931cd-6abe-448d-a8d4-fe56b9a44da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_A2023EmployeeStockPurchasePlanMember_6c00b1f9-49ec-4a85-bfd9-9c6ddb542965" xlink:href="ngne-20250331.xsd#ngne_A2023EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f95af20f-9d61-4a54-b04f-96b671ac4adb" xlink:to="loc_ngne_A2023EmployeeStockPurchasePlanMember_6c00b1f9-49ec-4a85-bfd9-9c6ddb542965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_61cea535-f5ff-4b5c-a73b-5234cb81ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_08813009-b33c-4934-8a9b-c1c583165355" xlink:to="loc_us-gaap_ClassOfStockLineItems_61cea535-f5ff-4b5c-a73b-5234cb81ef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e250ffb8-1083-4424-9dc6-1d82e79b3ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_61cea535-f5ff-4b5c-a73b-5234cb81ef4d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e250ffb8-1083-4424-9dc6-1d82e79b3ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b4b7e37-f4db-4aa1-b902-d1bbfdc9e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b4b7e37-f4db-4aa1-b902-d1bbfdc9e24c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9db85705-1df6-4bba-b9a7-d15625142380" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1de3b178-1b19-4fcc-834d-d5dfaa95bc76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1de3b178-1b19-4fcc-834d-d5dfaa95bc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_512b01af-8cd5-4df7-b830-445332874e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f7549a74-ca13-4b16-ba38-a4957c21d12f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_512b01af-8cd5-4df7-b830-445332874e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56f978eb-1a50-4df5-b1ce-b596daf5b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9de8883c-17c3-4842-930c-429b9986eb7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56f978eb-1a50-4df5-b1ce-b596daf5b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3fb4f15-38d7-42fe-a31a-b801a4ef518c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56f978eb-1a50-4df5-b1ce-b596daf5b6c9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3fb4f15-38d7-42fe-a31a-b801a4ef518c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_930c1da9-82d7-44d5-8ba8-7c30fb9713b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_930c1da9-82d7-44d5-8ba8-7c30fb9713b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39ea78ae-74e4-439a-9cf7-326c9f48bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_39ea78ae-74e4-439a-9cf7-326c9f48bde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea2ba569-61f9-4484-9e76-8a5d973f349d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea2ba569-61f9-4484-9e76-8a5d973f349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_257ec107-0be6-4f38-8663-b372c1c85378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_257ec107-0be6-4f38-8663-b372c1c85378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_45898e99-a8f3-44aa-bddf-53dee58ee1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_45898e99-a8f3-44aa-bddf-53dee58ee1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b9ef591e-7ffa-4bb0-aa16-b3dd2b1ff6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e80d429d-9888-422e-94cc-6d8d9b02fb75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b9ef591e-7ffa-4bb0-aa16-b3dd2b1ff6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_385237a6-a8b2-42f2-8a84-e5f465c4e62f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_930c1da9-82d7-44d5-8ba8-7c30fb9713b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_385237a6-a8b2-42f2-8a84-e5f465c4e62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_930c1da9-82d7-44d5-8ba8-7c30fb9713b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5618fd3a-ecec-43d2-9af6-e419c27e6bba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5618fd3a-ecec-43d2-9af6-e419c27e6bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d10616c8-5ed3-4842-97c5-6efd74b85697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d10616c8-5ed3-4842-97c5-6efd74b85697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3259ac89-2015-49e3-a44a-05777e7cc0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3259ac89-2015-49e3-a44a-05777e7cc0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1a87f870-7fd8-4e9e-a5cc-50c3eb31767d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1a87f870-7fd8-4e9e-a5cc-50c3eb31767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1ec954eb-76bc-4a48-99ce-deba4b76bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7feab3c1-aaf5-4223-8a48-fb278d4520aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1ec954eb-76bc-4a48-99ce-deba4b76bedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_de31582e-3c82-42da-b076-0f3d7a507a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_930c1da9-82d7-44d5-8ba8-7c30fb9713b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_de31582e-3c82-42da-b076-0f3d7a507a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d222cee8-d199-4eb5-88fc-5877c2c60065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_930c1da9-82d7-44d5-8ba8-7c30fb9713b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d222cee8-d199-4eb5-88fc-5877c2c60065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5cdf56ba-43c6-4dec-b301-cacc5d8ce1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d222cee8-d199-4eb5-88fc-5877c2c60065" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5cdf56ba-43c6-4dec-b301-cacc5d8ce1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6c3ac4a4-4626-4ac0-8ae8-07c2f46f8d53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d222cee8-d199-4eb5-88fc-5877c2c60065" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6c3ac4a4-4626-4ac0-8ae8-07c2f46f8d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd874304-8be1-4025-98ac-8be8d89ad7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd874304-8be1-4025-98ac-8be8d89ad7a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:to="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2ddb38ff-e99c-49aa-8e59-51ee41034279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df6eb187-0205-439d-81d1-1e69dd717eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df6eb187-0205-439d-81d1-1e69dd717eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2f8b7be8-32b0-4ac5-bc6b-81caa3bf8999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:to="loc_us-gaap_RestrictedStockMember_2f8b7be8-32b0-4ac5-bc6b-81caa3bf8999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad840a45-39c7-4a35-9642-e142e5e21426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ba47a71-c54f-4c81-96f1-0e8fa61c60e7" xlink:to="loc_us-gaap_PerformanceSharesMember_ad840a45-39c7-4a35-9642-e142e5e21426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:to="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_c6403304-9982-47fc-996d-83ea2d8c6013" xlink:to="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_204aa543-44e8-49e2-83ff-2b2e21deabb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_204aa543-44e8-49e2-83ff-2b2e21deabb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cef8667f-83da-4471-b87a-4a761d3aefc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f153649b-85fb-426b-a2a1-716a26330001" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_cef8667f-83da-4471-b87a-4a761d3aefc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b62dae5d-d87f-49dd-9d09-ed2eb32eb7ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c7b65689-a49b-4a82-a407-47f30fecf351" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c7b65689-a49b-4a82-a407-47f30fecf351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ef3aeb42-b258-4f4e-b13b-4b8ec0ebd0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ef3aeb42-b258-4f4e-b13b-4b8ec0ebd0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfc10e79-3fe0-41d5-ac91-a3a1cc7cc4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfc10e79-3fe0-41d5-ac91-a3a1cc7cc4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_807c9549-c969-4d05-99df-fa4da2520f59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_807c9549-c969-4d05-99df-fa4da2520f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93ca693d-3632-489e-8b4a-6329dfa8f012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_93ca693d-3632-489e-8b4a-6329dfa8f012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66016404-861e-4dd1-b698-3420d52114e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_66016404-861e-4dd1-b698-3420d52114e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8d839070-38d6-48d5-b1e7-1ee904086214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8d839070-38d6-48d5-b1e7-1ee904086214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedPaymentArrangementNumberOfTranches_5e21d3aa-c49f-4290-9fd5-c76a2859b76e" xlink:href="ngne-20250331.xsd#ngne_ShareBasedPaymentArrangementNumberOfTranches"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_ShareBasedPaymentArrangementNumberOfTranches_5e21d3aa-c49f-4290-9fd5-c76a2859b76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_b8e63b5a-3a94-40d0-a254-c050a18c7d45" xlink:href="ngne-20250331.xsd#ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests_b8e63b5a-3a94-40d0-a254-c050a18c7d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_bce189d5-6970-4c70-8563-127e2c7510dd" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest_bce189d5-6970-4c70-8563-127e2c7510dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_b9023afc-0d34-4afe-8656-27eca61f8266" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a578ae2a-3469-45fb-afda-a3aaead5c422" xlink:to="loc_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest_b9023afc-0d34-4afe-8656-27eca61f8266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9eda0ff9-0f63-4652-a5a8-5fccf477d38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9eda0ff9-0f63-4652-a5a8-5fccf477d38e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:to="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d64abbd-5c7d-41ce-91f2-c28566370186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9b7abdf8-68e4-4df9-ae54-20a24036437c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d64abbd-5c7d-41ce-91f2-c28566370186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_deb9a589-4f63-40f1-98d1-82c423f1a962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d64abbd-5c7d-41ce-91f2-c28566370186" xlink:to="loc_us-gaap_EmployeeStockOptionMember_deb9a589-4f63-40f1-98d1-82c423f1a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:to="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77582a1a-beca-4e81-bb40-aab358eb32c8" xlink:to="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b180021d-01c8-4401-800a-bf23a97f65a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:to="loc_srt_MinimumMember_b180021d-01c8-4401-800a-bf23a97f65a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_147c87c6-3dc7-4aed-b871-74095358ed2a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0e83167-2706-4200-a2a4-0f0ad1ecdb8d" xlink:to="loc_srt_MaximumMember_147c87c6-3dc7-4aed-b871-74095358ed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77852215-211a-4dc0-b268-236dfc29baca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5b8c23a2-bbf8-4a52-9e34-82e87bc846fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5b8c23a2-bbf8-4a52-9e34-82e87bc846fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4a3124e1-4544-4606-822e-7af9f98c0752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4a3124e1-4544-4606-822e-7af9f98c0752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0aec3238-5637-467d-82c3-8dc671e44834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0aec3238-5637-467d-82c3-8dc671e44834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7c9cc761-ca77-4ec7-9d30-bc012941e7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7c9cc761-ca77-4ec7-9d30-bc012941e7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c13e6dfb-b99f-44e7-ba3a-8adf4fce2b76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c13e6dfb-b99f-44e7-ba3a-8adf4fce2b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1df536e7-0079-4da6-b2e6-d9ef34e00c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fae5907-152a-4332-a021-56132b7469fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1df536e7-0079-4da6-b2e6-d9ef34e00c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#StockBasedCompensationSummaryofOtherAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_953aba71-7bd9-44f6-a19d-05ba9d292493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_953aba71-7bd9-44f6-a19d-05ba9d292493" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:to="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bfa211fb-3e13-47bd-a2b1-0e6e4d1bc9ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c03b1a14-5026-4970-bc99-d1e23d59c205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:to="loc_us-gaap_RestrictedStockMember_c03b1a14-5026-4970-bc99-d1e23d59c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_aca61584-319d-41a1-af35-3ddcac3782e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649d9e09-ccbd-4519-8203-cea756c9a586" xlink:to="loc_us-gaap_PerformanceSharesMember_aca61584-319d-41a1-af35-3ddcac3782e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75ae8b07-0d12-4a85-82b9-cea2716239d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b298ae25-64af-4869-985e-5dc27d53c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b298ae25-64af-4869-985e-5dc27d53c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_356db58c-3232-4d34-95b2-66f0d4db1560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_356db58c-3232-4d34-95b2-66f0d4db1560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b1316059-fc53-477f-b1cc-2efdf2e01ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b1316059-fc53-477f-b1cc-2efdf2e01ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80535cff-152a-4837-a7e6-366e46234a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80535cff-152a-4837-a7e6-366e46234a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1644fdbf-aa42-4d99-bb8e-0055450ea151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_11dd1b1d-dabc-4f4f-96fc-51d3e51ff999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1644fdbf-aa42-4d99-bb8e-0055450ea151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8cae853f-9c34-488f-8ef5-8887f46780cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a08809b5-8c55-4a72-9427-68a2e71dd663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a08809b5-8c55-4a72-9427-68a2e71dd663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c42fa478-f565-4c4f-99a2-7e29a86ec953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c42fa478-f565-4c4f-99a2-7e29a86ec953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7061b749-f890-4b7a-bf69-98c69449fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7061b749-f890-4b7a-bf69-98c69449fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_996d8ee4-0a07-4c51-b218-739c903e890a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_996d8ee4-0a07-4c51-b218-739c903e890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d9638341-ff49-48f6-b56d-015d8558f37b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fe7666db-b903-40e3-96d8-8c518ece26a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d9638341-ff49-48f6-b56d-015d8558f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f1a6074e-1a31-4b31-b17a-8a31d16d4bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f1a6074e-1a31-4b31-b17a-8a31d16d4bbe" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_049ccfb0-51ed-48b3-aa82-f475adae8625" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_RettSyndromeMember_7ebc0c8b-5f97-417a-bd9d-0f179230a08b" xlink:href="ngne-20250331.xsd#ngne_RettSyndromeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_RettSyndromeMember_7ebc0c8b-5f97-417a-bd9d-0f179230a08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_BattenDiseaseMember_d504eaab-0664-4cc5-a684-2e7080287e65" xlink:href="ngne-20250331.xsd#ngne_BattenDiseaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_BattenDiseaseMember_d504eaab-0664-4cc5-a684-2e7080287e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_EarlyDiscoveryMember_2980ff87-3f8d-489d-992f-b80d37789442" xlink:href="ngne-20250331.xsd#ngne_EarlyDiscoveryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_EarlyDiscoveryMember_2980ff87-3f8d-489d-992f-b80d37789442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PersonnelRelatedExpenseMember_983c7f0d-75b5-4b53-932f-127064d4d319" xlink:href="ngne-20250331.xsd#ngne_PersonnelRelatedExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_PersonnelRelatedExpenseMember_983c7f0d-75b5-4b53-932f-127064d4d319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ShareBasedCompensationExpenseMember_1c1cbc7b-0fcd-4a92-b230-7d537d31a048" xlink:href="ngne-20250331.xsd#ngne_ShareBasedCompensationExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_ShareBasedCompensationExpenseMember_1c1cbc7b-0fcd-4a92-b230-7d537d31a048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ManufacturingExpenseMember_9e32569a-378a-448d-afed-25aed2d4b945" xlink:href="ngne-20250331.xsd#ngne_ManufacturingExpenseMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_ManufacturingExpenseMember_9e32569a-378a-448d-afed-25aed2d4b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenseMember_d9c44c41-7bad-4d83-a17a-30766d033cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_us-gaap_OtherExpenseMember_d9c44c41-7bad-4d83-a17a-30766d033cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ProfessionalAndConsultantFeesMember_a195cd6c-1a4e-44ec-8065-a1ba60855279" xlink:href="ngne-20250331.xsd#ngne_ProfessionalAndConsultantFeesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_ProfessionalAndConsultantFeesMember_a195cd6c-1a4e-44ec-8065-a1ba60855279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_OfficeRelatedExpenseMember_ffbe14b6-5b63-4832-b784-740108f8bec2" xlink:href="ngne-20250331.xsd#ngne_OfficeRelatedExpenseMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_805df7c9-c492-4a37-9e6b-84832fd6c276" xlink:to="loc_ngne_OfficeRelatedExpenseMember_ffbe14b6-5b63-4832-b784-740108f8bec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_edb499f9-484c-480f-9422-afde308034b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4aaabbfe-d977-4527-b16b-893748ba8c60" xlink:to="loc_us-gaap_SegmentDomain_edb499f9-484c-480f-9422-afde308034b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_ReportableSegmentMember_5bd1179c-967f-4e13-ac3e-a116c1b58f96" xlink:href="ngne-20250331.xsd#ngne_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_edb499f9-484c-480f-9422-afde308034b7" xlink:to="loc_ngne_ReportableSegmentMember_5bd1179c-967f-4e13-ac3e-a116c1b58f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_258349f1-8ec5-412a-9da5-081a0d3a44d1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bbdfa788-cde8-4d8b-9e1b-48dcba7a4fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bbdfa788-cde8-4d8b-9e1b-48dcba7a4fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ce0d4f6b-eebd-4e81-8e69-461b4d9f660d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NumberOfReportableSegments_ce0d4f6b-eebd-4e81-8e69-461b4d9f660d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_b1e16403-cb76-41ac-a333-85189390cb68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_b1e16403-cb76-41ac-a333-85189390cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fff9b997-e135-461c-9188-b010a76fbe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseAbstract_b1e16403-cb76-41ac-a333-85189390cb68" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fff9b997-e135-461c-9188-b010a76fbe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02f57eb8-4dc7-49cc-b9ba-e8d0ca3801d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02f57eb8-4dc7-49cc-b9ba-e8d0ca3801d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6ecc9a78-7c0c-45bf-90a9-78050ae71d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02f57eb8-4dc7-49cc-b9ba-e8d0ca3801d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6ecc9a78-7c0c-45bf-90a9-78050ae71d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_81e5ff8d-daf8-48a3-a021-5c93019e0c61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_81e5ff8d-daf8-48a3-a021-5c93019e0c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e2732b8-aea4-4368-9c7e-e981c3d3fbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_443ab70d-5934-4416-b90f-7156239ebfca" xlink:to="loc_us-gaap_NetIncomeLoss_1e2732b8-aea4-4368-9c7e-e981c3d3fbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurogene.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ngne-20250331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.neurogene.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f2fd2d7f-c9c2-454b-91f5-289d308565d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f2fd2d7f-c9c2-454b-91f5-289d308565d2" xlink:to="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08638540-478f-421d-862c-487e28f4f2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26550317-5d99-42c1-ad8b-109af0412dfb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_08638540-478f-421d-862c-487e28f4f2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_988108a6-5cc6-4397-bcc3-d4d69fc33506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_08638540-478f-421d-862c-487e28f4f2fc" xlink:to="loc_us-gaap_SubsequentEventMember_988108a6-5cc6-4397-bcc3-d4d69fc33506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ee131e25-4406-404f-b589-714d32768d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f51f61c3-9643-4e47-89fd-c6d035365f93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ee131e25-4406-404f-b589-714d32768d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_PreFundedWarrantsMember_88acd5ee-de61-4336-a579-ed98b8110f8d" xlink:href="ngne-20250331.xsd#ngne_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ee131e25-4406-404f-b589-714d32768d7e" xlink:to="loc_ngne_PreFundedWarrantsMember_88acd5ee-de61-4336-a579-ed98b8110f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cf244929-4575-42c9-a9e6-5098812d9c56" xlink:to="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ed508fca-e560-4f51-a7e6-e3fc2cc5a8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ed508fca-e560-4f51-a7e6-e3fc2cc5a8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_58df43aa-b1dd-4fb4-baed-a91229e555cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_58df43aa-b1dd-4fb4-baed-a91229e555cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7c88247-cfad-4cf3-91ab-8fb3080226a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a7c88247-cfad-4cf3-91ab-8fb3080226a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd887f52-360f-4043-a015-52c8463a564d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd887f52-360f-4043-a015-52c8463a564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3755cc96-2188-4d58-87af-a6b3a73dcc37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8fd9a885-d129-40c1-bd44-ab2a2ac9bbf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3755cc96-2188-4d58-87af-a6b3a73dcc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ngne_StuartCobbMember" xlink:href="ngne-20250331.xsd#ngne_StuartCobbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ngne_StuartCobbMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ngne-20250331_g1.jpg
<TEXT>
begin 644 ngne-20250331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Y ]<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^AW_ /*3??\ QBC_ (;M^!O_ $.__E)OO_C%?D;11_8N'_FE^'^0?V91[O\
M#_(_7+_ANWX&_P#0[_\ E)OO_C%'_#=OP-_Z'?\ \I-]_P#&*_(VBC^Q</\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1ORIOU73YWO?T'*O4C*45&]KOY=/Z\CQ6;]BWXT02*LG@:X0-"T^\WEML55
M)W-YN%//W203S@<&O$J_0[]F/X(?$CX7_%+QIJWC'7+>;3]2TNZ*L-32=M7?
M<I%PL88MA1D[F (W@=S7YXUIAL1*M*46TTK:KSOYLNA6=24DVG:VWF%%%%>@
M=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIO\ U[1_^@"M"ORV6[/@WN%%%%(04444 %%%% !1110 4444 %%%% !1110
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M_P $R_\ R51_:6%_F_!_Y!]=H?S?@_\ (^%:*^ZO^'9>G?\ 17K7_P $R_\
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M^"9?_DJC^TL+_-^#_P A_7:'\WX/_(^%:*^ZO^'9>G?]%>M?_!,O_P E4?\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_P :?\C+>?\  /\
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M]E?Q3\-%U;PZ-=U3Q<^OPW!N9_LJVY$>%9O)W!_D/ 4CIS7IOC[]GCQ_X?\
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MO&4,')X5L'D5]U?!<^(Q\*?#!\6_V6->^Q)]H_L;S/LNWGR]OF?-GR]F[/\
M%NQQBOF35/V+?&U[\!?C'X)35- &J^,O%IU[3YFN)_(B@,\4FV4^3N#XC;A5
M89(YKZ^T'2VT[PYIVG7!5W@M([>0H3M)5 IP>#CBJIQES7EV*@G>[/S"_;8\
M?:S^T]I?C7Q+H5RT7PH^',\%E:SKRFK:E-/'%)(O8JJ.V#SA=I_Y:G'Z9^!?
M^1(\/?\ 8.M__12U\I?&S_@FK\-]<^'&I6?PS\,V/A[QE(T)L]0U+5[]X(U$
MJF0,"\HY0.!\AY(Z=:^HOACX#T_X8_#_ $'PMI=NMK9:7:I L4<KR*&ZN0SD
ML06+'GU[4J<9QFW+J$(R4FV>F> /^0ZW_7%OYBN=G_UTG^\?YUT7@#_D.M_U
MQ;^8KG9_]=)_O'^=7'^)+Y#7QL^,O^"FJO)X$^&*QZ;'K,C>,[4+ILS*J79\
MJ7$+%@5 ?[I)&.>:B^"O@'7?@+XK^*_QK\6^#M-^%OA5]%79X)T.\BN@#"%8
MRYB B#'80H7',K9 ZGUO]JSX%Z]\<]/\!0:#=Z;:/H/B:UUFZ.HRR('AC#AE
M38CY?YA@' ]Z]4^('@G3OB3X'UWPKJP?^S=8LY;*<Q'#JKJ5W*>S#.1[@5/L
MVYN7W"Y;R;/D/6/VI/VB;/X*7?Q>B\!>"XO!LUM]KL[&2YN9-1@MW8".XE 9
M4D3!!(7:V#G %-\4_MF?%K_A*OAUX9\&^#-#\2:[XO\  FG^(T@,<R+!>3%F
MF))F \A8XWPI.[)7YST+M;_99_:'O/@K>?"&W\?>#9O!D-N+2ROIK6YCU&>W
M1@8[>4A62-. "5W-@8R17??#7]F'Q3X-^-7PR\7WM_H\NF^&/A[:>$KR*":4
MS27<2L&>,&( Q'<,$E6_V16?[QNVI'O^9\[V=QX[L_C]^U;=:YI_@_5K.U\-
M37&O6+B[,4\2:?(]FD.&5N=L0EW,I^_L(.#7I_@/]I*_\&?!3X)>"_AUX(TJ
MY\<^,+"6:PT:.:6'3=/A1Y&DFD9W>1EX=L%RQVN2V<!NZU#]F'Q3=^/OVB]<
M2_T<6GQ&\/\ ]DZ2C32^9!+]C,&ZX'E85=QSE"YQVSQ6 G[&WBW1_ ?PBU'P
MYXFTO1/BK\/K.2SCO&22XTZ]BD+[X7RJN%P[#<%S\[#'0@49QO;S_,%&2V_K
M4]-\#ZU\:+AO$.F?%/PIX/?1_P"S9)8M5\.WLS02L5(-N\$W[PY&<ME1V&<\
M?+/PU_:8\0_"C]F+X27O@#P'X;BNO%7BBYTM]!MQ="*5C,541/).[K(YP-SL
MX''RX&*^K?AOX;^-]U>:W/\ $KQ)X0FL;JQ:UM=&\-64PBCE.?WQGEPXX."N
M&'0C&.?CCXK? ?Q7\%_A#^SI\/KK6["T\4KX\(M]6TS?/#;2S3@Q2@2(A8H6
M4D$#.,9HGS)75_Z:'*Z5T?1>G_M$?%7X9_%SP;X4^,7AKPS;Z3XRG-EI6K>%
M9YW%O=94+#.)3EB2Z+E0!\V1G!Q5LOVC?B_\8/'/C*W^$'A/PO=>$_"=^^F7
M%]XFNIHYM2N(_OI;^6=J>Q<$8*DD9P+>G?L[_%/XE_%KP?XL^,?B;PU<Z7X-
MG-YI.D^%;>=%N+K*E9YS*,@@HC84D?+@8R<UK7]G'XN_"'QQXQN/@_XM\,6G
MA3Q9?/J=S8>)K6:273;F3[[V_EC:_L'(& H(.,FO?\[?B/WOE^)P$/[=7Q";
M]E/Q=\3+CP_X?LO$FC^+O[ CTZ2"=H$AV0L1(/.#-(#(PW!E' ^6N[TK]I+X
MN^%OC%X#\*_$;PCX9TO3?'D$YT@Z1<SRW%C,B!A'<E_E<@M&K;% ^?()P17"
M0?L*?$)/V4?%WPRN/$'A^]\2ZQXM_M^/49+B=8'AV0J3(?)+"0F-C@*PY'S5
M[S\:/@;KWQ&^-'P6\7:;=Z=!IO@J[O)]0BNI)%FE698 HA"HP8CRFSN*]1UI
M+VF[\O\ @B7/OZ'AW[ O_">_\+I^/']N_P#".?8_^$@N/[9_L[[1YG]I^<^/
MLV_C[/CSOO\ S_<]Z[/_ (*">'_%OC;P_P##CPYX9\&:AXTMYO$D5_J-E:)B
M)XH%.(II2"D22>81N?Y1M]L5W_[._P #M>^$GCGXOZSK%WIUS:^,/$<FKV"6
M,DCO%"SR,%E#(H#X<<*6'7FMGXT>&/B]J&JZ1JWPN\9:/I7V562\\/\ B*P$
MEC>YSAS-&AG1AG&%;!P.G.ZE!^RY65R^Y9G)?LE^/O!'BUO&.F:%\,]/^%/C
M'1+J.T\0Z%:6=O$P;Y_*;S8402IQ)@D<<XX8$_0M>&_LV_ '6?A9JWC3Q?XR
MUNUU[QWXQNX[G4IM.B:.SMTC#".&$-\Q WGYB 2 HQQD^Y5M3ORJY<;VU/9X
M/]3'_NC^525'!_J8_P#='\JDKP#R@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO+_&G_(RWG_ /_0%KU"O+_&G_(RWG_ /_0%KMPGQOT.G#_$8E%%%>L=X4444
M %>+>(OVC);?]H_1OA#X=\-?\)!J$EE_:6M:DU_]GBTFWR,$J(G,C$%<+E>9
M(QGYB5]IKY"_981=2_;%_::U*\^;4K>\T^TA9OO"#$PP/;$47Y"LIR::2ZD2
M;NDAFL?MY>(].USXCM:?!VZU?PGX#U:;3-7URS\00^9&J2M&)1;/$K'(0M@,
M0.[=Z]/U[]J33[+QQ\&=&TK1FU73/B7;RW5KJ3W7D-:1+%'*I,6QMY82 $;E
MQCO7S#\#/V=-$^/GQ@_:*B\1>(?$]GH]MXVN4N-#TC5#;6-^#<3M_I$84E\%
M1@@@BMS]J3X"^ [S]JS]GS1G\/QKI>K17&FWEK%<31H]M:11BVC&UQL" D?+
M@GOFN=2J<O-_6YBI3M?^MS[5T?PSHWP]\.7%GX6\-6>G6<(DGCTG1;:&T263
M&2%4;$#,0!EB!G&2.M>1_L^_M+:W\8?B%XY\&^(_ /\ P@VM>%%MS<PG6(]0
MW-+N(7,<:J,  \,WWO:NL^%_P^\&^$_B'\2-8\.Z_-JNNZY?0SZY8R:DER+"
M94;8@C',.0Q.&R<  <  >*?LV_\ )[7[2?\ O:9_Z*:MFVG&QHV[H]0^&7[1
MDOC'XV^-?A=XA\-?\(MXC\/QK=VA6^^U1:G:,0//0^4FWAXCMY^^1G*FO::^
M0OBLBZ;_ ,%(O@O<VF%N-1\/W]M>!>"\20W3IGZ-S_P$5]>U4&W=/HRHMZIA
M1116I84444 =1X9_Y%O7?^N8_DU<O74>&?\ D6]=_P"N8_DU<O6$/CE_70SC
M\4@HHHK<T"BBB@#S7]H?XX:9^SS\*]4\9:E;-J#6[)!::>DOEM=W#G"1AL';
MW8G!PJL<'&*\X^*_[57BKX6>&_A<\WPQ74/%OCJX^R1^'5UY83:3-Y?EQ-.\
M&UF/F*#D*%.1D@9KD_V_$74O%'[/NCWGS:/?>.K07:-]U@'C49_X#))^9K._
MX*!:%_PE'Q$_9WT?^T+_ $G[?XJ-M]OTN?R;JWWO;KYD,F#L=<Y5L'! -<LY
M2]ZSVL82D];'?>&/VQ6U3PG\59=;\#WGAKQI\/+!K_4O#5U?I*LJ^4TB;+E%
M((8+UVG&Y2-V:])^$>J:%\8/"OA'XJ2^%=.T_P 1:GI2-%=/''/=VL+Y8P+<
M[%<IEF.!@?,>.:\-^,7[)?@'X<_LQ_%MUCU7Q%JUWILVKW6MZ]J$EQ?7%S;Q
M.\#O(NW(1B3MQ@Y^8&L[]G7X%?#23X#_  'U'4=3F\-:DE_#XALX(]7, U/5
M'C0,I20G?D1)^[CQP#C 9LM2FI6E_6HTY7LSK?''[9VI:=XN\::5X&^&&J>/
M]-\$DKXBU:'4(K2.U90QD6)&5FF9=K@@8.5/&,$Z'Q"_;*LO"'PH\"_%'2?#
M,WB#X?:_<1PZAJ N_)N-)#OL+-"(W$FUED4@.HW* "=P-<C^V)^T)J.J7Y^!
M'POA_MOXB>)8S9WTD)_=Z5:R+^\+M_"Y0DD_P*2QY*YV/B]\&]+^%'_!/WQ)
MX#,JWEMHOAYV:=EP);E7\\R =LS98#MD4N:5Y6>PKRULSZ>M;J*]MHKBWD6:
M"9!)'(ARK*1D$'N"*EKRO]E6^N-2_9K^&,]T2TQ\/62EFZD+"JJ3^ %>J5T1
M=TF;)W5PHHHJAA6CX=_Y#MA_UV7^=9U:/AW_ )#MA_UV7^=1/X63+X66O&G_
M ",MY_P#_P! 6L2MOQI_R,MY_P  _P#0%K$J:?P1]!0^%!1116I8445G>(KJ
M:R\/ZI<6W_'Q#:RR1_[P0D?K2 \.\'_M72^/M:^+$FB>$OM'A'P#%<*=?DU+
M;_:-U#&6:&.(0D!?D?Y]YP"AV_/@<'X!_;YU37+?P/K/BOX4WGA3P7XQU :9
MI?B*WUN&_C-P9&C >(1HZ#<C<D9PI(!%<]^QG9V]O_P3Q\3W$.#<7EIKD]TW
M=I/+D3)]3L1*J?L-_LM^%_&7P:^&?C[Q%J_B37Y[*6XO=/T&_P!3+Z383QW<
MJK)#;A1M.4#'+$%B21VKD4JDN6SWU.=2F[69[]:_%;2/BO\ '/X@?!37O!ME
MJ.E:#86E[-<:BZ74%]Y@AE5&MGBVC:SJ02S<H#@=NK^+GQ#N?@]X+M;G0/!&
ML>,KUIH[&QT3P]:$A<@X,C*I6")0N-Y&!P,5\H?"OX*^"X_^"A7Q?C&F-;1Z
M3ID>I6<J7LRM;W%Y;Q_:90V_JWVB;KD+N^4# Q[IX'\4?";]FWX9^"O".F^.
MC+HVMW,]GH6KW,QU".XN&E)8&XB3R5"O)CYBB\'T8UI&3:=]-RU)ZW)?@_\
MM,:C\3=?\9^#=4\#S>#_ (E>&[9;F3P[?:DDT,ZN@,96ZC0@ ED!(0X#J1NY
M V/V:_VAH?V@O#>MW%QH<GA7Q'H6I2Z7JVA3W'GO:RJ3@[]B9!P1]T8*L.<9
M/S[^S+:ZO\*OVSO'G@SQ5JEG\0?%&O:1'J\WC*W#)<1QH546TT(8I$N-I"KT
M_=]05"])^SZBZ/\ MZ_M$:;8_+I]Q;:=>2JGW3.8HW)/ONFE_,U,9RTOW:)C
M)Z7/KVBBBNHW"BBB@ KJ-0_Y$#3?^O@_SDKEZZC4/^1 TW_KX/\ .2L*F\?4
MRG]GU.7HHHK<U"BBB@ KQ?X]?M&/\(O%7@;PCHGAO_A+_&'BV\-O::9]N^R)
M#"N-\\DGER84$C^'HKG/RX/M%?(6I(NJ?\%/-*^W?-_9O@9I+ -_"S22*Q'O
MB645E4;25NI$FTM#J?B9^U=XM\*_'*[^&7A'X4OX[U6TTB/69I(=?BLV$)(#
M[4DBPQ4LHP&R<]*J:[^W1I%M^S;I7Q;T;PS<:E%=ZK'I$^CW5V+:2VF)8/F0
M(X8#:",#D,.AR*\O^(/POB^+G_!1+7-"G\2^(_"\(\%1SO=>&-0^QW$JB2-3
M$[[6S&V_)7')5?2J7[>O[//@3X8_LN^$+'0=&-NN@:TEM93/<2-(%NCNN2_S
M8=G,4?+ XV@+M'%8.52TFGHC)RGJS[FT;PCH7AW4-4O])T33M,OM4E$^H75G
M:1PRWD@SAY64 R-\S<MD\GUKPC]IO]M'1/V=?%GACPO%H_\ PD_B#6)4,UHE
MZ+864#-L65V\M\EFSA<#(5B2.,Z%O\*/ 'P;\:7_ (D\)/>7?B[0?!KV5CX)
MM]5,S2641+Q[(#NF)9U"!B6!)Z%N:_.7XD7&M_\ "+R^+?B#\/\ QW:_$O7O
M&5I?76L:KH#VUA':QI*([&U=VW%SE2$VC(C4?P9+J5'!66C'.;BM#]+O%'[1
MDO@;]HKPW\-/$'AK[#I/B:W=M&\3)?;TN+A0-UN\)B&QL\9#M]^/^\=OM-?&
M7[?&J+J/@7X&^+[:RN],UA?&.FW%K;7T7E7=L)8GE:.1,G8ZM'&&7)P5QVK[
M-K:,FY-,TBW=H****U+"BBB@#I? '_(=;_KBW\Q7.S_ZZ3_>/\ZZ+P!_R'6_
MZXM_,5SL_P#KI/\ >/\ .L(_Q)?(R7QL91116YJ%%%% &3XN\4Z=X'\+:OXA
MU>?[-I>EVDMY<RXR5CC4LV!W.!P.YXKYJO?VVM6TK]F!OC/J'PX^QV5Q?I;:
M=I+ZU^]N8&<IY[/]G_=_,&PNUL@9S@BM[_@H;>7%C^Q_X^>V9D9ULHG9>H1K
MV!6'X@D?C7EG[:EA:Z7_ ,$]?#=G8JJV<%OHL<(7IL$: ?I7-4E)-VZ(QG)J
M]NB/8/A/^U)JGBSXJK\./'7P]O/AWXLN=-_M:PA?4X=1@NK<$@D2Q@ 'Y6.,
M'[K9(. ;_P !_B9H7[5WA2?Q+K/@C3K:;PWXBGL[&.^,>H-#- (V6YB=HE\M
M\N,;1D;?O52^'?['/@;PX=4U75]0\2>.M7US1WT:YU'Q7JSW5PME*FV2"-U"
M%%()&1\P!.",FOF7]D#X$_#7Q1^S3\4G\57DGA:POO$<NEWNM1ZH;3R[6W>"
M2",O*3& )'(RRY;=@D\87---)^8KR329]9?M&?M"7WP0F\&:;HGA(^-?$GBK
M4CIUAI*ZDMCN(4$MYC(R\%D'.!\V21BL[5?CE\3_  U\&?$_C77O@R-)U71'
M\[_A'_\ A)X;E[FS50TLZS0PN 4Y.PKDA2<] >2^-WP(\)_&?XH^ ;-?C#+X
M6U3PCITAMM(T?48EU<HZ+BY24R%TX2/+;&W =1G-2_L._$#Q!\3/A_XYT/Q5
MJQ\967A_7[K0[/Q!, ?[3M5  +,/OG!SNR20ZY)ZFN:7.U?TV'=\UCW+X3_$
MK3/C!\-_#_C+1\BPU>U6X6-CEHFY62-CW9'#*?=376U\C_\ !,.XD?\ 9ON[
M4R&6ULO$-];VK'IY>(GX_P"!.Q_&OKBM*<N:*;-(OFBF%%%%:%!1110![/!_
MJ8_]T?RJ2HX/]3'_ +H_E4E?.'CA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M7^-/^1EO/^ ?^@+7J%>7^-/^1EO/^ ?^@+7;A/C?H=.'^(Q****]8[PHHHH
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M*** "L'4M>O[*^DAATM;F)<8E-R$SD ]-O%;U8>I?\?LGX?R% %3_A*-4_Z
MB_\ @8O_ ,31_P )1JG_ $!%_P# Q?\ XFEK!TGQ_P"&->\1:GX?TSQ'I.HZ
M]I>#?Z7:7T4MU:9X'FQ*Q9.H^\!UH W?^$HU3_H"+_X&+_\ $T?\)1JG_0$7
M_P #%_\ B:6B@!/^$HU3_H"+_P"!B_\ Q-'_  E&J?\ 0$7_ ,#%_P#B:6B@
M!/\ A*-4_P"@(O\ X&+_ /$T?\)1JG_0$7_P,7_XFEK*\4>+=#\#Z+/K/B/6
M=/\ #^D0%1+J&J74=M;QEF"J&D<A1EB ,GDD"@#4_P"$HU3_ * B_P#@8O\
M\31_PE&J?] 1?_ Q?_B:;;W$5U!'-#(DT,BATDC8,K*1D$$=017!/^T-\*X]
M:FT=_B9X/35H9FMY;!M>M!/'*K%6C:/S-P8$$%2,@C% '?\ _"4:I_T!%_\
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M,/\ X$C_  KU2BCZS5[A[:?<\K_X0SQ!_P ^,/\ X$C_  H_X0SQ!_SXP_\
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M/N>5_P#"&>(/^?&'_P "1_A1_P (9X@_Y\8?_ D?X5ZI11]9J]P]M/N>5_\
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M0TWPUXU^,G@3PI9?#G6[N&VG;P[=W#:EHOG#*-<K(2DF #D1]QC(. >IT?\
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M% !1110 4444 %;FF_\ 'E'^/\S6'6YIO_'E'^/\S0!:HHHH **** "BBB@
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M5[?_ (0+PS]GUB.*'4H?['M]EZD6/*68;,2!,#:&R%P,8K>^V:S_ - RU_\
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M_P #3_\ &ZV+"^UX6D872+-EYY-^1W/_ $RH Z.BL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\
M^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\
M\:H_M#7_ /H#V?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#
MV?\ X,#_ /&J -NBL3^T-?\ ^@/9_P#@P/\ \:H_M#7_ /H#V?\ X,#_ /&J
M -NBH+*2XEM4:ZA2WG.=T<<GF*.>,-@9XQVJ>@ HHHH **** "BBB@ K#U+_
M (_9/P_D*W*P]2_X_9/P_D* ,^^OK?3;.XO+R>*UM+>-I9KB=PD<:*,LS,>
M  22>F*I>&?%&C>--$MM9\/:O8Z[H]UN,&H:9<I<6\NUBK;)$)5L,K*<'@@C
MM7@__!0CX@-\//V1_'L\#D7VK6RZ);(OWG:Z<1.![^4TI_X#7R'\$OCQK?[,
M/['?Q.^',Q9_B9X=\53>%M#LK<[G:XO!F*2,=3AEN91Q@X4?Q4 ?I/I/Q$\*
M:]I&K:KIGB;1]1TO2998=1OK2_BE@LI(E#2I,ZL5C9%(+!B"H.3BN=T/]HKX
M4>)M7M-*T?XG>#=6U2[D$5O8V.OVDT\SGHJ(LA9C[ 5^>'[-\][\*_\ @G+^
MTWIVHR*NHZ?K>J:/<,C[AYTEM:VK8/?YF.#7J/[%>N?#[2?!?@"RF_9O\3Z9
MXITW1#>R^/M1\#V\%K))';M,TR7Y/F'S,;4;&6WKT!X /N'Q?\0/"_P^LX[O
MQ3XDTCPU:2':D^L7\5HC'T#2, 35CPSXPT'QII8U/P]K>G:[II) O-,NX[B$
MD=1O0D?K7Q%^Q;\&=!_:JT'4/CU\7["U\=>(_$%_<PZ=IVJK]HL-)LXI"BP1
MP-E/O!OO \8/4L6]W\0?!?X=?LT?#WXM^.O!/AJU\,7UQX?NKJ[6Q9D@/D6\
MCH(X<[(^>R 9- 'HWA7XY?#?QWJBZ9X:^(/A;Q#J3 E;/2M:MKJ8@#)(2-R>
M![5I>+/B;X/\!W-G;>)O%>A^';B\.+:'5M1AM7G.<?()&!;GTK\F?@;\']6^
M+?PA^"6@>!_A!K7A[QCIFOKK.I_%2\TY+&V:T%Q,X\JXSNN0$:+ /0Q84<YK
MZD_;G^&7P?\ A;HWQ$^*7C2"X\8^./&6FC0M!T?5FBG2VN/*$<9L8Q&&BV'$
MC/N)'.""^& /N96$BAE(96&00<@BL23QUX:A\71>%9/$.E)XHF@^U1Z(U[$+
MUX>?W@@W;RGRM\V,<'TK@/V2?!_B+P#^S7\.] \5O*=?LM)B2YCG),D&<LD+
M>\:,L?\ P"OSN^/WQ$UCPU_P4*\0_&"R8OX8^'>MZ)H6J2+G,=M<V[QS_AE;
ME?JRT ?JCJGCKPWH7B#2]!U+Q!I6GZYJF[[!IEU>Q17-YM^]Y43,&DQWV@XK
M;K\E/VD/B5JGBC]NK3/B?9S"3P3\/?%^B>$/M"M\K.[32W.,<<,EPI/H8_6O
MNOPA^T#XB\0?MI>.OA#<66F)X;T+P];ZM;7444@O'E<V^5=C(4*_OFP @/ Y
M]0#VWQ+XHT;P9HESK/B#5K'0M'M0IGU#4KE+>WBW,%7?(Y"KEF4#)Y) [U=L
M[RWU*S@N[2>.ZM;B-989X7#I(C#*LK#@@@@@CKFOS3_:$_: ^(G[0/[$?QLO
M+BS\,6>G^'_&1T&_$45Q'*^GQ3VQB:+,C@SF9XMQ;"[-^ &Q7I^D_M)?%OPS
MH?P<^#_ACP[X3UWXM:UX=CU6>ZEEN4T;3],4,MN\@R)6D,<8WX( <?*&#+@
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MX?S/N=4S\M?6G@?PW9^#?!>@:!I]B-,L-+L(+*WL5N7N!;QQQJBQB5_F<*%
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M4?X_S-8=;FF_\>4?X_S- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH RO.US_ )]=/_\  F3_ .-T>=KG_/KI_P#X$R?_ !NM6B@#*\[7/^?73_\
MP)D_^-UL6$WB'[)'ML],*\];N0'J?^F5,K<TW_CRC_'^9H SO/\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
M@7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q
M//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7
M_P"!<G_QJCS_ !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_
M !'_ ,^6E_\ @7)_\:K;HH Q//\ $?\ SY:7_P"!<G_QJCS_ !'_ ,^6E_\
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MKO2M/DL;=_F)7;"\\S+A=H.9&R03QG  ->BBB@ HHHH **** "BBB@ HHHH
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M7:I8_$?2M:O(7NEUJ6RD\+0Q*#&T4:NH4*=X&X%?W> ,AL@'V?\ LF?M%?\
M#47PA@\<_P#"/_\ ",^;>3VGV#[;]KQY9 W>9Y<?7/3;Q7LM?&W_  2;P/V0
M['!R/[9ON?\ @2U]DT %;FF_\>4?X_S-8=;FF_\ 'E'^/\S0!:HHJCHVN:=X
MBTZ/4-)O[75+"0LJ75G,LT3%6*, RD@D,K*?0@CM0!>HHHH ***IWVL6&ES6
M45[>V]G+?3_9;2.>54:XFV,_EQ@GYFV1NVT9.$8] : +E?-W[66B>.OB'JGA
M;P7IW@37/$GPRN)1?>*Y]#OM.AN+Z.-LQ:<JW-W 1&[J&E8=4 52=S8^D:*
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MM9:\73[^UOFLKAK2Z6VF60P3* 6B?!.UP&4E3R P]: +M%%% !1110 4444
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M@5Z'^SOX4^"/PD^*D_\ PK;X\6%YHNKVZVEK\/D\66VH6_VHMGS(5:1Y"V
M%'S=<L00H -;]K;X$^(_VCOBE\(_#4OAV&;X::/J3:YX@UJ::#+,BD1V:1E_
M-(?!#D+MQ(ASE#7U&H"@ # '  KXQ_X)F_\ (#^-_P#V474O_08Z]2_;I\/^
M//$_[,/C&P^',MVOB)HHW:'3V*W-Q;+(IGBB(YW% W Y8 J,EL$ ['XQ_LU_
M#/\ : 6Q_P"$^\)6?B"6QR+>X=Y()XU)R5$L3*^W/.W.,]JQO"/['?P:\!KX
MC30_ =A90>(K%--U2U\V:2"YMT "H8G<H#\H)90&+98DDDUX3_P3;NO@UKVC
M:OK'PW.M>'/$1M8;?7?!NH:O/<06<RGYKB..1COWL/\ 6')'W<)D@[__  4U
MT?QGJ'P(TZ]\.6E[J_AW3-7AO?%&C:?.\$M[IJABZ,R?-Y8.-V,X!#XPA( /
M:/@[^R[\+/@#?7]]X"\'VF@7U\GE3W2S33S,F0VP/*[LJY .U2!D#C@5T'Q&
M^#?@_P"+4_AR;Q7I']JR>'M1CU;3&^TS0_9[I#E)/W;KNQC[K97VKYW_ &2_
M'WP)^'O[/'BCX@^ ]<U>P\%6Y^VZIH^L:C+=/HDBH/\ 1HXF8[2Q/!!8R%A\
MS8 %SPK^V9\1?%UMI/B*P_9O\6W'P_U62/[)K-OJ5M)?20N0$F^PX#!""&W%
M]N.=V.: /??#7P>\(>#_ (@>*/&VD:1]D\3^)Q"-6OOM,S_:?*7;'\C.43 X
M^15SWS6)X?\ V:/AEX8^&^K> +'PE:MX/U6YDO+S2KR66ZCEF?:6?,KLP.44
MC!&TJ",&N-^-7[5LOP^^(NE_#CP3X&U'XF?$:^LSJ+Z)97<=G%9VN<>9/<2
MK'D] 1Z9(W+NXJZ_X* 66F_"WXEZQJG@34-#^('P_6W;5_!.J7JQN5FFCC22
M*Y5&#Q_O =P3^[QAE8@':>&_V!?@'X0U;1M4T?X>6UEJ6CZC%JME=K?W;2Q7
M$3AXVW&8EE# '8V4XY6O1O"OP/\  _@K5O&FI:1H$4-UXSN#<Z_Y\TMQ'?N=
MX.Z.5F101(X*J IW=*\ TG_@H9IMQ\(;GQ[J/P_UW3H;_6X]#\*Z0K&2]\12
MO&KK)$A1=L9W@;AN!Z#+$+72^ ?VO-:F^)V@>!/BI\+-3^%&L>)$D;0;BXU.
M'4;2^= "T1EB"B.7!'R$'D@'!*Y -;1OV"?@!H'BJ/Q%9?#/2TU..7SD\V6>
M6W1P<@BW>0Q#!Z )@5UWQB_9C^%_Q^FL9_'O@^SU^ZL5V6]TTDL$Z)G.SS(G
M1BF23M)(R3QS7J%% 'D/@S]DGX2?#NQ\6V?AOP=!H]IXLL!I>LP6UW<!+FV$
M;1[ OF8C)5WRT>UB6))SS6Y_PS[\.W^$UK\,I_"UG>>!K6,10:1>L]PL8#%@
M0\C%PP+$AMVX9X->A44 >1?"']DGX1? ?6)M6\#^"++1=5D0QF^:6:YG53]Y
M4>9W9 >X4C-4_''[&'P4^)'CAO%_B/X>Z9J7B"1Q)-<LTL:3L/XI8D<1R'CD
MNI)[YKVFB@#C?A+\'O"'P-\'Q^%_!&D?V)H4<TEPMI]IFN,2.06.^5W;G'3.
M*[*BB@ K<TW_ (\H_P ?YFL.MS3?^/*/\?YF@#F/C-XFN/!/P?\ '/B*T8K=
M:1H5]?Q,.SQ6[R*?S45X;HNC^,M'\0_![X5^#_%LG@_PQ;^ Y+O4;JTL;:XN
MG:W>RB0PM/'(JNQF8EG5U(+_ "[BK+]#>//"T7CGP-XB\-SOY<.L:=<:>[8S
MA98FC)_)JXOX3_#^^73? ?BKQ3;7.F>-M-\*+H5]IXGBE@1W-N\YRF[<?,MQ
MM8-C:QR,] #R*#Q/\6[_ .'GQ.UV3Q\EG=_#R[U*TLEM])M2FN_9(_/62^#(
M2@=62,K;&'!1G!^8(G>77C+Q1\6OB)#X5\.>()O VE67AO3_ !#J.I6-M;W%
M_.UZ]PD$$/VB.2)$46LK.YC8DL@&W!-=S'\(-&A\+^.-!%S?&S\7W%[<W[F1
M/,C:ZB$<@B.S  4?+N#8/7/2L[Q!\"]-U230;[2M?USPGK^C:>NE0:YHLL N
M9;08_<S)-%)#*N5W#?&=K%BNW<<@'FE]\9/&_A6'Q%X%GOK#5O&5KXATO0=,
M\27%J$A>&_021W%Q A5?.B59@40JLC+%C8),+%\0O"7C3PG\3?@B-5\=W'C3
M1+CQ>?-75[&TM[JWN!I6HE3"UM%$IB(\P%75G!V$.1NKTZW_ &>_":^!=8\,
MWW]H:O\ VQ=KJ6HZQ>WC'4;B]0H8KKSTVE)(S%%Y?EA1&(T"@ 8K(MOV:;*?
MQIX5\4Z_XY\8>+=6\,7;76E_VM=VRPP[H)870Q06\2/E9<EV!DRB_/@L& /'
M+?X_>*?'A\1Z_8^*/&7AEK74[VRT30=+^&FHZMI<L=M.\"O>7,=A*TIE:)F/
MV>>/RPP7EE:NS\)^/OB!\4OC)I$;:KJ?@'PU%X&T;Q-J7AMM,@^W)?3W5XLE
MM(T\+.B%8"C@ /\ (I0QDL3W.M?LZV.H7NK?V7XR\6^%M$UBXDNM2T'0[V&&
MTN)923,ZLT+30&0EF;R)8\LS-]YB3U?AWX6Z)X4\73>(-+6:UD?0['P]'8JR
M_9H;6TDN'A"+MW!O])<$EB,*N ,$D \1T_4_BO\ $#X&CXM:/\1%T*_U/1CK
M^E^%_P"R[.72H;9XC-#!/(T9N&E\LJ'E655#DD1E1M-"QL_$'C?XP?LY>);O
MQMK5K<W_ (.O+^ZM;6WL!!*X339)E.ZV9PLY?#[6! 1?+,1W$]_J_P"REH>I
M:/JGAVW\7^+M(\#ZD93<>$=-OH8[#$I)D1',)N(XF+,3$DRQ\D;=IQ7::/\
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M_A:_PY\+Z_J%_I$>AZ_XKUV^\0:CI\<BR"U:>9C'!N5F4[(]F[:2N]I"O#4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\D8_\:Z&B@#GO[%U[_H9/_)&/_&C^Q=>_P"AD_\ )&/_ !KH:* .>_L77O\
MH9/_ "1C_P :/[%U[_H9/_)&/_&NAHH Y[^Q=>_Z&3_R1C_QH_L77O\ H9/_
M "1C_P :Z&B@#GO[%U[_ *&3_P D8_\ &C^Q=>_Z&3_R1C_QKH:* .>_L77O
M^AD_\D8_\:/[%U[_ *&3_P D8_\ &NAHH Y[^Q=>_P"AD_\ )&/_ !H_L77O
M^AD_\D8_\:Z&B@#GO[%U[_H9/_)&/_&C^Q=>_P"AD_\ )&/_ !KH:* .>_L7
M7O\ H9/_ "1C_P :/[%U[_H9/_)&/_&NAHH Y[^Q=>_Z&3_R1C_QH_L77O\
MH9/_ "1C_P :Z&B@#GO[%U[_ *&3_P D8_\ &C^Q=>_Z&3_R1C_QKH:* .>_
ML77O^AD_\D8_\:/[%U[_ *&3_P D8_\ &NAHH Y[^Q=>_P"AD_\ )&/_ !H_
ML77O^AD_\D8_\:Z&B@#GO[%U[_H9/_)&/_&C^Q=>_P"AD_\ )&/_ !KH:* .
M>_L77O\ H9/_ "1C_P :/[%U[_H9/_)&/_&NAHH Y[^Q=>_Z&3_R1C_QH_L7
M7O\ H9/_ "1C_P :Z&B@#GO[%U[_ *&3_P D8_\ &C^Q=>_Z&3_R1C_QKH:*
M .>_L77O^AD_\D8_\:/[%U[_ *&3_P D8_\ &NAHH Y[^Q=>_P"AD_\ )&/_
M !H_L77O^AD_\D8_\:Z&B@#GO[%U[_H9/_)&/_&C^Q=>_P"AD_\ )&/_ !KH
M:* .>_L77O\ H9/_ "1C_P :/[%U[_H9/_)&/_&NAHH Y[^Q=>_Z&3_R1C_Q
MH_L77O\ H9/_ "1C_P :Z&B@#GO[%U[_ *&3_P D8_\ &C^Q=>_Z&3_R1C_Q
MKH:* .>_L77O^AD_\D8_\:/[%U[_ *&3_P D8_\ &NAHH Y[^Q=>_P"AD_\
M)&/_ !H_L77O^AD_\D8_\:Z&B@#GO[%U[_H9/_)&/_&C^Q=>_P"AD_\ )&/_
M !KH:* .>_L77O\ H9/_ "1C_P :/[%U[_H9/_)&/_&NAHH Y[^Q=>_Z&3_R
M1C_QH_L77O\ H9/_ "1C_P :Z&B@#GO[%U[_ *&3_P D8_\ &C^Q=>_Z&3_R
M1C_QKH:* .>_L77O^AD_\D8_\:/[%U[_ *&3_P D8_\ &NAHH Y[^Q=>_P"A
MD_\ )&/_ !H_L77O^AD_\D8_\:Z&B@#GO[%U[_H9/_)&/_&C^Q=>_P"AD_\
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M^@U\L?$SQMJ?@;]@?]F"ZTM=/::[UG0+.7^T=,MK]?+:UG8E5N(W5'RBD2*
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M[+^Q>5]B\B/9_K?,/F;NOW5Q[UQ/P^_8L_X03]F/Q]\(/^$Q^W?\)5<7T_\
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MH **** "BBB@ HHHH *W--_X\H_Q_F:PZW--_P"/*/\ '^9H M4444 %%%%
M!1110 5R7Q7BU*3X<^()-(UV^\-ZC;V<ES#J.G16\DL;1J7P%N(I8R&V[3E"
M<$X(.".8N/V7OAE)<-=V_AG^RM4D8O-J^CW]UI^HSL3DM+=P2I-(3ZNYK?\
M$GAO3O"/P@U[2-)MOLFGVNDW:Q1;V<\QNS%F8EF8L22S$DDDDDF@"E\"O&%]
MXJ_9_P#A[XJ\0WJW&I:EX8T_4]1O&18P\LEI')+(54!5RQ8X4 #L *\>_95\
M>7'QL\.^'/$T_P >KS6=?NH!JNH>"].DT)XK2*1BR02QQV9N8PJ,BG,H;(/S
M5UWP=\2P>#_V*/ASK-WH>H^)+.T\#Z0]QI>E6RW-S/$;*$.$B9@),*2Q7.2
M0 QP#POC[QAX'^,'C7X.67PFN=-UWQ%HOB.VU":^T!%(T7241_MD=RZ >0LL
M9\H0/AF9U^7Y<@ ^KZ*** "BBB@ HHHH **** "BBB@ HHHH ***X_QS\'_!
M?Q-N+:;Q;X;L/$;6J,ENFIQ^?'!DY+QHV51_^FB@-QC- '85XMX#\1>);?\
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M#=/@%C83:)>1W5L%C^4J)49@S @[B226R3SF@#M**** "BBB@ HHHH ****
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M+N&_.7VC"*S8&,5U?P^T_P 0Z7X)T2U\6:I%K7B:.U3^TKZWA6&*6X(R^Q%
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MD'H<<5\]_L5_M&>.OVB-+U+5?$B>!KC1UMH)K>Y\)7\S3V\TF2UK<VTV71T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6H_";]I3PO%JOAY;_P")7BHZYI$C7,_E00&^6XVW!\G*OL!&$#C/?'-?;M%
M'S)=_LQ^*;CX]?L_^-UO](&E?#_0)]+U2$S2^?-*]F\ : >7M9=S Y9D..V>
M*CC_ &<?B+HO[07QT^(_ASQ#H.D3>--(L;+0I[B*2ZDM)X+>&-GGA**F"8VV
MX=^JDJ>5/T_10!\F?LM_LF^,/A?\;/$_Q/\ &EUX0T_4]6TH:7_8O@2UFM["
M4^8CM=2K(%Q*3&,A5QEV/>OK.BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "MS3?^/*/\?YFL.MS3?\ CRC_ !_F: +5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML_\ H(:K_P"!S_XUTU% ',_\(%9_]!#5?_ Y_P#&C_A K/\ Z"&J_P#@<_\
MC7344 <S_P (%9_]!#5?_ Y_\:/^$"L_^@AJO_@<_P#C7344 <S_ ,(%9_\
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M_P#05UC_ ,&$G^-=#10!SW_"&0_]!76/_!A)_C1_PAD/_05UC_P82?XUT-%
M'/?\(9#_ -!76/\ P82?XT?\(9#_ -!76/\ P82?XUT-% '/?\(9#_T%=8_\
M&$G^-'_"&0_]!76/_!A)_C70T4 <]_PAD/\ T%=8_P#!A)_C1_PAD/\ T%=8
M_P#!A)_C70T4 <]_PAD/_05UC_P82?XT?\(9#_T%=8_\&$G^-=#10!SW_"&0
M_P#05UC_ ,&$G^-'_"&0_P#05UC_ ,&$G^-=#10!SW_"&0_]!76/_!A)_C1_
MPAD/_05UC_P82?XUT-% '/?\(9#_ -!76/\ P82?XT?\(9#_ -!76/\ P82?
MXUT-% '/?\(9#_T%=8_\&$G^-'_"&0_]!76/_!A)_C70T4 <]_PAD/\ T%=8
M_P#!A)_C1_PAD/\ T%=8_P#!A)_C70T4 <]_PAD/_05UC_P82?XT?\(9#_T%
M=8_\&$G^-=#10!SW_"&0_P#05UC_ ,&$G^-'_"&0_P#05UC_ ,&$G^-=#10!
MSW_"&0_]!76/_!A)_C1_PAD/_05UC_P82?XUT-% '/?\(9#_ -!76/\ P82?
MXT?\(9#_ -!76/\ P82?XUT-% '/?\(9#_T%=8_\&$G^-'_"&0_]!76/_!A)
M_C70T4 <]_PAD/\ T%=8_P#!A)_C1_PAD/\ T%=8_P#!A)_C70T4 <]_PAD/
M_05UC_P82?XT?\(9#_T%=8_\&$G^-=#10!SW_"&0_P#05UC_ ,&$G^-'_"&0
M_P#05UC_ ,&$G^-=#10!SW_"&0_]!76/_!A)_C1_PAD/_05UC_P82?XUT-%
M'/?\(9#_ -!76/\ P82?XT?\(9#_ -!76/\ P82?XUT-% '/?\(9#_T%=8_\
M&$G^-'_"&0_]!76/_!A)_C70T4 <]_PAD/\ T%=8_P#!A)_C1_PAD/\ T%=8
M_P#!A)_C70T4 <]_PAD/_05UC_P82?XT?\(9#_T%=8_\&$G^-=#10!SW_"&0
M_P#05UC_ ,&$G^-'_"&0_P#05UC_ ,&$G^-=#10!SW_"&0_]!76/_!A)_C1_
MPAD/_05UC_P82?XUT-% '/?\(9#_ -!76/\ P82?XT?\(9#_ -!76/\ P82?
MXUT-% '/?\(9#_T%=8_\&$G^-'_"&0_]!76/_!A)_C70T4 <]_PAD/\ T%=8
M_P#!A)_C1_PAD/\ T%=8_P#!A)_C70T4 <]_PAD/_05UC_P82?XT?\(9#_T%
M=8_\&$G^-=#10!SW_"&0_P#05UC_ ,&$G^-'_"&0_P#05UC_ ,&$G^-=#10!
MSW_"&0_]!76/_!A)_C1_PAD/_05UC_P82?XUT-% '/?\(9#_ -!76/\ P82?
MXT?\(9#_ -!76/\ P82?XUT-% '/?\(9#_T%=8_\&$G^-'_"&0_]!76/_!A)
M_C70T4 <]_PAD/\ T%=8_P#!A)_C1_PAD/\ T%=8_P#!A)_C70T4 <]_PAD/
M_05UC_P82?XT?\(9#_T%=8_\&$G^-=#10!SW_"&0_P#05UC_ ,&$G^-'_"&0
M_P#05UC_ ,&$G^-=#10!SW_"&0_]!76/_!A)_C1_PAD/_05UC_P82?XUT-%
M'/?\(9#_ -!76/\ P82?XT?\(9#_ -!76/\ P82?XUT-% '/?\(9#_T%=8_\
M&$G^-'_"&0_]!76/_!A)_C70T4 <]_PAD/\ T%=8_P#!A)_C1_PAD/\ T%=8
M_P#!A)_C70T4 5]/LQI]G';K+-.$S^\N)#(YR2>6/)ZU8HHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ngne-20250331_g2.jpg
<TEXT>
begin 644 ngne-20250331_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '<!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_X6=+_T#D_[_'_XFC_A9TO_ $#D_P"_Q_\ B:XBBCV%/L'L:?8[?_A9TO\
MT#D_[_'_ .)H_P"%G2_] Y/^_P ?_B:XBBCV%/L'L:?8[?\ X6=+_P! Y/\
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MU/\ >'\Z]SKDKTXPMRG+6A&%N4****Y3F"BBB@ HHHH **** "BBB@ HHHH
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M<YXV^"_[1GB3X Z9\'W\*>%9='T*6UCCUJWU55EU"""0&/9&V!&P&"Q;&<$
M<UES32T7ZF5YI?TSTJY_:1A^%GCKX[ZUXBUKQ!XBT#PQ-I:QZ''96Z+8_:%P
M!;OY@+@DC=OV].YKN?A5^UUX4^*WCZ'PA;Z)XD\/:I>6']IZ:VO:=]FCU&W
MR9(?F)(QD@D $ XZ5XO\8/V8?B'XOC_:&73-)MYO^$QFT5]&W7T*>>+?'G;L
MM\F,<;L9[5Z_K7PE\1WG[2GPB\8PV,)T+P[X>O-.U&X\] T4TD!1%"9W,-QZ
M@$#-4N>_]=QISO\ UW.[^,GQL\-_ _P]:ZGKYN[F:^N!::?I>FP&>[OISTCB
MC'4_4@=/45XUXV_;4LI_@_\ $/4?#NA>(-"\?>&[)9G\/Z]IGEW=J)&"I<O$
M6PT*D@L<G QD<C/9?M*_"7Q5XTU3P'XU\"M87'BWP5J#WEMINJN4MKV.10LD
M9<?=; &&/OR*\H\2? 'XJ?%O_A:/C?Q9I.D:'XHUKPFWAG1/#6FWZS*JEPY>
M><X3)(XP<8/.,<N3G=I#DY7:1[5^RGXQ\6>/O@-X>\1>,9+JZU^_22=FO-.3
M3W="28R(U)781@JXQN4AL#.*\B_9C^,GQ8^*WQ6OH->\3>'88+&_NK;7/ MU
MIYM=0TF)#B&2!Q\TP8XRS$@?B*^COA?X?U+PO\)/".AW:QVVL:;H5G93*Q$J
M1SQVZ(P)4_, RGH>0.#7S;I_P=^,_CKX]> O%/C/0O"OAZY\*WTDMYXQT&Z(
MFUBTYV6WD [@N./GZ GZ$=URC=URDWP9_:^NU\+:E_PF+W?BOQ3?>,KS0="T
M71K6%;N>&,K@A1L78@.6D8_B:Y_XV?'SQCX!U+X_7&@>,-2-]X<DT(6FG7VG
M6SVNG"Y8;Q"Q+>9N&0=RC!YYZUF_"W]DWXE?"+Q!??$O0]/L9/&\6OWQ?0;R
M\B:#4])G=3B.7)%O,/F(.1GH?0Z/Q@_9J^(WCR\^/E[IVA0H?&9\/R:5#/J$
M 9OLV#<*Y#X4KR.3AL<9K/W^7S_X!G[_ "G8Z=^U7/X%\;?&^Z\<ZA)<^%O"
M<VEPZ99VEK&)O,N(@3&I 7<6<]7; &>0*^@OAUXX?X@^'1JK^']6\.$R&,6N
ML)&)'  (=&C=T="#PRL0>:^<KK]GWQ+)X@^.UQJ_@>Q\7Z)XN?2_L.F3ZM':
MFY6&(+(RR#)BD0C*EL9('.*G^ ?AGQK^R[\-+70+[2;G6+KQ#XM%MH?AYM0^
MTG2;&0;G\ZX1=GR1QNYVC:3C'WC5Q<D]=BXRDGKL>S_M'>,=6^'OP)\<>)-"
MN%M-8TO3)+FUG:-9 D@Q@[6!4_0BOGI?BQ\;/@OX+\#_ !(\:>*-'\?> M<%
M@=4MXM*2QO=-6[12KH8\+(%+@'/7T&<CZ'_:,\&:K\0_@9XX\,Z%"MUJ^J:9
M);6L4DBQJ[G& 68@#ZDU\\O\(_C=\9? W@KX:>,_#>A>!? NB_8%U.]M]56^
MO-0CM%4*D:IE4W% 3GIZG&"YWOH$[WT/6?B+^UQX9\!^,K[PS8>'?%/CC4],
MB6?5?^$5TPW<>FQL-P,S9&#MYP,G%;.G_M,^#]8USX=V=@;N[T[QW#.VCZRB
M*+7SHAEK>7+!DEXP%*]>,U\T?&3]C'Q0_P 9/%OB?0/"UKXYTCQ)*EU'&_B6
M;2)M-EVX8.%($J9Y&.<<<=_2O%G[)]W'^RGI?@[PG;6^A^-]"NH]>TK[)?O-
M';ZD'W.L<\V&VL"PRV!G'I2YJEWH'-.[T.]N?VLO!%CHWCK6KL7]OHGA/5!H
MLE_Y2NNHWN.8;558M(P. <@?EDU0\,?M6:1XZCU[1ET'Q+X%\76^CW&J6.G>
M*],^RRW421EO-B!)5P#@D>G;&:X'QM^Q?>:Y^R3X9^'FG7=NOBG2+J/6YY+J
M9EAOKYMS7"R2+\P#&1E#CD;5_#G/@I^R7K6E>)-5\0:W\/K7PI>VNDW5MI;#
MQ;/J<TEQ+$T9X8F,1D,?O'(..M'-4NM!<T[I':?#K]KZWT+]GKX9Z_XT&I>*
M_'7BN&<VVD>']/62]OFCGD0LD*;55555!/'\ZZ@_MH>"%^$_BSQP^G:Y;OX5
MF@M]9\.75JL&J6<DLJQH&C=@N"6SG=CY6[C%>3^#_P!F_P"*?PO\)_!KQ7X<
MTW2=0\<^#]+O-'U/PWJ-ZJ17%O/<32 Q3J2JN!)USCGV(/(?M"?"GQCHW[/W
MQ]^)?Q CT[3?$WB[^R(AHNDS>=#96\%W J!I/XW/&2../? GFFE\OT%S32_K
ML?0G@;]M+P?XT\8Z#H$_A_Q5X73Q#A=$U3Q!I9MK/4G(!"Q/N.2<X!(P21CJ
M*YO4O^"A7@;2[K7TD\*>,IK/0-5?2M5U*WTU);6S*R>6)7D$F K,&P/O''3I
M6+8?#KXR_'#5OA/;^.='\.>'/"/A"\L]>.JZ7>F>;5)(HQY2I%C,0(/S!AQG
M@\ 56TO]FWQ[:_L]_M!>%)-+MUUSQAXBO-1TB$7D16>"26)D9GW80X5N&((_
M&GS3Z?D/FGT/4? O[8W@OQ]\2-,\(6NF>(M.;6HI)M$U?5--:WLM61 2S6[,
M=Q7 ."5 /XBLJ\_;G\"VNK71BT/Q7?>$K.Z^Q77C6UTEI-&@E#;2&F!SM!XW
M 8YJ'Q5\#_$VL>.OV=KV#3X1I?@^RN+;6G6YC0V^^TCB 09R_P RD?+GIFOG
M+3/V _%WAFZ?PL_@S2_%6C&[8IXDF\67-E&;5GSMEM$YWA>/E!&?7K0Y5%L#
ME46Q]0?$K]LKPO\ #?XB7/@L>&?%'B?68]+CU:(>';)+M9X7&[*X<$ +EBQ
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M&F6YO/ >I6=SKJ_:HO\ 1XXT <J<_O.1T7.:A2G_ %ZD\TS1^)_[;GAO0/\
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MV@:_J6M:?IVKVMW?Z)((M3MHY 9+-RI8+(/X> 3^%?%'[4/B*:3XLW&H>#?
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M8SG!KM/#OB+2O%VC6FKZ)J-MJVEW:[X+RSE$D4B],AA7RC8_ 3P=)^W_ *G
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M587M):JQ]F^)OVE/A]X=^#_BKQAX:\0:)XAL?#-HP%K97JJAF"XAM]P!V;V
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M&HZ==1B6"ZM9!)'*AZ,K#@BKE>=_L[ZMXFUSX(^#K[QCI::+XDFL0;RQC@$
M0AF"'RP $+($8J ,%B,#I7HE;IW5S=.ZN%%%%,84444 %%%% !1110 ^+_6I
M_O#^=>YUX9%_K4_WA_.O<ZX,5T.'$] HHHKA.(**** "BBB@ HHHH **** "
MBBB@ HHHH **** /*_'W_(S3_P"XG\JYVO0O$UQX>CUB1=0MYY+K:NYH\XQC
MCO65]K\(_P#/G=?K_P#%5ZM.=HI69Z<)VBM&<E176_:_"/\ SYW7Z_\ Q5'V
MOPC_ ,^=U^O_ ,55^T_NLOVG]UG)45UOVOPC_P ^=U^O_P 51]K\(_\ /G=?
MK_\ %4>T_NL/:?W6<E176_:_"/\ SYW7Z_\ Q5'VOPC_ ,^=U^O_ ,51[3^Z
MP]I_=9R5%=;]K\(_\^=U^O\ \51]K\(_\^=U^O\ \51[3^ZP]I_=9R5%=;]K
M\(_\^=U^O_Q5'VOPC_SYW7Z__%4>T_NL/:?W6<E17>V=CX8O-,N[V.SF\FW^
M_N)W=.W-9_VOPC_SYW7Z_P#Q5)5;_98O:7Z,Y*BNM^U^$?\ GSNOU_\ BJ/M
M?A'_ )\[K]?_ (JG[3^ZQ^T_NLY*BNM^U^$?^?.Z_7_XJC[7X1_Y\[K]?_BJ
M/:?W6'M/[K.2HKK?M?A'_GSNOU_^*H^U^$?^?.Z_7_XJCVG]UA[3^ZSDJ*ZW
M[7X1_P"?.Z_7_P"*H^U^$?\ GSNOU_\ BJ/:?W6'M/[K.2HKK?M?A'_GSNOU
M_P#BJ/M?A'_GSNOU_P#BJ/:?W6'M/[K,OP?_ ,C+8?[Y_P#034?BG_D8M0_Z
MZFNGT&Y\-/J]LME;7"718^6SYP#@^_I3-:NO#*ZM="[M;A[D.?,9<X)]OFK/
MG_>7L]C/G]^]GL<-176_:_"/_/G=?K_\51]K\(_\^=U^O_Q5:>T_NLT]I_=9
MR5%=;]K\(_\ /G=?K_\ %4?:_"/_ #YW7Z__ !5'M/[K#VG]UG)45UOVOPC_
M ,^=U^O_ ,51]K\(_P#/G=?K_P#%4>T_NL/:?W6<E176_:_"/_/G=?K_ /%4
M?:_"/_/G=?K_ /%4>T_NL/:?W6<E176_:_"/_/G=?K_\51]K\(_\^=U^O_Q5
M'M/[K#VG]UG)45UOVOPC_P ^=U^O_P 56AJ%CX9T^QL[J6SF\JY7<FTDGIGG
MFE[7I9B]I;HS@J*ZW[7X1_Y\[K]?_BJ/M?A'_GSNOU_^*I^T_NL?M/[K.2HK
MK?M?A'_GSNOU_P#BJ/M?A'_GSNOU_P#BJ/:?W6'M/[K.2HKK?M?A'_GSNOU_
M^*H^U^$?^?.Z_7_XJCVG]UA[3^ZSDJ*ZW[7X1_Y\[K]?_BJ/M?A'_GSNOU_^
M*H]I_=8>T_NLY*BNM^U^$?\ GSNOU_\ BJ/M?A'_ )\[K]?_ (JCVG]UA[3^
MZSDJZ[P3_P @K7O^N _DU)]K\(_\^=U^O_Q5;GAV?0WLM3-C!-'"L8\\/U*X
M;IS]:RJ3O&UF95)WCLSS9?NBBNL^V>$/^?.Z_7_XJE^U^$?^?.Z_7_XJM?:?
MW6:^T_NLY*BNM^U^$?\ GSNOU_\ BJ/M?A'_ )\[K]?_ (JCVG]UA[3^ZSDJ
M*ZW[7X1_Y\[K]?\ XJC[7X1_Y\[K]?\ XJCVG]UA[3^ZSDJ*ZW[7X1_Y\[K]
M?_BJ/M?A'_GSNOU_^*H]I_=8>T_NLY*BNM^U^$?^?.Z_7_XJC[7X1_Y\[K]?
M_BJ/:?W6'M/[K.2HKK?M?A'_ )\[K]?_ (JK&G+X5U*^AMHK.X\R0X7>2!TS
MS\U+VEM>5B]I;HSBJ*[34/\ A%-/O9K:6SN/,C;:VTDC/M\U0?:_"/\ SYW7
MZ_\ Q5/VE_LL/:?W6<E176_:_"/_ #YW7Z__ !5'VOPC_P ^=U^O_P 51[3^
MZQ^T_NLY*BNM^U^$?^?.Z_7_ .*H^U^$?^?.Z_7_ .*H]I_=8>T_NLY*BNM^
MU^$?^?.Z_7_XJC[7X1_Y\[K]?_BJ/:?W6'M/[K.2HKK?M?A'_GSNOU_^*H^U
M^$?^?.Z_7_XJCVG]UA[3^ZSDJ*ZW[7X1_P"?.Z_7_P"*H^U^$?\ GSNOU_\
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M $'A^E/VL?/[A^TC_2.4W' &>!TI1(RJ0&(![9KM)/!NC164=TVKLL$APLI
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M#_?/_H)J/Q3_ ,C%J'_74UE_R\^7ZF7_ "\^1E4445J:A1110 4444 %%%%
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M9-X"D_>&.XKJ:!!1110,Z+P#_P C-!_N/_Z#61JW_(4O/^NS_P#H1K7\ _\
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MNQOZ;]OS;>N.:=K?QJ\+^'_%OB#PW>37:ZKH.@GQ)?)';,R+9!MI96_B;/\
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MYJEQ9^(/$FEZG<QW<<+/ \ M9GD$;NHC*8XWCZTO:J]K![17M8^T/%GC;0O
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M]5(_"MHQY58UC'E5AM%%%46=%X!_Y&:#_<?_ -!K(U;_ )"EY_UV?_T(UK^
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M-+O+/PM<:!XGO(+_ ,/:KXJG%GX@\B,-)':WK3;S&N<J@DVYSAB<9^QO@_\
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MAO4/&FKZ3INN+<O;WVI:0L(",[]3D;U#$9Q[BOT7MK=+2VA@C!$<2+&H)R<
M8'/?I6D9<QI&7,=CJO\ R3_2O^NO_P 57)5UNJ_\D_TK_KK_ /%5R533V?JR
M:>S]6?+G[36I67P[_:"^%'Q'\76$U[\/]+M;VPN+I+<W$>EWLN#%<R( < C"
M[L<;?I76V?[1O@/XJ:YKME\-9(_%GC>RT&ZN+35K;37:")PN8X&N&48+/M.S
MH<>O%>YS0QW,+PS1I-#(-KQR*&5AZ$'@BJ^FZ/8:+ T.G6%KIT+'<8[.!(E)
M]2% &:KE=W9E<KOHS\W?AYXDTB&\^%NK>#?&?BK5_CWJFO00^*M'OIYW5HB[
M"\2XA90B1H/ND=!SVXB\;>"S=> /VB_B7!XF\06?B+PGXXF&C+:ZG(EO:L+B
M(,WE@X+,),9/0*N.^?THM]%L(-0FOH-/M8K^88ENHK=%FD'HS@;C^)IC>'],
M>WNK9M*LF@NG\RX@:V0I._'S.N,,>!R<GBLO9:6N9^RTM<^'-4\)R?!WXMZO
MI6E>(]=U"U\3?"_4M6U7^UM0>X,]XB']^,GY6Z].G(%<5X5^#ZV>F_LS7=MX
MR\6VMW\1(9+#7I(]8D!EM?)600Q\_NU .SCG'/7FOT+\42:'X;T;4?$.M6EM
M'9:;8RO<W<EH)'CME4M(O"EBNT'*CKZ5R_AGXF?#[Q9K/AG1](DMKB^N]'77
M]'A_LUXPEDV%$L;-&%B)R!MR&QVINFK[A[-7W/B;7[>_\!?#'XJZ!8ZEJ][X
M9\"_$K3)XO.GDN)K.PR&E&[[Q0$C/XD]ZV?B5X_M/B5'^U+XR\):M/J7A1?#
M6EV5KJ<!D2%KA6!<1D@<@=<>OO7WTFD6</VHI86\?VP[K@K H\\XQE^/G...
M<U%'X=TRWTM].CTFSBTUOOV:6J+ V>3E -IS]*/9O:X_9^9\(6?@T_!WXD6N
MGZ1XCUZ]@\2_"O4-4U4:GJ+SB>Z2#*R@$_*1VQT P.]>Q?L_^+OB5:_"'X+V
MV@>#;+Q)X;O-$M&U;7+S6%@GM27(D*Q-\TA"8;W)Q7T?)HVGS2I+)I]I)*D1
MMUD:!"RQ'@Q@XX4_W>E36MI!8V\=O:P16UO&NV.&% B(/0*. /I51I\KT92A
M9Z,FK<\$_P#(S6?U;_T$UA5N^"?^1FL_JW_H)JJGP,=3X64O$'_(=U#_ *[O
M_.L^M#Q!_P AW4/^N[_SKC_B#XVL/AOX&U[Q3J;!;'2+*6\DYQNV*2%'NQPH
M]S3C\*''X49/A_XT>#_%'Q*\0^ =-U87'BK08EFO[+RF41JVW[KD;6(WKD G
M&>:[C8W'RGYNG'6ORY^'7B'Q'\*?$W@#XM:_\/?$^A75UK%S/XM\57T(6PO;
M/49%$>#U CRC+GJ2?:O3_B]\5[/X>>)OVJ=!UWQ%/I>KZU86<GAJU>67=<[[
M7:#;8_VR,[<=_2L55TNS)5=+L^SF^)&@K\3A\/S<RCQ2=)_MO[+Y#[/LGF^3
MO\S&W._C;G/>NI*,J@E2 >AQ7Y]#P#J?A_\ :7L=3T[^U+GQSIWP<37;:UDN
MW??JD:BW6-D/WD.,F,\%^3S61\*_&&G6?B#X-ZMX%^)/B3Q9\4_$.JPQ>+M
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M_$6@QIKZ:9"8+N.YD!P\#!D29,$' XSCMD_5_B#]G#X<>)OAOIW@.^\+6O\
MPC&FD-96L!:)[9QGYXY%(=7.3ELY.3G-9UC^RK\,=+^'4W@>S\._9O#\][%J
M-PD=U*)Y[B-@R223;M[$$#J<5FX3[F?)/N?-_P 1/C-\;[.X^.7B30/&FEV'
MAKX=:Q%'#I-SI$4TEU&VP&'S, J@# YY8DXR!1-_PLV7]K3Q[XD\*:Q;7^N/
M\/[;5+/1)-/CV3K+%^YM-Y(/[N4^8&ZO@*>#7U+J'[/O@C4]'\=:7<:;.]EX
MVN%NM<07<@-Q(NW!4YS']T<+BI;KX#^#+S6-4U.73[C[;J>B1>'KF1+V5-UE
M'C8@VL-K# ^88)]:?LY=_P"M0Y)=SPGX/WMO^UA\%_$/ASXB:UXDU;4M'U"&
M76=#FTZ+2[V*2-=XMG6)<2Q.RMM^56.%!Y&:J_!7]EF7Q-\.?'-QJNGW/POM
M/&FH6][:>$].5HSH\=N2L>X2#(DDQN;;C'&".WT5X#^#7A7X;Z3K-AHMI= :
MRQ?4;R]OIKJ[NB4V O/(Q<X7@<\=JV/ ?@?2/AMX3T_PWH,4T&DV"E(([BX>
M=P"Q8Y=R6/)/4U2AMS%*&W,<G\ ?@G;_  (\"KX?AU:XUF1V26:XG4*-XB2,
MB->2J?)D*S,0#C. *]*HHK1))61JE961L^#_ /D9;#_?/_H)J/Q3_P C%J'_
M %U-2>#_ /D9;#_?/_H)J/Q3_P C%J'_ %U-9_\ +SY?J9_\O/D<3J7P[\,:
MSK5[K%]H5C=ZK>Z:^CW-Y+%F26R<DM;L>Z$DY'O4<7PS\*0Q^&HX_#]@B>&>
M-%41<:?\NW]U_=^7CZ5TM%:61I9'COQC_9KT/XG:!)8::MEX=N+SQ#9^(-4N
M5L_._M"2!B2)%W#)8'&X]/0UUNB_!+X?>&M*US3-(\&:+IFFZVC1ZE:VMHJ)
M=HP(*28ZK@GCIS7:T4<JO>PN57O8YG6OAAX1\1^#[;PIJOAO3=1\-VJ1QP:7
M<VX>")4&$"J?N[1P,5=\->"] \&^'TT+0=&L=(T9%95L;.!8XL-][*@<Y[YZ
MULT4[(=D8ND^"?#^A>%8_#&GZ+8VOAV.%K==*2!?L_EL2638>"#DY!]:R_ O
MPA\$?#&6ZE\)>$])\.RW7^ODT^U6-I!UP2.<>W2NNHHL@LCSMOV<_A:^L2ZL
M?A_X?&IR7*7C72V*+)YR-N60$=""<\=ZZR\\&Z%J'BJQ\37.D6<_B&QA>WM=
M3DB!GAC?[R*W8')_,^M;%%*R["L@KK?%7_(L^'_^N?\ [**Y*NM\5?\ (L^'
M_P#KG_[**SG\43.?Q1.2HHHK4V/FSX^>-/B0W[0G@/X?>!?&.G>$(-=T>\N;
MBXU&PBNAOC88:-6 +28Z+N /)(.*\\N/VIOB+X1\!^,/#FHW^BZUXWT?Q=9>
M$K?Q6L BL"+I687,T:_*&CV,"HXR1Z'/K7QK_9?L_CE\9O">O>(H+._\(Z9I
M%W8W5FUQ+%=>?(P:*2(H!C:1UW ^QKLM'_9O^&^A_#&\^'UKX6M3X4O&,EU9
MS%I&GD./WKR,=YD&!ALY&!C%8<LVW8PY9-NQ\X?$+XB_$/P+8_%/X8^//$.C
M?$27_A!+OQ%9ZO%I,4'D,AVF&XM^8V4Y!7(YP/6L^Q^(7QB\0ZI'X;\#^,=+
M\)Z1HOPTTGQ$R2:-!,/.-LK-'$NT! YR#G(4#Y5KZ,\(_LG?"_P/X5\2^']'
M\.M!9>([5K+5)I+N66YG@(P8_.9BRKST!%;VB? GP9X=U"[O;'3IHKFZT&#P
MU*S74C9L(4V1QX)X(7^+J?6CDEW%R2[GR%:>(O'OQ>^.'[,7C-?$5II^I:QX
M;U"[6S33T:)'B1OM29)SBX4!<_\ +/.5S7?? /QMXG^//_"P/AC\6=;US1O%
M$MDRWV@#38=/:V@:4J9+.Y0$O$5*+\X)Y)#$&O>-#_9[\#^'9_!DUAID\4G@
M^QN=.T<F\E/D07"E95;YOG)#'D\CM4_PY^!/@[X5ZQ>ZKH%E=_VG=0):M>:C
M?SWLJ0*Q988VE=BD8)SM7 HC"2>K_JPU"5]3Q?\ 9C^ Z^$_C%XL\8Z;X4E^
M'7AFRMCX8T[1)$D2;55B=6.HS[N#OQ\I YY.>.?J>N:\"_#K0_AQ:ZI;Z%#<
M01:E?RZE<BXNI)R9Y#ER"[':./NC@5TM:QCRJQI&/*K!77>"?^05KW_7 ?R:
MN1KKO!/_ ""M>_ZX#^35%7X/N_,FK\)R*G&".M<A:_!_P196NG6UOX6TV&#3
M=1;5K.-8<""\;):=?1SD\UUZ_=%%:FECFY/AMX5FF\33/H%B\OB9$BUIS%SJ
M"JA15E_O *Q7Z&O,M5_9,\(Z_P#%A?$FJZ?I>I>%XO#</AZW\+W.GAXH!%-Y
MB2HY;C ^4 *"/7M7N-%)Q3W0G%,YF/X8^$H8?#L,?AS38HO#LAET>.. *M@Y
M&"T0'"DBJGBSX-> _'FN6>M>(_!^C:YJUH (+R^LTDD0 Y R1R >@.:[&BBR
M'9&3XA\(Z)XMM+2UUK2K35+:SN8KRWBNH@ZQ31G,<BCLRGH:I^./ASX6^)FF
MQZ?XL\/:=XBLXW\Q(=1@64(W]Y<\@_2NBHIV061S:_#7PDG@P^$5\-:4OA8Q
M^4='%HGV4KG.-F,=><]<\U1\%_!?P'\.-1^W^%?".D>'[TV_V4W&GVPB<Q;M
MVPD=1NYYKLJ*5D%D8WAOP7H'@UM2.A:/9Z0=3NVOKW['$(_M%PWWI7QU8^M=
MCX1_Y&73_P#KH?\ T$UCUL>$?^1ET_\ ZZ'_ -!-3/X&3+X6,\5?\C'J'_74
M_P A69L;IM.?I7&?M<>-KWX<?"GXF>)=.;9J&GZ?,]M)_<E8!$;\"X/X5\V:
MU^S;K;_!;X;:=H&G1>*K&WT.XEO[&^UJ33R=3NHHY(]4:4??,3;_ )2<@,-O
M2I4K))+H0I62270^Q@K*<[3Q[5X1\.OV1/!GA>]\0ZAXETK1_&.J:AXFO?$-
MG?7FF*)+(7#(P@!+-N"E,Y/!)^Z*\*^%NH> O!OCK0/$'BGQ!K^HV&CV:1Z7
M<W=SJ&IP7$^1!-J\V\NMM:F7=' 3M!^9^ZX]Z_;&^(&N?#_X+O<>'=1_L:_U
M74[/2#K(P?L$4\@5YP>@(7H>V<T<RDN9K8.927,UL>D>//A/X/\ B=!:Q>+_
M  MIGB..T8M;_P!HVJR>43UVD\C/IT-33_#?PO<7&@3R>'M/\S0%==)98 HL
M5=-CB(# 4%>#CM7C&A?L3^$_!NK:-KF@^+_&&E>(K2YBFNM7_MIY6U3!&Y)D
M?*$/ST'?O7A5S\7/BA\)?&'[1?BGPEI&@ZGX8T/Q2MUJIUJXF\]U*JGDVRH<
M*0#N+,<<C -)RY=9('+EUDC[0M?A#X)L=%T'2+?POIL.EZ!>#4=*M$AQ'97(
M8L)8Q_"P+,<^YJOJGP0^'^MZ7JFFZAX.T>]L-4OVU6]MY[8,L]V1@SMG^,CC
M<*\CU_X[?$WQQ\5;SP?\)] \.RC0=+L=5UFX\3W$J>8;J,2Q6\/E]&*G[Y!&
M<YQCG@=,_:T^*_B#X?\ PGNM*T'PS-XN\8>(=4T2XL[D2QVL7V=@J$.)"5QR
M6/S9V\ 9I\T>P<T=K'U7>?#/PGJ'@D>#KGPYILWA01K$-&:W7[,%5@RC9TX8
M _49KHH(8[6&.&%%BAC4(D:#"JH&  .P KY&M_VOO'.B_#7Q)'K?AK1KOXE:
M9XPC\%VT&GS2)IUS=2#*2DL=RH!NXSS\O3)QH:7^T5\4_A_\5[_PK\5]*\+Q
MV6F^$;SQ-+<^&?/<W(A;@+YK?)W4J5.2,@XH]I$?/$^K*4@KU&*^'OA;^W=X
MM\2>-/"9US3O#5SX<\3WT=FFG:&EZVIZ3YIQ')<-(@BD7)7=L/&<UZE\$(3\
M/OVHOB_X!L9'_P"$>NK>S\46EJ6)6TFG^6=$ST5F .!P,4U44M@512V/M3X9
M_P#()N_^N_\ [*M8/Q%_Y&%?^N"_S:M[X9_\@F[_ .N__LJU@_$7_D85_P"N
M"_S:N:'\=G/'^,SEZ***[3M/DK]JC0?$?B7]J+X&Z?X3\2Q^$==ELM:,&K26
M"7HA BC+#R7.UMR@CGIG-9_BOXF'X-_M">*;3X@>-FM;>X^&L2VEY=,UM;7M
M^C,LDD,0.Q96(SM7GG KZVNO#^EWVK6.JW.FV=QJEBKK:7TMNC3VX<8<1N1N
M0,.#@C/>JOB+P7X>\8"V&O:#I>N"U?S(/[2LH[CRF_O)O4[3[BLG!W;1DX.[
M:/A3PKX>\2_$:Z_9:\):OXP\4: FM>%]5NM3FT_49(KJY4,TJ;F8GDH5&X@D
M \52L_B9XLT_]G_PYHNK>.-:TGPM_P )_>^'-:\8J[27MGI\38B5I<$KN;(W
MGITZ<5^@4WA[2KC5K'5)=,LY-3L8VBM+UK=#-;HPPRQOC<@(X(! -5K?P;X?
MM-)O-+@T+3(=,O)'EN;*.SC6"=W.79T"[6+'DDC)J?9OO_6A/LWW/B+XH^&?
MA[=?LQ_&#3_!?QA\0>/K73+:WU![.?6Q>):.&P!Y@0%T?<VY<XRH[BLK4=?\
M7?"%OB%9^"]6UF^GTGX:Z-<VGVNX:[DMO-E4SW"J>"R([D'' 4>E?=-E\.O"
M>FZ!=:%:>%]%M-$NN+C38-.A2VF_WXPNUOQ%7K7POHUCJ4FH6VD6%O?R6Z6D
MEU%;(LKP)]R(L!DH.RYP/2CV?4/9GQ3\)?$VG>&_C7X*TCX9_%37/B;I6O:+
M>W/BFWU*_-ZED4@W1W&<#R',GR[.O;N*X/X,P^)O#'@?]G+XB_\ "P?%.I:G
MXI\3MHU[I]_J+S67V0S3*8Q&V<G]V3N))^;C&!7Z%Z!X'\.>%&NSHGA[2M&-
MX=UR=/L8H#,3W?8HW?C3(? 7ABVT_2["'PYI$5CI4WVC3[6.QB6*SER3YD*A
M<1MEF.Y0#R?6CV;[_P!:![-]S>/4TE%%;FYT7@'_ )&:#_<?_P!!K(U;_D*7
MG_79_P#T(UK^ ?\ D9H/]Q__ $&LC5O^0I>?]=G_ /0C62_B/T,5_$?H9M_I
M]KJMG+:7UK#>VDHQ);W$:R1N/0JP(/XU5TOPSH^AZ=)I^FZ18:=829WVEI:Q
MQ0MD8.44 '(]JT:*U-2@OA_2ET4:.NEV2Z1L\H:>+9!;[/[OEXVX]L8J./PK
MHD6B'1DT;3DT=@5.G+:1BV(/)'E;=N/PK3HH QKCP3X<O-'M](N/#VDSZ3;D
M&'3Y;")K>(CH5C*[5_ 5IRV-M<63V<MO#)9O&86MWC!C:,C!0J1@KCC'3%34
M4 9R^&]'5=-4:38!=,_X\%%K'BTXQ^YX_=\<?+CBG)X?TN-M09-,LD;4#F]*
MVR W1QC,O'S\<?-GBK]% &79^%-#T[1YM)M-%TVUTJ8,LMA!:1I;R!AA@T87
M:01UR.:+_P *Z)JNE0:7?:+IU[ID 416-Q:1R01[1A=L;*5&!TP.*U** *,N
M@Z9.]@\NFV<CZ>=UFSVZ$VQQC,1(^0XX^7'%7J** .MU7_DG^E?]=?\ XJN2
MKK=5_P"2?Z5_UU_^*KDJRI[/U9E3V?JPHHHK4V/D[]JKQ(+CXV^"?!_C#QOJ
M?PX^&%]I5Q>2ZMIMU]C-[J"286V>XP?+54PW/!W?3''_ !-\6:=X8^ 7ANP\
M&?%[7M<\!W_BZ/2=?\9-=?:+O2K)L[HDF"!@N=OSG.<\'!Q7V?X@\,Z/XLTY
MM/US2;'6K!F#&UU&V2XB)'0[7!&:;#X3T.WT$Z'%HNG1Z(4\LZ:EI&+8H?X?
M*QMQ[8K)P;;U,7!MO4_.ZZL_#VM>+OC3X5\*_%/Q'XY\'6/PVGO8IYM::Y%O
M<1W$4GE+*!MD7@!CC[LC)FK?P]U3Q/\ #"#PG'X-U#5=3OE^"]QKEI875R]P
MGVQY@^Y(OND("=BX. H7FOO73_ACX.TE)DL?"6A6236C6$JV^F01B2V)W&!L
M*,QD\E#QGM5ZP\'Z!I5[9WEEH>FV=Y9V@L+:XM[.-)(+8'(A1@N5CR =@X]J
MCV3WN3[-[GPM\)?&5GH_Q&^#-SX!^+6O?$/Q%XKGV^+M"U"^-U#%"8M\TK1%
M?]&,;YP,YX].O)Z1;^*-'^&>G?%6'XA^*FUB'XE'1H=.DU%GL5M&N2CHT;9W
M9]SC'&*_1+1O!'ASPYJ5WJ.D^']*TO4+PYN;NRLHH99CG/SNJ@M^)J/_ (0'
MPO\ V4-+_P"$;TC^S1=?;A9_8(O)%QG=YVS;M\S/._&<\YI^S?</9ON=#*H6
M5P.@8BF4I)/)Y-)6YT!6[X)_Y&:S^K?^@FL*MWP3_P C-9_5O_0345/@9G4^
M%E+Q!_R'=0_Z[O\ SK%U32;'7+&6RU*RMM1LI0!);7<*RQ/@Y&Y6!!Y ZBMK
MQ!_R'=0_Z[O_ #K/JH_"BH_"BGJ&C:?J^FOIU_86M]ITBA'L[F!9(648(!1@
M5(&!@8["H+WPKHFI7=G=7FC:==W5E@6L]Q:1R26^.GEL5RGX8K3HIC*G]CV'
M]K?VK]@M?[5\G[-]N\E?/\K=N\OS,;MF[G;G&>:@L?#.C:7JESJ5EI&GV>HW
M7^OO+>UCCFF_WW #-^)K2HH R6\'Z ]C<6+:%IC65Q/]JFMC91&*6;(/F,NW
M#/D [B,Y'6I-4\,:-KL]M/J>CZ?J4]J=UO+>6L<S0GU0L"5/TK2HH JR:38R
MZI#J;V-L^I0QF**]:%3-&A.2JOC<%/< XJG_ ,(AH']FOIW]A:9_9[S?:6L_
ML47DM+G=YA3;M+Y .[&<\UK44 48=!TRV^W^3IMG#_:#%[SR[=%^TL1@M+@?
M.<<9;-,T/PWH_AFW>#1M)L-(@=MS1:?:QP(Q]2$ !-:-% !76W/_ "3FV_Z^
M?ZM7)5UMS_R3FV_Z^?ZM653[/J9U.GJ<E1116IJ%%%% 'QW\:/!VH?%/]L34
MO"S^,_$GAO1+;X=?VJ]OH.H/;>=*MVZKGL.2I) R0@&<&O%_$?QA\=:]\"_@
M#:ZOXDO;;0-;BOUUC6/[;&D/=RP2LL$,E\8Y/+^1<\K\V.3QFOT<;PYI+ZT^
MLMI=DVKR6WV)]0-NGVAK?=N\DR8W%-W.W.,\XJDW@'PQ)X;7PZ_AO2&\/K]W
M26L(C:+R3Q%MV#DD].I-8NFW>S,'3;OJ?#>AS?$7Q-^S3XFL],^(FE26$/B.
MWCT6:[\6B::[@4$S:8^H*L)W$A65AM)!(! YK.\??$+5_$W[.WPT\8:'?WFG
MZ-I']I2:OX0U+Q;-;W]\L+[&FM[S>))UB.=HRW51M?!!^];CP#X7N_#:^'I_
M#>CS: N-NE26$36HQTQ$5V_I4>I?#GPEK%AIUC?^%M%OK+3L?8K:YTZ&2.UQ
MT\I64A,?[.*7LW;</9NVXOP[UR'Q/\/_  UK%M%>06]_IEM=1QZ@Q:X57B5@
M)&/)?!Y)ZGFN@H50J@   #  Z"BMS8****!CXO\ 6I_O#^=>YUX9%_K4_P!X
M?SKW.N#%=#AQ/0***\Q_:,^+\GP-^%M[XMBL!J36]Q!#]G+;<^9($SGVS7)"
M$JDE"*U9R1BYR48[L].HK\_?^'GM[_T)R_\ @0/\*/\ AY[>_P#0G+_X$#_"
MO1_LS%_R?BO\SL^HXC^7\C] J*_/W_AY[>_]"<O_ ($#_"C_ (>>WO\ T)R_
M^! _PH_LS%_R?BO\P^HXC^7\C] J*_/W_AY[>_\ 0G+_ .! _P */^'GM[_T
M)R_^! _PH_LS%_R?BO\ ,/J.(_E_(_0*BOS]_P"'GM[_ -"<O_@0/\*/^'GM
M[_T)R_\ @0/\*/[,Q?\ )^*_S#ZCB/Y?R/T"HK\_?^'GM[_T)R_^! _PH_X>
M>WO_ $)R_P#@0/\ "C^S,7_)^*_S#ZCB/Y?R/T"HK\_?^'GM[_T)R_\ @0/\
M*/\ AY[>_P#0G+_X$#_"C^S,7_)^*_S#ZCB/Y?R/T"HK\_?^'GM[_P!"<O\
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MK4_X1&__ .?VW_[]'_&C_A$;_P#Y_;?_ +]'_&CZ[1[A];I=S+HK4_X1&_\
M^?VW_P"_1_QH_P"$1O\ _G]M_P#OT?\ &CZ[1[A];I=S+HK4_P"$1O\ _G]M
M_P#OT?\ &C_A$;__ )_;?_OT?\:/KM'N'UNEW,NBM3_A$;__ )_;?_OT?\:/
M^$1O_P#G]M_^_1_QH^NT>X?6Z7<RZV/"/_(RZ?\ ]=#_ .@FH_\ A$;_ /Y_
M;?\ []'_ !JSIOA_4M-OH;J.\MC)$<C="Q'3'K4RQE%Q:N3+%4FFKG&_M >
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M.*^(_P#V&[C_ -"KLC4G]8Y'MRW_ !.E2E[7E>UKGF-%%%=AT!1110 4444
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M49R 1R**T*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#H/#O_'K+_O\
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MSG****Z38**** "BBB@#]-OV%?\ DV_1?^OV]_\ 1S5[_7@'["O_ ";?HO\
MU^WO_HYJ]_K\DS#_ 'NK_B?YGY[C/]XJ>K"BBBN Y HKS/XN?$U_"\?]DZ<&
M74YDW-.1Q"A[CU8_I6#\*/BVRM%HNNSE@3MM[V0\_P"XY_D?SKRI9EAX8CZN
MWKWZ7['%+%THU?9-GM5>7?%;XK+H"R:1I$H;4V&V:=>1;CT'^W_*CXK?%9?#
MZ2:1I$H?4V&)IU.1;@]A_M?RKPFSL[K6+^.WMXY+J[N'PJKRSL?\]:\K-,TY
M6\/AW[W5_HO/^MSBQF,Y?W5+<ZSX8^-=5\.^((X+6.748;V0":S!RSL?XU]&
M'K^=?3?Z5Q'PU^&MOX)LQ<3[9]7F7][,.1&/[B^WJ>]=O7HY7AZV&H<M9[].
MQUX.E4HT[3?R[!1117LG>%%%% !114=U=0V5M-<7$J06\*-))+(<*BJ,EB>P
M !- $E%?+6D_\%$OAWJOB"PC.A>*[/P?J.HG2K+QS=:9LT>XN<[=HDSN SW(
MXP2<5]34VFMQM-;B44_RW_N-^5>._M ?M")\"=6^'%B^@OK9\8Z\FAJZW7D?
M9"VW]X1L;?\ >^[\O3K22OH@W/7Z*>T;!F&TG!QTIE @HHHH *[5?NCZ5Q5=
MJOW1]*ZJ'4Z*746BBBNLZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *S?$'_'A_P,5I5F^(/^/#_@8K.I\+(G\+.;HHHKSCB"BB
MLSQ-=:C8Z#>3Z3;+=Z@B$Q1,< GU]R/3O42ERQ<GT%)\J;+/]J6?]I?V?]IB
M^W>7YOV?<-^S.,XJU7R VNZE'KAU1KJ9=467S#.QPX;_ #QC\*]=/Q^B_P"$
M3\P6W_%0?ZOR\?NLX_UF?3_9]?:OG\/G5&IS>U]VVWFO\SRZ684YWY]+?U]Y
MU?Q*^)5OX)L_(@VSZO,O[J$\B,?WV]O0=Z^;[R\NM8OY+BYDDNKNX?+,W+.Q
M[?\ UJ+R\NM8OY+FYDDNKNX?+,W+,Q_STKW;X4_"E?#ZQZOJ\8;4V&88&Y%N
M/4_[7\J\24J^=5^6.D%^'_!/.E*IF%2RTBOP_P""=)\+])UG1_"D$&M3^9-U
MBA;EH8\<(Q[G^72NMHHK[BE35&FJ:=['T<(JG%170****V+"BBB@#&\90^(;
MGPMJ4/A.XT^T\1R0E+&XU9'>VBD/ >14^9@!D[1U( XKP#]BOXZ^,_BSX5^(
M\_Q#O=.N[_PIXAN-)-SI=I]GB:.% 7;;GG)#$9YQBOIJ/_6+]:^)_P!@/2_[
M>\*_M&:8'V&\\;ZK;!LXP70J#^M6OA9:V9S+?M>?'?Q!\*]>^//A[3/"H^%6
ME:D\,?ANYBD.HW5DDHC>?SQPK98>PP>#CG[D\&>*;+QUX1T3Q'II8V&KV4-]
M;[NH21 P!]QG'X5^8&B?&BQ\!?L0>*OV<]6TS5$^, N[C0[;PXFGRF2Z$MT'
M69&"[2N-W?)P,9!S7Z2?!#PA=_#_ .#_ (&\,W^/MVD:-:65P%.0)$B4,/P.
M1^%5-6')'E.H?\%"/V?]+:1+KX@PQ317<EE)#_9UV9(Y$.&+*(LA<\;S\IP<
M'BO/?V[?VOH/AM\'_!6K_#OQM':ZEXBU&&ZL[ZPMUN8[K3DW"X(9D9!AFC&#
MAL].AKPO]CG]H[X/_!/PG\6-.^(>GM:ZAJ/B._87$FDR72:Q!T%HCJA&Y3N^
M1B!^\!KC_%/@C7_!/_!.[P__ &]I\^C6^J_$B+5-)TN[&V2TL94?RU(/(R5=
M^>S9JU!*1:BDS]!?$?[:'P9\+VV@W6H^,X[>'7;%-4LE6QN9'%HYPD\JK&6A
M0^L@6O8M-U*UUC3K6_L;B.[LKJ)9X+B%MR2QL 593W!!!K\XO^"@<6B^#?CE
MJOC7P7\0IO"GQ0MM*@AN_#E]I\LEIK]NQVB&$E&CE;;M#Q,"I&.AS7V'\._C
M]I]UJ7P_\">*;6XT;XE:[X;BUF;2H[)UMX,(/,0OC"$$-\O;&#@XSFXZ)HS<
M=$T>Q4445F0=!X=_X]9?]_\ H*H^(/\ C_'^X/YFKWAW_CUE_P!_^@JCX@_X
M_P ?[@_F:ZI?PD;O^&C-HHHKE, HHKB/B1\3+;P/:B" )<ZO*,QP$_*@_O/[
M>@[UA6K0P\'4J.R1G4J1IQ<IO0[>BN:\"^.K+QQI8G@Q#=Q@"XM2?F0^H]5/
M8UE_$OXF6_@FT-M;[9]8F7,<741#^^W]!WK.6*HQH^W<O=)=:FJ?M&] ^)GQ
M+M_!5F;:V*SZQ,O[N+J(A_?;^@[US_PJ^+AUB2/1]<F'VYCB"Z; $V?X6]&]
M/6O$+JZNM6OI)YWDNKNX?+,>6=C7O/PI^%*^'HX]6U:,/JC#,4+<BW![_P"]
M_*OF,-C,7CL8I4M(+ITMY^?];'CT<17Q%>\-(K\O\ST^BBBOLCW@HHHH ***
M* "BBB@ HHIDTT=O"\LKK%$@+,[G 4#J2:0#Z*\H_P"%]6/_  EGV;R?^)'_
M *O[9SOW9^_C^[[=>_M7J7VR#[)]J\Z/[+L\SSMPV;<9W9],5RT,51Q'-[*5
M[;F%.M3JWY'>P^::.WA>65UCB0%F=C@*!U)->&^+/CI=GQ##_8FW^S+5_F\P
M?\?78Y]%]/SK+^*?Q3D\53/INFNT>D(?F;H;@CN?]GT'XUR_@OP7?>-M66TM
M%V0K@SW##Y8E_J?05\QCLSJ5ZBP^#?7==7Y>7];'D8C&3J35*@?2WA/Q98^,
MM)2^L7_V986^]$W=3_CWK:K+\->&K'PII,5A81;(EY9S]Z1N[,>YK4KZRC[3
MV<?:_%UL>W#FY5S[A1116Q84444 %%%% !139IH[>%Y976.)%+,[G 4#J2:\
MK7X]6!\6?93#C0_]6+SG=NS]_']W]>_M7)7Q5'#<OM96N8U*U.E;G=KGJU,G
MGCM89)IG6**-2SNYP% ZDFFM>0+:&Z,T8M0GF>=N&S;C.[/IBOGKXI?%*3Q9
M,^G:<[1:/&W+=#<$=S_L^@_&L,;CJ>#I\TM6]EW_ . 9XC$1P\;O?H:GBKXZ
M7C>(H6T3:-,M7Y$B_P#'UV.>X'IW[UZ[X3\66/C+24O[%^/NRQ-]Z)NZG_'O
M7S5X)\$WWC?51:VH\N!,&>Y8?+$O]2>PKZ;\.>'+'PKI<5AI\7EPIRS'[SMW
M9CW)KRLIK8O$3E5J/W'^?E_7XG#@:E>K)SG\+_K0TZ***^G/8"BBB@ HHHH
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M\N%.68_>D;NS'N:TZ**^[C&,(J,59(^DC%15EL%%%%6,**** "BBB@ HHHH
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M%V @8Y+'D\\G(I#YNYZ=11169F=!X=_X]9?]_P#H*H^(/^/\?[@_F:O>'?\
MCUE_W_Z"J/B#_C_'^X/YFNJ7\)&[_AHS:***Y3 **** "BBB@ HHHH ****
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MNG0F.*P4592_/IL?']%?8'_#%7PR_P"C@M%_\!(?_DFC_ABKX9?]'!:+_P"
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M $![K_ON/_&C^U[O_H#W7_?<?^-'*PLS4HK+_M>[_P"@/=?]]Q_XT?VO=_\
M0'NO^^X_\:.5A9FI167_ &O=_P#0'NO^^X_\:/[7N_\ H#W7_?<?^-'*PLS4
MHK+_ +7N_P#H#W7_ 'W'_C1_:]W_ - >Z_[[C_QHY6%F:E%9?]KW?_0'NO\
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M_P! 2\_[[C_^*HYH]PYEW.JHKE?^$XE_Z EY_P!]Q_\ Q5'_  G$O_0$O/\
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MH^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\
M\118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H
M'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:
MS_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118
M+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_
M (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#
MK7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I1
M67]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G
M_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P
M+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]J
MUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(
MH^U:S_T#K7_P+/\ \118+&I167]JUG_H'6O_ (%G_P"(H^U:S_T#K7_P+/\
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M96'J"*DI;ZH HHHI@%%%% !1110 4444 %%%% !1110 4444 =!X=_X]9?\
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M<G/3CY37-:/^RSXENM>\6V6LZMHWA;3?#-P+6_UG5KC9:^:P!14.,L64ANG
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MZCX3U>U\-ZC;Z1K\UL\=C?W<)FBMYB,+(R C<!UQ0!^</Q]^"/@;X=V_PJ^
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ML/"^C69D:6!W!$D\Y90NXAI.%)ZK_=R125[@I+<^@****S,SH/#O_'K+_O\
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M^WOWKLJ*\VGE^'IUWB(QU?W+T.2.%I0J.JEJ%%%%>D=84444 %%%% !1110
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M:?\ @SM__BJ/^&$?C+_T+MI_X,[?_P"*K;VU/^9&?LY]CY_HKZ _X81^,O\
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MROL'*^QIT5F?\)-I/_/_  _G1_PDVD_\_P##^='*^P<K[&G169_PDVD_\_\
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MS_0_F:.5]@Y7V-*BLW_A)M*_Y_H?S-'_  DVE?\ /]#^9HY7V#E?8TJ*S?\
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MPH_X2C3/^?H?]\-_A1ROL%GV-2BLO_A*-,_Y^A_WPW^%'_"4:9_S]#_OAO\
M"CE?8+/L:E%9?_"4:9_S]#_OAO\ "C_A*-,_Y^A_WPW^%'*^P6?8U**R_P#A
M*-,_Y^A_WPW^%'_"4:9_S]#_ +X;_"CE?8+/L:E%9?\ PE&F?\_0_P"^&_PH
M_P"$HTS_ )^A_P!\-_A1ROL%GV-2BLO_ (2C3/\ GZ'_ 'PW^%'_  E&F?\
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M&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:*
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MK,VA:JMBQ:VEFC /F1Y)(!SC&3R#V(KQ_P".TWQ#\<_MW>&OASX9^)NM> ]
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M?,O4P$_Q+[>HKPJN;4J.)]A-675^?^7F>=/&PIUO926G<^D68(I9B%4#)).
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M--76J*U6IS'P-^!WAC]GSP'%X5\+17'V7SGNKF[O)/,N+RX?&^:5N[' ''
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M_9I;3[0F_P F888?XCT/<5I4#   & .!17V\4U%*3NSZ)722844458PHHHH
M**** "BBH[BXCM+>6>9MD4:EW;T &2:6P$E%?//BSXTZGJ'B*"YTB1K33[1\
MQ1-_RW[$R#T([=OK7KGA/XBZ5XFT"34C,EFULN;N*5L>3[^X/8_UKR\/F6'Q
M%25.#V_'T..EBZ563A%[?B=)>7L&G6DMU=2K!;Q+O>1S@*/6OG#XE?$ZX\97
MGV>T9[?2(6S&F<-*P_C;^@[?6CXF?$R?QI=FUM2T&CQ-\D9X,I_OM_0=JS_
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M?>.8FND;[C%6A"Y[='>OH3XS?$_Q!\,]/TZZT#X<:]\1IKN9XYK;0GC5[4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\0?\>'_
MQ6E6;K__ !X?\#%9U/A9$_A9S=%+M/I1M/I7G'$)12[3Z4;3Z4 )12[3Z4;3
MZ4 )12[3Z4;3Z4 )12[3Z4;3Z4 )12[3Z4;3Z4 )12[3Z4;3Z4 )12[3Z4;3
MZ4 )12[3Z4;3Z4 )12[3Z4;3Z4 )12[3Z4;3Z4 )12[3Z4;3Z4 ;_AW_ (]9
M?]_^@JCX@_X_Q_N#^9J]X=_X]9?]_P#H*I:__P ?X_W!_,UU2_A(W?\ #1F4
M4M%<I@)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
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MC_WX/^-7]4TWP?X5\-^&;G4/#\M])J5OYDLT5Y(C*0%R0N<'.?:L;Q/\,_\
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M[_GB_P#W_D_^*K4HKW>9]SR>9]S+_P"$9T[_ )XO_P!_Y/\ XJC_ (1G3O\
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M<S[AS/N9?_",Z=_SQ?\ [_R?_%4?\(SIW_/%_P#O_)_\56I11S/N',^YE_\
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MZ>O_  *D_P :/^$!TG_IZ_\  J3_ !KI**+(+'-_\(#I/_3U_P"!4G^-'_"
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M #TNO_ A_P#&C_A';7_GI=?^!#_XUITM>9S/N<%V9?\ PCMK_P ]+K_P(?\
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M **** "HY_\ 4R?[I_E4E1S_ .ID_P!T_P J3V XJEI*6O*//"BBBF 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<_\
MJ9/]T_RJ2HY_]3)_NG^5)[ <52TE+7E'GA1113 *3/\ A0QPI."<<X'6OFSX
MB_$C4_$6N;(C-IMK8R_N8,E) X/WV_VO;M7FX['0P,%*2NWLCEQ&(CAXW>MS
MZ4JMJ6HVVDV,UY>3+;VT*[GD8\ 5Y]X ^,%EK.E2)K4\=E?VL>^21N%F4?Q+
M_M>J_E7E_P 1OB-<^-[[RHMUOI,+?N8.['^^WO[=JY<1FU"G056F[M[+_,PJ
MXVG"FIQ=V]O^")\1OB-<^-[[RH]T&E0M^Y@[N?[[>_MVKN_@+K6M74-Q8RQ-
M/HT _=W#G'E-_<7U'MVK@/AY\.[OQQJ&3NM],A;]_<8Z_P"POJW\J^E-+TNU
MT73X;*RA6"VA7:B+_/W/O7E971Q&(K_7*DFE^?EZ'%@Z=6K4^L3?_!_X!;HH
MHK[$]X*5:2E6@!:*** "BBB@ HJGJ^L6F@Z=-?7TRP6T(RS-_(>I/I7DVB_'
MS[1XHE2_@6WT28A(6 ^>'T9O4'OZ5PU\90PTHPJRLW_6ISU,13HM1F]SV6J>
ML:Q::#ITU]?3+!;0C+.W\AZD^E-U+7+'2=)DU*ZN8TLD3?YP.0P/3'J3VKYJ
M^(7Q"N_'6HY.Z#383^XML_\ CS>K']*Y\?F$,'#O)[+]7Y&6)Q4</'NWL;6J
M?&W6+CQ5'J-H?)T^$E$L6/RR(3SO_P!H^O:O<_"_B:S\7:+#J5D6$4G#(XPR
M,.JGZ5\^_#7X:W'C:\^T7 :#2(6_>3=#(?[B?U/:OI&QL;?2[.&TM(5@MX5V
M)&@P *X,H>+J<U:L_=EW[^79'-@77G>=1Z,GHHHKZ4]85?O#ZUVM<4OWA]:[
M6NNAU.BEU"O/?CO_ ,DYN_\ KM#_ .ABO0J\]^.__).;O_KM#_Z&*\/B;_D2
M8S_KW/\ )GOY/_R,</\ XH_F?,B_>'UKZ%N-#@;Q58:0/!=C)HMW:JT^I+;[
M2IV<D..%P<<=3FOGKN*[G7O%WB/Q?'>WVGQWUGI,-O'#=1V\S-",+C+=!R/:
MOY;X;S##8&E6]K!SDW!J*BFW&/,Y)WBTHVMS;.WHS]DS7"U<3.GR244E)-MM
M6;Y;;-7?;I<Z?1M&M]$\-V%QHWAVV\527E]-!<S3Q>=Y2+(50#'W<KSNZ=_2
MM/2_#?AVS\7>(=&M[2$7$DL0M)[JU^TP1L4W- ?[ISGN#COQ7F&FV_BS0M'D
MU&P74['391N>> ND;#IDX[>]-L6\5:/HTVJ6DFI6>F7#9DNHW94D).W).>3G
MC->Y0SJC15%2P3]Q*37*K**BXMQ=E*TV^9R;T:5KGGU,OJ5'4MB%[SLM7J^9
M-)[J\;622U6YW>K2#_A5=EI=U%I]F/[7>RDNEBRL6UB3(,'KQ@GN.*J_#/3;
M70/B(JV&JV^KJ-/FD\Z!"JJV/ND'Z?K7FK:G=R6"V+7,K6:N95@+DH'/5L>O
MO2:?J5WI5QY]E<RVLVTIYD+E6VGJ,CM7B_ZQ47C<-BY4;^R4$G?WDH=%9J.O
M=JYZ']EU/J]:BI_'S=-/>ZOK]S/:M6?3=4^&?B/Q!9 1IJA@:[M5_P"64R.!
M(!]<Y_'/>JWB[1]3U[Q-I,MK<ZA;^%7MH_L<^EQM*(B$X&Q.ASW->00ZM>V]
MC/917<T=I<$&6!7(1R.A([U9TWQ1K&C0&"PU2\LX2<F.&9E7/T!KT*G%.%Q2
MC#$46ERQYN5VO*,YR?;W9N;;2:L[6V.6&35J+<J51-W=KJ]DXQ2^<>71V=UO
MN>NZ99R>%OB9?RG5Y=:U"/19KB26Z3#(P"[489] /SJ+Q+'I]Y\+-<US3"$@
MU:>">2W'_+&8$"1?SY_&O'K?5KVUN)KB&[FBGF5DEE60AG5OO GN#21ZI>0Z
M?+8I=3)92L'>W5SL9AT)'3/%1_K50]A6PZH6C/VMM;N,IKE3N]7I?FOO>_1%
M?V-4]I3JNI[T>2^EKJ+NU9:+6UNWS-+Q%H-AHT=LUEKEMK!ESO6W1E,>,=<^
MN?TK#HHKX#$5(5:CG3IJ"[)MI?>V_P 3Z:G&4(J,Y<S[NWZ604445S&A[Q\)
M?^1)M?\ KK+_ .A&NPKC_A+_ ,B3:_\ 767_ -"-=A7]F<._\B;"?]>X?^DH
M_FO.O^1EB/\ '+\PHHHKZ(\8\]^*7PPC\86YU"P"QZQ$N!DX6=1_"?0^AKYY
M_P!)TJ^_Y:6EW;O[J\; _H17V17G/Q3^%L?BR%]2TY5BUB->5Z"X ['_ &O0
M_A7S&:99[6]>@O>ZKO\ \'\SR,9@_:?O*>_Y_P#!/G_4=2N]:OI+N\FDNKN8
MY:1^68]A_P#6KVWX3_"<:6L6M:U"#>GYK>U<<0^C,/[WMV^M,^%'PE.F-%K.
MN0XO =UO9N/]5_MM_M>@[?7IZY665Y8[_6<2M>B?YOS,\'@_^7M7<****^L/
M;"BBB@ HHHH *9-#'<PO%-&DT3C#1R*&5AZ$'@T^B@#,_P"$5T/_ * FF?\
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M">VDU?6;I<LD-P500PENA<&.'W^9NX-)6;N+2]S[6HHHK$R.@\._\>LO^_\
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MPP1*$2-!@*!T J2OK,#@:>"I\L=6]V>WA\/'#QLM^H4445Z1UA1110!-:?\
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ME2JQ4HR5FGJFNS.NG4E2DIP=FMF>0?\ #.6F?]!2?_OV/\:/^&<M,_Z"D_\
MW['^->OT5\__ *LY)_T!T_\ P"/^1ZG]KYA_S_E_X$SR#_AG+3/^@I/_ -^Q
M_C1_PSEIG_04G_[]C_&O7Z*/]6<D_P"@.G_X!'_(/[7S#_G_ "_\"9Y!_P ,
MY:9_T%)_^_8_QH_X9RTS_H*3_P#?L?XUZ_11_JSDG_0'3_\  (_Y!_:^8?\
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MZC_T'3_X")_C7745KR1[$<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\
MX")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_C774
M4<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_C7744<D>P<L>
MQR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>
MH_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_
M (")_C1_PA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_
MPA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0
M=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_
MC7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_C7744<D>
MP<L>QR/_  A>H_\ 0=/_ (")_C5_^Q]<_P"A@'_@$G^-;]%-14=D-)+8P?['
MUS_H8!_X!)_C1_8^N?\ 0P#_ , D_P :WJ*H9@_V/KG_ $, _P# )/\ &C^Q
M]<_Z& ?^ 2?XUO44 8/]CZY_T, _\ D_QH_L?7/^A@'_ (!)_C6]10!@_P!C
MZY_T, _\ D_QH_L?7/\ H8!_X!)_C6]10!@_V/KG_0P#_P  D_QH_L?7/^A@
M'_@$G^-;U% &#_8^N?\ 0P#_ , D_P :/['US_H8!_X!)_C6]10!@_V/KG_0
MP#_P"3_&C^Q]<_Z& ?\ @$G^-;U% &#_ &/KG_0P#_P"3_&C^Q]<_P"A@'_@
M$G^-;U% &#_8^N?]# /_  "3_&C^Q]<_Z& ?^ 2?XUO44 8/]CZY_P!# /\
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M  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\
M0=/_ (")_C1_PA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")
M_C1_PA>H_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H
M_P#0=/\ X")_C7744<D>P<L>QR/_  A>H_\ 0=/_ (")_C1_PA>H_P#0=/\
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M+_C6]151BH[%)*.Q@X\3_P![2?\ OF7_ !HQXG_O:3_WS+_C6]15#,''B?\
MO:3_ -\R_P"-&/$_][2?^^9?\:WJ* ,''B?^]I/_ 'S+_C1CQ/\ WM)_[YE_
MQK>HH P<>)_[VD_]\R_XT8\3_P![2?\ OF7_ !K>HH P<>)_[VD_]\R_XT8\
M3_WM)_[YE_QK>HH P<>)_P"]I/\ WS+_ (T8\3_WM)_[YE_QK>HH P<>)_[V
MD_\ ?,O^-&/$_P#>TG_OF7_&MZB@#!QXG_O:3_WS+_C1CQ/_ 'M)_P"^9?\
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D=G11[.'8.2/8XU?#OB ,"9]-QG^[)_C7944548J.PU%1V/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Neurogene Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0542593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">535 W 24th St.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">5th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">508-3568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.000001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NGNE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,262,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 70,771<span></span>
</td>
<td class="nump">$ 136,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">221,831<span></span>
</td>
<td class="nump">175,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,796<span></span>
</td>
<td class="nump">3,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">296,398<span></span>
</td>
<td class="nump">315,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="nump">15,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,803<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">315,301<span></span>
</td>
<td class="nump">335,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,063<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,849<span></span>
</td>
<td class="nump">9,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">3,036<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,094<span></span>
</td>
<td class="nump">15,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">8,606<span></span>
</td>
<td class="nump">9,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent value rights liability, non-current</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,506<span></span>
</td>
<td class="nump">25,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.000001 par value; $50,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 0 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.000001 par value; $450,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; $14,929,566 and $14,854,725 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">576,740<span></span>
</td>
<td class="nump">572,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(284,945)<span></span>
</td>
<td class="num">(262,298)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">291,795<span></span>
</td>
<td class="nump">310,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 315,301<span></span>
</td>
<td class="nump">$ 335,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share (in dollars per share)</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share (in dollars per share)</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">14,929,566<span></span>
</td>
<td class="nump">14,854,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">14,929,566<span></span>
</td>
<td class="nump">14,854,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 17,760<span></span>
</td>
<td class="nump">$ 13,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">8,159<span></span>
</td>
<td class="nump">5,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,919<span></span>
</td>
<td class="nump">18,779<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,919)<span></span>
</td>
<td class="num">(18,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,206<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(602)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,647)<span></span>
</td>
<td class="num">$ (16,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic (in shares)</a></td>
<td class="nump">20,996,287<span></span>
</td>
<td class="nump">16,903,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted (in shares)</a></td>
<td class="nump">20,996,287<span></span>
</td>
<td class="nump">16,903,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid- In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,823,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 186,024<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 373,178<span></span>
</td>
<td class="num">$ (187,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,921)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,860,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 170,777<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">374,852<span></span>
</td>
<td class="num">(204,075)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">14,854,725<span></span>
</td>
<td class="nump">14,854,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 310,375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">572,673<span></span>
</td>
<td class="num">(262,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,647)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">14,929,566<span></span>
</td>
<td class="nump">14,929,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 291,795<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 576,740<span></span>
</td>
<td class="num">$ (284,945)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,647)<span></span>
</td>
<td class="num">$ (16,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization and accretion of premiums/discounts on held-to-maturity investments</a></td>
<td class="num">(1,747)<span></span>
</td>
<td class="num">(446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_IncreaseDecreaseInContingentValueRightsLiability', window );">Change in contingent value rights liability</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,694<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(2,203)<span></span>
</td>
<td class="num">(4,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,774)<span></span>
</td>
<td class="num">(21,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(780)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of held-to-maturity investments</a></td>
<td class="num">(88,965)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from maturities of held-to-maturity investments</a></td>
<td class="nump">44,700<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(45,045)<span></span>
</td>
<td class="nump">29,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Offering costs in connection with pre-closing financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Transaction costs related to reverse merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the issuance of common stock upon exercise of options</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(6,524)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(65,815)<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">136,925<span></span>
</td>
<td class="nump">148,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">71,110<span></span>
</td>
<td class="nump">150,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additions to operating lease right of use assets from new operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_IncreaseDecreaseInContingentValueRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Contingent Value Rights Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_IncreaseDecreaseInContingentValueRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Organization and Description of Business</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurogene&#160;Inc. (formerly known as Neoleukin Therapeutics, Inc.) (the &#8220;Company&#8221; or &#8220;Neurogene&#8221;) is a clinical-stage biotechnology company that is a result of the reverse merger discussed below. The operating entity of Neurogene Inc. is the wholly owned subsidiary incorporated in the state of Nevada and also named Neurogene Inc. (&#8220;Neurogene OpCo&#8221;). Neurogene OpCo was incorporated as a limited liability company in Delaware on January 26, 2018 and converted into a Delaware corporation on July 3, 2018, and then merged with a wholly owned subsidiary of the parent company and re-domiciled to Nevada on December 18, 2023 after completing a reverse merger with Neoleukin Therapeutics, Inc (the &#8220;Closing&#8221;), in accordance with the terms of the Agreement and Plan of Merger, dated as of July 17, 2023 (the &#8220;Merger Agreement&#8221;). Both Neurogene and Neurogene OpCo have a principal place of business in New York, NY. Neurogene was formed to harness the power of gene therapy, combined with its EXACT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene regulation technology, to turn today&#8217;s complex devastating neurological diseases into treatable conditions. The Company&#8217;s first clinical-stage program to utilize the EXACT technology is NGN-401, which is in an ongoing Phase 1/2 clinical trial for the treatment of Rett syndrome. Since beginning operations, the Company has devoted substantially all its efforts to research and development, recruiting management and technical staff, administration, and raising capital.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Risks and Uncertainties</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Risks and Uncertainties</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of pre-clinical studies, clinical studies and clinical trials, the need to obtain marketing approval for its drug candidates and its consumer products, fluctuations in operating results, economic pressure impacting therapeutic pricing and reimbursement, dependence on key personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to transition from pilot scale manufacturing to large scale production.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $22.6 million and $16.9 million for the three months ended March 31, 2025 and 2024, respectively. In addition, the Company used cash in operations of $20.8 million and $21.7 million for the three months ended March 31, 2025 and 2024, respectively, and had an accumulated deficit of $284.9 million as of March&#160;31, 2025. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had cash, cash equivalents and short-term investments of approximately $292.6 million. The Company expects its available cash and cash equivalents on hand as of the issuance date </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these financial statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be sufficient to fund its obligations as they become due for at least one year beyond the issuance date of these financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company&#8217;s operations, a sale of assets, or other alternatives with strategic or financial partners. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Summary of Significant Accounting Policies </span><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, these financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March 24, 2025.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2025, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December&#160;31, 2025. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining the incremental borrowing rate for calculating lease liabilities and related right-of-use assets and finance lease assets, clinical trial accruals, accrual estimates for all contingent value rights (&#8220;CVRs&#8221;), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the value attributed to employee stock options and other stock-based awards. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines and presents operating segments based on the information internally provided to the Chief Operating Decision Makers (&#8220;CODM&#8221;) in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 280,&#160;Segment Reporting. The Company&#8217;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has one reportable segment. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information related to the Company&#8217;s segment. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with original maturities of 90 days or less at time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and are stated at fair value.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds in which the carrying value equals the fair value. Restricted cash includes $0.3 million in cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of March&#160;31, 2025, the Company had $70.6 million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the reverse merger, the Company entered into a CVR Agreement on December 18, 2023 with the Rights Agent named therein (the &#8220;CVR Agreement&#8221;) prior to Closing. Included in the CVR Agreement are three different types of CVRs: (i) the Lease CVR, (ii) the Intellectual Property CVR, and (iii) the Sales Tax CVR (each as defined in the CVR Agreement). The Company evaluated each of the CVRs to determine if they qualified as derivatives under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that since certain scope exceptions were met, the CVRs did not qualify as derivatives. Instead, the Company records a contingent consideration liability associated with the CVRs when payments are probable and estimable under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In assessing whether payments are probable and estimable, the Company considers the existence of or ability to enter into agreements with third parties or government agencies and the timing of potential payments. Refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the CVRs.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit and Disposal Costs</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the reverse merger and through early fiscal 2025, the Company has incurred costs to wind-down Neoleukin&#8217;s Phase 1 trial of the NL-201 study. This trial has ceased further development, and the Company has no plans to continue developing Neoleukin&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein technology. As a result, the trial&#8217;s activities do not provide the Company any future economic benefit. In accordance with ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accrued the remaining costs incurred in the trial. The liability was classified as accrued expenses and other current liabilities in the condensed consolidated balance sheet.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the accrued liabilities activity recorded in connection with the wind-down of Neoleukin&#8217;s Phase 1 trial of NL-201 for the three months ended March&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amounts Paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial wind-down costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 NL-201 Trial</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">209&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(109)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited financial statements filed with the Company&#8217;s Annual Report on Form 10-K for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the date of those financial statements, there have been no changes to the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net income attributable to the Company by the weighted-average number of shares of common stock outstanding during the period. In periods of losses, diluted net loss per share is computed on the same basis as basic net loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive. Outstanding pre-funded warrants as of March&#160;31, 2025 and March&#160;31, 2024 are 6,124,996 and 4,062,361 respectively. Pre-funded warrants are considered outstanding as of their issuance date and are included in basic and diluted net loss per share because they are fully vested and exercisable for nominal cash consideration.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-indent:37.11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"></td><td style="width:66.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,086,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,475,458</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,530</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,617,916</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,950,112</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its condensed financial statements or disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which requires public entities to provide disaggregated disclosure of income statement expenses. Public entities are required to disaggregate, in a tabular presentation, each relevant expense caption on the face of the consolidated statements of operations such as the following expenses: purchases of inventory, employee compensation, intangible asset amortization, and depreciation. In January 2025, the FASB issued ASU 2025-01 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to clarify the effective date. The updated effective date for the Company to adopt ASU 2024-03 is for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2024-03 will have on its financial statement disclosures. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span> to expand the disclosure requirements for income taxes. Upon adoption, the Company will be required to disclose standardized categories in the rate reconciliation in both percentage and dollar amounts. ASU 2023-09 will also require income taxes paid to be disaggregated by jurisdiction, among other disclosure requirements. The Company adopted ASU 2023-09 for annual periods beginning January 1, 2025. The adoption does not have a material impact to the interim financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Investments </span><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following table summarizes the Company&#8217;s investment securities as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:35.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized cost, as adjusted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments mature within the next 12 months.</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:35.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized cost, as adjusted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair Value of Financial Instruments</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:54.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:54.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are cash equivalents and are included in cash and cash equivalents in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Prepaid expenses and other current assets</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:68.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds and other receivables </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,796&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Property and Equipment, Net</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,422&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded depreciation and amortization expense of $0.7 million and $0.8 million for the three months ended March&#160;31, 2025 and 2024, respectively.  </span></div>Management has reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. During the three months ended March 31, 2025 there were no impairment losses and for the three months ended March 31, 2024, the Company recorded impairment losses on idle equipment of $0.1 million. Impairment losses are charged to research and development expenses in the condensed consolidated statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Accrued Expenses and Other Current Liabilities</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:69.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, bonuses and related benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Commitments and Contingencies</span><div style="margin-top:10pt;padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Headquarters Lease</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company commenced a sub-lease of approximately 6,000 square feet of office space for the corporate headquarters in New York, New York with a term expiring in June 2023. In connection with the lease, the Company established an irrevocable letter of credit for approximately $0.4 million. Monthly lease payments were approximately $0.04 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the sublessor was released from the original lease by the landlord, and the Company attorned to the landlord the executory terms and provisions of the sub-lease. In February 2022, the Company entered into an extension of the New York office lease (retroactive to December 2021) through June 2026, with new monthly lease payments ranging from approximately $0.03 million to $0.04 million. The Company accounted for the amendment as a contract modification, and accordingly, recorded an additional operating&#160;right-of-use asset of approximately $1.0 million and an additional operating lease liability of approximately $1.0 million.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Houston Lease</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into an agreement to lease approximately 26,905 square feet in Houston, Texas to build a manufacturing facility and office with a term expiring in August 2029. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset. Monthly rent payments were approximately $0.03 million. In connection with the lease, the Company paid a security deposit of approximately $0.04 million and prepaid rent of approximately $0.04 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company amended the lease agreement to further increase the rentable space to 42,342 square feet. The commencement date of the expansion space lease was January&#160;1, 2021 and the monthly rent payments increased to a range of approximately $0.05 million to $0.06 million. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Blaine Lease in Seattle</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the reverse merger, the Company assumed an operating lease for approximately 33,300 square feet of office space in Seattle, Washington for offices, a laboratory for research and development, and related uses. The lease expires on February 1, 2029, with the option to extend the lease for two five-year terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eastlake Lease in Seattle</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the reverse merger, the Company assumed an operating lease for approximately 6,272 square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses (the &#8220;Eastlake Lease&#8221;). The lease expires on September 30, 2026. The Company also assumed the existing agreement to sublease the Eastlake Lease to an unrelated third party (&#8220;Eastlake Sublease&#8221;). Pursuant to the terms of the Eastlake Sublease, Neurogene is entitled to receive approximately $1.6 million in lease payments. The Company recorded sublease income of $0.1 million for the three months ended March 31, 2025 and $0.1 million for the three months ended March 31, 2024. Sublease income is included in other income in the statement of operations. The term of the sublease is through September 30, 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental lease expense for the three months ended March 31, 2025 and 2024 was as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:69.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CVR Agreement, each CVR holder is eligible to receive certain net savings, if any, realized by June 30, 2029 in connection with certain legacy lease obligations. As of March&#160;31, 2025, approximately $1.2&#160;million was recorded as a component of the contingent value rights liability on the Company&#8217;s condensed consolidated balance sheet consisting of lease commitments that were probable and estimable at the Closing. The commitments relate to Neoleukin&#8217;s sublease agreement, effective October 31, 2023, for one of its properties with an unrelated third party for the remainder of the lease term.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CVR Agreement, each CVR holder is eligible to receive 100% of the net proceeds, if any, derived from any consideration paid as a result of the disposition of Neoleukin&#8217;s pre-merger legacy assets pursuant any agreements entered into before the Closing, and 80% of net proceeds, if any, derived from any consideration paid as a result of the disposition of Neoleukin&#8217;s pre-merger legacy assets pursuant any agreements entered into within one year after the Closing (the &#8220;Intellectual Property CVR&#8221;). Contingent consideration liabilities related to the CVR Agreement will only be recorded if the liabilities are probable and estimable as of the balance sheet date. Refer to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2023 CVR Licensing Agreement and April 2024 CVR Licensing Agreement subsections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for further detail on the current agreements related to our Intellectual Property CVR. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2023 CVR Licensing Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Closing, Neoleukin entered into a licensing agreement on December 13, 2023 with an unrelated third party to develop and commercialize certain legacy Neoleukin assets (the &#8220;December 2023 CVR Licensing Agreement&#8221;). In June 2024, an upfront payment of $0.2&#160;million was received by the Company and $0.2&#160;million was recorded as licensing revenue within the consolidated statements of operations. Since the December 2023 CVR Licensing Agreement was entered into before the Closing, the CVR holders are eligible to receive 100% of the net proceeds derived from the December 2023 CVR Licensing Agreement. The December 2023 CVR Licensing Agreement contains development, regulatory and commercialization milestones totaling up to approximately $13.4 million, as well as royalty payments. However, as of March&#160;31, 2025, no other development and sales milestones were achieved nor deemed probable of achievement under the December 2023 CVR Licensing Agreement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">April 2024 CVR Licensing Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a licensing and intellectual property assignment agreement with another unrelated third party to develop and commercialize certain legacy Neoleukin assets (the &#8220;April 2024 CVR Licensing Agreement&#8221;). In April 2024, the Company received a one-time upfront payment of approximately $0.8 million and reimbursement of $10,000 for patent expenses under the April 2024 CVR Licensing Agreement. Accordingly, the Company recorded $0.8 million as licensing revenue within the condensed consolidated statements of operations. Since the April 2024 CVR Licensing Agreement was entered into within one year after the Closing, the CVR holders are eligible to receive 80% of the net proceeds derived from the April 2024 CVR Licensing Agreement. The April 2024 CVR Licensing Agreement contains development, regulatory and commercialization milestones totaling up to approximately $11.0 million, as well as royalty payments. However, as of March&#160;31, 2025, no other development and sales milestones were achieved nor deemed probable of achievement under the April 2024 CVR Licensing Agreement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2023 CVR Licensing Agreement and April 2024 CVR Licensing Agreement collectively account for the total Intellectual Property CVR. The total amount of $0.9 million due under the Intellectual Property CVR was offset by approximately $0.4 million due to permitted deductions under the Merger Agreement and the remaining $0.5 million was paid to the CVR holders as discussed below. As of March&#160;31, 2025, $0.3 million is recorded within the contingent value rights liability on the Company&#8217;s condensed consolidated balance sheet arising from offsets to permitted deductions to the Intellectual Property CVR that were incurred subsequent to the CVR payment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Tax CVR</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Closing, Neoleukin entered into an agreement with an unrelated third party for refund analysis services of Washington state sales tax. As discussed and defined within the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Value Right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the terms of the CVR Agreement include that CVR holders are eligible to receive net proceeds derived from an anticipated sales tax refund from Washington state relating to tax returns filed by Neoleukin prior to Closing. As of March&#160;31, 2025, it was deemed probable that the Company will receive proceeds from Washington state for the sales tax refund and will remit the proceeds to the CVR holders. As of March&#160;31, 2025, $0.4 million is accrued as a component of the contingent value rights liability arising from the Sales Tax CVR in the condensed consolidated balance sheet.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CVR Payment</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company made the first CVR payment to CVR holders, net of expenses, for $0.6 million. $0.5 million was applied to the Intellectual Property CVR and $0.1 million was applied to the Lease CVR, reducing the respective liabilities. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the contingent value rights liability in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.272%"><tr><td style="width:1.0%"></td><td style="width:41.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease CVR</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property CVR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Tax CVR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CVR liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the CVR Agreement, the total amount owed to CVR holders, after deductions permitted under the Merger Agreement, must be at least $0.5 million to trigger a CVR payment prior to the end of the CVR term. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other payments under the CVR Agreement were not considered probable and estimable as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and therefore no additional contingent consideration liability has been recorded. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will evaluate the probable and estimable range of outcomes under the CVR Agreement at each reporting period until the end of the CVR term and adjust the amounts accrued for as necessary.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has employment and consulting agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Development Arrangements </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had standing agreements with consultants, contractors or service providers that generally can be terminated by the Company with 30 to 60 days written notice, unless otherwise indicated.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Legal Proceedings</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to litigation and other claims that arise in the ordinary course of business. While the ultimate result of outstanding legal matters cannot presently be determined, the Company does not expect that the ultimate disposition will have a material effect on its results of financial condition, results of operations or cash flows. However, legal matters are inherently unpredictable and subject to significant uncertainties, some of which are beyond the Company&#8217;s control. As such, there can be no assurance that the final outcome of any particular legal matter will not have a material adverse effect on the Company&#8217;s financial condition results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Licenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Licenses</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with The University of Edinburgh</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the University Court of the University of Edinburgh (the &#8220;University of Edinburgh&#8221;) and Neurogene entered into the Master Collaboration Agreement (&#8220;MCA&#8221;). Under the MCA, Neurogene and the University of Edinburgh agreed to collaborate on certain research and development projects (&#8220;Projects&#8221;) and Neurogene agreed to provide funding for such Projects for a 40-month initial term,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which term was extended in November 2023 for an additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months and may be further extended by mutual agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In exchange for such funding, the University of Edinburgh granted Neurogene the option to exclusively license any intellectual property arising from such Projects. If Neurogene exercises an exclusive option for a particular Project, Neurogene will enter into a separate exclusive license agreement on its own terms with the University of Edinburgh. Under the MCA, Neurogene is obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the 40-month period. Either party may terminate the MCA for convenience upon 90 days&#8217; notice. If Neurogene terminates the MCA, it would be responsible for all non-cancellable costs and commitments related to any particular Project and any and all funding costs for any person working on such Project. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Neurogene exercised its option through the collaboration under the MCA and entered into a License Agreement (the &#8220;March 2022 Edinburgh License Agreement&#8221;) with the University of Edinburgh, pursuant to which Neurogene licensed certain patents and know-how related to the EXACT technology and optimized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MECP2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cassettes on an exclusive basis. Under the March 2022 Edinburgh License Agreement, Neurogene obtained an exclusive, worldwide license to the licensed patents to develop, manufacture, supply, sell, and commercialize any products that utilize the licensed patents (the &#8220;Licensed Products&#8221;) in exchange for low single-digit percentage royalties on future commercial net sales of the Licensed Products. Royalties are payable on a Licensed Product-by-Licensed Product and country-by-country basis until the latest of the expiration of the last licensed patent covering such Licensed Product in the country where the Licensed Product is sold, or, if no licensed patent exists or has expired in such country, then ten years from first commercial sale of such Licensed Product in such country. In connection with the license, Neurogene is also obligated to pay the University of Edinburgh up to $5.3 million in regulatory-related milestones and up to $25.0 million in sales-related milestones based on annual net sales of Licensed Products in excess of defined thresholds. During the year ended December 31, 2023, the Company expensed $0.3 million for a milestone related to the first patient dosing in the Phase 1/2 trial for Rett syndrome.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, Neurogene and University of Edinburgh amended the MCA. Under the amended MCA, Neurogene and University of Edinburgh agreed to continue collaborating on certain Projects and Neurogene agreed to provide funding for such Projects through December 2026, or an additional 33 months. Neurogene is obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the entire period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2025 and 2024, the expense recorded by the Company related to the MCA was $0.4 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Virovek</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Neurogene entered into a Non-Exclusive License Agreement with Virovek, Inc., pursuant to which Neurogene has a license to use certain patents and know-how on a non-exclusive basis related to Neurogene&#8217;s baculovirus (&#8220;baculo&#8221;) process in exchange for low single-digit percentage royalties on future commercial net sales of each product using the baculo process, development milestone payments of up to $0.2 million in the aggregate, and a nonrefundable annual license fee. During the three months ended March 31, 2025, no milestone expense was recorded. During the three months ended March 31, 2024, the Company recorded a milestone expense of $0.1 million for the Rett Syndrome Investigational New Drug filing. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Sigma-Aldrich Co</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Neurogene entered into a Non-Exclusive License Agreement with Sigma-Aldrich Co. LLC, pursuant to which Neurogene has a license to certain patents and know-how on a non-exclusive basis related to certain cell lines used in Neurogene&#8217;s baculo process in exchange for a small annual fee on a product-by-product basis, payable once the first product candidate enters the clinic. In addition, on a product-by-product basis, Neurogene is obligated to pay up to $2.5 million in the aggregate for development-related milestones. The Company recorded a license expense of $0.06 million for the three months ended March 31, 2025 and $0.06 million for the three months ended March 31, 2024.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Stanford</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into a Nonexclusive License Agreement with the Board of Trustees of Leland Stanford Junior University (the &#8220;Stanford License Agreement&#8221;) to license, on a non-exclusive basis, certain biological materials used by the Company in the manufacturing process of Neurogene&#8217;s product candidates, including NGN-401. Over the 10-year term of the Stanford License Agreement, the Company is obligated to pay up to $0.5 million in licensing fees. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expenses were recorded related to other in-process license agreements during the three months ended March 31, 2025 and 2024. None will be due under these agreements unless and until certain development milestones are reached.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Stockholders&#8217; Equity (Deficit)</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock and pre-funded warrants</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company&#8217;s board of directors approved the Neurogene Inc. 2025 Inducement Plan, which reserves for issuance up to 500,000 shares of common stock underlying inducement awards.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has pre-funded warrants outstanding to purchase an aggregate of 6,124,996 shares of common stock as of March&#160;31, 2025. The pre-funded warrants are exercisable at any time for exercise prices ranging from $0.000001 to $0.001, except that the pre-funded warrants cannot be exercised by a holder if, after giving effect thereto, such holder would beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. However, any holder may increase or decrease such percentage to any other percentage (not in excess of 19.99%) upon at least 61 days&#8217; prior notice from the holder to the Company. The holders of the pre-funded warrants will not have the right to vote the shares underlying the pre-funded warrants on any matter except to the extent required by Delaware law. These warrants were classified as equity. Information on the outstanding warrants is as follows: </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:29.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Type of Financing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.000001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425,987</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy pre-funded warrants outstanding</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.000001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,708,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023 Preferred stock conversion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.000001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,825,635</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023 Pre-Closing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,165,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2024 private placement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,124,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for future issuance as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,086,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,387,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2023 Equity Incentive Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,218,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,458,188</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2025 Inducement Plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future issuance under the 2023 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">321,770</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173,223</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-funded warrants outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,124,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,124,996</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total common stock reserved</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,782,754</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,618,617</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Stock-Based Compensation</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option activity:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,387,556</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">725,191</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,086,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.36</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">655,763</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.34</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the aggregate intrinsic value of outstanding options and exercisable options was approximately $0.7 million and $0.7 million, respectively. The aggregate intrinsic value of options exercised was immaterial for the three months ended March 31, 2025.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $12.78 and $25.97 per share for the three months ended March&#160;31, 2025 and 2024, respectively. The Company recorded stock-based compensation related to stock options of approximately $1.8 million and $1.0 million for the three months ended March&#160;31, 2025 and 2024. As of March&#160;31, 2025, the total unrecognized compensation expense related to unvested stock option awards was approximately $25.5 million, which the Company expects to recognize over a weighted-average period of 3.12 years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option was estimated on the grant date using the weighted average assumptions in the table below:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.99%-96.49%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.39%-87.64%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.97%-4.42%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.97%-4.32%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.60-6.96</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.77-6.08</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit (&#8220;RSU&#8221;) activity and related information for the three months ended March 31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSUs of approximately $0.6 million for the three months ended March 31, 2025 and $0.1 million for the three months ended March 31, 2024. As of March&#160;31, 2025, there was approximately $7.2 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 2.26 years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A summary of the Company&#8217;s performance stock unit (&#8220;PSU&#8221;) activity and related information for the three months ended March 31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:63.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSUs were granted with vesting in two equal tranches based on certain performance conditions. Each PSU entitles the holder to receive one share of the Company's common stock when the PSU vests. Stock-based compensation expense for PSUs will be recognized when it is probable that the performance conditions will be achieved. As of March&#160;31, 2025, the performance conditions underlying the first tranche of 126,062 PSUs were deemed probable of achievement for the first milestone and are currently considered probable to vest. The Company recorded stock-based compensation expense related to PSUs of approximately $1.6 million for the three months ended March 31, 2025. As of March&#160;31, 2025, the second tranche of 126,062 PSUs were not deemed probable of achievement and are not currently considered probable to vest. As of March&#160;31, 2025, there was approximately $7.5 million of unrecognized compensation cost related to PSUs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Segment Information</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODMs in deciding how to allocate resources and in assessing performance. The Company&#8217;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has one reportable segment. In addition to reviewing the expenses in the consolidated statement of operations, the CODMs are provided with research and development costs for Rett syndrome, Batten disease, Early Discovery and Discontinued Programs, as well as categorized general and administrative expenses. The research and development programs are considered significant by the Company. The CODM assesses the financial performance of the segment and decides how to allocate resources based on net loss on a consolidated basis. The measure of segment assets is reported on the consolidated balance sheets as total consolidated asset</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODMs also assess performance of the segment according to preclinical and clinical data, the stage of development of the research and development programs, along with program specific expenses and market conditions in the pharmaceutical and biotechnology sectors. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and 2024, the Company did not have any significant long-lived assets located outside of the United States. Information on the segment and reconciliation to net loss is as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:58.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program specific expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rett syndrome</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batten disease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early Discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated internal expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative specific expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional and consultant fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,921)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other expense segment items category within research and development expense is mainly comprised of: Consultant fees for programs not specified above, IT Software and network support and rent expenses. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other expense segment items category within general and administrative expense is mainly comprised of: Insurance, IT software and network support, market research, and tax expenses.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) included in net loss includes interest income, interest expense, other income and other expense.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Subsequent Events</span><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2025, the Company entered into an exchange agreement with existing stockholders to exchange an aggregate of 667,500 shares of the Company&#8217;s common stock for an aggregate of pre-funded warrants to purchase 667,563 shares of the Company&#8217;s common stock at an exercise price of $0.001 per share.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From April 1, 2025 until the financial statements were issued, the Company granted 7,695 options to employees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,647)<span></span>
</td>
<td class="num">$ (16,921)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2025, no director or officer (as defined in Section 16 of the Exchange Act) adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) as amended (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Rule&#8221;), or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Item 408(a) of Regulation S-K,  except as described below:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name &amp; Title</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date Adopted</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Character of Trading Arrangement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate Number of Shares of Common Stock to be Purchased or Sold Pursuant to Trading Arrangement</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Material Terms</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date Terminated</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stuart Cobb, Chief Scientific Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rule 10b5-1 Trading Arrangement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 27107 shares sold</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/17/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except as indicated by footnote, each trading arrangement marked as a &#8220;Rule 10b5-1 Trading Arrangement&#8221; is intended to satisfy the affirmative defense of the Rule.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table. This trading arrangement only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule. This arrangement also provides for automatic expiration in the event of death, a personal bankruptcy filing, public announcement of a merger, recapitalization, acquisition, tender or exchange offer, or other business combination or reorganization resulting in the exchange or conversion of the common stock of the Company into shares of another company, or the conversion of the Company&#8217;s securities into rights to receive fixed amounts of cash or into debt securities and/or preferred stock (whether in whole or in part).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ngne_StuartCobbMember', window );">Stuart Cobb [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Stuart Cobb<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">2/6/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">3/17/2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">404 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">27,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ngne_StuartCobbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ngne_StuartCobbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, these financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March 24, 2025.</span></div>In management&#8217;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2025, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December&#160;31, 2025.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining the incremental borrowing rate for calculating lease liabilities and related right-of-use assets and finance lease assets, clinical trial accruals, accrual estimates for all contingent value rights (&#8220;CVRs&#8221;), and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the value attributed to employee stock options and other stock-based awards. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines and presents operating segments based on the information internally provided to the Chief Operating Decision Makers (&#8220;CODM&#8221;) in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 280,&#160;Segment Reporting. The Company&#8217;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has one reportable segment. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information, </span>for further information related to the Company&#8217;s segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash&#160;and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with original maturities of 90 days or less at time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and are stated at fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#8217;s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of March&#160;31, 2025, the Company had $70.6 million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ContingentValueRightsPolicyTextBlock', window );">Contingent Value Rights</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the reverse merger, the Company entered into a CVR Agreement on December 18, 2023 with the Rights Agent named therein (the &#8220;CVR Agreement&#8221;) prior to Closing. Included in the CVR Agreement are three different types of CVRs: (i) the Lease CVR, (ii) the Intellectual Property CVR, and (iii) the Sales Tax CVR (each as defined in the CVR Agreement). The Company evaluated each of the CVRs to determine if they qualified as derivatives under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that since certain scope exceptions were met, the CVRs did not qualify as derivatives. Instead, the Company records a contingent consideration liability associated with the CVRs when payments are probable and estimable under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In assessing whether payments are probable and estimable, the Company considers the existence of or ability to enter into agreements with third parties or government agencies and the timing of potential payments. Refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on the CVRs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Exit and Disposals Costs</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exit and Disposal Costs</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the reverse merger and through early fiscal 2025, the Company has incurred costs to wind-down Neoleukin&#8217;s Phase 1 trial of the NL-201 study. This trial has ceased further development, and the Company has no plans to continue developing Neoleukin&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein technology. As a result, the trial&#8217;s activities do not provide the Company any future economic benefit. In accordance with ASC 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accrued the remaining costs incurred in the trial. The liability was classified as accrued expenses and other current liabilities in the condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net income attributable to the Company by the weighted-average number of shares of common stock outstanding during the period. In periods of losses, diluted net loss per share is computed on the same basis as basic net loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive. Outstanding pre-funded warrants as of March&#160;31, 2025 and March&#160;31, 2024 are 6,124,996 and 4,062,361 respectively. Pre-funded warrants are considered outstanding as of their issuance date and are included in basic and diluted net loss per share because they are fully vested and exercisable for nominal cash consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its condensed financial statements or disclosures.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which requires public entities to provide disaggregated disclosure of income statement expenses. Public entities are required to disaggregate, in a tabular presentation, each relevant expense caption on the face of the consolidated statements of operations such as the following expenses: purchases of inventory, employee compensation, intangible asset amortization, and depreciation. In January 2025, the FASB issued ASU 2025-01 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to clarify the effective date. The updated effective date for the Company to adopt ASU 2024-03 is for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2024-03 will have on its financial statement disclosures. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span> to expand the disclosure requirements for income taxes. Upon adoption, the Company will be required to disclose standardized categories in the rate reconciliation in both percentage and dollar amounts. ASU 2023-09 will also require income taxes paid to be disaggregated by jurisdiction, among other disclosure requirements. The Company adopted ASU 2023-09 for annual periods beginning January 1, 2025. The adoption does not have a material impact to the interim financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ContingentValueRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ContingentValueRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 420<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Costs Associated With Exit or Disposal Activities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the accrued liabilities activity recorded in connection with the wind-down of Neoleukin&#8217;s Phase 1 trial of NL-201 for the three months ended March&#160;31, 2025 is as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amounts Paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial wind-down costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 NL-201 Trial</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">209&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(109)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:13.5pt;text-indent:37.11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"></td><td style="width:66.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,086,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,475,458</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,530</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,617,916</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,950,112</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of Debt Securities, Held-to-Maturity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following table summarizes the Company&#8217;s investment securities as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:35.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized cost, as adjusted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,488&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments mature within the next 12 months.</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:35.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized cost, as adjusted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:54.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288,488&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:54.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,362&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid, and Other Current Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:68.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refunds and other receivables </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,796&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,422&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:69.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, bonuses and related benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued severance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental lease expense for the three months ended March 31, 2025 and 2024 was as follows (in thousands):</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:69.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock', window );">Schedule of Asset Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the contingent value rights liability in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.272%"><tr><td style="width:1.0%"></td><td style="width:41.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease CVR</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property CVR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Tax CVR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CVR liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Exercise Of Pre-Funded Warrants</a></td>
<td class="text">Delaware law. These warrants were classified as equity. Information on the outstanding warrants is as follows: <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:29.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Type of Financing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.000001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">425,987</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy pre-funded warrants outstanding</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.000001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,708,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023 Preferred stock conversion</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.000001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,825,635</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023 Pre-Closing</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock pre-funded warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,165,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2024 private placement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,124,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for future issuance as follows:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,086,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,387,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2023 Equity Incentive Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,218,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,458,188</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future grant under the 2025 Inducement Plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares available for future issuance under the 2023 Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">321,770</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173,223</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-funded warrants outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,124,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,124,996</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total common stock reserved</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,782,754</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,618,617</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations (in thousands):<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-Based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option activity:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price<br/>per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">term</span></div><div style="margin-top:10pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,387,556</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">725,191</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired/Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,086,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.36</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">655,763</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.34</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option was estimated on the grant date using the weighted average assumptions in the table below:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.468%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.99%-96.49%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.39%-87.64%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.97%-4.42%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.97%-4.32%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.60-6.96</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.77-6.08</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted stock unit (&#8220;RSU&#8221;) activity and related information for the three months ended March 31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:67.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of Share-Based Payment Arrangement, Performance Shares, Activity</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A summary of the Company&#8217;s performance stock unit (&#8220;PSU&#8221;) activity and related information for the three months ended March 31, 2025 is as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:63.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSUs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">252,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Results Of Operations by Reportable Segment</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and 2024, the Company did not have any significant long-lived assets located outside of the United States. Information on the segment and reconciliation to net loss is as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:58.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program specific expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rett syndrome</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Batten disease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early Discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated internal expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative specific expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional and consultant fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,647)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,921)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other expense segment items category within research and development expense is mainly comprised of: Consultant fees for programs not specified above, IT Software and network support and rent expenses. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other expense segment items category within general and administrative expense is mainly comprised of: Insurance, IT software and network support, market research, and tax expenses.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) included in net loss includes interest income, interest expense, other income and other expense.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Uncertainties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 22,647<span></span>
</td>
<td class="nump">$ 16,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="nump">20,774<span></span>
</td>
<td class="nump">$ 21,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">284,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and investments</a></td>
<td class="nump">$ 292,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash | $</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits', window );">Cash and cash equivalents, at or above FDIC insurance limits | $</a></td>
<td class="nump">$ 70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares) | shares</a></td>
<td class="nump">6,124,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,062,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, At Or Above FDIC Insurance Limits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 70,771<span></span>
</td>
<td class="nump">$ 136,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 71,110<span></span>
</td>
<td class="nump">$ 136,925<span></span>
</td>
<td class="nump">$ 150,479<span></span>
</td>
<td class="nump">$ 148,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Accrued Liabilities Activity (Details) - Phase 1 NL-201 Trial<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2024</a></td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Liability Adjustment</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Amounts Paid</a></td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at March 31, 2025</a></td>
<td class="nump">$ 187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ngne_Phase1NL201TrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ngne_Phase1NL201TrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Potentially Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">2,617,916<span></span>
</td>
<td class="nump">1,950,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">2,086,334<span></span>
</td>
<td class="nump">1,475,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">279,458<span></span>
</td>
<td class="nump">222,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">252,124<span></span>
</td>
<td class="nump">252,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost, as adjusted</a></td>
<td class="nump">$ 288,419<span></span>
</td>
<td class="nump">$ 307,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross unrealized holding gains</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross unrealized holding losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated fair value</a></td>
<td class="nump">288,488<span></span>
</td>
<td class="nump">307,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost, as adjusted</a></td>
<td class="nump">66,588<span></span>
</td>
<td class="nump">131,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated fair value</a></td>
<td class="nump">66,588<span></span>
</td>
<td class="nump">131,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost, as adjusted</a></td>
<td class="nump">221,831<span></span>
</td>
<td class="nump">175,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Gross unrealized holding gains</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Gross unrealized holding losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 221,900<span></span>
</td>
<td class="nump">$ 175,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">U.S. treasury notes</a></td>
<td class="nump">$ 288,488<span></span>
</td>
<td class="nump">$ 307,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">U.S. treasury notes</a></td>
<td class="nump">221,900<span></span>
</td>
<td class="nump">175,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">288,488<span></span>
</td>
<td class="nump">307,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">66,588<span></span>
</td>
<td class="nump">131,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">U.S. treasury notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">U.S. treasury notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_RefundsAndOtherReceivablesCurrent', window );">Refunds and other receivables</a></td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,203<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid and other current assets</a></td>
<td class="nump">$ 3,796<span></span>
</td>
<td class="nump">$ 3,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_RefundsAndOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refunds And Other Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_RefundsAndOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">$ 26,726<span></span>
</td>
<td class="nump">$ 26,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(11,919)<span></span>
</td>
<td class="num">(11,171)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="nump">15,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ngne_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">3,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ngne_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">6,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">15,396<span></span>
</td>
<td class="nump">15,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, cost</a></td>
<td class="nump">$ 1,403<span></span>
</td>
<td class="nump">$ 1,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ngne_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ngne_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ngne_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ngne_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">$ 749,000<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses on idle equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation, bonuses and related benefits</a></td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">$ 4,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">4,765<span></span>
</td>
<td class="nump">5,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent', window );">Accrued severance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,849<span></span>
</td>
<td class="nump">$ 9,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_AccruedSeveranceBonusAndRetentionCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Severance, Bonus, And Retention Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_AccruedSeveranceBonusAndRetentionCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance leases</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">$ 892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,803<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount', window );">Intellectual property total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions', window );">Intellectual property contingent value rights liability, current, deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_AssetAcquisitionContingentConsiderationCashPayment', window );">Asset acquisition, contingent consideration, cash payment</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions', window );">Asset acquisition, contingent consideration, covenant, minimum amount owed, net of deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_IntellectualPropertyCVRNettingMember', window );">Intellectual Property CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_SalesTaxCVRMember', window );">Sales Tax CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ngne_IntellectualPropertyCVRNettingMember', window );">Intellectual Property CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_AssetAcquisitionContingentConsiderationCashPayment', window );">Asset acquisition, contingent consideration, cash payment</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ngne_LeaseCVRMember', window );">Lease CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_AssetAcquisitionContingentConsiderationCashPayment', window );">Asset acquisition, contingent consideration, cash payment</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_April2024CVRLicensingAgreementMember', window );">April 2024 CVR Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage', window );">Collaborative arrangement, rights and obligations, eligibility to received net proceeds, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage', window );">Collaborative arrangement, rights and obligations, eligibility to received net proceeds, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_April2024CVRLicensingAgreementMember', window );">April 2024 CVR Licensing Agreement | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsReimbursement', window );">Collaborative arrangement, rights and obligations, reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_April2024CVRLicensingAgreementMember', window );">April 2024 CVR Licensing Agreement | License | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_December2023CVRLicensingAgreementMember', window );">December 2023 CVR Licensing Agreement | License | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_NewYorkHeadquartersLeaseMember', window );">New York Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_OperatingLeaseMonthlyPayments', window );">Operating lease, monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_NewYorkHeadquartersLeaseMember', window );">New York Headquarters Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_OperatingLeaseMonthlyPayments', window );">Operating lease, monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_NewYorkHeadquartersLeaseMember', window );">New York Headquarters Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_OperatingLeaseMonthlyPayments', window );">Operating lease, monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_HoustonLeaseMember', window );">Houston Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_OperatingLeaseMonthlyPayments', window );">Operating lease, monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_LesseeOperatingLeaseNumberOfRenewalTerm', window );">Number of renewal terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_HoustonLeaseMember', window );">Houston Lease | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_OperatingLeaseMonthlyPayments', window );">Operating lease, monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_HoustonLeaseMember', window );">Houston Lease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_OperatingLeaseMonthlyPayments', window );">Operating lease, monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_BlaineLeaseInSeattleMember', window );">Blaine Lease in Seattle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_LesseeOperatingLeaseNumberOfRenewalTerm', window );">Number of renewal terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_EastlakeLeaseInSeattleMember', window );">Eastlake Lease in Seattle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_AssetAcquisitionContingentConsiderationCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_AssetAcquisitionContingentConsiderationCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Covenant, Minimum Amount Owed, Net Of Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Maximum Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Reimbursement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Contingent Value Rights Liability, Current, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Contingent Value Rights Liability, Current, Total Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_LesseeOperatingLeaseNumberOfRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_LesseeOperatingLeaseNumberOfRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_OperatingLeaseMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_OperatingLeaseMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_IntellectualPropertyCVRNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ngne_IntellectualPropertyCVRNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_SalesTaxCVRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ngne_SalesTaxCVRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ngne_IntellectualPropertyCVRNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ngne_IntellectualPropertyCVRNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ngne_LeaseCVRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ngne_LeaseCVRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ngne_April2024CVRLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ngne_April2024CVRLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ngne_December2023CVRLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ngne_December2023CVRLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_NewYorkHeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_NewYorkHeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_HoustonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_HoustonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_BlaineLeaseInSeattleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_BlaineLeaseInSeattleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_EastlakeLeaseInSeattleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ngne_EastlakeLeaseInSeattleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Contingent Value Rights Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="nump">$ 1,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent value rights liability, non-current</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_LeaseCVRMember', window );">Lease CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent value rights liability, non-current</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_IntellectualPropertyCVRNettingMember', window );">Intellectual Property CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent value rights liability, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_SalesTaxCVRMember', window );">Sales Tax CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent value rights liability, current</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent value rights liability, non-current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_LeaseCVRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ngne_LeaseCVRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_IntellectualPropertyCVRNettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ngne_IntellectualPropertyCVRNettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ngne_SalesTaxCVRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ngne_SalesTaxCVRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_UniversityOfEdinburghMember', window );">University of Edinburgh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_UniversityOfEdinburghMember', window );">University of Edinburgh | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsTerm', window );">Collaborative arrangement, rights and obligations, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm', window );">Collaborative arrangement, rights and obligations, additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate', window );">Research collaboration and license agreement, option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_UniversityOfEdinburghMember', window );">University of Edinburgh | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Regulatory-Related Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_UniversityOfEdinburghMember', window );">University of Edinburgh | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Sales-Related Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsExpense', window );">Collaborative arrangement, rights and obligations, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_VirovekIncMember', window );">Virovek, Inc License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsExpense', window );">Collaborative arrangement, rights and obligations, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_VirovekIncMember', window );">Virovek, Inc License Agreement | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_SigmaAldrichCoMember', window );">Sigma-Aldrich Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000.00<span></span>
</td>
<td class="nump">$ 60,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_SigmaAldrichCoMember', window );">Sigma-Aldrich Co | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ngne_StanfordLicenseAgreementMember', window );">Stanford License Agreement | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_CollaborativeArrangementTermOfAgreement', window );">Term of agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Additional Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementRightsAndObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementRightsAndObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_CollaborativeArrangementTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_CollaborativeArrangementTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration and License Agreement, Option to Terminate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ngne_UniversityOfEdinburghMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ngne_UniversityOfEdinburghMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ngne_RegulatoryRelatedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ngne_RegulatoryRelatedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ngne_SalesRelatedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ngne_SalesRelatedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ngne_VirovekIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ngne_VirovekIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ngne_SigmaAldrichCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ngne_SigmaAldrichCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ngne_StanfordLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ngne_StanfordLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">10,782,754<span></span>
</td>
<td class="nump">9,618,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_PercentageOfOutstandingStockPerStockholderMaximum', window );">Percentage of outstanding stock per stockholder, maximum</a></td>
<td class="nump">0.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum', window );">Percentage of outstanding stock per stockholder, upon notice, maximum</a></td>
<td class="nump">0.1999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ClassOfWarrantOrRightNoticePeriod', window );">Class of warrant or right, notice period</a></td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">6,124,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,062,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ngne_A2025InducementPlanMember', window );">2025 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ClassOfWarrantOrRightNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ClassOfWarrantOrRightNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_PercentageOfOutstandingStockPerStockholderMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Outstanding Stock Per Stockholder, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_PercentageOfOutstandingStockPerStockholderMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Outstanding Stock per Stockholder, Upon Notice, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ngne_A2025InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ngne_A2025InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Schedule of Exercise Of Pre-Funded Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares', window );">Class of warrant or right exercise price of warrants or rights amount (in shares) | shares</a></td>
<td class="nump">6,124,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants | Legacy pre-funded warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares', window );">Class of warrant or right exercise price of warrants or rights amount (in shares) | shares</a></td>
<td class="nump">425,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants | December 2023 Preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares', window );">Class of warrant or right exercise price of warrants or rights amount (in shares) | shares</a></td>
<td class="nump">1,708,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants | December 2023 Pre-Closing</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares', window );">Class of warrant or right exercise price of warrants or rights amount (in shares) | shares</a></td>
<td class="nump">1,825,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants | November 2024 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares', window );">Class of warrant or right exercise price of warrants or rights amount (in shares) | shares</a></td>
<td class="nump">2,165,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ngne_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ngne_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ngne_December2023PreferredStockConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ngne_December2023PreferredStockConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ngne_December2023PreClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ngne_December2023PreClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Reserved Shares for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">10,782,754<span></span>
</td>
<td class="nump">9,618,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ngne_A2023EquityIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">1,218,072<span></span>
</td>
<td class="nump">1,458,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ngne_A2025InducementPlanMember', window );">2025 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ngne_A2023EmployeeStockPurchasePlanMember', window );">2023 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">321,770<span></span>
</td>
<td class="nump">173,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">279,458<span></span>
</td>
<td class="nump">222,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">252,124<span></span>
</td>
<td class="nump">252,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">2,086,334<span></span>
</td>
<td class="nump">1,387,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ngne_PreFundedWarrantsMember', window );">Pre-funded warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved (in shares)</a></td>
<td class="nump">6,124,996<span></span>
</td>
<td class="nump">6,124,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ngne_A2023EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ngne_A2023EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ngne_A2025InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ngne_A2025InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ngne_A2023EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ngne_A2023EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ngne_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ngne_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Operating Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">$ 4,048<span></span>
</td>
<td class="nump">$ 1,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,387,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">725,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/Forfeited (in shares)</a></td>
<td class="num">(24,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,086,334<span></span>
</td>
<td class="nump">1,387,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">655,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 28.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/Forfeited (in dollars per share)</a></td>
<td class="nump">35.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">24.23<span></span>
</td>
<td class="nump">$ 28.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 22.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding option intrinsic value</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, intrinsic value</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.78<span></span>
</td>
<td class="nump">$ 25.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 4,048<span></span>
</td>
<td class="nump">$ 1,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount</a></td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition</a></td>
<td class="text">3 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount</a></td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">2 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ShareBasedPaymentArrangementNumberOfTranches', window );">Share-based payment arrangement, number of tranches | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests', window );">Number of shares common stock holder to receive when restricted stock unit vests (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest', window );">Share-based compensation arrangement by share-based payment award, equity instruments other than options, probable to vest | shares</a></td>
<td class="nump">126,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest', window );">Share-based compensation arrangement by share-based payment award, equity instruments other than options, not probable to vest | shares</a></td>
<td class="nump">126,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Not Probable To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Probable To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ngne_ShareBasedPaymentArrangementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ngne_ShareBasedPaymentArrangementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ngne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="nump">93.99%<span></span>
</td>
<td class="nump">86.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="nump">96.49%<span></span>
</td>
<td class="nump">87.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.97%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.42%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Other Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">222,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">135,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(73,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(5,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">279,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">16.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">36.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">36.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 26.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">252,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">252,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 17,760<span></span>
</td>
<td class="nump">$ 13,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">8,159<span></span>
</td>
<td class="nump">5,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,647)<span></span>
</td>
<td class="num">(16,921)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ngne_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">17,760<span></span>
</td>
<td class="nump">13,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">8,159<span></span>
</td>
<td class="nump">5,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,647)<span></span>
</td>
<td class="num">(16,921)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_RettSyndromeMember', window );">Rett syndrome | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,524<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_BattenDiseaseMember', window );">Batten disease | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_EarlyDiscoveryMember', window );">Early Discovery | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_PersonnelRelatedExpenseMember', window );">Personnel-related | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">5,404<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_ShareBasedCompensationExpenseMember', window );">Stock-based compensation | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_ManufacturingExpenseMember', window );">Manufacturing | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">3,107<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Program specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_ProfessionalAndConsultantFeesMember', window );">Professional and consultant fees | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ngne_OfficeRelatedExpenseMember', window );">Office-related | Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative specific expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">$ 632<span></span>
</td>
<td class="nump">$ 604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ngne_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ngne_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_RettSyndromeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_RettSyndromeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_BattenDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_BattenDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_EarlyDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_EarlyDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_PersonnelRelatedExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_PersonnelRelatedExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_ShareBasedCompensationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_ShareBasedCompensationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_ManufacturingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_ManufacturingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_ProfessionalAndConsultantFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_ProfessionalAndConsultantFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ngne_OfficeRelatedExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ngne_OfficeRelatedExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 14, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,124,996<span></span>
</td>
<td class="nump">4,062,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="nump">667,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">667,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ngne_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &HZJ5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( &HZJ5JW+$]0\P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL]* S$0AU]%<M^=S1;%ANU>6CPI"!84;R&9
MMJ&;/R0CNWU[LVN[5?0!A%PR\\LWWT :%83R$9^C#QC)8+H9;.>24&'%#D1!
M "1U0"M3F1,N-W<^6DGY&O<0I#K*/4)=57=@D:26)&$$%F$FLK;12JB(DGP\
MX[6:\>$C=A-,*\ .+3I*P$L.K!TGAM/0-7 %C##":--7 ?5,G*I_8J<.L'-R
M2&9.]7U?]HLIEW?@\/;T^#*M6QB72#J%^54R@DX!5^PR^76QWFP?6%M7]6U1
MY;/<<B[X4O#[]]'UA]]5V'IM=N9_&=?5-^.+8-O KW_1?@)02P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    " !J.JE:[L3=W=H%  "K'P  &
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M^.#)8F>X.%%BE6^NSH12(LX/EYP%7.H'X/Y<"+4_T7^@W)\?_ ]02P,$%
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MZ&O*MY*6B5S8"MAH3#MN5[YO5B8C*[OH"R]5*M&OP" Y];=!12>%'*3<DTG
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M%&9R)K0!O%]SK@XW>H%NRH_^ U!+ P04    " !J.JE:)JER.SP%  #A'0
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M."V0:99=B%(-4V0%O:$D#AOB>T,;A6.B=X[L$"L=HT<1<4HELD6M7=4C8TB
M!&PWP\N-9 1A2#[$O81+^(QS"$QVCLWB,.JEL29M.)(H4#0-R?DJ^$:UQ@)9
M$9*$\+IN!2^[('YZ976HJ/_8QP^",_6S^=J9DC7R"5LR '%DE*EKPXYS OBA
MS;R2=JJDUE& 2#E-?0[8:,04>39VDX."<PN@(&9S646$.>(XP0K8$*F Q6D
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MI$7C!>B^U/0>_<8;&&;W^CM02P,$%     @ :CJI6MD"1C6? @  * 8  !D
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M2D.3Q2US&N6HK .=9U*:@V$#='\.\Y]02P,$%     @ :CJI6DP\_2<F P
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MC]H!Z'ZEE-T9+D#_%S+[ U!+ P04    " !J.JE:[)8=0?4.  "=,0  &0
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MJ#RL-=N(?+![;ETV8 ?HBJFJRKH"%"K;&\E?](U.:[S?L$[%>\#M9^/94:"
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MKQ*O/D-5R#$&^;3@REKEYC=H%!LAWB $(U^1[VR7/0VE7"]4VFP:;+LS'A(
M0Y]].P]V8V\2'5\V:4UU+WN"56F+X*RRQ0W;\2KYK/):2T[PW3Q1=&&=0&3\
MX)&GB1FY9$:?O,U-QD@T4SD;4SI^]"I@&]9KC-$V!*JEJB2Y0889FYG\%HX!
M>?A;)8OG*/6*15LC-00$ ,D@/VF;Z_J3*2*',=Y4QZKSN9:MW)NTLAQWHLBI
M9!+HAC@U( V.X/WLAU+7'P+<)B:=IB9E)GOS?G(>LL/GU"JLX95OA?3F3_'
M\6CTCV9%\D+PG6J===P0DS$P;-.E40*S9 &I0F&]F]PSX[G"#G&\JV"4U?<E
M\S=.RS6$IS)$\@NGNT8BW]^BS304I[OFE8KK4L3Y.XE"_D'9 <[#E9R:5XU)
M1;)>,7'0%=H$_;R-RKZ 772,OFAWO0<LY2B&"B#"3+<88()C=JBH6X(OU@3]
MJ*9('R;O])R$E,6[79$IL_(*95C!LK=,$?GKTIE<LLNA80A<+\CHP3VR%H=8
ML[-"7:M,WL 2-H.\P>F8IJ,76[O#D3<\DNNWJ,&CH-%5HP]M-1Z@W(9$6\Z!
MV;C6>"J <P>J@%8H3UEMO#%TJ>&$LITK6EZ"UW;=[2@A6]=[V78LSP;,7HE@
M:[>0H3#;23*:XS)T_&*I*Z78X8S4*HNV$D6MFU@*N:E-++',\MMUUGM#KGF\
M%Q(/=R)1$U&"O1(F7X*^?:0ZFCG)<,?)0:D;3N#[FU:G%W4NNYYMOQ$(@2DT
M=;@T-;=0(Q'1NN0MQ58E,6V[R ,RUAIQ1'^=W:B\VG0J^A=V33O!08",[1*E
ML*%RWMYP>05>NAQ)PRA=&DVZ*RQ-T;1/BA!%O0IYSU3JF#V/U.\1^$-=QCCJ
MMB9C-]8+?M@B3=D@#4+2+(I5#Z2:V!>M_,4 <+?$O>@_)'J,<46)[CZ2A-Z'
M#3N-I,M>*\YILYHAI\8=T[WQB,]CN'V!27@:-CN^8]R[98!ENTWM+<X%</K<
MW(T^^PK<8W#H"!_; :$[:XCC,>GR6$@Z1JL?CI/G+P>CSJG WP",CM7LGUHW
MI9;1!S;.X_%0VS'@_? MQ="'.$BM>*8D^JL8,!GBHY7P\(9FS7J?TS$1RH'#
M)Y-,$)8NJ4U946PA1NM0][4+O9:RO*^-=K]%*@#5\UZ)P?N 3ET<(\;35B"M
M/84UEY:'=M4@V1[$F4[1TD>(OW#OK)SQ\9A0].D/JBO(>M@H[4X;*$4U<R9E
M]J^U;ON -##$$>",P^&#NN''7U8$%[NI[I;-L]/SFD\,5;[QT#7=:*!F/=FE
MT\9GY U16JD;MEQK3>GGSDW1MU%G)_61;<37@A):)(W;00NZJ,K?R\4A>O0>
M*9O/3#'O6B*);/$6MN)["X/=OFE__Q6ZAJ+W8T#[,%*3-K%\:DI)0(T"&KWQ
MH!T]L;*Y]V_#X*IV\)2YR:5.;VU7-K:-;9;],6$D;6V#((O8S;>\]VSDBC+M
M9[.!IQVIR)Z!$-R=QT12NY%]2QB?=<,8J.CJ/] ,ZP4E3>E'R>VE0R^^AQ)6
MH7#J'FQO%UXKE4E9,3?.5]T@99NU2ABP$T&6IH"2GA9TT#FZV\%* '1NVC;"
M80C9Z:OOF1T;JY3[@4[-X9/3O@R-MT[S09*.=*9YI!R2<ABBRO5!F<%*_G@S
M?8$=]E8)+&O,S<WQP$[O?&O2[H3GH3OQDRWN-Y_W/6O[T?>2L[,I?C^87M+G
MZ05]'E_>8I;)U3E7^N/)H][GOF=.+T;Q3?>SM,EI1*N]>\EX,+JZC%S0MW'@
M V%6[F]75COUPUK\HN>A4M9V,E>;S@ZG_$&RHM"8<3^8NJI5WXW)^> #-$?U
MXJ/L9BW-%S4BZ]*7O:8V&9>#\8B\WM^0;0]AFY9<%P3W=<[V^!2M)-V&HG>=
M([VKX2=W169:%[$4Z1^D,59JB@=NB"\/=O7BD;^M*SK'.BPPE,T]:*=+.M)!
M@,IY=$+9,#^D4[G]D_V'+%;QK23RAA9Z^<#6 ZJ0X3W2[3#Y?E7F5@QVW;;Q
MNL*1[+H=)7N)@CJ\O3Y;Z-1_TAOBU-,!2RY7QC(&;:Q,: )($.5RU4][!88#
M.I,)V^K4N+1>(4,5<F? Q](B($L'S[I\14:&R1MVJG?=X^;O.AN.:\=V$*[W
MYZZJIP#>>1;9/GF#*E D@-?FUI=%K0%Y0RT5M$ %"*=K.LQU*D=%CA*' DON
M"@@\;K:R.9:8CBB*@!N9VF!51Q%;4#" ]@#^0+<")8[6AD]/,[IO1C[Z"BZ^
M:-7]2B\$P"B3TVE9S\Z&3VW^ \WRI:W^5 G3-%=F%:2@;!S/87GO3^4;JC4G
M]SYG-9(U.!LFORQ-+E%!/K.2 JDY(4 @1-WFS!\&\$U/*(<"GF_9%I4TTYM[
M%3KKFRBS""4:3=F7!&C*HKAB]Q2"PW6IZ.R<5D-<85DYG:)=@^$^-C'HVS-4
M(T AH#'HOF_;$&3S%$56,J?3WLYFN"^8XHT @1&+51<EW25-JX@7'3/X3BU<
M%R%$*'T/$A].ZM=+0SX.HC.]L?U+GMU=3^5LSJ6:K]/E0-"P\<!"+D5(+$;E
MS?DZ:8 JWF_S53# 45KGRO7$$J62";85JS*YI](J>!^#>[1\E)+W7;H^[5R9
MYX,E^L< T@&P4&[/QZ?Q?P^NY<I].US^<0&XL*#.2J[GF#H:/C@_D8JG^5+9
MDB_@SVQ5V15_I/O*VM$ O)];;'#"%UH@_D?&T_\"4$L#!!0    ( &HZJ5I*
M'88N%PD  &(;   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;,U9:V_C
MN!7]*X1WL=@"?L5)9J<S28 DDVUW,4F#R>RV0-$/M'1MLR.1*DG%<7]]SR4I
M67[.HRC0+XE,\K[/?5"Z6!K[R2V(O'@I"^TN>POOJS>CD<L65$HW-!5I[,R,
M+:7'3SL?N<J2S -168PFX_&K42F5[EU=A+5'>W5A:E\H38]6N+HLI5W=4&&6
ME[V37K/P0<T7GA=&5Q>5G-,3^=^J1XM?HY9+KDK23ADM+,TN>]<G;V[.^'PX
M\+NBI>L\"[9D:LPG_O%+?MD;LT)44.:9@\2_9[JEHF!&4.-?B6>O%<F$W>>&
M^\_!=M@RE8YN3?%7E?O%9>]U3^0TDW7A/YCEGRG9<\[\,E.X\%<LX]G3<4]D
MM?.F3,30H%0Z_I<OR0\=@M>'"":)8!+TCH*"EN^DEU<7UBR%Y=/@Q@_!U$ -
MY93FH#QYBUT%.G_U7F7P,+F+D0<W7AMEB?(F4DX.4)Z*>Z/]PHD[G5.^23^"
M%JTJDT:5F\E1AO?2#L7I25],QI/S(_Q.6]-. [_3XZ:)Z[DE HZ\$W^_GCIO
M@81_[+,WLCO;SXZSXXVK9$:7/<#?D7VFWM4/WYV\&K\]HNQ9J^S9,>Y'X_!E
ME&+'7D#)+\3'!8G?-*!OG?(K86;B+E=Z6MOY0ORBQ3O*J)R29:^/^\)OGKXU
MM?5,XX]P^9$W?_CN]60R?GO@3-@]>?L'(74N'JBV9DZ:!)0D2[E0VIL@XEXZ
MK$!L4<BIL3)D[MJ@'Y.4^]OKAN,0:N4@"=2WU_T.=Y9U3&_)?''$B*R51P("
M,[(>]4QPF*7-%H%33L\H8570H[+FGR@KKE7H,2T<L',M"93/*B<QJS7TF N4
M511$B&@XA!4ISL:#DM,+KE%>R4+ +65?+!<*9_E9+*43].*)LP^GQ(-Y;@-Y
M&KF@Z.6Y8A^"P>FI*&/"LFZE7(DIJV'A(;MF-%V)LO8USLO&ZT.&";UD"ZGG
MM%8X6; #F0T7SZU$B+NNX-.F"G&%.\"VJ!UHBY4H$GZE7C$@4*CA#]8$/JL0
MD9605KG@-&O*3:]!QUD75R]D,\5)(?5:1B,W>KB2UJNL+J1MN'2QLU1%$>$9
MP2F%(U P0-;\6HU;@(*[0@S-4H<@N9B"1SQT!+X*?*:%FDN?H(.0.2K50&K-
M;E':>5D4$9!R%2N<I0)) Q^!H,$8Y&7&)6C!D\YH346  5"//8V6+*<%Q1.L
M2@L_'%<F'XH[%7#"3EL%\+!Y2K,_DNJ!%KR>22O2&8FZ@C?^.!:Y7(6\./GI
MK= &/J>M:+6LW-H-"M7+U$7.($4:@I53T##&#J'11@\R"3&<N%B/!K))F2E+
MY3O>B-YC5.V&/%#P5O@/OHW/U@X+A,%I8< (#M4;Z L)<A\*!7)OTM\#Q#S"
M(N%^84T]C[#(-BI=W<5"T&FC0LH]-;Y;?-<Z=%)PAZ2M49_#9E]4M74U,I@=
M&$O/VK0$_KRMEA5<K5,0/FFS'"RX!:XCP)+N_G9]^Q$!SQ;:%&8>_<YN*=6_
M<>K^[O9Q(C+I''F& X]MW03&_*7<1LI\D<7=B)@I*TOY!N,^A[;(EUR9FZ1.
M&K=F-N9A/;6"/A)!US.,$[4%"U=75;'"?V"RWT*1XR\+6!>!9$U><Y7W"^E%
M[578V2NG&]CWS>9CHF]CJ+9*,X9LP36RH$&NYL@B0!>T'@.VL&8E"Z^B7V<U
M:]U146A< 9SD*I#Z_8[4H?C0LI @1M4)R<=AVCD]F*X&VVO)*[7V=L7[Z3'&
M%>B'/Z(SN!BT<P>]5"HE2%HI,"9L>PQ\ 6).SY";.Z*53@D712Y1SFBOF5QX
MG2GROC 6A6B&6K,CBUX4UP<X?!':,!2,73C(3C)":^1&H,4*<X2+?6NFK/-=
MO[//V;"#:G=YAEJ3<0&/MYHVAY.&6PU$%L[L=I%C';NN^-3WYT.,"^B!+"-,
M0G.436\0MB:CL8L8&4TQXQ/=Y'PX[A(&0.VCX:M4'A,\=+,-].T@+^&<7-C&
MK2ND, HIN05"!62^JT/LV31VMHCC3#O=IGO%:1Q7;DU9<3HB<%'.]^..O7$^
M:'7=KF$Q@ ""8B3D)HPD"5V/@ .)D]%$>,NQ958?4,N$6^D<T:<0OXU1;7MB
M/3BMEM&DU!VZ5;#9VC/_?LGLB[33]48KBCVN*>SM:/KM0VW3\KJWC5><8(>&
MU.'_R2 $7HHK71J#?D[+C#QJYNGD_-"*FOMK8(J'LWY3PD)3L909F^;L+A"W
M(,;=G^=[P/*LA25S["[TPV!$X;5&@<)PX/[WNT)TZ!/C[HDJW[WL';B(20!4
M#^[:KGN<<1^<L^'Q68&+I.QVUAK_CLX-H:7PD+?5_+N>:OFGZ9*+"J8[8-'6
MZZM97&L;)K :RLC_JG&2A.6IS</,IB9%+1KI_8W;Y+K2M.@%HU10Q\-)MYZ&
M=)\C$)P-<<H(?K+$( _=.&5%X^T9T49U_"QT^]SPUCHUT&4\-O#]*H9G_2VH
MIQ20>X3 ;EA\LE&*F3C4T*=40P&X9]!Q08A5XX&6XIVM47@P3^GYP51X4O-2
M#JZ+W#(\;PWGQ*\8X23F@>U2_"T9L<T?BKR__<K,^*^SHF' 5R/!+XL<9UM\
M17 @80XF!6Z])=^*$J0 I:A"M1[Q&J@'/?J=D3"C;K=,IW!ERU4>;M'LWWCA
MRZ"ERD)G;%I!_W-RCG>'9A@9GA_,G6!?)POWS"C#\.YL#VZ;<&VB=OQJ![9?
MUB:^C?;L,,R]U."2LT.OZWD-_^^FX2Z^Z7/P9O(;(\$8!G]$C?64QC6X#G:T
M<G^MM8(5G=FC>YEICQV^F7JSGF</8;[?(GVJ^"ZI,B"T1 AY\$J8W^JR"0/K
M6QN7L ;[9K8G/W9P"[%*0X\P3SS\Z6%P-CX9BK\\ITGL9#P(TV=X0Y<N*X?M
MW8S($2"/-X$<?1,F+6*8/I@&BDXL^5K38K53%TQX@:/TH#%XY^V5$_E7M(EV
MPAD&\,0W9E,"#UJ_Q]AD7^N"!8?K0KCK-1'<VPWC'=-R0T7'V?>.?=3Y[H%F
M/ ]?=UR\*L5/(.UJ^P'I.GXW61^/7Y]@VQQSI"AH!M+Q\*?SGK#QBT[\X4T5
MOJ),C?>F#(\+DC"3#V!_9HQO?K" ]K/:U7\ 4$L#!!0    ( &HZJ5H8N<J,
M<04  $ -   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*57:V_;-A3]
M*Q=>5[2 :DOR.TT,)&F+%EB[H&FW#\,^T!)E<Y5$E:3L^-_O7$J6G=;)UJT(
M*E+B/??<-WV^U>:+74OIZ*[(2WO16SM7G0T&-EG+0MB^KF2)+YDVA7#8FM7
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M:WKH?N-TY>_(2^UPX_;+-7[B2,,'\#W3:+3MAA5T/YH6?P-02P,$%     @
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MLC1Z_+*D68_:.=#Y1BF[,UR [N^Q^ =02P,$%     @ :CJI6@&^$V-# @
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M!*^DXX7\UZM!0/&UEE8V+SXN?%6&3;%%TTB0"K7/IZ2V6$VLI45**(G:DFH
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MVS37+,V+TY6_VDBTPV;,/^; L1FB"3A./?GFA11TEUV+_P!02P,$%     @
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M=K72GM&I/7OZ_CJ?"L"$S@'*K7KVT54$4NPZY"1S):YN-@,ZV*O=EBRMJ&S
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M$MT!( A4#%[8K=OS;2Q4D99A,6]N^1U4I.OFXB3T/%;\7Z$2,)\RA,YQ2*W
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M43L%>E\I9?>"<]#^&TS_ %!+ P04    " !J.JE: 5I!4:<#  "F"   &0
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MU$Z!]G=*V>/$'=#]-5G\ U!+ P04    " !J.JE:*WOW)Q8$  #&"0  &0
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MB.2NNE=#-S"R;F_JI31T[[?=G!Y:J.P"FL^D-"\#ZV!XNLW_!5!+ P04
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MK'TGV) ,F =*QXZ_T$LY\708/:7OC<S20;.I?.L>3*'^T/;]C-8->N'W@\%
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M,J7+1ND:0XN-4Y>5T$:KW+(P/P>4UL&<YT+HO6$3M+^;Y ]02P,$%     @
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M O3[%==3N[S)#AFK0^7@?U!+ P04    " !J.JE:^S:X4JX"   Y!P  &0
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M)ZIBWC3J9B)997K=FDG5.<TP5_\VX#I [6>,R=>);I_=WS+^"U!+ P04
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M(/#)7*J2&MRJA:\K!31WH)+[81 ,_)(RX:6)BTU5FLBEX4S 5!&]+$NJ7D;
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MQ0.Z63Q F\6H9J&:C6H.JKFHYJ&:CVH!JH6H)E M0K68TM1@,=M@T3>+ZRO
MY-5AS-,QS&15E-E<YJ?ZCRO5FT=GB[GS<OC%=A_90J>T4<U!-1?5/%3S42U
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MLLK3\KLQE<NL2#LOZJ$GCHX-M%.*:C:J.:CFCG;;L]LO*7OHC#ZJ!:@6HII
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M\^;AG+.$BWH#]?O'LI3K)W4#FUMM7?T/4$L#!!0    ( &HZJ5KK+_IF!00
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MGPG1;#$U)XI7]1[*$U>*%_7A$E@*P@S0]^><J]<3XZ#;Z)O^"U!+ P04
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M\( A86C>@SOOHV#SG@J:_V:._P!02P,$%     @ :CJI6I>*NQS     $P(
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ :CJI6IE<G",0!@  G"<  !,
M             ( !Y0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !J.JE:[L3=W=H%  "K'P  &               @($F"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ :CJI6E8+TE[U!0  #1H  !@
M             ("!-@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( &HZJ5J"M5$O"0,  (T*   8              " @6$4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !J.JE: WOO7S $  #Q
M#P  &               @(&@%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ :CJI6B:I<CL\!0  X1T  !@              ("!!AP
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &HZJ5JK6'+(
M9@<  )P@   8              " @7@A  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " !J.JE:FXEXWO,$   ?"P  &
M@($4*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ :CJI
M6H10?*K[!@  EA   !@              ("!/2X  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( &HZJ5HU8.^C[0\  *$J   8
M      " @6XU  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &HZJ5H6E_P7N0(  $X&   9              "
M@8Y2  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ :CJI
M6NR6'4'U#@  G3$  !D              ("!?E4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " !J.JE:2AV&+A<)  !B&P  &0
M        @(&J9   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( &HZJ5H8N<J,<04  $ -   9              " @?AM  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ :CJI6C:O<FYE!P  B!4
M !D              ("!H',  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " !J.JE:Q;Y)4UT&  !P#P  &0              @($\>P
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &HZJ5J1VP6Y
MQP(  $D&   9              " @="!  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ :CJI6@&^$V-# @  F@4  !D
M ("!SH0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !J
M.JE:]P1[I%(&  #X$@  &0              @(%(AP  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &HZJ5IYCW[>3@T  *PD   9
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M970R-RYX;6Q02P$"% ,4    " !J.JE:IZQ)NNH"  !W!@  &0
M    @('DJ0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M &HZJ5K,HU ^R0(  !D&   9              " @06M  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ :CJI6@%:05&G P  I@@  !D
M             ("!!;   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " !J.JE:*WOW)Q8$  #&"0  &0              @('CLP  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &HZJ5KW9[W+D04
M -$/   9              " @3"X  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ :CJI6B1X)MB4!   2 H  !D              ("!
M^+T  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !J.JE:
M2[O3RB<#  #F"0  &0              @('#P@  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( &HZJ5K-4Q='S0,  '$.   9
M      " @2'&  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ :CJI6I*7F-3, @  D D  !D              ("!)<H  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !J.JE:S*&K1+<"  !Z!@
M&0              @($HS0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( &HZJ5H.%C1 AP,  )H/   9              " @1;0  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ :CJI6J'4K8#C
M P  G!   !D              ("!U-,  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " !J.JE:=HK(J/\#  !@%@  &0
M@('NUP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( &HZ
MJ5K[-KA2K@(  #D'   9              " @23<  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ :CJI6I]?&K<$!   I18  !D
M         ("!"=\  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    " !J.JE:,JGS"Y,"  "(!@  &0              @(%$XP  >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &HZJ5I:L[1,U0(  ,('
M   9              " @0[F  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
M4$L! A0#%     @ :CJI6K>00"D> P  ZPD  !D              ("!&ND
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !J.JE::S[Q
M:W 2   -.@$ &0              @(%O[   >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+ 0(4 Q0    ( &HZJ5KC@![*80,  !$0   9
M  " @1;_  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M:CJI6B+_O,AC"   =FL  !D              ("!K@(! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " !J.JE:ZR_Z9@4$   @$P  &0
M            @(%("P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( &HZJ5K$J :&U0,  "T3   9              " @80/ 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ :CJI6G@MX71*!
M%A@  !D              ("!D!,! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " !J.JE:)!G:T1T#  !J"P  &0              @($1
M& $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &HZJ5J*
M/ "#+00  !,3   9              " @64; 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ :CJI6N7M.<'#!0  =B   !D
M     ("!R1\! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M" !J.JE:X<PHJ<<#  #F$   &0              @('#)0$ >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( &HZJ5K..ZE6!P0  /T2   9
M              " @<$I 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L!
M A0#%     @ :CJI6MQ@+A&G!@  BRX  !D              ("!_RT! 'AL
M+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !J.JE:8YKT"4\$
M  #T&P  &0              @('=- $ >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;%!+ 0(4 Q0    ( &HZJ5H;42X<2 ,  -H4   -              "
M 6,Y 0!X;"]S='EL97,N>&UL4$L! A0#%     @ :CJI6I>*NQS     $P(
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9>&UL4$L%!@    !" $( !1(  +-& 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>168</ContextCount>
  <ElementCount>262</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statement of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/RisksandUncertainties</Role>
      <ShortName>Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets</Role>
      <ShortName>Prepaid expenses and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Licenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/Licenses</Role>
      <ShortName>Licenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/Investments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Prepaid expenses and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables</Role>
      <ShortName>Prepaid expenses and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/CommitmentandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/SegmentInformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/RisksandUncertaintiesDetails</Role>
      <ShortName>Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/RisksandUncertainties</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Summary of Accrued Liabilities Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Accrued Liabilities Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Potentially Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Potentially Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/InvestmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails</Role>
      <ShortName>Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Property and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Commitment and Contingencies - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails</Role>
      <ShortName>Commitment and Contingencies - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Commitment and Contingencies - Contingent Value Rights Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails</Role>
      <ShortName>Commitment and Contingencies - Contingent Value Rights Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Licenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/LicensesDetails</Role>
      <ShortName>Licenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/Licenses</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Stockholders??? Equity (Deficit) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stockholders??? Equity (Deficit) - Schedule of Exercise Of Pre-Funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Schedule of Exercise Of Pre-Funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stockholders??? Equity (Deficit) - Reserved Shares for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Reserved Shares for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stock-Based Compensation - Summary of Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Stock-Based Compensation - Summary of Other Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Other Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/SegmentInformationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ngne-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurogene.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurogene.com/role/SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ngne-20250331.htm">ngne-20250331.htm</File>
    <File>ngne-20250331.xsd</File>
    <File>ngne-20250331_cal.xml</File>
    <File>ngne-20250331_def.xml</File>
    <File>ngne-20250331_lab.xml</File>
    <File>ngne-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ngne-20250331_g1.jpg</File>
    <File>ngne-20250331_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="516">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ngne-20250331.htm": {
   "nsprefix": "ngne",
   "nsuri": "http://www.neurogene.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "ngne-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "ngne-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ngne-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ngne-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ngne-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ngne-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 231,
   "keyCustom": 31,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 35,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 1,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "contextCount": 168,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 535,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 516,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 11
   },
   "report": {
    "R1": {
     "role": "http://www.neurogene.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity",
     "longName": "9952154 - Statement - Condensed Consolidated Statement of Stockholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statement of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.neurogene.com/role/OrganizationandDescriptionofBusiness",
     "longName": "9952156 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.neurogene.com/role/RisksandUncertainties",
     "longName": "9952157 - Disclosure - Risks and Uncertainties",
     "shortName": "Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.neurogene.com/role/Investments",
     "longName": "9952159 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.neurogene.com/role/FairValueofFinancialInstruments",
     "longName": "9952160 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets",
     "longName": "9952161 - Disclosure - Prepaid expenses and other current assets",
     "shortName": "Prepaid expenses and other current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.neurogene.com/role/PropertyandEquipmentNet",
     "longName": "9952162 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952163 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.neurogene.com/role/CommitmentandContingencies",
     "longName": "9952164 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.neurogene.com/role/Licenses",
     "longName": "9952165 - Disclosure - Licenses",
     "shortName": "Licenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.neurogene.com/role/StockholdersEquityDeficit",
     "longName": "9952166 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.neurogene.com/role/StockBasedCompensation",
     "longName": "9952167 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.neurogene.com/role/SegmentInformation",
     "longName": "9952168 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.neurogene.com/role/SubsequentEvents",
     "longName": "9952169 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.neurogene.com/role/InvestmentsTables",
     "longName": "9955513 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:HeldToMaturitySecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:HeldToMaturitySecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.neurogene.com/role/FairValueofFinancialInstrumentsTables",
     "longName": "9955514 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables",
     "longName": "9955515 - Disclosure - Prepaid expenses and other current assets (Tables)",
     "shortName": "Prepaid expenses and other current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.neurogene.com/role/PropertyandEquipmentNetTables",
     "longName": "9955516 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9955517 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.neurogene.com/role/CommitmentandContingenciesTables",
     "longName": "9955518 - Disclosure - Commitment and Contingencies (Tables)",
     "shortName": "Commitment and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.neurogene.com/role/StockholdersEquityDeficitTables",
     "longName": "9955519 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.neurogene.com/role/StockBasedCompensationTables",
     "longName": "9955520 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.neurogene.com/role/SegmentInformationTables",
     "longName": "9955521 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.neurogene.com/role/RisksandUncertaintiesDetails",
     "longName": "9955522 - Disclosure - Risks and Uncertainties (Details)",
     "shortName": "Risks and Uncertainties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InvestmentsAndCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ngne:CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Summary of Accrued Liabilities Activity (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Accrued Liabilities Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Potentially Antidilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Potentially Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.neurogene.com/role/InvestmentsDetails",
     "longName": "9955527 - Disclosure - Investments (Details)",
     "shortName": "Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955528 - Disclosure - Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails",
     "longName": "9955529 - Disclosure - Prepaid expenses and other current assets (Details)",
     "shortName": "Prepaid expenses and other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ngne:RefundsAndOtherReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ngne:RefundsAndOtherReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails",
     "longName": "9955530 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails",
     "longName": "9955531 - Disclosure - Property and Equipment, Net - Narrative (Details)",
     "shortName": "Property and Equipment, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9955532 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails",
     "longName": "9955533 - Disclosure - Commitment and Contingencies - Lease Costs (Details)",
     "shortName": "Commitment and Contingencies - Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
     "longName": "9955534 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
     "longName": "9955535 - Disclosure - Commitment and Contingencies - Contingent Value Rights Liability (Details)",
     "shortName": "Commitment and Contingencies - Contingent Value Rights Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.neurogene.com/role/LicensesDetails",
     "longName": "9955536 - Disclosure - Licenses (Details)",
     "shortName": "Licenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-98",
      "name": "ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
     "longName": "9955537 - Disclosure - Stockholders\u2019 Equity (Deficit) - Narrative (Details)",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ngne:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ngne:PercentageOfOutstandingStockPerStockholderMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails",
     "longName": "9955538 - Disclosure - Stockholders\u2019 Equity (Deficit) - Schedule of Exercise Of Pre-Funded Warrants (Details)",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Schedule of Exercise Of Pre-Funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
     "longName": "9955539 - Disclosure - Stockholders\u2019 Equity (Deficit) - Reserved Shares for Future Issuance (Details)",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Reserved Shares for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ngne:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ngne:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails",
     "longName": "9955540 - Disclosure - Stock-Based Compensation - Summary of Operating Expenses (Details)",
     "shortName": "Stock-Based Compensation - Summary of Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails",
     "longName": "9955541 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955542 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails",
     "longName": "9955543 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails",
     "longName": "9955544 - Disclosure - Stock-Based Compensation - Summary of Other Awards (Details)",
     "shortName": "Stock-Based Compensation - Summary of Other Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-136",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.neurogene.com/role/SegmentInformationDetails",
     "longName": "9955545 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.neurogene.com/role/SubsequentEventsDetails",
     "longName": "9955546 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ngne-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ngne_A2023EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "A2023EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Employee Stock Purchase Plan",
        "label": "2023 Employee Stock Purchase Plan [Member]",
        "documentation": "2023 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_A2023EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "A2023EquityIncentivePlanMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Equity Incentive Plan",
        "label": "2023 Equity Incentive Plan [Member]",
        "documentation": "2023 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_A2025InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "A2025InducementPlanMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Inducement Plan",
        "label": "2025 Inducement Plan [Member]",
        "documentation": "2025 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r652"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization and accretion of premiums/discounts on held-to-maturity investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ngne_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research And Development, Current",
        "documentation": "Accrued Research And Development, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_AccruedSeveranceBonusAndRetentionCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "AccruedSeveranceBonusAndRetentionCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued severance",
        "label": "Accrued Severance, Bonus, And Retention Costs, Current",
        "documentation": "Accrued Severance, Bonus, And Retention Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r127",
      "r495"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r652",
      "r914"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid- In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r776",
      "r777",
      "r778",
      "r779",
      "r854",
      "r915"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r337"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r688",
      "r698",
      "r730"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r733"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r726",
      "r734",
      "r738",
      "r746"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total expense",
        "terseLabel": "Share-based payment arrangement, expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r371"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ngne_April2024CVRLicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "April2024CVRLicensingAgreementMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2024 CVR Licensing Agreement",
        "label": "April 2024 CVR Licensing Agreement [Member]",
        "documentation": "April 2024 CVR Licensing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of real estate property",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r851",
      "r852"
     ]
    },
    "ngne_AssetAcquisitionContingentConsiderationCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "AssetAcquisitionContingentConsiderationCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, contingent consideration, cash payment",
        "label": "Asset Acquisition, Contingent Consideration, Cash Payment",
        "documentation": "Asset Acquisition, Contingent Consideration, Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, contingent consideration, covenant, minimum amount owed, net of deductions",
        "label": "Asset Acquisition, Contingent Consideration, Covenant, Minimum Amount Owed, Net Of Deductions",
        "documentation": "Asset Acquisition, Contingent Consideration, Covenant, Minimum Amount Owed, Net Of Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value rights liability, current",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value rights liability, non-current",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Asset Acquisition, Contingent Consideration",
        "label": "Asset Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r30"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r101",
      "r129",
      "r150",
      "r177",
      "r184",
      "r209",
      "r213",
      "r256",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r385",
      "r387",
      "r422",
      "r490",
      "r560",
      "r622",
      "r623",
      "r652",
      "r669",
      "r816",
      "r817",
      "r867"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r135",
      "r150",
      "r256",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r385",
      "r387",
      "r422",
      "r652",
      "r816",
      "r817",
      "r867"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r641"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r882",
      "r883"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r282",
      "r882",
      "r883"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_BattenDiseaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "BattenDiseaseMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Batten disease",
        "label": "Batten disease [Member]",
        "documentation": "Batten disease"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_BlaineLeaseInSeattleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "BlaineLeaseInSeattleMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blaine Lease in Seattle",
        "label": "Blaine Lease in Seattle [Member]",
        "documentation": "Blaine Lease in Seattle"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r125",
      "r608"
     ]
    },
    "ngne_CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents, at or above FDIC insurance limits",
        "label": "Cash And Cash Equivalents, At Or Above FDIC Insurance Limits",
        "documentation": "Cash And Cash Equivalents, At Or Above FDIC Insurance Limits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash\u00a0and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r91"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r71",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r71"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r179",
      "r307",
      "r308",
      "r309",
      "r311",
      "r314",
      "r319",
      "r321",
      "r532",
      "r533",
      "r534",
      "r535",
      "r634",
      "r756",
      "r774"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ngne_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right exercise price of warrants or rights amount (in shares)",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Shares",
        "documentation": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ClassOfWarrantOrRightNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ClassOfWarrantOrRightNoticePeriod",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, notice period",
        "label": "Class of Warrant or Right, Notice Period",
        "documentation": "Class of Warrant or Right, Notice Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/Licenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r118"
     ]
    },
    "ngne_CollaborativeArrangementRightsAndObligationsAdditionalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsAdditionalTerm",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, additional term",
        "label": "Collaborative Arrangement, Rights and Obligations, Additional Term",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Additional Term"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license maintenance fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, eligibility to received net proceeds, maximum percentage",
        "label": "Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Maximum Percentage",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Maximum Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, eligibility to received net proceeds, percentage",
        "label": "Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Percentage",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Eligibility To Received Net Proceeds, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, expense",
        "label": "Collaborative Arrangement, Rights and Obligations, Expense",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsReimbursement",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, reimbursement",
        "label": "Collaborative Arrangement, Rights and Obligations, Reimbursement",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementRightsAndObligationsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsTerm",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and obligations, term",
        "label": "Collaborative Arrangement, Rights and Obligations, Term",
        "documentation": "Collaborative Arrangement, Rights and Obligations, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_CollaborativeArrangementTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "CollaborativeArrangementTermOfAgreement",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of agreement",
        "label": "Collaborative Arrangement, Term Of Agreement",
        "documentation": "Collaborative Arrangement, Term Of Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r288",
      "r289",
      "r600",
      "r811",
      "r813"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock reserved (in shares)",
        "terseLabel": "Total common stock reserved (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661",
      "r662",
      "r664",
      "r665",
      "r666",
      "r667",
      "r776",
      "r777",
      "r779",
      "r854",
      "r913",
      "r915"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par or stated value per share (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r548"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r60",
      "r548",
      "r566",
      "r915",
      "r916"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.000001 par value; $450,000,000 shares authorized as of March\u00a031, 2025 and December\u00a031, 2024; $14,929,566 and $14,854,725 shares issued and outstanding as of March\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r492",
      "r652"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r111"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ContingentValueRightsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ContingentValueRightsPolicyTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Value Rights",
        "label": "Contingent Value Rights [Policy Text Block]",
        "documentation": "Contingent Value Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares converted (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exit and Disposals Costs",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r303",
      "r309",
      "r446",
      "r466",
      "r488",
      "r611",
      "r613"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/InvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost, as adjusted",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r241",
      "r243",
      "r485"
     ]
    },
    "ngne_December2023CVRLicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "December2023CVRLicensingAgreementMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2023 CVR Licensing Agreement",
        "label": "December 2023 CVR Licensing Agreement [Member]",
        "documentation": "December 2023 CVR Licensing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_December2023PreClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "December2023PreClosingMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2023 Pre-Closing",
        "label": "December 2023 Pre Closing [Member]",
        "documentation": "December 2023 Pre Closing"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_December2023PreferredStockConversionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "December2023PreferredStockConversionMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2023 Preferred stock conversion",
        "label": "December 2023 Preferred Stock Conversion [Member]",
        "documentation": "December 2023 Preferred Stock Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid, and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization of property and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r177",
      "r189",
      "r213",
      "r622",
      "r623"
     ]
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsAbstract",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Derivative Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r339",
      "r367",
      "r368",
      "r370",
      "r640"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ngne_EarlyDiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "EarlyDiscoveryMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early Discovery",
        "label": "Early Discovery [Member]",
        "documentation": "Early Discovery"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share information:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r167",
      "r169",
      "r171",
      "r172",
      "r173",
      "r176",
      "r380",
      "r383",
      "r398",
      "r399",
      "r486",
      "r500",
      "r614"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r169",
      "r171",
      "r172",
      "r173",
      "r176",
      "r380",
      "r383",
      "r398",
      "r399",
      "r486",
      "r500",
      "r614"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r175"
     ]
    },
    "ngne_EastlakeLeaseInSeattleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "EastlakeLeaseInSeattleMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eastlake Lease in Seattle",
        "label": "Eastlake Lease in Seattle [Member]",
        "documentation": "Eastlake Lease in Seattle"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation, bonuses and related benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, nonvested award, option, cost not yet recognized, amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "verboseLabel": "Options outstanding",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r120",
      "r138",
      "r139",
      "r140",
      "r153",
      "r154",
      "r155",
      "r157",
      "r162",
      "r164",
      "r166",
      "r178",
      "r257",
      "r258",
      "r279",
      "r323",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r445",
      "r498",
      "r523",
      "r524",
      "r525",
      "r537",
      "r586"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r688",
      "r698",
      "r730"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r685",
      "r695",
      "r727"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r857"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r411",
      "r412",
      "r414",
      "r453",
      "r454",
      "r455",
      "r632",
      "r633",
      "r636",
      "r637",
      "r638",
      "r641",
      "r644"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r405",
      "r641",
      "r859",
      "r862"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r409",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r484",
      "r641",
      "r645"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r328",
      "r333",
      "r402",
      "r412",
      "r453",
      "r636",
      "r637",
      "r638",
      "r641"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r328",
      "r333",
      "r402",
      "r403",
      "r412",
      "r454",
      "r632",
      "r633",
      "r636",
      "r637",
      "r638",
      "r641"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r402",
      "r403",
      "r404",
      "r405",
      "r412",
      "r455",
      "r632",
      "r633",
      "r636",
      "r637",
      "r638",
      "r641",
      "r644"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r405",
      "r641",
      "r859",
      "r862"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r411",
      "r412",
      "r414",
      "r453",
      "r454",
      "r455",
      "r632",
      "r633",
      "r636",
      "r637",
      "r638",
      "r641",
      "r644"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r862"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on finance lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r437",
      "r651"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, current",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, non-current",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r441"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails",
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "verboseLabel": "Amortization of finance leases",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r437",
      "r651"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r305",
      "r319",
      "r395",
      "r419",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r499",
      "r629",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r805",
      "r806",
      "r807",
      "r808",
      "r855",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurogene.com/role/SegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "Total general and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r570"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative specific expenses:",
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/InvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized holding gains",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r249"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/InvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized holding losses",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r250"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurogene.com/role/InvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "verboseLabel": "U.S. treasury notes",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r248",
      "r402",
      "r411",
      "r485",
      "r489"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt Securities, Held-to-Maturity",
        "label": "Debt Securities, Held-to-Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ]
    },
    "ngne_HoustonLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "HoustonLeaseMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Houston Lease",
        "label": "Houston Lease [Member]",
        "documentation": "Houston Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r282",
      "r284",
      "r406",
      "r408",
      "r413",
      "r520",
      "r522",
      "r571",
      "r605",
      "r643",
      "r884"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r284",
      "r406",
      "r408",
      "r413",
      "r520",
      "r522",
      "r571",
      "r605",
      "r643",
      "r884"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ngne_IncreaseDecreaseInContingentValueRightsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "IncreaseDecreaseInContingentValueRightsLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in contingent value rights liability",
        "label": "Increase (Decrease) In Contingent Value Rights Liability",
        "documentation": "Increase (Decrease) In Contingent Value Rights Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r772"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r726",
      "r734",
      "r738",
      "r746"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r750"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r750"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r750"
     ]
    },
    "ngne_IntellectualPropertyCVRNettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "IntellectualPropertyCVRNettingMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual Property CVR",
        "label": "Intellectual Property CVR, Netting [Member]",
        "documentation": "Intellectual Property CVR, Netting"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property contingent value rights liability, current, deductions",
        "label": "Intellectual Property Contingent Value Rights Liability, Current, Deductions",
        "documentation": "Intellectual Property Contingent Value Rights Liability, Current, Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property total amount",
        "label": "Intellectual Property Contingent Value Rights Liability, Current, Total Amount",
        "documentation": "Intellectual Property Contingent Value Rights Liability, Current, Total Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r770"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r145",
      "r146"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r187",
      "r213",
      "r622",
      "r769"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and investments",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r880"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r119",
      "r222",
      "r225",
      "r420",
      "r421",
      "r876"
     ]
    },
    "ngne_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_LeaseCVRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "LeaseCVRMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease CVR",
        "label": "Lease CVR [Member]",
        "documentation": "Lease CVR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r651"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease, Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r443"
     ]
    },
    "ngne_LesseeOperatingLeaseNumberOfRenewalTerm": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerm",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Term",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, operating lease, payment to be received",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding, amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r150",
      "r256",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r386",
      "r387",
      "r388",
      "r422",
      "r547",
      "r615",
      "r669",
      "r816",
      "r867",
      "r868"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r93",
      "r494",
      "r652",
      "r775",
      "r809",
      "r863"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r124",
      "r150",
      "r256",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r386",
      "r387",
      "r388",
      "r422",
      "r652",
      "r816",
      "r867",
      "r868"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_LicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "LicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Abstract]",
        "documentation": "License Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing equipment",
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ManufacturingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ManufacturingExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing",
        "label": "Manufacturing Expense [Member]",
        "documentation": "Manufacturing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r334",
      "r372",
      "r405",
      "r482",
      "r519",
      "r521",
      "r528",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r603",
      "r604",
      "r628",
      "r634",
      "r639",
      "r644",
      "r645",
      "r649",
      "r650",
      "r655",
      "r818",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r334",
      "r372",
      "r405",
      "r482",
      "r519",
      "r521",
      "r528",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r603",
      "r604",
      "r628",
      "r634",
      "r639",
      "r644",
      "r645",
      "r649",
      "r655",
      "r818",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.neurogene.com/role/RisksandUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurogene.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedTerseLabel": "Cash used in operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.neurogene.com/role/SegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity",
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.neurogene.com/role/RisksandUncertaintiesDetails",
      "http://www.neurogene.com/role/SegmentInformationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedTerseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r73",
      "r96",
      "r122",
      "r136",
      "r137",
      "r140",
      "r150",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r170",
      "r256",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r380",
      "r383",
      "r399",
      "r422",
      "r497",
      "r568",
      "r584",
      "r585",
      "r668",
      "r816"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_NewYorkHeadquartersLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "NewYorkHeadquartersLeaseMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York Headquarters Lease",
        "label": "New York Headquarters Lease [Member]",
        "documentation": "New York Headquarters Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r726",
      "r734"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/SegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r781"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r627",
      "r781"
     ]
    },
    "ngne_NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares common stock holder to receive when restricted stock unit vests (in shares)",
        "label": "Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests",
        "documentation": "Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_OfficeRelatedExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "OfficeRelatedExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office-related",
        "label": "Office-Related Expense [Member]",
        "documentation": "Office-Related Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r616",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r651"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "ngne_OperatingLeaseMonthlyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "OperatingLeaseMonthlyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, monthly payments",
        "label": "Operating Lease, Monthly Payments",
        "documentation": "Operating Lease, Monthly Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/OrganizationandDescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Description of Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r90",
      "r529",
      "r530"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r652"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/Prepaidexpensesandothercurrentassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Expense [Member]",
        "documentation": "Primary financial statement caption encompassing other expense."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r652"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r690",
      "r700",
      "r732"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r693",
      "r703",
      "r735"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r693",
      "r703",
      "r735"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amounts Paid",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r771"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Offering costs in connection with pre-closing financing",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transaction costs related to reverse merger",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of held-to-maturity investments",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r224"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ngne_PercentageOfOutstandingStockPerStockholderMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "PercentageOfOutstandingStockPerStockholderMaximum",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding stock per stockholder, maximum",
        "label": "Percentage Of Outstanding Stock Per Stockholder, Maximum",
        "documentation": "Percentage Of Outstanding Stock Per Stockholder, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_PercentageOfOutstandingStockPerStockholderUponNoticeMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "PercentageOfOutstandingStockPerStockholderUponNoticeMaximum",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding stock per stockholder, upon notice, maximum",
        "label": "Percentage of Outstanding Stock per Stockholder, Upon Notice, Maximum",
        "documentation": "Percentage of Outstanding Stock per Stockholder, Upon Notice, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units",
        "verboseLabel": "Unvested performance stock units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_PersonnelRelatedExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "PersonnelRelatedExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related",
        "label": "Personnel-Related Expense [Member]",
        "documentation": "Personnel-Related Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_Phase1NL201TrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "Phase1NL201TrialMember",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 1 NL-201 Trial",
        "label": "Phase 1 NL-201 Trial [Member]",
        "documentation": "Phase 1 NL-201 Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ngne_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legacy pre-funded warrants outstanding",
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Funded Warrants",
        "verboseLabel": "Pre-funded warrants outstanding",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par or stated value per share (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r307"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r548"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r307"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r548",
      "r566",
      "r915",
      "r916"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.000001 par value; $50,000,000 shares authorized as of March\u00a031, 2025 and December\u00a031, 2024; 0 shares issued and outstanding as of March\u00a031, 2025 and December\u00a031, 2024",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r491",
      "r652"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r267",
      "r268",
      "r609"
     ]
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid rent",
        "label": "Prepaid Rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r630",
      "r810"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2024 private placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of held-to-maturity investments",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities",
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r786"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock upon exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r483",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r606",
      "r635",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r814",
      "r815",
      "r819",
      "r881",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r483",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r606",
      "r635",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r814",
      "r815",
      "r819",
      "r881",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "ngne_ProfessionalAndConsultantFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ProfessionalAndConsultantFeesMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and consultant fees",
        "label": "Professional And Consultant Fees [Member]",
        "documentation": "Professional And Consultant Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r443"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r112",
      "r115",
      "r116"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment, cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r126",
      "r496"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r443",
      "r487",
      "r496",
      "r652"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r443"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r327",
      "r334",
      "r362",
      "r363",
      "r364",
      "r372",
      "r405",
      "r456",
      "r465",
      "r482",
      "r519",
      "r521",
      "r528",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r603",
      "r604",
      "r628",
      "r634",
      "r639",
      "r644",
      "r645",
      "r649",
      "r650",
      "r655",
      "r662",
      "r812",
      "r818",
      "r859",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r327",
      "r334",
      "r362",
      "r363",
      "r364",
      "r372",
      "r405",
      "r456",
      "r465",
      "r482",
      "r519",
      "r521",
      "r528",
      "r539",
      "r540",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r603",
      "r604",
      "r628",
      "r634",
      "r639",
      "r644",
      "r645",
      "r649",
      "r650",
      "r655",
      "r662",
      "r812",
      "r818",
      "r859",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r685",
      "r695",
      "r727"
     ]
    },
    "ngne_RefundsAndOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "RefundsAndOtherReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/PrepaidexpensesandothercurrentassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refunds and other receivables",
        "label": "Refunds And Other Receivables, Current",
        "documentation": "Refunds And Other Receivables, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_RegulatoryRelatedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "RegulatoryRelatedMilestonesMember",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory-Related Milestones",
        "label": "Regulatory-Related Milestones [Member]",
        "documentation": "Regulatory-Related Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r303",
      "r309",
      "r446",
      "r466",
      "r488",
      "r612",
      "r613"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurogene.com/role/SegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Total research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r605",
      "r622",
      "r875"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Program specific expenses:",
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ResearchCollaborationAndLicenseAgreementOptionToTerminate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ResearchCollaborationAndLicenseAgreementOptionToTerminate",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research collaboration and license agreement, option to terminate",
        "label": "Research Collaboration and License Agreement, Option to Terminate",
        "documentation": "Research Collaboration and License Agreement, Option to Terminate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r686",
      "r696",
      "r728"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r687",
      "r697",
      "r729"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r694",
      "r704",
      "r736"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r773",
      "r877",
      "r880"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.neurogene.com/role/FairValueofFinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r766",
      "r773"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock units",
        "terseLabel": "Unvested restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2024",
        "periodEndLabel": "Balance at March 31, 2025",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286"
     ]
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAccrualAdjustment1",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liability Adjustment",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesSummaryofAccruedLiabilitiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurogene.com/role/RisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r86",
      "r493",
      "r526",
      "r527",
      "r536",
      "r549",
      "r652"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r153",
      "r154",
      "r155",
      "r157",
      "r162",
      "r164",
      "r166",
      "r257",
      "r258",
      "r279",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r389",
      "r391",
      "r392",
      "r394",
      "r397",
      "r430",
      "r431",
      "r523",
      "r525",
      "r537",
      "r915"
     ]
    },
    "ngne_RettSyndromeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "RettSyndromeMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rett syndrome",
        "label": "Rett syndrome [Member]",
        "documentation": "Rett syndrome"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to operating lease right of use assets from new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r651"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_SalesRelatedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "SalesRelatedMilestonesMember",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-Related Milestones",
        "label": "Sales-Related Milestones [Member]",
        "documentation": "Sales-Related Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_SalesTaxCVRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "SalesTaxCVRMember",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesContingentValueRightsLiabilityDetails",
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Tax CVR",
        "label": "Sales Tax CVR [Member]",
        "documentation": "Sales Tax CVR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPotentiallyAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ngne_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Held-to-Maturity Securities [Line Items]",
        "label": "Schedule of Held-to-Maturity Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ]
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfHeldToMaturitySecuritiesTable",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Held-to-Maturity [Table]",
        "label": "Debt Securities, Held-to-Maturity [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r443"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r91",
      "r880"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs Associated With Exit or Disposal Activities",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r79",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Results Of Operations by Reportable Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Arrangement, Option, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r82",
      "r84",
      "r85",
      "r86",
      "r130",
      "r131",
      "r132",
      "r179",
      "r307",
      "r308",
      "r309",
      "r311",
      "r314",
      "r319",
      "r321",
      "r532",
      "r533",
      "r534",
      "r535",
      "r634",
      "r756",
      "r774"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exercise Of Pre-Funded Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r177",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r220",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r285",
      "r287",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r619",
      "r622",
      "r623",
      "r631",
      "r657",
      "r881",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r177",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r196",
      "r198",
      "r199",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r220",
      "r617",
      "r620",
      "r621",
      "r622",
      "r624",
      "r626",
      "r627"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r216",
      "r219",
      "r618",
      "r619",
      "r625"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, not probable to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Not Probable To Vest",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Not Probable To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, probable to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Probable To Vest",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Probable To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOperatingExpensesDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired/Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired/Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding option intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOtherAwardsDetails",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitReservedSharesforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_ShareBasedCompensationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ShareBasedCompensationExpenseMember",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Compensation Expense [Member]",
        "documentation": "Share-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Arrangement, Performance Shares, Activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ngne_ShareBasedPaymentArrangementNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "ShareBasedPaymentArrangementNumberOfTranches",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, number of tranches",
        "label": "Share-Based Payment Arrangement, Number Of Tranches",
        "documentation": "Share-Based Payment Arrangement, Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r767"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments:",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r607"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r651"
     ]
    },
    "ngne_SigmaAldrichCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "SigmaAldrichCoMember",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sigma-Aldrich Co",
        "label": "Sigma-Aldrich Co [Member]",
        "documentation": "Sigma-Aldrich Co"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r148"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "ngne_StanfordLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "StanfordLicenseAgreementMember",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stanford License Agreement",
        "label": "Stanford License Agreement [Member]",
        "documentation": "Stanford License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.neurogene.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r121",
      "r177",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r220",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r285",
      "r287",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r619",
      "r622",
      "r623",
      "r631",
      "r657",
      "r881",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r60",
      "r63",
      "r64",
      "r120",
      "r138",
      "r139",
      "r140",
      "r153",
      "r154",
      "r155",
      "r157",
      "r162",
      "r164",
      "r166",
      "r178",
      "r257",
      "r258",
      "r279",
      "r323",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r445",
      "r498",
      "r523",
      "r524",
      "r525",
      "r537",
      "r586"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r178",
      "r431",
      "r483",
      "r531",
      "r538",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r663"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r178",
      "r221",
      "r431",
      "r483",
      "r531",
      "r538",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r663"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r689",
      "r699",
      "r731"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r59",
      "r60",
      "r86"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity",
      "http://www.neurogene.com/role/StockBasedCompensationSummaryofOptionActivityDetails",
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r59",
      "r60",
      "r86",
      "r348"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r60",
      "r63",
      "r64",
      "r86"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurogene.com/role/CondensedConsolidatedStatementofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r63",
      "r64",
      "r75",
      "r550",
      "r566",
      "r587",
      "r588",
      "r652",
      "r669",
      "r775",
      "r809",
      "r863",
      "r915"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity (Deficit)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r149",
      "r306",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r396",
      "r589",
      "r590",
      "r599"
     ]
    },
    "ngne_StuartCobbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "StuartCobbMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stuart Cobb [Member]",
        "documentation": "Stuart Cobb"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r448"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r448"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r448"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r448"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r448"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.neurogene.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r449"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.neurogene.com/role/StockholdersEquityDeficitNarrativeDetails",
      "http://www.neurogene.com/role/StockholdersEquityDeficitScheduleofExerciseOfPreFundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.neurogene.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses on idle equipment",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r78"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurogene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r305",
      "r319",
      "r395",
      "r419",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r499",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r805",
      "r806",
      "r807",
      "r808",
      "r855",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://www.neurogene.com/role/InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury notes",
        "label": "US Treasury Notes Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ngne_UniversityOfEdinburghMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "UniversityOfEdinburghMember",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University of Edinburgh",
        "label": "University of Edinburgh [Member]",
        "documentation": "University of Edinburgh"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.neurogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r108",
      "r110",
      "r113",
      "r114"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurogene.com/role/CommitmentandContingenciesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r651"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.neurogene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "ngne_VirovekIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurogene.com/20250331",
     "localname": "VirovekIncMember",
     "presentation": [
      "http://www.neurogene.com/role/LicensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Virovek, Inc License Agreement",
        "label": "Virovek, Inc [Member]",
        "documentation": "Virovek, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r173"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.neurogene.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r173"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "420",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-12"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001404644-25-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001404644-25-000041-xbrl.zip
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M1Z9TCN2G:<N0EA"*QJ1 P]8P1=%])0ICNGQ.:X715%I7DE3:S$E&G1.(-6Y
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M0;8$8\''/C+'(QIOMT?=]1@%^LN9*7ZOH)XK6/?*^\9H11R?,?!4),KB0$L
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MJ$G^ DW2#U%*T^.L >JXK"3WS;Y+EVEE+M4:FC)[!?LF^3MYR:>Y?>>#0>4
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M\!'%%\8_KLWPJA#6*^@]TS9G*F_[**6\1VVQJ@U':@QO/#X7LJ%7YTG_4OB
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M00O?@W#*4\$YC/@J&N=-&*]AS0AKPP$=T;8:MBN9QL0.#4=D&NZ<:9C"]!%
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MFTX_O.,2KA)(X. J@00.KA)(X. J@00.KA)(X. J@00.KA)(X. J@00.KCK
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M%F 9!_9'28-B/+-8E(OW?[UOZ+)2!XZWS1%^@LR#@N+5PT4^XNPX2?FDIN^
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MMQOS0+R16?IB+-&SAFJL1V  'OYS/=1<(I_ME?HMLU"@ZQ^0K(:* F*FB:)
M@2,"G8L.*C949TQK+9.M9'4>YMP;C['[-YRKL8\;;LL .J/\;:^@\'M27Z^B
MXL7CVEK7:S 8>7[80*=?=J(R/IDJT#^!2T.DM/T8?#%C*'W1M4NKTO/XF([[
M6W>JSA-NPJZ(<.,-# SF&:*]3UQK>?.PA1'U5Z?.SG38 Y*(E.= 6YD'>RR<
MI\DL>5DKN4L^ULIF/#U$R8P\.2>)!L!"B<U!9>(4KD;%1;(B*I6P0PW6S\)Q
MXA)I2@P?+IAZL7TRCYNU8#@'WKYCEC\(.'=>=-H!,!ZE;( N59])UG!?. SJ
M61=?@B$?N<!G5C.<!#\D#P6W9#@@!%SJ8@YB/^?8F":%6B#A07%X9=>BO <&
M=^!K%,4@.VPW%;@+5KJ4(ZQ7BF607&2,81B?/AG.%U@_C:%$Z#ER4@=&CH]W
M[C2BE@858K16NXY/R]LFFBG4OTG -,:+9@2%R6-P! 9-Z0SH:2EAKD RG&1Y
M5".(*4%B>@QND'U-C_<Q+9"/XY*IO0?D2%D\Y=<HZP-L2M<T_@3K0243;RBR
M+!H;&A#BH@L&8VT6RG1#&H!*%J\*E9 Q"9:5C\2%RF**S(D/G\'BF)K/Z)\>
M:N.)0]U%+-(ZIUO$C0#H,0H?!D,C=95E>@"DNHD= RQVZ]&=(Z6;'OJ$LD&M
MK;SJ(B-Q549BJY2,1%T6&8DB(_&LXE':;O&HYYDK[IK5:L..'T$Z@YX7Y.1%
M]7)B5#V.8U3/T7@<YVUDMBK-]BHEFY5VBUO1S>> 1*T5Q,1O>+8]#!>P,&4_
MES&AR<NOU>0<3)R+AY["!_&83>P[2P4.K(#(HK&^/76FG#0@8T;X<>8-NNV9
M1XCF&Y@8&)BE@7UWZ4)HUB2%_C4E9B/-^/K>?&Y*?[V^?DRSWE GFH#:$QG,
M4*3:5>20(.OW2IS%R^]XG@\<) U!4,D;@ZF(2$_>_7Q[D[XUK=2TQQGX9(IQ
MEU725;;VHE+L.*D;8?8XUB3,\T)6GY):7H.IE(*$+BK.\EKQKMA/$SD6L]\,
M*Q[2_B_0IV=3VFD<;T84&T@A;K*Q6$.3;<R19V9=NR#<'.F)@)F&IKKT!38K
M*7+COU*_'+7=F7\YR6J;<U#I=5B1DX0T\0[ $3Z*>:/Q>^J,75:"LQ*WDFR\
MZH2@0AFM_IF]GC%LP:!.0BN[L3WH1 YF&R"59DVW#WBKS?K9T2YW0+=.)MJ6
MN?:CY!)TUM+8OT>CWFB,#PT;4V2I9WEF.L<VQ8*IOMKO7D]:%F-LG4U331W7
MJ?,N]CRCIPBVD3C8XX40BWD#$^Y.GI5^'?NEPW0;&*8$@@ Q19W;\-+D'FHZ
M@@: S,:\BL2:^<\C>'E"X0BC7!)'XETTVA:.H4+G_O> / QO 5'HC9UE VGG
M>Y)_9Q9QNN?=BR0Y$P%(I>SP-;(\DLNW.6?S[-R(3Y,@Z^,#SAP;/X!L$[ Q
M,8]ND$G<W)#Z1>@XD-BE@8(<^6/,FC#-^S46_1CS;3$9?;_2 ,R*>]A;,E[;
MU:?1JN4D+: D*TX[2:^C&@H5!#0*S< :7[+BX)YSB=( =3;18 :W^/@;>@Z(
M'2H+,=8W[P:]0E&)N4Y)]LP*UR2F*%AD2&A>0VC\S ++9Y/#I3?#B8\$ ]^(
M"*_C^C XYE!G);MZ\7V3W/Y:=3[#%Q9ASN($BS2"&C='&7B^SR"-[EBF%1F.
M2?7 O-::<]"C#I.&-VQD^G/.&K3&(V939_!"DBYM-483RN+?,F20'#<92D=,
MQ1U!@U3+O/G[4S!+K<=7GS(8@[!ERS1"V.,@8CF!$CHSO2G!P@T<8A[/+*?+
M9=YQ^GD#\\B! ]\-WPJ:TL-<JC/UKLY'&'WR9I-W%GF;00Y?YU)!D<1_IRRD
M""8%"RDF6DDVJ0W3'9/,?@1]0#NL9E5J%C7*Q/A09P\CJK>P\QO#%I8-(LY/
M/=%!1B1NKU<N'9AK"NN+.53(*U+]4R+$-ECQ.3F_6E[.[V+AZ6E+]U<T1&);
M!W&=HO3 >OXJE5O-<\K IRH'&<*)H(S%7*S%!IE$U(#!,9 8LWKNDNU)56&7
M&NSI8-G8TKX9V60HI?E%J,/:U&C^!LJ#GY%J#Y^_S0K5EI61C(<,#'/70H$!
M>[#H<1IFK?#KYYD5KG;E.E/G$F)(&2&_? .7P;H[?+ _9C9P^Q,L%:J]/V#0
M&:-[ *P/=GP1^H!L*\D.8;?,DC;C6^:3".:*\:2-Q7@,'21@823,!'+(,H[2
MW,:5*13QA6OSWN2EK+$(S8Z'(0,>2L(8G/.-_8$<36SN_PZ8 R)*,RWDF7S1
M:GW/)<MY%G[ZY&0K34 5RE4L70.H2(J6KVF<KC5(CGRISWEMYP-I7#D!J.Q!
MC6,8^?0XSK)SHNHD++S (PF"RK4[XQ$2FT9,+ XFI ?9C+[T(E8JMR?739)*
M1'_);/=,C-)$!E*?D(7' "J^([C*F38<FOH^ER(VB7QS1 \?>A9XH!';F(,R
MQNHEIJ*#?=*3P?B;4F7.H?F+H K:+"4@>0"2]( L96@UI9N5R5N)VY5^,2(.
M=5<.##<N-<*C@II\%KX/?51,'=Z@^A73X<P1L2*'/ SSF8 &%W.4N?82,^SX
MVDU<F//N5F%&Y)9:9X8Y.Z!B%8=5QV,J!YB)LYRDW/S'U.LX-R@ML4(,A^HY
MP8B0Q"<81.-$_(8>VJRQO1\ AC"9=91Z+8(1M@S(5LFG:9497^8'>H$7 2RL
MX.-5,3ERRIXJO793:VM%6ZJT>DU=T]>V5-GV44JWJ?7:A1ZU^G-=[9:U*%57
MMVD9LZH_3%GM6'.Z*\8I.J?I09A_H*;%!]2<1J_Y%JUP+PM$:5>(#)3T.2@=
M:2K329M5KM0#Q!!+,3QOKR&6RUK3=7AC^#X&Q/^.&F/1&7G8Q* CUSN=LCJL
M<S.L<O-"Q!A+P8D[3U@OGQ.[;))ZJ[M<0<0;*QYI#,))Z>5IWLY:J>IM,0G^
MS.>];SBWYNW^/,KOU?J:MO>,5GXFP G:V%:2;J0-+&K@AS8NP7AY\9+1+RLJ
M</WU@G'+4REVWRQ.\15ZUKZ@.1_9L84]=+19XKH"=I)25Y2RQK&5@6M.)Z<(
M#A<<7IJ==3P.5YG]U4.W;J59/*</^U+YUSD4)]PL:B=Q=0!&K<:>2Z9Q=SW:
MU8&FZ[$R:5JX'9OJ<=HA-F]Q6,UT)OHJ/2W%VF@8-RBUN\@*'7C66437:GVY
MN3R0*.T/A,4UN#R+T$J&^?KQ,5:OPW_!K$DP!IXQ!8C&V4(LDDK+!6S?)V^>
M2:-S#@E#PAKRF3ZQ;%J8D29UX)\L3373*T,4@N]5"-Y>4P@N:KHONZ9[=:UN
M7HO='DB=HKE3V$_"C9LG8QO<&\KT^-M,%.G+[]+U8@6Z)SU0BN9096%")2$#
MBH10N:!Z/XKC_I=,"2J<65&FGTK:'SAS\F"_GDRMBKD$2W:JT-:QZ=D]Z\F9
MY)[D!5+S\VY779Y.;*\GZ5RTK 9[<&'#3VE(K+A2V*85 !;K2XP-7[;O65:&
M2N"^NF1E=.'!OQYX;^3+Y[N;.S=N5O>5KC-/9VAA7&]=BT]0&G#[05JQO!H*
MV6P[.M" U4XDZ4?#.;*PPRA3N94I7AH0QR9OK-)B0$4>YNHE1( *F!U.2\H'
M98!,:V!H0.:)5L"L*EK0E_/<>.7@XC(L*06B<) H((Y3[I._HM49J-O#=<.P
M2'Y%[-V*2OCY62GS\H5JJ;,A,#=_?\I,.LD=QI(^EE$]7(Z7LC$WM.\E\.W<
MM)7L(]/*!Q#&'DV>CX>Q8-7B0KG]W%(,/^G:RNJ9:(GG=,(R:['D["JMB/A*
M30?XK#XK@,#)K Z66&%UU&-2*$BOB0LEX@N?:5_F%^,G??\'8F J8T#[N[HK
MUO9QH?LBJU^$B^G-22$D+!&WFY:S2/:058)1\32TV?@8D)/V6]R2C:I]TO7S
MC=156KP5%WS.+!0A^#=B@1A[/66I7YTO")VT[#&>\!1S%-.C:#?SN.D<'.O
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MP/P2_$@F")FV#R94$.+X'YP29(%@"!$_1L@&!AF^/\5ZBC<<.87L '"A#<X
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M.9#6\'[+?:"':D0&UAHCH9_!6(7,RZ$QO/,Z>LX!/-#T[-I,4#]S_'D+7;M
M.P[4 N6R(!R8@&=56S K6,ZG<+^/GTG 'VS VQS?%N$ HE0XWMB-"6/!RSN8
M>0QQ&@$N3!1$@$2QR%B3P,A:\B0@H;OS@\4C_>8!W:-^:X/W5B3 G%L.Q?/@
M?0=(%IO1-<">QC;-],E^52.[>-T[_K:\3;8W^( B0F"T@4# 2+S@DK_P5WUE
MN9%N?[/+>AG&24\0M1II7B*WF]F:N*4LU"0.J#(%A#C@<LM%7;3%4\8%/E;,
M:+6.8K3ZX%AW6F9>?9-NM+CVDGDRVC=BG<B8$^R0Q8-0OEE.(PRN_P7V# )9
M'F!P=)FFBI]GN2I)4I'":8OBS)QD7#$1:!]22Q'"3)Z5WS7&['<.N;P^+2\+
M,K^KP)Z5U_RS:\'ON-.,MO2>65'D7H+_?(,!?\#"V%7P'@$6=,,^P<]X9,&2
MR@I#\#\H!ET./+/IU&*:Z3B9[3X$@^VVV2Z:VDX.W33^M,(I[#L2X&[\<Z$)
MA'2M$>:],2V'?UD%^62F.OJQQ9]K0DY(<K\Y"I;*V'$=-S03WR3QNRE7IUN1
MXCYW]P0^]W"%S[W>T<Y)L^_O: \:I7>T+UBYOK?"R+6^5>KU1=5K[RCJ==#$
MB\-6?[W?MZ5V-?FFM5PG_PXJ3TW3)G>/*R'VEM6M\0:ICHUKK<9/:?ZC7S9_
M^F&%1D[\^7:#=')O*;GNAKXZ1N[$.B$=8\JWI[LBZ=,O"0!/5L6>7' T=0((
MW2P$NWRSO.9[\:!DV5_B((PM_AJ"9:3[(<%\F>_A16P<^(^@V P'81LC!TY!
M !:.&=[K[.,A]S;=D>)]65IY2R?TP?\9%#DMP<YQ2 >(0%Q?[8\B3Z7OEM('
MI2XOU%& #O=GQ>%O^_V7VV-[/>KDUM";W>)HN?W!RVVK<Z!M=>J*C^7I.6'*
M%OLR@J:_<=N\$DCS04B+=GLJGAVJJ\RL_$LK=6PKN];N+/D+:]&"JS+8;!EL
M<TT9;%71^KHK6E>7,+9R2QC;5P7+2$F78O/T"HS203=3&7J6SO%]/)^[I(E5
M48S$H"]FV- 44%X0_C\')PWW@R8]2QQ2H,9%XY!V-^\OITE,'@N('SO-IS;T
MUJYMN!YF/G8>4)X/)+>?N-R^1[FE5IP$!'4S]NGQB:UU%F[;#%7R8]@29G;'
M2:L72:_.B['F$=G\_/OU[Y;27WG#J ^#;'C93;NOIRVWN0&9(Y6I0.\ZI^5V
MT+NZ[@RR50EE0]:L0&PKX3FH\'0/(3P01'=;YRH\9VC3SPV![(/C(4[<&HM^
M,*"J\GS_#/EJ#:)>LU=O]\O,8_JT/DSF372>RR Z54B/V[I/0G;S6BYR!R1J
M9@';+[+%MQ4ZZ/GSS :O80^>P7$2A\*]J?R%S5B!S4')]?I'ZN7!&61>6J>O
M ^RK<"MW4>^2U&)<7XYX#AM7UV5!KJS@34^DT;=@D^;5]=Z&_T79Y R5^+DE
M<O^P D?@;VR,^BJ/:H.:EL1<EX89MD#JNGNKY\KA+B%[;%#/6[%'&QL@*M_Z
ME>?B[J<0@-6HVG%/Q?PZ'*,-BIG(B?TF:T4/!U[L#<5<^<TE9(\-BGD[]NA"
M5%7YRZ_<7^:#"O8N>JAPS"L<\_U,VEI5U;NZ'O2S+;3G!4Q>316HI+$TTKC!
M@U@KC7V0QN&A(OYR26-)/([L^((BPPJ.TFI!3RP*0WW[Q]<+Z++^'3M^>"/U
M'U^-&]EH:QK,&D_I=U/?Q8]@ARMLP$%VUCI<Q\"3EN,9'@..MIZ BT/3<":&
MY1'*)>SYW\Q&P%8",A6-?T/L)UQ&C9)/<MFC-9;@IGZ"]5TW;J@7EPKAN7S*
M3A9SGT;;YOIF37[G.OXK=GBOWBTLQ;%%Y^-# *2?L"!@"61]E/K$=EW@28/G
MD! 75RDDV>7)47(EA"@''IW-0>H\U2L_5NLQGBPW9AP9(=31$CR]@9Y&D?9_
M"O&+-MY*H(1[I*2HE7IDN71S&$ZQ"QW_))JSX7W2Y4Z@[:.I%7&(!SB7$26Q
ML=N(P5=F_*>(O]SU0WA(@F8D'\ [N)'3/C/?9?$WQU,K5,VEEL:NDPGC6+IW
MX\BG)E/.'&W>"@^TP94Z\.@Y;]!W0(@X=-^JCG'9216PF>60G C:)A 5!<$E
M3J4""BHXO)]R7:!G#/&4Q#.H%!XIO)6JQ2-<ETPO^' =/LPM=L 1&@,\^B8@
M9"U<#95\X" ,;=;!>UH,B>Z#+UO$/[,(S@>\#SO\9('^BV=?6(#=(=9C<JV(
MS952O6!U2 Z S]\E:Z,>GXLG)HH<Z(%O$]#2!-"OZ3B![)?%ZT!_0+0XXZ^R
MDCP/6(V#>4BU3Y M(:*^<"0& H:0AQ2F<4E'#"24Z7J$HP.5]HC6G@VP*_BB
M*X[FG(X%E2KB!X#&15 @@_J[]5-*08BLU#4)+$=B6I<VJ-6O*(P2 =V1$FY8
MDNO"@L U&+'$<#I"FVM/L=98+(4$DC:%:![K!O 2;I*_/ _7X!C:/%_CZ<CR
M;2+,;\X8(>KA)!(2X69OYH'C\I;@51\#VQMRKRU\X5VNW1.<H^L_DX666(\V
M _?1E5Z-G$FJ,:G&(7X<&"L9[USP,U^"#<YCYVOW^25P?"6)RBXH);<$;0W2
M+XF0H P!#REJ-=O<C=S@*\*S!&H221(!<P9CA^*?Y= F68M0J[H^W.J8$MWX
M,9GVTC%I>7.P!@EZ9V%,GD%C?3R$RAB?\R>0XQ9!LV?)U.8M,:]ZB<FCJ2U;
M1CMD3>7L#P4:512<Y[C[:Q78GXKF$I9$P#,O9M*DBK@N"<H4'D^X#,AS[Z"%
MPB]LI_YQ#1N=*VE8N8?,K>7!?>3623WD3J-=P$-.>V!;4YN'N]L=#)(*=$>8
M!L$,V&/L<@RW977#72/@+8:(]@S![-%$P$/C.0&D[9XJ&:S(E10^*7$2-X^P
M3?@5^R17*V&PX(S@U.QXG(. W6E@,4![S; G$Z7H&:P[_C?P%Y8;+30LLU_]
M9P02-(5+EYM0\GP!@+6,A1?"8D*=O!RP?3QU&#*"Y^-7&$+8*3\2H9+YW^DI
ML8I MV26\S#*!=V1S;[F>6Q[XX@-M<]U$S9T-\2C7R:^Z5SZIN MP!YG*;=6
MNB6<65_8-]E\9BG'9-76E2VW,$BL08#%\MR6?115:R\CG]4X7;3C@_43 @+F
MS$80(+/=_*X5@^T+Z]:O^C(*@I!V&CA6J9$_OI#0>"W$]Y)84Z&FRS;S1MVX
MT4=@+7$$]WY.>\K]3:>\V3?+2YUOXZ5M$7IG7+2-B98C>6PG3)D-5J?,-OMJ
MV[#LPW9G4RHO;858'-M+HT;$G.%AY^:E;<,F%6;H7IBAK0HSM,(,+8P9VL[%
M#.V<*Z;G]CF!+7/UL'"77XJ[:G1I @]*Q;)KDN /ZD,6#5TN[-&VUY@A_;WR
MM<DUSQ]8L, MDO+7;GE"GVI\5TV![C0;Z,%E^P24!V>#PY9H]I6[)U_+GTQP
MXNIHL8\Q?A$BO&-H<]%$Y]%@PR1LH@%X&',<I1&A?VJKQVFT^<3O_]),EU1#
M(*<5\THZ:RB14V235TQS:X53X7OD;9R2K6NF0.&ATIVH=D>H'.,0KT7'<8C>
M.UTNK:TW*K;U#>/.M]S],A?DD8!0[]<,6W:T3',Z<'G!8B$K<$(UF)I+5;B2
M \79K!;-I+0(@B>DA,TO)?^*63*Y 3\H7,G++-&Y)P?WP?I^(64YQ6[MO&P"
M;$T-%W@E,0U_MMQ%"!( 2WS"L5,HW=I *@K31>006=])_A.=P.>B3!PO+3GE
MNNK7*B7(?!AD/TYY4?_250(%"62(XH63UBY@S8T/K-8V2\8^]_%LAB/38('W
MH"-H@#VPT@UW'5&%?P$5/];@8DY!/S,[FR==[2.FF'!+L4WV:W6:"#4-['SL
MS'DF3RH'J5/H0QD=PJ-Y'%+FBP]'<0"V;>*X_ 8[T6MSJ?=4)>P:K\/A2<#E
MS 7M4T^G4KF3W)S:6/Y:93R0V1HJ//$@L-+T&?6HK -U0&]IP^"C WI+G0V>
M,M@*")N">(\BZY3O@U])&6YC?>(XY49=IA^#1! N_7GL;^-]GYKZOG3K-;-L
MGNJ?.$$8Z1XJB7\B2B;I(^ P><O"*]B+"=&*R5H'C+;H2FS=4-NRA8>]+<)#
MB/1=)ZDB71V%%*\[6C$4[( ;[&^8#9:S0=7*A)<5$(/)R9H!"^>BGT(KCUW.
M<Q<:S;/E'O,']W2:@T,.[FEC;O>$:3X^:8>(S0?DD.,%#PF%.1!V)MS>T!2P
M)*MO5(BM90XR]:?.?E.!MCB+(X\*ZM=;_5;144&=9GTPS/]3X:D\K7JG6W0D
MT*K?EW)1_7:G?(OJ]@\T5 D7M7ZHTFL<7I2>,+8%1OE%4D'=XDCEF2)$-6<I
M%0"(1HUJUM+V-/OL>[4"='MEU*DXZH <=?&@45DPAVI$5C7E)QN^#]>#S.R;
ME6PGD>[PZKK3.=34ATN @*I$K!*Q'40,;-IXI92U&E?7_7:VUKN2LDK*+EK*
MAHUC&;)6$PQ9.WM#4(E8)6*5B!W,D+7 D#7+;\@N'A9^,VA6!0V_H3+V)8U1
M^^JZ-<S>_I8)(KQ"D"\'%^GZ5F^?G3C?F5W[-PO\/ ;K7%U3673KIXK)+I#)
MAALPOP^HJKJ5JJJXZ"555:]LJNKB;QGRVS6J(6X;BG]?4LOVKZ[;O4/-82A!
M#J+BHA?CHMVT[.!@6K9BLA(RV;!U-%4UK%15Q44OJ*K:C;*IJHO/%O)99=A)
MH$JXBSK=1QV0=#I*;7_?<$BZ;.35TQ%D=_B)P]FH;5#E-/W2O+INFHWAWK<4
M!SSA[;42GO1A$B&51%<273*)7GNWV&X=I$BFDMI*:E^YU';*88?;W [O/<*^
MDNA*HBN)/IX=[ARDQN>44GN 4:"E1'RX"1'&+&^>7)3!3WSF??<IJ >.V:SA
MGR6@:*NQ^$QCAA@3(QJCB,,(HWU "=L[01'X3\RSO.B3XQ%&,&WQ[IFPF^\F
M:P$*V]T-0 R(30"\A%NV4C@9<QTDC'FV#O]#TQA?<E3"2GDZ&JOA##-".Y8@
MR1J++,T[0W@\ST_FI>EP07ECS4Z)YY2#0Y"WG)/37R)@!GPRCN<;J!"1=4'&
M-8"&_!EU"V,*I!XQYBD$QOI)R?ZP#!C%$%F"AJY.5P[!([QP0K&/H[$_8ZM9
M$#033=0,V-P/" P+-)OCHUJ+''>5!-/K+!M%DG[/56<"PX1 .$!&CXU9&%K!
MXC)!D=[/YJ[/5=Y-,K_N/+:Z-<^A.+!DHQP@W\,YE8X^C$T,Z?W&%LA (0Z-
MII$H3XY-N%K $ B7PKR0RQNAOR-P/.&=X)QI,>!D[ 3C>!9&^/N04.4EG*.
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M;G7KV3YCG0 DX'E[!Q&$7Y#");\ZI0TRFD#H';K$GJA"###Q+,322- 4[^)
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MDU]_#KK@TO7;9JN5G3+^NJ[XOQ3 7:A,M<;#)[\H'?3*7D-YF0=_\CN]P5J
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M*9EJ\%)V ,<2#<J-.GJ&VOX,8T)>!"-RSCLZ 'N5+ERVT[H?:2Y(E9W$.O9
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M!\^"AP\UBA+>UEJM>E<2;2L2328O0Z+V\.]\%3::19* M]R!@4_!<JS2K,4
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M]"L7.Q>OX/F*),@+01\Z(#781RD%GXN#D"*@BI!KD3-,%(R>>1*9-5T\2&_
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M]*K!ET[$9FJF\((&JCK>QN9_'(@YLQS/Y4.R X?F]4[>&K?IJD>:@JQ&#.-
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M!RC*H<C!>%MKM4B*MJ?K9/(R=&T/_\Y7 8Z;'Q 3O@7WA05<FO]AE68MQC1
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M87P0CZ/?-7_B;#..8H[-S54#[C;"S#N\51QQY,SPS8(G<C\Y)DUE.Y,)!&9
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MN[GY@\O+,^\ $)*)5VNBB<6*^":H!*!N_+KR]5C"Y*EVD2F;^?.I]>B/%U1
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M7"%!&E 9%F6[>):D@1&(0M=4&\19W0WSOO<<S7&#$QH1MTNL1 QSESA:7,A
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MX-N'!1ERE7H:"VM^['KM<(2*"B0H/)I>RS\B^UG3JBMFFNK3,@F]8M^1PB(
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M^-#A-O%U.0X%#4-7 V\AD@G<8I3>-6P.1$BNG,&G:K>"8T!#$NA&UV6T=+@
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M/V 5V+L0\/-$]]?.FA6B"K+T5XKD-;T,US4E 47LE<=0&MOP/%UE>4'*)W@
M"H%HJJHD=KZLC-TL/J W^P\DV3<Z$7_])/#?TR>W /^=?S?BC7FYSA^S^I>!
M%%J1I?R \#985YR<2OW'-LB+A9>LE7Q70'R:C.JEJ4PLPDX>ZS12E=$L)E&V
MTAY%DTO>&Z"&O^P']LHO"#^#5WM'W4I<GR?NR6SE( Z:-K[EZOV'BW<??-.5
M9G1T]/8[)RU"F$Y^@[586%>Y/AP_ON+:7PQ3//UK_3 *]-T*M'2TDZV8@M;?
M*<V^C 0JC:;E"1"9$Y0HB2@ U/J&&QTB)^ULILN]^I^+%Q^.TW!\\^IW)!<E
M1NL+A*O(W+&K/".\05NC1_*!E,"W!TWG@$O28A9@/#!W>&#ZJ"0LK3D[[ ?D
M&WR.(EE6,U>$U+>F[;'MGIFQ+S4K7<+3SK#)5;7BZU]>JE(\<9@,X;X 3N\0
M!$O&"$73AQ!H VJ;Z)&7F(VI$?N( Y/H;X1'B!].>C\SY%:&.+=;TDPT\IB"
MOO_E;V\;KZ*Y<,TO5?V>3[EN*H\VRN'AY-"#7(G0/P *FFR.T"IBX4/0(,9X
M(%Y!K#:WD2['$(9>]F[<X#O<8(OCXWID#,1,O<^ER%F!Z2E<EM*8J>*0\"^8
M#*\%4CYN[5$X7809HQF2$HP&/YY+X .P,8C+]4L2%U N9]S"P_G-L%A"K2_[
MY(LZ\ZH>*AN.FW7'FT50U%H<*,81\!@+7Y;R X?'O;GCO6$&%CH]2)YG6[G9
MY"'6\9(<6Z\L-W7CN&UWO&TS"'E.$%TO-7-)K;,G0OAY8]W&W;G#W0G0+U,$
MD5!@68&[6-6Y3)R%P(&A!P-(@W'/[OI$=6%FO7IX@XE=XPTRENZD6XV[=<>[
M)4X?31Y"?P*[J'S+"Y5!L=&I:\(80)X(I.".T7P=0QT'!\VYJ<M7+?\X1,5&
MG4(KZDA")V283"[NUD&$E75D/!YXW/9CV/;4;SIE4;#M1D%? WV?''9#D'VR
M^4="C^525+^=I(Q[?@2:VB=,^^S-2DTZ)=-;@N9>Y"ONTV9,9OB ]/AJN9X:
M [3/ES4"B51(U0EN,S,#'BD%;]J#1^&X8^'@WLENY3&MMNYI#O V<@@O2<I.
MK^"A2V0PC0DF5D32-37EE>G/;][Z\LH.7GM#*N%^7V'O9AA1')56!5%B.Q]"
MMG^0LL53DB;X,&%Z\7P 25S9OI(>N'W4:W<INJ Q%(92.]W T#*D&Y<:$4Y[
M F;($G[K,BHE*?L47E9_AX"I&E76MT,$()Y!9-S]NR[_#5N?$V:9H)W,>DW
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M,FK$C&./!K8;1RVAHLS\'/!ZD_*$')LZ;N^4#MPXZYTF49\RM=$.0_KHD^1
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MGQT,LHF".WC54)T4C)Z8;M.[<@0!%>PGZW.?V_1Y+37T?2Q%2"H%4LGAK&?
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MDCGI]/$5,7W+MQ*4FMIE"V_UX*^&BLM#P6&8=3N,+FL]8#%ZB6O2N/QVX'&
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M?0T8T<>H"N[1K_H_$,L9N'(*P/*MY_T/&;\D--CT*BL$1(FF"-?#DW6%4"(
MO@@+1M\V7S%E(V&9L2T[9D23O?80\[ ?W&M\PN'!BKZPF"9O_O;N(C7[>5-5
M2B:D(68FC28,6TP),T=]#EA$Q'N"X::2-@J T[J_F>;9?"_&O]5)M&.CA[$\
M= )Y?R/MOG!(8J#:(PB\%?#3Y#V>[@UCVNA..C_B:)+#AZ:+DK'_\+B(]ED+
M>QQG09"09$'L"VW@;Z>Y=<(E8KE9;-LX\ZV0@9BC3>5NWZ[WL(G,>E&F$<:;
M#72+<=>$PE*B2RB1 OI*& 1E UX^YXM\D;@*\[.'B<G2[3X:!]GL.@UY0<10
MK9, /,N3S*P@M8#V4=P:W#Z0'T6\2I6[%S* H243 <$8XLKH)"Z(1]%O,FP3
MJ7Z$2>J(1(SJB5F_LH$4_FI69]?:#,8U5<4PQ$DSA/)DA9PT'65!'B;[(H++
MY)185_L ?]O:Q>$5V8:M*WF:?-#'."'^?[?I2IOK, [()Q%%'ZM"I-Q$8!%C
M;>EFX51:6K AWXM2&?$<]5MXJ\E;_YG8!,66]Q.Y-K56'M("[*I4$'K\1Z=0
ME-DEPPM])I$$GOK^,*: =2,!HQX@;1Y5]"R>FC_V<"5F*2A'HLC)H'W$;QQ"
MLZ!7 ,^LCPFN :C7TA6GR84=@4@@#HFE_W_VOK6Y;6/+]J_PPYVJI K629SS
M]B?%>4SF)G'*=B;W*T2"$F(2X "D%,ZOO[W7?O3N1H.2G)PX1U+5U)Q8$L%&
M/W;OQ]IKS8;LA9 \HCU2=!G[S!HQWS'@?4(*3)$"?WM""CPA!1X'X\ <V#(!
M6(I8]7O84E4HG00BWG$$DA+86TT$UR9STAT0YQ(P2MU.IQR37-LBV'786>A2
MHO Y]P3.-[[S&-ITVAQO5[7<>>_E;^/%Y.F'#G(X=&<2L62=Y3Z%;Z[TNLR?
MIPYU^<6$VS+Z?^C1RKZ">E &-TU>ZI.*\1="!NIJUQ:WC-(]%.'O3B>&GOR,
M"@#NX;XOANL2T5M!?"]AN\\>N*)4*>9)M%4]K7*L/@!5R+X4,A&&T^:$Q)+S
M $RQ-I-O84TEEN%^1E2TTK7SL)-W/TDZBY&.[%N:W+C&S5RP(+)I:Q<(<_CE
M_SM_^7:11&+%S&],-B6BST9/[1NY]3/&<:M@3R:>XL[ZIAXT:$'GR?=?>.X]
MQZPUB_8NYKGEQ/O#JTGM4BNDO9,/#J*?G7304/T(G3=5UC:B84U$>X:W^6#L
M>/<L+[ Q_$-V6W]CI.I)YZ:EV$ 'BQ)@VB6@/"=WL_.(ED5K[-"1T>$"8 ,M
MU,6NW:%1,J+_M>W#E"[$^X<,E95/TQVI2FB_/C1X9-4O4> 5##=-H7H/AN%V
M5#^GJ_O6-)%M%U0WZW;#::(=QD:Z9EWJ# EVBN3/)?&XEFYO[C>1[<"-1M"'
MO,1=24-^%_;0%77N<C,3>6</^TI2J(Q66G35XK87CLD0AZE6@T'R&Z?J"@E/
M+#R):]?#\FJ1"SQ:9K@S3G9N\75),.]%)F L4 KNXT")_(5IB8H- TI7OB5Z
M='&M2]]20@.$7\:??FI9Z-RIW3+#X64?D^38WBTG[ UIR'U,ECF+.:'2KN64
MJ-DZO*INSU*=]8D.ZX/283UR!BSWTS\^ ]8KMDVP#VH^:.#$\SQ:YZ@7IRA?
M-M<M4X>XTZC5$S"BVW4C^>K$$K#8 !J\X=IW5E#$[<85Q5D+FDAPF&:H4SRU
M\.U(*KC*!"CC#.&IC+UD;3.]N>5!^G,-#[V_:F:A'GN*K"U#/^5]+4NRH!@7
M%BKLNO$*.$*NX]&B":E%[>-O2W2$ +B^D&14%>ZL)3GY7+.15KK^6%/-M1X&
M GMNM93&JEG6)1],M?,*48B"SX +@\I55+A;&TL#T3!#?VN3BO?D&#/>5_$U
MI$'R_92]_]T]0ZW)%;L78T*$LQ%Y4>QDI6%Q.F1P8%H63[2>RVE)CNF&(OUR
MY1@NN:"ZA!PXL6,\HXT=+IKZV MMLT WY;K0B@3M".XTB*0>ZP3O:MH3KC$=
M ;2RL3'3N]B$,(^')L+[6?)H\+L_U9!ZX)[K'??5I#G]CN0&,XDK6Z+(;#[=
M1[NKXWAR'\G>D:KC9,, 2S79#$R# 0N4; ;:"-;.FQ63E<7;NM"O&BTC^[=#
M^J7? (Y5"Q4(DS) 7@C;4SY))A.I9,,<4ZB-&8AE.YX8])9PC"67'.C/)<4=
MW)=G>MSY)U9IIHB##CTI/\_F ]HNZF&2J1Z=>CJL\ETD,K[C%4Q:,ACHY((*
M(T:7M&52R2?RHMA!$OO]'96[\>HDEL.!_5?]CN8]\6-](5_DQ>22U;G0.KM^
M(W?AK"<FDN8!H )\'(MD_D*5FQY'RQM<XNM6%32G1JW\5FAPXN8%X Y'YE'Q
M;/;6?3(T[?8B1$R-+A?? 86UCJ@4D. H[*CYI1V5N$S!6.8:@/?_N]\&@HH=
M'U7'(+D@1\NG6?6T<7%#.NJ%GM[+<CYHN_Q&S=%4R$Q:XE+Y-N&6ZD2#*9=
M:,;ET%XTZ4F&@91LLR@ZF8'REWC\;ZVLA'B][L1#(YO<CW#MC5'.&VG>L+3$
MEW3PF?=8>W78UV^ON=."BEJ#[9-8*!$PF#8H3KP;Y;FI/'2*P1#(1PHO#OO:
M%5OCY#>0W B'*&R(D0&;43R6.Y78F%/FW_6Y?3,U$Z<\J7:,8R<J#0O=S;7J
MHG?%T$X".<53=W$4UX2)Q:JBMX,TRD OYBI/F=]31_MG9!TP6ZP/-FB_90S#
MGE 9]T%E_/T)E?&$RGBD_ U:GF7VGZ1I;%5$C*H%VI X#UU0,= #5GW?DOMC
MR#3E+(L9ZIQA*WYA\?ND.$7- ?"I&#PM#JM1VB8>T(-V-=YKP6(H(JTE$D %
M_W/95 [GVZ-)<A^\#^[U7=8[QFXBC?>VM\NO$-!+!FPV[44./[&)(G9OYO F
ME(:UGDGKF.9JC23/CJ:".U(;"0>AGH#5>O;<KN#/U'O[?I<FXX)"$1_=.]E?
M287-9KWX:$PATS?L\/'< U4"S][V-=;"KP+WNNQV]*;.=^,08"_97(9Z"J99
MJ/?K1>0R)="+]\W!Y2\%W[2']-9#R)25X@Q5_D@JKBHCG>:9PK_40V( $HNH
MFS/'NS"=-S,=E4Y4\IPF#$VK#=D'-5'L17ZYW3F+7TM^J7];(CH?LEY=[B]*
MMQ=J.N'/PV_Z8].XJ-?89'$_^88-YVP3Q6;,I84_)1@!$"&,A<D;D98*4ZYI
MXCFB $%U81;]OJ&*29S(6_^<-^M%XS2_\5Y347"&'7 9D,[CICYTRRMI99^<
M)=:8,Z;!2#%7#L4O#BVR^;=LE_1%ORG0@?*#=,<FYBU]E#=V$L!3KTJ\9FA1
M.]K$FF8IM_$7^ARFUC") L3A'RW3B39G-QEH__;9,/7U<8@?679]<@6J=FK'
MM>091>0T=K*I13YI*@(SZ;:*J,12]C71(3A!BRN=9"8895J)L9$G8R2U_HND
M:<YQ%-Z=<U+?GEDF,]U8:^4H*K;0W,8!""JTW<=N5Q&9:!X^G!&X6?"B*JU$
M >^!%". ?HW!:PO$LH ^R'X%E*J][O>%?4/?-*Q8&U*JU'=;?;<_M31;9GQ<
MO P.T5'I[TMG!P685#K)2_/0^2&PPMMS!AA90RZ;0<"*>(^+W'!9HMZS_*2D
M/K;57.8]P@),A.#-V_/7;R,D(@P<97OY@1%_7RB9MBEXA%%;HS?Y4@ <U^S;
MDIT81$B<-+"7DIRA19!F(<""<%M&/Q27ER1U5L/A<E)!#5;@4EE9U]RS>1Z^
M43O%SW7Y%%=!G_F!H*OT@=>@&..R#<(Q\JUBOS!\!@S0%HU-0#AKI-U*KR=K
M<#GP2Q(&9<1GXCW]TVP_^@D=OUJEH!5;Y?N8=7<(B<UN:,(.ABZ'$TA08&&S
M/.PS5RQ8;.)I.UM\KMPS>U.YV41N[2G5X*0C.Y4;O ]3<88$:[I+.L(>]N(\
MNU-G=)SBS!-E"<>%ZW5\X&(5C86#)Y^X!@QMG^MI)/H],R37,?N/! "W%B!H
M 5QDG:."<FOB,3<7)@VII;3:,!]9O^?,ZR@PFCN<4\D(?;EPM+ =PY5G@D3^
MG@9;U%[S]B)]81CQ?.*+3?!GE$LR>@)/^#O#3(_SK^8!=$FTUQM%5O %X;0Q
MIE="O;BII2UYT]0KP6O8)#EC#6++6VE_73=]EM#G;5G6/F$&Y/A5($CH?8+>
M[>&(.?.F,.N;GQU@I0SH[2K2@RE4KAR]%\!S50SI564^.CI21*[-HD;YQ^1T
M3Y!P:J)Y#6S[GRW.;9O1MF@*)7Q/"YY20,DYI.6[DY#68F0H4O@X]H?[EFW3
M[,7(+F<%O!QE*K><)RN=44Z\?5\?5,\J<CB.LM-9:G$[0&32)JI81KJ1U?,U
MW;61G<29&KOF?1^WL::'M1+7DVV?(G-73&?J6D12$X"FJN0@%H!IW)0[5<.)
M!J4@2C&H>U=PXOBH15:,1"3Q(,&C:WN9;=B.06O6KC3RMA:)Q8LZK$LB'BG>
MK^/#5-U+IE[(Z""% Q7&)U%MBP><=8_X3^@ZXHUV<;S[CGK8\<97LN*^[TG;
M/E2-A"_EX'\_:^BF,4(1[76*V%N%?;)@& #B[$27F; H<<F$!F(F14E"HF7Q
M]@6I<6*54G!/'GMKBY4&#U-%,@ZR1G89+'1>1P3$K4CZF]BJ(5YHZB?$4]H+
MPP;^'5D(9F?78R&D*$'Y B2PI3V1-0/[(8&.J':4XNG"(5Y)FMIN)T[Q9:FR
M]U&T_2VD:*/TK-*0S$G0RKO6>TH54R$\/"]JREK[FQ.6)>_EWGJQ3S7N>]2X
M__%4XWZJ<?\6->X/=T&6D\&OX7B\CH['=]ZP/Z[$^-<13*D20UVX-S:5>(6_
M<'.%5T**UV## #/<][/W9+AHPZ;:F@ZE7BA1?96C%A?:S9 =ST>@$64[8:UY
MV+[>VRL_W3BZ>9L7.^G4XD5=\0*;\XO+^8*6E0B35GL%9PCU/R" KO&+R/[Q
M>+0'>0U?X2LG%&JL4$J?,Z<*M/XG).#&)V4-QQJWY*W[8<M=D0NH#8X-M';;
M\:J)!;MT XK\Z-&C:^VI:4^*E=#GLPE6?>&HG9$%ZIGYM9":G[9P0B481./\
M['2,E/*/-4*9,O:PX*Y&P#0+&[JHR;J@+H=ZU4PGD.L.!1*$NY4 /_G#6KK[
M'(PAA]HB5TS&HEX*F#2>E6UX1SXATI5(Y=\E\FT=X"]ARWS]W0])HD/4,+D]
MC04RU2D6 /D(3E?ZW^@TNT0),[%8T9\S 1K_@R=$X=RLB9OH-Q,&IU\>1 _"
M4 <27*2YF^1;V7;#ET8&RT@LD0D?#J#05QN=GU6K!-1;IY];$OVCN(JGCK.H
M;#(LP0["RB^_.X_!U"WQNQ3M94+2=;Z1.;&N1+>0Y2\KA9_5HMTO<OZ,L"&7
M?(B96Y*4 *2<<$BBNIQH8TU7$?W!SP=Y0KA?V^N6^-BZ>B-L[G=@X["\3F6@
MI*&Y[E4Q;FS:_X4T"DK.9.I';F<M79JZWS,J=NSUJ",SH ]V$PLKT@YQ=#KV
M!?YT9&<R:5&-<T\P#'/?IQ.BX&!=@2M+@81()YG:R^P&/-&3Q 2'^;B@/&)I
M@35S*%ZV,@6GH4_E3@SQ=<!U7&8%=TDSS=YK,Q&2: _;;_F\U/1 /5#=E>AH
MG/ YSS=2#KZ)5-I6<KC[7J!T"&7(PZ8%>U<C.<@VQ+97Z P@;L]HV&)Q3C*8
MK6'T8X)%KWL93SL:- JI]WI4G= R 3&C_%+?8-N$UUW)GB(':\L=QZ(DD9Z[
MJ(-0<%T<OTO,IW,7/'MUB?L':E[O^;D1&KZI.%0YQ9.KH4Z*;1"T046PX)C&
MDAJ/E/X."7.!K=(/8TT\*LQ7H-DFJEW-KB>+&,QNN(2EGVMHJ$M%J;.3IHZ6
MG3JJR+3H!'EU2'XGP]-II/)TI$N[RPB2 ?#EI'5ORP:FV ?"^+1;8[N@(WS8
M)2;U#M\3G P@H,*]-;87DN8L[=X><%MYMFYAUV_2ZM$*NY'JA@+6%AA=5/;Y
MD$0;KZ;U09M;!$17#3>I"SR6VJID N*>M4!FU'K_)+Q=@@$)-Q[5"]5KDGI3
M#"EX5N.C'>=NUUPBU4@((98,RFX=;]:B(\^/Y@*GZ]!/<Z).+\JQ,'$#(DF4
M6-T3;"-Q_.+US8[_#\I?<4XLVP/@4:B\+\E.TVSYX\&G8\$E$<P13HAP%9I!
MX@0T,3LRM[5;>.Y+5<\Y)C-*99%R1H,J)*,5R!+U[+!ZA%=JI>8!))V\E#F*
M[*5/=7W,-&?FX%*X7;@PE_/T(QX* ^J*]#_NNFC11SSLO; >!RL*G+#F9G],
MZ&P%T]YWJC#!)#/^?KTAK$4S<;J#.>FXZWC/D,-#%WMCE2#OU-&D*8OT")9Y
M>M@.UBOM2"ZVEV;W<)44QA'^7DB9G>[:X/1+W;<>1]IY@,4VS5[[T9MGAOV0
M'G6]^\38>"SB1<,VM8WT5H7D1*5Z$FDH"3/K>@MR<HR,.,(CMT6H7MDBB8&]
M&4CZ2\=,)8H^#,W8K80<:5)_2P-.@LJGE4"G_M*3.[7<\*GPO0D1/*3N'>,/
M9$P*E*+1BN=IC/O[*$9:&CA9L+VV=4PJA[<<+]6KZ_/[1VZ!R <X(F?EB2-H
M'^AJ">K+_IE:0$YW/3X(ND:3)]*%Y^?__8\I8,(SMVE.B9W&L)#&"I8;7(_2
M8.B-WQ/%)"D\R<[W+Q$ *3PHW6DS&59Q@KJ9AQ\CYY;JOB3PH"K^7'UAZJ]8
MB@"B)G3(\G ^*K;(T#'O+IMN/Y?I>MC6GJHP:;\>UZZ#[;UJ=Z/B+:9$UM$?
MUEQ*YC7$G%;P#L9MNQ+H03L<2,BQ>X?+54)8T4:8N85/97W^&\]C<"S;%/@"
M<JW/IK =P!MQ:L<]2&'T'>NM\.NMG%86=TNX:A6!FE?]3:<Y,2Y6*8BD9&%G
M-G<M2N 1NVFU";3A+,%$=)#<*N74,N"IZR6*'8#:#&!JO/+?L!\896I$N,@1
M)KB12[V)1OB6J@?W$"ZO]-\:]B& (G;"0;CN5MXZB3>5XF[1>Z2;*P'P2=IR
MG 0U\O2IERBC:2-MD^PGI0X)BQ<WGWTIWZ>8 V[H6_5;'7X):)LTF=(2;0C9
M=V"_B0IA1VW:I/9-J!3E!'?D VD;6%B@;ESS.$8, $]G8.")AWOKF%MXK@%9
M^^83G.4><):_?/($9WF"LSP.(8WS8+>I@ )WKNVN^\UU)!WCWAF/"%="G=G:
MG;\J:I9\5Z\@X9<Z509/S/HL5#]U?*,:='1[ST",&Q\%<3@N_[M7B>PWVE:;
M4PH*+:"&HB>:0#4>3C+7!<@IU83A9H]^O*.P(LUZ1=*UM&Q6J-Q]Y&6?Z0O>
M-0V%C!];0UV&ZD=0H7D]FI'_.=3P1UB$<C2'H>=[GZ5%\"3]R_ ASO^WE\;*
M:[F"SO,P^=FD*21=KMX8NURMT27)@0?I+%4F-V#\,UK$U37O5Z*IDURUA=/T
M\)J*D)UH9 ,-CR(>]$"SO)-<J-*0/>ZG!>MBL<Y!C2F9L>0<6GCFNG7SH>D#
MI.T4H5+>]=@VZEG!D=.V'"W5UYIF5;0UMK,F;,9(.^%0N1]1T^+S3UY\_BW:
M%Y]_^N+CJ"&,S$*"FB]]]+MS]]$<N\^5#A<-TOKG.TIWXBU_1O&%T$VYC.,<
MHIGF2Q()88M*$B9F%C3?HPXYG*+P6OQO2T+DZ(<L3O3G4IH*1:T@49@Y3CJ?
MIGJF17+@._2>;8F\VJE?AG^$X[YG?Y5=O7HN?C9;;N^66?.[#M64_")?1+YZ
M:K7SV4RF,,ZLG&Q'+L(8">O4JW3;'%7R\$!O2@B)12:P.J/:+(J5/E6Q=H@8
M%:\,[R2><C:O-&1 1Y@'Q3W'?W1VSU%Z?.^>E734S\-6B @OW4\NV9I*NUQ"
M#^:!M\._GFL5&/O)V7!BS7X"(U6(WD.5G1TR-KSNDWJ WSB#5+-.&R762%8>
M@[CT\5N($GY/" (R)JY=RZ..9NP/;4QZE^M@\(L8URR)WI=4?/DW1$,^)@0O
M2G(,WI?)L"M!3_%YWC37=9HY,QA4$KI3*FW5(F5=CW!6O(H($=!P$N%/].24
M^D7(P;FZ%OF&<)6K.Z,&0AZI/$&<!@\NWT!W9P\)K+"N8+%)I8DG_=<3C\_L
MWLP#EQM6ZV:_4JPN5[<$1I?/@$+  $LZC-:R8VP^V $W5_T6E79U%68D-AVP
MS?%AEK.V\*PU)2H*O&7VH7L8JE:<-7ZMI#/8L&_FH%;"XZPMDM1A3]?>^C R
M6D3<13JO0N3O_1$F_R)B8/ <Z*XG%AMQ@?1G4J)5G)O4.=83'T$#$?F%\A&H
M+HG\V,1);E4P4B:Z@HA1HBG^L UVVHS<KM6I92'HKHE1@=^<5& S$*F4& <O
M.Y64-5+8P20U24>0=- I;0J(7/)-C'S01.F%Q#5 =:D40KT(#K/:IN  \W/%
M[)3%TJ)R]J8^<OFD=%H,5:A6TE$$:)8:9IXV>CY!).N@QB,+4&,<=;9X$XS(
M\BJ%("#$J,TE3)!;P@5&'> CJS5)C[F^FP)]C8V&&R7G\L/60/FP-_I;=0L1
MC_!^8)T3[E !-'J=NZ6)H^]X4UQ=)'9CWZ^UI4ID5H+=#7]%X#($Q:,%YY-N
M[OE>;<\FD5#T.;G+-H=*)84WO<(. +A[ +PDUM,2"&&&Z4)UWKVG;(]?@NH'
M9^M<"@&5;+>U"8,?OC/,)4/=1S'C)7G."UDS1HW<J.W9T,6F@9$!C85.C>>D
M>X3T:)YM/+H;:7TP0\5-@#ZG:3@D:1#F7TL[8S/S9>REM1G 2>Z=@]8SHTY)
MBJA[9#U@/S6.X71NZ:; 1D6=2RK5C)46@G=)ANX47-^A\YE8:79==0\LK\)1
M;I"U4X6X>LGEWHL)#:B'N,;AV[U'95TZP-34Z3/3!B'0W"1PKT.[9,_5][+X
MY%4LBO-P@PD)#@>9]N55LSILFM'I=?A+=]5L&?VP2I&\QV3^B\BW@^@I^Y-4
M;.,3R>AQ2_DT(Q.EM>F:RU[91C:8DLN&;W\>BC/.T2$@F8P07O.\<+P7PJ].
MV,$@ JU]"0B&?YI%NJ<7!G(:OF"M;7=Z="7YK"6*'+ML.!'UJ1#E[]MQ?61<
MDD,L94&R7\H$__&$1'[ 2.0_)!!9T@8,7LC:Z?18TL:.ZYYWG/"RZ+\![9&;
M;68]9@H<AW!>-A*"Q!W&0U./IXJAF>6T5O$XK2%8^%,!-P&^V]KW!OA 3=Z?
M:C1$[2X,4P:>0)*/LA(^Z-L<DS\A4 7G8 0<B7RTM49*U4=$XM.CE;,-YUR*
M3F3T/EYY=LF@-T7OC$S$K$"*6:)I^C7BRT\PD/O 0#Y]@H$\P4 >J7+'%]:E
MXJ#H!G),O FIIF;TYJ[ H:H.L7=8B2F1%F/)/1;T=,_PY82#\)A>]_LD:Q:E
M/VK3U(;%QF6Q[V='FVG,1Z();\?]%?!(\EI*QULOB+5@IK2L,N%A<_QG'UZ-
MZIMOFU]4,$^J,:/W,JV%@6;[HNW=3_PLAS!+W/Z(N@WA3E.':[T@,D<"R0G4
M1L(+&56*M]7[]1F37^@B$YNT]B#B'E[UHS3_D!L QE[^MMMI>_D?/ E>H;'I
M0E2Y@>,MVI6.1K> WF4XDFWSPG?D<.#@?H>--G*DIE*G!:)X=>0<Q82+/',J
M0$U*Z^^"G[WL$>&J&L8IM4,-PSQ.6)/L:=Y.R5B2]<(394ZB+DD!)>*>==,/
M[Q[V 7W%-!21#Q-M/GTINQ;104A.N,*9%N::?_K)\X%';!T,YT""Y#]1^9>Z
MT@785+G.ZFV]64>^"EM'PV.)K#3IY1APOEJ$GQ\&[KVJQSU(#=-0#NUDE!9J
M!F)%)V6",,0^O/[>P4?"&:J'2I2HPXN#/20,Z><&G2(W34V3]DR)<)A<J*('
MX,\O^]7B(^7,$0 XZZA00VAXYL>Q&"K$1!?-L?<-.HR70R,:X.Q+\ #G9:(X
MH]FV):OC.9$0RW.9EG$Q*;1F6MI_KQ:6A^.LH*74;[42+<V)+(@US$[32\Z3
MF82,W-% *3]/I!WSI*?7?Z[[-^+S8AKQ09NTKZ7;N&%[,&4FRYJI]YI2K6$'
MN5_8+;ZT&"?[0;)6)387EQ_1;I@2"*ZSY8CB1#(60DA4,>%21@%PU]$!2(G=
M8:_@V56]#1OO;/$&]UHIXVO9]E-[&-E:EOI<L4-MP CQD,-7 ):2\I30ISQY
M"CV.ED OX(L$9#TY8TP<%"8\)B#T+%6Y\>>_Y4\9<Y#F9 YC<F4AL:.O(YGS
M9:E?_!1Q2[[FFJ,<]))9[!.1I;PKLE3;L$,;V0$\)*"XP8IAA#5XGD255"<V
M$[$L$5CKL1G[,M=SHGUPASPGH-26AM0R@.0PJ=AP3/-LQG:6U]#3\+CT52E"
M@BOMD61@HF!\K[KROZW1?]LO3+ ,$:>/XPH!#[NA6@7RI1LK_JW[)'H)QKG_
MI:7WN4P#P$@/^8WC&M"P*T_#SNA.,I?0'$8C]MV+C>90<[U(Y);+:M 1IYI'
MAGY;E[>T#_DH@(^!(;<X2J7NHMY32!:6:YSC3D_.4[BQFEK@T:)\.&W>M?YK
MK<K,6^;6M1+T#%!Y%G7XMI3_1S.D"@.\<?"OJ+DB]!'4*_OLL%.D7TXSY;)(
M;G:NPW*M>+DTR!7$E\M,*'FYQ"#*-L%FH1X\CE5^.(?CI_X.+U? :YTU >B&
M%B9SH,5 8BZ<,ES).OW^KN.SJ%8X:R9O7;!;K>6$FG=VM\]4-C(0KL@]ZFZ:
M'*<2<H==0_EY'=E]I'%F<ZQ.\!"^'Q;DX5RL+V-SE!&-% @AIVX2%=J4:8+/
MFX$'G3T""JU7D.2#OMS.Q](AVHD48LR!33-MU%P^WUZH$FJQ%FEG)W<RQ.EN
M.1-)%7.!7UP'FX+6.78>];;R)W>G8G::%"F3#,H-J$O/+9DHZ%(F=M,+_\P-
M@T=9:I5:URB?%Z+R+7%B3GH;>=+"40Q?UU">IUUJZ**6;TE2@GS%4OBG=(Y'
MI_V@!0=A4 !11(\P)EPPHT/IVS,=@G.N]:_7HG*4"U+V4G;V'=L.3HYP9)54
M>!A97Q+Z&IU@F0%@8L16X$34*;>YS.;K%.S84GD$^0]39_ 8:2'AS>79=^7
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M1?>#RD@QM$=6&':L91:5Q%E.98;#K>NEJOUDJCO4PAB\@EJ3^<&K6 &@)W=
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M[(6%20C<*1^#H!WD*G' ,6G1) '2XRI-OU2QVW5R,\RT')N8@)55Z\%E<[#
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MR*@)L3F^0;K]9M6]M(3 $XG>8MFLJE7"ED\?-C-@4GL<#U#'RB-''DU8.DA
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MZN)\9.2GQ/L"_4+ZF7MMHFRNM3RPDE,5Y4Z_(Q(^WIN?_K5://_DT\^J&=L
M/QQE=J[#*SH1 0TRWMH'>A.L _WG?A.Q"SP0%''H*CWL1Z7=.?4UP,+6A0UZ
MXCO"S)##57ZUV*J5';NJ<(-!.@<;0^ K_#2,+EP@SVAT_*/Q&)9^RQ#0EA07
MZF1Q(H@SQ)/[ R#_=UVJ.!^JTG/+Q(C^2'ERT(#E%7+2^I:5RQ-4R(U8^SNM
M/FU,W!%5:9I-Q;JE,C2]O ^]?ZL[X)1A/VW+4P.=Z=C]AIU[N#=^3:_8OZWO
M,NF&5=,LL:*A%#0E/$F5S_(,7+3(4"QE/I,L\VB,JM0_1 #GN,'.^!Y]<]C1
M>0Q./M!"X1'X,?\S//Y\MVOH05IH_4H05R_;87EH@R4_;%"KPP9A5+?D_*Q=
M-5Y#*KU07]?M!E<;50REK69)3]Q2[FG9:(F]?M=T\KB("]!#S:K'[@EA+@_:
M9A"O'9E,2FD!EAUF8S2UX.V%XNO"@QOVX0@MK?B]>!Y+,NGN@DP:D11C%P'_
MS-U #VI61-9)]2I)MDONWA!)1S;*O K=Y8#S!$N4@MWT;.,NYK^ D\MZ5NBR
MP@,O*6/4>1XX/M+L+]'T'+JP!RA4P9)0Q,X6_#Y'/VWA*M##R?)7FL%T$U9X
M0%+7>-BVX>NFW_64QJ.RD.Z"V>"RA7!)0XIVZ&(9F&+TM[E(!A\!N*/V:X*%
MW/L_7RY[D*51M\4<AE3K;AS^*B_@7:Z8F>O%8&*/3)4L;;];?'F@.E<8WX\4
M6(5E^8$7F,V]:GS]^,-+#507RQK\V)P49B3L?QU"1/3\D^>?<2@7_II1%U)
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MDJ$-JFCO+/DIQ;65=5.'AQM6@<I?4F%\3_Z0]X'03DK5J^KNWV'-:1J=I!4
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M$,NT/6<EAFW@XV4M]M[!K=VE>V_ CKVAR'"#F\]5M(T:1,BUIJ^F)?VW*@_
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M=4Z<>_0V<#5,=_)/^LOL([._2AL _7F>X_V9'+?U@I(PXJCQU5%E"HH^&Y]
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MW.+Z_5.6U-77$.7:">@$5.8K='N'SMZ>G11'K4AI)<T(+1NEY<R)[^PAI&%
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MA$([#&P.8-&E)4""0SH5+_Z(Z_D!OM)WO)B^C.8SOMS$Z,X$+U9Y;FI,LM(
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M]C%MP*'X0#K,R7E7E**;7;&C=L_ ^C+D2C@0;5;\P/<]0)<<#5[,U=@QK&F
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M?.R.NV=B&F1,5_F@I<+FX;19)HNBNMB18OG6),U?V]V@.8 XPT6U#5#;K5:
M6*DN0(BSQ!-Z4?"R7A0=K-)657NA$8J+C25H%0,G8]X@R@12?M@/R?E <$D:
M$F$MV#>1WS@GWO^2#F:?%73K8597^F">/R=<>SW3Z[V^: $-KQ#,P/87U.VV
MT>!>G175%(8=!WACG9X9J"JVT<AP97*"'9I0/*OS#(DWI)G._RY* DK(<5[!
M<M(4OW$6S<TG2;JJH-3<$GP1Q"]!^1JY\9>8*_NKR^=R$7E4ZB%D?\C%_T3[
MB_Y7V70KX@U:$-=C^ %=8 +_P"!C \3^8,^@EX-ZCTMJHQ! U!P0 3DP\OM
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M:H29Y=HZG^JE<:+%@7"7-!N=+_#9<@]?XYERBA$]B*=L5)-R+"D%<O*UK1+
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M0M^665KC164>T"ELV \BC,K\W#G*J%".P,"-V9R4J3+C$GI[WCDA!]0LB/F
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M>D5DL!ARR?"X.873O3F9T)&(NWN*D?B _9&K$  >4$5L-H7IC08[(IC2K:V
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M.F^H]]72F6[\P1*>@'C?;:4W;J"2(NJ]_+S_%.B/NQ7C?&*WOO!T<+NO=*-
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MK'!?)[GBH\]$KOAH+UC, [L7+/Z:24:'";C>N4=*VYW%VI]\'>\R0M9L5;+
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MDP8*D\@,S A9;4[!J1QNLRL[/VU,R3NM](=A.%EH] +=0_<1X/QLD2U$6W3
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MQ@N+Z]>%T3I@.?G,N0='=B(H)CWXI#D(Z;C5DI>D36/MWP'14O/W6?IWU=Y
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M^+6CIP=<-I7N +&GN'0'>(<)/S=7;5?J[*B7 U%(9+2!JPPVDPN@C!2UT:8
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M6]=5?1C1$;&C3>2TH0)Z2!:X5EKJ%7Z:8AHNRT?BIQ$NQ#[.J]I[B]^O'<R
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M5:]?Q,^+R$?)@[MD]T=*=K*U;X_3,R%#;6N;)4WJ4,@--=H #9/\4UZ<,.;
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M%IUB=8\I[_I+GZ#RMI;9,=W:N,JBOQ:)KPG0]23]'Y,1/68TG']Y&^:X(NM
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MBS63:O7K^B72QO'?__'_ U!+ P04    " !J.JE:%)"T6G'-   A#0$ %
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M^0?]9114[_AI:E<'#5#%<&UQK7W1P^*H1JOI_Q-B--I3!!T4$9')2&>S#1K
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M _;%/YNO:XQRN813;B WDA;,;WLC2Y(H/\BEUP\&>_Y3EG.V:( HLK<OB 8
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M\]OFL1#^)K]!,1#^+,4VEQ[;BJ0![&D$E;G9D3"RDLSOG!,VGA4HEUS(4-I
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M!W1U-,FVXU$%Z.[UK*@M?@9S&F^".2TD[MBT'U\=PW0 JT'!L9[1IP-:.^D
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M^]W_)^R\#*WRCU.BLI-8B$I-^?VRHADOG@<IOGZE.6F;=29<V\QQB;\S4"-
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M,V9SD+R*;(K6_"D?";7KB:US8J9")@V'P9'OZ_5K,55U/1"?V^NX)*>WF[>
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ME;VYS*(3PC+D\]^=S.'+:EIN7DS>[.J5B&\6%H(OFSH[O_WBO92MKS#P#0$
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MS'MW_":P=X+8?=#3#1V97*[2QPK!Q%W<\E;)<HVQDO,+Z]19GJGG-%XMOP_
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MMW^ 4(DP!2T_[+!P>QOSM-9-+$,<2$E;9W:]M2F:U]4]G_)G2+64#F#UG0#
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M.L37>),5B11^S^:\,*@R]^LZ,+NG S](@;E1_->198)X'5Q+>B/JR=5EP!E
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MO3;E_5O*?PJI[H.)(_>)>7*AW2P#[/M_O.'DD105[G2G[ Z5\]@L@]@2V@W
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M$I.=/AC; F.Q\>![/ME;(^8S9V-5X?/ER<U',CU#KU:&U=:S-GY#R%)$2VQ
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M^B&GK>=J_+%;CS#E*WM?,NLVG/_^E!9[.21T\@1H.@75%'LPS)1/QU0K-C[
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M8-]#3[3(1M!Z%,*/XTOF.VM>\?! F@[RYQMZL%>X &B;\<KHK!3VJ$>.!AI
M?(TU93=K(*:M5.KTW9F 7BE:ZMYT\Z(>KDT1[ZKIG>!L?/3FQQ_;DP[+7W^]
M!"N$M-/DWPAX7FUR)UQH>K#3C(,HLMAK.*8LE1X_\>?AHMJ>#)^[%8?D$XKQ
M&+UHWGFUO-E)@G+T*)8 QPJ""5[C.CP>:"F9'>Z^OHSFHO4YT2?C6D9I2BZJ
M%&_?7-+,:PX]_4^VQOMOI8/_7SPX^[VF^=ZBZ_9IR@GN20O5(3F.PE?W0K81
M_Q0^N>1[(F=Y!OBX3KXC21P_S2@_ XR= SQQ=I)7(G'VQ!BJ?IH#^I5)O@))
M(+,2ZRU3I.=V5%5UO PXFDZ_@1LI9JH4<Z42QL\ X.2P+$+T\7!>-\^EK*Q(
M/EL[LQ*'6]3?!G?YGF)HJ0Q6&U2J=)XI7/UKNY::W[#C2[#53S"X\&P0ZI06
M>/  V-O@_I$1O-/J2([(^W,U;\60X( X ]P<);TUPU=F7:7D_R_MS"$.X(<Z
MA,^C1-0N4G]E%WQ":]"$M*6K"AW0'MF<%9Q2Z4SJDN+_D)*D<2 %7%[:O8:;
M)+Q.^H.DP Z9L6C'6GQMM%H+A[S%\?1<%]V5A/_HA0P#_!W_:5GR/ZVR5;I/
MH_HOEA7\BU73JLDZ-XAZF-RO&%/A[F84P;L FXTO=L>=9GF$3KVX$Y9=8$ _
MA)!][#M=1"S#.W6BJ$B\?MA1/D_4CT7A>LA*UN'.P6A]3OCE639%@6K*U[I\
M>?^I$0Z.N C"(%$;O]V3C$%<@*!. FQ-W)!>CCM#0]#;47HJF_GZR\WG5'"B
MM3A,'O4_O=L5R?%+W%!QG%[')+&\M[F1(!O!6-TEOC1;G'=IW1.>(JHJB6[>
M6+4N,&99XZ&A_3%&8_A?W9%A#@KXOSXK=_+0U!E@0_T,D!I'5J[5!SC!7+;.
M +\$S@ #M\]Q,?"?MCI!]8A=&.8HU5R^>OP]Q&D&,$[YZB_XM=!AI27WYC=A
M*3^5GF2*04>C?BO/_C?/Y#]:X.709SC#-W61F/#L\. T7G'^9++\G\T$[I2B
M)]P.9X#\M#. F--?!E7[[1_S @\,@/BJZ'C .NJ?GPO^[U]NN'^\%/R_@_]W
M\/\._M_!_[\=C"CI\@&["018 KUR?)O!TA)[]]0$+MT 7JS^CSIR?R^JM5C[
M>ZDM &*X>PZ#)3+PCN1V;N Q$[0:K]B+SGN->@*;#=\VL=<N;IE^Q: .JWLU
MY/7[ #WM+VZ!57T,_90B$K8BP)KF"(:"B%YG (8$C%P\B?6TX#3EM/6I>/(<
M,AG8ORB/<EU;2#;MVG;07-G_@2*S)\\>82R[F(EW0\^I,=U?2Z.%T:C94+>Y
MMB'&ZN<'2,S:WJ%OSC"\J6/$G7(HNV^ICKMG%#VT NQ*IB(93R*O8)88^SR4
M*WM^1H&#Q5NTKEJ(#2;&N+X<OO(RWV <C9SK. /46>XJXS4)3_"&/>5@@0TA
M03-*$^7*WCRN"(Z);1!-7Y:Q_<$7C)CY!7'^^,:%?F4"N LX.T/F7#JG'_%
M=ACF,GGLG/7.6R?OH*H#'9\=B,Z2&[_IN.ZA_'SV[<RZ]G_4DEG,9I/[ENB
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MHZ$^7TYHHV%/EHB&,&<4+^G\3R+7=X5Q*5LRI3#O,X SZ$3'^34A4"APB5S
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MJH,6 1?]-UM]R(4?9;RW$Z.B2772':^H38Z0G0Q\).;T"KZIG[ K<5,]_YL
MR1_!S5\HQR.9AF^_.;N]_?YUWP(."):^2KD:N:H@<">W>/,*CP3!,AJ,N9*S
M/1/(=.L]I5-KXWJ<'SYBWJW/=+V',"2.:@Q]3+EU9S7I"7OL?M[=?"1JI0^#
MQ$["(]QE&W4P?!;9(@*@?G%[4+W?L!M#"(-4"4KA*/W0!SBEMT+WZ#ZW$WI>
MFC&[IZ>M_I7B\[]YK/I_L^.?_)6>]!D'/LW[>N#B9)O'FCH'#>",M'O^T[U
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MDZ-+@>ZB=54E2Q8!MV1YSNII!BPELMS: @T$BUV>G_K6A.A )U(N 3OS"KS
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M#<J"\R_Q5R%3+P!IDB,0^09@GF_-\BV:Z0O"Y(O.NC<]=P]AX;'62*LL4A'
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M4?&3J7:U?&XR&@7/S0*U=7G-3_RG+;"_6NQ.H;>"&P$(+)AEY1S1REU%:=I
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M!B*2K%WIF@41'EZ78QTLEKR=C54#29WO2+GQ6'_IK)W!A35I,R,-<+ #/!!
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M=[+!L6*BF?*B.BN<34^=;")FM!WS-[Q[@["MG, ;3*@;;MX!K\Q@#7DC,>7
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M_W4^ DA_(,H$H;(K=S27'>;!#JP4N]EA:&\X^&5\]W%K'Z+X*OS*]X++!H]
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MHJ;QM=(6OT@/;Q](.:K![48H")296&S&88G3^M7#O*-+4W+]S#O.,@FT.[]
MEB[(-X7!%L\V@-6[05**P!YCL^XT^2DH>M&EMI/9G<+MUG:;7GK/L1I59/+F
M CA85"I&3R]%I_[4I3!'97'STXTC_5E;+FEN= >$FO:C)<(X<-",!"A_F& V
M= 4/]G<]?0%CQM&&@6Y!S'G':X6!3T/-[!ZF:4=IM42J3T*_>$6X"6E_FPY\
M;AU"&9]:BC4\,DKIG*>!>;B5K!^#J;85'(I,YM!0'6V#Z#7<=$+ES@WJ"-[N
ME>EHMR#Y $8R/>:,>->\36DVX?P?;/W,8ZZBK@6-38VWI<_O]W8-,K\=XBRU
M_AI(.0)BA^KH8.>"&7XX2%]]=GE'A,L'4&F=XOYB3T=//[M.3)/=@P/Q%1CD
M30*<5[C:"@PSJ)^P\=9X59^A'(/AC0Z?3"C>LQ&4N$XC\49PI"BG1N.VC6-2
M4GSU @GPF]4)/ \^N5)$T/L?B;I/-/[%=;L_2= 6Q0A"\V\.[7SL;@?;8*U_
MF86]@8Q?^4[JB>+ <N4K#:?TA(DM_VS>9?\Q-Y@$-D\,[WB? +:,6,R4?$[G
M5DAH@GN=S:?$Y7O6&"2K)JO%$JS/4@_ $>@+R6R.4U!OS'ZG="#WN(C!T"#Q
M1\(EW@CFUWV6;O4'!U(3:Z@+K4 H1'-2<H"G+57D4\&F_?"&P9<OD1'>T9<%
M^.0JKBP52J&'U>ZV;(D\]_^YXH4,Y:+# 8.WFP5*\*Y/QF RCO$]EU(\7+@N
M)UVZ?A?15/-:S! FM=!"T=8*?$*E-%SF&</*F.3DM/ "TQ&P5<2QVNHW,<"P
M%69CM0ZZ@B6&++X@B!6N?9%NY8QEJC,3X+:H_NVD8?,3RKV\##3NQXJV R_
MQ)(W+*Y =32P6W46F\NCVP;2[[W:>-+]/2L:(X6">O>_G*43F5HK1<H"@7B8
MH[MI_I*9<*10IKOTK_=T/X(\>OPV1178LQVY[E;BI ;C[<#A3B_]_<VTU=]F
MLLSOWJJS=(=+;)HP_+%BW!5U719[0G@XD8RTMG(:[F["GI, MX;(F'H30?PF
M*$O0E4!TT2?D1 KJ6:\,Q65*XM_/U_"_(0*AS-UR/N^X)SW]^].B8E3;!;-;
MI5GLQ]\(\\F)+-#R!D?N]\>ATS"B[V"42[0TCC(G(K5+ <"N"?,;=3CCK[<^
MWUHW"OD^C/S&IAA]-59<+7NH' 8Y2]DBRL)>83-;,'>$=@D\!0[,WC(&SFY"
MAN:P:#:!6W<N2<=/O@9U-PD#CUSQKMD$L69\ &01HK>HU2UN9O3=6#7S8=Q<
M<[3/ITN7V&596+I>]DO/1LO:3%?NAW6*AJ.N$ZBL<3J+<7$*#W-ACU*(U[50
M=$8;. <QI65QS@+VJ$!K6]F+[K)?#\M.@>$6+,T/2]06413X'BUL9GP.07($
M]JB/+^9"QZ#TMP$.K9H+-.XT[@RT29"UH<O$OGDJ NVBQ0T\7 V[J62+D3>H
M&N=+V#%RL7L3S4)8L?K6?'#!X"@"R]^6R3DFLNODN9[3T/C#$CM6-OE,VNGF
MD_B>(.A->%3Q86Z"65>?R&JO0>8MW&[7;BRPFCEZLM,@-3"_#.KZM,E$<G0X
M1RV"?5LCP2,JY)P'"2"TGS3@,P\@.&/@9&3[&<1",)HX'&#ONC$E/F]/\21,
M!V+/]JQ 2_[#A6853='!*\OO.]F.8VB/_+'@,#NLS02;#4YCX90]0UZ-;T]O
M6>EUOJW![U;WAUPZ/+4ZV-4%G>!6QDWFQHJWMCYGA5[GC6M7<N&*6\7G*VU#
MI9-^YEFF;YM>Y;G"7THLD[IBH=?UI_3VF\U%<+2Y$"XV;5$CD!/ZZMM/O+7V
M,*_&#>?G5E[614--P2B@ $6F-G1UPV^EF0J[^1#O!BDQ67LZH\24#Q?)=Q<1
MR4O_M"SK3E6)OG^:^]9,&,*R5\JFJE#2]F^*#C(&TC;M\R';W>^Z!<E-WH1@
MX6U,!HU>M:B0FI^6HUY,XV5++UYS-SLE9P1P+.^;^?TI2^A@G9:X6!?R*JUS
M%/36:@__Z8:PPW?3C:M%N@86NX RPS7(]UJ+*8EV.1*@*P3'5UJX[I<2@L'.
M@+CJL"V#F5QW+NCY1MR5=;D'>GH^2-'?L'Y8HTOQ1[J>[$<B"UZ3!29/'<@Q
M:A754<7J"5UZ<_>G+(OP=0Z!6R70ZH7)-P3?"J--<QYL8$R%X\2;RZ*B92,:
MURG>BZMQ<[U9:6*[4\49GX@!7E[+%*ZIJ9VH*7WR##VX(M@/K<BAJ7S"^MW]
MSM8W/[;"I;@P$!/^4T%/(;ZZ ^T37K8$%[LY9FFD+'.<HA!\4!$9Z:UDXP'!
M3K9K+'0L,F(G/K0RB?U64V.*.'K6,"AMS>D[9+JO#V/&6GR%TT@!Z_"&[7)J
M8;M/4%-/NA%.MSR8MJ>O<*KN^%9\BS10LK&&NK;Y40:;/)-CBK/+X]3>1B(#
M>Z[';3-?.\Z'>5EOFL7][4FB]43/W_Y^3+STN)5)XL^K&1O_[=4,HS3V@E%$
MOANBMB<&&<@!$\!_PIC)?G%D"T1(3&N<];VXH$J@"L8;#J1.;DV7H]I<0]'>
M;PM5,*7L 308DU/V;<<G"AG:&W>6X_0=U.;%I$F #^EO.EPUDP1Y$]:4DQ(T
M/$'=5[]YU."VS>FPFT>/L'8AN["'1= 4S6&"=8DC%U\+[EK&X<K''*V;KWO;
M 5K2"_D2B6W\.Y%89$ACV)MF]J5RBDXN =PE5-%/^R,'KA0/'X\BQ]>F.O$7
MT,W3_>6UQ2F>K^EK@)].*Q0WC[KQ;RM@8+S(,1?G&+P2>6BF/:0NU]MV>D&O
MEW&5,NNF']?4 ,<WK4_EP9\T/*0JU[D4\#ID/QGQP[@+0P)0.63RQ Y'F9
M]NBR3%U%[\3>H<*'>CK8^?9C9K8+>U!_G7W)BUXC1I97A9Z/6H>_^?K4,#AV
M?(F->4MG$7QI RW=D(5'=;,9AI>+6*5N&A+1OB;Z;>P)-K!LVB&E^1;H\Z&N
MH4C@%=C+4Q5\8;NQ:G QWOHA3G/6L="X/FW(ZV[Q\O1=#@' CE /1S2%1G^*
M$;?[KPGU4^7)1=H@)T\S2O4Z;&L:34J6^34US1IU-\ZD7JOV%SW8ST(]H)72
M#<0%$'#3S[RX8(.+9GC724KK:-S5>?4+=?5L?+"\';YWZ3629Y(H#WN"Z^DR
M&:(D\/]0D+_SP[.)T]"H'J?86;S"7M19:=+QZ\"J</>]JD>Z=2;EX[-RD" ^
M>)$,(/W+!96PW^=$<&'A7D]N8 :7M3C++.PLBQY&7#%U?T&8FO[*6CC U3;
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MU%_VL!*:',L.\'U[SC-@H,$CNFA'4%!WDF"&#6F]:807-9AP+1P)9%N;E$9
MZB$-PLU3^D.O2Z!"X3M*/>?4\@-&;;&;[7XN;[VRC:$6*C7#(O7UHY:CV5H.
MJ/EHD0F"BGDMMC7&NEBCR,2!B>EXSR0_+T77Y-8W+/],^&?6._(BKQ7O' 4\
MG$(P$&[CI#,643&!5T= K 3]21#?NO%1E+\')BU DS"7'Z\NH^:63GOS.T)D
ML*4I<H%(W8%QI88"C]S_/'ZGHNR22R[$(.B_Q/@7SF^(2J5,48\*1*M.]9U-
MR4?PKRRQ,)XP9T')828#I#J'S-OAF,59=\]3EBP)^MFC.[/XT9M8YE#AFC.1
M=B"- ]V+=;V 7)W:V.[;D8.FB2O*V6[LMA]WGM+R3\2].B4!C"FK P:6QD9T
M55Q</,W/D0#QJ;3'0!) J2S&A*B<@CB<(@$.>(R)_^J.D2@&_)"1H+;V:G[]
MJ+$\_4O*Q.<YM*;8[99."*^+XM7/W$0I0RWL8%SV^HC#B4O\R\(7&AE'R<F5
M750VEK\8 .Z*I:J18V-9K<"1%!4VN75OK3RGO=!,X?<F6\3=E)CZH^Z[]PF"
M.2HYG*R2SK*2WA>UT[_$1UG1\OJ:>"]AR^7N4+ MM8$XFH>W#Z+B:!TDUJ67
M63Q_.]V"0,/7#,2;#+&,A<(QM5V)4_VNU,FNK"'E<_>L[7O;E/,L*^[W/-8?
M>WK)'>^J]GQ4WT'ZG.<0'JL+X1*^W[,#/9OG@-5CTC.!(TO.2HF/JU3':%PU
MI[EEU%B^-\,(;OMVD2@5@.T47N_A:(UO3=H3YB>U(P7453^5'-A,>EE>!JLR
M.USPZETAK^?5M=2*I$LI 3GKDXTVYQX9R##%]UWP5V5V<LI7I7Q,(_@L$I K
M$ER@?40KDF;'L[[JE:;82._D%MVI_IOF_F^W+O.<2,"FE\5O_A/#,R\2 %.:
M4%%'CBH2X/GP20OBW8:[WS*'QC_I39U\_J]AQ?(NNK0S:&G)-0@&7*)EWX#3
M@%@L' R9$S;0SI,_!W:R$EXZ9RY1]C]_+*/ .?_8C02@AQD50JT7F$.W%%AQ
M_N:3"I1PS-I!!KS[B==15,O=ONI&WH_<E@W3^^FK"AP<AE-$;O)R8@9D:\X\
M-"HGREB#V<U4IT1N\7K*F]*E.H'H?VP?T&=WY:P/KX4H5!?DYUG]S"8"!=G=
MMB/[VKX<BKUV;M$9W"P%TT+,1?"CBQ97"7HX8"R,TQJ+]O]9F&8,B7=UX^Q\
MYJMUA]W&'& =U\3#YSC?,:O720)0<V/3 Z^-29EI_PZDFH$D)S,;BKY&./D&
M[ZBWKE^^\K/^_E7FU--)';SUPO9M/BW@%7L##:G<%YI?3FSH(H0C9BR=[GRW
MV7N*RQSWZV@[N93D;^=KF[W^Q2?9.Z@=C9D;E$R@LG2_J4J5%,?-&1SG&&=S
MW  :V($)8U.Z#?S G:[!,J!S^%HD["&..7)U&K--];15YFG7E2C82(T*?#C:
M-9UZ-4Z[.3/>%1,#7,S,P!D PP/O.EL!(]14P[03=>TJ350;[JP-?_&QFUGB
ML$(]JG&] /7H2$V:R\W#PS5'#JDZTM*:!.]D)UNG$W9*J +Y<LD.BK*=!)AZ
MJ$7^S56=.,!LX<($MXSJ8V:=776:KOL^)(]+WT\-'#BF?76:05W"9$B1927P
M(2^Q;WG$8/7!7UXQ@URM@Y'Q/8\48AQU0*^KM_#*"\3T#$=)"/.B/=DA 08K
MO9[P]9A6)O<_J_HRYI0/T'#VN=I/O[#L8G"!Z\&&(*03N,<Y!MXD.T*YH9*X
M]DCRQR\TIG#C!+(^><14A_:,I-O:L32Z:<O"S6"I__;MV]CVK!9L142QV=2L
MN3W::W8\^6+9,5GX;[?*^3H9"N"M:M8*Q N/%,..ZHZ0/X7AM3!$=4!3GP7X
MVVQ3_[Y8TZL=[U76E:Q*[&!,_D:*7%)R?.'4AHS%YJ[PMG4LV2:_II#!0#0C
M 7VNE&NTUFY6:*:/$X;T9R40:UNZ2*,JVH_]==2_ 3L\LIR.3_0ZV*2;%&M.
M,N,*-_30&1-[<\8]$LH!3S_?UAFI*<JZ6N4@+;[Q?L/5VNGD@]C'G!9[_0$V
M^H02_ S#,0!33 9,-[/@KUHSSD(*X';-\PX0<*7*<DW#[ K#=$WK _G*]'WC
ML:<763PYQ:>WB=II=K1'P<S->]O#@2.=EC7U0-D>5J=12?"U-2)K'532F:]#
M_>VTATHANN>\V.%-P(6)& : H0DY^.1=F2:VPDL-;YLY#Q$2TUQ/?A/+C?1/
M005><G[I2?_C37<@)\$>ZYV-TSGJ'&L6(DK@^$,/M%S#+-!(UZP-6N=5S3J7
MTLR.A+SWXLKGTMEP<#K"2]Q$"U9TX5H%$J,U[4QA$GGF%6-]ZN1 ZR-THZJ-
M.J5;5@$5[_&-\',9EWK&X4KC(%H.JD*;)3KNF01$'%*X(.PA =/-B7PR#+.#
M,TL*F&*9-S Q_M#)#N1BR\UF$,I' W(Y)F=/A\[YIRSOP<83J_4Z?PG*)TT;
M,)GL 1QSYWRU3D39P5!XJG[R=7SLG"(3!,444=#T5DG"(:[H;KO/#<:DT!$E
M[NNR9;M F/(XX<FI/$P2%QH&]RU<0ZL=?4A%O9,291IPA<,^MW:GSNU#$[S"
M5^W[O71KL4JG$TM?0<Q-6#3>#WYM;=^>*J91/YE.JJCG\2-#UW7=#0L:V.VR
M%PX3,D2F8=>RFJV 2/2J=JCZMMOH-X-G], M3$JU]XQBVA<,07[R)@[<00)<
M@S -FRNYP@M,S-2XLKHJ&,UO6_):]\&X-#9\*X)"GI8  (![@+4[Y0-_WL6T
MQORCPL-?SAM?Z/*\[Z9X/E+P.]Q^*&H/=@UOXH_Y678I;^+X^L,C]VF/%75Z
MV:,!=^4;Q;<OEQOUL33TJ<I7CQ8AA^;QOMN[9U?Z28"W%(0[)$!8YAPYV$M'
MX:^#VUN 6]\M]@(%"8-#11APRA[XP?_B'^+^^_<[-N['_2+$_;@KN'],Y/+W
M)P&4W4F A0=D]P1>7*U#'?"+$B_08G-/)9@)B$@2X-Y)+,]O.,_!U4C"V3_U
M^+?1B-^[2 !^#.H[*#><:-%[=CX'!8;_M<-_'JQ:#-Z'1^[3_F\A?V/W'^>X
MEUF$@.1;S[)@]) E708Y]:;D%Z!O7QLL!+[9<<?6#WC-8\/G28"A;=39"7C)
MJ%E%3G1J2+7&^J13P#]QUMYVV!CQUR^H$6[)D #[IZXD0& <?N1DFVOQL-'L
M>Z.@'I&.G03X?59' J#4"/9DJZU* A#ASB3 [C )P 9J4JL/<$GQ$(D<^^=;
MX$4Z% F F(:?'L"[XRJ&=X F^3/].;5_OXY_1!YR]6B>> ;$Y6[6^(=-K/N(
MKY7K_.WZWVGX[\0-Q-'">U,J2(#,]@:Y=:># 8,>K:9*K7X]QJ$Y/J8A[7DI
M.W@[#YP$ '\A 8[72("81VX?])RK[V.*^0[__1".Q":UAL+_VY3\'V+3;2R<
M$/T%N(LXNS 6*$#&LU%_,CT*RM8;+^7GSS_T8OQ5F2#QGHV)IT 18GRZ.%=<
M;*[E)5+HR)M4=^\%._"$\0[&X1NL[^"VE< W'S5F%2\4MK06>'+5A 28#_U3
MG(P$"#$C__CQ;)Y(($L'HTF U2?D!/>?^GMD06W2)0&R\E%G>%?BW3C\<W3<
MV45RX+3; <?I!UA]#+"BO/V_[E%M0B#L_XL.GT_@2XDJ"%H28!)\]D'WGSJO
MD:*]L,D6$Y.1UYCT,7;<.]O$NV^)@S">7MK6!^K4K&'7J6S3-7,EW-U6(P8E
MDX5G$84O 2\:.H(/&/XL\#42H,L \:+ XO\?O/C+J>C%_S2+YQ]A@J5XE^XM
ME2)C]11NU=,LIP-%D*O?MX);-$*#^=#[Z9I_-D+_28^ ?[,<D_;'P/_LJB*^
M:=T.WA-?)P$.?Y  :_\5A_ZMZ^H"//S9J&MV8^S>SSZZWEDJNE&N6O%N73?'
MY7Y&C8(*-U0-Y9M%?/:B*P=4%6-Q2_'5B+^8M,2O:OY>$B#8&1SB:Q%,H"#'
M)X%#K5Q8GYA,BZN.R;B'A1 M6TF/VK.R^P8O?L60 -[5MXKX=P$O+&W83IB?
M8H_RB^8&/&YO?_8U<9NFLOX]#O\K\7F5GD(5)S<J)9TJAAAPQUO3BTBNC>L#
M1]MZ#ZJ=09RW2( GPP7JSK7L+ B8P:B LK) +_O5=#'6MHK-[DS*'\2;>*VG
MV*%PR;5:SALGP%O^1A)!+>$\[Y4 0;(7*,SB_F;QR3RX3*:/0)PF2U,N4<K"
M-'L&6:X+LL7.;^DL!M :CX@@";9+B!OKQHKM9@ZI-)45"LG2"3>_V^HJ)]91
M #+'1S9(@&K:T$,$+4QW>&7L4+\.'^9_M*WY"%HWC>KO!/,!?JO-73/?_/M
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ML=>3\7YIE13_8:Q:'3E H,_7-)],VH9D6JLP&+[\\=>:FX%I@>VH/><3T;/
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M^ST->?H%CH.].VZX#3'V:;_PUT\+,IA_XGSL=>]=$=K=K;:.V#RHI8-/JG!
MW%C"+8N;(.CX<M!9\=E<AIG?7V0$4[#ROS6:$\.]REY",F[,W1I/_2_LO6=8
MD]VZ+AH_5%005*I2HH+2!%2:M$141$! 0+H0$:F1)E4(Q$8OH0@( E%ZCW2D
M)-)5I)?0N_224)*0>N*<>[;US;7.NO8^^]=9/UY^<#T9XWG'>,I]C_&,=R@-
M[>N&UG]Q,G["YU9GTX).>$.P)VEX?O2W:S^.-S !\6/=]>.?Z2<?&4I!.TP>
M62E_E:!]^*56Z5,]BL2*S?$A6" <S])./*?U%B97J)5[^T7^V$&MV>ZWJ(M'
M]&_-\3NBE$NS(UNG5Z$U/93QF1<N35)3[C6]6Z!G6>BB/OB3325+4A)OBNO\
M6#68?4U8&'2Q/Z\R\L9V-3_QR([)I<>1LW':8OPB^3<.%N:50FUQCK$^I1Q3
M/MRA'7.?3(9+0YKZ6(#KI\X<(@N>?C-=FQ^>;_GH<\"6ZXF^@H,G/<\CQ<L2
M_W;C-LO>!(&':7+N_?!U I%I<@J!-'_6#2D&X/(,,XYC-[?IL2Y$,C7Q*@,0
M6$P7.T!F+H"G)0-^;_J]7#PA]9,N ].#LW72$O./6NL_G1R,;Q,/1)B"<Q]3
MQ4DU/_J=ZC=^O5)UW7ZJQ@#4+1\ >QH+'<S]GX#*IIO(D/+V*];BPP2]S&$;
M:[S5?,4*V^7X'!T!8]L:9VR\FSHK!?X#$3G#D]*Z^OO_0&/;B'SC>#=.6SIV
M!W6\LK)^1':AMC96M[@AK*5HIZ>3NH^2DN]6MFJ=FVD:ID?UDB?G.^R4X3ZZ
M7B4DNP5KLU;T^5@V\U]#MDUQQTN:NU2!"Y"[PIB,("6RV6D<=JX4\_I9>QO%
M<7@),OU3^31B2[:V<-NZ*4#91KCF7)BT(T:_TX8C24=^4VEG@QEN \7\__K!
M8RT?GY-)55B^,SF\N&QMT0I!2<GH9+'/ *Z;9PPATLY@G*%L6  J_(J("E_D
M!A58L":F4X'O'DFMU*K[TC.5=7^+1?W;PN%TLZ&A<:AGU<B\H<'.#"7FP"R6
MW@>LN@@[/HP6-$>_)H_A8QO3SM5/O0 ^E:XEOGWFRIR0+6J3RH .^?SD/EEB
M4^"H;56ZH'?>@_._Y[9L.'B%;,9C743KWRLK$M*/M-9D3EG)RG^\&O8_?;KQ
MK%1_^-=V9U/W</!"*_VHE J2[2*<3;E>/*MQ(5P\JU)-SZ=@=$4I<56QRZ_@
M(A?W?8_C^T21P:8[N5U\8GU&L,**7D(NDI!"@(\_H?BE+-&0'C.5-WHDAV$O
MQ[=RA>M\[M:G^FBF_)0K;PUE -3L<"AK,)!I=&\-?O+.X!_ BW?PE)(%FD,0
M>&R?@$*V+C]T\0J$^$Z\0.VJU5N$*,\@=>&0%\-4'5*2^^P'\,63E6N[LEN?
MU,([B1,3?7ZH#]NR,M51!S(R3Q/6MN9V?DY6EF\R "-9.SOKYIB$I25MF;(M
MX)7N+CG@[D#3Q)Q!2Q*.W%F\A@\=&G7@%V :H $%\J-16P?M TE6T0@&X@Q4
MC K?/ZP8D&+FM]?>2+:]#$<M7,XIJ/%!HD\D[Z]/"$$1X>4#[[*:2*DM">.'
MSD7.TYW]+9+I#\UN,L?^R>];?MG=S]Z>%T"RN3P@Z2\85.$%X]Z5UPW'3X]+
M<!Y:?'CP_E!BE<]Y#JFOX">86+0<J7(.$KY+O=TT6+9-E9@7B!&=7/5%.D9D
MAQSRG<A\?OMTIF<DV06\'[6/BF  'JO+4@);,%4.[X&VC7AT\3.!&\W>DISK
MIFA>R['TKF L4HBJ@4/9D';G-N5:LN=,DPK5KI'<EB0XLGV>)H1/P]4\2I.%
M6UG?Q 8OXAPCGS7ZS EQM04XV]D6C]T.<F\HT#YUE772$1@2_-@)>>X*[ CE
ME'\QP6NXJML0=)6M(89CHC4B_\?3^C-3K!;QKS>E8J9V/*[%>4%RD(?5+O@Q
MQVR6"0L:Y>"(6N=S"KE)7XWC1.^]NTKET)HS4;#]+FQ<P,QT8$>:=(XN*OQJ
MN[S9<PMM3H+/6(+RJ;DH\:@+7AV[.^F"PE*]<+>9<3)GZ PKE:>8JHJO\JU/
M":_F=RO9+I$>65(M559B>WTV/LXV[=J;T%[]T$99@C(M&\U)Y<(AVV-4YX4S
M1^I#L^=5"7QGG*];7RYGU7"*+;C[2Q5]]WPP[MP"U7@V!MX,QNEO<S( [LZ[
M*R-D5%MXM9Z8;H/ TZKR)&"7$:?()>N#C;'B!SJ:!3F]?9#3]''@49BLZ\<I
M%Y!<[+20;[N"[B4K@51!2^46 \D2^T^WU\];$J25C*I'Y->M* +A6QME61:S
M=2&UHN6?CU@8>&@<Q=S S'[T=$*?)/TJ(F&;X:?R</GM;*Z2Q]RHRD'Y79?R
M,&Z=3J%G#+.3:C8YN?[(L?O4'<1,F@L$I$\A#(P3BW1UDW>/L-P.G1]Q&,BN
M\*E]<TRM33;ZPF&EK@G^&S=ZW%0N1T]ZZPFW:W*;/A5B#8,OC$"8T?YC$>@\
M X# TV?I#BA_/[JZ/0, )Y_(9D(X)FS:XER"%D%:[FZ3G+J9]ON."1_K$!%
M+NE&3I?S+R_UH,1_>G#M?*3O4@(X]D-<^EJ;APHVXC-TXO/Y))HXIB.7&MD6
MBF4%G9_X7SLY^9@MRBCX*2A[V,#. GZ&?MF*=+EOPFH3:9[J)6A]YS9ED\8:
MT&->="U[<[)IP-K%!5GE?I.4BI>9:39U&!\M(;=U4>KJP\.($V2._5ZJ)*G.
M)T*D?_][V,3[>;:\KUR.)*O^)G5HFTQ9635T52QCL;ZA#E8I;#&*;:1*D(S0
MPK'J5J;1H(+6:[<FHSP"&8 F:O'2U=&?-JK\N;KW9#*DEY=IS_SW/'GP/-LG
M+V)D=]5!3-Q:H3[[KXCSZ:"6.UN75(GA^2L]RX=NKFGGL*R@Q!F D'T[!N"X
MXU@CDA3/ !13'%6)CML+%/14(,6L,*B"LR*HN >QT:#6J^HQ5GMV"GG?3)K=
M1%!+J2)I\TN(RM#:3/QTZU*:JK^-A;5=Q"$'WQLG6(WT_-VC0"K6R%.MM(A:
MRO5ANOM5>"?6#JFY1UV7G4>V*ZN9R*W60ZL";@%3ZP5>JR()0:P+CS"OJ7Q!
M"ZX6KM)\3Z7>J+=R)E^BY_>9_;2K5$E:NP(ZN3_E$VP#&>F,#^_0SQF69!V8
MYL+;(Z*KWJ'+X03[$/2>WI0!B5A:U(7#AI; )'+:;6UYOZ4D>Q%SW#8ZOY3J
MD'^ !L<ZQZG6SP(]EGX]HH1P&UKQ_IW &#O\[26X*U73C[ 47FXL#58W!_(&
MO6N-X:29-R[[;M"H<+_][<U'2?B''I/H$=,O,3I#JU89X\O%QF*9JN9/TQS-
MLV)T5;]\?:"2X%SZXH]Q@6SY)T-BJ<MN HH+JI6KD0?K\RGM$FH6<JOC7E66
M:JY=WDJ'_< ;9,Z.SQT+A;.KN[JF!&MFM#D[?^UT:\=V<&A^)%K%1BG\DRN7
MTZ T)/XBDQY@[3)G _RV;1KFP+SFI"YM70K?PE875]#*AWHD?ANBX"_6K#2M
M-*Q96K S>__LECFL7'9?[#,JCZH\UP4\L>II[HQ_X9%_I7-;U<]!_3M*2J(T
MJDW?Q 7L20^&8.<]9EW,BL64J;+DOD&FYZSV/OY7QM5(G-=J#U<3D#0?S?&K
MS]2(YZ?&RV;;D<(W)TJ]L"@#3E:CXHKKA4;RV=U*3P-X>*)^:^G/U'*=CP%P
M,#>GXI6(S%DJTV6:@3A5BHUI!B5IC5&[2H9NG%YT[$<J5.5]D7P!Y87N%/5[
MAM,MX?XF%J;HC;^)-J!^3FG6J?=2;-[@\ZA2I(),\0CY)KT1=6N^XQ=F'QV:
MH6T;3C?^<6.K&CH;+MK06!?,>F7G&K@0E17,3[T:UCS2%1A0K%@NN3-U!\
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M!8VC[PU$Z$B\.YEU*]N#M:#WD=D/.&"3?@%F0VHN\B]^2$HM(B%^GRD- AM
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M8^H;+\I3I\'5RG6[K^(@\=Y/\,??YV_[O5=K:F#/NA)$P\RE>]JHSB$C1NA
MDM@"^ ]%I/S@.K%&R7.ZY*7HQ:D*DY2SHA2S/B"N'<*.69FM@E /AS$ "4P
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M4XA^]GLD7$;@*T)0!N"5(P,0GKUIV4MC*87CKC =F]O\RO\(_(_ _PC\_U<
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ML82\!7(_'3DGS6KBD("3D=[RT(Z_V8,ELF "=C!5GQD <W+3_O8 +5:V=("
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MB^6%@JQ94054Z/>?O\)CA1I!M,");_/M]46)WIC9C.V7C8&."QE*W5&GICL
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M5X>M5EL=5=<#)GY<5-"!(Z?(H)"J>>>+'##H?VYWTAV!ML',FN$*,<8ZF+U
MM.[6P\25\0<A&G%G'UZ@;W<ZK7!BX_/ 1V.9W (C];GY\*8?"&,3)=$7[SI+
MI"5]?@#.QJJT<Q!M5M\";6$GW;L:*0 F]A8^^N*!G1YCS8BF 44/H02):T%T
MW,F?U'+?J5VA$ZIBQ#WF#X-OBX]#9[XC*("0##*'^JP$Z61%*DZJ\L#M9_1C
M3J^'KW RJZZB0%T-Z1.932//S/LN!.V'95MMAO\XE>[!4<Y^[!Q34L]RY7,>
M2SE>*;,+2$:^YWB)M;W9C>.3/>=7C=K2LB<-VXJOJM^!B&LYFS"T%[H",4U
M3NB2:1D%T)@,/TA01;P2V0;!L]L!,98.%$#K@VP-'UC[%T29#V/J$NP3$.GO
M*TD!]-5:40!^BM"#1%B_'WEA?3EP0<WWNT_D/U4]8T*/_)3O?U3M'/@?]N8B
MR#W3W'4X=4Q65Q/YTA6KFJG,X>8N>R%# ..Y9XKQ9^>8S%*I+/=:# 4 Q)!=
M-MW]IPQEII)R:FVM^@U3,3%6P"T*@'%1G2@X#B)2S:C]4:#H&EAT[>_<[>\D
MT/[OS;^]J76 XU@JCOO(%A'@,7F(N68(U2KU3]*D %*7H%('#X.I#]_:3Y2'
M/)KW";\D*DL^8R=*AJ81>_BIS4"V2(P+S^=]_&)WI7,*$#B-,M@^.6A+&MJD
MG0GMW08F9,3N,H#'!M)+H4BA ?@BGK^[__]O?6+^VF?W09\:U#YQ4 4@M2)T
MD<S__;>;]_[WYG_E9NE_Y%8V?7I(K/RD_/3XTV3]NV>"TKX6(-ALV#Q]<XHG
M[PHX<9RU$PY+O6&J"_HA:#LX=UM:'T*\P&5))#$2D/"F2)RF=.\^GG^O&1K@
M]+*AC<TG7%-4@GPF7(KL&T3"()#JOU2FCN$R@>O]WVV !_;%</? \^X7&#_F
MO57JUC9P(Y ".$&ENM*U Y^57X% I,@@<'$)BCA%9GG9T&@Y]M/_[Q<@M$DG
M"]K;1P$T<!-%YGW>]!;_="'\%4K%6,9=*L;2* !O69Q.)X$FU5PWI.L/8"JI
MJB502?46&>> H9+R296V3-;XWT-_?771M?\9Z"BE?5LVLNR4FBZ+TZ6^MT8V
MM+>=?(LZV#C3H$X"UP-]!Z)@HAN1")V[]K,!P4'XXBP%<*X2I],EWOC_L1K_
M )L%_TM\__/F8MY/_Q78-1"S5<#0R;2/%( CO*E>J"8G"^:4'KMS8BMR_,C]
MF@$RU[2)X627E5S*:<& SBLT;1ZL2SL+_&5NQ.@)!![G1P&HG5CL-C90*(2*
M$L.P]F,>Y3]2KT*;[% 2>(85"(Z% IA5)PI-GZ< /JUG4@"O06298(1+0^PJ
ME"\6K(518:%?%OW(^!36N4PP>I_W<-$7W>#FJB+$L^F?W4V:\!6F*EK4QOCQ
MC-; OS1VCMK8[I\:6VNX@B47S@"/N-.59=B?6>B2:E4ZL2HT?/=(BKI>WPAM
M9)T\LL=ZMDE%T /<G&A1S\R-."_6Q1(B:?C ,P5(/^IC(G9G2J]@,J-SW--*
MU 6NE3_=_F"I4U8GU[70-VFBD$B,E*>2Q$0+<)MO"(JY>.!SC-.NNT6U5='J
M%,#A5*)-+LX'UH5$,%ES00+1:Q(;&\^>7R[WN36WV6=)SQ)&'^&QRUI*N/U#
MU3)_Z8GQ4VW3M2T?EZ-"<O;\$>#BLXM;K$'%.9B!EDNP*5<;8X=^!'BTO";!
M2]Z+_:'V,LG>8^/WV)/^/6X-RL!)Z#P*0(KP'60%7+ 8_4]JZ_Q6N7D<M)]0
M3J7BRF#XDF(N=$;O9T;9)/=0LE]-/)D&B!L18_&RAG>3,;LQ9 N[?_Q!0U7Y
MQF%;P#KESQ1 0NI=(D]=JBZ&M[!U<L#41&G0/L[B<ONBLD;1Q/-MUB9O1@H@
MVLV2 C#-HBKG/6ZQ> N:RH LQ+-]?DC02!CWFO^X,@VW^J?,]-J(U]<B;ZCU
M+UU\_NGHGX&OF)]OL]CQO8D+ 6AG].F4>9XP$CGT7ZK&.G[9ILP[(SO3,78<
M-L6ON?+32@2)';CH*963EXBY0V##/MFN P^^R)]0%Q8 XM?;]X]X'USD;(X2
M,C:S=:Z?^GF1\?.)9%7 _]U'\V4AJ@3:*7YOUT+-/R=UL=1#/@4A+66HKTU]
M9RU5C_;32>J?,J@H*;M_F(J5\(P^W?[K='^^#1#J7Q*AHN3 ^_#?4,T!]^+)
MB F]]\$)=67HG[:^:_]!]$M%:8OHD/DK[ =_ )/^1$V10TYJ5B*?:'HX/Z>_
M^M? LM[RY")H#KF\U&":FP(  X>@1C]@-^._1G1"3YP022^7_IN3Z$\1*Q#2
M(#%WNP,^U$%>)C](^>KX)E[Z/?B]!VHA;$#G[O_).'X%=QVL/FBBXC<8"UW+
M1V_E]JOG@#_X]B,VM1R@JRA&$H?HX&HW\/G&_H5*^ Z6EAS&VIL K=:G $X2
M@]N@M4/;EM_0G5%HL];9<*]&,[D^9Z!LBZR^V[C%Q[-LRX_6!=^)S%3(S9G+
MS)+<>6V&RB5>9S6KU;J,GH\W*2TQ)H3+KJWE%/.YQ\L)AQ";:=&9)Z*R:031
M7OO6A7FCWW#=P#+'1'\]4ZKISQ#.:VZ&D0VK$T5JB8$A=8.+ W:W=5L=GJX;
MQ-Z_;OO(W,',AKO53!JS$5:./J(!K;#R/360OLDT>WTP1?ZE_.KKL91LUL8E
M/$,FBC,SZ&YQ"MD@0[+F>E+(I[-L H."OB[Y5%&%:(78$B2( N.1XTIPV:Y-
M!M=%3N*JX9-BUED7#</Q79"Q;4J#Z67C0OWT >YQO++=()EC$D-J?Y55/"*=
M;&AOIU%E.;CS#2DA$L84X,R+459,^9#K*^P^JS%2QL^(\U+U2IH0NV!,4L&Z
M=H@RA1T:8H159CKB00$NR9[K7J:*6C5U596HYZC@&'ZY9D^G>Z68B,H<ZU*K
MN''MR7'_(Y(3E]4]?=3MR^,KBY:]Y 8UM+0^K^_4PPN]O^W&\LBSN W:X2?P
M0]_2L^I*4T$U<>,+[)55;T,T6$(#]7EOL)[RL)->^WZP?'?ZSZM>V]E?*8!]
M85?HSK@#B7[4PX3_]V5([B/HE!4TP%?]QV.X'^-M%AU5-]YSOVV%AC6RE)[.
MRQ",>45;"!!CC4%2 *Q69B+&,5FFF;T_YJYV5+YAA%4IA]L\4'/,J4Y??QOV
M/A:U_N;/JU\_?]FV=K45R0U5J*3K-"RZ4C1M=SB78ZZ?_/->ZV\II"[]C$1C
M^N @)T&H*@N5X?V]2&Y__+'^)2/@0 'B-+0]B$BO[Z+"=IO,YN2L<\!Y_KH"
M*.DQ6QZHD>42(C)46OLS?<@[QO0J*#W1I)^HC3H9+GZ^CW>L(O%60-5.>]HV
M;4X1JCC#*-E]2S>V_^.EF^EUO$TA(H4]O^VJ3\Q:HEEG0#\6FN_48=MR59+Y
M"A4G?A26?ZR4U%Q*2YH/8WYU?'$2_'FT$UY.^Q4:"F$A*WM+82V;T:#F&M-L
M?[%UH1 [NY3[E=%/GW[-<SN5!I"?V1K/NRB;JU/JF3*,L9RM]".K/'<;A_N)
M;TA<MBWR[9":-NBR;M).^\*F>C3LRIRCV6LS)@*_;U_B*/K(C+(KA,6J8MPR
MA"A5T)-FG?^DM3 S\0IC I_&69Y93B6_L1 L!1 QZ'T+VXN>0L*"5#AQ287N
MC-?K,?D0LZ*D:VXT'K(?,AS>:X[IP#GOTZ%#O&O*5$QM?=)RS+*2LJ?,-#E:
M[4YV(]4T'NJV\^%8FXETN!^?R'VII]:\[9"U7@33\YM6GR*4-04C7O3+JW5F
M?&E3YQGM&!ET)S3R<RLY$)16H<Q$=50XK0G&>WP]%B6?I5-@99M@$=;C]ZY)
M5B^E^VI8(A;B=PW(JD05T$?7(EN!].6P,];LLGABZKBGC__7KFPK3->5A(+K
MNN96'&FN@)39M+RYP9?5TD#]'%@"_!$T9-RM-34 7S\<%*ZD@5H6<SD?:8-J
M58,/Q+YC?9T%P>',.-Z"A*->AX$'99+T7:6LOS>JLN@R_3L<P;]]E^HU^8.#
MXN]^D>?;:I/?%#G&R?%@1 X]_]/<F,(@\-7D#/Q(C[F[ \F$ M AV5C4GX <
M5KQ(/)A 0WU_W/"[& /-C?FCL'A/I7/UE-]M&UQJ2,N9L+HF969VMV*WKV@Q
MJA>@S^^G!,W$H3A[0J6=;K8HUXTQ5BI=4V9<-N@LE.O1>[F7\BU(+E>D,E]!
M4R2]XO+?]"P89:[F]NRV3G3W"\".4+2A+L>T!J]Y^+$%5SD P^?$_0U4=JLZ
M]G9DYK)]__+Q%YL,IQKYX&L$-QB0.SS[37:/&$1U<K[EB4!0^#S<?,F^+D*5
M=8[_2)U=KG72ME;.L]K*RDAGMV3OM!\<>WS)JZ.K)N)"<C6:!0KQ:B6%-'(!
M+#JF%JC_X!R!V6.".K1#K)X"@ 4#MQ_!0+ KI SX7-PT!3#:PH^_ E9Y1IXW
M)DIL"G"2-_3Z4P7!>=:(,T6TC?F\I\KCAERXEPV%[\D:3:0=,A?F5*Q: 7&R
MSKO )/QVEA[%64EKJ\D]N;]Y9Z2$YJ' V9B(8Z*;8<K69>^'10F=O4[(Y0<?
M6:H5\GD=&J&GC7%.][&LW7O]5IL5D9+&'0+^0B:Y]ZM7)E^(?@Y"*:TB'8*N
M4DV)VTTK8M<KTE4&MX);_/@<Y"?*4NKS.\IZCCP8B=,?+)NHW0G=2'K.=1UN
MPB R6,8+,HA^^F6P:,.,*4%_^I@3/V&,QU=F6)W3+%9NT-]Y9&(/M%U<KJ1Z
MY\9-47P-- WM-BTX4+[D#<Y8]A4IQTRMC7<T:%_OUA6M"N:A8^_;BL#E7Z52
MN'8-=@C;F+,L._Y\\%'QD+V,?-AATON/=;8WYE]Z[J#'1F.FB(I#EXE''% )
M1]_0V=,?._;ZM>J2H-B@E9+SBC5_4 -=/(KV+;-Z(/KRY^<I.I>#3;RK9@&1
M1AOX=='QFR=2ZT5E%I+1\Z.+H[G#.R&3V$AQ&/E474T,KDMCX.F03 ](?;AP
M_DL$H?/-B*%AT05=R:<FF]\8/(1E.D8A5!D]C>=E;V4?=1+[/'ZT@WZDD%/H
M9COGJ11:J.=P.>X6;WG >_)9[+5D9%?2\)D;EB]/=I5M6S9R.VV8/<4,YX,2
M],IWIKM<:^IE!J;5>7*&<D5S)LC\O?;MR?VF"V\Q<1M&V&%$P."#TJV92IN
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ME!EJ@: GJF"GJ['J+5SQ[9#3[K%BBYA)SP^I6K655AS25R=>5SZ"B)R1Z_[
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M$9=+:A]-%M:B)*/?O(SIFTZO.]D$X=XY"3VM+51&=DURWK_D1U:N/9Q!:,C
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MYU,K_%M(%PK EYLH^FTNWCPH=O=B_]^O(S(7_VC>)\3Y8>^:SRVRMSA\X^"
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ML"QT9YR?1 ^.;6'->[SY\:&UY/S[QT*)4](IV96Q@P$F+EPNK(/1VMZ]8A1
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M AO:Q\'%QKY<F;F5CZD>F^U'Y*AQKGAE//[$(@6I9_'0L=VLK:3N,6M%J6P
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M&9J:A\B(K[<?>D ?#7I$8^%NWIHH'%[FON/ :,/&M1LK('EA-^EE_.G2B\V
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MH"=,R-Y_$,M# :P\I0"<*8!+H$=R>4::1IN12M3A_S4SST.O58*/Y(!6?O7
M^/35^.A; :S2+R\7YV?0JG'JZ[U3S\ET\3I!HM5196ECR=?0+ .4_1VGK$LD
MY$[12%7FSY5HE[X59]T5UD4X%4ES'Z>HL_$Y=/NJ68"9%Q9!UNA!D%R#*(!;
MK$BL+/'M5>K<A,8H$U/):G)0K/J6RM,C@@RI1KOU_,U&$;%($-,R/K/@'>A"
MJ :I?G&_7XOMD$'@NE_.[.BRF;#^YV&81:FQ>GV5UT/"%^D"<W[5[Z+[W!>Z
MEYY%Y^H6R@H-:O9<R+.:7FZH;<T5T_5,K9K%Q%X-N>H?K3&UA)<>+C>M< /-
MN5( Q^(8T6*N-J%W'-A.73+TU_OT3)!5>146V?(N6:(Q,:VO+,,C?Y(4C6SH
MOCK_%M 4\6IK=+Q.?WH7U=M];:OK4)0F,&[>[>)*-J]ZN2)!;;7K#;!<>WZB
M8@G<+1=>^C&GEW;9K,BT!?X#)X<T/_5P9]!-KA-?%*4;2:IS1)6D%H)=,L70
M"'O]0KAKZK?=@+[!6T$M@S@'M?)AE^!RO4.5B>>$HPYQ<M]/29"C '8>?G F
M"6ACYUO4-3:+BLIPVLU&QB>#MPE!<O(FIP_-5F[UN..+:BV?D>IB3%M/M60Q
M>Y:^&Y";>W-C$LH%86@N6ADO;<_0<L7[YWU?H.M4?#T4$Y7ZO;[36_6>S$6]
M;#]KDXZV:]J&6]*H:KVZ]]'V) EN*P<%0Y./PA=']<N31KLT%,<[QT5=1@O1
M[KW-\>/VU07?^NG0=NO=NJ;&S26G%]]5\5Q<S'1R@3$D%4PM*X0WB34O[Y;D
MFR[<O?3MWJ%GPC$IN'PC(%6N,KF_Z46[<FFWMA8O"Y_@7JX*([-BAC'EQ541
MMKQTA+UH_9>N"UY6KG&CZPG;#U9O,6H.KZA/E=0/+%6.JH],%3@-Z=>G^N^$
MHHWL)'D5+(;.Z6X:7QE?R>"4D]OA3]8/NM50-;!>SE)A45+AR#,P!PCS/"R5
MN-60_;:<]+%F&VJ)HNJ/GKLK+EZ>D.\U+J:N!+R;2+\JZS?;?X-D$7V'>XL]
M,_@5[WML(ESW&:FUPA-:,1T"-.K"0;":0([;EV78[KCX<W+LZSNN9!3OL#9A
MWPN8/IZLWU@%Z26C+N:E=-2#;A4IHF1;;"!'#.Q,?T9!"_7>I@#LZFFW,GZ#
M+Q/ =FVYDF040ADXX7"#N+I0KZ5;.[)#YR!QP2NI>N(RND/XRY'!/G!LPH(-
M??(E$(((G_EHT&U9;/(.!Q<8:. E/JTK'N:;,$M>7UO_/"G\..YUQQHMAN"*
M-MO[N*D CO$6QMV3S@PU&DGK6>8N1)M <ZD\/VBOOM;'9L0F7S1"2!HXSD=P
MVT]Z-*LO30%XDGZF<>B8_KGQE8I2MI>@Q[D]'!$.] J67M6 "0:.2PF67'YN
MDB<R_R'@ZY'<\V6B$JUFEP;J3B$+02T*\RM6XRKQ]GMN;B\M;75R.NSE@3>&
M^FB;\4%H'^Q$HR\#!M&ZP>[NT.SIUFSJ9&QZQ=V@5=JSIT!\/5]4\1$;:>(C
M4R\/P&:=D/_-=FVA-F'7N)GY[OH-)*L;\^LUT<V!U=TBG _!P+?/U>PL+FU6
M%$I#%,'8#4PNI7#6A'@(#Z^K3Z5 +W( KM =Q5S)R)?Q378O;DDY/<K#$SA8
M=!QHD%B>6%Y6_#FV, U)U5-ICI%2QA5I*8" A$?I.R$M7 -+K,VL0M>?=)L+
MY,\P]6IN]4[H[;94XA11#GXC*3S8 @67BL*<YMQ5,0=K\8RJ?MZ*_3RR\9O/
MGU-7OI-58K=@:ZF$6T1&G!>!:W7Z##8E&HB\,*0RS0^*T?!X.IK0=5F(\R:K
MXKVA^<"FZGR%R-=$]1G^5]#BMA@43K!B."CB:+Z5<U7<]+1&+.IMXYQW </@
MH.NE_3//-C_WUM3I$"#>O!C[VL>?5_D4BK_4-U2^69>.OAC22M\).WD7>:*Y
MVO#.UHD454]\R;>\SL;8P%L7OYW=EMEW)#PQ-22*DC*4'L]*!#3(J6'+A^=C
M*VHQJ_J#@@DR;N<.<[O_.&%RMBGZZN9IS<H;D$_3G#@$<LH-=1O.\#3:RX'7
M<*G/AAUO50&]='R.+O;,K-79*@[RI]<?,YXF2KVWC5%/HRIV"?]-?L'W$9 ;
M6>-:+BZ2C0YGXCQX9D189^$8.!Q50!7HOT5C)R&FJ?:R(04PAO<:91/@5#^!
MRNL<)3?,IA1Z.MMF[2FGI]75^8'*XQ86'KZ9OB"^*?_UON*0@%&Q FCW0VTH
M =BUY=M?.S>QFKB/0%FV=!"MG.WLM&YDM" $+?TN\K<A^EP+KE;AW16\)RI+
MR#5,P2WMC-SUQF-]6(>VPGN$EBN@C&\C-3X9"W)C4-B:5N1-15?\:(D[?YMK
MBFQ_W.[47=VT'TIB%,!E!*_4I"?7_N)7E4-UV.^9\^T?+I\70+/??I%!R!@.
M][F:OE3ARS?X^,L7_QMVI[_J#.&CO6)6S<STE$RM.NO!Z\#>;ZBOG?4:"C&^
MJ^0R">I'V*']\A.3FZDM#J^!_T][UQW55+;N8T$4442*J$ &04$!4:DB)"(#
M,91!>B<ZB)0(* C28Z-($04!980H'2F1$EH@D1H%E-X[H1=)I"1 RCMA[LS5
M67/OG;7>6G?=]];](__D[/-]9^_]U;U_W]Z"E8<W]><(0DQ>^%C>SZXHG0B]
M+@4$GZZ$&/>U[95&DBH0*^'KGK@L<?!EGP'B$9Y:%-><J 0%DKTKZHWSC$1Y
M5=GG#]5B,-!!N 0()!%;;S!F(. <I$P>3L+,))R@7NZ\9AUA'<M7/]4PXO6@
M(@<$$__ANJ>^$O:D4K0 XRD+Y+AT@,[;KN:<XT,T+B!04%&*V8I5/XD<U^GK
MQPE";"RKU7 ';ZG>'Y"L"8)JDOI0HZG#_*B0GD1]PN-1LGUSR<8HJM#N1XF$
MY@>7T.>^B C=.27]1>X@+4>+;!<-R1O?9T?4;'_- EG[9PU*',CP<QB\)RU9
MJVRWAS+1S90GTQ,YPQR_)O:##S@SM>H>0"AY-1/!TW%#3UR>)PW83W5/M[!
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MJ\MMM)==S_&Q#\Y2V0]'4NZI$&C:E4 0I+XRLCG%+F+@Q; G6)D]P<CBE$)
M.F" L"'HXG9; N'^F[#UL(7MEU^%K=_0X->)KP><ON+6S+._?VOJ?=A33]B:
M^O3?IOZ?\XQVW%_]491XZ'LF@!I\2]G[N>'"6.]Y\=YQ%FCLR)9 H]@"'?T=
MZ?SV</57%SC_M ,CWW7@/UU;6FC:]*U^M?QMR/Y.&5GTVY#]"\OQMQ$CF=?B
M?^#>@]9O0.& SW708BM;K:%A+ZOO?P!02P,$%     @ :CJI6A88('X2X0
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MBLM_\/J7[8;M!FEF?LCC(&20>"F7VH)+@\'/!*2I""**,HK,DO'.@YE99S1
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MXMC/$ XA;4;T15A(,U*$T(\]/Z9)QBDVRAWO+[Y<^H)%G>01%_04A2UM9BI
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MB? 9 (N*ZS"!KT5SY$ES7^+[?]8OU[^7K'*76V2PY&)91?\A;:$:O%-_/?@
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M5,D_YS##B0?CR MXZ",4!\'.2_6F.W#LBC+;@SVD15FK>1.;]8,UO*.YGR#
M*R!9WM+D\)9GS317]S]S!):]&5HSZ.3.:+^2Q6WR[JO\J/Q/'P//?RASO.[N
M%W&<D2!.?9CZ/%3UO$2-J(M@%-/(RZ(()0;-]<_#F/D8:( "'WSZ*#\F'S2
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M,&W6O&\./V=\T;,"+Z/43*VWZU^!Z[HN<[*ME3]#=1&[PVY[_0W3Y#+Q^AC
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M&2)12(IPEDM$\S1":4@93=(TSSAHZVE&UK-UT)2#FG2PI5T;AR_7OP:_:P:
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M#_]BW[7N?%Q4VT8&=1!NDV+T,N%Y1IA@#$5)KCXB&'-4"/5-B8N<TBA*""M
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MX0P4(S4E[-G<-&Q<'88WK[;S:U>+@ H]@[;F!MB6RQ1<LWV"#\A@QF:#UD&
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MHT#]!8R,&LV_'+##D+^#%6V;%ZHMAR['@_4N;&_R["9I$M!6A1MQAG<+UI+
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MT[H?UOJ<;CK_\60W9V S9W.0S53?#W0P:Z!1J_N_WW51^V6#VJZOLX\9>7
M7+5T-B<\;D]G,"!'39WA*\ =Z]I]^V7.J]G+0\=I-]_EGEW \R=?D12*IGZ?
M=V3-'>SS<@^[V4Y$ANEV33(X*;/3G>R@:%8N]_E51W.\!P7KNM_#%]M]V^]$
M59>N*F[K@_7-SBY,XC0+XP()6NKB@H0B$I(4L3CA<<J+)(E @QK.T/&LD1VJ
M;0[M>CZ%CO Y!U$9%H+A)$>"* \'1Y*A0J&"&,5EKM#+BS2$G9TY ,GJS.R7
MMC.:SBSSAY>9V^(  Y@=Z[XC#44/X\8&I'+D>)RC,JJ7,2#JH4LQ=+GM=&W]
M1M>QGYOY>T%7UW/^F53_$"L=:6WB1!TS.N?O1*7KN=JP;3/%Z?UVCLMNF&U(
M\J),X@CQ.M\@CZ52>K7+D306*0TQC6#%J[X8]6Q8.VQ#AWQ[>C!FUN4MP TS
M3QV.=7:GYKD^JMQQO6DQV_&_?M!7M*QO1QHWS/\8[-AW/,%X+)"=33GWQ.;(
MX]+]@GT\=]TS/9C!YV(ZN5;<<,W1QQEYF/"$$9Z$&*6,"X1YAE')>(18RDA1
M% F/B%&=P='*OD](-[0"3<S,JAY+WV\&+Y()N#TT$\?8N)QEO6?[I^YI#('Z
M8:?_QRN-HK!G!=AHV/D+X"KQ8;Y2>OA5/-2Y1//5%_(H)IPGF"11B&292*49
MA?9=BA QGLFDY"0MA%';I7,$?)]AUB2#'<U $S57E).8#.O+I9+"U 8H)$A]
M^B2QTJ*3"XZF3'WB='6J]SJ+\"3_^_WBRV)^)Q9?Q$*7*7R<[]Q0TQ!EWR*^
M/S3;<_%@M="#!]#=A]O@B_J_O<JDCXO%:KY8 =)T^I$Q"&*Z @7XI8+AX=AI
M-A;<+LS9N_)XH4X3 ??"G48WV(Y55FM</SU5@DWK1_M5EP0MOUU__6:>QF.\
MF&=E;LJVNPP$#0?!#XH'\)#&06C,MME.48%I\Q @'H)[QM(ZFT,]1&_D8=2&
MXA]/I#:]T:*7R,U\)68SP59K,KNK%D]J%_KR;C'7R1'*TC=S/FIRVRR)=FA[
M74#2'&!-:!+1,-;E1&68(YR&!2(8$Q261'G/A A<".,N(RXX\A[6V[&H,QUJ
M'H,Z72(@_6=ZGIY O[UY%5RA\;L.I!OV@AU_[32GUD9M6;P*6B:O@J:B:>!(
MU1/\@"8G8S\&N_8G(ST.6),4E]#UMD]Q0FB\QBHN<=EKN>)T83LO]+W8???4
MSS/15I*HQ:M56V4RR3&A*<LYPB+!"(<L0303#(E4LK!,$AZ'H$;9)D0]?V*Z
M+#3EF1W:]:#QC5+J/XI_KJ=/6LMA?JP1N&:NK&O(8%^/+O6K8$N_J>/L<.#.
MF87(Z\B?-2(YJDL+ >'0JP7=>^F<['K:QI2M!-=Y>?JT1?U''\(\DYD^HMF%
M7V12B(B%.JN>),J>9.JG,BQ1FHF$T#)+DBRTFY-MS(/OK7!GJO.&I[HICM*7
M.@FU/A35/W28LYV/;0Z\X8[9+YPPJV.,7CL3._!RC'P!),['8YMS\$KCL<$0
MG1^/#5_*,L?WQ*1!2(;OZ/,C.\-WR5);F=WD/F"6+WC&HB.A@8'Q.L/7TWA"
M XGL$WM?:["?@5!'2;W.!^0=#/.!MG X=[O'D.W!]"<_+1:&Y/(S_NF5&B$,
M"3LP .K2=@4[7[CI9OINL5PMWY&GJ=H]3_\M=+N$)S+EZMM23VD^3 H"OK$7
M4O&Y>VN;Z]:<704=WJZ"EKNKVK%J1L(W'.XEZ'E0!$=P.=O\7<;-R/M")] =
M;QG=+&NGI$WUEJA+1NNHUZW\92EJ8GOQDK(L0RY"7<Q9Y CG181H',5(R#))
M>2%Y'(,:^!K2]9YVMQ]^:BHY15.U'52:+[20:+W43I_&'[9C- 67",QQD90H
M3!**,&,8T3()45J$6!9E$28L@A63>(#7JKBD%V!/:)I]-SP@!/L^M QL2N6_
M;EXVQ47S+;CR%.0#2N[(U)M2'=6D Z$X--W0VRU-]&9K<#-_6J^6G\2SF,6;
M,4!Y$LN<8Y2D,=?#-#-49H0I*XW3O&",2@F:=]U#R[,IKDD%,= D]$!C: ;<
M" Q4_>U6^BIHZ%X%K?P>,E0,1'2EXSV4QM7K89&/=-G@E@OU][.R$\ISJ\LG
MMK_\ZU14:LGO+^\7CV0ZG^2Y#&48YRCB4:@<+5P@0M,($1X6:1JF)2]+*XTV
MH3Y>#&U+N-X!?;G^-?B]80$XZQH&+M FN(;,UDK8H&5O)B!2NS8<1K1?QY1
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MW#'EY:3+'A-'IMF"@5'-J#U AR;O@I7@H=3?J@]SW@8J#@,3[YXK_EMU&+Z
M15)MUQ\CD"KFW#1D]TZ'^]2/=<!OY2YR:@W_<.!T#.0MXJ;>0'<<*+T4/JLX
MJ371T<*DE\+2C9)>O):=-W97M?UC.RFBA!<)36*.LI10A!/.41EG"4IR40J:
M\U 04/WT"1J>+=J68G]JL(?,X-!#_B_,$SSU1,U<O0N?$\S^[1Z1W]3?'J$<
M.6.G*(SJ;?6(>.A.]5UJD0;\TXQ,YTT#TYOY-T%6JYEHO\EAGF0$$XFX"".U
M9Y,9(NI7*(Y2&H4RI#%)C). S]/Q;$@:PDV37?T5;FD#\E][(.K72H>"PS3S
MC,PVR;\]P@-2?]V 8)?X"WT!8'F_PY+U9OWVW#Y>SN^P#'L9OP:7CWP"U(;
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M=2'YYGZ]_%\I_KE9Z1N]?U055:7$:8(A07D"<8(#2&20P" 3$<$A5<K#ZE[
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MQ5]L1BTNGU[;',U^%V789>? TH6WBE\_;!Y>?8>=EW3_/^FOTS$=\W77Z2+
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M);:.4D2/F+K<YIT7S@6A(4F=0-4#JR@5@^!"4;%04!);>UL[2!FW'.'T6#I
M 3WB:'M/9\:+$+4''BCT4"$RB-E4^6 41GCC[8 ;X&$>UF")U=,CZE!5?%_C
M"Z[ENIR7RXI^^FVS9.J.QP^82-V'H49)U-<S(@6O7W@#0YNXMP4A,X*,PBS
M6\Z (S.JPHCYU@MW!RG-+M]<]I*]::*#MG >50$5&1G:+!T$C74R7$@NQIRB
M:MTI9B<QXR9$6Z!@Y]V:H^3>P0;W@71!!-3NZ*_P=SR;KYN$7G(U22%R[LA
M.VM5O;QAP(=";"GN'1( N&Y=$_,H0>,"J9'2[[>[:Z2!#N#T;V3_%^&,>'F1
MSZ>S:95/G8Y^Q4[)P<F2!/#H-4G+402!R* (5 Z-9:)Y!Y@G2!HWCSX,I%IJ
MH0-0W1/21)><O/0.#/K:,H*$XPUJ8,;I''(DSW*P#AY71(R;*Q\&.,=)NH."
MF&L&-IO^F_ER.1%6J]H( C2ZVFFD<(A!9,A6!,LMLN):YY >(&-<.S.H#W2@
MK#N R]OY;'Z;BZN9#%<"*E&YY#,#,HST!V,!R'9:B$P+HQ-GV;2N(G^2J'$M
MSQ!0:JN'#K:LFS$Q&W9>S^C9],G$F:REHUU7<N9 )1$A\.RA!!N3T-FEYM6<
MNV@9UYENK/+Y /+O D<;NB]ELRVT"<]2*<$M6&4$;?2T]#S3&:3WI2A,4F#K
MMAJ/D#/N_C8TFMIHX?F \AM S?!S39U]:GMC_+[0)HH$$;0LI/H40/%Z3)US
M;9B;I$J%]G/9NJ9N!RGC;G+#XJF%]#LP3O?8N(HO30P</?E^O-1B&AXX!*0E
MDE+Q:+F76)J'9SMH&;?LY,0P.D3^_=BDM[C:BB2L]5I$&4%DC&17@ZQM:Q,4
M+UC4P3)56N>O;Q$P+G &<;(/EF\'D=K5%:^K(I>;!22-E?5 &17Y<LH7XH,)
M4_.E@H#.+*V@QCC91<NXI4=#0*:)U#O8J>[R\5-83M,D%,]MK-51F!"41@^^
M& LR.NDTX\[GUMO4@X2,&XBUT?$3P'F^P#M$S:OIV07M>)/DM76&"_+QE:ZM
MBS5MKZ8.(S+6HDG.-<\^[R!EW*#K),@Y1.@=8.<_L$X\P_SB=_+-/N/;B_.(
MBW?E7N7*9F&@1(O%)- HR O4D;Q &4I-NB?N-/)06A^+/8O <8.Q07 VG(+Z
M1=_E6KI?/F6#4J86IANA?#UEMD#K*8))O-AL WK9.BOY3!+'=<=/B< F2OI.
M:]SFY8'[XLU+W1Y\RRDJWIYFK_WMX4>NN <1'+E> 4Q,M*4FVE=C#@BI9"64
M#AR;^[][$79\$XW+EWRJ<W F(3!FJ\.94->K72Q##,E"L,JGPJ1SLG7SPML4
M=',?N!$6[O?1.%C>'>R5U]1O)/)R?OYU/JOEJ2_^G"XG6<BD??:UH4@@HXN.
M@I=B@:'*GK& (;6N@'N4H$ZP=("F=X'F:+%W@*$[/+R:GX?I;"+JK2OF(H00
M:[4[4_4&? ">2LK&)!%LZP.Z!PGI!#/'*_INJ'BTU#N SM:UAE^Q>H 3EI//
MG'MPY,^ 8G5@6](<A'3<:LE+TJTSFO>(&#DE=;QB=U\>.4#*'<!D1_N\2V:4
MR:EXXT"RHD 992@,8627N1!%D8W6S9L(/$K0R'FIYO!I)_T.H'2W:]XE%S([
MXW7RD)U,H)Q-X#0M#98S)QN=!;>M<U /4S)RLJDY>!K(NP/47&_C%!'C:_IQ
M.9%)R6"C!)VRJB=+"6*L9>08C# Z8O2M!U[<IZ*3/C@-'>+#!-P!1%[/TJ*.
M@7F%F_^^GMT/.#_,S\Y^F2_^"(L\\4%KID4 74>+*E?9LY+,*'J/%(Y*9EKO
M6L\DL1//^4!$W*MB&TX]':#OT?O!Q9IDLY8D*$?&EAL$CYF!+8%KU"Q'.Z!/
M?5@V>\@+D<,!X3FWMI^CE8,1]A47TWG-P2Y60[7H]35%)CV#H,QZ*Z\S7I2"
M&L-RF[WUIG6MTH%]58>\8'(R3!VI@6Z0]"+_[XM-D?KRTWQ'B+%>-#&L3Q3.
M:W7?6J,?<#/5"C_BXO=IJJU_B+(/F.:?9^NG;#KSEY1(J"0+-))V"^4X"9DQ
M$-9%6[(+.;8^UAN:I]'OOIP,Y5VAHX/]?2WI31>95Q<+VCXV;&UVE?4OWWU=
MMY+X^4]<I"G)9&)=DA2#>["UU9KBH9"WY!08Q6T@YTDR-4CK]&=1.7JAZ6GM
M]G :[!>CZ_7V,(-1,9.YB6#(M0=E<QU-H'0MT32L\!RL:WU&\&PB1Z]K'1NA
MC?37+T W2_ #+E>+:5I=-K%\4<7Y%FM#I_FBX'1U0=^99&?(3[<1G*KS7(N2
M$+@1H!D%IDB"U[;U=).CB1ZW;U\' !Y(OQT ^O:E!LQ<A5 '@0CIZXA-#<Z2
M<V.L] X9%UJV/JU__J61P9KZG1)HA\O]8-#\CHLX/T6RB*..148#7BE&CG&M
MYPLID8E'+0-:BC5];\FBP?KZ=9,L>HY6C@SQ?Y[EH5)%S%HG@U>@M7!7XN$.
MK+'&&0PZ-&_+=F"JR/]W0-21&FB*HY.WBWP9EE]^.9O_,4RWR)NGGZA9Y YV
MVI?,7K_HNCHR,\^4RG46:D0*0R6%H<$S2"9CE,RBY:T;1CY&3P.GJ3[S_6+^
M^Y0D]].WWTCLKV?7#7U>I-7T]\WXJNNN4L86X4N-<TH&Q;P#Q[P&+GW [*)E
MKO6>^'PJ.SFN.Q9!#_A:0ZJK.R\^BL),)))]=K33HZ&86J4(2<CU;2\36.O#
MNN=[\<,UQAE8VX\Z\L\1?0>XN94CKPGN69J>X2V6/LV?*\V$B"(Y5ZLV$BAI
M$$)""UIP)[,MRJ36+MH0?(S<D.>T*!X="!TLAJN+UK</@R:VQ"(D9N"L4&SN
M(_F[3M<9-#[(HH/'U+Q*ZT%*QC6KXR/D;FARO+HZ -TKI#>GZ9IV^OD,U_J<
MY1?G\\5J^E^7/ DLD4L+0H5Z=YMB.5>(.QN\4)F6=6I^R+$/7>-:R.X V5R5
M'<#SQ7)) CW_&J:+*NF7M.8^UZZVV83H&2=OG")_E74@;]Q8*":OI\ IU_SF
MX\.4C%O.T!T$&ZBK ]!=2^=-36]=->42&9'DX$'D>M.IR$SNC<Z0B!WCD2DG
M6E>[/DC(N/4&W4'N>&5U@+C-Q!U<L_"A=A5X5TAJZ]5TRWH+J6-QS$&1@1:2
MR@9<9 A9.66BQ1Q4:U]P3]+&K3'H#I5#*+0#G+Y(:;%Q*[:8J"TOEFE^4:^$
MSO+[!9Y/+\Z7-QU\EY.D=%*V.L'*D$]<4($O/('+V:7(48KFD[X/HW3<0H/N
M4'P"=8_?OK(>G3QPIO5R/JL2)8;6U4/K1;Q\,PUQ>E9/H81RLI0ZNSJ8]44.
M22X-BQ"]*Q@86J[NE-'</Z(YZ,WCEBAT ]'AM=:!N;W/W[48+PN(KV4H RLB
MJT)"DWP3U_F,!B3+KN3,DQ.M3>S^U(U; =$-9@=6:Y> I?V!HL'\ZI*>J_;)
ML[QN?KQVB)83*P3S7"1(*%2M6=,0748PM($P-*[0SC$X>/>AM+=[7VUP\R0\
MFRMQ_%W_$9E6GFZ6_H8Y[A.WO!!SF0M0SG-P/DA(.KML;& YMRY,W(^RWFZ-
MG0B11RNI9P22V[UVK]^';^M;Z106II!H93%5FU<FI< 59L$XZPL:9)JU'Q3R
M!%&]W>,Z$>Z.44V7^W,-\2Z(CDL7N;HXEV;])K%V\[N)$9)%X1%0U6IAPRT$
M%178(C.31J$[@1U\'LV]W<\Z'5*'4FR70+Z=![X)^;!(SK34@*@,;0JT5H.N
M4Q!II] Z)*URZ\*WO8GK[6+6J3;O!JKJ (/[E\A,:AMAYV@YQ1)+[2M39SB0
M@\PP8RC"D'?<>@??G[J1)S6=O%QN"*5U,&%E!V>;Q.RN)(;4,24!T?@ZDCHQ
M<#9IT"[5!$8*HK0NBWX^E9TTB#I147 K=75@'\E'ONI^D/YQ,5T@\4K+;/7M
M_5F8K<@;J1<ZUL/2)]DAFMH1B:&O=SIH;?N8.?#$?>:8 PNA,1#WIZ[+<N)F
M.)F?1&G]A-OW&/P;GN5/\U_#ZF)!3LA'3/6_U?Z31\P4SP8P<7)'?' 0O$:P
MG 6K,V.N>1_7O8GKLCCX9)ALHK*.(+F8)\2\_(4$_3&<U<3J%6_ORDY>4^'2
MUGXO-M=3UN X>$^KL81LT(J8?6K=[_,@0KMT+P>#ZN"J[&!CWU^FDXQ*H$,)
M,:$ E>IES?6H0B_(H4ZR:&Q=-+<_=2//%CTM,@=26K^!SZ8$ZV%!,E48!L^!
M%1Y 91$@))T@D!@+"R:@.A$L'Z%R7,-YZL"GE;HZL(]7_LJ[<LW4R_ERM9QX
MI8L)+H(.A8.RK'86EAZX$\7IZC>[UOW,=M'295#3# ,[',BC%-*1OWC-SJ^X
M^(R+#WA67[!FZ0$1DNBT*<8+\"C(GD=:K:$V4&"%I"BXDHZW3H$_D\0NPYGA
MT=A>?1V!=-L3?KCUFN%HZ_ .YK4FKU=+<*@LF)"L]L$6UKQD[4FBN@Q6!@-B
M4Q5UL/%N5]V_7TQ)9E]KP]7-<IN$J')ATH 0/I+3HLAIR2X#CR6'K$2PJG65
MV:,$=1E^#(6U=JKIQ\3M+\*)Q9*5K#%4+3=61B-$-&)]/2E[SQECK2\L[D_=
MN,?0)P;B0$KK( ZN;-7_KQGZW\-975@W'2/K+U[,\NT/MKZYZ3-Y_ZP^G5W4
M[FT__YF^A-EG_$ KZ.=2D)2@68K,H"&/.:VS!!J"=H9$%$KB%"#2[QM#^K0<
MCFN?!XN_.X;)][Z()BPRX5Q@$##4=M>*#!-+&HKA.6NA)$68/:V)<2U_GQ!_
MEA*[F45Q',LHE0T"::?+M(VJ(B-X;Q&<=BEH'SWZUF6=P^-VL'N:G>+V.4KL
MI,'JV_DL$1<WAQ"S?.V(K0=FW1Q]2"Y2%(6XR?6(C#.(@@O0,OMD4G'1-B]5
MVI>X<:]D#I>H'T0Y':0)[ES(?Q<W\QU?SZ[<EU_FBUTUJDQ';97F@*884"I*
MB-[6D45.%)YHW\BM*SF/('?D+/\P +H[GO-$VNP N)=EV>O[=WG3[Y]<[XM*
MR4\7J[?SU7_BJLX7FN3(>4F.^&+%@HJ&M@+)/6@EA+%,8O2MSS?WI6WD5/])
M(#F(GCK W\>+KU_/UGM-.+O::U[/RGQQOE'@E>R4X,;7[MP<2QT*+Q"\< &2
MUHH^,I&A: R_/4D;]R;Z8%OU$(KI &^O9_0L6JAUK;S%U805YHPK#+CA&I0M
M'$)Q&C1*LM_%:VP>7M\A8>0.U4.H^=YUG<-EW@PRK5OMOUM\#K/+_C5AEE_A
M,BVFZ\.N>?GI8DG^PO*@)OM[/;=->_WGL]"HL?[VBV]:^V]:2[[?XN>ZN"*<
MW73]O[%NCG.>O(.@C:F5%@:"L1*DS<*21"W'U@<@30@_NI?@,4341DMG\R7Y
M#Y](F3_1<_\^D87IXDF&F7-R&4HRX"QSH$71D=MDVJ=J6O,PKA$]/9[OM2P<
M$Q/=VN@/T^7?EV39?ILE7-08;GTT>8!1?OA!;:SP'D1V979=B5+8D$&AI]U;
MYPB.B9K:SEY:6TSFK3WQ+LSNVUIDC^_*9>!/9$Q2CLZ@]F!+H0C?HH-8Y^09
MD;*6*4GOFT^EN$?%?P?3]QQ,W<LI'J>7;HW7QXOS\[#X-B\?IY]GTS)-];+<
MIE=('>)(@DX'6K,]G]S&O!W"1B-[=_\UUX#3SANK$P,A:V\*BP(\+P:,(; 9
M)U.(K6\Z[:;FZ!S*8Y*]V=)%UD5E4VA+#\1S(=?"(Y.0%2KM)<^T"ENG4/:B
M;.0I$&U0<B]_TEXIW9JJ[7:W!]BC>]URCS8Z.PEJ9%FVGO\*X]4=YNT+>-<8
MLEGZ$".OK6H#*-I\('I.^UOA5CGT+H;V":9]J3L^FW;]IM>SRW?]&A9_QU5M
M977OK;/\<N/B?EJ$?-UD[:'P0X427(P2.,49H(C%6B6,@-:J%$/BKGEQXU"\
MC-W@<1"DWD_Q=0"$;NWC+V&Z6#</GM]XP:]G)/:+@VWF4X]L8T>?17@CVWK]
MSALX;.W(BG.,IEYKKLWQI!805(4#<J<=_>BPM0_S&#U'WRYXX-DWV#>.)5%B
M &%J\RJ?"BW(@.!S0:\(^ .,9GB,H'$M63-<W+M'T$P)W1J@RVZ[N.FR6[--
M\]JV;WU^3,_?M'T]P KM]=PVINCY+#2R1U<MBM>7Z2Z/X:?_A?F2H-LMBV\@
M='/JKZ) ;S0DXTHM [% @&041!3.H[7.Y]9E9D>2?/0!Q4,/WUI1,H2@K(68
M%*<M76?ZR3F(JM84YD)^1NMZI\<I&M>NG1)?]XX-VFFJ8]NWZ385MAI-U6/W
M@\S=PX]J9>'V(+214=O9@NOF0E3(F)2-P%V6H+!X"-HRD$SYD+GR)K=V/IXD
MJL$%XH=?\!#XT66,B R$8!0.127!FQ3!6ZF=\8YKQDXE@.Z,5EO\/'"+>!@]
M=6ND+ELK_WSCW:Q-\\N-=[/=>OH L[7_P]L8L@.9:67:-GW4:Y)A34@XVVKS
M*B4Z$PHX93,HDR-$3 :L3$(2AC"T-VJ[R6DP.FV[<_SN]MQ;']VLH$MUW"PD
ME@6Q7S@X(1,H72*$; TP=#Q2F!.M:#[DO"D'(YO$1KA[8&+:6%KNUER^G)^?
M3]?I1C(NUP.Z#CT/?>1I;0SBON0VLH WKUMG6K??]T#\P%CV)=?6UR51_*!Y
M@H Z0-:RR%!\=+RU37P6@4??<-CG93?KHTA;K^(SR,$)4-G34G5%UD$<+'I:
M)5*U#M>?1^&X5FXX;-V[\3"<WKJU:V^F:>TR'6+%KO]M&YOU,"E'6JCUB,7+
M)[_XO, [94 V,ETP4I!0@B>XL 0^20\I.^:<# *]?DH,C[_B>&-R1I_.:Z'1
M[_ABL:B7P78%)FS=W+*>ZF-<MV!-$)GD8!2&2*PB,ZVKPYY!WCAFI"$ [MN+
M8533K;%8]]?Z,C\C32TW)ZROL$S3]*#4UNZ'-2H#VX_81A[0Y@TWVQ /GL#$
M:KM9#8H;2^HVDOX(6O&"UK#6W0IO4W!TA=<]Z;V=K_ A9&<II,(4(7.5-S-I
M8V$<E J6?J$0;>OD^M[$C>NY'(&)>[5=@ZBC;T/S4UC6,XKSFM-9/_)@*W/_
M20U-S!-DMCH3O%;UN[+]LNV^FQ^_$"QC)>>J)]W-D8TKM)WQ#)QCK;2Q!;S(
M&DSD3(AB(C8?3GL<Q<?:K[W?_M/VV[=RO-EJQK6 %#C6CD^T3DTT$%+1*22>
MBVN=FCJ2Y)'/%$^'S[NV\92J[M=BXN?*UM9%VH.LY?VG-+*43Y#7R$I>ON8#
M?ITOUIT1KO 5;,ZVH <;<DT+T*[H';GY0FC-57':Z]8UL;MH.=HSN_/<AYP
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MP0P(JTVM& S@C"3TJ)13M6"B^0S$ 3L3IB^8+\YP,YS@?G"]%O%6[4\*M:L
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MRQ@(#&M:*=7+J0[!&N>DX4@+M'75^I-$?3?-A9^#G;O6JZUJNC5&3S3;/=Q
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MZQ+YIZGJO<WQ<["R=YOCPW32K6':NQ_PX:;JN:\X<:/C(<W9(VUGN6'&&<U
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M2EK-.5 <9AD4ZR-Q8TWDK2OM'R%GY.MI;12^#XP.D/[8A?/D./]R41V:JWL
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MFT]L/"#*&&,8XS'8.4+(/;AJ1/,=V-^;*7G[@ZUO3HS1=3PSIQ7!:[X'R2%
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ML[<2_BY;%20S(+VK"?^"$$WB(- ('UC1T35ON+H?:>.:JB,!<+>)Z@#:Z"+
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ME.S8P/CIC+B_.DCXB&&U.KMB0S*78@D.!"K"=Y06O&0>@BGD/M0KC7=OXN\
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M.7L@+><9X6_ <X!C]OP:_&<0<%[([_DOY/7F@(X)3@N%!6PW2<)>EZLM&:M
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MC8E)@8W75.O;@IVNG#4)\?"8IGJ3Y(DW6_EG]I+MR+[<^QM02P$"% ,4
M" !J.JE:P2[O @H:   +K@  '@              @ $     83(P,C5I;F1U
M8V5M96YT<&QA;F9O<FUO9F\N:'1M4$L! A0#%     @ :CJI6L!G>?*'0@(
M2A44 !$              ( !1AH  &YG;F4M,C R-3 S,S$N:'1M4$L! A0#
M%     @ :CJI6JX"A[2>#P  R*P  !$              ( !_%P" &YG;F4M
M,C R-3 S,S$N>'-D4$L! A0#%     @ :CJI6@_]7<5^%@  ZM,  !4
M         ( !R6P" &YG;F4M,C R-3 S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M &HZJ5J@4GP;U$0  +$6 P 5              "  7J# @!N9VYE+3(P,C4P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " !J.JE:%)"T6G'-   A#0$ %
M        @ &!R ( ;F=N92TR,#(U,#,S,5]G,2YJ<&=02P$"% ,4    " !J
M.JE:7N/&B6TB 0#Q;0$ %               @ $DE@, ;F=N92TR,#(U,#,S
M,5]G,BYJ<&=02P$"% ,4    " !J.JE:%A@@?A+A  #C'PD %0
M    @ '#N 0 ;F=N92TR,#(U,#,S,5]L86(N>&UL4$L! A0#%     @ :CJI
M6N![P?BVA   JU0& !4              ( !")H% &YG;F4M,C R-3 S,S%?
M<')E+GAM;%!+ 0(4 Q0    ( &HZJ5IH";DE?P<  -DD   >
M  "  ?$>!@!N9VYE+3(P,C5F;W)M<3$Q,'AQ>&5X,S$Q<"YH=&U02P$"% ,4
M    " !J.JE::ZD=NI<'  !<)0  '@              @ &L)@8 ;F=N92TR
M,#(U9F]R;7$Q,3!X<7AE>#,Q,G N:'1M4$L! A0#%     @ :CJI6KXQ<1H?
M!@  XQL  !T              ( !?RX& &YG;F4M,C R-69O<FUQ,3$P>'%X
?97@S,C$N:'1M4$L%!@     ,  P /0,  -DT!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>ngne-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ngne="http://www.neurogene.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ngne-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2025-05-05</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ngne:Phase1NL201TrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ngne:Phase1NL201TrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ngne:Phase1NL201TrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ngne:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:NewYorkHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:HoustonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:BlaineLeaseInSeattleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:EastlakeLeaseInSeattleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:EastlakeLeaseInSeattleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ngne:EastlakeLeaseInSeattleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:April2024CVRLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:December2023CVRLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:December2023CVRLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:April2024CVRLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:April2024CVRLicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:IntellectualPropertyCVRNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:IntellectualPropertyCVRNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:SalesTaxCVRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:LeaseCVRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:LeaseCVRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:LeaseCVRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:IntellectualPropertyCVRNettingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ngne:SalesTaxCVRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:RegulatoryRelatedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:SalesRelatedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ngne:SalesRelatedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:UniversityOfEdinburghMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:VirovekIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:VirovekIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:VirovekIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:SigmaAldrichCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:SigmaAldrichCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:SigmaAldrichCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ngne:StanfordLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2025InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ngne:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ngne:December2023PreferredStockConversionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ngne:December2023PreClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2025InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ngne:A2023EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:RettSyndromeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:RettSyndromeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:BattenDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:BattenDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:EarlyDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:EarlyDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:PersonnelRelatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:PersonnelRelatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ShareBasedCompensationExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ShareBasedCompensationExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ManufacturingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ManufacturingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:ProfessionalAndConsultantFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:OfficeRelatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ngne:OfficeRelatedExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ngne:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-14</startDate>
            <endDate>2025-04-14</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ngne:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-14</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ngne:StuartCobbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ngne:StuartCobbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ngne:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>ngne:Term</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>ngne:tranche</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001404644</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-266"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <ecd:TrdArrDuration contextRef="c-167" id="f-620">P404D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36327</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Neurogene Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">98-0542593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">535 W 24th St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">5th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">10011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">855</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">508-3568</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common stock, par value $0.000001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">NGNE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">14262066</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">70771000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">136586000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">221831000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">175819000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">3796000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">3518000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">296398000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">315923000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">14807000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">15422000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">2803000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">3000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">58000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">71000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">339000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">339000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">896000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">975000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">315301000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">335730000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">3063000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1336000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">6849000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">9731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">3036000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">2945000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">48000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">54000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">1098000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">1091000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">14094000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">15157000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">8606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">9403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">17000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">26000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">738000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">718000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">51000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">51000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">23506000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">25355000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-77" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-80" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-83"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-84"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-85" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-87" unitRef="shares">14929566</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-88" unitRef="shares">14929566</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-89" unitRef="shares">14854725</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-90" unitRef="shares">14854725</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">576740000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">572673000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">-284945000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">-262298000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-97" unitRef="usd">291795000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">310375000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-99" unitRef="usd">315301000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">335730000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">17760000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">13541000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">8159000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">5238000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">25919000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">18779000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">-25919000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">-18779000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">3206000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">2320000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">2000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">3000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">148000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">143000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">80000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">602000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">-22647000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">-16921000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-119"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-120"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-121"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-122"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-123" unitRef="shares">20996287</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-124" unitRef="shares">20996287</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-125" unitRef="shares">16903735</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-126" unitRef="shares">16903735</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-127" unitRef="shares">14854725</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-128" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">572673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-130" unitRef="usd">-262298000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-131" unitRef="usd">310375000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">4048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">4048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-10"
      decimals="INF"
      id="f-134"
      unitRef="shares">1683</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-9" decimals="-3" id="f-135" unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-10"
      decimals="INF"
      id="f-137"
      unitRef="shares">73158</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-138" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-139" unitRef="usd">-22647000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-22647000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-141"
      unitRef="shares">14929566</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-142" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">576740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-144" unitRef="usd">-284945000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-145" unitRef="usd">291795000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-146"
      unitRef="shares">12823665</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-147" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-148" unitRef="usd">373178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-149" unitRef="usd">-187154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-150" unitRef="usd">186024000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-151" unitRef="usd">1045000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-152" unitRef="usd">1045000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-20"
      decimals="INF"
      id="f-153"
      unitRef="shares">37330</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-154" unitRef="usd">629000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-155" unitRef="usd">629000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-156" unitRef="usd">-16921000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-157" unitRef="usd">-16921000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-158"
      unitRef="shares">12860995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-159" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-160" unitRef="usd">374852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-161" unitRef="usd">-204075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-162" unitRef="usd">170777000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">-22647000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-164" unitRef="usd">-16921000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">4048000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-166" unitRef="usd">1045000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">749000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-168" unitRef="usd">814000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-5" decimals="-3" id="f-170" unitRef="usd">91000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">197000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-5" decimals="-3" id="f-172" unitRef="usd">176000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">13000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-5" decimals="-3" id="f-174" unitRef="usd">11000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">1747000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-176" unitRef="usd">446000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <ngne:IncreaseDecreaseInContingentValueRightsLiability contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">27000</ngne:IncreaseDecreaseInContingentValueRightsLiability>
    <ngne:IncreaseDecreaseInContingentValueRightsLiability contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">329000</ngne:IncreaseDecreaseInContingentValueRightsLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">278000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-180" unitRef="usd">1417000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">-79000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-5" decimals="-3" id="f-182" unitRef="usd">-21000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">1694000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">135000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-2203000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">-4879000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-706000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-188" unitRef="usd">-609000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-20774000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">-21650000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">780000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">65000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">88965000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">44700000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">30000000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-45045000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">29935000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">4287000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">2855000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">19000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">629000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">15000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">11000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">4000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">-6524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-65815000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">1761000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-211" unitRef="usd">136925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-212" unitRef="usd">148718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-213" unitRef="usd">71110000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-3" id="f-214" unitRef="usd">150479000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">60000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">80000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">141000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">2000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-3" id="f-220" unitRef="usd">3000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-221">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Organization and Description of Business&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurogene&#160;Inc. (formerly known as Neoleukin Therapeutics, Inc.) (the &#x201c;Company&#x201d; or &#x201c;Neurogene&#x201d;) is a clinical-stage biotechnology company that is a result of the reverse merger discussed below. The operating entity of Neurogene Inc. is the wholly owned subsidiary incorporated in the state of Nevada and also named Neurogene Inc. (&#x201c;Neurogene OpCo&#x201d;). Neurogene OpCo was incorporated as a limited liability company in Delaware on January 26, 2018 and converted into a Delaware corporation on July 3, 2018, and then merged with a wholly owned subsidiary of the parent company and re-domiciled to Nevada on December 18, 2023 after completing a reverse merger with Neoleukin Therapeutics, Inc (the &#x201c;Closing&#x201d;), in accordance with the terms of the Agreement and Plan of Merger, dated as of July 17, 2023 (the &#x201c;Merger Agreement&#x201d;). Both Neurogene and Neurogene OpCo have a principal place of business in New York, NY. Neurogene was formed to harness the power of gene therapy, combined with its EXACT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; transgene regulation technology, to turn today&#x2019;s complex devastating neurological diseases into treatable conditions. The Company&#x2019;s first clinical-stage program to utilize the EXACT technology is NGN-401, which is in an ongoing Phase 1/2 clinical trial for the treatment of Rett syndrome. Since beginning operations, the Company has devoted substantially all its efforts to research and development, recruiting management and technical staff, administration, and raising capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-222">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Risks and Uncertainties&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of pre-clinical studies, clinical studies and clinical trials, the need to obtain marketing approval for its drug candidates and its consumer products, fluctuations in operating results, economic pressure impacting therapeutic pricing and reimbursement, dependence on key personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to transition from pilot scale manufacturing to large scale production.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $22.6 million and $16.9 million for the three months ended March 31, 2025 and 2024, respectively. In addition, the Company used cash in operations of $20.8 million and $21.7 million for the three months ended March 31, 2025 and 2024, respectively, and had an accumulated deficit of $284.9 million as of March&#160;31, 2025. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company had cash, cash equivalents and short-term investments of approximately $292.6 million. The Company expects its available cash and cash equivalents on hand as of the issuance date &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of these financial statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will be sufficient to fund its obligations as they become due for at least one year beyond the issuance date of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company&#x2019;s operations, a sale of assets, or other alternatives with strategic or financial partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-223" unitRef="usd">-22600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-224" unitRef="usd">-16900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-225" unitRef="usd">-20800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-5" id="f-226" unitRef="usd">-21700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-227" unitRef="usd">-284900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:InvestmentsAndCash contextRef="c-3" decimals="-5" id="f-228" unitRef="usd">292600000</us-gaap:InvestmentsAndCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-229">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, these financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March 24, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In management&#x2019;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2025, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determining the incremental borrowing rate for calculating lease liabilities and related right-of-use assets and finance lease assets, clinical trial accruals, accrual estimates for all contingent value rights (&#x201c;CVRs&#x201d;), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the value attributed to employee stock options and other stock-based awards. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines and presents operating segments based on the information internally provided to the Chief Operating Decision Makers (&#x201c;CODM&#x201d;) in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 280,&#160;Segment Reporting. The Company&#x2019;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has one reportable segment. Refer to Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further information related to the Company&#x2019;s segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with original maturities of 90 days or less at time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of money market funds in which the carrying value equals the fair value. Restricted cash includes $0.3 million in cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of March&#160;31, 2025, the Company had $70.6 million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Right&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the reverse merger, the Company entered into a CVR Agreement on December 18, 2023 with the Rights Agent named therein (the &#x201c;CVR Agreement&#x201d;) prior to Closing. Included in the CVR Agreement are three different types of CVRs: (i) the Lease CVR, (ii) the Intellectual Property CVR, and (iii) the Sales Tax CVR (each as defined in the CVR Agreement). The Company evaluated each of the CVRs to determine if they qualified as derivatives under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and concluded that since certain scope exceptions were met, the CVRs did not qualify as derivatives. Instead, the Company records a contingent consideration liability associated with the CVRs when payments are probable and estimable under ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In assessing whether payments are probable and estimable, the Company considers the existence of or ability to enter into agreements with third parties or government agencies and the timing of potential payments. Refer to Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on the CVRs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exit and Disposal Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the reverse merger and through early fiscal 2025, the Company has incurred costs to wind-down Neoleukin&#x2019;s Phase 1 trial of the NL-201 study. This trial has ceased further development, and the Company has no plans to continue developing Neoleukin&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; de novo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; protein technology. As a result, the trial&#x2019;s activities do not provide the Company any future economic benefit. In accordance with ASC 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company accrued the remaining costs incurred in the trial. The liability was classified as accrued expenses and other current liabilities in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the accrued liabilities activity recorded in connection with the wind-down of Neoleukin&#x2019;s Phase 1 trial of NL-201 for the three months ended March&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liability Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amounts Paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trial wind-down costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 1 NL-201 Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited financial statements filed with the Company&#x2019;s Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Since the date of those financial statements, there have been no changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net income attributable to the Company by the weighted-average number of shares of common stock outstanding during the period. In periods of losses, diluted net loss per share is computed on the same basis as basic net loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive. Outstanding pre-funded warrants as of March&#160;31, 2025 and March&#160;31, 2024 are 6,124,996 and 4,062,361 respectively. Pre-funded warrants are considered outstanding as of their issuance date and are included in basic and diluted net loss per share because they are fully vested and exercisable for nominal cash consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:13.5pt;text-indent:37.11pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,086,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,475,458&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,458&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,530&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,617,916&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,950,112&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its condensed financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which requires public entities to provide disaggregated disclosure of income statement expenses. Public entities are required to disaggregate, in a tabular presentation, each relevant expense caption on the face of the consolidated statements of operations such as the following expenses: purchases of inventory, employee compensation, intangible asset amortization, and depreciation. In January 2025, the FASB issued ASU 2025-01 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to clarify the effective date. The updated effective date for the Company to adopt ASU 2024-03 is for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2024-03 will have on its financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt; to expand the disclosure requirements for income taxes. Upon adoption, the Company will be required to disclose standardized categories in the rate reconciliation in both percentage and dollar amounts. ASU 2023-09 will also require income taxes paid to be disaggregated by jurisdiction, among other disclosure requirements. The Company adopted ASU 2023-09 for annual periods beginning January 1, 2025. The adoption does not have a material impact to the interim financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-230">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, these financial statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on March 24, 2025.&lt;/span&gt;&lt;/div&gt;In management&#x2019;s opinion, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position of the Company as of March&#160;31, 2025, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December&#160;31, 2025.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-231">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determining the incremental borrowing rate for calculating lease liabilities and related right-of-use assets and finance lease assets, clinical trial accruals, accrual estimates for all contingent value rights (&#x201c;CVRs&#x201d;), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the value attributed to employee stock options and other stock-based awards. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-232">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines and presents operating segments based on the information internally provided to the Chief Operating Decision Makers (&#x201c;CODM&#x201d;) in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 280,&#160;Segment Reporting. The Company&#x2019;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has one reportable segment. Refer to Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Information, &lt;/span&gt;for further information related to the Company&#x2019;s segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-233" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-234">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with original maturities of 90 days or less at time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and are stated at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-236">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-235">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash in the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.242%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-237" unitRef="usd">70771000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-238" unitRef="usd">136586000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-3" id="f-239" unitRef="usd">339000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="-3" id="f-240" unitRef="usd">339000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-241" unitRef="usd">71110000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-242" unitRef="usd">136925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-5" id="f-243" unitRef="usd">300000</us-gaap:RestrictedCash>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-244">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company&#x2019;s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of March&#160;31, 2025, the Company had $70.6 million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality.</us-gaap:ConcentrationRiskCreditRisk>
    <ngne:CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits contextRef="c-3" decimals="-5" id="f-245" unitRef="usd">70600000</ngne:CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits>
    <ngne:ContingentValueRightsPolicyTextBlock contextRef="c-1" id="f-246">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Right&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the reverse merger, the Company entered into a CVR Agreement on December 18, 2023 with the Rights Agent named therein (the &#x201c;CVR Agreement&#x201d;) prior to Closing. Included in the CVR Agreement are three different types of CVRs: (i) the Lease CVR, (ii) the Intellectual Property CVR, and (iii) the Sales Tax CVR (each as defined in the CVR Agreement). The Company evaluated each of the CVRs to determine if they qualified as derivatives under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and concluded that since certain scope exceptions were met, the CVRs did not qualify as derivatives. Instead, the Company records a contingent consideration liability associated with the CVRs when payments are probable and estimable under ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In assessing whether payments are probable and estimable, the Company considers the existence of or ability to enter into agreements with third parties or government agencies and the timing of potential payments. Refer to Note 9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on the CVRs.&lt;/span&gt;&lt;/div&gt;</ngne:ContingentValueRightsPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock contextRef="c-1" id="f-247">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exit and Disposal Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the reverse merger and through early fiscal 2025, the Company has incurred costs to wind-down Neoleukin&#x2019;s Phase 1 trial of the NL-201 study. This trial has ceased further development, and the Company has no plans to continue developing Neoleukin&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; de novo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; protein technology. As a result, the trial&#x2019;s activities do not provide the Company any future economic benefit. In accordance with ASC 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company accrued the remaining costs incurred in the trial. The liability was classified as accrued expenses and other current liabilities in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-248">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the accrued liabilities activity recorded in connection with the wind-down of Neoleukin&#x2019;s Phase 1 trial of NL-201 for the three months ended March&#160;31, 2025 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liability Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amounts Paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trial wind-down costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 1 NL-201 Trial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-26" decimals="-3" id="f-249" unitRef="usd">209000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="c-27" decimals="-3" id="f-250" unitRef="usd">-87000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:PaymentsForRestructuring contextRef="c-27" decimals="-3" id="f-251" unitRef="usd">109000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-28" decimals="-3" id="f-252" unitRef="usd">187000</us-gaap:RestructuringReserve>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-253">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net income attributable to the Company by the weighted-average number of shares of common stock outstanding during the period. In periods of losses, diluted net loss per share is computed on the same basis as basic net loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive. Outstanding pre-funded warrants as of March&#160;31, 2025 and March&#160;31, 2024 are 6,124,996 and 4,062,361 respectively. Pre-funded warrants are considered outstanding as of their issuance date and are included in basic and diluted net loss per share because they are fully vested and exercisable for nominal cash consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-254"
      unitRef="shares">6124996</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-255"
      unitRef="shares">4062361</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-256">&lt;div style="margin-top:10pt;padding-left:13.5pt;text-indent:37.11pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the diluted per share calculations as they would be anti-dilutive: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.275%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,086,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,475,458&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,458&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,530&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,617,916&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,950,112&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-31" decimals="0" id="f-257" unitRef="shares">2086334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-32" decimals="0" id="f-258" unitRef="shares">1475458</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-33" decimals="0" id="f-259" unitRef="shares">279458</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-34" decimals="0" id="f-260" unitRef="shares">222530</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-35" decimals="0" id="f-261" unitRef="shares">252124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-36" decimals="0" id="f-262" unitRef="shares">252124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-263" unitRef="shares">2617916</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-264" unitRef="shares">1950112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-265">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its condensed financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which requires public entities to provide disaggregated disclosure of income statement expenses. Public entities are required to disaggregate, in a tabular presentation, each relevant expense caption on the face of the consolidated statements of operations such as the following expenses: purchases of inventory, employee compensation, intangible asset amortization, and depreciation. In January 2025, the FASB issued ASU 2025-01 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to clarify the effective date. The updated effective date for the Company to adopt ASU 2024-03 is for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that ASU 2024-03 will have on its financial statement disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt; to expand the disclosure requirements for income taxes. Upon adoption, the Company will be required to disclose standardized categories in the rate reconciliation in both percentage and dollar amounts. ASU 2023-09 will also require income taxes paid to be disaggregated by jurisdiction, among other disclosure requirements. The Company adopted ASU 2023-09 for annual periods beginning January 1, 2025. The adoption does not have a material impact to the interim financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-267">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Investments &lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following table summarizes the Company&#x2019;s investment securities as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amortized cost, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s investments mature within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amortized cost, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="c-1" id="f-268">&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following table summarizes the Company&#x2019;s investment securities as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amortized cost, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s investments mature within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.628%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amortized cost, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss contextRef="c-37" decimals="-3" id="f-269" unitRef="usd">66588000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-37" decimals="-3" id="f-270" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-37" decimals="-3" id="f-271" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-37" decimals="-3" id="f-272" unitRef="usd">66588000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss contextRef="c-38" decimals="-3" id="f-273" unitRef="usd">221831000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-38" decimals="-3" id="f-274" unitRef="usd">76000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-38" decimals="-3" id="f-275" unitRef="usd">7000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-38" decimals="-3" id="f-276" unitRef="usd">221900000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-277" unitRef="usd">288419000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-3" decimals="-3" id="f-278" unitRef="usd">76000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-3" decimals="-3" id="f-279" unitRef="usd">7000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-3" decimals="-3" id="f-280" unitRef="usd">288488000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss contextRef="c-39" decimals="-3" id="f-281" unitRef="usd">131420000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-39" decimals="-3" id="f-282" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-39" decimals="-3" id="f-283" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-39" decimals="-3" id="f-284" unitRef="usd">131420000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss contextRef="c-40" decimals="-3" id="f-285" unitRef="usd">175819000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-40" decimals="-3" id="f-286" unitRef="usd">126000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-40" decimals="-3" id="f-287" unitRef="usd">3000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-40" decimals="-3" id="f-288" unitRef="usd">175942000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-289" unitRef="usd">307239000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain contextRef="c-4" decimals="-3" id="f-290" unitRef="usd">126000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss contextRef="c-4" decimals="-3" id="f-291" unitRef="usd">3000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-4" decimals="-3" id="f-292" unitRef="usd">307362000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-293">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds are cash equivalents and are included in cash and cash equivalents in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-294">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, financial assets measured at fair value on a recurring basis are categorized in the table below based upon the lowest level of significant input to the valuations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;175,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-295" unitRef="usd">66588000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-42" decimals="-3" id="f-296" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-43" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-44" decimals="-3" id="f-298" unitRef="usd">221900000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-45" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-46" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-44" decimals="-3" id="f-301" unitRef="usd">288488000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-45" decimals="-3" id="f-302" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-46" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-47" decimals="-3" id="f-304" unitRef="usd">131420000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-48" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-49" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-50" decimals="-3" id="f-307" unitRef="usd">175942000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-51" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-52" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-50" decimals="-3" id="f-310" unitRef="usd">307362000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-51" decimals="-3" id="f-311" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-52" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c-1" id="f-313">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-314">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refunds and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <ngne:RefundsAndOtherReceivablesCurrent contextRef="c-3" decimals="-3" id="f-315" unitRef="usd">596000</ngne:RefundsAndOtherReceivablesCurrent>
    <ngne:RefundsAndOtherReceivablesCurrent contextRef="c-4" decimals="-3" id="f-316" unitRef="usd">648000</ngne:RefundsAndOtherReceivablesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-317" unitRef="usd">2203000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-318" unitRef="usd">1889000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-319" unitRef="usd">997000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-320" unitRef="usd">981000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-321" unitRef="usd">3796000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-322" unitRef="usd">3518000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-323">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Property and Equipment, Net&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded depreciation and amortization expense of $0.7 million and $0.8 million for the three months ended March&#160;31, 2025 and 2024, respectively.  &lt;/span&gt;&lt;/div&gt;Management has reviewed its property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. During the three months ended March 31, 2025 there were no impairment losses and for the three months ended March 31, 2024, the Company recorded impairment losses on idle equipment of $0.1 million. Impairment losses are charged to research and development expenses in the condensed consolidated statement of operations. Fair value for the idle assets was determined by a quoted purchase price for the assets</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-53" decimals="-3" id="f-325" unitRef="usd">3297000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-54" decimals="-3" id="f-326" unitRef="usd">3259000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-55" decimals="-3" id="f-327" unitRef="usd">6326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-56" decimals="-3" id="f-328" unitRef="usd">6326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-57" decimals="-3" id="f-329" unitRef="usd">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-58" decimals="-3" id="f-330" unitRef="usd">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-59" decimals="-3" id="f-331" unitRef="usd">15396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-60" decimals="-3" id="f-332" unitRef="usd">15396000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-61" decimals="-3" id="f-333" unitRef="usd">285000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-62" decimals="-3" id="f-334" unitRef="usd">285000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-63" decimals="-3" id="f-335" unitRef="usd">1403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-64" decimals="-3" id="f-336" unitRef="usd">1308000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-337" unitRef="usd">26726000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-338" unitRef="usd">26593000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-339" unitRef="usd">11919000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-340" unitRef="usd">11171000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-341" unitRef="usd">14807000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">15422000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-343" unitRef="usd">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-5" id="f-344" unitRef="usd">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-345" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-5" decimals="-5" id="f-346" unitRef="usd">100000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-347">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.340%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation, bonuses and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-348">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.340%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation, bonuses and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-349" unitRef="usd">1339000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-350" unitRef="usd">4235000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ngne:AccruedResearchAndDevelopmentCurrent contextRef="c-3" decimals="-3" id="f-351" unitRef="usd">4765000</ngne:AccruedResearchAndDevelopmentCurrent>
    <ngne:AccruedResearchAndDevelopmentCurrent contextRef="c-4" decimals="-3" id="f-352" unitRef="usd">5047000</ngne:AccruedResearchAndDevelopmentCurrent>
    <ngne:AccruedSeveranceBonusAndRetentionCostsCurrent contextRef="c-3" decimals="-3" id="f-353" unitRef="usd">0</ngne:AccruedSeveranceBonusAndRetentionCostsCurrent>
    <ngne:AccruedSeveranceBonusAndRetentionCostsCurrent contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">107000</ngne:AccruedSeveranceBonusAndRetentionCostsCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-355" unitRef="usd">745000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-356" unitRef="usd">342000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-357" unitRef="usd">6849000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">9731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-359">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Commitments and Contingencies&lt;/span&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company commenced a sub-lease of approximately 6,000 square feet of office space for the corporate headquarters in New York, New York with a term expiring in June 2023. In connection with the lease, the Company established an irrevocable letter of credit for approximately $0.4 million. Monthly lease payments were approximately $0.04 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the sublessor was released from the original lease by the landlord, and the Company attorned to the landlord the executory terms and provisions of the sub-lease. In February 2022, the Company entered into an extension of the New York office lease (retroactive to December 2021) through June 2026, with new monthly lease payments ranging from approximately $0.03 million to $0.04 million. The Company accounted for the amendment as a contract modification, and accordingly, recorded an additional operating&#160;right-of-use asset of approximately $1.0 million and an additional operating lease liability of approximately $1.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Houston Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company entered into an agreement to lease approximately 26,905 square feet in Houston, Texas to build a manufacturing facility and office with a term expiring in August 2029. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset. Monthly rent payments were approximately $0.03 million. In connection with the lease, the Company paid a security deposit of approximately $0.04 million and prepaid rent of approximately $0.04 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company amended the lease agreement to further increase the rentable space to 42,342 square feet. The commencement date of the expansion space lease was January&#160;1, 2021 and the monthly rent payments increased to a range of approximately $0.05 million to $0.06 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Blaine Lease in Seattle&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the reverse merger, the Company assumed an operating lease for approximately 33,300 square feet of office space in Seattle, Washington for offices, a laboratory for research and development, and related uses. The lease expires on February 1, 2029, with the option to extend the lease for two five-year terms. The renewal periods were not included in the lease term for purposes of determining the lease liability or right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Eastlake Lease in Seattle&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the reverse merger, the Company assumed an operating lease for approximately 6,272 square feet of office space in Seattle, Washington, for additional office and laboratory space for research and development and related uses (the &#x201c;Eastlake Lease&#x201d;). The lease expires on September 30, 2026. The Company also assumed the existing agreement to sublease the Eastlake Lease to an unrelated third party (&#x201c;Eastlake Sublease&#x201d;). Pursuant to the terms of the Eastlake Sublease, Neurogene is entitled to receive approximately $1.6 million in lease payments. The Company recorded sublease income of $0.1 million for the three months ended March 31, 2025 and $0.1 million for the three months ended March 31, 2024. Sublease income is included in other income in the statement of operations. The term of the sublease is through September 30, 2026&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental lease expense for the three months ended March 31, 2025 and 2024 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease CVR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the CVR Agreement, each CVR holder is eligible to receive certain net savings, if any, realized by June 30, 2029 in connection with certain legacy lease obligations. As of March&#160;31, 2025, approximately $1.2&#160;million was recorded as a component of the contingent value rights liability on the Company&#x2019;s condensed consolidated balance sheet consisting of lease commitments that were probable and estimable at the Closing. The commitments relate to Neoleukin&#x2019;s sublease agreement, effective October 31, 2023, for one of its properties with an unrelated third party for the remainder of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intellectual Property CVR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the CVR Agreement, each CVR holder is eligible to receive 100% of the net proceeds, if any, derived from any consideration paid as a result of the disposition of Neoleukin&#x2019;s pre-merger legacy assets pursuant any agreements entered into before the Closing, and 80% of net proceeds, if any, derived from any consideration paid as a result of the disposition of Neoleukin&#x2019;s pre-merger legacy assets pursuant any agreements entered into within one year after the Closing (the &#x201c;Intellectual Property CVR&#x201d;). Contingent consideration liabilities related to the CVR Agreement will only be recorded if the liabilities are probable and estimable as of the balance sheet date. Refer to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2023 CVR Licensing Agreement and April 2024 CVR Licensing Agreement subsections&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below for further detail on the current agreements related to our Intellectual Property CVR. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2023 CVR Licensing Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Closing, Neoleukin entered into a licensing agreement on December 13, 2023 with an unrelated third party to develop and commercialize certain legacy Neoleukin assets (the &#x201c;December 2023 CVR Licensing Agreement&#x201d;). In June 2024, an upfront payment of $0.2&#160;million was received by the Company and $0.2&#160;million was recorded as licensing revenue within the consolidated statements of operations. Since the December 2023 CVR Licensing Agreement was entered into before the Closing, the CVR holders are eligible to receive 100% of the net proceeds derived from the December 2023 CVR Licensing Agreement. The December 2023 CVR Licensing Agreement contains development, regulatory and commercialization milestones totaling up to approximately $13.4 million, as well as royalty payments. However, as of March&#160;31, 2025, no other development and sales milestones were achieved nor deemed probable of achievement under the December 2023 CVR Licensing Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;April 2024 CVR Licensing Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company entered into a licensing and intellectual property assignment agreement with another unrelated third party to develop and commercialize certain legacy Neoleukin assets (the &#x201c;April 2024 CVR Licensing Agreement&#x201d;). In April 2024, the Company received a one-time upfront payment of approximately $0.8 million and reimbursement of $10,000 for patent expenses under the April 2024 CVR Licensing Agreement. Accordingly, the Company recorded $0.8 million as licensing revenue within the condensed consolidated statements of operations. Since the April 2024 CVR Licensing Agreement was entered into within one year after the Closing, the CVR holders are eligible to receive 80% of the net proceeds derived from the April 2024 CVR Licensing Agreement. The April 2024 CVR Licensing Agreement contains development, regulatory and commercialization milestones totaling up to approximately $11.0 million, as well as royalty payments. However, as of March&#160;31, 2025, no other development and sales milestones were achieved nor deemed probable of achievement under the April 2024 CVR Licensing Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2023 CVR Licensing Agreement and April 2024 CVR Licensing Agreement collectively account for the total Intellectual Property CVR. The total amount of $0.9 million due under the Intellectual Property CVR was offset by approximately $0.4 million due to permitted deductions under the Merger Agreement and the remaining $0.5 million was paid to the CVR holders as discussed below. As of March&#160;31, 2025, $0.3 million is recorded within the contingent value rights liability on the Company&#x2019;s condensed consolidated balance sheet arising from offsets to permitted deductions to the Intellectual Property CVR that were incurred subsequent to the CVR payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Tax CVR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Closing, Neoleukin entered into an agreement with an unrelated third party for refund analysis services of Washington state sales tax. As discussed and defined within the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Value Right&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; section&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the terms of the CVR Agreement include that CVR holders are eligible to receive net proceeds derived from an anticipated sales tax refund from Washington state relating to tax returns filed by Neoleukin prior to Closing. As of March&#160;31, 2025, it was deemed probable that the Company will receive proceeds from Washington state for the sales tax refund and will remit the proceeds to the CVR holders. As of March&#160;31, 2025, $0.4 million is accrued as a component of the contingent value rights liability arising from the Sales Tax CVR in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CVR Payment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company made the first CVR payment to CVR holders, net of expenses, for $0.6 million. $0.5 million was applied to the Intellectual Property CVR and $0.1 million was applied to the Lease CVR, reducing the respective liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of the contingent value rights liability in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease CVR&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual Property CVR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales Tax CVR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As per the CVR Agreement, the total amount owed to CVR holders, after deductions permitted under the Merger Agreement, must be at least $0.5 million to trigger a CVR payment prior to the end of the CVR term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other payments under the CVR Agreement were not considered probable and estimable as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and therefore no additional contingent consideration liability has been recorded. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will evaluate the probable and estimable range of outcomes under the CVR Agreement at each reporting period until the end of the CVR term and adjust the amounts accrued for as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employment Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has employment and consulting agreements with key personnel providing for compensation and severance in certain circumstances, as defined in the respective employment agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Development Arrangements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company had standing agreements with consultants, contractors or service providers that generally can be terminated by the Company with 30 to 60 days written notice, unless otherwise indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation and Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to litigation and other claims that arise in the ordinary course of business. While the ultimate result of outstanding legal matters cannot presently be determined, the Company does not expect that the ultimate disposition will have a material effect on its results of financial condition, results of operations or cash flows. However, legal matters are inherently unpredictable and subject to significant uncertainties, some of which are beyond the Company&#x2019;s control. As such, there can be no assurance that the final outcome of any particular legal matter will not have a material adverse effect on the Company&#x2019;s financial condition results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-65" decimals="0" id="f-360" unitRef="sqft">6000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-65" decimals="-5" id="f-361" unitRef="usd">400000</us-gaap:LettersOfCreditOutstandingAmount>
    <ngne:OperatingLeaseMonthlyPayments contextRef="c-66" decimals="-4" id="f-362" unitRef="usd">40000.00</ngne:OperatingLeaseMonthlyPayments>
    <ngne:OperatingLeaseMonthlyPayments contextRef="c-67" decimals="-4" id="f-363" unitRef="usd">30000.00</ngne:OperatingLeaseMonthlyPayments>
    <ngne:OperatingLeaseMonthlyPayments contextRef="c-68" decimals="-4" id="f-364" unitRef="usd">40000.00</ngne:OperatingLeaseMonthlyPayments>
    <us-gaap:OperatingLeaseLiability contextRef="c-69" decimals="-5" id="f-365" unitRef="usd">1000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-69" decimals="-5" id="f-366" unitRef="usd">1000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-69" decimals="-5" id="f-367" unitRef="usd">1000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-69" decimals="-5" id="f-368" unitRef="usd">1000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-70" decimals="0" id="f-369" unitRef="sqft">26905</us-gaap:AreaOfRealEstateProperty>
    <ngne:LesseeOperatingLeaseNumberOfRenewalTerm contextRef="c-70" decimals="INF" id="f-370" unitRef="term">2</ngne:LesseeOperatingLeaseNumberOfRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-70" id="f-371">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ngne:OperatingLeaseMonthlyPayments contextRef="c-71" decimals="-4" id="f-372" unitRef="usd">30000.00</ngne:OperatingLeaseMonthlyPayments>
    <us-gaap:SecurityDeposit contextRef="c-70" decimals="-4" id="f-373" unitRef="usd">40000.00</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidRent contextRef="c-70" decimals="-4" id="f-374" unitRef="usd">40000.00</us-gaap:PrepaidRent>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-72" decimals="0" id="f-375" unitRef="sqft">42342</us-gaap:AreaOfRealEstateProperty>
    <ngne:OperatingLeaseMonthlyPayments contextRef="c-73" decimals="-4" id="f-376" unitRef="usd">50000.00</ngne:OperatingLeaseMonthlyPayments>
    <ngne:OperatingLeaseMonthlyPayments contextRef="c-74" decimals="-4" id="f-377" unitRef="usd">60000.00</ngne:OperatingLeaseMonthlyPayments>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-75" decimals="0" id="f-378" unitRef="sqft">33300</us-gaap:AreaOfRealEstateProperty>
    <ngne:LesseeOperatingLeaseNumberOfRenewalTerm contextRef="c-75" decimals="INF" id="f-379" unitRef="term">2</ngne:LesseeOperatingLeaseNumberOfRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-75" id="f-380">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-76" decimals="0" id="f-381" unitRef="sqft">6272</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-76" decimals="-5" id="f-382" unitRef="usd">1600000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-77" decimals="-5" id="f-383" unitRef="usd">100000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-78" decimals="-5" id="f-384" unitRef="usd">100000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-385">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental lease expense for the three months ended March 31, 2025 and 2024 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">484000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-387" unitRef="usd">524000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">13000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-5" decimals="-3" id="f-389" unitRef="usd">11000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-5" decimals="-3" id="f-391" unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">352000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-3" id="f-393" unitRef="usd">331000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">19000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-5" decimals="-3" id="f-395" unitRef="usd">23000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">870000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-5" decimals="-3" id="f-397" unitRef="usd">892000</us-gaap:LeaseCost>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-1" decimals="-5" id="f-398" unitRef="usd">1200000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage
      contextRef="c-79"
      decimals="INF"
      id="f-399"
      unitRef="number">1</ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage>
    <ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage
      contextRef="c-79"
      decimals="INF"
      id="f-400"
      unitRef="number">0.80</ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage>
    <us-gaap:ContractWithCustomerLiability contextRef="c-80" decimals="-5" id="f-401" unitRef="usd">200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-80" decimals="-5" id="f-402" unitRef="usd">200000</us-gaap:ContractWithCustomerLiability>
    <ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage contextRef="c-79" decimals="2" id="f-403" unitRef="number">1</ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsMaximumPercentage>
    <ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-81" decimals="-5" id="f-404" unitRef="usd">13400000</ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <us-gaap:ContractWithCustomerLiability contextRef="c-82" decimals="-5" id="f-405" unitRef="usd">800000</us-gaap:ContractWithCustomerLiability>
    <ngne:CollaborativeArrangementRightsAndObligationsReimbursement contextRef="c-83" decimals="-3" id="f-406" unitRef="usd">10000</ngne:CollaborativeArrangementRightsAndObligationsReimbursement>
    <us-gaap:ContractWithCustomerLiability contextRef="c-82" decimals="-5" id="f-407" unitRef="usd">800000</us-gaap:ContractWithCustomerLiability>
    <ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage
      contextRef="c-79"
      decimals="INF"
      id="f-408"
      unitRef="number">0.80</ngne:CollaborativeArrangementRightsAndObligationsEligibilityToReceivedNetProceedsPercentage>
    <ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-82" decimals="-5" id="f-409" unitRef="usd">11000000.0</ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <ngne:IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount contextRef="c-3" decimals="-5" id="f-410" unitRef="usd">900000</ngne:IntellectualPropertyContingentValueRightsLiabilityCurrentTotalAmount>
    <ngne:IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions contextRef="c-3" decimals="-5" id="f-411" unitRef="usd">400000</ngne:IntellectualPropertyContingentValueRightsLiabilityCurrentDeductions>
    <ngne:AssetAcquisitionContingentConsiderationCashPayment contextRef="c-84" decimals="-5" id="f-412" unitRef="usd">500000</ngne:AssetAcquisitionContingentConsiderationCashPayment>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-85" decimals="-5" id="f-413" unitRef="usd">300000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-86" decimals="-5" id="f-414" unitRef="usd">400000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <ngne:AssetAcquisitionContingentConsiderationCashPayment contextRef="c-87" decimals="-5" id="f-415" unitRef="usd">600000</ngne:AssetAcquisitionContingentConsiderationCashPayment>
    <ngne:AssetAcquisitionContingentConsiderationCashPayment contextRef="c-84" decimals="-5" id="f-416" unitRef="usd">500000</ngne:AssetAcquisitionContingentConsiderationCashPayment>
    <ngne:AssetAcquisitionContingentConsiderationCashPayment contextRef="c-88" decimals="-5" id="f-417" unitRef="usd">100000</ngne:AssetAcquisitionContingentConsiderationCashPayment>
    <us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock contextRef="c-1" id="f-418">&lt;div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of the contingent value rights liability in the condensed consolidated balance sheet as of March&#160;31, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.451%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease CVR&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual Property CVR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales Tax CVR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total CVR liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-89" decimals="-3" id="f-419" unitRef="usd">443000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-89" decimals="-3" id="f-420" unitRef="usd">738000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-90" decimals="-3" id="f-421" unitRef="usd">436000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-90" decimals="-3" id="f-422" unitRef="usd">718000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-85" decimals="-3" id="f-423" unitRef="usd">295000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-85" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-91" decimals="-3" id="f-425" unitRef="usd">295000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-91" decimals="-3" id="f-426" unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-86" decimals="-3" id="f-427" unitRef="usd">360000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-86" decimals="-3" id="f-428" unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-92" decimals="-3" id="f-429" unitRef="usd">360000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-92" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-3" decimals="-3" id="f-431" unitRef="usd">1098000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-432" unitRef="usd">738000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c-4" decimals="-3" id="f-433" unitRef="usd">1091000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-434" unitRef="usd">718000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <ngne:AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions contextRef="c-3" decimals="-3" id="f-435" unitRef="usd">500000</ngne:AssetAcquisitionContingentConsiderationCovenantMinimumAmountOwedNetOfDeductions>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-436">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Licenses&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with The University of Edinburgh&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the University Court of the University of Edinburgh (the &#x201c;University of Edinburgh&#x201d;) and Neurogene entered into the Master Collaboration Agreement (&#x201c;MCA&#x201d;). Under the MCA, Neurogene and the University of Edinburgh agreed to collaborate on certain research and development projects (&#x201c;Projects&#x201d;) and Neurogene agreed to provide funding for such Projects for a 40-month initial term,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which term was extended in November 2023 for an additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months and may be further extended by mutual agreement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In exchange for such funding, the University of Edinburgh granted Neurogene the option to exclusively license any intellectual property arising from such Projects. If Neurogene exercises an exclusive option for a particular Project, Neurogene will enter into a separate exclusive license agreement on its own terms with the University of Edinburgh. Under the MCA, Neurogene is obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the 40-month period. Either party may terminate the MCA for convenience upon 90 days&#x2019; notice. If Neurogene terminates the MCA, it would be responsible for all non-cancellable costs and commitments related to any particular Project and any and all funding costs for any person working on such Project. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Neurogene exercised its option through the collaboration under the MCA and entered into a License Agreement (the &#x201c;March 2022 Edinburgh License Agreement&#x201d;) with the University of Edinburgh, pursuant to which Neurogene licensed certain patents and know-how related to the EXACT technology and optimized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MECP2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cassettes on an exclusive basis. Under the March 2022 Edinburgh License Agreement, Neurogene obtained an exclusive, worldwide license to the licensed patents to develop, manufacture, supply, sell, and commercialize any products that utilize the licensed patents (the &#x201c;Licensed Products&#x201d;) in exchange for low single-digit percentage royalties on future commercial net sales of the Licensed Products. Royalties are payable on a Licensed Product-by-Licensed Product and country-by-country basis until the latest of the expiration of the last licensed patent covering such Licensed Product in the country where the Licensed Product is sold, or, if no licensed patent exists or has expired in such country, then ten years from first commercial sale of such Licensed Product in such country. In connection with the license, Neurogene is also obligated to pay the University of Edinburgh up to $5.3 million in regulatory-related milestones and up to $25.0 million in sales-related milestones based on annual net sales of Licensed Products in excess of defined thresholds. During the year ended December 31, 2023, the Company expensed $0.3 million for a milestone related to the first patient dosing in the Phase 1/2 trial for Rett syndrome.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, Neurogene and University of Edinburgh amended the MCA. Under the amended MCA, Neurogene and University of Edinburgh agreed to continue collaborating on certain Projects and Neurogene agreed to provide funding for such Projects through December 2026, or an additional 33 months. Neurogene is obligated to pay semi-annual installment payments relating to funding of costs for personnel and lab consumables for the entire period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the three months ended March 31, 2025 and 2024, the expense recorded by the Company related to the MCA was $0.4 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Virovek&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Neurogene entered into a Non-Exclusive License Agreement with Virovek, Inc., pursuant to which Neurogene has a license to use certain patents and know-how on a non-exclusive basis related to Neurogene&#x2019;s baculovirus (&#x201c;baculo&#x201d;) process in exchange for low single-digit percentage royalties on future commercial net sales of each product using the baculo process, development milestone payments of up to $0.2 million in the aggregate, and a nonrefundable annual license fee. During the three months ended March 31, 2025, no milestone expense was recorded. During the three months ended March 31, 2024, the Company recorded a milestone expense of $0.1 million for the Rett Syndrome Investigational New Drug filing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Sigma-Aldrich Co&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, Neurogene entered into a Non-Exclusive License Agreement with Sigma-Aldrich Co. LLC, pursuant to which Neurogene has a license to certain patents and know-how on a non-exclusive basis related to certain cell lines used in Neurogene&#x2019;s baculo process in exchange for a small annual fee on a product-by-product basis, payable once the first product candidate enters the clinic. In addition, on a product-by-product basis, Neurogene is obligated to pay up to $2.5 million in the aggregate for development-related milestones. The Company recorded a license expense of $0.06 million for the three months ended March 31, 2025 and $0.06 million for the three months ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Stanford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company entered into a Nonexclusive License Agreement with the Board of Trustees of Leland Stanford Junior University (the &#x201c;Stanford License Agreement&#x201d;) to license, on a non-exclusive basis, certain biological materials used by the Company in the manufacturing process of Neurogene&#x2019;s product candidates, including NGN-401. Over the 10-year term of the Stanford License Agreement, the Company is obligated to pay up to $0.5 million in licensing fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expenses were recorded related to other in-process license agreements during the three months ended March 31, 2025 and 2024. None will be due under these agreements unless and until certain development milestones are reached.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ngne:CollaborativeArrangementRightsAndObligationsTerm contextRef="c-93" id="f-437">P40M</ngne:CollaborativeArrangementRightsAndObligationsTerm>
    <ngne:CollaborativeArrangementRightsAndObligationsAdditionalTerm contextRef="c-94" id="f-438">P33M</ngne:CollaborativeArrangementRightsAndObligationsAdditionalTerm>
    <ngne:CollaborativeArrangementRightsAndObligationsTerm contextRef="c-93" id="f-439">P40M</ngne:CollaborativeArrangementRightsAndObligationsTerm>
    <ngne:ResearchCollaborationAndLicenseAgreementOptionToTerminate contextRef="c-93" id="f-440">P90D</ngne:ResearchCollaborationAndLicenseAgreementOptionToTerminate>
    <ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-95" decimals="-5" id="f-441" unitRef="usd">5300000</ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-96" decimals="-5" id="f-442" unitRef="usd">25000000.0</ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <ngne:CollaborativeArrangementRightsAndObligationsExpense contextRef="c-97" decimals="-5" id="f-443" unitRef="usd">300000</ngne:CollaborativeArrangementRightsAndObligationsExpense>
    <ngne:CollaborativeArrangementRightsAndObligationsAdditionalTerm contextRef="c-94" id="f-444">P33M</ngne:CollaborativeArrangementRightsAndObligationsAdditionalTerm>
    <ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-98" decimals="-5" id="f-445" unitRef="usd">400000</ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-99" decimals="-5" id="f-446" unitRef="usd">400000</ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-100" decimals="-5" id="f-447" unitRef="usd">200000</ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <ngne:CollaborativeArrangementRightsAndObligationsExpense contextRef="c-101" decimals="INF" id="f-448" unitRef="usd">0</ngne:CollaborativeArrangementRightsAndObligationsExpense>
    <ngne:CollaborativeArrangementRightsAndObligationsExpense contextRef="c-102" decimals="-5" id="f-449" unitRef="usd">100000</ngne:CollaborativeArrangementRightsAndObligationsExpense>
    <ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct contextRef="c-103" decimals="-5" id="f-450" unitRef="usd">2500000</ngne:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-104" decimals="-4" id="f-451" unitRef="usd">60000.00</ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-105" decimals="-4" id="f-452" unitRef="usd">60000.00</ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <ngne:CollaborativeArrangementTermOfAgreement contextRef="c-106" id="f-453">P10Y</ngne:CollaborativeArrangementTermOfAgreement>
    <ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee contextRef="c-106" decimals="-5" id="f-454" unitRef="usd">500000</ngne:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-455">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common stock and pre-funded warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025, the Company&#x2019;s board of directors approved the Neurogene Inc. 2025 Inducement Plan, which reserves for issuance up to 500,000 shares of common stock underlying inducement awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has pre-funded warrants outstanding to purchase an aggregate of 6,124,996 shares of common stock as of March&#160;31, 2025. The pre-funded warrants are exercisable at any time for exercise prices ranging from $0.000001 to $0.001, except that the pre-funded warrants cannot be exercised by a holder if, after giving effect thereto, such holder would beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. However, any holder may increase or decrease such percentage to any other percentage (not in excess of 19.99%) upon at least 61 days&#x2019; prior notice from the holder to the Company. The holders of the pre-funded warrants will not have the right to vote the shares underlying the pre-funded warrants on any matter except to the extent required by Delaware law. These warrants were classified as equity. Information on the outstanding warrants is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.491%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Type of Financing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.000001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425,987&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legacy pre-funded warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.000001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,708,332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023 Preferred stock conversion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.000001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,825,635&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023 Pre-Closing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,165,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 2024 private placement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,124,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,086,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,387,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant under the 2023 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,218,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,458,188&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant under the 2025 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future issuance under the 2023 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;321,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,223&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-funded warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,124,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,124,996&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,782,754&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,618,617&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-456"
      unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-457"
      unitRef="shares">6124996</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-29"
      decimals="INF"
      id="f-458"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="INF"
      id="f-459"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ngne:PercentageOfOutstandingStockPerStockholderMaximum contextRef="c-1" decimals="4" id="f-460" unitRef="number">0.0999</ngne:PercentageOfOutstandingStockPerStockholderMaximum>
    <ngne:PercentageOfOutstandingStockPerStockholderUponNoticeMaximum contextRef="c-1" decimals="4" id="f-461" unitRef="number">0.1999</ngne:PercentageOfOutstandingStockPerStockholderUponNoticeMaximum>
    <ngne:ClassOfWarrantOrRightNoticePeriod contextRef="c-1" id="f-462">P61D</ngne:ClassOfWarrantOrRightNoticePeriod>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-463">Delaware law. These warrants were classified as equity. Information on the outstanding warrants is as follows: &lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.491%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Type of Financing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.000001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;425,987&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legacy pre-funded warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.000001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,708,332&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023 Preferred stock conversion&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.000001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,825,635&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023 Pre-Closing&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock pre-funded warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,165,042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 2024 private placement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,124,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-109"
      decimals="INF"
      id="f-464"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares contextRef="c-109" decimals="0" id="f-465" unitRef="shares">425987</ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="INF"
      id="f-466"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares contextRef="c-110" decimals="0" id="f-467" unitRef="shares">1708332</ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="INF"
      id="f-468"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares contextRef="c-111" decimals="0" id="f-469" unitRef="shares">1825635</ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="INF"
      id="f-470"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares contextRef="c-108" decimals="0" id="f-471" unitRef="shares">2165042</ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares>
    <ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares contextRef="c-3" decimals="0" id="f-472" unitRef="shares">6124996</ngne:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsShares>
    <ngne:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-473">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,086,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,387,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant under the 2023 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,218,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,458,188&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future grant under the 2025 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares available for future issuance under the 2023 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;321,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;173,223&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-funded warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,124,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,124,996&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,782,754&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,618,617&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ngne:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-112"
      decimals="INF"
      id="f-474"
      unitRef="shares">279458</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-113"
      decimals="INF"
      id="f-475"
      unitRef="shares">222530</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="INF"
      id="f-476"
      unitRef="shares">252124</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-115"
      decimals="INF"
      id="f-477"
      unitRef="shares">252124</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-116"
      decimals="INF"
      id="f-478"
      unitRef="shares">2086334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-117"
      decimals="INF"
      id="f-479"
      unitRef="shares">1387556</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-118"
      decimals="INF"
      id="f-480"
      unitRef="shares">1218072</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-119"
      decimals="INF"
      id="f-481"
      unitRef="shares">1458188</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-482"
      unitRef="shares">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-120"
      decimals="INF"
      id="f-483"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-121"
      decimals="INF"
      id="f-484"
      unitRef="shares">321770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-122"
      decimals="INF"
      id="f-485"
      unitRef="shares">173223</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-123"
      decimals="INF"
      id="f-486"
      unitRef="shares">6124996</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-124"
      decimals="INF"
      id="f-487"
      unitRef="shares">6124996</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-488" unitRef="shares">10782754</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-489" unitRef="shares">9618617</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-490">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Stock-Based Compensation&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;br/&gt;per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,387,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;725,191&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,086,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;655,763&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the aggregate intrinsic value of outstanding options and exercisable options was approximately $0.7 million and $0.7 million, respectively. The aggregate intrinsic value of options exercised was immaterial for the three months ended March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted was $12.78 and $25.97 per share for the three months ended March&#160;31, 2025 and 2024, respectively. The Company recorded stock-based compensation related to stock options of approximately $1.8 million and $1.0 million for the three months ended March&#160;31, 2025 and 2024. As of March&#160;31, 2025, the total unrecognized compensation expense related to unvested stock option awards was approximately $25.5 million, which the Company expects to recognize over a weighted-average period of 3.12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option was estimated on the grant date using the weighted average assumptions in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.99%-96.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.39%-87.64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.97%-4.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.97%-4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.60-6.96&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.77-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit (&#x201c;RSU&#x201d;) activity and related information for the three months ended March 31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(73,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSUs of approximately $0.6 million for the three months ended March 31, 2025 and $0.1 million for the three months ended March 31, 2024. As of March&#160;31, 2025, there was approximately $7.2 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 2.26 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A summary of the Company&#x2019;s performance stock unit (&#x201c;PSU&#x201d;) activity and related information for the three months ended March 31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PSUs were granted with vesting in two equal tranches based on certain performance conditions. Each PSU entitles the holder to receive one share of the Company's common stock when the PSU vests. Stock-based compensation expense for PSUs will be recognized when it is probable that the performance conditions will be achieved. As of March&#160;31, 2025, the performance conditions underlying the first tranche of 126,062 PSUs were deemed probable of achievement for the first milestone and are currently considered probable to vest. The Company recorded stock-based compensation expense related to PSUs of approximately $1.6 million for the three months ended March 31, 2025. As of March&#160;31, 2025, the second tranche of 126,062 PSUs were not deemed probable of achievement and are not currently considered probable to vest. As of March&#160;31, 2025, there was approximately $7.5 million of unrecognized compensation cost related to PSUs.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-491">The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations (in thousands):&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-3" id="f-492" unitRef="usd">1570000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="-3" id="f-493" unitRef="usd">564000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-494" unitRef="usd">2478000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="-3" id="f-495" unitRef="usd">481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-496" unitRef="usd">4048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-497" unitRef="usd">1045000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-498">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;br/&gt;per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,387,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;725,191&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired/Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,086,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;655,763&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-499" unitRef="shares">1387556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-500"
      unitRef="usdPerShare">28.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-129" id="f-501">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-502" unitRef="shares">725191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-503"
      unitRef="usdPerShare">16.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-504" unitRef="shares">1683</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">10.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-506" unitRef="shares">24730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">35.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-508" unitRef="shares">2086334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">24.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-510">P8Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-511" unitRef="shares">655763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-512"
      unitRef="usdPerShare">22.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-513">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-5" id="f-514" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-5" id="f-515" unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">12.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-517"
      unitRef="usdPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-5" id="f-518" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-5" id="f-519" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-116" decimals="-5" id="f-520" unitRef="usd">25500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-130" id="f-521">P3Y1M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option was estimated on the grant date using the weighted average assumptions in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.138%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.468%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.99%-96.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.39%-87.64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.97%-4.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.97%-4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.60-6.96&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.77-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-1" decimals="4" id="f-523" unitRef="number">0.9399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-1" decimals="4" id="f-524" unitRef="number">0.9649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-5" decimals="4" id="f-525" unitRef="number">0.8639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-5" decimals="4" id="f-526" unitRef="number">0.8764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-1" decimals="4" id="f-527" unitRef="number">0.0397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-1" decimals="4" id="f-528" unitRef="number">0.0442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-5" decimals="4" id="f-529" unitRef="number">0.0397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-5" decimals="4" id="f-530" unitRef="number">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-132" id="f-531">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-133" id="f-532">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-134" id="f-533">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-135" id="f-534">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-130" decimals="3" id="f-535" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-131" decimals="3" id="f-536" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-537">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted stock unit (&#x201c;RSU&#x201d;) activity and related information for the three months ended March 31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.153%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(73,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-136"
      decimals="INF"
      id="f-538"
      unitRef="shares">222530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-136"
      decimals="2"
      id="f-539"
      unitRef="usdPerShare">36.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-137"
      decimals="INF"
      id="f-540"
      unitRef="shares">135205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-137"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">16.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-137"
      decimals="INF"
      id="f-542"
      unitRef="shares">73158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-137"
      decimals="2"
      id="f-543"
      unitRef="usdPerShare">36.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-137"
      decimals="INF"
      id="f-544"
      unitRef="shares">5119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-137"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">36.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-138"
      decimals="INF"
      id="f-546"
      unitRef="shares">279458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-138"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">26.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-5" id="f-548" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-139" decimals="-5" id="f-549" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-138" decimals="-5" id="f-550" unitRef="usd">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-137" id="f-551">P2Y3M3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-552">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A summary of the Company&#x2019;s performance stock unit (&#x201c;PSU&#x201d;) activity and related information for the three months ended March 31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;252,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-115"
      decimals="INF"
      id="f-553"
      unitRef="shares">252124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-115"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">36.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-140"
      decimals="INF"
      id="f-555"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-140"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-140"
      decimals="INF"
      id="f-557"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-140"
      decimals="2"
      id="f-558"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-140"
      decimals="INF"
      id="f-559"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-140"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-114"
      decimals="INF"
      id="f-561"
      unitRef="shares">252124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-114"
      decimals="2"
      id="f-562"
      unitRef="usdPerShare">36.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ngne:ShareBasedPaymentArrangementNumberOfTranches
      contextRef="c-114"
      decimals="INF"
      id="f-563"
      unitRef="tranche">2</ngne:ShareBasedPaymentArrangementNumberOfTranches>
    <ngne:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests contextRef="c-114" decimals="0" id="f-564" unitRef="shares">1</ngne:NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests>
    <ngne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest
      contextRef="c-141"
      decimals="INF"
      id="f-565"
      unitRef="shares">126062</ngne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsProbableToVest>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-141" decimals="-5" id="f-566" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ngne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest
      contextRef="c-142"
      decimals="INF"
      id="f-567"
      unitRef="shares">126062</ngne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNotProbableToVest>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-143" decimals="-5" id="f-568" unitRef="usd">7500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-569">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Segment Information&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODMs in deciding how to allocate resources and in assessing performance. The Company&#x2019;s CODMs are (i) the Chief Executive Officer and (ii) the President and Chief Financial Officer. The Company is a clinical stage biotechnology company that operates as a single operating segment and has one reportable segment. In addition to reviewing the expenses in the consolidated statement of operations, the CODMs are provided with research and development costs for Rett syndrome, Batten disease, Early Discovery and Discontinued Programs, as well as categorized general and administrative expenses. The research and development programs are considered significant by the Company. The CODM assesses the financial performance of the segment and decides how to allocate resources based on net loss on a consolidated basis. The measure of segment assets is reported on the consolidated balance sheets as total consolidated asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;s. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODMs also assess performance of the segment according to preclinical and clinical data, the stage of development of the research and development programs, along with program specific expenses and market conditions in the pharmaceutical and biotechnology sectors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and 2024, the Company did not have any significant long-lived assets located outside of the United States. Information on the segment and reconciliation to net loss is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Program specific expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rett syndrome&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Batten disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early Discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unallocated internal expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative specific expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional and consultant fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income (expense)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Other expense segment items category within research and development expense is mainly comprised of: Consultant fees for programs not specified above, IT Software and network support and rent expenses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Other expense segment items category within general and administrative expense is mainly comprised of: Insurance, IT software and network support, market research, and tax expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income (expense) included in net loss includes interest income, interest expense, other income and other expense.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-570"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-571"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-572">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and 2024, the Company did not have any significant long-lived assets located outside of the United States. Information on the segment and reconciliation to net loss is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Program specific expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rett syndrome&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Batten disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early Discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unallocated internal expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative specific expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Personnel-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional and consultant fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income (expense)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Other expense segment items category within research and development expense is mainly comprised of: Consultant fees for programs not specified above, IT Software and network support and rent expenses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Other expense segment items category within general and administrative expense is mainly comprised of: Insurance, IT software and network support, market research, and tax expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income (expense) included in net loss includes interest income, interest expense, other income and other expense.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-144" decimals="-3" id="f-573" unitRef="usd">4524000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-145" decimals="-3" id="f-574" unitRef="usd">2019000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-146" decimals="-3" id="f-575" unitRef="usd">845000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-147" decimals="-3" id="f-576" unitRef="usd">1190000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-148" decimals="-3" id="f-577" unitRef="usd">1287000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-149" decimals="-3" id="f-578" unitRef="usd">1466000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-150" decimals="-3" id="f-579" unitRef="usd">5404000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-151" decimals="-3" id="f-580" unitRef="usd">4718000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-152" decimals="-3" id="f-581" unitRef="usd">1570000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-153" decimals="-3" id="f-582" unitRef="usd">564000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-154" decimals="-3" id="f-583" unitRef="usd">3107000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-155" decimals="-3" id="f-584" unitRef="usd">2979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-156" decimals="-3" id="f-585" unitRef="usd">1023000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-157" decimals="-3" id="f-586" unitRef="usd">605000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-158" decimals="-3" id="f-587" unitRef="usd">17760000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-159" decimals="-3" id="f-588" unitRef="usd">13541000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-150" decimals="-3" id="f-589" unitRef="usd">2484000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-151" decimals="-3" id="f-590" unitRef="usd">2101000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-152" decimals="-3" id="f-591" unitRef="usd">2478000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-153" decimals="-3" id="f-592" unitRef="usd">480000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-160" decimals="-3" id="f-593" unitRef="usd">1277000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-161" decimals="-3" id="f-594" unitRef="usd">1502000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-162" decimals="-3" id="f-595" unitRef="usd">632000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-163" decimals="-3" id="f-596" unitRef="usd">604000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-156" decimals="-3" id="f-597" unitRef="usd">1288000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-157" decimals="-3" id="f-598" unitRef="usd">551000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-158" decimals="-3" id="f-599" unitRef="usd">8159000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-159" decimals="-3" id="f-600" unitRef="usd">5238000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-158" decimals="-3" id="f-601" unitRef="usd">3272000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-159" decimals="-3" id="f-602" unitRef="usd">1858000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-158" decimals="-3" id="f-603" unitRef="usd">-22647000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-159" decimals="-3" id="f-604" unitRef="usd">-16921000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-605">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Subsequent Events&lt;/span&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 14, 2025, the Company entered into an exchange agreement with existing stockholders to exchange an aggregate of 667,500 shares of the Company&#x2019;s common stock for an aggregate of pre-funded warrants to purchase 667,563 shares of the Company&#x2019;s common stock at an exercise price of $0.001 per share.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From April 1, 2025 until the financial statements were issued, the Company granted 7,695 options to employees.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-164"
      decimals="INF"
      id="f-606"
      unitRef="shares">667500</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-165"
      decimals="INF"
      id="f-607"
      unitRef="shares">667563</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-165"
      decimals="INF"
      id="f-608"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-166" decimals="0" id="f-609" unitRef="shares">7695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-610">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-611">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-612">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-613">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended March&#160;31, 2025, no director or officer (as defined in Section 16 of the Exchange Act) adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) as amended (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x201c;Rule&#x201d;), or any &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as defined in Item 408(a) of Regulation S-K,  except as described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.977%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.728%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.977%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.977%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.977%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Name &amp;amp; Title&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Date Adopted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Character of Trading Arrangement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate Number of Shares of Common Stock to be Purchased or Sold Pursuant to Trading Arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Duration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Material Terms&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Date Terminated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stuart Cobb, Chief Scientific Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rule 10b5-1 Trading Arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up to 27107 shares sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3/17/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Except as indicated by footnote, each trading arrangement marked as a &#x201c;Rule 10b5-1 Trading Arrangement&#x201d; is intended to satisfy the affirmative defense of the Rule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table. This trading arrangement only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule. This arrangement also provides for automatic expiration in the event of death, a personal bankruptcy filing, public announcement of a merger, recapitalization, acquisition, tender or exchange offer, or other business combination or reorganization resulting in the exchange or conversion of the common stock of the Company into shares of another company, or the conversion of the Company&#x2019;s securities into rights to receive fixed amounts of cash or into debt securities and/or preferred stock (whether in whole or in part).&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-167" id="f-614">Stuart Cobb</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-167" id="f-615">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-167" id="f-616">2/6/2025</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-167" id="f-617">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-168"
      decimals="INF"
      id="f-618"
      unitRef="shares">27107</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-167" id="f-619">3/17/2026</ecd:TrdArrExpirationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
